<SEC-DOCUMENT>0001193125-21-218024.txt : 20210719
<SEC-HEADER>0001193125-21-218024.hdr.sgml : 20210719
<ACCEPTANCE-DATETIME>20210719070124
ACCESSION NUMBER:		0001193125-21-218024
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		36
FILED AS OF DATE:		20210719
DATE AS OF CHANGE:		20210719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TScan Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001783328
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				825282075
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-255491
		FILM NUMBER:		211096838

	BUSINESS ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		857-399-9500

	MAIL ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d107876d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT COLOR="#32406b"><B>Filed Pursuant to Rule 424(b)(4)<BR>Registration No.
333-255491<BR>Registration No. 333-257938 </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>PROSPECTUS </I></FONT></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>6,666,667 Shares </I></FONT></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g78x09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>COMMON STOCK </I></FONT></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #32406b;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT"><FONT COLOR="#32406b"><B><I>TScan Therapeutics, Inc. is offering 6,666,667 shares of its common stock. This is our initial public offering and no public market
currently exists for our shares of common stock. The initial public offering price is $15.00 per share. </I></B></FONT></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT"><FONT COLOR="#32406b"><B><I>Our common
stock has been approved for listing on the Nasdaq Global Market under the symbol &#147;TCRX.&#148; </I></B></FONT></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #32406b;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We
are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; as defined under the federal securities laws. </I></B></FONT></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><I>We have two classes of common stock: the voting common stock offered hereby and which has one vote per share, and non-voting common stock. For a description of the rights of the voting common stock and non-voting common stock,
please see &#147;<A HREF="#rom107876_16">Description of capital stock</A>&#148; beginning on page 205 of this prospectus. We are offering voting common stock in this offering, and unless otherwise noted or unless the context provides otherwise, all
references in this prospectus to our &#147;common stock&#148;, &#147;common shares&#148; or &#147;shares&#148; refers to our voting common stock. </I></FONT></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Investing in our common stock involves risks. See &#147;<U><A HREF="#rom107876_2">Risk Factors</A></U>&#148; beginning on
page&nbsp;14. </I></B></FONT></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #32406b;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>PRICE $15.00 A SHARE </I></FONT></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #32406b;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #32406b; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><FONT COLOR="#32406b"><B><I>Per&nbsp;Share</I></B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #32406b; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><FONT COLOR="#32406b"><B><I>Total</I></B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Initial public offering price</I></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b"><I>$</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"><I>15.00</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b"><I>$</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"><I>100,000,005</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><I>&nbsp;</I></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Underwriting discounts and commissions (1)</I></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b"><I>$</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"><I>1.05</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b"><I>$</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"><I>7,000,000</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><I>&nbsp;</I></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Proceeds, before expenses, to us</I></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b"><I>$</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"><I>13.95</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b"><I>$</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"><I>93,000,005</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><I>&nbsp;</I></FONT></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #32406b;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b"><I>(1)</I></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b"><I>See &#147;Underwriters&#148; for a description of the compensation payable to the
underwriters. </I></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>We have granted the underwriters an option to purchase up to an additional 1,000,000
shares of common stock at the initial public offering price less underwriting discounts and commissions to cover over-allotments. If the underwriters exercise this option in full, the total underwriting discounts and commissions payable by us will
be $8.1&nbsp;million, and the total proceeds, before expenses to us will be $107.0&nbsp;million. </I></FONT></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>The Securities and
Exchange Commission and state securities regulators have not approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </I></FONT></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>The underwriters expect to deliver the shares of common stock to purchasers on July&nbsp;20, 2021. </I></FONT></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #32406b;width:21%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><FONT COLOR="#32406b"><I>MORGAN&nbsp;STANLEY</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#32406b"><I>JEFFERIES</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"><I>COWEN</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"><I>BARCLAYS</I></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Prospectus dated July&nbsp;15, 2021 </I></FONT></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #32406b"><FONT COLOR="#32406b"><B>Page</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_1">Prospectus summary</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_2">Risk factors</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_3">Special note regarding forward-looking
statements</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_4">Market, industry and other
data</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_5">Use of proceeds</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_6">Dividend policy</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_7">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_8">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_10">Management&#146;s discussion and analysis of financial
 condition and results of operations</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_11">Business</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_12">Management</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #32406b"><FONT COLOR="#32406b"><B>Page</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_13">Executive compensation</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_14">Certain relationships and related party transactions
</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_15">Principal stockholders</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_16">Description of capital stock</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_17">Shares eligible for future
sale</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_18">Material U.S. federal income tax consequences for
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our common stock</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_19">Underwriters</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_20">Legal matters</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_21">Experts</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_22">Where you can find additional
information</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#rom107876_23">Index to financial statements</A></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap">F-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #32406b;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B>Through and including August&nbsp;9, 2021 (the 25th day after the date of this prospectus), all dealers effecting transactions in shares of our common stock, whether or not participating in this offering, may be required to
deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We and the underwriters have not authorized anyone to provide you with any information or to make any representations
other than those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give
you. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or in any applicable free writing prospectus is accurate
only as of the date of this prospectus or any such free writing prospectus, as applicable, regardless of its time of delivery or of any sale of our common stock. Our business, financial condition, results of operations and future growth prospects
may have changed since that date. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For investors outside the United States: Neither we nor any of the
underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">TScan, the TScan logo and our other registered or common law trademarks appearing in this prospectus are the property of
TScan Therapeutics, Inc. This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork
and other visual displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> symbols, but such references are not intended to indicate in any way that we will
not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#146; trade names, trademarks or service marks to
imply a relationship with, or endorsement or sponsorship of us by, any other entity. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">i
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety
by the more detailed information and financial statements included elsewhere in this prospectus. It does not contain all of the information that may be important to you and your investment decision. You should carefully read this entire prospectus,
including the sections titled &#147;Risk factors,&#148; &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; and our financial statements and related notes before making an investment decision. In
this prospectus, unless context requires otherwise, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;TScan,&#148; or &#147;the Company&#148; refer to TScan Therapeutics, Inc. </I></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Overview </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We are a preclinical-stage biopharmaceutical company focused on developing a robust pipeline of T cell receptor-engineered T cell, or <FONT STYLE="white-space:nowrap">TCR-T,</FONT> therapies for the treatment of patients with
cancer. Our approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not. Using one of our proprietary platform technologies, TargetScan, we analyze the T
cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system naturally recognizes and eliminates tumor cells in these patients. This allows us to precisely identify the targets of T cell receptors, or TCRs,
that are driving these exceptional responses. We aim to use these anti-cancer TCRs to treat patients with cancer by genetically engineering their own T cells to recognize and eliminate their cancer. In addition to discovering <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapies against novel targets, we are using our ReceptorScan technology to further diversify our portfolio of therapeutic TCRs with TCR-T therapies against known targets. We believe this <FONT
STYLE="white-space:nowrap">two-pronged</FONT> approach will enable us to discover and develop a wide array of potential treatment options for patients with cancer. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are advancing a robust pipeline of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates for the treatment
of patients with hematologic and solid tumor malignancies. Our lead liquid tumor product candidates, <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> are in development for the treatment of
patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation, or HCT. <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT>
target <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2</FONT> antigens, respectively, which are well-recognized TCR targets that were identified in patients with exceptional responses to <FONT
STYLE="white-space:nowrap">HCT-associated</FONT> immunotherapy. We plan to submit Investigational New Drug, or IND, applications for each of <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> with the
U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2021. In addition, we are developing multiple <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates for the treatment of various solid tumors. One of the key goals for
our solid tumor program is to develop what we refer to as multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. We are designing these multiplexed therapies to be a combination of up to three highly active TCRs that are customized for
each patient and selected from our bank of therapeutic TCRs, which we refer to as ImmunoBank. We are currently advancing four solid tumor programs, TSC-200, TSC-201, <FONT STYLE="white-space:nowrap">TSC-202,</FONT> and TSC-203, through lead
optimization, and expect to submit IND applications for at least three of our four solid tumor TCR-T therapy candidates in the second half of 2022, with the fourth IND expected to be submitted in 2023. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">T cells are an essential component of the adaptive immune system and provide protection against cancer, infection, and
autoimmune disease. Multiple approaches have been and are continuing to be explored to develop effective T cell-based therapies for the treatment of cancer, including tumor infiltrating lymphocyte, or TIL, therapy and chimeric antigen receptor T
cell, or <FONT STYLE="white-space:nowrap">CAR-T,</FONT> therapy. The success of TIL therapy depends on the specific T cells present in the patient. If their TILs do not have appropriate anti-cancer specificities, the therapy is unlikely to be
effective. In addition, TIL therapy has, to date, shown limited applicability for the treatment of liquid tumors. In contrast, <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy has proven effective in certain hematological malignancies of
lymphoid origin, but has not yet shown efficacy or safety in myeloid malignancies. Additionally, this type of treatment is limited to targets on the surface of tumor cells and has not yet been shown to effectively penetrate solid tumors. Both TIL
and <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies, as well as other immunotherapies such as checkpoint inhibitors, </FONT></P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">1
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
harness the power of cytotoxic T&nbsp;cells in fighting cancer. Despite demonstrating compelling efficacy, they are only effective in a subset of patients. To address a broader patient
population, we believe additional T&nbsp;cell-based approaches are needed that more closely mimic the way the immune system recognizes and fights cancer in patients who are responding to immunotherapy. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our decision to develop <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies for the treatment of cancer is based on
our conviction that we can learn from the natural interaction between T&nbsp;cells and tumor cells and harness this information to treat patients by reprogramming their immune systems. We believe that <FONT STYLE="white-space:nowrap">TCR-T</FONT>
therapy combines the benefits of TIL and <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies while uniquely addressing their key limitations. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B>Our Pipeline </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are leveraging our proprietary platform technologies to develop a
robust pipeline of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies with the goal of building our ImmunoBank of TCRs to treat a wide range of tumor types. In addition, we are applying our platform to identify targets and TCRs in therapeutic
areas outside of oncology, such as autoimmune disorders and infectious disease, through strategic partnerships. Our current proprietary pipeline is summarized in the figure below. </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g06m17.jpg" ALT="LOGO">
 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">TSC-200 will only be developed in HPV-positive cancers, which include head &amp; neck,
cervical, and anal cancers. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">For additional information regarding the targets for TSC-201 and TSC-202, see
&#147;Business - Solid Tumor Program - TSC-200 Series.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Acute myeloid leukemia, or AML; myelodysplastic syndrome, or MDS; and acute lymphocytic
leukemial, or ALL. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Non-small cell lung cancer, or NSCLC. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition to our proprietary pipeline programs noted above, we also are in the discovery phase for our TSC-102
program. Beyond our proprietary pipeline programs, we have also entered into collaborations with strategic partners for applications of our platform technologies. We have a collaboration and license agreement with Novartis to identify novel cancer
antigens from the T&nbsp;cells of patients with one specific type of cancer. Novartis has the option to license and develop therapies for up to three discovered targets. In addition, we have partnered with QIAGEN Sciences, LLC to develop a highly
specific diagnostic test to determine prior exposure to SARS-CoV-2 based on the presence of anti-viral T cells. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our
Approach </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our approach is based on the central premise that we can <B>learn</B> from patients who are
winning their fight against cancer in order to <B>treat</B> those who are not. Using our proprietary platform technologies, we are analyzing the T&nbsp;cells of cancer patients with exceptional responses to immunotherapy to discover clinically
relevant targets and TCRs. We are building ImmunoBank with the goal of delivering customized multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy to a wide range of patients with cancers. </FONT></P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">2
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Learning </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">When a patient responds to an immunotherapy drug such as an immune checkpoint inhibitor, their tumor shrinks because T
cells in their tumor become activated and drive an anti-tumor cytotoxic response. The TCRs of their T cells recognize tumor-specific antigens on tumor cells and signal the T cell to kill the cancer cells. Our approach starts with isolating
clinically active anti-cancer T cells from tumor samples of patients who are actively responding to immunotherapy agents. We then use our proprietary TargetScan technology to determine the precise targets being recognized by their TCRs. This
provides us with a novel TCR/target pair that can be developed into a <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidate. We select TCRs that are highly active with no apparent problematic
<FONT STYLE="white-space:nowrap">off-target</FONT> effects to be added to our ImmunoBank. In addition to discovering novel TCR/target pairs, we are leveraging our proprietary ReceptorScan technology to identify highly active TCRs against previously
identified and clinically validated targets. The diagram below illustrates our proprietary discovery process where therapeutic TCR candidates are discovered using either TargetScan or ReceptorScan and those that we characterize as the best TCRs are
added to ImmunoBank. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Our Proprietary Target and TCR Discovery Process </B></FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g01a22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Treating </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our discovery process enables us to build and expand ImmunoBank with what we believe represents the most active TCRs
isolated from a large group of diverse patients who are responding to immunotherapy. We are developing <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies that use these clinically relevant TCRs to reprogram the T cells of patients who do not
spontaneously generate effective anti-cancer T cells and thus do not respond to immunotherapy. Our manufacturing process begins with obtaining white blood cells from either the patient or a healthy donor using a procedure called leukapheresis. We
will then transport these white blood cells to our <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing facility, where we isolate the T cells and genetically engineer them using TCR sequences from ImmunoBank. We believe the continued
expansion and diversification of ImmunoBank will enable us to deliver customized multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy to patients, where each patient&#146;s T cells are engineered with multiple TCRs that are matched to
their specific tumor and HLA type. Once the T cells are engineered with a combination of the most relevant TCRs, they will be transported back to the hospital and reintroduced into the patient by intravenous
</FONT></P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">3
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
infusion. Following the infusion, the engineered T cells, which are designed to recognize multiple targets expressed by the patient&#146;s tumor, will proliferate <I>in vivo</I> and mount an
anti-cancer immune response. Our patient treatment and manufacturing process is summarized in the graphic below. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#32406b"><B>Our Patient Treatment and Manufacturing Process </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g21x97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We believe that our approach provides us with the following key advantages:
</FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies are based on highly active
TCRs that are clinically relevant.</I><B> </B>Many other approaches to T cell therapy rely on specifically expanding T cells that are already present in the patient. Our platform analyzes anti-cancer T cells from a wide variety of patients who are
responding to immunotherapy in order to find the most active and clinically relevant TCRs against each target. We believe this will allow us to develop <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies for a wide range of patients, including
those who do not have T cells that efficiently recognize their cancers. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies are designed to be used in
combination with each other.</I><B> </B>We are building our diverse ImmunoBank of TCRs to allow for multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy, which has the potential to address the heterogeneous nature of solid tumors and to
prevent resistance developing due to loss of a single target. We believe this approach may allow us to overcome the limitations and challenges of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy development to date.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Our approach is expandable.</I><B> </B>ImmunoBank has the flexibility to be used with
new and optimized methods of T cell engineering that we may develop over time. We are building ImmunoBank to be compatible with both autologous and allogeneic engineering technologies in order to potentially transition to generating <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf,</FONT></FONT> allogeneic T cells that have been <FONT STYLE="white-space:nowrap">pre-engineered</FONT> with our TCRs for direct administration to patients.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our Platform </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our proprietary platform is designed to: (i)&nbsp;discover anti-cancer TCRs from patients with exceptional responses to
immunotherapy; (ii)&nbsp;determine novel targets of clinically relevant TCRs; (iii)&nbsp;discover novel TCRs </FONT></P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">4
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
that recognize clinically validated targets; (iv)&nbsp;identify <FONT STYLE="white-space:nowrap">off-targets</FONT> of TCRs to eliminate candidates that could potentially pose a safety risk; and
(v)&nbsp;manufacture TCR-T therapies efficiently and consistently without the use of viral vectors using our T-Integrate technology. The three central elements of our platform that differentiate us from other cell therapy companies are TargetScan,
ReceptorScan, and <FONT STYLE="white-space:nowrap">T-Integrate.</FONT> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>TargetScan.</I> At the core of our
proprietary platform is our TargetScan technology that enables us to identify the natural target of a TCR using an unbiased, genome-wide, high-throughput screen. We have developed this technology to be extremely versatile and applicable across
multiple therapeutic areas, including cancer, autoimmune disorders, and infectious diseases. It can be applied to virtually any TCR that plays a role in the cause or prevention of disease. TargetScan is also designed to identify potential <FONT
STYLE="white-space:nowrap">off-targets</FONT> of a TCR and eliminate those TCR candidates that cross-react with proteins expressed at high levels in critical organs. We believe this will allow us to reduce the risk and enhance the potential safety
profile of our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates early in development before we initiate clinical trials. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>ReceptorScan. </I>To further expand our ability to discover and develop therapeutic TCRs, we have developed our
proprietary ReceptorScan technology to enable us to identify and clone highly active TCRs that recognize previously identified clinically validated targets. We <FONT STYLE="white-space:nowrap">co-culture</FONT> hundreds of millions of CD8<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP> T cells from either healthy donors or cancer patients with dendritic cells, that display the target antigen of interest to the T cells. T cells that recognize the target of interest proliferate, and
are subsequently isolated based on their ability to recognize a fluorescently labeled version of the target. We then use single cell sequencing to identify the specific TCR sequences that recognize the target. Our novel technologies allow us to
gene-synthesize hundreds of TCRs simultaneously and to rapidly sort through hundreds of target-specific TCRs in a single high-throughput screen to identify the most active clones. Using ReceptorScan, we have identified our two lead <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates, <FONT STYLE="white-space:nowrap">TSC-100</FONT> targeting <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> targeting <FONT
STYLE="white-space:nowrap">HA-2.</FONT> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I><FONT STYLE="white-space:nowrap">T-Integrate.</FONT> </I>Cell
therapy manufacturing is highly complex, and associated challenges have led to significant delays or failures in the development of many cell therapies. To enable the rapid, cost-effective, and consistent manufacturing of TCRs, we have developed a <FONT
STYLE="white-space:nowrap">non-viral</FONT> vector delivery system that we refer to as <FONT STYLE="white-space:nowrap">T-Integrate.</FONT> Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates are manufactured using a
transposon/transposase system, in which the DNA encoding the TCR is manufactured as a Nanoplasmid, a <FONT STYLE="white-space:nowrap">non-viral</FONT> vector. The Nanoplasmid, together with an mRNA sequence encoding a transposase enzyme, is
introduced into the T cell by electroporation. After the T cell translates the mRNA into protein, the transposase enzyme inserts the TCR sequence from the Nanoplasmid into the genome of the T cell. This system is highly reproducible, as the only
required components are a Nanoplasmid, which is different for each TCR product, and an mRNA, which is constant for all TCR products. Unlike lentivirus, both of these components are routinely manufactured in a cost-effective manner without the need
for extensive process development. We believe our manufacturing platform will enable us to efficiently develop and manufacture many different <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies, allowing us to deliver customized multiplexed
therapy to patients with cancer. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our Programs </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">With our differentiated platform as the foundation, we are building a three-pillar research and development strategy to
create transformational <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies for patients. </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">1.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b"><I>Our Liquid Tumor Program.</I> We are developing our liquid tumor program to treat patients with hematologic malignancies who are undergoing allogeneic HCT. In the first phase of our clinical
development strategy, we are initially focusing on well-recognized cancer targets that have been discovered in patients with exceptional responses to <FONT STYLE="white-space:nowrap">HCT-associated</FONT> immunotherapy, including <FONT
STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2.</FONT> In addition, to further expand our liquid tumor program, we are developing additional product candidates that target other similarly validated antigens,
enabling us to expand the addressable patient population. </FONT></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">5
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We plan to conduct clinical trials of our lead <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates, <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> in parallel, with patients enrolled in treatment arms based on their genotype. Patients
who are positive for the target antigen, <FONT STYLE="white-space:nowrap">HA-1</FONT> or <FONT STYLE="white-space:nowrap">HA-2,</FONT> as well as the <FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> allele, which is the HLA type required to
display <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2</FONT> on the cell surface for recognition by a T cell, will be eligible for enrollment. Furthermore, eligible patients will require donors who are
negative for either the target antigen or the <FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> allele. We plan to incorporate additional product candidates into this trial design as they advance into the clinic, which we believe will allow us to
provide a broad array of therapeutic options for the majority of patients with hematologic malignancies receiving HCT. In our clinical trials of <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> we
also plan to evaluate the potential benefit of combining the two therapies as a multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy for patients who are positive for both <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT
STYLE="white-space:nowrap">HA-2.</FONT> </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Through the development of our liquid tumor program, we are building
a foundation of manufacturing, clinical, and regulatory capabilities, which will be applied to the future development of our broader portfolio of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates for solid tumors. </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">2.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b"><I>Our Solid Tumor Program.</I> We are developing a portfolio of autologous <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates that are designed to be used in combination with each
other to treat and eliminate solid tumors. Our <FONT STYLE="white-space:nowrap">TSC-200</FONT> series of TCR-T therapy candidates are designed to elicit an anti-tumor response in patients by targeting cancer-specific antigens in their tumor cells.
Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates include: (i) either well-recognized cancer targets that have demonstrated anti-tumor activity in clinical trials or novel targets that were identified by TargetScan from the T
cells of patients responding to immunotherapy and (ii)&nbsp;naturally occurring TCRs specific to a patient&#146;s HLA type that recognize these cancer-specific targets. Such targets are not only commonly shared among patients with the same cancer
type, but also frequently expressed in multiple solid tumor types, enabling clinical development across multiple indications. Our first four solid TCR-T therapy candidates include a combination of known targets, such as HPV16 for TSC-200 and PRAME
for TSC-203, as well as targets that are novel antigens for TCR-T therapy, such as for TSC-201 and TSC-202. In addition to our four lead solid TCR-T therapy candidates, we have identified over 40 novel antigens based on tumor samples from patients
who are actively responding to immunotherapy using our TargetScan technology. We are in early stages of analyzing these additional novel antigens and plan to advance those that we believe have the best potential as a TCR-T product candidate into
preclinical development. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our vision is to create and continuously expand ImmunoBank to enable
customized multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy for a wide range of solid tumor patients. For each patient with a solid tumor malignancy, we plan to analyze their tumor to determine which targets are expressed at high
levels in their particular cancer. We will then access ImmunoBank and select up to three TCRs that match their HLA type and address the most highly expressed targets in their tumor. We will use this set of TCRs to genetically reprogram their T cells
to recognize these targets, and the resulting T cells will be infused back into the patient as a multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">3.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b"><I>Strategic Partnerships and Collaborations.</I> T cells play a fundamental role in many other therapeutic areas beyond cancer, such as autoimmune disorders and infectious disease. We believe that
our TargetScan technology is well suited to discover novel antigens for the development of therapeutics, diagnostics, and vaccines in these other therapeutic areas. We intend to opportunistically pursue collaborations with strategic partners for
applications of our platform technologies outside our core focus of oncology. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our Strategy </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our mission is to create life-changing <FONT STYLE="white-space:nowrap">T-cell</FONT> therapies for patients by
unleashing the untapped potential of the human immune system. Our goal is to use our proprietary platform for the identification of novel </FONT></P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">6
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
<FONT STYLE="white-space:nowrap">tumor-specific</FONT> antigens and clinically active TCRs to become a leader in the development of engineered <FONT STYLE="white-space:nowrap">T-cell</FONT>
therapies for the treatment of liquid and solid tumors. Our strategy includes the following key elements: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Leverage our proprietary platform technologies to build our diverse ImmunoBank of
therapeutic TCRs to treat a wide range of tumor types; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Advance our lead liquid tumor product candidates,
<FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> through clinical development; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Apply experience from our liquid tumor program to efficiently develop our solid tumor
program targeting both novel and previously identified antigens; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Continue to develop internal manufacturing capabilities based on our <FONT
STYLE="white-space:nowrap">non-viral</FONT> <FONT STYLE="white-space:nowrap">T-Integrate</FONT> system; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Develop next generation <FONT STYLE="white-space:nowrap">T-cell</FONT> engineering
capabilities, including allogeneic technologies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Opportunistically pursue strategic partnerships and collaborations to maximize the full
potential of our platform in therapeutic areas outside of oncology, such as autoimmune disorders and infectious disease. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B>Our History and Team </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We were founded in early 2018 to discover and develop
transformational therapies using a novel <FONT STYLE="white-space:nowrap">T-cell</FONT> target discovery platform developed by Drs. Stephen Elledge and Tomasz Kula at Brigham and Women&#146;s Hospital and Harvard Medical School. Since then, we have
made substantial progress building our target and TCR discovery platform technologies, discovering new targets and TCRs, advancing our two lead programs into <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, developing <FONT
STYLE="white-space:nowrap">in-house</FONT> manufacturing capabilities, and, in response to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, identifying the targets of T cells from recovering
<FONT STYLE="white-space:nowrap">COVID-19</FONT> patients. In addition, we have entered into multiple strategic collaborations, including with Novartis Institutes for Biomedical Research, Inc. and QIAGEN Sciences, LLC. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have assembled a highly qualified team with deep experience in <FONT STYLE="white-space:nowrap">T-cell</FONT>
biology, high throughput screening, engineering and manufacturing of cell therapies, as well as in all phases of research and clinical development, from early-stage discovery and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies through
registrational clinical trials. Our team includes industry veterans with prior experience at academic and research institutions such as Harvard University, Harvard Medical School, and Massachusetts General Hospital, and companies such as BlueRock
Therapeutics, LLC, CRISPR Therapeutics, Inc., Editas Medicine, Inc., Human Genome Sciences, Inc., Kite Pharma, Inc., KSQ Therapeutics, Inc., Merrimack Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Repertoire Immune Medicines, Inc., and SQZ
Biotechnologies Company. Our research efforts also benefit from the informal advice and guidance provided by our scientific advisory board (SAB) members, including Drs. Elledge and Kula, who receive equity and/or cash compensation. Since our
inception, we have raised an aggregate of $160&nbsp;million from leading biotechnology investors, including RA Capital Management, Novartis Venture Fund, Novartis Institutes for Biomedical Research, Longwood Fund, Bessemer Venture Partners, GV, 6
Dimensions Capital, Astellas Venture Management, and Pitango HealthTech. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Associated with Our Business
</B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Investing in our common stock involves substantial risk. Our ability to execute our business strategy is
subject to numerous risks, as more fully described in the section entitled &#147;Risk Factors&#148; immediately following this prospectus summary. Some of the most significant challenges and risks are more fully described in the section entitled
&#147;Risk Factors&#148; and are summarized in the section entitled &#147;Risk Factors&#151;Risk Factor Summary.&#148; </FONT></P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">7
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Corporate Information </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We were incorporated in the State of Delaware in April 2018. Our principal executive offices are located at 830 Winter
Street, Waltham, Massachusetts 02451. Our telephone number is (857) <FONT STYLE="white-space:nowrap">399-9500.</FONT> Our website address is www.tscan.com. Information contained on the website is not incorporated by reference into this prospectus,
and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As a company with less than $1.07&nbsp;billion in revenue during our most recently completed fiscal year, we qualify as
an &#147;emerging growth company&#148; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company,
we may take advantage of certain exemptions from requirements that are otherwise applicable, in general, to public companies. These provisions include: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">being permitted to present only two years of audited financial statements in addition to
any required unaudited interim financial statements with correspondingly reduced disclosure in the section titled &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148;, in registration statements,
including this prospectus, subject to certain exceptions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">an exemption from compliance with the auditor attestation requirement on the effectiveness
of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">an exemption from compliance with any requirement that the Public Company Accounting
Oversight Board may adopt regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">reduced disclosure about our executive compensation arrangements in our periodic reports,
proxy statements, and registration statements, including this prospectus; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">exemptions from the requirements to obtain a
<FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation or a stockholder approval of any golden parachute arrangements; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">extended transition periods for complying with new or revised accounting standards.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We will remain an emerging growth company until the earliest to occur of: (i)&nbsp;the
last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least $700&nbsp;million of equity securities held by <FONT
STYLE="white-space:nowrap">non-affiliates;</FONT> (iii)&nbsp;the date on which we have issued, in any three-year period, more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (iv)&nbsp;the last
day of the fiscal year ending after the fifth anniversary of the completion of this offering. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may take
advantage of these exemptions until such time that we are no longer an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.
Further, pursuant to Section&nbsp;107 of the JOBS Act, as an emerging growth company, we have elected to take advantage of the extended transition period for complying with new or revised accounting standards until those standards would otherwise
apply to private companies. As a result, our operating results and consolidated financial statements may not be comparable to the operating results and financial statements of other companies who have adopted the new or revised accounting standards.
It is possible that some investors will find our common stock less attractive as a result, which may result in a less active trading market for our common stock and higher volatility in our stock price. </FONT></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">8
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are also a &#147;smaller reporting company,&#148; meaning that the
market value of our stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue was less than $100 million during the most recently completed
fiscal year. We may continue to be a smaller reporting company after this offering if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most
recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions
from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our future annual
reports on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For certain risks related to our status as an emerging growth company and a smaller reporting company, see the section
titled &#147;Risk Factors&#151;Risks Related to Our Common Stock and this Offering&#151;We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company,&#148; and we cannot be certain if the reduced reporting applicable to
emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.&#148; </FONT></P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">9
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>THE OFFERING </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Common stock offered by us</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">6,666,667 shares</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Option to purchase additional shares of common stock from us</FONT></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">1,000,000 shares</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Common stock to be outstanding after this offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">18,798,733 shares, or 19,798,733 shares if the underwriters exercise their option to purchase additional shares of common stock in full</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Non-voting common stock to be outstanding after this
offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">5,139,633 shares</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total common stock and non-voting common stock to be outstanding after this
offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">23,938,366 shares, or 24,938,366 shares if the
underwriters exercise their option to purchase additional shares of common stock in full</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Directed Share Program</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">At our request, the underwriters have reserved up to 333,333 shares, or up to 5% of the shares offered by this prospectus, for sale at the initial public offering price through a directed share program to
certain of our directors, officers, employees and business associates and other parties related to us. If purchased by these persons, these shares will be subject to a <FONT STYLE="white-space:nowrap">180-day</FONT>
<FONT STYLE="white-space:nowrap">lock-up</FONT> restriction.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">The number of shares available for sale to the general public will be reduced to the extent that such persons purchase such reserved shares. Any reserved shares not so purchased will be offered by the
underwriters to the general public on the same basis as the other shares offered by this prospectus. Morgan Stanley &amp; Co. LLC will administer our directed share program. See the sections titled &#147;Certain Relationships and Related Party
Transactions&#148; and &#147;Underwriters&#151;Directed Share Program.&#148;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Use of proceeds</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">We estimate that the net proceeds from the sale of 6,666,667 shares of common stock in this offering will be approximately $90.1 million (or approximately $104.1 million if the underwriters exercise their
option to purchase additional shares in full), based upon the initial public offering price of $15.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">We intend to use the net proceeds from this offering, together with our existing cash, to conduct clinical trials for TSC-100, <FONT STYLE="white-space:nowrap">TSC-101,</FONT> and TSC-102, conduct IND-enabling
activities and initiate clinical trials for TSC-200, TSC-201, TSC-202 and TSC-203, continue</FONT></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">10
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">development of our preclinical discovery programs and platform technologies, further expansion of our existing manufacturing facility, as well as for working capital and other general corporate purposes. See
the section titled &#147;Use of Proceeds&#148; for additional information.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Risk factors</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of risks you should carefully consider before investing in our common stock.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Nasdaq trading symbol</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&#147;TCRX&#148;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The number of shares of our common stock and non-voting common stock to be outstanding
after this offering is based on 17,271,699 shares of our common stock outstanding as of March&nbsp;31, 2021, after giving effect to the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 15,616,272 shares of
common stock (of which 5,139,633 shares will be non-voting common stock) upon the completion of this offering, and excludes the following: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">2,525,506 shares of common stock issuable upon the exercise of options outstanding under
our 2018 Stock Plan, as amended, or the 2018 Plan, as of March&nbsp;31, 2021, with a weighted-average exercise price of $4.98 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">150,889 shares of common stock reserved for future issuance under our 2018 Plan, based on
the number of shares available for issuance as of March&nbsp;31, 2021, which shares will be added to the shares to be reserved under our 2021 Plan, at the time our 2021 Plan becomes effective in connection with this offering;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">3,278,048 shares of common stock that will become available for future issuance under our
2021 Plan, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021
Plan; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">254,390 shares of common stock that will become available for future issuance under our
2021 Employee Stock Purchase Plan, or the 2021 ESPP, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock
reserved for future issuance under the 2021 ESPP. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Unless otherwise indicated, all
information in this prospectus reflects and assumes: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a 1-for-8.2 reverse stock split of our common stock and our preferred stock which became
effective on May&nbsp;13, 2021; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the filing and effectiveness of our amended and restated certificate of incorporation and
the adoption of our amended and restated bylaws, each of which will occur immediately prior to the completion of this offering; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">no exercise of the underwriters&#146; option to purchase additional shares of common stock;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">no exercise of the outstanding options described above after March 31, 2021.
</FONT></P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">11
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>The following tables set forth a summary of our historical consolidated financial data as of, and for, the periods
ended on the dates indicated. The summary consolidated statements of operations data for the years ended December&nbsp;31, 2019 and 2020 are derived from our audited financial statements and related notes included elsewhere in this prospectus. The
consolidated statement of operations data for the three months ended March 31, 2020 and 2021 and the consolidated balance sheet data as of March 31, 2021 have been derived from our unaudited condensed consolidated financial statements included
elsewhere in this prospectus. The unaudited interim financial statements have been prepared on the same basis as our audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring
adjustments that are necessary to state fairly the unaudited interim financial statements. You should read these summary consolidated financial data together with our financial statements and related notes appearing elsewhere in this prospectus and
the information in the section titled &#147;Management&#146;s discussion and analysis of financial condition and results of operations.&#148; The summary consolidated financial data in this section are not intended to replace our consolidated
financial statements and the related notes and are qualified in their entirety by the consolidated financial statements and related notes included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results to
be expected in the future and the results for the three months ended March 31, 2021 are not necessarily indicative of results to be expected for the full year or any other period. </I></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Three Months Ended<BR>March 31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>(in thousands, except share and per share
data)</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Statement of operations data:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Revenue:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Collaboration and license revenue</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,085</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">20,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">General and administrative</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,741</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,606</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">14,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">27,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9,945</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(14,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(26,233</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other income:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Interest income</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(13,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(26,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(35.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(28.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(6.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Weighted average common shares outstanding, basic and
diluted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">385,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">916,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">776,769</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,218,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>As of March&nbsp;31, 2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Pro<BR>forma(1)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Pro&nbsp;forma&nbsp;as<BR>adjusted(2)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands, except share and<BR>per share data)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Balance sheet data:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">121,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">121,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">211,601</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Working capital(3)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">105,035</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">105,035</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">195,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">140,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">140,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">231,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Convertible preferred stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">159,411</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(51,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(51,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(51,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total stockholders&#146; (deficit) equity</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(49,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">109,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">199,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">12
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #32406b;BORDER-LEFT:1.00pt solid #32406b;BORDER-RIGHT:1.00pt solid #32406b;BORDER-TOP:1.00pt solid #32406b;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #32406b;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Pro forma balance sheet data gives effect to the automatic conversion of all outstanding
shares of our convertible preferred stock, into an aggregate of 15,616,272 shares of common stock (of which 5,139,633 shares will be non-voting common stock) upon completion of this offering, as if such conversion had occurred on March&nbsp;31,
2021. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">The pro forma as adjusted column gives further effect to the sale and issuance of
6,666,667 shares of our common stock by us in this offering at the initial public offering price of $15.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">We define working capital as current assets less current liabilities.
</FONT></P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">13
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_2"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described
below, together with all of the other information in this prospectus, including &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and the accompanying
notes included elsewhere in this prospectus before deciding whether to invest in shares of our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of or that
we deem immaterial may also become important factors that adversely affect our business. If any of the following risks actually occur, our business, financial condition, liquidity, operating results, and prospects could be materially and adversely
affected. In that event, the market price of our common stock could decline, and you could lose part or all of your investment. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>RISK FACTOR SUMMARY </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our business operations are subject to numerous risks and uncertainties, including those outside of our control, that
could cause our actual results to be harmed, including risks regarding the following: </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to Our Business and
Industry </B></FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Our business depends upon the success of our proprietary platform.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Our limited operating history may make it difficult to evaluate the success of our
business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">We have incurred significant losses since inception, and we expect to incur losses over the
next several years and may not be able to achieve or sustain revenues or profitability in the future. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">We have never generated, and may never generate, any revenue from sales of cell therapy
products. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Even if this offering is successful, we will need to obtain substantial additional funding
to complete the development and any commercialization of our product candidates, if approved. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Raising additional capital may cause dilution to our existing stockholders, restrict our
operations or require us to relinquish rights to our intellectual property or product candidates on unfavorable terms. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B>Risks Related to the Development of Our Product Candidates </B></FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Our approach to the discovery and development of product candidates based on our
proprietary platform represents a novel approach to cancer treatment, which creates significant challenges for us. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">If we are unable to advance our product candidates through clinical development, obtain
regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Although many of our personnel have extensive experience in clinical development and
manufacturing at other companies, we have no direct experience as a company in conducting clinical trials or managing a manufacturing facility for our product candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety,
potency and purity of any of our product candidates, which would prevent or delay development, regulatory approval and commercialization. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Our business could be adversely affected by the effects of health epidemics, including the
evolving effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and responses thereto. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">We may rely on third parties to manufacture our clinical product supplies, and we may rely
on third parties to produce and process our product candidates, if licensed. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">14
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Our product candidates may cause undesirable side effects or have other properties that
could halt their clinical development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential, or result in significant negative consequences. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">If we encounter difficulties enrolling patients in our clinical trials, our clinical
development activities could be delayed or otherwise adversely affected. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">The market opportunities for our product candidates may be relatively small and our
estimates of the prevalence of our target patient populations may be inaccurate. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">We face significant competition, and our operating results will suffer if we fail to
compete effectively. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to Manufacturing </B></FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Manufacturing and administering our product candidates is complex and we may encounter
difficulties in production. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">We plan to expand our existing manufacturing facility and infrastructure in lieu of relying
on third parties for the manufacture of our product candidates for certain clinical purposes, which will be costly and time-consuming and may not be successful. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">We may have difficulty validating our manufacturing process as we manufacture TCR-T therapy
candidates from an increasingly diverse patient population for our clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to
Government Regulation </B></FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">The FDA regulatory approval process is lengthy and time-consuming, and we may experience
significant delays in the clinical development and regulatory approval of our product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">We may be unable to obtain regulatory approval for our product candidates under applicable
regulatory requirements. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction
does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Recently enacted and future legislation may increase the difficulty and cost for us to
obtain marketing approval for and commercialize our product candidates and affect the prices we may obtain. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to Our Intellectual Property </B></FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">If we are unable to obtain and maintain patent protection for any product candidates we
develop and for our technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products, product candidates and technology similar or identical to ours, and our ability to
successfully commercialize any product candidates we may develop may be adversely affected. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">We are currently, and expect in the future to be, party to material license or
collaboration agreements. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Third party claims of intellectual property infringement, misappropriation or other
violations may prevent or delay our product discovery and development efforts. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to Our
Reliance on Third Parties </B></FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">If the third parties we plan to rely on to conduct our clinical trials do not properly and
successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">15
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">We may not realize the benefits of our current or future collaborations, alliances, or
licensing arrangements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to Our Business and Industry </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our business depends upon the success of our proprietary platform. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our success depends on our ability to use our proprietary platform to discover the natural targets of clinically relevant
TCRs through our TargetScan technology, to discover highly active TCRs for known targets through our ReceptorScan technology, to genetically engineer patient- or donor-derived T cells safely and reproducibly through our <FONT
STYLE="white-space:nowrap">T-Integrate</FONT> technology, to obtain regulatory approval for product candidates derived from our proprietary platform and related technologies, and to then commercialize our product candidates addressing one or more
indications. All of our product candidates will require significant additional clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> development, review and approval by the FDA or other regulatory authorities in one or more
jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before they can be successfully commercialized. Our platform and our product candidates have not yet been evaluated in
humans and may never become commercialized. Moreover, all of our current product candidates are being developed using our proprietary platform and leveraging the same or similar technology, manufacturing process and development program. As a result,
an issue with one product candidate or failure of any one program to obtain regulatory approval could adversely impact our ability to successfully develop and commercialize all of our other product candidates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, the success of our proprietary platform in discovering novel targets for
<FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy is dependent on us obtaining tumor samples from cancer patients who actively respond to cancer immunotherapies.&nbsp;If our ability to obtain a significant amount of such tumor samples in a
timely manner is compromised due to unforeseen circumstances, we may not be successful in discovering novel targets and creating new product candidates based on such targets. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our limited operating history may make it difficult to evaluate the success of our business to date and to assess
our future viability. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are a preclinical-stage immunotherapy company with a limited operating
history. We commenced operations in April 2018, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications,
identifying potential product candidates, undertaking preclinical studies, entering into collaborations, establishing manufacturing for initial quantities of our product candidates, and establishing arrangements for component materials for such
manufacturing. All of our product candidates are still in preclinical development. We have not yet demonstrated our ability to successfully initiate, conduct or complete any clinical trials, obtain marketing approvals, manufacture clinical or
commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions about our future success or
viability may not be as accurate as they could be if we had a longer operating history. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, as a
young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We eventually may need to transition at some point from a company with a research and development focus to a company
capable of supporting commercial activities. We may not be successful in such a transition. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We expect our
financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, the results of any quarterly or annual periods
should not be relied upon as indications of future operating performance. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">16
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We have incurred significant losses since inception, and we expect to
incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Investment in biopharmaceutical product development is a highly speculative undertaking and entails substantial upfront
capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We are still in the early stages of
development of our product candidates and have not yet initiated our first clinical trial. We have no products licensed for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research
and development and other expenses related to our ongoing operations. We have financed our operations primarily through private placements of our preferred stock. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have incurred significant net losses in each period since our inception in April 2018. For the years ended
December&nbsp;31, 2019 and 2020, we reported net losses of $13.7&nbsp;million and $26.1&nbsp;million, respectively, and $7.9 million for three months ended March 31, 2021. As of March&nbsp;31, 2021, we had an accumulated deficit of
$51.4&nbsp;million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and as we: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">continue our research and development efforts to identify and develop lead product
candidates and submit investigational new drug applications, or INDs, for such lead product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">conduct preclinical studies and commence clinical trials for our current and future product
candidates based on our proprietary platform; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">develop processes suitable for manufacturing and clinical development
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">continue to develop and then expand our manufacturing capabilities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">seek marketing approvals for any product candidates that successfully complete clinical
trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">build commercial infrastructure to support sales and marketing for our product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">expand, maintain and protect our intellectual property portfolio;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">hire additional clinical, regulatory and scientific personnel; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">operate as a public company. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Because of the numerous risks and uncertainties associated with biopharmaceutical product research and development, we
are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we succeed in commercializing one or more of our product candidates, we will continue to
incur substantial research and development and other expenditures to develop, seek regulatory approval for, and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors
that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue
to have an adverse effect on our stockholders&#146; equity and working capital. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We have never
generated any revenue from sales of cell-therapy products and our ability to generate revenue from cell-therapy product sales and become profitable depends significantly on our success in a number of areas. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue
from sales of any of our product candidates. We do not expect to generate significant revenue unless or until we successfully complete clinical development and obtain regulatory approval of, and then successfully commercialize, at least one of our
product candidates. All of our product candidates are in the preclinical stages of development and will require additional preclinical studies, process development, clinical development, regulatory review and approval, substantial investment, access
to sufficient commercial </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">17
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. None of our product candidates have completed
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. <FONT STYLE="white-space:nowrap">TSC-100,</FONT> one of our lead product candidates targeting <FONT STYLE="white-space:nowrap">HA-1,</FONT> an epitope present on leukemia cells, is in the
early stages of development and has not yet been evaluated in clinical trials and will require additional regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing
efforts before we can generate any revenue from product sales. Our other product candidates are in early preclinical stages. We have not yet administered any of our product candidates in humans and, as such, we face significant translational risk as
our product candidates advance to the clinical stage. Our ability to generate revenue depends on a number of factors, including, but not limited to: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to develop processes suitable for clinical manufacturing and to obtain related
CMC regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">timely completion of our preclinical studies and clinical trials, which may be
significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third party contractors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to complete <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and
successfully submit INDs or comparable applications; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">whether we are required by the U.S. Food and Drug Administration (FDA) or similar foreign
regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory
authorities the safety, potency, purity and acceptable risk to benefit profile of our product candidates or any future product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the prevalence, duration and severity of potential side effects or other safety issues
experienced with our product candidates or future product candidates, if any; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the timely receipt of necessary marketing approvals from the FDA and similar foreign
regulatory authorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the willingness of physicians, operators of clinics and patients to utilize or adopt any of
product candidates or future product candidates to treat liquid or solid tumors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability and the ability of third parties with whom we contract to manufacture adequate
clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with
current good manufacturing practices (cGMP); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to successfully develop a commercial strategy and thereafter commercialize our
product candidates or any future product candidates in the United States and internationally, if licensed for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">patient demand for our product candidates and any future product candidates, if licensed;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to establish, obtain, maintain, protect and enforce intellectual property and
proprietary rights in and to our product candidates or any future product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Many
of the factors listed above are beyond our control, and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or commercialize our product candidates. Even if we are able to commercialize our product
candidates, we may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue
operations without continued funding. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">18
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Even if this offering is successful, we will need to obtain
substantial additional funding to complete the development and any commercialization of our product candidates, if approved. If we are unable to raise this necessary capital when needed, we would be forced to delay, reduce or eliminate our product
development programs, commercialization efforts or other operations. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Since our inception, we have
financed our operations through private placements of preferred stock. The development of biopharmaceutical product candidates is capital intensive and we expect our expenses to increase substantially during the next few years. As our product
candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our clinical, regulatory, quality and manufacturing capabilities. In addition, if we obtain marketing approval for any
of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution. Furthermore, upon the completion of this offering, we expect to incur additional costs associated with
operating as a public company. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of March&nbsp;31, 2021, we had $121.5&nbsp;million in cash and cash
equivalents. Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our anticipated level of operations through at least the next 12 months without the proceeds from this offering. With
the expected net proceeds from this offering, we believe that our cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into 2024. Accordingly, the expected net proceeds from this offering
will not be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates through equity
offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We may also need to raise additional funds sooner if we choose to pursue additional
indications for our product candidates or otherwise expand more rapidly than we presently anticipate. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We
have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements
will depend on many factors, including: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the scope, rate of progress, costs and results of our drug discovery, preclinical
development activities, laboratory testing and clinical trials for our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the number and scope of clinical programs we decide to pursue;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the scope and costs of manufacturing development and commercial manufacturing activities
and our ability to scale them up or out; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other
product candidates and technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cost, timing and outcome of regulatory review of our product candidates, including the
potential for regulatory authorities to require that we conduct more studies and trials than those that we currently expect to conduct and the costs of post-marketing studies or risk evaluation and mitigation strategies that could be required by
regulatory authorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">potential changes in the regulatory environment and enforcement rules;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cost and timing of establishing sales and marketing capabilities, if any of our product
candidates receive marketing approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the costs of preparing, filing and prosecuting patent applications, maintaining, obtaining,
protecting and enforcing our intellectual property and proprietary rights and defending intellectual property-related claims; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to establish and maintain collaborations on favorable terms, if at all;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other
external disruptions on our business, results of operations and financial position; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our efforts to enhance operational systems and our ability to attract, hire and retain
qualified personnel, including personnel to support the development of our product candidates; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">19
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">potential changes in pharmaceutical pricing and reimbursement infrastructure;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the costs associated with being a public company; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cost associated with commercializing our product candidates, if they receive marketing
approval. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Identifying potential product candidates and conducting preclinical studies and
clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval. In addition, our product candidates, if approved, may
not achieve product sales or commercial success. We do not expect to have any products commercially available for sale for many years, if at all. Accordingly, we will need to obtain substantial additional funding in connection with our continuing
operations. Adequate additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market conditions. If we are unable to raise capital when needed or on attractive terms, we would be
forced to delay, limit, reduce or eliminate our research and development programs or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. In
addition, attempting to secure additional financing may divert the time and attention of management from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and distract from our research and
development efforts. We may also seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us
to relinquish rights to our intellectual property or product candidates on unfavorable terms to us. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may seek additional capital through a variety of means, including through collaboration arrangements, public or
private equity or debt financings, third party (including government) funding and marketing and distribution arrangements, as well as other strategic alliances and licensing arrangements or any combination of these approaches. However, there can be
no assurance that we will be able to raise capital on commercially reasonable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholder ownership interest will be
diluted, and the terms may include liquidation preferences or other rights, powers or preferences that may adversely affect rights of our stockholders. To the extent that debt financing is available and we choose to raise additional capital in the
form of debt, such debt financing may involve agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise
additional capital pursuant to collaborations, licensing arrangements or other strategic partnerships, such agreements may require us to relinquish rights to our technologies or product candidates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If we are unable to raise additional funds through equity or debt financing or through collaborations, licensing
arrangements or strategic partnerships when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to the Development of Our Product Candidates </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our approach to the discovery and development of product candidates based on our proprietary platform represents a
novel approach to cancer treatment, which creates significant challenges for us. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our future success
depends on the successful development of our product candidates, which target liquid and solid tumors utilizing <FONT STYLE="white-space:nowrap">T-cell</FONT> receptor therapies, or TCR-T therapies. Advancing our product candidates creates
significant challenges for us, including: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">educating medical personnel about the administration of TCR-T therapies on a stand-alone
basis or in combination with <FONT STYLE="white-space:nowrap">built-in</FONT> immune and tumor modulators; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">20
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">while no such side effects have been observed to date in any of our preclinical studies,
educating medical personnel regarding the potential side effect profile of our product candidates, such as the potential adverse side effects related to cytokine release syndrome (CRS), graft vs. host disease, neurotoxicity or autoimmune or
rheumatologic disorders, which are the most common adverse side effects associated with engineered T-cell therapies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">administering chemotherapy to patients in advance of administering our product candidates,
which may increase the risk of adverse side effects; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">sourcing clinical and, if licensed, commercial, supplies for the materials used to
manufacture and process our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">manufacturing TCR-Ts efficiently and consistently without the use of viral vectors using
our <FONT STYLE="white-space:nowrap">T-Integrate</FONT> technology; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">developing a complete shipment lifecycle and supply chain, including efficiently managing
shipment of patient cells from and to clinical sites, minimizing potential contamination to the cell product and effectively scaling manufacturing capacity to meet demand; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">developing processes suitable for clinical manufacturing and obtaining related CMC
regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">managing costs of inputs and other supplies while scaling production;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">using medicines to manage adverse side effects of our product candidates, which may not
adequately control the side effects and/or may have a detrimental impact on the potency of the treatment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">obtaining and maintaining regulatory approval from the FDA for our product candidates; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">establishing sales and marketing capabilities upon obtaining any regulatory approval to
gain market acceptance of a novel therapy. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In developing our product candidates, we have
not exhaustively explored different options in the design of the TCR construct and in the method for manufacturing <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies. We may find our existing TCR-T therapy candidates and manufacturing process
may be substantially improved with future design or process changes, necessitating development of new or additional TCR constructs and further clinical testing and delaying commercial launch of our first products. For example: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">We have made several TCR constructs and used preclinical studies to select product
candidates to advance into clinical trials. The preclinical studies are limited in their ability to predict behavior in patients. As we gain experience working with TCR constructs, we may decide to select other TCR constructs for clinical
development. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">The process by which patient cells are converted into a TCR-T product has many steps that
can influence quality and activity. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have explored a subset of variables and expect to
continue to improve and optimize the manufacturing process. Depending upon the nature of the process changes, we may be compelled to perform bridging studies and/or to <FONT STYLE="white-space:nowrap">re-start</FONT> clinical development, causing
delays in time to market and potentially introducing a risk of failure if new processes do not perform as expected. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>We are very early in our development efforts. All of our product candidates are still in preclinical development. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and
ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are very early in our development efforts. All of our product candidates are still in preclinical development, with <FONT
STYLE="white-space:nowrap">TSC-100,</FONT> our most advanced product candidate, still in preclinical development and not having completed <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. Our ability to generate product revenues, which
we do not expect will </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">21
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
occur for many years, if ever, will depend significantly on the successful development and eventual commercialization of one or more of our product candidates. The success of our product
candidates will depend on several factors, including the following: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">successful development of a process suitable for clinical manufacturing
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">successful completion of preclinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">successful initiation of clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">successful patient enrollment in and completion of clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">receipt and related terms of marketing approvals and licensures from applicable regulatory
authorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for
our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">making arrangements with third party manufacturers, or establishing manufacturing
capabilities, for both clinical and commercial supplies of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">establishing sales, marketing and distribution capabilities and launching commercial sales
of our product candidates, if and when approved, whether alone or in collaboration with others; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">acceptance of our product candidates, if and when approved, by patients, the medical
community and third party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">effectively competing with other cancer therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">obtaining and maintaining third party coverage and adequate reimbursement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">maintaining a continued acceptable safety profile of our product candidates following
licensure; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">effectively competing with other therapies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays
or be unable to successfully commercialize our product candidates, which would materially harm our business. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Although many of our personnel have extensive experience in clinical development and manufacturing at other
companies, we have no direct experience as a company in conducting clinical trials and little direct experience managing a manufacturing facility for our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Although many of our personnel have extensive experience in clinical development and manufacturing at other companies, we
have no direct experience as a company in conducting clinical trials at TScan. In part because of this lack of experience, we cannot be certain that our ongoing preclinical studies will be completed on time or if the planned preclinical studies and
clinical trials will begin or be completed on time, if at all. Large-scale clinical trials would require significant additional financial and management resources and reliance on third party clinical investigators, contract research organizations
(CROs) and consultants. Relying on third party clinical investigators, CROs and consultants may force us to encounter delays that are outside of our control. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We currently intend to further expand our existing cell manufacturing facility for Phase 1 and Phase 2 clinical trials,
which will require significant resources, and we have limited direct experience as a company in expanding or managing a manufacturing facility. In part because of this lack of experience, we cannot be certain that the further expansion of our
existing manufacturing facility will be completed on time, if at all, or if the planned clinical trials will begin or be completed on time, if at all. In part because of our inexperience, we may have unacceptable or inconsistent product quality
success rates and yields, and we may be unable to maintain adequate quality control, quality assurance and qualified personnel. In addition, if we switch from manufacturing in our own facility to manufacturing in a different facility (for example,
at an external contract manufacturing </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">22
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
organization) for one or more of our product candidates in the future or make changes to our manufacturing process, we may need to conduct additional preclinical studies to bridge our modified
product candidates to earlier versions. Failure to successfully further expand our existing manufacturing facility could adversely affect our process and clinical development timelines, regulatory approvals, and the commercial viability<B><I>
</I></B>of our product candidates. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our business is highly dependent on our current product candidates,
<FONT STYLE="white-space:nowrap">TSC-100,</FONT> <FONT STYLE="white-space:nowrap">TSC-101,</FONT> <FONT STYLE="white-space:nowrap">TSC-102,</FONT> <FONT STYLE="white-space:nowrap">TSC-200,</FONT> <FONT STYLE="white-space:nowrap">TSC-201,</FONT> <FONT
STYLE="white-space:nowrap">TSC-202,</FONT> and TSC-203, and we must complete <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and clinical testing before we can seek regulatory approval and begin commercialization of any of our product
candidates. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">There is no guarantee that any of our product candidates will proceed in preclinical or
clinical development or achieve regulatory approval. The process for obtaining marketing approval for any product candidate is very long and risky and there will be significant challenges for us to address in order to obtain marketing approval as
planned or, if at all. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">There is no guarantee that the results obtained in current preclinical studies or our
planned <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of <FONT STYLE="white-space:nowrap">TSC-100,</FONT> <FONT STYLE="white-space:nowrap">TSC-101,</FONT> <FONT STYLE="white-space:nowrap">TSC-102,</FONT>
<FONT STYLE="white-space:nowrap">TSC-200,</FONT> <FONT STYLE="white-space:nowrap">TSC-201,</FONT> <FONT STYLE="white-space:nowrap">TSC-202,</FONT> and TSC-203 will be sufficient to obtain regulatory approval or marketing authorization for such
product candidates. Negative results in the development of our lead product candidates may also impact our ability to obtain regulatory approval for our other product candidates, either at all or within anticipated timeframes because, although other
product candidates may target different indications, the underlying proprietary platform, manufacturing process and development process is the same for all of our product candidates. Accordingly, a failure in any one program may affect the ability
to obtain regulatory approval to continue or conduct clinical programs for other product candidates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In
addition, because we have limited financial and personnel resources and are placing significant focus on the development of our lead product candidates, we may forgo or delay pursuit of opportunities with other future product candidates that later
prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs
and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular future product candidate, we
may relinquish valuable rights to those future product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to
such future product candidates. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our preclinical studies and clinical trials may fail to demonstrate
adequately the safety, potency and purity of any of our product candidates, which would prevent or delay development, regulatory approval and commercialization. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through
lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Preclinical and clinical testing is expensive and can take many years to complete, and
its outcome is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, and, because our product candidates are in an early stage of development, there is a high risk of failure and we may never
succeed in developing marketable products. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The results of preclinical studies and early clinical trials of
our product candidates may not be predictive of the results of later-stage clinical trials. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials.
Product candidates in later stages of clinical trials may fail to show the desired safety, potency and purity profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical
industry have suffered significant setbacks in advanced clinical trials due to lack of potency or efficacy, insufficient durability </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">23
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
of potency or efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies and clinical trials are never
approved as products. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any preclinical studies or clinical trials that we may conduct may not demonstrate the
safety, potency and purity necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety, potency and purity of
our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing
approval for such product candidates. In some instances, there can be significant variability in safety, potency or purity results between different preclinical studies and clinical trials of the same product candidate due to numerous factors,
including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Clinical development involves a lengthy and expensive process with an uncertain outcome, and results
of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or
experience delays in completing, or ultimately be unable to complete, the development of such product candidate. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We cannot be certain that our preclinical study and clinical trial results will be sufficient to support regulatory approval of our product candidates. Clinical testing is expensive and can take many years to complete, and its
outcome is inherently uncertain. Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Failure or delay can occur at any time during the clinical trial
process. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may experience delays in obtaining the FDA&#146;s authorization to initiate clinical trials
under future INDs, completing ongoing preclinical studies of our other product candidates, and initiating our planned preclinical studies and clinical trials. Additionally, we cannot be certain that preclinical studies or clinical trials for our
product candidates will begin on time, not require redesign, enroll an adequate number of subjects on time, or be completed on schedule, if at all. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures
related to: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the FDA or comparable foreign regulatory authorities disagreeing as to the design or
implementation of our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">delays in obtaining regulatory approval to commence a clinical trial;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the
terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">obtaining institutional review board (IRB) approval at each clinical trial site;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">recruiting or retaining an adequate number of suitable patients to participate in a
clinical trial, including as a result of actions taken by governments and individuals in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">having subjects complete a clinical trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">clinical trial sites deviating from clinical trial protocol or dropping out of a clinical
trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">addressing subject safety concerns that arise during the course of a clinical trial;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">adding a sufficient number of clinical trial sites; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">obtaining sufficient product supply of product candidate for use in preclinical studies or
clinical trials from third party suppliers. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">24
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may experience numerous adverse or unforeseen events during, or as a
result of, preclinical studies and clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">we may receive feedback from regulatory authorities that requires us to modify the design
of our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">clinical trials of our product candidates may produce negative or inconclusive results, and
we may decide, or regulators may require us, to conduct additional clinical trials or abandon our research efforts for our other product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the number of patients required for clinical trials of our product candidates may be larger
than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of our clinical trials at a higher rate than we anticipate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our third party contractors may fail to comply with regulatory requirements, fail to
maintain adequate quality controls or be unable to provide us with sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">we or our investigators might have to suspend or terminate clinical trials of our product
candidates for various reasons, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding that
the participants are being exposed to unacceptable health risks; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cost of clinical trials of our product candidates may be greater than we anticipate;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the effects of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> global
pandemic; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the quality of our product candidates or other materials necessary to conduct preclinical
studies or clinical trials of our product candidates may be insufficient or inadequate; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">regulators may revise the requirements for approving our product candidates, or such
requirements may not be as we anticipate; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our current or future collaborators may conduct clinical trials in ways they view as
advantageous to them but that are suboptimal for us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If we are required to conduct
additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or
tests are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may incur significant additional costs. Accordingly, our clinical trial costs are likely
to be significantly higher than those for more conventional therapeutic technologies or drug product candidates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board (DSMB) for such clinical
trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical
trial protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit
from the product candidates, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If we experience delays in the completion, or termination, of any preclinical study or clinical trial of our product
candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our preclinical
studies or clinical trials may increase our costs, slow down our product </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">25
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial
condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our business could be adversely affected by the effects of health epidemics, including the evolving effects of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in regions where we, our partners or other third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business
operations. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has had and may continue have a material effect on our operations as well as the business or operations of our partners or other third parties with whom we or our partners
conduct business. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Health epidemics in regions where we have concentrations of potential clinical
trial sites or other business operations could adversely affect our business, including by causing significant disruption in the operations of third parties upon whom we rely. For example, the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic has presented a substantial public health and economic challenge around the world and is affecting employees, patients, communities and business operations, as well as the U.S. economy and financial markets. Our headquarters is located in
the Greater Boston Area. In addition, several of our third party suppliers and contractors are located in countries and regions that have been negatively impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic. In March
2020, the U.S. government imposed bans and restrictions on travel between the United States, Asia and certain other continents and countries and other countries have restricted travel to and from the United States. Although, the Commonwealth of
Massachusetts has permitted businesses to <FONT STYLE="white-space:nowrap">re-open</FONT> on a limited basis, we have implemented work-from-home policies for a vast majority of our employees. The effects of our work-from-home policies may negatively
impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of any current or future restrictions and other limitations on our ability to conduct
our business in the ordinary course. In connection with these measures, we may be subject to claims based upon, arising out of or related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and our actions and responses thereto, including any
determinations that we may make to continue to operate or to <FONT STYLE="white-space:nowrap">re-open</FONT> our facilities where permitted by applicable law. These and similar, and perhaps more severe, disruptions in our operations could negatively
impact our business, financial condition, results of operations and growth prospects. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, our
planned clinical trials may be affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak. Site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain
patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and adversely impact our planned clinical trial operations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Furthermore, while the potential economic impact brought by, and the duration of, the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may be difficult to assess or predict, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in
the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially affect our business and the value of our common stock.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">While we expect the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to continue to adversely
affect our business operations, the extent of the impact on our development and regulatory efforts and the future value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with
confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to
contain and treat <FONT STYLE="white-space:nowrap">COVID-19.</FONT> In addition, to the extent the evolving effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business and results of operations, it may
also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#147;Risk Factors&#148; section. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">26
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We may rely on third parties to manufacture our clinical product
supplies, and we may rely on third parties to produce and process our product candidates, if licensed. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We currently intend to establish facilities to manufacture our clinical scale product candidates for our Phase 1 and
Phase 2 clinical trials for <FONT STYLE="white-space:nowrap">TSC-100,</FONT> <FONT STYLE="white-space:nowrap">TSC-101,</FONT> <FONT STYLE="white-space:nowrap">TSC-102,</FONT> <FONT STYLE="white-space:nowrap">TSC-200,</FONT> <FONT
STYLE="white-space:nowrap">TSC-201,</FONT> <FONT STYLE="white-space:nowrap">TSC-202,</FONT> and TSC-203. However, we rely on outside vendors to manufacture supplies for our manufacturing process, and we expect to rely on outside vendors to
manufacture our product candidates for registration-enabling additional clinical trials as well as commercial sales. We have not yet caused any product candidates to be manufactured or processed on a commercial scale and may not be able to do so for
any of our product candidates. We plan to make changes as we work to optimize the manufacturing process. For example, we may switch or be required to switch from research-grade materials to commercial-grade materials in order to get regulatory
approval of our product candidates, which could delay regulatory approval, if any. We cannot be sure that even minor changes in the process will result in therapies that are safe and effective and licensed for commercial sale. In addition, changes
in the manufacturing process may result in the need to conduct additional bridging clinical trials to demonstrate product comparability. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The facilities used by us or any contract manufacturers to manufacture our product candidates must be approved by the
FDA or other foreign regulatory authorities following inspections that will be conducted after we submit an application to the FDA or other foreign regulatory authorities. If we engage contract manufacturers, we may not control the manufacturing
process of, and may be completely dependent on, such contract manufacturing partners for compliance with cGMPs and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of our product candidates. We have
limited control over the ability of any contract manufacturers we engage to maintain adequate quality control, quality assurance and qualified personnel. Even with oversight, the third party may not be able to meet proper quality standard or its
contractual obligations. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative
manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if licensed. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We, and any contract manufacturers we engage for registration-enabling clinical trials, may experience manufacturing
difficulties due to limited manufacturing experience, resource constraints or as a result of labor disputes, the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the U.S.-China trade war or unstable political environments. If we or
any contract manufacturers we engage were to encounter any of these difficulties, our ability to manufacture sufficient product supply for our preclinical studies and clinical trials, or to provide products for patients once approved, would be
jeopardized. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Many of the materials and regents we expect to use in our processes are single or sole source,
and/or have limited stability and as such supply disruptions could materially impact our ability to develop or manufacture products. For example, the type of cell culture media and cryopreservation buffer that we currently use in our manufacturing
process for <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> are each only available from a limited number of suppliers. In addition, the cell processing equipment and tubing that we use in our
current manufacturing process is currently sourced from a single supplier. Any interruption in the supply by those single source suppliers could impact our ability to continue development of any and all of our product candidates on the anticipated
timelines or at all. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We cannot guarantee that our product candidates will show any functionality in
the solid tumor microenvironment. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">There are no approved TCR-T immunotherapies for solid tumors. While
we plan to develop product candidates for use in solid tumors, including <FONT STYLE="white-space:nowrap">TSC-200,</FONT> we cannot guarantee that our product candidates will show any functionality in the solid tumor microenvironment. The cellular
environment in which solid tumor cells thrive is generally hostile to T cells due to factors such as the presence of immunosuppressive cells, humoral factors and limited access to nutrients. Our TCR-T-based product candidates may not be able to
access the solid </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">27
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
tumor, and even if they do, they may not be able to exert anti-tumor effects in a hostile tumor microenvironment. As a result, our product candidates may not demonstrate potency in solid tumors.
If we are unable to make our product candidates function in solid tumors, our development plans and business may be significantly harmed. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Since the number of patients that we plan to dose in our initial clinical trials may be small, the results from
such clinical trial, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder our efforts to obtain regulatory approval for our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The preliminary results of clinical trials with smaller sample sizes can be disproportionately influenced by various
biases associated with the conduct of small clinical trials, such as the potential failure of the smaller sample size to accurately depict the features of the broader patient population, which limits the ability to generalize the results across a
broader community, thus making the clinical trial results less reliable than clinical trials with a larger number of patients. As a result, there may be less certainty that such product candidates would achieve a statistically significant effect in
any future clinical trials. If we conduct any future clinical trials, we may not achieve a statistically significant result or the same level of statistical significance, if any, that we might have anticipated based on the results observed in our
initial clinical trials. In addition, patients who are undergoing allogeneic hematopoietic cell transplantation are very sick and may pass away from complications of their standard clinical transplantation thus making it difficult to ascertain the
beneficial effects of the added <FONT STYLE="white-space:nowrap">T-cell</FONT> therapy. Further, toxicities of the <FONT STYLE="white-space:nowrap">T-cell</FONT> therapy would be difficult to distinguish from the toxicity of the transplantation
itself. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We may not be able to file INDs or IND amendments to commence additional clinical trials on
the timelines we expect, and even if we are able to, the FDA may not permit us to proceed. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We expect
to submit an IND for <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> in the fourth quarter of 2021 and submit IND applications for at least three of our four solid tumor TCR-T therapy candidates in
the second half of 2022, with the fourth IND expected to be filed in 2023. However, we may not be able to file such INDs on the timelines we expect. For example, we may experience manufacturing delays or other delays with <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical
trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future.
These considerations also apply to new clinical trials we may submit as amendments to existing INDs. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In
addition, one of our key goals is to develop treatments consisting of a combination of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies, which we refer to as multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. Our plan is to
assess the safety and preliminary efficacy of multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy early in the clinical development of our product candidates (e.g., Phase 1). We cannot guarantee, however, that the FDA will permit us to
combine our product candidates with each other in a multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy before more extensive safety data are available for each individual product candidate or each variation or combination of a
multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. Any such requirements could result in material delays in the development timelines of our multiplexed TCR-T therapy candidates. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our product candidates may cause undesirable side effects or have other properties that could halt their clinical
development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential, or result in significant negative consequences. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Undesirable side effects caused by our product candidates could cause us or regulatory authorities, including IRBs, to
interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Further, clinical trials by their nature utilize a
sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to
the drug. Because of the design of the dose escalation of our </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">28
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
our planned Phase 1 clinical trials, undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical
trials. Additionally, results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics, which may stem from our therapies specifically or may be due to an illness from which
the clinical trial subject is suffering. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For example, there could be an increased risk of graft-versus-host
disease (GvHD) with the TCR-T treatment. GvHD is a common toxicity in patients undergoing allogeneic hematopoietic stem cell transplantation, the focus of our liquid tumor program. GvHD occurs because donor T cells, which are part of the standard
stem cell product, misrecognize antigens in the patient as foreign and attack tissues and organs that express those antigens. GvHD may be worsened by our TCR-T therapy candidates because they are derived from donor T cells. While the engineered T
cells express a new <FONT STYLE="white-space:nowrap">T-cell</FONT> receptor that is specific for the intended target antigen and is not expected to cause GvHD, those T cells may have low levels of endogenous
<FONT STYLE="white-space:nowrap">T-cell</FONT> receptors that have the potential to misrecognize patient antigens as foreign and worsen GvHD. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In solid tumor patients, autoimmunity may occur after TCR-T treatment. TCR-T therapies are generated from a
patient&#146;s own T cells isolated from their peripheral blood. There is a risk that this process will expand a patient&#146;s own T cell that has autoreactivity, or that may recognize healthy cells, and upon
<FONT STYLE="white-space:nowrap">re-infusion</FONT> may trigger an autoimmune reaction resulting in damage to normal tissues and potentially even death. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Autoimmune reaction triggered by an interaction between a patient&#146;s naturally occurring antibodies and engineered T
cells is a theoretical safety risk of product candidates we develop using our proprietary platform. If a patient&#146;s self-generated antibodies were directed to a target expressed on the surface of cells in normal tissue (autoantibodies),
engineered T cells would be directed to attack these same tissues, potentially resulting in <FONT STYLE="white-space:nowrap">off-tumor</FONT> effects. These autoantibodies may be present whether or not the patient has an active autoimmune disease.
In our clinical testing, we plan to take steps to minimize the likelihood that this occurs, for example by excluding patients with a history of severe autoimmune disease from our trials. There is no guarantee, however, that we will not observe
autoimmune reactions in the future and no guarantee that if we do, that we will be able to implement interventions to address the risk. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, immunogenicity, which is the reaction between a patient&#146;s immune system and a foreign protein outside
of the autoimmune context, is an additional theoretical safety risk of product candidates we develop using our proprietary platform. Patients&#146; immune systems may recognize the TCR construct on the TCR-T product as a foreign protein and fight
against it, potentially rendering it ineffective, or even provoking an allergic/anaphylactoid response or other adverse side effects. The immunogenic potential of novel therapeutics like <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies is
difficult to predict. There is no guarantee that we will not observe immunogenic reactions in the future and no guarantee that if we do, that we will be able to implement interventions to address the risk. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If unacceptable toxicities arise in the development of our product candidates, we could suspend or terminate our
clinical trials or the FDA or comparable foreign regulatory authorities, or local regulatory authorities such as IRBs, could order us to cease clinical trials. Competent national health authorities, such as the FDA, could also deny approval of our
product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. In
addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from <FONT STYLE="white-space:nowrap">T-cell</FONT> therapy are not normally encountered in the general patient
population and by medical personnel. We expect to have to train medical personnel using our product candidates to understand the side effect profile of our product candidates for both our planned clinical trials and upon any commercialization of any
product candidates, if licensed. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient deaths. Any of these occurrences may significantly harm our reputation as well as business,
financial condition and prospects. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">29
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Certain patients may lack sufficient T Cells for our autologous
product candidates to be effective. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For autologous <FONT STYLE="white-space:nowrap">TCR-T</FONT>
therapy, our TCR-T therapy candidates are manufactured by using a vector to insert genetic information encoding the TCR construct into the patient&#146;s own T cells.&nbsp;This manufacturing process is dependent on a collecting a sufficient number
of T cells from the patient.&nbsp;We may not be able to effectively treat some patients if they have an insufficient number of T cells to enable our manufacturing process, which could adversely impact our ability to progress the clinical development
of such product candidates and could also adversely impact the commercial viability of such product candidates. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Our product candidates may target healthy cells expressing target antigens leading to potentially fatal adverse effects. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our product candidates target specific antigens that are also expressed on healthy cells. Our product candidates may
target healthy cells, leading to serious and potentially fatal adverse effects. In our planned clinical trials of our product candidates, we plan to use a dose escalation model to closely monitor the effect of our product candidates on vital organs
and other potential side effects. Even though we intend to closely monitor the side effects of our product candidates in both preclinical studies and clinical trials, we cannot guarantee that products will not target and kill healthy cells.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our product candidates may have serious and potentially fatal cross-reactivity to other peptides or
protein sequences within the body. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our product candidates may recognize and bind to a peptide
unrelated to the target antigen to which it is designed to bind. If this peptide is expressed within normal tissues, our product candidates may target and kill the normal tissue in a patient, leading to serious and potentially fatal adverse effects.
Detection of any cross-reactivity may halt or delay any ongoing clinical trials for any TCR-T therapy candidate and prevent or delay regulatory approval. Unknown cross-reactivity of the TCR-T binding domain to related proteins could also occur. We
have also developed a preclinical screening process to identify cross-reactivity of <FONT STYLE="white-space:nowrap">T-cell</FONT> binders. Any cross-reactivity that impacts patient safety could materially impact our ability to advance our product
candidates into clinical trials or to proceed to marketing approval and commercialization. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>The vectors
used to manufacture our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies may incorrectly modify the genetic material of a patient&#146;s T cells, potentially triggering the development of a new cancer or other adverse events.
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates are manufactured by using a
vector to insert genetic information encoding the TCR construct into the patient&#146;s T cells. The TCR construct is then integrated into the natural TCR complex and transported to the surface of the patient&#146;s T cells. Because the vector
modifies the genetic information of the T cell, there is a risk that modification will occur in the wrong place in the T cell&#146;s genetic code, leading to vector-related insertional oncogenesis, and causing the T cell to become cancerous. If the
cancerous T cell is then administered to the patient with the TCR-T therapy candidates, the cancerous T cell could trigger the development of a new cancer in the patient. We use <FONT STYLE="white-space:nowrap">non-viral</FONT> transposon /
transposase or lentiviral vectors to insert genetic information into T cells. The risk of insertional oncogenesis remains a concern for gene therapy and we cannot assure that it will not occur in any of our ongoing or planned preclinical studies or
clinical trials. There is also the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of vectors used to carry the genetic material.
The FDA has stated that vectors possess characteristics that may pose high risks of delayed adverse events. <FONT STYLE="white-space:nowrap">Non-viral</FONT> transposon/transposase systems have limited clinical history and such their safety profile
is still to be determined . If any such adverse events occur, further advancement of our preclinical studies or clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">30
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If we encounter difficulties enrolling patients in our clinical
trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may
experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of
patients who remain in the clinical trial until its conclusion. The enrollment of patients depends on many factors, including: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the patient eligibility criteria defined in the clinical trial protocol, particularly those
who meet the requisite genetic criteria. For example, for our liquid tumor program, patients would have to be <FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> positive and positive for the minor antigen
<FONT STYLE="white-space:nowrap">HA-1</FONT> or <FONT STYLE="white-space:nowrap">HA-2</FONT> to be eligible for treatment with <FONT STYLE="white-space:nowrap">TSC-100</FONT> or <FONT STYLE="white-space:nowrap">TSC-101,</FONT> respectively;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">for our liquid tumor program, the ability to find a donor who has to be mismatched with the
patient either for the HLA type or the minor antigen type to ensure that the engineered <FONT STYLE="white-space:nowrap">T-cell</FONT> therapy does not recognize donor-derived blood cells; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on clinical
trial initiation and enrollment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the size of the patient population required for analysis of the clinical trial&#146;s
primary endpoints; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the proximity of patients to clinical trial sites; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the design of the clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to recruit clinical trial investigators with the appropriate competencies and
experience; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to obtain and maintain patient consents; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">reporting of the preliminary results of any of our clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">risk that patients enrolled in clinical trials will drop out of the clinical or pass away
from disease-related complications or complications from their standard clinical therapy before they can experience benefits of the engineered <FONT STYLE="white-space:nowrap">T-cell</FONT> therapy ; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">for patients in our solid tumor program, the patients need for sufficient T cells in order
for the engineered <FONT STYLE="white-space:nowrap">T-cell</FONT> product to be manufactured from their autologous T cells. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same
therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our clinical trials may instead opt to enroll in a clinical trial
being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the
number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may
be inclined to use conventional therapies, such as chemotherapy and hematopoietic stem cell transplantation, rather than enroll patients in any future clinical trial. Additionally, because some of our clinical trials are expected to be in patients
with relapsed/refractory cancer, the patients are typically in the late stages of their disease and may experience disease progression independent from our product candidates, making them unevaluable for purposes of the clinical trial and requiring
additional patient enrollment. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Delays in completing patient enrollment may result in increased costs or may
affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these clinical trials and adversely affect our ability to advance the development of our product candidates. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">31
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Research and development of biopharmaceutical products is inherently
risky. We may not be successful in our efforts to use and enhance our TScan technology discovery platform and TCR technologies to create a pipeline of product candidates and develop commercially successful products, or we may expend our limited
resources on programs that do not yield a successful product candidate and fail to capitalize on product candidates or diseases that may be more profitable or for which there is a greater likelihood of success. If we fail to develop additional
product candidates, our commercial opportunity will be limited. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A key element of our strategy is to
use our TScan technology discovery platform to discover the targets of <FONT STYLE="white-space:nowrap">T-cells</FONT> in oncology, autoimmune and infectious disease applications to build a pipeline of novel product candidates. We and our
collaborators are simultaneously pursuing clinical development of multiple product candidates developed employing our TCR technologies. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are at an early stage of development and our TScan technology discovery platform has not yet led, and may never lead,
to approved or commercially successful products. All of our current product candidates are being developed by leveraging the same or similar underlying proprietary platform, manufacturing process and development program. As a result, an issue with
one product candidate or failure of any one program to obtain regulatory approval could lead to a failure of our entire pipeline of product candidates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Even if we are successful in continuing to build our pipeline, obtaining regulatory approvals and commercializing
additional product candidates may require substantial additional funding and are prone to the risks of failure inherent in medical product development. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Investment in biopharmaceutical product development involves significant risk that any potential product candidate will
fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of these additional product candidates
through the development process. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development or commercialization for many reasons, including the
following: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our research methodology, including our screening technology, may not successfully identify
additional product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our pursuit of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-drug</FONT></FONT> targets may make it challenging to design potential product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">results of clinical trials conducted by others on similar indications or on compounds with
similar mechanisms of action could result in our having to conduct additional or cost prohibitive clinical trials, which could delay development and possibly make commercialization prohibitively expensive; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">we may encounter product manufacturing difficulties that limit yield, produce undesirable
characteristics, that increase the cost of goods, cause delays, or make the product candidates unmarketable; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our product candidates may cause adverse effects in patients or subjects, even after
successful initial toxicology studies, which may make the product candidates unmarketable; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our product candidates may not demonstrate a meaningful benefit to patients or subjects;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our collaboration partners may change their development profiles or plans for potential
product candidates or abandon a therapeutic area or the development of a partnered product. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would
have a material adverse effect on our business, operating results and prospects and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We
may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">32
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If we are unable to identify suitable compounds for preclinical and
clinical development, we will not be able to obtain revenues from sale of drugs in future periods, which likely would result in significant harm to our business prospects and financial position. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>The market opportunities for our product candidates may be relatively small as it will be limited to those
patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cancer therapies are sometimes characterized as first line, second line, or third line, and the FDA often approves new
therapies initially only for a particular line of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, antibody
drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation,
antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include hematopoietic stem cell transplantation in certain cancers, chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more
invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates in most instances at least as a second or third line therapy, for use in patients to prevent relapse in patients undergoing hematopoietic
stem cell transplantation. Subsequently, for those product candidates that prove to be sufficiently safe and beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no
guarantee that our product candidates, even if licensed as a second or third or subsequent line of therapy, would be licensed for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.
Consequently, the potentially addressable patient population for our product candidates may be extremely limited or may not be amenable to treatment with our product candidates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with
these cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of
sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of the cancers that we are targeting.
Consequently, even if our product candidates are approved for a second or third line of therapy, the number of patients that may be eligible for treatment with our product candidates may turn out to be much lower than expected. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our product candidates rely on the use of protein binding domains, or binders, to target specific cancers, which
we may develop or which may be developed by third parties. We are limited in our ability to apply our product candidates to a wider range of potential target cancers by our ability to develop, partner for or acquire these binders on commercially
reasonable terms. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">TCR-T therapies require the use of antigen-specific protein binding domains, or
binders, which guide the TCR-Ts and bind to the antigens on the surface of a tumor to target specific types of cancers. Our ability to develop and commercialize our product candidates will depend on our ability to develop these binders or partner
for such binders on commercially reasonable terms for use in clinical trials as well as the availability of such binders for use in commercialized products, if licensed. We cannot ensure that we will have a steady supply of binders that we can
utilize in combination with the TCR construct to develop future product candidates. If we are unable to enter into such collaborations on commercially reasonable terms or fail to realize the benefits of any such collaboration, we may be limited to
using antibody fragments that we are able to independently develop which may limit the ability of our product candidates to target and kill cancer cells. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The failure to enter into a successful collaboration or to develop our own binders may delay our development timelines,
increase our costs and jeopardize our ability to develop future product candidates as a commercially viable drug, which could result in delays in product development and harm our business. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">33
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We currently have no marketing and sales organization and have no
experience as a company in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if licensed, we may not be able to generate product
revenue. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We currently have no sales, marketing or distribution capabilities and have no experience as
a company in marketing products. We intend to develop an <FONT STYLE="white-space:nowrap">in-house</FONT> marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to
compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our product candidates, if licensed. However, there
can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties,
which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face
competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">There can be no assurance that we will be able to develop <FONT STYLE="white-space:nowrap">in-house</FONT> sales and distribution capabilities or establish or maintain relationships with third party collaborators to commercialize
any product in the United States or overseas. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Even if we obtain regulatory approval of our product
candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The use of engineered T cells as a potential cancer treatment is a recent development and may not become broadly accepted
by physicians, patients, hospitals, cancer treatment centers and others in the medical community. Various factors will influence whether our product candidates are accepted in the market, including: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the clinical indications for which our product candidates are licensed;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">physicians, hospitals, cancer treatment centers and patients considering our product
candidates as a safe and effective treatment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the potential and perceived advantages of our product candidates over alternative
treatments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to demonstrate the advantages of our product candidates over other TCR-T
therapies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the prevalence and severity of any side effects; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the prevalence and severity of any side effects for other adoptive cell therapies, TCR-T
therapies and public perception of other adoptive cell therapies, TCR-T therapies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">product labeling or product insert requirements of the FDA or other regulatory authorities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">limitations or warnings contained in the labeling approved by the FDA;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the timing of market introduction of our product candidates as well as competitive
products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cost of treatment in relation to alternative treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the availability of adequate coverage, reimbursement and pricing by third party payors and
government authorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">willingness of patients to pay <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of coverage by third party payors and government authorities; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">34
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">relative convenience and ease of administration, including as compared to alternative
treatments and competitive therapies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the effectiveness of our sales and marketing efforts. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, although we are not utilizing embryonic stem cells or replication competent vectors, adverse publicity due
to the ethical and social controversies surrounding the therapeutic use of such technologies, and reported side effects from any clinical trials using these technologies or the failure of such clinical trials to demonstrate that these therapies are
safe and effective may limit market acceptance of our product candidates. If our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical
community, we will not be able to generate significant revenue. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, although our product candidates
differ in certain ways from other <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy approaches, serious adverse events or deaths in other clinical trials involving engineered TCR, or other <FONT STYLE="white-space:nowrap">T-cell</FONT> products
or with our use of licensed TCR-T therapy candidates, even if not ultimately attributable to our product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the
testing or licensing of our product candidates, stricter labeling requirements for those product candidates that are licensed, and a decrease in demand for any such product candidates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Even if our product candidates achieve market acceptance, we may not be able to maintain that market acceptance over
time if new products or technologies are introduced that are more favorably received than our product candidates, are more cost effective or render our product candidates obsolete. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>A variety of risks associated with marketing our product candidates internationally could materially adversely
affect our business. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We plan to seek regulatory approval of our product candidates outside of the
United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">differing regulatory requirements in foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">unexpected changes in tariffs, trade barriers, price and exchange controls and other
regulatory requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">economic weakness, including inflation, or political instability in particular foreign
economies and markets; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">compliance with tax, employment, immigration and labor laws for employees living or
traveling abroad; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">foreign taxes, including withholding of payroll taxes; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">foreign currency fluctuations, which could result in increased operating expenses and
reduced revenue, and other obligations incident to doing business in another country; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">difficulties staffing and managing foreign operations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">workforce uncertainty in countries where labor unrest is more common than in the United
States; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign
regulations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">challenges enforcing our contractual and intellectual property rights, especially in those
foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">production shortages resulting from any events affecting raw material supply or
manufacturing capabilities abroad; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT>
actions, including war and terrorism. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">35
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">These and other risks associated with international operations may
materially adversely affect our ability to attain or maintain profitable operations. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We face
significant competition, and our operating results will suffer if we fail to compete effectively. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The
biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other products or drugs that are able to achieve similar or better results. Our potential competitors include larger
biotechnology and pharmaceutical companies with greater resources than us, academic institutions, governmental agencies, public and private research institutions and early stage or smaller companies. Many of our competitors have substantially
greater financial, technical and other resources, such as larger research and development staff, experienced marketing and manufacturing organizations and well-established sales forces. Further, our competitors may have more financial resources,
greater access to capital and diversified product offerings and revenue sources which may give our competitors an advantage over us in weathering the effects of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic. In
addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Mergers and acquisitions in the biotechnology and
pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for
investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily
commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will
affect the development and commercial success of our product candidates are safety, potency, purity, tolerability, reliability, convenience of use, price and reimbursement. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Specifically, by genetically engineering <FONT STYLE="white-space:nowrap">T-cell</FONT> therapies, we face significant
competition in the TCR space from multiple companies, including Kite Pharma Inc., a subsidiary of Gilead, Inc., Adaptimmune Therapeutics, Plc., Juno Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb, Inc. (including Yescarta, which is
approved for the treatment for your large B-cell lymphoma or follicular lymphoma, two types of non-Hodgkin lymphoma), Iovance Biotherapeutics, Inc., Achilles Therapeutics plc, Geneos Therapeutics, Inc., PACT Pharma, Inc., Celyad, S.A., Fate
Therapeutics, Inc., Nkarta, Inc., Medigene AG, Ziopharm Oncology, Inc., Bayer AG, Novartis AG (including Kymriah, which is approved for the treatment of B-cell acute lymphoblastic leukemia), Selecta Biosciences, Inc., TCR2 Therapeutics Inc.,
Adaptive Therapeutics, Inc., Immatics US, Inc., Lyell Immunopharma, Inc., Allogene Therapeutics, Inc., Sana Biotechnology, Inc., 3T Biosciences, Inc. and Regeneron Pharmaceuticals, Inc. Even if we obtain regulatory approval of our product
candidates, the availability and price of our competitors&#146; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product
candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product
candidates for use in limited circumstances. Moreover, the development and manufacturing costs associated with engineered <FONT STYLE="white-space:nowrap">T-cell</FONT> therapies may make it difficult to compete with alternative products that may be
simpler and cheaper to develop and manufacture. For additional information regarding our competition, see &#147;Business&#151;Competition.&#148; </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our internal computer systems, or those used by our third party CROs or other contractors or consultants, may fail
or suffer security breaches or other unauthorized or improper access, which could result in a material disruption of the development programs of our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Despite the implementation of security measures, our internal computer systems and those of our current and future CROs
and other contractors and consultants are vulnerable to a variety of disruptions and data privacy and information security incidents, including data breaches, attacks by hackers and other malicious third parties (including the deployment of computer
viruses, malware, ransomware, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, social </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">36
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
engineering, and other events that affect service reliability and threaten the confidentiality, integrity, and availability of information), unauthorized access, natural disasters, fires,
terrorism, war, telecommunications or electrical interruptions or failures, employee error or malfeasance or other malicious or inadvertent disruptions. Additionally, the increased usage of computers operated on home networks due to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stay-at-home</FONT></FONT> advisories or similar restrictions related to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic may make our or our partners&#146; systems more susceptible to security breaches. While we have not experienced any such material system failure or security breach to date, if such an event were to
occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of data from completed or future preclinical studies and clinical trials could
result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, to the extent we rely on third parties for the manufacture of our product candidates and to conduct clinical trials,
similar events relating to their computer systems could also have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Unauthorized disclosure of sensitive or confidential data, including personally identifiable information, whether
through a breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by our employees or third parties, could result
in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws and regulations around the world. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As we become more dependent on information technologies to conduct our operations, cyber incidents, including deliberate
attacks and attempts to gain unauthorized access to computer systems and networks, may increase in frequency and sophistication. These threats pose a risk to the security of our systems and networks and to the confidentiality, availability and
integrity of our data, and these risks apply both to us and to third parties on whose systems we rely for the conduct of our business. Because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change
frequently and often are not recognized until launched against a target, we and our partners or collaborators may be unable to anticipate these techniques or to implement adequate preventative measures. Further, we do not have any control over the
operations of the facilities or technology of our cloud and service providers, including any third party vendors that collect, process and store personal data on our behalf. Our systems, servers and platforms and those of our service providers may
be vulnerable to computer viruses or physical or electronic <FONT STYLE="white-space:nowrap">break-ins</FONT> that our or their security measures may not detect. Individuals able to circumvent such security measures may misappropriate our
confidential or proprietary information, disrupt our operations, damage our computers or otherwise impair our reputation and business. We may need to expend significant resources and make significant capital investments to protect against security
breaches or to mitigate the impact of any such breaches. There can be no assurance that we or our third party providers will be successful in preventing cyber-attacks or successfully mitigating their effects. To the extent that any disruption or
security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product
candidates could be delayed. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Security incidents, loss of data or modification of information, and
other disruptions could compromise information related to our business or prevent us from accessing critical information, result in a significant disruption of our activities and expose us to liability, which could adversely affect our business and
our reputation. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the ordinary course of our business, we collect and store information, including
personal information, intellectual property and proprietary business information that we own or control or have an obligation to protect. For example, we collect and store research and development information, employee data, commercial information,
customer information and business and financial information. We and our service providers, including security and infrastructure vendors, manage and maintain our data using a combination of <FONT STYLE="white-space:nowrap">on-site</FONT> systems and
cloud-based data centers. We face a number of risks related to protecting critical information, </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">37
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
including inappropriate use or disclosure, unauthorized access or acquisition, or inappropriate modification of, critical information. We also face the risk of being unable to access our critical
information or technology systems due to actual or threats of ransomware, unauthorized encryption, or other malicious activity. We face the risk of being unable to adequately monitor, audit and modify our controls over our critical information.
These risks extend to third party service providers and subcontractors we use to assist us in managing our information or otherwise process it on our behalf. The secure processing, storage, maintenance and transmission of our critical information is
vital to our operations and business strategy, and we devote significant resources to protecting such information. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Although we take reasonable measures to protect critical information and other data from unauthorized access, acquisition, use or disclosure, our information technology and infrastructure and that of our service providers handling
and storing information on our behalf may be vulnerable to a variety of disruptions, including data breaches, attacks by hackers and other malicious third parties (including the deployment of computer viruses, malware, ransomware, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, social engineering, and other events that affect service reliability and threaten the confidentiality, integrity, and availability of information),
unauthorized access, natural disasters, fires, terrorism, war, telecommunications or electrical interruptions or failures, employee error or malfeasance or other malicious or inadvertent disruptions. In particular, the risk of a security breach or
disruption, particularly through cyber-attacks or cyber intrusion, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all
types of security threats, and we may not be able to implement preventive measures that are effective against all such security threats. Because the techniques used by cyber criminals change frequently, may not be recognized until launched, and can
originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates or terrorist organizations, we and our services providers and other partners may be unable to anticipate these
techniques or implement adequate preventative measures. Further, we do not have any control over the operations of the facilities or technology of third parties that collect, process and store sensitive information on our behalf. Any unauthorized
access or acquisition, breach, or other loss, of information could result in legal claims or proceedings, and liability under federal, state or foreign laws regarding the privacy and protection of information, including personal information, and
could disrupt our operations and harm our reputation. In addition, notice of breaches may be required to affected individuals, regulators, credit reporting agencies or the media. Any such publication or notice could harm our reputation and our
ability to compete. The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we may maintain, and there can be no assurance that the limitations of liability in
any of our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above. Any of the foregoing could have a material adverse effect on our business, financial
condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to Manufacturing </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Manufacturing and administering our product candidates is complex and we may encounter difficulties in production,
particularly with respect to process development or scaling up of our manufacturing capabilities. If we encounter such difficulties, our ability to provide supply of our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates for clinical
trials or for commercial purposes could be delayed or stopped. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The process of manufacturing and
administering our product candidates is complex and highly regulated. The manufacture of our product candidates involves complex processes, including the manufacture of a transposon containing the genetic information for our TCR construct, a
transposase used to insert the transposon genetic information into the <FONT STYLE="white-space:nowrap">T-cell</FONT> genome, and manufacturing operations to ensure the safety, integrity, strength, purity, and quality of the final product. More
specifically, the manufacture of our product candidates includes harvesting white blood cells from the patient, isolating certain T cells from the white blood cells, combining patient T cells with our delivery vector through a process known as
transduction, selection of modified T&nbsp;cells from the population, expanding the selected transduced T cells to obtain the desired dose, aseptically filling product into vessels suitable for storage, distribution, and clinical dosing, and
ultimately infusing the modified </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">38
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
T&nbsp;cells back into the patient&#146;s body. As a result of the complexities entailed in this process, our manufacturing and supply costs will be higher than those at more traditional
manufacturing processes and the manufacturing process is less reliable and more difficult to reproduce. Additionally, the number of facilities that are capable of harvesting patients&#146; cells for the manufacture of our product candidates and
other autologous cell therapy products and product candidates is limited. As the number of autologous cell therapy products and product candidates increases, the limited number of facilities capable of harvesting patients&#146; cells could result in
delays in the manufacture and administration of our product candidates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Although we plan to futher expand
our existing manufacturing facility, we currently rely on third parties for the manufacture of our vector and other components of our manufacturing process. These third party manufacturers may incorporate their own proprietary processes into our
components. We have limited control and oversight of a third party&#146;s proprietary process, and a third party may elect to modify its process without our consent or knowledge. These modifications could negatively impact our manufacturing,
including product loss or failure that requires additional manufacturing runs or a change in manufacturer, both of which could significantly increase the cost of and significantly delay the manufacture of our product candidates. In addition, we are
currently reliant on a single manufacturer for our transposon and transposase, and many of the critical raw materials and reagents used in the process are single or sole source. These third party providers may not be able to provide adequate
resources, capacity to meet our needs, timely delivery of material, or may change internal processes or specifications that adversely affect our process or product candidates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our manufacturing process is and will be susceptible to product loss or failure due to logistical issues, manufacturing
issues associated with the differences in patients&#146; white blood cells, interruptions in the manufacturing process or supply chain, contamination, equipment or reagent failure, process design flaws, operator error, power failures, supplier error
and variability in patient characteristics. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, product rejection, or other supply disruptions. If for any reason we lose a
patient&#146;s white blood cells, such material gets contaminated or processing steps fail at any point, the manufacturing process of the TCR-T therapy candidate for that patient will need to be restarted, if possible, and the resulting delay may
adversely affect that patient&#146;s outcome. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates or critical raw materials or reagents are made or
administered, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As our product candidates progress through preclinical studies and clinical trials towards licensure and
commercialization, it is expected that various aspects of the manufacturing and administration process will be altered in an effort to optimize processes and results. We have already identified some improvements to our manufacturing and
administration processes, but these changes may not achieve the intended objectives, and could cause our product candidates to perform inadequately affecting the results of ongoing or future clinical trials. In addition, such changes may require
amendments to be made to regulatory applications or necessitate development of new or additional TCR constructs and further clinical testing, which may further delay the timeframes under which modified manufacturing processes can be used for any of
our product candidates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Developing a commercially viable process is a difficult and uncertain task, and
there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, increased costs, potential problems with process <FONT STYLE="white-space:nowrap">scale-out</FONT> or <FONT
STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues, lot consistency, facility suitability or capacity, staffing, and availability of reagents or raw materials. Competitors have had difficulty reliably producing <FONT
STYLE="white-space:nowrap">T-cell</FONT> therapies in the commercial setting. If we experience similar challenges manufacturing product candidates to approved specifications, this may limit our product candidates&#146; utilization and our ability to
receive payment for these product candidates once approved. We may ultimately be unable to reduce the expenses associated with our product candidates to levels that will allow us to achieve a profitable return on investment. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">39
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We plan to further expand our existing manufacturing facility and
infrastructure in lieu of relying on third parties for the manufacture of our product candidates for certain clinical purposes and the use of third party manufacturing suites, which will be costly, time-consuming, and which may not be successful.
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are in the process of expanding our existing manufacturing capacity to support our Phase 1 and
Phase 2 clinical trials for <FONT STYLE="white-space:nowrap">TSC-100,</FONT> <FONT STYLE="white-space:nowrap">TSC-101,</FONT> <FONT STYLE="white-space:nowrap">TSC-102,</FONT> <FONT STYLE="white-space:nowrap">TSC-200,</FONT> <FONT
STYLE="white-space:nowrap">TSC-201,</FONT> <FONT STYLE="white-space:nowrap">TSC-202,</FONT> and TSC-203.<B><I> </I></B>We have no experience as a company in setting up, building or managing a manufacturing facility or manufacturing suite, and may
never be successful in developing our own manufacturing suite, manufacturing facility or manufacturing capability. We will need to hire additional personnel to manage our operations and facilities and develop the necessary infrastructure to continue
the research and development, and eventual commercialization, if licensed, of our product candidates. If we fail to recruit the required personnel, manage our growth effectively, have inadequate facility design or construction, or fail to select the
correct location, the development and production of our product candidates could be curtailed or delayed. Even if we are successful in establishing a manufacturing suite or manufacturing facility, our manufacturing capabilities could be affected by
cost-overruns, unexpected delays, equipment failures, design or construction flaws, labor shortages, supply disruptions, natural disasters, power failures and numerous other factors that could prevent us from realizing the intended benefits of our
manufacturing strategy and have a material adverse effect on our business. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, the FDA, the
European Medicines Agency (EMA), and other foreign regulatory authorities may require us to submit samples of any lot of any licensed product together with the protocols showing the results of applicable tests at any time. Under some circumstances,
the FDA, the EMA or other foreign regulatory authorities may require that we not distribute a lot until the relevant agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and
stability, may result in unacceptable changes in the product that could result in lot failures or product recalls, or inability to manufacture product in the future. Lot failures or product recalls could cause us to delay or forgo product launches
or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. Problems in our manufacturing process could restrict our ability to meet market demand for our product
candidates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We also may encounter problems hiring and retaining the experienced scientific, quality-control
and manufacturing personnel needed to operate our manufacturing processes and facility, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential
partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We may have difficulty validating our manufacturing process as we manufacture TCR-T therapy candidates from an
increasingly diverse patient population for our clinical trials. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have limited process development
experience and have not yet established lot to lot or donor consistency with healthy or unhealthy donors. As we develop our clinical products, we may encounter unforeseen difficulties due to quality, quantity, supply timing, or variability issues
with donor starting materials and may not be able to develop a robust process or incur additional costs or delays in developing a robust process due to starting material variation or supply. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Although we believe our current manufacturing process is scalable for commercialization, we may encounter challenges in
validating our process due to the heterogeneity of the product starting material. While we anticipate that during the early phases of our clinical trials we will be able to adapt our process to account for these differences resulting in a more
robust process, we cannot guarantee that issues relating to the heterogeneity of the starting material will not impact our ability to manufacture our product candidates for clinical or commercial distribution. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">40
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to Government Regulation </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the
clinical development and regulatory approval of our product candidates. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have not previously
submitted a Biologics License Application (BLA) to the FDA or similar licensure applications to comparable foreign regulatory authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product
candidate&#146;s safety, purity, and potency for each desired indication. The BLA must also include significant information regarding the manufacturing controls for the product. We expect the novel nature of our product candidates to create further
challenges in obtaining regulatory approval. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and licensure may not be obtained. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related
to: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the availability of financial resources to commence and complete the planned trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the
terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">obtaining approval at each clinical trial site by an IRB or ethics committee;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">recruiting suitable patients to participate in a clinical trial;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">having patients complete a clinical trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">clinical trial sites deviating from trial protocol or dropping out of a trial;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">adding new clinical trial sites; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">manufacturing sufficient quantities of qualified materials under cGMPs, including current
Good Tissue Practices (cGTPs), and applying them on a subject by subject basis for use in clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We could also experience delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established
safety, efficacy, potency and purity profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted, the Data Monitoring Committee for such trial, or by the FDA or
other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or
other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative
actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed,
and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product
sales and generate revenue. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Securing regulatory approval also requires the submission of information about
the biologic manufacturing process and inspection of manufacturing facilities by the relevant regulatory authority. The FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities, whether run by us
or our contract manufacturing organizations (CMOs). In addition, if we make manufacturing changes to our product candidates in the future, we may need to conduct additional preclinical or clinical studies to bridge our modified product candidates to
earlier versions. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">41
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Many of the factors that cause, or lead to, a delay in the commencement or
completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely
impact our potential to generate revenue, our business and our results of operations. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The research,
testing, manufacturing, labeling, licensure, sale, marketing and distribution of biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ
from country to country. We are not permitted to market our product candidates in the United States or in any foreign countries until they receive the requisite licensure from the applicable regulatory authorities of such jurisdictions. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The FDA or any foreign regulatory authorities can delay, limit or deny licensure of our product candidates for many
reasons, including: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign
regulatory authority that any of our product candidates are safe, potent and pure; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the FDA&#146;s or the applicable foreign regulatory agency&#146;s disagreement with our
trial protocol or the interpretation of data from preclinical studies or clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our inability to demonstrate that the clinical and other benefits of any of our product
candidates outweigh any safety or other perceived risks; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the FDA&#146;s or the applicable foreign regulatory agency&#146;s requirement for
additional preclinical studies or clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the results of clinical trials may not meet the level of statistical significance required
by the FDA or comparable foreign regulatory authorities for licensure; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the FDA&#146;s or the applicable foreign regulatory agency&#146;s failure to approve our
manufacturing processes or facilities or those of third party manufacturers upon which we rely; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the potential for approval policies or regulations of the FDA or the applicable foreign
regulatory authorities to significantly change in a manner rendering our clinical data insufficient for licensure; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the data collected from clinical trials of our product candidates may not be sufficient to
the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain licensure of our product candidates in the United States or elsewhere;
or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the approval policies or regulations of the FDA or comparable foreign regulatory
authorities may significantly change in a manner rendering our clinical data insufficient for approval. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Any of these factors, many of which are beyond our control, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and
prospects. Of the large number of biological products in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized. Even if we eventually complete clinical testing and receive
licensure from the FDA or applicable foreign regulatory authorities for any of our product candidates, the FDA or the applicable foreign regulatory agency may grant licensure contingent on the performance of costly additional clinical trials which
may be required after licensure. The FDA or the applicable foreign regulatory agency also may license our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA, or applicable
foreign regulatory agency, may not license our product candidates with the labeling that we believe is necessary or desirable for the successful commercialization of such product candidates. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">42
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, even if the trials are successfully completed, preclinical and
clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more clinical trials could be required before we
submit our product candidates for approval. To the extent that the results of the clinical trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, approval of our product candidates
may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional clinical trials in support of potential approval of our product candidates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization
of our product candidates and would materially adversely impact our business and prospects. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We may
seek orphan drug status for <FONT STYLE="white-space:nowrap">TSC-100,</FONT> <FONT STYLE="white-space:nowrap">TSC-101,</FONT> <FONT STYLE="white-space:nowrap">TSC-102,</FONT> <FONT STYLE="white-space:nowrap">TSC-200,</FONT> <FONT
STYLE="white-space:nowrap">TSC-201,</FONT> <FONT STYLE="white-space:nowrap">TSC-202,</FONT> and <FONT STYLE="white-space:nowrap">TSC-203</FONT> and some of our other future product candidates, but we may be unable to obtain such designations or to
maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or
condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing
and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. In the United States, orphan drug
designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. After the FDA grants orphan drug designation, the
generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active
ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic for the same
indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the
availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still
approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may seek orphan drug designation for <FONT STYLE="white-space:nowrap">TSC-100,</FONT>
<FONT STYLE="white-space:nowrap">TSC-101,</FONT> <FONT STYLE="white-space:nowrap">TSC-102,</FONT> <FONT STYLE="white-space:nowrap">TSC-200,</FONT> <FONT STYLE="white-space:nowrap">TSC-201,</FONT> <FONT STYLE="white-space:nowrap">TSC-202,</FONT> and
TSC-203 and some or all of our other future product candidates in additional orphan indications in which there is a medically plausible basis for the use of these products. Even when we obtain orphan drug designation, exclusive marketing rights in
the United States may be limited if we seek licensure for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is
unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, although we intend to seek orphan drug designation for other product candidates, we may never receive such
designations. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On August&nbsp;3, 2017, the Congress passed the FDA Reauthorization Act of 2017 (FDARA).
FDARA, among other things, codified the FDA&#146;s <FONT STYLE="white-space:nowrap">pre-existing</FONT> regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a
previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period
regardless of </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">43
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug
regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to
a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We plan to seek a Breakthrough Therapy designation for <FONT STYLE="white-space:nowrap">TSC-100,</FONT> <FONT
STYLE="white-space:nowrap">TSC-101,</FONT> <FONT STYLE="white-space:nowrap">TSC-102,</FONT> <FONT STYLE="white-space:nowrap">TSC-200,</FONT> <FONT STYLE="white-space:nowrap">TSC-201</FONT> and <FONT STYLE="white-space:nowrap">TSC-202</FONT> and may
seek Breakthrough Therapy designation for some or all of our future product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious
or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, or biologic, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient
path for clinical development while minimizing the number of patients placed in ineffective control regimens. Biologics designated as breakthrough therapies by the FDA may also be eligible for other expedited approval programs, including Accelerated
Approval. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we
believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a
product candidate may not result in a faster development process, review or licensure compared to candidate products considered for licensure under <FONT STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures and does not assure
ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we intend to
seek Breakthrough Therapy designation for <FONT STYLE="white-space:nowrap">TSC-100</FONT> and some or all of our future product candidates for the treatment of various cancers, there can be no assurance that we will receive breakthrough therapy
designation. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>A Fast Track designation by the FDA, even if granted for
<FONT STYLE="white-space:nowrap">TSC-102,</FONT> <FONT STYLE="white-space:nowrap">TSC-200,</FONT> <FONT STYLE="white-space:nowrap">TSC-201,</FONT> <FONT STYLE="white-space:nowrap">TSC-202,</FONT> and TSC-203 or any other future product candidates,
may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the
potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA Fast Track designation for a particular indication. We plan to seek Fast Track designation for <FONT STYLE="white-space:nowrap">TSC-100,</FONT> <FONT
STYLE="white-space:nowrap">TSC-101,</FONT> <FONT STYLE="white-space:nowrap">TSC-</FONT> 200, <FONT STYLE="white-space:nowrap">TSC-201,</FONT> TSC 202, and TSC-203 and may seek Fast Track designation for certain of our future product candidates, but
there is no assurance that the FDA will grant this status to any of our proposed product candidates. Marketing applications filed by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures
offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant Fast Track designation, so even if we believe a particular
product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or licensure compared to
conventional FDA procedures, and receiving a Fast Track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from
our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">44
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Accelerated approval by the FDA, even if granted for <FONT
STYLE="white-space:nowrap">TSC-100,</FONT> <FONT STYLE="white-space:nowrap">TSC-101,</FONT> <FONT STYLE="white-space:nowrap">TSC-102,</FONT> <FONT STYLE="white-space:nowrap">TSC-200,</FONT> <FONT STYLE="white-space:nowrap">TSC-201,</FONT> <FONT
STYLE="white-space:nowrap">TSC-202,</FONT> and TSC-203 or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will
receive marketing approval. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We plan to seek approval of
<FONT STYLE="white-space:nowrap">TSC-100,</FONT> <FONT STYLE="white-space:nowrap">TSC-101,</FONT> <FONT STYLE="white-space:nowrap">TSC-102,</FONT> <FONT STYLE="white-space:nowrap">TSC-200,</FONT> <FONT STYLE="white-space:nowrap">TSC-201,</FONT> <FONT
STYLE="white-space:nowrap">TSC-202,</FONT> and TSC-203, and may seek approval of future product candidates using FDA&#146;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening
condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured
earlier than irreversible morbidity or mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated
approval perform adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence. In addition, the FDA currently requires as a condition for accelerated approval <FONT
STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or
regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate FDA approval. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not
guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in
others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those
countries. Approval and licensure procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical
trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be
approved for sale in that jurisdiction. In some cases, the price that we intend to charge for any of our product candidates for which we receive marketing approval is also subject to approval. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the
United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in
significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable
marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, the United Kingdom left the European Union on January&nbsp;31, 2020, an event commonly referred to as
&#147;Brexit,&#148; and following the &#147;transition period,&#148; on December&nbsp;30, 2020, the European Union, the European Atomic Energy Community and the United Kingdom signed a Trade and Cooperation Agreement. Brexit imposes new regulatory
costs and challenges that may have a material adverse effect on us and our operations. We may face decreased chances to obtain market approval for our product candidates in the European Union, including the possibility that the European Medicines
Agency will not accept data from our clinical trials conducted in the United Kingdom or will only do so if we comply with certain conditions. Conversely, since a significant proportion of the United Kingdom&#146;s regulatory framework affecting the
pharmaceutical and biotechnological industry is derived from European Union directives and regulations, Brexit could materially alter the regulatory regime with respect to our product candidates in the United Kingdom, which may increase
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">45
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
the time and costs associated with obtaining regulatory approval from the relevant authorities. It may also be time-consuming and expensive for us to alter our internal operations in order to
comply with new regulations. Altered regulations could also add time and expense to the process by which our product candidates receive regulatory approval in the United Kingdom and the European Union. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Furthermore, following the Brexit vote, the European Union moved the European Medicines Agency&#146;s headquarters from
the United Kingdom to the Netherlands. This transition may cause disruption in the administrative and medical scientific links between the European Medicines Agency and the UK Medicines and Healthcare products Regulatory Agency, including delays in
granting clinical trial authorization or marketing authorization, disruption of import and export of active substance and other components of new drug formulations and disruption of the supply chain for clinical trial product and final authorized
formulations. The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Even if we receive regulatory approval of our product candidates, we will be subject to ongoing
regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product
candidates. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any regulatory approvals that we receive for our product candidates will require
surveillance to monitor the safety, potency and purity of the product candidate. The FDA may also require a risk evaluation and mitigation strategy in order to license our product candidates, which could entail requirements for a medication guide,
physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our
product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing
regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs, cGTPs and good clinical practices (GCPs) for any clinical trials
that we conduct post-licensure. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our manufacturing processes (or those of third parties we engage),
or failure to comply with regulatory requirements, may result in, among other things: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the
product from the market or voluntary or mandatory product recalls; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">revisions to the labeling, including limitation on approved uses or the addition of
additional warnings, contraindications or other safety information, including boxed warnings; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">imposition of a Risk Evaluation and Mitigation Strategy (REMS), which may include
distribution or use restrictions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">requirements to conduct additional post-market clinical trials to assess the safety of the
product; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">fines, warning letters or holds on clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">refusal by the FDA to approve pending applications or supplements to approved applications
filed by us or suspension or revocation of license approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">product seizure or detention, or refusal to permit the import or export of our product
candidates; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">injunctions or the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be
enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">46
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are
not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>The insurance coverage and reimbursement status of newly-approved products is uncertain. Our product candidates
may become subject to unfavorable pricing regulations, third party coverage and reimbursement practices, or healthcare reform initiatives, which would harm our business. Failure to obtain or maintain adequate coverage and reimbursement for new or
current products could limit our ability to market those products and decrease our ability to generate revenue. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may significantly change the approval
requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after
marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing
approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of
the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the United States and markets in other countries, patients generally rely on third party payors to reimburse all or
part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully
commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health
insurers and other organizations. Government authorities and other third party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The
availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments such as gene therapy products. Sales of these or other product candidates that we may identify
will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by
government health administration authorities, private health coverage insurers and other third party payors. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully
commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Reimbursement by a third party payor may depend upon a number of factors, including, but not limited to, the third party
payor&#146;s determination that use of a product is: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a covered benefit under its health plan; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">safe, effective and medically necessary; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">appropriate for the specific patient; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">cost-effective; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">neither experimental nor investigational. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">47
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A primary trend in the U.S. healthcare industry and elsewhere is cost
containment. Government authorities and third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. In many countries, the prices of medical products are subject to varying
price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor
and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the
reimbursement for products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and
coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS,
an agency within HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for products
exists among third party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to
provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. It is difficult to
predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement
in the United States and have not been approved for reimbursement in certain European countries. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including
research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of
the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Our inability to promptly obtain coverage and profitable
payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our
overall financial condition. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net prices for drugs may be reduced by mandatory discounts or rebates required
by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain
coverage and profitable reimbursement rates third party payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall
financial condition. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Increasingly, third party payors are requiring that drug companies provide them with
predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the
level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to obtain reimbursement, physicians may need to show that patients have superior treatment
outcomes with our product candidates compared to standard of care drugs, including lower-priced biosimilar versions of standard of care drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates due
to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures
and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">48
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Recently enacted and future legislation may increase the difficulty
and cost for us to obtain marketing approval for and commercialize our product candidates and affect the prices we may obtain. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we
obtain marketing approval. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the United States, the Patient Protection and Affordable Care Act, as amended
by the Health Care and Education Affordability Reconciliation Act (Affordable Care Act or ACA), was signed into law, intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against
fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Among the provisions of the Affordable Care Act that are of importance to our potential product candidates are the
following: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">an annual, nondeductible fee payable by any entity that manufactures, or imports specified
branded prescription drugs and biologic agents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid
Drug Rebate Program; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">an increase in the discount rate for the federal 340B program to eligible hospitals;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to
offer 70% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">extension of manufacturers&#146; Medicaid rebate liability; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">expansion of eligibility criteria for Medicaid programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">expansion of the entities eligible for discounts under the Public Health Service
pharmaceutical pricing program; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a new requirement to annually report drug samples that manufacturers and distributors
provide to physicians; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and
conduct comparative clinical effectiveness research, along with funding for such research. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care
Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. For example, legislation informally titled the Tax Cuts and Jobs Acts (TCJA) was enacted, which, among other things, removed penalties
for not complying with the individual mandate to carry health insurance. On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the
Affordable Care Act, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the Affordable Care Act are invalid as well. On December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District
Court&#146;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the
case, although it is unclear when the Supreme Court will make a decision. It is also unclear how other efforts to challenge, repeal or replace the Affordable Care Act will affect the law or our business. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In
August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments, will
remain in effect through 2030, with the exception of a temporary </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">49
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
suspension from May&nbsp;1, 2020 through March&nbsp;31, 2021, unless additional Congressional action is taken. In addition, on January&nbsp;2, 2013, President Obama signed into law the American
Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, including hospitals, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to
five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We expect that other healthcare reform measures that may be adopted in the future may result in additional reductions in
Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other
government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize our product candidates, if approved. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Moreover, there has recently been heightened governmental
scrutiny over the manner in which manufacturers set prices for their marketed products. Individual states in the United States have become increasingly aggressive in implementing regulations designed to contain pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Legally mandated price controls on payment amounts by third party payors or
other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical
products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively
affect our business, results of operations, financial condition and prospects. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Legislative and regulatory
proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations,
guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#146;s approval process may significantly
delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare
spending on us is currently unknown, and may adversely affect our business model. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our revenue
prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations
or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state
levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the
Affordable Care Act. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:
</FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the demand for our product candidates, if we obtain regulatory approval;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to set a price that we believe is fair for our product candidates;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">50
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to obtain coverage and reimbursement approval for a product candidate;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to generate revenue and achieve or maintain profitability;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the level of taxes that we are required to pay; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the availability of capital. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments
from private payors, which may adversely affect our future profitability. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Regulatory requirements in
the United States and abroad governing cell therapy products have changed frequently and may continue to change in the future, which could negatively impact our ability to complete clinical trials and commercialize our product candidates in a timely
manner, if at all. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Regulatory requirements in the United States and abroad governing cell therapy
products have changed frequently and may continue to change in the future. The FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research to consolidate the review of gene therapy and
related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee, among others, to advise this review. Recently, the National Institutes of Health proposed to revise its guidelines for overseeing gene therapy
research, including deleting the protocol registration and reporting requirements for certain therapies and eliminating Recombinant DNA Advisory Committee review and reporting requirements for human gene transfer research. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and
retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our
business may rely, which could negatively impact our business. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The ability of the FDA to review and
approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review
times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to
the political process, which is inherently fluid and unpredictable. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Disruptions at the FDA and other
agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several
times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the
ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access
the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Separately, in response to the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020,
the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products through April 2020, and subsequently, on March&nbsp;18, 2020, the FDA announced its intention to temporarily postpone routine surveillance
inspections of domestic manufacturing facilities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged
government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the
FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">51
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our employees, independent contractors, consultants, commercial
partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors,
consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the regulations of the FDA and other similar foreign regulatory authorities, provide
true, complete and accurate information to the FDA and other similar foreign regulatory authorities, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign
fraudulent misconduct laws or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our
potential exposure under such laws and regulations will increase significantly, and our costs associated with compliance with such laws and regulations are also likely to increase. These laws may impact, among other things, our current activities
with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements
in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and
promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for
clinical trials. The laws that may affect our ability to operate include, but are not limited to: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and
willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or
the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">federal civil and criminal false claims laws and civil monetary penalty laws, which
prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third party payors that are false or fraudulent or knowingly making a false
statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which
created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises,
any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (for example, public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or
device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act
of 2009 (HITECH), and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for
them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the federal Physician Payment Sunshine Act, created under the Affordable Care Act and its
implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">52
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">
Program (with certain exceptions) to report annually to HHS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists,
podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">federal consumer protection and unfair competition laws, which broadly regulate marketplace
activities and activities that potentially harm consumers. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additionally, we are subject to
state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Effective upon the closing of this offering, we will adopt a code of business conduct and ethics, but it is not always
possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations
or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and
regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one
or more of such laws. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and
regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions including monetary penalties,
damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate
integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, reputational harm, and we may be required to curtail or restructure our operations, any of which could
adversely affect our ability to operate our business and our results of operations. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The risk of our being
found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for
violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. The shifting compliance environment and the need to
build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The provision of benefits or advantages to physicians to induce or encourage the prescription,
recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States, such as the U.K.
Bribery Act 2010, or the Bribery Act. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must
be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the
EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">53
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We are currently subject to, and may in the future become subject to
additional, federal, state and foreign laws and regulations, industry guidelines, and contractual requirements, imposing obligations on how we collect, store, use and process personal information. Our actual or perceived failure to comply with such
obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are, and may increasingly become, subject to various laws and regulations, as well as contractual obligations and
mandatory industry standards relating to privacy and security in the jurisdictions in which we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing requirements
applicable to our business, and enforcement practices are likely to remain uncertain for the foreseeable future. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is
possible that they will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the United States, various federal and state regulators, including governmental agencies like the Federal Trade
Commission, have adopted, or are considering adopting, laws and regulations concerning personal information and data security. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal
information than federal, international or other state laws, and such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act of 2018, or CCPA, which increases privacy rights
for California residents and imposes obligations on companies that process their personal information and meet certain revenue or volume processing thresholds, came into effect on January&nbsp;1, 2020, and was further amended by the California
Privacy Rights Act (CPRA) on November&nbsp;3, 2020. Among other things, the CCPA requires covered companies to provide new disclosures to California residents and provide such residents new data protection and privacy rights, including the ability
to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information. The CPRA significantly modifies the CCPA by expanding residents&#146; rights with respect to certain personal information and creates a new state agency to
oversee implementation and enforcement efforts. Many of the CPRA&#146;s provisions will become effective on January&nbsp;1, 2023. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches.
This private right of action may increase the likelihood of, and risks associated with, data breach litigation, including class action litigation. In addition, laws in all 50 U.S. states require businesses to provide notice to individuals if certain
of their personal information has been disclosed as a result of a qualifying data breach. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law to which we may likely become
subject, if enacted. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Internationally, laws, regulations and standards in many jurisdictions apply broadly to
the collection, use, retention, security, disclosure, transfer, marketing or other processing of personal data. For example, the EU General Data Protection Regulation (GDPR), which became effective on May&nbsp;25, 2018, is wide-ranging in scope and
imposes numerous requirements on companies that process personal data. Specifically, the GDPR greatly increased the European&#146;s Commission&#146;s jurisdictional reach of its data privacy and security laws and introduced a broad array of
requirements for handling personal data, including, for example, requirements to establish a legal basis for processing, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals,
a strengthened individual data rights regime, requirements to implement safeguards to protect the security and confidentiality of personal data that requires the adoption of administrative, physical and technical safeguards, shortened timelines for
data breach notifications to appropriate data protection authorities or data subjects, limitations on retention and secondary use of information, increased requirements pertaining to health data and obligations to take certain measures when engaging
third party processors in connection with the processing of personal data. EU member states are tasked under the GDPR to enact, and have enacted, certain implementing legislation that adds to and/or further interprets the GDPR requirements and
potentially extends our obligations and potential liability for failing to meet such obligations. The GDPR, together with national legislation, regulations and guidelines of the EU member states governing the processing of personal data, impose
strict obligations and restrictions on the ability to collect, use, retain, disclose, transfer and otherwise process personal data. In particular, the GDPR also imposes strict obligations, restrictions and rules concerning the rights of individuals
to whom the personal data relates, the transfer of personal data to countries outside the </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">54
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
European Economic Area, including the United States, security breach notifications and the security and confidentiality of personal data. The GDPR permits data protection authorities to impose
large penalties for violations of the GDPR, including potential fines of up to &#128;20&nbsp;million or 4% of annual global revenues, whichever is greater, and other administrative penalties. The GDPR also confers a private right of action on data
subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive
process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our
European activities. Following the withdrawal of the United Kingdom from the European Union, data privacy and security laws that are substantially similar to the GDPR are in effect in the United Kingdom, which carry similar risks and authorize
similar fines for certain violations. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Certain legal regimes outside of the United States, including in the
United Kingdom and under the GDPR, prohibit the transfer of personal data to the United States unless certain measures are in place, including, for example, executing Standard Contractual Clauses, or historically, relying on the receiving
entity&#146;s certification under the <FONT STYLE="white-space:nowrap">EU-US</FONT> and/or <FONT STYLE="white-space:nowrap">Swiss-US</FONT> Privacy Shield Frameworks, or the Privacy Shield Frameworks. The Privacy Shield Frameworks were invalidated,
and the adequacy of Standard Contractual Clauses is now in question, following the Court of Justice of the European Union&#146;s July 2020 decision in the <FONT STYLE="white-space:nowrap">so-called</FONT> Schrems II case (Data Protection
Commissioner v. Facebook Ireland Limited, Maximillian Schrems (Case <FONT STYLE="white-space:nowrap">C-311/18)).</FONT> There is no guarantee that any transfer mechanism upon which we rely will be deemed to be valid by the relevant legal
authorities, or that mechanisms that are currently deemed to be valid will remain valid in the future. This uncertainty, and its eventual resolution, may increase our costs of compliance, impede our ability to transfer data and conduct our business
and harm our business or results of operations. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">All of these evolving compliance and operational
requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. In
addition, such requirements may require us to modify our data processing practices and policies, utilize management&#146;s time and/or divert resources from other initiatives and projects. Any failure or perceived failure by us to comply with any
applicable federal, state or foreign laws and regulations relating to data privacy and security could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action
privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, injunctions, penalties or judgments. Any of the foregoing could have a material adverse effect on our business, financial condition, results
of operations and prospects. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If we fail to comply with environmental, health and safety laws and
regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations
also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury
resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to
injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be
asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">55
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Even if we are able to commercialize any product candidates, the
products may become subject to unfavorable pricing regulations, third party reimbursement practices or healthcare reform initiatives, which would harm our business. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely
from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a
drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical
trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted.
As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the
revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing
approval. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our ability to commercialize any product candidates successfully also will depend in part on the
extent to which coverage and adequate reimbursement for these products and related treatments will be available from government healthcare programs, private health insurers and other organizations. Government authorities and third party payors, such
as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities
and third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, government authorities and third party payors are requiring that drug companies provide them with
predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement
may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our product candidates may be difficult. We may be
required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to
limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside
of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and
distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in
which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third party payors often rely upon Medicare coverage
policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could
have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">56
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to Our Intellectual Property </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If we are unable to obtain and maintain patent protection for any product candidates we develop and for our
technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products, product candidates and technology similar or identical to ours, and our ability to successfully
commercialize any product candidates we may develop, and our technology may be adversely affected. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our success will depend in large part on our ability and the ability of our licensors and collaborators to obtain and
maintain patent protection and other intellectual property and proprietary rights in the United States and other countries with respect to our technology and our product candidates, their respective components, formulations, combination therapies,
methods used to manufacture them and methods of treatment and development that are important to our business, as well as, our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property
rights of others. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Given the early stage of development of our product candidates, our patent portfolio is
similarly at a very early stage. In particular, we do not own or exclusively license any issued patents and all of the patent applications we own are provisional applications. In addition, although we plan to file patent applications with respect to
TSC-102, TSC-200, TSC-202, and TSC-203, we currently have not filed any patent applications with respect to these product candidates. Accordingly, our current patent rights do not provide us any legal right to prevent third parties from competing
with us in any way. If we do not obtain meaningful patent coverage for our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, competitors may be able to
erode or negate any competitive advantage we may have, which would likely harm our business and ability to achieve profitability. To establish our proprietary position, we have filed provisional patent applications in the United States related to
our novel product candidates that are important to our business, and we have exclusively licensed certain patent applications from The Brigham and Women&#146;s Hospital, Inc. (or &#147;BWH&#148;); we may in the future also license or purchase issued
patents or pending patent applications filed by others. U.S. provisional patent applications are not eligible to become issued patents until, among other things, we file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application
within 12 months of filing of one or more of our related provisional patent applications. With regard to such U.S. provisional patent applications, if we do not timely file any <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent
applications, we may lose our priority date with respect to our provisional patent applications and any patent protection on the inventions disclosed in our provisional patent applications. While we intend to timely file <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications relating to our provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patents that provide us with any competitive
advantage. If we are unable to secure or maintain patent protection with respect to our antibody technology and any proprietary products and technology we develop, our business, financial condition, results of operations, and prospects could be
materially harmed. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If the scope of the patent protection we or our existing and potential licensors obtain,
if any, is not sufficiently broad, we may not be able to prevent others from developing and commercializing technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace
may be unavailable or severely limited and may not adequately protect our business or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our owned or exclusively licensed pending patent applications
that mature into issued patents will include claims with a scope sufficient to protect our current and future product candidates or otherwise provide any competitive advantage. In addition, to the extent that we license intellectual property now or
in the future, we cannot provide any assurances that those licenses will remain in force. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited
lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be
available; however, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition. Given the
amount of time required for the </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">57
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
development, testing and regulatory review of new product candidates, any patents that we may obtain in the future protecting such candidates might expire before or shortly after
commercialization of such candidates, if any. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Even if they are unchallenged, our pending patent applications, if issued, may not provide us with any meaningful
protection or prevent competitors or other third parties from designing around our patent claims to circumvent any patents that may issue by developing similar or alternative technologies or therapeutics in a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For example, a third party may develop a competitive therapy that provides benefits similar to one or more of our product candidates but that uses a formulation and/or a device that
falls outside the scope of our patent claims. If any patent protection that we may obtain in the future from the patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our
ability to successfully commercialize our product candidates could be negatively affected, which would harm our business. Similar risks apply to patents or patent applications that we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> or may
in the future <FONT STYLE="white-space:nowrap">in-license.</FONT> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Patent positions of life sciences
companies can be uncertain and involve complex factual and legal questions and are subject of much litigation. No consistent policy governing the scope of claims allowable in the field of antibodies has emerged in the United States. The scope of
patent protection in jurisdictions outside of the United States is also uncertain. Changes in either the patent laws or in their interpretation in any jurisdiction that we seek patent protection may diminish our ability to protect our inventions,
obtain, maintain, protect and enforce our intellectual property and other proprietary rights; and, more generally, may affect the value of our intellectual property, including the narrowing of the scope of any patents that we may obtain in the
future and any that we may license. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The patent prosecution process is complex, expensive, time-consuming and
inconsistent across jurisdictions. We may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent rights at a commercially reasonable cost or in a timely manner. In addition, we do not intend to pursue, and
may not obtain, patent protection in all potentially relevant markets. It is possible that we will fail to identify important patentable aspects of our research and development efforts in time to obtain appropriate or any patent protection or fail
to file patent applications covering inventions made in the course of development and commercialization activities before a competitor or another third party files a patent application covering, or publishes information disclosing, a similar,
independently-developed invention. Such competitor&#146;s or other third party&#146;s patent application may pose obstacles to our ability to obtain patent protection or limit the scope of the patent protection we may obtain. While we enter into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development efforts, including for example, our employees, corporate
collaborators, external academic scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed,
thereby endangering our ability to seek patent protection. In addition, publications of discoveries in the scientific and scholarly literature often lag behind the actual discoveries, and patent applications in the United States and other
jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Consequently, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent rights and patent applications or were the first to file for patent protection on the inventions claimed in our pending patent applications. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#146;
patent rights are highly uncertain. Our and our licensors&#146; pending and future patent applications may not result in patents being issued that protect our technology or product candidates, in whole or in part, or which effectively exclude others
from commercializing competitive technologies and product candidates. Further, the scope of the invention claimed in a patent application can be significantly reduced before the patent is issued, and this scope can be reinterpreted after issuance.
Even where patent applications we currently own or that we license now or in the future issue as patents, they may not issue in a form that will provide us with adequate protection to prevent competitors or other third parties from competing with
us, or otherwise provide us with a competitive </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">58
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
advantage. Any patents that eventually issue may be challenged, narrowed or invalidated by third parties. Consequently, we do not know whether any of our product candidates will be protectable or
remain protected by valid and enforceable patent rights. Our competitors or other third parties may be able to evade or circumvent our patent rights by developing new alternative technologies or products in a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The issuance or grant of a patent is not
conclusive as to its inventorship, scope, validity or enforceability, and our patents we may obtain in the future may be challenged, invalidated, narrowed or held to be enforceable, including in the courts or patent offices in the United States and
abroad, or circumvented. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or
enforceability of a claim, but which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. We may become subject to a third party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art or
opposition, derivation, revocation, <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant and <I>inter partes</I> review, or interference proceeding and other similar proceedings challenging any patent rights we may obtain in the future
or the patent rights of others, including based on priority of invention or other features of patentability, in the U.S. Patent and Trademark Office (USPTO) or other foreign patent office. An unfavorable determination in any such submission,
proceeding or litigation could reduce the scope of, or invalidate, any patent rights we may obtain in the future, allow third parties to use or commercialize our technology or product candidates and compete directly with us, without payment to us
(as they can now), or extinguish our ability to manufacture or commercialize product candidates without infringing third party patent rights. Such proceedings also may result in substantial cost and require significant time from our scientists and
management, even if the eventual outcome is favorable to us. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could have a material adverse effect on the price of our common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In
addition, given the amount of time required for the development, testing and regulatory review of new product candidates, any patents we may obtain in the future protecting such candidates might expire before or shortly after commercialization of
such candidates, if any. As a result, our intellectual property may never provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Moreover, any patents or patent applications that we may own or
<FONT STYLE="white-space:nowrap">in-license</FONT> in the future may be <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain an exclusive license to any such third party
<FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in any such patents or patent applications, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our
competitors, thereby enabling our competitors to market competing products and technology. In addition, we or our licensors may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of any patents that we may own or <FONT
STYLE="white-space:nowrap">in-license</FONT> in the future in order to enforce such patents against third parties, and such cooperation may not be provided to us or our licensors. Any of the foregoing could have a material adverse effect on our
competitive position, business, financial conditions, results of operations and prospects. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We could be
unsuccessful in obtaining meaningful patent protection on one or more components of our platform technology. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We believe that an important factor in our competitive position is our screening technology platform to identify future product candidates and therapeutic targets. Our screening platform is based in part on technology processes that
are (or will be) publicly disclosed in patent applications owned by or licensed to us and we do not currently own or <FONT STYLE="white-space:nowrap">in-license</FONT> any issued patents that protect our screening platform. Even if these patents
issue from these patent applications and provide broad protection, it may be difficult or impossible to detect whether a competitor is practicing the proprietary methods claimed in such patent applications in order to discover their own product
candidates and therapeutic targets. In such case, any patents that may issue from patent applications owned by or licensed to us would not provide us protection to prevent such activity. Additionally, a competitor may also practice such methods in a
jurisdiction where we have no relevant patent protection. Our competitive position could be weakened by competitors or other third parties practicing the methods claimed in these patent applications in a manner we do not detect or in jurisdictions
in which we or our licensors do not obtain any relevant patent protection. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">59
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If we fail to comply with any of our obligations under existing or
future agreements pursuant to which we license intellectual property rights or technology, if the licenses are terminated or if disputes regarding these licenses arise, we could lose significant rights or technology that are material to our business
and could interfere with our ability to operate our business. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are a party to technology licenses,
including <FONT STYLE="white-space:nowrap">in-license</FONT> agreements with BWH and Provincial Health Services Authority (or &#147;PHSA&#148;), and we may enter into additional licenses in the future. See &#147;Business&#151;License and
Collaboration Agreements&#148; for more information regarding our agreement with PHSA. Such licenses do, and may in the future, impose commercial, contingent payment, royalty, insurance, indemnification, and other obligations on us. If we fail to
comply with these obligations, our licensors may have the right to terminate the license, in which event we could lose valuable rights under our collaboration agreements and our ability to develop product candidates could be impaired. Additionally,
should any such license agreement be terminated for any reason, there may be a limited number of replacement licensors, and a significant amount of time may be required to transition to a replacement licensor. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of third
party licenses, pursuant to which we have acquired rights from the applicable licensors. Our rights with respect to such intellectual property may terminate, in whole or in part, if we fail to meet applicable requirements or milestones relating to
development and commercialization. We may also lose our rights to develop and commercialize our product candidates under such agreements if we fail to pay required milestones or royalties. In the event of an early termination of our license
agreements, all rights licensed and developed by us under these agreements may be extinguished, which may have an adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We rely on certain of our licensors to prepare, file and prosecute patent applications and maintain patents and
otherwise protect the intellectual property we license from them and may continue to do so in the future. We have limited or no control over these activities or any other intellectual property that may be related to our <FONT
STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. For example, we cannot be certain that such activities by these licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid
and enforceable patents and other intellectual property rights. We have limited or no control over the manner in which our licensors initiate an infringement proceeding against a third party infringer of the intellectual property rights, or defend
certain of the intellectual property that is licensed to us. It is possible that any licensors&#146; infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">These agreements may be complex, and certain provisions in such agreements may be susceptible to multiple
interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our
financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, a third party may in the future bring claims that our performance under our license agreements, including
our sponsoring of clinical trials, interferes with such third party&#146;s rights under its agreement with one of our licensors. If any such claim were successful, it may adversely affect our rights and ability to advance our product candidates as
clinical candidates or subject us to liability for monetary damages, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We are currently, and expect in the future to be, party to material license or collaboration agreements.
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are currently, and expect in the future to be, party to material license or collaboration
agreements. These agreements typically impose numerous obligations and restrictions on us, such as various diligence, commercialization, insurance and payment obligations, among others, in order to maintain such licenses. Any of these restrictions
or obligations could delay or otherwise negatively impact a transaction that we may wish to enter into. In addition, any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our
product candidates. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">60
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Licensing of intellectual property is of high importance to our business
and involves complex legal, business and scientific issues. Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the scope of rights granted under the license agreement and other interpretation-related
issues; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">whether, and the extent to which, our product candidates, technology and processes infringe
on intellectual property of the licensor that is not subject to the licensing agreement; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our right to sublicense patent and other intellectual property rights to third parties
under collaborative development relationships; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the calculation and existence of certain payment obligations under the license agreement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our diligence obligations with respect to the use of the licensed technology in relation to
our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the inventorship and ownership of inventions,
<FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property and proprietary rights resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the priority of invention of patented technology. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current
licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are generally also subject to all of the same risks with respect to protection of intellectual property that we
license, as we are for intellectual property that we own, which we describe below, and our success will depend in part on the ability of our licensors to adequately obtain, maintain, protect and enforce patent protection for our licensed
intellectual property, especially with respect to patent rights which we exclusively <FONT STYLE="white-space:nowrap">in-license.</FONT> If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize
products could suffer. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We rely on certain of our licensors to prepare, file and prosecute patent
applications and maintain patents and otherwise protect the intellectual property we license from them and may continue to do so in the future. We have limited control over these activities or any other intellectual property that may be related to
our <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. For example, we cannot be certain that such activities by these licensors have been or will be conducted in compliance with applicable laws and regulations or will result
in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding against a third party infringer of the intellectual property rights, or
defend certain of the intellectual property that is licensed to us. It is possible that any licensors&#146; infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves or may not be conducted in accordance
with our best interests. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Furthermore, certain of our licenses may not provide us with exclusive rights to
use the licensed intellectual property and technology, or may not provide us with exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize
our technology and product candidates in the future. For example, a portion of our intellectual property portfolio is <FONT STYLE="white-space:nowrap">non-exclusively</FONT> licensed to us and may be used by our licensors or licensed to third
parties, and such third parties may have certain enforcement rights with respect to such intellectual property. Thus, patent rights licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against
our licensors or another licensee or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons. As a result, we may not be able to prevent competitors or other third
parties from developing and commercializing competitive products, including in territories covered by our licenses. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">61
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our proprietary position may depend upon
patents that are manufacturing, formulation or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patents, which may not prevent a competitor or other third party from using the same product candidate for
another use. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Composition-of-matter</FONT></FONT> patents are
generally considered to be the strongest form of intellectual property protection for drug products because such patents provide protection without regard to any particular method of use or manufacture or formulation of the API used. We do not have
any issued patents, but our pending owned U.S. provisional patent applications include claims that cover compositions of matter of our TSC-100 and <FONT STYLE="white-space:nowrap">TSC-101</FONT> TCR-T therapy candidates. We cannot be certain that
claims in any patent that may issue from our pending owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications will cover the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> of any of our current or future product candidates. If we are unsuccessful in obtaining issued patents that cover the composition of matter of any
of our current or future product candidates, competitors may be able to erode or negate any competitive advantage we may have and our business, financial condition, results of operations and prospects could be materially harmed. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not
adequate, we may not be able to compete effectively in our market. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Biotechnology and pharmaceutical
companies generally, and we in particular, compete in a crowded competitive space characterized by rapidly evolving technologies and aggressive defense of intellectual property. The USPTO and various foreign governmental patent agencies require
compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial
or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We rely upon a combination of patent rights, confidentiality agreements, trade secret protection and license agreements
to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors or other third parties to quickly duplicate or surpass our
technological achievements, thus eroding our competitive position in our market. We, or any partners, collaborators, licensees or licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization
activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">It is possible that defects of form in the preparation or filing of our patent applications may exist, or may arise in
the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or any partners, collaborators, licensees or licensors fail to establish, maintain or protect such patent
rights and other intellectual property rights, such rights may be reduced or eliminated. If any partners, collaborators, licensees or licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any
patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patent applications, any patents that may issue from such patent applications may be invalid and/or
unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition,
results of operations and prospects. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Currently, our patent applications are directed to our TCR-T therapy
candidates and accompanying technologies. We seek or plan to seek patent protection for our proprietary platform and product candidates by filing and prosecuting patent applications in the United States and other countries as appropriate. As of
April&nbsp;16, 2021, our patent portfolio consisted of one patent family exclusively licensed from BWH, which family includes one pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application and six pending foreign <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">62
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
directed to a granzyme B (GzB)-based antigen screening technology platform compositions of matter and certain screening methods thereof, and seven patent families encompassing an aggregate of 16
U.S. provisional patent applications. The claims of these patent applications are drawn to subject matter in the following main technology areas: certain compositions of matter directed to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> immunodominant antigens, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-SARS-CoV-2</FONT></FONT></FONT> TCRs,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-SARS-CoV-2</FONT></FONT> vaccines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HA-1</FONT></FONT> TCRs (including the
<FONT STYLE="white-space:nowrap">TSC-100</FONT> <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidate), <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HA-2</FONT></FONT> TCRs (including the <FONT
STYLE="white-space:nowrap">TSC-101</FONT> <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidate), TCRs targeting the antigen of TSC-201, and certain therapeutic and diagnostic uses thereof, as well as a phospholipid scrambling
reporter-based T cell antigen screening platform and certain screening methods thereof. Any patents that may issue from any non-provisional patent applications claiming priority to these provisional patent applications would be expected to expire on
various dates from 2038 through 2042, in each case without taking into account any possible patent term adjustments or extensions. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We anticipate additional patent applications will be filed both in the United States and in other countries, as
appropriate. However, we cannot predict: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">whether and when any patents will issue; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the degree and range of protection that any patents that may issue will afford us against
competitors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">whether any of our intellectual property will provide any competitive advantage;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">whether any patents that may issue may be challenged, invalidated, modified, revoked,
circumvented or found to be unenforceable; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">whether or not others will obtain patents claiming inventions similar to those covered by
our patent applications; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">whether we will need to initiate or defend litigation or administrative proceedings, which
may be costly regardless of whether we win or lose. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additionally, we cannot be certain
that the claims in our pending patent applications covering the composition of matter of our product candidates will be considered patentable by the USPTO or patent offices in foreign countries. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Method-of-use</FONT></FONT> patents protect the use of
a product for the specified method. If we obtain any of these types of patents, they would not prevent a competitor from making and marketing a product that is identical to one of our product candidates for an indication that is outside the scope of
the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products <FONT STYLE="white-space:nowrap">&#147;off-label.&#148;</FONT> Although <FONT
STYLE="white-space:nowrap">off-label</FONT> prescriptions may induce or contribute to the infringement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patents, the practice is common, and such
infringement is difficult to prevent or prosecute. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The strength of patents in the biotechnology and
pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our
product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being
narrowed, invalidated or held unenforceable. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to
develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.
Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Various
post-grant review proceedings, such as <I>inter partes</I> review and post-grant review, are available for any interested third party to challenge the patentability of claims in any patents issued to us or our licensors. While these post-grant
review proceedings have been used less frequently to invalidate biotech patents, they have been successful regarding other technologies, and these relatively new procedures are still changing, and those changes might affect future results. No
assurance can be given that, if challenged, any patents that we or our licensors may </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">63
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
obtain would be declared by a court to be valid or enforceable or that, even if found valid and enforceable, a competitor&#146;s technology or product would be found by a court to infringe any
such patent. We may analyze patents or patent applications of our competitors that we believe are relevant and conclude that our activities do not infringe any valid claims of those patents or patent applications, but our conclusions may be
erroneous or our competitors may obtain patents with issued claims, including in patents we consider to be unrelated, that block our efforts or that our product candidates or our activities infringe. Others may independently develop products that
have the same effect as our product candidates without infringing any patents we may obtain or any of our other intellectual property rights, or they may design around the claims of any patents that we may obtain. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Recent and future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of
our patent applications and the enforcement or defense of any patents we may obtain. In March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, the United States moved from a &#147;first to invent&#148; to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system. Under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, assuming the other
requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act included a
number of other significant changes to U.S. patent law, including provisions that have affected the way patent applications are prosecuted, redefined prior art and established a new post-grant review system. The effects of these changes are still
unclear as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act, and many of the substantive changes to patent law, including the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> provisions, only became effective in March 2013. Moreover, the courts have yet to address many of these provisions. Overall, the America
Invents Act and its implementation have increased the uncertainties and costs surrounding the prosecution of our patent applications and any enforcement or defense of any patents that we may obtain, which could have a material adverse effect on our
business and financial condition. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The degree of future protection for our proprietary rights is uncertain
because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">others may be able to make or use compounds or cells that are similar to the biological
compositions of our product candidates but that are not covered by the claims of any patents that we may obtain; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the active biological ingredients in our current product candidates may eventually become
commercially available in biosimilar drug products, and no patent protection may be available with regard to formulation or method of use; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">we or our licensors, as the case may be, might not have been the first to file patent
applications for these inventions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">there may be prior public disclosures that could invalidate any patents that we or our
licensors may obtain; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the inventors of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
applications may become involved with competitors, develop products or processes that design around any patents that we may obtain, or become adverse to us or patent applications on which they are named as inventors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">it is possible that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause any patents that may issue from these patent applications to be held invalid or unenforceable;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">we have engaged and may continue to engage in scientific collaborations, and such
collaborators may develop adjacent or competing products to ours that are outside the scope of any patents that we may obtain; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">we may not develop additional proprietary technologies for which we can obtain patent
protection; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">product candidates or diagnostic tests we develop may be covered by third parties&#146;
patents or other exclusive rights; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the patents of others may have an adverse effect on our business.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">64
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If we are unable to protect the confidentiality of our trade secrets,
our business and competitive position would be harmed. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition to the protection afforded by any
patent rights we may obtain, we seek to rely on trade secret protection, confidentiality agreements, and license agreements to protect our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, technology and other proprietary
information that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT>
information, or technology that we have not sought to protect through patent applications. For example, significant elements of our product candidates, including aspects of sample preparation, methods of manufacturing, cell culturing conditions,
computational-biological algorithms, and related processes and software, are based on unpatented trade secrets that are not publicly disclosed. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored
researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements generally provide that all confidential information concerning our business or financial
affairs developed or made known to the individual or entity during the course of the party&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the
agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary
information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. Despite these
measures, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent
information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. Courts outside the United States are sometimes less willing to
protect trade secrets. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we choose to go to court to stop a third party from using any of our trade
secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. If we are unable to prevent unauthorized disclosure of our material intellectual property to third parties, we will not be
able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. For more information, see &#147;Risk Factors&#151;Risks Related to Our Intellectual
Property&#151;&#147;We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.&#148; </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Third party claims of intellectual property infringement, misappropriation or other violations may prevent or
delay our product discovery and development efforts. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our commercial success depends in part on our
avoiding infringement, misappropriation or other violation of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and
pharmaceutical industries. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or technologies infringe their intellectual property
rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates or identifying potential product candidates. As the
biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry
participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Because of the large number of patents and patent applications in our fields, there is a risk that third parties may allege they
have patent rights encompassing our product candidates, technologies or methods. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">65
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If a third party claims that we infringe, misappropriate or otherwise
violate its intellectual property rights, we may face a number of issues, including, but not limited to: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">infringement, misappropriation and other violation of intellectual property claims which,
regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#146;s attention from our core business; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">substantial damages for infringement, misappropriation or other violation which we may have
to pay if a court decides that the product candidate or technology at issue infringes on, misappropriates or otherwise violates the third party&#146;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay
treble damages and the patent owner&#146;s attorneys&#146; fees; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a court prohibiting us from developing, manufacturing, marketing or selling our product
candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">if a license is available from a third party, we may have to pay substantial royalties,
upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our product candidates or using our proprietary technologies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">redesigning our product candidates or processes so they do not infringe third party
intellectual property rights, which may not be possible or may require substantial monetary expenditures and time. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Some of our competitors or other third parties may be able to sustain the costs of complex patent litigation more
effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds
necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting
preclinical and clinical trials and other development activities in the United States is not considered an act of infringement. If any of our product candidates is licensed by the FDA, a third party may then seek to enforce its patent by filing a
patent infringement lawsuit against us. While we do not believe that any claims that could otherwise have a materially adverse effect on the commercialization of our product candidates, if licensed, are valid and enforceable, we may be incorrect in
this belief, or we may not be able to prove it in litigation. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#147;clear and convincing&#148;, a heightened
standard of proof. As a result, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If any third party patent were held by a court of competent jurisdiction to cover the manufacturing
process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, or aspects of our formulations, processes for manufacture or methods of use, including combination therapy or
patient selection methods, the holder of any such patent may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patent, or until such patent expires or it is finally determined to be
held invalid or unenforceable. In any case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third party patent on commercially reasonable terms, or at all, our
ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our
competitors access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings
or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Any of the foregoing events could harm our business, financial condition, results
of operations and prospects. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Parties making claims against us may seek and obtain injunctive or other
equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">66
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of
infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may
be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of
litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at
all. In that event, we would be unable to further develop and commercialize our product candidates. Any of the foregoing events could harm our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We may not be successful in obtaining or maintaining necessary rights to product components and processes for our
development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Because additional product candidates may require the use of proprietary rights held by third parties, the growth of our
business will likely depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these proprietary rights. In addition, while we have certain patent rights directed to certain TCR constructs, we may not be
able to obtain intellectual property to broad <FONT STYLE="white-space:nowrap">T-cell</FONT> or TCR-T constructs. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Our product candidates may also require specific formulations to work effectively and efficiently and rights to these formulations may be held by others. Similarly, efficient production or delivery of our product candidates may also
require specific compositions or methods, and the rights to these may be owned by third parties. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any formulations, compositions, methods of use, processes or other
third party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may
need to cease use of the compositions or methods covered by such third party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional
costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors
access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. Moreover, the specific antibodies that will be used with our product candidates
may be covered by the intellectual property rights of others. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additionally, we may collaborate with academic
institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in
technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the
intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third party intellectual property or to maintain the existing intellectual property rights we
have, we may have to abandon development of such program and our business and financial condition could suffer. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">The licensing and acquisition of third party intellectual property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire
third party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater
clinical development and commercialization capabilities. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">67
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We may eventually become involved in lawsuits to protect or enforce
our intellectual property and proprietary rights, including any patents that we or our licensors may obtain in the future, which could be expensive, time-consuming and unsuccessful. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the future, competitors or other third parties may infringe any patents that we or our licensors may obtain. To
counter any such future infringement or unauthorized use, we may eventually be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert
counterclaims against us alleging that we infringe their patents or that our licensors&#146; patents are invalid or unenforceable. In addition, in a patent infringement proceeding, a court may decide that one or more patents that we may obtain in
the future is not valid or is unenforceable, in whole or in part, construe the patent&#146;s claims narrowly or may refuse to stop the other party from using the technology at issue on the grounds that such patents, if any, do not cover the
technology in question. An adverse result in any litigation or defense proceedings could put one or more of such patents, if any, at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk
of not issuing. Asserting any patent rights we may obtain in the future, and defending challenges to our rights, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from
our business and we may find it impractical or undesirable to enforce our intellectual property against some third parties. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Post-grant, interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the validity or priority of inventions with respect to our or our licensors&#146;
patent applications or any patents that may issue therefrom. An unfavorable outcome could result in a loss of any patent rights we may have. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceeding. In addition, there could be public announcements of the results of hearings, motions or
other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Any of the foregoing events could harm our business,
financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Obtaining and maintaining our patent
protection depends on compliance with various procedures, document submission, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Some of our patent
applications may be allowed in the future. We cannot be certain that an allowed patent application will become an issued patent. There may be events that cause withdrawal of the allowance of a patent application. For example, after a patent
application has been allowed, but prior to being issued, material that could be relevant to patentability may be identified. In such circumstances, the applicant may pull the application from allowance in order for the USPTO or foreign patent agency
to review the application in view of the new material. In that circumstance, the USPTO or the other agency may not <FONT STYLE="white-space:nowrap">re-allow</FONT> an application in view of the new material. Further, periodic maintenance fees,
renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to be paid to the USPTO and foreign patent agencies at several stages over the lifetime of the patents and/or patent applications. The
USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary and other similar provisions during the patent application process and following the issuance of a patent. We also may be
dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in
accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits,
<FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, our competitors and other third parties might be able to enter the market without infringing our or our
licensors&#146; patents and patent </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">68
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
applications, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If we obtain any patents covering our product candidates, they could nonetheless be found invalid or unenforceable
if challenged in court or the USPTO. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The issuance of a patent is not conclusive as to its
inventorship, scope, validity or enforceability. Our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, and any of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications that may issue in the future, may be
challenged at the USPTO or foreign patent offices in <FONT STYLE="white-space:nowrap">re-examination,</FONT> <I>inter partes</I> review, post-grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such
proceedings could result in the revocation of or amendment to such patents in such a way that they no longer cover our product candidates or technologies. If we or one of our licensing partners initiates legal proceedings against a third party to
enforce a patent that we may obtain in the future covering one of our product candidates, the defendant could counterclaim that such patent is invalid and/or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity
and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <FONT
STYLE="white-space:nowrap">re-examination,</FONT> <I>inter partes</I> review, post-grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to any
patents we may obtain in the future in such a way that they would no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example,
we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if
we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of any patent protection we may eventually obtain on our product candidates and technologies. Such a loss of patent protection could have a
material adverse impact on our business, financial condition, results of operations and prospects and our ability to commercialize or license our technology and product candidates. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Changes to patent law and its interpretation in the United States and in foreign jurisdictions could diminish the
value of patents in general and may impact the validity, scope or enforceability of our patent rights, thereby impairing our ability to protect our product candidates and technologies. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property,
particularly any patents that may issue from our pending patent applications. Changes in either the patent laws or in their interpretation in any jurisdiction that we seek patent protection may diminish our ability to protect our inventions, obtain,
maintain and enforce our intellectual property and proprietary rights and, more generally, may affect the value of our intellectual property and proprietary rights. The United States continues to adapt to wide-ranging patent reform legislation that
became effective starting in 2012. Moreover, various courts, including the U.S. Supreme Court, have rendered decisions that have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in
certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by
the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in the future. For
example, in the case <I>Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</I> the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. We cannot predict how future decisions by the courts, Congress or the USPTO may
impact the value of our pending patent applications. Similarly, any adverse changes in the laws and regulations governing patents in other jurisdictions could have an </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">69
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
adverse effect on our ability to obtain and effectively enforce our patent rights and have a material adverse effect on our business and financial condition. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We have limited foreign intellectual property rights and may not be able to protect our intellectual property
rights throughout the world. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the United States, we have filed only provisional patent
applications, and outside the United States we have made no filings; our only rights outside the United States consist of seven pending patent applications that we exclusively license from BWH. Filing, prosecuting and defending patents on product
candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as the laws in the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able
to prevent third parties from practicing our inventions in some or all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors or other
third parties may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may also export otherwise infringing products to territories where we have patent protection, but
enforcement is not as strong as in the United States. These products may compete with our product candidates and our patent rights or other intellectual property rights may not be effective or sufficient to prevent them from competing. In addition,
certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or
government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents. Most of our patent portfolio is at the very early stage. We will need to decide whether, and in which
jurisdictions, to pursue protection for the various inventions in our portfolio prior to applicable filing deadlines. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor
the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products and biotechnology, which could make it difficult for us to stop the infringement, misappropriation or
other violation of our intellectual property rights, including any infringement of any patents we may obtain in the future in such countries, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce
any patent rights we may obtain in the future in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patent applications at risk of not issuing, any patents
we obtain in the future at risk of being invalidated or interpreted narrowly and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not
be commercially meaningful. Accordingly, our efforts to establish our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We may be subject to claims challenging the inventorship or ownership of our patent rights and other intellectual
property. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may be subject to claims that former employees, collaborators or other third parties
have an interest in our intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> It is our policy to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and
contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, such agreements may not be honored and may not effectively assign intellectual
property rights to us. For instance, the assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against current or former
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">70
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
employees, consultants, and contractors, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Moreover, there may be
circumstances where we are unable to negotiate for such ownership rights. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Disputes regarding ownership or
inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to inventions or other intellectual property, such a dispute could be
expensive and time consuming. If we are unsuccessful in defending such claims, in addition to paying monetary damages, unless we are able to obtain a license, which might not be available on commercially reasonable terms or at all, we could lose
valuable rights in intellectual property, such as the exclusive ownership of, or right to use, intellectual property that we regard as our own or that is important to our business. Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction to management and other employees, and certain customers, licensors or partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a
material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We
may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed trade secrets or other confidential information of their former employers or other third parties or claims asserting ownership of
what we regard as our own intellectual property. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have received, and will continue to receive,
confidential and proprietary information from third parties. In addition, we have employed and expect to continue to employ individuals who were previously employed at university or other biotechnology or pharmaceutical companies, including our
competitors or potential competitors, in some cases until recently. Although we try to ensure that our employees, consultants, advisors and independent contractors do not use the proprietary information or
<FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we, our employees, advisors, consultants or independent contractors have deliberately, inadvertently or otherwise used or disclosed
intellectual property, including trade secrets or other proprietary information of these former employers, competitors or other third parties, or to claims that we have improperly used or obtained such trade secrets. We may be subject to claims that
we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#146; former employers or our consultants&#146; or contractors&#146;
current or former clients or customers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and
employees. If we are not successful in defending such claims, in addition to paying monetary damages, we could lose access or exclusive access to valuable intellectual property rights and face increased competition to our business. Any of the
foregoing could harm our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We may be
subject to claims, and damages resulting from claims, that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of <FONT STYLE="white-space:nowrap">non-competition</FONT> or <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> agreements with our competitors. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Many of our
employees were previously employed at other pharmaceutical companies, including our competitors or potential competitors, in some cases until recently. We may be subject to claims that we or our employees have inadvertently or otherwise used or
disclosed trade secrets or other proprietary information of these former employers or competitors. In addition, we have been and may in the future be subject to claims that we caused an employee to breach the terms of his or her <FONT
STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims,
litigation could result in substantial costs and could be a distraction to management. If our defense to those claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Any litigation or
the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates or potential products, which could have an adverse effect on
our business, results of operations, financial condition and prospects. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">71
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Patent terms may be inadequate to protect our competitive position on
our product candidates for an adequate amount of time. If we do not obtain patent term extension and data exclusivity for any of our current or future product candidates, our business may be materially harmed. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Depending upon the timing, duration, conditions and specifics of any FDA marketing approval of any of our current or
future product candidates that we may receive, one or more U.S. patents that we may obtain in the future may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman
Amendments, and one or more of our foreign patent rights may be eligible for patent term extension under similar legislation, for example, in the European Union. In the United States, the Hatch-Waxman Amendments permit a patent extension term of up
to five years as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product
approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, there are no assurances that the FDA or any comparable foreign regulatory
authority or national patent office will grant such extensions, in whole or in part. For example, we may not be granted an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within
applicable deadlines, fail to apply prior to the expiration of relevant patents, or otherwise fail to satisfy other applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we
request. If we are unable to obtain patent term extension or term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product candidate will be shortened, and our competitors or
other third parties may obtain approval to market competing products following expiration of any patents that we may obtain in the future, and our business, financial condition, results of operations, and prospects could be materially harmed.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If our trademarks are not adequately protected, then we may not be able to build name recognition in
our markets of interest and our business may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We rely on both registered and
common law protection for our trademarks, and have filed applications to register various trademarks, including &#147;TSCAN THERAPEUTICS&#148; and &#147;TSCAN,&#148; for use in connection with our product candidates and services in various
countries. These trademarks may not afford adequate protection. Our trademark applications may be provisionally or ultimately refused by the USPTO or the trademark agencies of other countries, or such applications may be challenged by others. We
also may not have the financial resources to enforce the rights under these trademarks, which may enable others to use the trademarks and dilute their value. Our trademarks may be challenged, infringed, circumvented or declared generic or determined
to be infringing the trademarks of others. In such a case, we may not be able to protect or derive any value from such trademarks, or may be required to cease using a conflicting mark entirely. The value of our trademarks may also be diminished by
our own actions, such as failing to impose appropriate quality control when licensing our trademarks. Any of the foregoing could impair the value of, or ability to use, our trademarks, reduce our ability to compete effectively, and have an adverse
effect on our business. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Certain of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
rights are, and our future owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights may be, subject to a reservation of rights by one or more third parties, including government <FONT STYLE="white-space:nowrap">march-in</FONT>
rights with regards to certain patents, that may limit our ability to exclude third parties from commercializing product candidates similar or identical to ours. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Certain of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights may be subject to a reservation of
rights by one or more third parties. Pursuant to the Bayh-Dole Act, the U.S. government has <FONT STYLE="white-space:nowrap">march-in</FONT> rights with regards to government-funded technology. For example, the U.S. government has certain rights,
including <FONT STYLE="white-space:nowrap">march-in</FONT> rights, to patent rights and technology funded by the U.S. government and licensed to us from BWH. When new technologies are developed with government funding, in order to secure ownership
of such patent rights, the recipient of such funding is required to comply with certain government regulations, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such
inventions. Any failure to timely elect title to such inventions may provide the U.S. government with the right to, at any time, take title to such </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">72
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
inventions. Additionally, the U.S. government generally obtains certain rights in any resulting patents, including a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license authorizing the
government to use the invention or to have others use the invention on its behalf. If the government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. These rights may permit the U.S.
government to disclose our confidential information to third parties and to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights to use or allow third parties to use our licensed technology. The U.S. government can exercise its <FONT
STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to
meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise
by the government of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations, and prospects. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to Our Reliance on Third Parties </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We plan to rely on third parties to conduct our clinical trials. If these third parties do not properly and
successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We plan to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs
and strategic partners to conduct our preclinical studies and clinical trials under agreements with us. We expect to have to negotiate budgets and contracts with CROs, trial sites and CMOs which may result in delays to our development timelines and
increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of
these clinical trials and the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies is conducted in
accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs,
which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors,
principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory
authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot provide assurance that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with
the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMP regulations, including cGTP regulations, and will require a large number of test patients. Our failure or any failure by these third
parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third
parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient
time and resources to our ongoing, clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may
also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if
they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended,
delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">73
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive
management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We have in the past and may in the future form or seek collaborations or strategic alliances or enter into
additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have in the past and may in the future form or seek strategic alliances, create joint ventures or collaborations, or
enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop.
Any of these relationships may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our
management and business. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, we face significant competition in seeking appropriate strategic
partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be
at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency and purity and obtain marketing approval. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Further, collaborations involving our product candidates are subject to numerous risks, which may include the following:
</FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">collaborators have significant discretion in determining the efforts and resources that
they will apply to a collaboration; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">collaborators may not perform their obligations as expected; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">collaborators may not pursue development and commercialization of our product candidates or
may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external
factors, such as a business combination that diverts resources or creates competing priorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">collaborators may delay clinical trials, provide insufficient funding for a clinical trial,
stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">collaborators could independently develop, or develop with third parties, products that
compete directly or indirectly with our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a collaborator with marketing and distribution rights to one or more products may not
commit sufficient resources to their marketing and distribution; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">collaborators may not properly maintain or defend our intellectual property or proprietary
rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential
liability; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">disputes may arise between us and a collaborator that cause the delay or termination of the
research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">74
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the number and type of our collaborations could adversely affect our attractiveness to
future collaborators or acquirers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">there may be conflicts between different collaborators that could negatively affect those
collaborations and potentially others; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">collaborations may be terminated and, if terminated, may result in a need for additional
capital to pursue further development or commercialization of the applicable product candidates; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual
property covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our product
candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business.
We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements
related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our collaboration agreements may grant our collaborators exclusive rights under certain of our intellectual
property, and may therefore preclude us from entering into collaborations with others relating to the same or similar compounds, therapeutic targets, indications or diseases. For example, our existing Collaboration and License Agreement with
Novartis Institutes for Biomedical Research (Novartis) grants Novartis options to obtain exclusive, worldwide licenses to certain target antigens identified in performance of such agreement and corresponding
<FONT STYLE="white-space:nowrap">T-cell</FONT> receptors for such target antigens. In addition, our collaboration agreements may place restrictions or additional obligations on our ability to license additional compounds in different indications,
targets, diseases or geographical locations. If we fail to comply with or breach any provision of a collaboration agreement, a collaborator may have the right to terminate, in whole or in part, such agreement or to seek damages. Many of our
collaborators also have the right to terminate the collaboration agreement for convenience. For example, Novartis may terminate its Collaboration and License Agreement with us at any time for any or no reason upon 90 days&#146; notice. If a
collaboration agreement is terminated, in whole or in part, we may be unable to continue the development and commercialization of the applicable product candidates, and even if we are able to do so, such efforts may be delayed and result in
additional costs. See &#147;Business&#151;License and Collaboration Agreements&#148; for more information regarding our collaboration agreements. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may in the future determine to partner with additional pharmaceutical and biotechnology companies for development and
potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the
collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. If we elect to fund and undertake development or commercialization activities
on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the
necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our discovery platform and our business, prospects, financial condition and results
of operations may be materially and adversely affected. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">75
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>In the future, we may rely on the use of manufacturing suites in
third party GMP facilities or third parties to manufacture our product candidates. Our business could be harmed if we are unable to use third party manufacturing suites or if the third party manufacturers fail to provide us with sufficient
quantities of our product candidates or fail to do so at acceptable quality levels, prices, or timing. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are in the process of adding manufacturing capacity at our facilities in Waltham, which we expect to be operational in
the second fiscal quarter of 2021, but the <FONT STYLE="white-space:nowrap">build-out</FONT> and staffing of the manufacturing suite may be delayed and the suite may never become operational. We have not yet caused our product candidates to be
manufactured or processed on a commercial scale and may not be able to do so for any of our product candidates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We expect to use third parties as part of our manufacturing process for registrational trials for our current pipeline, and we may also use them for product candidates in the future. Our anticipated reliance on a limited number of
third party manufacturers exposes us to the following risks: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">we may be unable to identify manufacturers on acceptable terms or at all because the number
of potential manufacturers is limited and the FDA must inspect any manufacturers for current cGMP and cGTP compliance as part of our marketing application; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a new manufacturer would have to be educated in, or develop substantially equivalent
processes for, the production of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our manufacturers may have little or no experience with autologous cell products, which are
products made from a patient&#146;s own cells, and therefore may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our third party manufacturers might be unable to timely manufacture our product candidates
or produce the quantity and quality required to meet our clinical and commercial needs, if any; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our third party suppliers or collaborators from whom we receive our antibodies used in
combination with our product candidates may be unable to timely manufacture or provide the applicable antibody or produce the quantity and quality required to meet our clinical and commercial needs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">contract manufacturers may not be able to execute our manufacturing procedures and other
logistical support requirements appropriately; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our future contract manufacturers may not perform as agreed, may not devote sufficient
resources to our product candidates or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our product , if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">manufacturers are subject to ongoing periodic unannounced inspection by the FDA and
corresponding state agencies to ensure strict compliance with cGMP, cGTP and other government regulations and corresponding foreign standards. We do not have control over third party manufacturers&#146; compliance with these regulations and
standards; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">we may not own, or may have to share, the intellectual property rights to any improvements
made by our third party manufacturers in the manufacturing process for our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our third party manufacturers could breach or terminate their agreements with us;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">raw materials and components used in the manufacturing process, particularly those for
which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our contract manufacturers and critical reagent suppliers may be subject to inclement
weather, as well as natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our contract manufacturers may have unacceptable or inconsistent product quality success
rates and yields, and we have no direct control over our contract manufacturers&#146; ability to maintain adequate quality control, quality assurance and qualified personnel; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">76
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our contract manufacturers may be adversely affected by the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the ongoing U.S.-China trade war, political unrest in countries where we or our partners operate, earthquakes and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters,
equipment failures, labor shortages, power failures, and numerous other factors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Each of
these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates. In addition, we will rely
on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA
could place significant restrictions on our company until deficiencies are remedied. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The manufacture of
biological drug products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in
production, particularly in scaling up or out, validating the production process and assuring high reliability of the manufacturing process (including the absence of contamination). These problems include logistics and shipping, difficulties with
production costs and yields, quality control, including stability of the product, intermediates, or raw materials, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced federal, state
and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and
remedy the contamination. We cannot provide assurance that any stability failures or other issues relating to the manufacture of our product candidates will not occur in the future. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may fail to manage the logistics of collecting and shipping patient material to our manufacturing site (or that of
any third party we engage) and shipping the product candidate back to the patient. Logistical and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could prevent or delay the delivery of
product candidates to patients. Additionally, we have to maintain a complex chain of identity and chain of custody with respect to patient material as it moves to the manufacturing facility, through the manufacturing process and back to the patient.
Failure to maintain chain of identity and chain of custody could result in patient death, loss of product or regulatory action. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Our product candidates rely on the availability of specialty materials, which may not be available to us on acceptable terms or at all. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our product candidates require specialty materials, some of which are manufactured by small companies with limited
resources and experience to support a commercial product. We do not have long-term contracts with many of these suppliers and may not be able to contract with them on acceptable terms or at all. In addition, a number of our suppliers normally
support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms or may divert their resources towards hospitals rather than us. Our suppliers may be <FONT
STYLE="white-space:nowrap">ill-equipped</FONT> to support our needs, especially in <FONT STYLE="white-space:nowrap">non-routine</FONT> circumstances like an FDA inspection or medical crisis, such as widespread contamination. We may experience delays
in receiving key materials to support clinical or commercial manufacturing. For example, in 2020, we experienced significant delays in receiving shipments of materials utilized in our cell expansion process as a result of the distributor
prioritizing distribution of such products for medical use, rather than product candidate development, and, subsequently, increased demand following the easing of state and federal workplace restrictions. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, some of our raw materials are currently sourced from a single supplier, or a small number of suppliers. For
example, the type of cell culture media and cryopreservation buffer that we currently use in our manufacturing process for <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> are each only sourced from
a limited number of suppliers. In addition, the cell processing equipment and tubing that we use in our current manufacturing process is only </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">77
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
sourced from a single supplier. We also use certain biologic materials, that are available from multiple suppliers, but each version may perform differently, requiring us to characterize them and
potentially modify some of our protocols if we change suppliers. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to
produce these materials for our intended purpose. Accordingly, if we no longer have access to these suppliers, we may experience delays in our clinical or commercial manufacturing which could harm our business or results of operations. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such
processes. Any failure to comply with relevant regulations could result in delays in or termination of our clinical programs and suspension or withdrawal of any regulatory approvals. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In order to commercially produce our product candidates either at our own facility or at a third party&#146;s facility,
we will need to comply with the FDA&#146;s cGMP regulations and guidelines, including cGTPs. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to
inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP, cGTP or other regulatory requirements or delay, interruption or other issues that arise
in the manufacture, fill-finish, packaging, or storage of our TCR-T therapy candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory
authority inspection could significantly impair our ability to develop and commercialize our TCR-T programs, including leading to significant delays in the availability of our TCR-T therapy candidates for our clinical trials or the termination of or
suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our Product candidates. Significant <FONT STYLE="white-space:nowrap">non-compliance</FONT> could also result in the imposition of
sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our Product candidates, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If our third party manufacturers use hazardous and biological materials in a manner that causes injury or violates
applicable law, we may be liable for damages. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our research and development activities involve the
controlled use of potentially hazardous substances, including chemical and biological materials, by our third party manufacturers. Our manufacturing is (and any third party manufacturers we engage are) subject to federal, state and local laws and
regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#146; procedures for using, handling, storing and disposing of these
materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local,
city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources.
We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research,
development and production efforts, which could harm our business, prospects, financial condition or results of operations. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to Employee Matters and Managing Growth </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly
qualified personnel, we may not be able to successfully implement our business strategy. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our ability
to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">78
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
dependent on our management, scientific and medical personnel, including our Chief Executive Officer, our Chief Business Officer, and our Chief Scientific Officer. The loss of the services of any
of our executive officers, other key employees and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in product development and harm our business. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We conduct our operations at our facility in Waltham, Massachusetts. This region is headquarters to many other
biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. Changes to
U.S. immigration and work authorization laws and regulations, including those that restrain the flow of scientific and professional talent, can be significantly affected by political forces and levels of economic activity. Our business may be
materially adversely affected if legislative or administrative changes to immigration or visa laws and regulations impair our hiring processes and goals or projects involving personnel who are not U.S. citizens. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided
stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more
lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with
our key employees, these employment agreements provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could leave our employment at any time, with or without notice. Our success also depends on
our ability to continue to attract, retain and motivate highly skilled junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and senior managers as well as junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and senior scientific and
medical personnel. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We will need to grow the size of our organization, and we may experience
difficulties in managing this growth. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of March&nbsp;31, 2021, we had 63 full-time employees and 1
part-time employee. As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other
personnel, as well as additional facilities to expand our operations. Future growth would impose significant added responsibilities on members of management, including: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">identifying, recruiting, integrating, maintaining and motivating additional employees;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">managing our internal development efforts effectively, including the clinical and FDA
review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">improving our operational, financial and management controls, reporting systems and
procedures. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our future financial performance and our ability to commercialize our product
candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to devote a substantial amount of time to managing these growth activities. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent
organizations, advisors and consultants to provide certain services, including substantially all aspects of regulatory approval, and clinical trial management. There can be no assurance that the services of independent organizations, advisors and
consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services
provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">79
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors
and consultants on economically reasonable terms, or at all. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If we are not able to effectively expand our
organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to effectively build out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary
to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and
expenses. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our operations, and those of our CROs, CMOs and other contractors and consultants, could be
subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters
or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Our ability to obtain
clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to
limit commercialization of our product candidates. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We face an inherent risk of product liability as a
result of the planned clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be
otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product,
negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be
required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">decreased demand for our product candidates or products that we may develop;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">injury to our reputation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">initiation of investigations by regulators; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">costs to defend the related litigation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a diversion of management&#146;s time and our resources; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">substantial monetary awards to trial participants or patients;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">product recalls, withdrawals or labeling, marketing or promotional restrictions;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">loss of revenue; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">exhaustion of any available insurance and our capital resources;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the inability to commercialize any product candidate; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a decline in our share price. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential
product liability claims could prevent or inhibit the commercialization of products we develop, alone or </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">80
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
with corporate collaborators. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have
no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such
amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>U.S. federal income tax reform could adversely affect us. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On December&nbsp;22, 2017, the United States enacted the &#147;Tax Cuts and Jobs Act&#148;, or TCJA, that significantly
reformed the Code. The TCJA, among other things, contained significant changes to corporate taxation, including a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net
interest expense to 30% of adjusted earnings (except for certain small businesses), the limitation of the deduction for net operating loss carryforwards (NOLs) arising in taxable years beginning after December&nbsp;31, 2017 to 80% of current year
taxable income and elimination of NOL carrybacks for losses arising in taxable years ending after December&nbsp;31, 2017 (though any such NOLs may be carried forward indefinitely), the imposition of a <FONT STYLE="white-space:nowrap">one-time</FONT>
taxation of offshore earnings at reduced rates regardless of whether they are repatriated, the elimination of U.S. tax on foreign earnings (subject to certain important exceptions), the allowance of immediate deductions for certain new investments
instead of deductions for depreciation expense over time, and the modification or repeal of many business deductions and credits. The financial statements contained herein reflect the effects of the TCJA based on current guidance. However, there
remain uncertainties and ambiguities in the application of certain provisions of the TCJA, and, as a result, we made certain judgments and assumptions in the interpretation thereof. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As part of Congress&#146;s response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Families First
Coronavirus Response Act (FFCR Act) was enacted on March&nbsp;18, 2020, and the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted on March&nbsp;27, 2020. Both contain numerous tax provisions. In particular, the CARES Act
retroactively and temporarily (for taxable years beginning before January&nbsp;1, 2021) suspends application of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">80%-of-income</FONT></FONT> limitation on the use of NOLs, which
was enacted as part of the TCJA. It also provides that NOLs arising in any taxable year beginning after December&nbsp;31, 2017 and before January&nbsp;1, 2021 are generally eligible to be carried back up to five years. The CARES Act also temporarily
(for taxable years beginning in 2019 or 2020) relaxes the limitation of the tax deductibility for net interest expense by increasing the limitation from 30% to 50% of adjusted taxable income. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Regulatory guidance under the TCJA, the FFCR Act and the CARES Act is and continues to be forthcoming and such guidance
could ultimately increase or lessen impact of these laws on our business and financial condition. It is also likely that Congress will enact additional tax legislation in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic,
some of which could have an impact on our company. In addition, it is uncertain if and to what extent various states will conform to the TCJA, the FFCR Act or the CARES Act. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation
undergoes an &#147;ownership change&#148; (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> net
operating loss carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change taxable income may be limited. As a result of our most recent private placements and other transactions that have
occurred over the past three years, we may have experienced, and, upon closing of this offering, may experience, an &#147;ownership change.&#148; We may also experience ownership changes in the future as a result of subsequent shifts in our stock
ownership. As of December&nbsp;31, 2020, we had U.S. federal net operating loss carryforwards of $17.6&nbsp;million and U.S. federal research and development tax credit carryforwards of $1.5&nbsp;million that expire through 2040 and which could be
limited if we experience an &#147;ownership change.&#148; The reduction of the corporate tax rate under the TCJA may cause a reduction in the </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">81
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
economic benefit of our net operating loss carryforwards and other deferred tax assets available to us. Under the TCJA, federal net operating losses generated after December&nbsp;31, 2017 will
not be subject to expiration. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Risks Related to our Common Stock and to this Offering </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>There has been no prior public market for our common stock, the stock price of our common stock may be volatile or
may decline regardless of our operating performance and stockholders may not be able to resell their shares at or above the initial public offering price. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">There has been no public market for our common stock prior to this offering. The initial public offering price for our
common stock was determined through negotiations between the underwriters and us and may vary from the market price of our common stock following this offering. If a purchaser of shares of our common stock in this offering, may not be able to resell
those shares at or above the initial public offering price. An active or liquid market in our common stock may not develop upon the completion of this offering or, if it does develop, it may not be sustainable. The market price of our common stock
may fluctuate significantly in response to numerous factors, many of which are beyond our control, including: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">overall performance of the equity markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our operating performance and the performance of other similar companies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">results from our ongoing clinical trials and future clinical trials with our current and
future product candidates or of our competitors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">delays in the commencement, enrollment and the ultimate completion of clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">changes in our projected operating results that we provide to the public, our failure to
meet these projections or changes in recommendations by securities analysts that elect to follow our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">regulatory actions with respect to our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">regulatory or legal developments in the United States and other countries;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the level of expenses related to future product candidates or clinical development
programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our failure to achieve product development or commercialization goals or regulatory
approval milestones in the timeframe we announce; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">changes in hospital or ECP practices; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">announcements of acquisitions, strategic alliances or significant agreements by us or by
our competitors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">developments or disputes concerning intellectual property or proprietary rights;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to obtain, maintain, protect and enforce our intellectual property and
proprietary rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">recruitment or departure of key personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the economy as a whole and market conditions in our industry, including conditions
resulting from <FONT STYLE="white-space:nowrap">COVID-19;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">variations in our financial results or the financial results of companies that are
perceived to be similar to us; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">financing or other corporate transactions, or inability to obtain additional funding;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">trading activity by a limited number of stockholders who together beneficially own a
majority of our outstanding common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the expiration of market standoff or contractual
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">82
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the size of our market float; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">any other factors discussed in this prospectus. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to
affect the market prices of equity securities of many biopharmaceutical companies. Stock prices of many biopharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the
past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of
management from our business and adversely affect our business. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If securities or industry analysts do
not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The trading market for our common stock will depend in part on the research and reports that securities or industry
analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or only very few securities analysts commence coverage of us, or if industry analysts cease coverage
of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely
decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Purchasers of shares of our common stock in this offering will experience substantial and immediate dilution.
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Purchasers of shares of our common stock in this offering will experience substantial and immediate
dilution in the pro forma net tangible book value per share after giving effect to this offering of $6.54 per share as of March&nbsp;31, 2021, based on the initial public offering price of our common stock of $15.00 per share, because the price that
a purchaser pays will be substantially greater than the pro forma net tangible book value per share of the common stock that the purchaser acquires. This dilution is due in large part to the fact that our earlier investors paid substantially less
than the initial public offering price when they purchased their shares of our capital stock. Purchasers in this offering will experience additional dilution upon exercise of options to purchase common stock under our equity incentive plans, upon
vesting of options to purchase common stock under our equity incentive plans, if we issue restricted stock to our employees under our equity incentive plans or if we otherwise issue additional shares of our common stock. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Substantial amounts of our outstanding shares may be sold into the market
<FONT STYLE="white-space:nowrap">when&nbsp;lock-up&nbsp;periods</FONT> end. If there are substantial sales of shares of our common stock, the price of our common stock could decline. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our
directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. After this offering, we will have 23,938,366 outstanding
shares of our common stock (including 5,139,633 shares of non-voting common stock), based on the number of shares outstanding as of March&nbsp;31, 2021. All of the shares of common stock sold in this offering will be available for sale in the public
market, unless purchased by our affiliates or existing stockholders. Substantially all of our outstanding shares of common stock are currently restricted from resale as a result of <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT>
agreements (which may be waived by Morgan Stanley &amp; Co. LLC, Jefferies LLC, Cowen and Company, LLC, and Barclays Capital Inc. with or without notice), as more fully described in &#147;Shares Eligible for Future Sale.&#148; These shares will
become available to be sold 181 days after the date of this prospectus. Shares held by directors, executive officers and other affiliates will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or the
Securities Act, and various vesting agreements. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">83
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">After our initial public offering, certain of our stockholders will have
rights, subject to some conditions and subject to the lock-up agreements described above, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our
stockholders, subject to lockup agreements. We also intend to register shares of common stock that we have issued and may issue under our employee equity incentive plans. Once we register these shares, they will be able to be sold freely in the
public market upon issuance, subject to existing market standoff or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements (including the lock-up agreements described above). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our
shares of common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell their shares. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>The concentration of our stock ownership will likely limit our stockholders&#146; ability to influence corporate
matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Prior to this offering our executive officers, directors, and 5% or greater stockholders beneficially owned, in the
aggregate, approximately 76.7% of our outstanding voting stock as of March 31, 2021, and, upon the closing of this offering, that same group will beneficially own approximately 45.7% of our outstanding voting stock (assuming no purchases of shares
in this offering by any members of this group (including through our directed share program), no exercise by the underwriters of their option to purchase additional shares, no exercise of outstanding options or warrants and after giving effect to
the issuance of shares in this offering, and further assuming that all shares of non-voting common stock are converted into voting common stock in accordance with the terms of our amended and restated certificate of incorporation). See
&#147;Description of capital stock&#151;Common Stock and Non-Voting Common Stock&#148;. As a result, these stockholders, acting together, will have significant influence over all matters that require approval by our stockholders, including the
election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders, including those who purchase shares in this offering, oppose them. This concentration of ownership might also have
the effect of delaying or preventing a change of control of our company that other stockholders may view as beneficial. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">In addition, we entered into a nominating agreement with Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the BBA Funds which was subsequently amended and restated on April 22, 2021), pursuant to which, among other
things, we agreed to support the nomination of, and cause our board of directors (or the nominating committee thereof) to include in the slate of nominees recommended to our stockholders for election as directors at each annual or special meeting of
our stockholders at which directors are to be elected, one person designated from time to time by the BBA Funds, subject to the requirements of fiduciary duties under applicable law and the terms and conditions of such nominating agreement. The
agreement only applies during the period beginning at the closing of our initial public offering and for the three years thereafter, as long as (1)&nbsp;the BBA Funds and their affiliates, collectively, beneficially own at least 75% of the Series C
convertible preferred stock purchased by the BBA Funds in such Series C convertible preferred stock financing, or such number of shares of our common stock issued upon conversion of such number of shares of Series C convertible preferred stock (in
either case, as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification or similar transaction), and (2)&nbsp;the BBA Funds and their affiliates, collectively, beneficially own at least 2% of our then
outstanding voting common stock. For more information regarding this nominating agreement, see the section entitled &#147;Management&#151;Board composition.&#148; This concentration of ownership may prevent or discourage unsolicited acquisition
proposals or offers for our common stock that you or other stockholders may feel are in your or their best interest as one of our stockholders. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">84
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller
reporting company,&#148; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are an &#147;emerging growth company&#148; as defined in the JOBS Act and we intend to take advantage of some of the
exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the option to present only two years of audited financial statements, in addition to any
required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">not being required to comply with the auditor attestation requirements of
Section&nbsp;404(b) of the Sarbanes Oxley Act; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">not being required to comply with any requirement that may be adopted by the Public Company
Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">not being required to disclose certain executive compensation-related items such as the
correlation between executive compensation and performance and comparisons of the chief executive officer&#146;s compensation to median employee compensation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">not being required to submit certain executive compensation matters to stockholder advisory
votes, such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay,&#148;</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-frequency,&#148;</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-golden</FONT></FONT> parachutes.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">The JOBS Act permits an &#147;emerging growth company&#148; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to take
advantage of this extended transition period. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We cannot predict if investors will find our common stock less
attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage
of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of
this offering, (b)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the
prior three-year period. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Even after we no longer qualify as an emerging growth company, we may still qualify
as a &#147;smaller reporting company,&#148; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section
404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we
may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Requirements associated with being a public company will increase our costs significantly, as well as divert
significant company resources and management attention. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">After the completion of this offering, we
will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or the other rules and regulations of the Securities and Exchange Commission, or the SEC, or any securities exchange relating to
public companies. Compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">85
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
management and we will incur significant legal, accounting and other expenses that we did not incur as a private company. We cannot provide assurance that we will satisfy our obligations as a
public company on a timely basis. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, as a public company, it may be more difficult or more costly
for us to obtain certain types of insurance, including directors&#146; and officers&#146; liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar
coverage. The impact of these events could also make it more difficult for us to attract and retain qualified personnel to serve on our board of directors, our board committees or as executive officers. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely
financial statements could be impaired, which could result in sanctions or other penalties that would harm our business. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">After the completion of this offering, we will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of the Nasdaq Global Market, or Nasdaq. The Sarbanes Oxley Act
requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. Commencing with our fiscal year ending the year after this offering is completed, we must perform system and
process design evaluation and testing of the effectiveness of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;filing</FONT> for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to
document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting
personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing
that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. This will require that we incur substantial additional professional fees and internal costs to
expand our accounting and finance functions and that we expend significant management efforts. Prior to this offering, we have never been required to test our internal controls within a specified period and, as a result, we may experience difficulty
in meeting these reporting requirements in a timely manner. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may discover weaknesses in our system of
internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system,
no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide
absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or
if we are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported
financial information, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities including equivalent foreign authorities. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively.
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We cannot specify with any certainty the particular uses of the net proceeds that we will receive
from this offering, but we currently expect such uses will include conducting clinical trials for TSC-100, TSC-101, and TSC-102, conducting IND-enabling activities and initiate clinical trials for TSC-200, TSC-201, TSC-202, and TSC-203,
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">86
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
continuing development of our pre-clinical discovery programs and platform technologies, further expanding our existing manufacturing facility, and other general corporate purposes, which may
include the hiring of additional personnel, capital expenditures and the costs of operating as a public company. We will have broad discretion in the application of the net proceeds, including working capital and other general corporate purposes,
and purchasers in this offering and other stockholders may disagree with how we spend or invest these proceeds. The failure by our management to apply these funds effectively could adversely affect our business and financial condition. Pending their
use, we may invest the net proceeds from our initial public offering in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We do not intend to pay dividends for the foreseeable future. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have never declared nor paid cash dividends on our capital stock. We currently intend to retain any future earnings to
finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable future. Consequently, stockholders must rely on sales of their common stock after price appreciation, which may never occur,
as the only way to realize any future gains on their investment. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>We could be subject to securities
class action litigation. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the past, securities class action litigation has often been brought
against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation,
it could result in substantial costs and a diversion of management&#146;s attention and resources, which could harm our business. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to
predict our future operating results. Our operating results may fluctuate due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the timing and success or failure of clinical trials for our product candidates or
competing product candidates, including the nature of the data obtained from such clinical trials, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to successfully recruit patients for preclinical studies and clinical trials,
and any delays caused by difficulties in such recruitment efforts; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to obtain regulatory approval for our product candidates, and the timing and
scope of any such approvals we may receive; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the timing and cost of, and level of investment in, research and development activities
relating to our product candidates, which may change from time to time; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cost of manufacturing our product candidates, which may vary depending on the quantity
of production and the terms of our agreements with manufacturers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to attract, hire and retain qualified personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">expenditures that we will or may incur to develop additional product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the level of demand for our product candidates should they receive approval, which may vary
significantly; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the risk/benefit profile, cost and reimbursement policies with respect to our product
candidates, if approved, and existing and potential future drugs that compete with our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the changing and volatile U.S., European and global economic environments, including impact
of <FONT STYLE="white-space:nowrap">COVID-19;</FONT> and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">future accounting pronouncements or changes in our accounting policies.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">87
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The cumulative effects of these factors could result in large fluctuations
and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. This
variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or
below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur
even when we have met any previously publicly stated guidance we may provide. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Delaware law and
provisions in our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect at the completion of this offering could make a merger, tender offer or proxy contest difficult, thereby depressing the
trading price of our common stock. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Following the completion of this offering, our status as a
Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period
of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws that
will be in effect at the completion of this offering will contain provisions that may make the acquisition of our company more difficult, including the following: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a classified board of directors with three-year staggered terms, which could delay the
ability of stockholders to change the membership of a majority of our board of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the ability of our board of directors to issue shares of preferred stock and to determine
the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the exclusive right of our board of directors to elect a director to fill a vacancy created
by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a prohibition on stockholder action by written consent, which forces stockholder action to
be taken at an annual or special meeting of our stockholders; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the requirement that a special meeting of stockholders may be called only by a majority
vote of our entire board of directors, the chairman of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of
directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the requirement for the affirmative vote of holders of at least 66 2/3% of the voting power
of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation or our amended and restated bylaws, which may inhibit the ability of an
acquiror to effect such amendments to facilitate an unsolicited takeover attempt; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">advance notice procedures with which stockholders must comply to nominate candidates to our
board of directors or to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise
attempting to obtain control of us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, as a Delaware corporation, we are subject
to Section&nbsp;203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A
Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this
provision. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">88
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">These and other provisions in our amended and restated certificate of
incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors,
including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for stockholders to realize value in a corporate
transaction. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For information regarding these and other provisions, see the section titled &#147;Description
of capital stock.&#148; </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Our amended and restated certificate of incorporation provides that the Court
of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a
favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our amended
and restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any
action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws or any action asserting a claim against us that is governed by the internal affairs doctrine. This provision
would not apply to claims brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our amended and restated certificate of incorporation provides further that the
federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, including claims arising from this offering. These choices of forum provisions may
limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar
choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware
courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive-forum provisions, and there can be no assurance that such
provisions will be enforced by a court in those other jurisdictions. If a court were to find the exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may
incur additional costs associated with resolving such action in other jurisdictions, which could harm our business. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">89
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">This prospectus contains forward-looking statements that involve substantial risks and
uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, future revenue, business strategy, prospects, product
candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are
forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking statements. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">The words &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;would,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148;
&#147;contemplate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions are intended to identify forward looking statements.
Forward-looking statements contained in this prospectus include, but are not limited to, statements about: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the beneficial characteristics, safety, efficacy, therapeutic effects and potential
advantages of our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our expectations regarding our preclinical studies being predictive of clinical trial
results; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the timing of the initiation, progress and expected results of our preclinical studies,
clinical trials and our research and development programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our plans relating to developing and commercializing our
<FONT STYLE="white-space:nowrap">TCR-T&nbsp;therapy</FONT> candidates, if approved, including sales strategy; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">estimates of the size of the addressable market for our TCR-T therapy candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our manufacturing capabilities and the scalable nature of our manufacturing process;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our estimates regarding expenses, future milestone payments and revenue, capital
requirements and needs for additional financing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our expectations regarding competition; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our anticipated growth strategies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to attract or retain key personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to establish and maintain development partnerships and collaborations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our expectations regarding federal, state and foreign regulatory requirements;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">regulatory developments in the United States and foreign countries;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to obtain and maintain intellectual property protection for our proprietary
platform technology and our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the anticipated trends and challenges in our business and the market in which we operate;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the sufficiency of our existing capital resources to fund our future operating expenses and
capital expenditure requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the effect of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including
mitigation efforts and political, economic, legal and social effects, on any of the foregoing or other aspects of our business or operations; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our anticipated use of our existing resources and the proceeds from this offering and our
ability to obtain additional financing in the future. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">These forward-looking statements are
subject to a number of risks, uncertainties and assumptions, including those described in the section titled &#147;Risk factors&#148; elsewhere in this prospectus. Moreover, we operate in a very
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">90
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the
forward- looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements
contained in this prospectus are made as of the date of this prospectus, and although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, advancements,
discoveries, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the
accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in
our expectations. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">You should read this prospectus and the documents that we reference in this prospectus and
have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from
what we expect. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">91
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_4"></A>INDUSTRY AND MARKET DATA </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">This prospectus contains estimates, projections and other information concerning our industry, our business and the
markets for our product candidates, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set forth in this prospectus from our internal
estimates and research, and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Industry publications and third party research, surveys and studies generally indicate
that their information has been obtained from sources believed to be reliable. Our estimates of the potential market opportunities for our product candidates include a number of key assumptions based on our industry knowledge, industry publications
and third party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. Information based on estimates, forecasts, projections, market research or similar methodologies is
inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other
data from reports, research surveys, studies and similar data prepared by us and third parties, industry, medical and general publications, government data and similar sources. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">92
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_5"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We estimate that the net proceeds from this offering will be approximately $90.1 million, or $104.1 million if the
underwriters exercise their option to purchase additional shares in full, based on the initial public offering price of $15.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of March&nbsp;31, 2021, we had cash of $121.5 million. We currently intend to use the net proceeds from
this offering, together with our existing cash, as follows: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">approximately $30.0 million to fund the Phase 1/2 clinical development of TSC-100, TSC-101,
and TSC-102, through completion of the Phase 1 portion and part of the Phase&nbsp;2 portion of our planned Phase&nbsp;1/2 clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">approximately $35.0 million to conduct IND-enabling activities and initiate the Phase 1
clinical trials for TSC-200, TSC-201, TSC-202 and TSC-203; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">approximately $25.0 million for the continued development of our discovery programs; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the remainder for continued development of our TargetScan and ReceptorScan platforms,
further expansion of our existing manufacturing facility, working capital and other general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">This expected use of the net proceeds from this offering represents our intentions based
upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be
received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures and the extent of our preclinical, clinical and future development activities may
vary significantly depending on numerous factors, including the progress of our and our development partner&#146;s development efforts, the status of and results from our planned clinical trials, the timing of regulatory submissions and the outcome
of regulatory review, the timing and costs associated with the manufacture and supply of product candidates for clinical development or commercialization, as well as any collaborations that we may enter into with third parties for our product
candidates, and any unforeseen cash needs. As a result, we will retain broad discretion over the allocation of the net proceeds from this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Based on our planned use of the net proceeds from this offering and our existing cash, we estimate that such funds will
be sufficient to enable us to fund our operating expenses and capital expenditure requirements into 2024. We have based these estimates on assumptions that may prove to be wrong and we could use our capital resources sooner than we currently expect.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may also use a portion of the net proceeds from this offering for the acquisition or <FONT
STYLE="white-space:nowrap">in-license</FONT> of other therapeutic products, businesses or technologies, although we have no current agreements or commitments for any material acquisitions or licenses of any products, businesses or technologies.
Pending our use of the net proceeds from this offering, we plan to invest the net proceeds in a variety of capital preservation investments, including short-term interest-bearing investment-grade securities, certificates of deposit or government
securities. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">93
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_6"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have never declared or paid any cash dividends on our capital stock and we do not currently intend to pay any cash
dividends on our capital stock for the foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Our future ability to pay cash
dividends on our capital stock may also be limited by the terms of any future debt or preferred securities or any future credit facility. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">94
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_7"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table sets forth our cash and our capitalization as of March 31, 2021: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">on an actual basis; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">on a pro forma basis to give effect to (i)&nbsp;the automatic conversion of all outstanding
shares of our preferred stock into an aggregate of 15,616,272 shares of common stock (including 5,139,633 shares of non-voting common stock) upon completion of this offering, as if such conversion had occurred on March&nbsp;31, 2021; and
(ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation, which will occur immediately prior to the completion of this offering; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">on a pro forma as adjusted basis to give further effect to the sale and issuance of
6,666,667 shares of our common stock by us in this offering at the initial public offering price of $15.00 per share of common stock, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">You should read this information in conjunction with our financial statements and the
related notes appearing elsewhere in this prospectus, as well as the section of this prospectus titled &#147;Management&#146;s discussion and analysis of financial condition and results of operations.&#148; </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>As of March 31, 2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Pro&nbsp;Forma</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Pro<BR>Forma<BR>as<BR>Adjusted</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT COLOR="#32406b"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per<BR>share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">121,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">121,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">211,601</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Convertible preferred stock (Series A Preferred Stock, Series&nbsp;B
Preferred Stock and Series C Preferred Stock), $0.0001 par value; 128,053,586 shares authorized; 15,616,272 shares issued and outstanding, actual; no shares authorized, issued, and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">159,411</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stockholders&#146; (deficit) equity:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Preferred stock, $0.0001 par value per share; no shares authorized, issued
and outstanding, actual; 10,000,000 shares authorized, no shares issued and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Common stock, $0.0001 par value per share; 165,210,543 shares authorized,
1,655,427 shares issued and 1,304,789 outstanding, actual; 300,000,000 shares authorized, 12,108,746 shares issued and 11,758,108 outstanding, pro forma; 300,000,000 shares authorized, shares 18,798,733 issued and 18,448,095 shares outstanding, pro
forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Non-voting common stock, $0.0001 par value per share; no shares authorized,
issued or outstanding, actual; 10,000,000 shares authorized, 5,139,633 shares issued and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT>
capital</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">160,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">251,011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(51,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(51,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(51,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total stockholders&#146; (deficit) equity</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(49,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">109,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">199,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">109,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">109,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">199,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">95
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The above discussion and table are based on shares of common stock
outstanding as of March 31, 2021 and excludes the following: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">350,638 outstanding shares of common stock from the number of issued shares of common stock
pursuant to U.S. generally accepted accounting principles, or GAAP, due to such shares being subject to a right of repurchase by us at March&nbsp;31, 2021; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">2,525,506 shares of common stock issuable upon the exercise of options outstanding under
our 2018 Plan, as of March 31, 2021, with a weighted-average exercise price of $4.98 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">150,889 shares of common stock reserved for future issuance under our 2018 Plan, based on
the number of shares available for issuance as of March&nbsp;31, 2021, which shares will be added to the shares to be reserved under our 2021 Plan, at the time our 2021 Plan becomes effective in connection with this offering;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">3,278,048 shares of common stock that will become available for future issuance under our
2021 Plan, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021
Plan; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">254,390 shares of common stock that will become available for future issuance under our
2021 ESPP, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021
ESPP. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">96
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_8"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of
the difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of March&nbsp;31, 2021, our historical net tangible book value (deficit) was $(51.0) million, or $(39.12) per share
of common stock. Our historical net tangible book value (deficit) represents our total tangible assets (including our right of use asset related to our lease) less our liabilities and preferred stock, which is not included in stockholders&#146;
(deficit). Our historical net tangible book value (deficit) per share represents historical net tangible book value (deficit) divided by 1,304,789 shares of common stock outstanding as of March&nbsp;31, 2021. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our pro forma net tangible book value as of March&nbsp;31, 2021, was $108.4&nbsp;million, or $6.40 per share of common
stock (including shares of non-voting common stock), after giving effect to the automatic conversion of all outstanding shares of our preferred stock, into an aggregate of 15,616,272 shares of common stock (including 5,139,633 shares of non-voting
common stock) immediately prior to the completion of this offering. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">After giving further effect to our sale
of 6,666,667 shares of common stock in this offering at the initial public offering price of $15.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net
tangible book value as of March&nbsp;31, 2021 would have been $199.6 million, or $8.46 per share of common stock (including shares of non-voting common stock). This represents an immediate increase in pro forma as adjusted net tangible book value of
$2.06 per share to our existing stockholders and an immediate dilution of $6.54 per share to investors purchasing common stock in this offering. We determine dilution per share to new investors participating in this offering by subtracting pro forma
as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by investors participating in this offering. The following table illustrates this dilution to investors participating in this
offering on a per share basis: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Initial public offering price per share</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">15.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Historical net tangible book value (deficit) per share as of March&nbsp;31,
2021</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(39.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Increase in historical net tangible book value per share attributable to
conversion of our outstanding preferred stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">45.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Pro forma net tangible book value per share as of March&nbsp;31,
2021</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Increase in pro forma net tangible book value per share attributable to new
investors in this offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Pro forma as adjusted net tangible book value per share immediately after
this offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Dilution per share to new investors purchasing shares in this
offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If the underwriters&#146; option to purchase additional shares of common stock in this
offering is exercised in full, the pro forma as adjusted net tangible book value would be $213.5 million, representing an immediate increase in pro forma as adjusted net tangible book value per share of $2.28 to existing stockholders and immediate
dilution per share to investors participating in this offering of $6.32, based on the initial public offering price of $15.00 per share of common stock, and after deducting underwriting discounts and commissions and estimated offering expenses
payable by us. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">97
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The table below summarizes, as of March&nbsp;31, 2021, on the pro forma as
adjusted basis described above, the number of shares of our common stock, the total consideration, and the average price per share paid to us by our existing stockholders and to be paid by new investors participating in this offering at the initial
public offering price of $15.00 per share, and before deducting underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares purchased</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total&nbsp;consideration</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Weighted-<BR>average<BR>price per<BR>share</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Number</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Existing stockholders</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">17,271,699</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">72.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">160,502,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">61.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9.29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">New investors participating in this offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,666,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">27.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">100,000,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">38.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">15.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">23,938,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">260,502,895</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">10.88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The table above assumes no exercise of the underwriters&#146; option to purchase
additional shares of common stock in this offering. If the underwriters&#146; option to purchase additional shares of common stock is exercised in full, the number of shares held by existing stockholders will be reduced to 69.3% of the total number
of shares of common stock to be outstanding upon completion of this offering, and the number of shares of common stock held by new investors participating in this offering will be increased to 30.7% of the total number of shares of common stock to
be outstanding upon completion of the offering. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The tables and discussion above are based on the number of
shares of our common stock outstanding as of March&nbsp;31, 2021 and gives effect to the conversion of all of our outstanding preferred stock into shares of our common stock (including non-voting common stock) upon the completion of this offering
and excludes the following: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">350,638 shares of common stock that were issued and outstanding but that were subject to a
right of repurchase by us at March 31, 2021 and are not included in stockholders&#146; equity pursuant to GAAP; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">2,525,506 shares of common stock issuable upon the exercise of options outstanding under
our 2018 Plan, as of March&nbsp;31, 2021, with a weighted-average exercise price of $4.98 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">150,889 shares of common stock reserved for future issuance under our 2018 Plan, based on
the number of shares available for issuance as of March&nbsp;31, 2021, which shares will be added to the shares to be reserved under our 2021 Plan, at the time our 2021 Plan becomes effective in connection with this offering;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">3,278,048 shares of common stock that will become available for future issuance under our
2021 Plan, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021
Plan; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">254,390 shares of common stock that will become available for future issuance under our
2021 ESPP, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021
ESPP. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To the extent that any outstanding options are exercised or new awards are granted
under our equity compensation plans, new investors will experience further dilution. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">98
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>You should read the following discussion and analysis
of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this
prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth
in the &#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements&#148; sections of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements
contained in the following discussion and analysis. </I></FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Overview </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are a preclinical-stage biopharmaceutical company focused on developing a robust pipeline of T cell
receptor-engineered T cell, or <FONT STYLE="white-space:nowrap">TCR-T,</FONT> therapies for the treatment of patients with cancer. Our approach is based on the central premise that we can learn from patients who are winning their fight against
cancer in order to treat those who are not. Using one of our proprietary platform technologies, TargetScan, we analyze the T cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system naturally recognizes
and eliminates tumor cells in these patients. This allows us to precisely identify the targets of T cell receptors, or TCRs, that are driving these exceptional responses. We aim to use these anti-cancer TCRs to treat patients with cancer by
genetically engineering their own T cells to recognize and eliminate their cancer. In addition to discovering <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies against novel targets, we are using our ReceptorScan technology to further
diversify our portfolio of therapeutic TCRs. We believe this <FONT STYLE="white-space:nowrap">two-pronged</FONT> approach will enable us to discover and develop a wide array of potential treatment options for patients with cancer. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are advancing a robust pipeline of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates for the treatment
of patients with hematologic and solid tumor malignancies. Our lead liquid tumor product candidates, <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> are in development for the treatment of
patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation, or HCT. <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT>
target <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2</FONT> antigens, respectively, which are well-recognized TCR targets that were identified in patients with exceptional responses to <FONT
STYLE="white-space:nowrap">HCT-associated</FONT> immunotherapy. In addition, we are developing multiple <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates for the treatment of various solid tumors. One of the key goals for our solid
tumor program is to develop what we refer to as multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. We are designing these multiplexed therapies to be a combination of up to three highly active TCRs that are customized for each
patient and selected from our bank of therapeutic TCRs, which we refer to as ImmunoBank. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Since our inception
in 2018, we have devoted our efforts to raising capital, obtaining financing, filing, prosecuting and maintaining intellectual property rights, organizing and staffing our company and incurring research and development costs related to the
identification of novel targets for TCRs and development of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies to target and eliminate cancer cells. We do not have any therapies approved for sale and have not generated any revenue from product
sales. To date, we have funded our operations primarily with proceeds from sales of convertible preferred stock and revenue received under our collaboration agreement with Novartis Institutes for Biomedical Research, Inc., or Novartis. Through
March&nbsp;31, 2021, we have received gross proceeds of $160.0&nbsp;million from sales of our convertible preferred stock. Under the terms of our Collaboration and License Agreement with Novartis, we received a $20.0&nbsp;million upfront payment and
agreed to invest an estimated $10.0&nbsp;million in research costs that will be reimbursed by Novartis over the research term. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We have incurred significant operating losses since our inception. We reported net losses of $26.1&nbsp;million and $7.9&nbsp;million for the year ended December&nbsp;31, 2020 and the three months ended March&nbsp;31, 2021,
respectively. As of March&nbsp;31, 2021, we had an accumulated deficit of $51.4&nbsp;million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We expect that our expenses </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">99
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
and capital expenditures will increase substantially in connection with our ongoing activities, particularly if and as we: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">continue our research and development efforts to identify and develop product candidates
and submit investigational new drug applications, or INDs, for such product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">conduct preclinical studies and commence clinical trials for our current and future product
candidates based on our proprietary platform; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">develop processes suitable for manufacturing and clinical development
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">continue to develop and expand our manufacturing capabilities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">seek marketing approvals for any product candidates that successfully complete clinical
trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">build commercial infrastructure to support sales and marketing for our product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">expand, maintain and protect our intellectual property portfolio;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">hire additional clinical, regulatory and scientific personnel; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">operate as a public company. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We will not generate revenue from sales of our therapies unless and until we successfully complete clinical development
and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support
the sales, marketing and distribution of those therapies. Further, following the completion of this offering, we expect to incur additional costs associated with operating as a public company. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth
strategy. Until such time as we can generate significant revenue from sales of our therapies, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, or other capital sources, including collaborations
with other companies, and other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such
agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of one or more of our product candidates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Because of the numerous risks and uncertainties associated with <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy
candidate development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are able to generate sales of our therapies, we may not become
profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We believe that the expected net proceeds from this offering, together with our existing cash will enable us to fund our
operating expenses and capital expenditures into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#147;&#151;Liquidity and capital
resources&#148; and &#147;Risk factors&#151;Risks related to our financial position and need for additional capital.&#148; </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In March 2020, the World Health Organization declared the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak a
pandemic. The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> global and national health emergency has caused significant disruption in the international and United States economies and financial markets. The spread of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> has caused illness, quarantines, </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">100
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
cancellation of events and travel, business and school shutdowns, reduction in business activity and financial transactions, labor shortages, supply chain interruptions and overall economic and
financial market instability and business disruptions for us and many of our vendors. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In response to public
health directives and orders and to help minimize the risk of the virus to employees, we have taken a series of actions aimed at safeguarding our employees and business associates, including implementing a flexible <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">work-at-home</FONT></FONT> policy. These disruptions could result in increased costs of execution of development plans or may negatively impact the quality, quantity, timing and regulatory usability of data that we would
otherwise be able to collect. While these disruptions are currently expected to be temporary, there is considerable uncertainty around the duration of these disruptions. Therefore, the related financial impact and duration cannot be reasonably
estimated at this time. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Components of Results of Operations </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Revenue </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To date, our revenue has been derived from our one collaboration and two licensing agreements. We have not generated any
revenue from the sale of therapies to date, nor do we expect to originate revenues therefrom in the near future, if at all. If our development efforts for our product candidates are successful and result in regulatory approval or if we enter into
additional license or collaboration agreements with third parties, we may generate additional revenue in the future from sales of our therapies, payments from license or collaboration agreements that we may enter into with third parties, or any
combination thereof. However, there can be no assurance as to when we will generate such revenue, if at all. We expect that our revenue for at least the next several years will be derived primarily from collaborations and licenses that we may enter
into in the future, if any. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Collaboration Revenue </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In March 2020, we entered into a Collaboration and License Agreement, or the Novartis Agreement, with Novartis Institutes
for Biomedical Research, Inc., or Novartis, to collaborate on their research efforts to discover and develop novel <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies. Under the Novartis Agreement, we will identify and characterize TCRs in
accordance with a research plan, transfer data arising from the research plan, and Novartis will have the option to license and develop TCRs for up to three novel targets identified in performance of the collaboration during the collaboration period
of the Novartis Agreement. Novartis will also have rights of first negotiation for certain additional targets and TCRs identified in performance of the collaboration during a defined period. We are free to develop TCRs against targets not licensed
by Novartis. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The collaboration includes an upfront fee and research funding together totaling
$30.0&nbsp;million and potential milestone payments contingent on clinical, regulatory and sales success that could aggregate in the hundreds of millions of dollars. In addition to the milestones, Novartis will pay us royalties equal to a percentage
in the <FONT STYLE="white-space:nowrap">mid-single-digits</FONT> to <FONT STYLE="white-space:nowrap">low-teens</FONT> on net sales for each therapy. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Novartis Agreement is within the scope of ASC 606 under which we have identified a single performance obligation
consisting of the research services, data reporting and participation in a joint steering committee. During the three months ended March&nbsp;31, 2021, we recognized $2.0&nbsp;million of revenue associated with the Novartis Agreement. We expect to
recognize the remaining arrangement consideration over the expected research term, which is not expected to exceed 3 years. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Operating Expenses </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Research and Development Expenses </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development expenses consist primarily of costs incurred in connection with our research activities,
including our therapeutic discovery efforts, preclinical trials and the development of our proprietary </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">101
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
platform technologies and product candidates. We expense research and development costs as incurred, which include: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">employee-related expenses, including salaries, bonuses, benefits, stock-based compensation,
and other related costs for those employees involved in research and development efforts; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">expenses incurred in connection with our research programs, including under agreements with
third parties, such as consultants and contract research organizations, or CROs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cost of raw materials, developing and scaling our manufacturing process, and
manufacturing our product candidates for use in our research and preclinical studies, including under agreements with third parties, such as consultants, contractors, and CMOs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">laboratory supplies and research materials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">facilities, depreciation, and other expenses, which include direct and allocated expenses
for rent and maintenance of facilities and insurance; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">payments made under third party licensing agreements. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We expense research and development costs as incurred. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance
payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are
performed, or when it is no longer expected that the goods will be delivered or the services rendered. Upfront payments under license agreements are expensed upon receipt of the license, and annual maintenance fees under license agreements are
expensed in the period in which they are incurred. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the
related amount is reasonably estimable. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our direct external research and development expenses consist of
costs that include fees, reimbursed materials, direct material costs, and other costs paid to consultants, contractors, CMOs and CROs in connection with our development and manufacturing activities. We do not allocate employee costs, general
laboratory supplies, and facilities expenses, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple programs and our platform technology and, as such, are not
separately classified. When our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates enter clinical development, we will begin to segregate related research and development expenses by product candidate. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Product candidates in later stages of clinical development generally have higher development costs than those in
preclinical and earlier stages of clinical development, primarily due increased size and duration of later stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our planned
preclinical and clinical development activities in the near term and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical
development of any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with therapeutic development and
commercialization, including the following: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the number and scope of preclinical and clinical programs we decide to pursue;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the timing and progress of preclinical and clinical development activities for each
program; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to raise additional funds necessary to complete preclinical and clinical
development of and commercialize our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the progress of the development efforts of parties with whom we may enter into
collaboration arrangements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to maintain our current research and development programs and to establish new
ones; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">102
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to establish new licensing or collaboration arrangements;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the successful initiation and completion of clinical trials with safety, tolerability and
efficacy profiles that are satisfactory to the U.S. Food and Drug Administration, or the FDA, or any comparable foreign regulatory authority; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the receipt and related terms of regulatory approvals from applicable regulatory
authorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the availability of raw materials for use in the manufacture of our product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to consistently manufacture our product candidates for use in clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to establish and operate a manufacturing facility, or secure manufacturing
supply through relationships with third parties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to obtain and maintain patents, trade secret protection and regulatory
exclusivity, both in the United States and internationally; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to protect our rights in our intellectual property portfolio;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the commercialization of our product candidates, if and when approved;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">obtaining and maintaining third party insurance coverage and adequate reimbursement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the acceptance of our product candidates, if approved, by patients, the medical community
and third party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">competition with other products and therapies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a continued acceptable safety profile of our therapies following approval.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A change in the outcome of any of these variables with respect to the development of any
of our product candidates could significantly change the costs and timing associated with the development of these product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates or in establishing market
acceptance for any product candidates that may be approved. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>General and Administrative Expenses </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">General and administrative expenses consist primarily of salaries and personnel expenses, including stock-based
compensation, for our personnel in executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include legal fees relating to corporate matters; professional fees paid for
accounting, auditing, consulting, and tax services; insurance costs; travel expenses; and facility costs not otherwise included in research and development expenses. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to
support our continued research activities and development of our product candidates. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as
investor and public relations expenses associated with operating as a public company. In addition, if we obtain regulatory approval for a product candidate and do not enter into a third party commercialization collaboration, we expect to incur
significant expenses related to building a sales and marketing team to support sales, marketing and distribution activities. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Other Income </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other income consists primarily of interest earned on our cash
balances held in financial institutions. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Income Taxes </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have
incurred in any year or for our earned research and development tax credits, due to the uncertainty of </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">103
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
realizing a benefit from those items. As of December&nbsp;31, 2020, we had federal and state net operating loss carryforwards of $17.6&nbsp;million and $16.7&nbsp;million, respectively, which may
be used to offset future taxable income, if any. These amounts expire at various dates through 2040. The federal net operating losses generated in and after 2018 can be carried forward indefinitely. As of December&nbsp;31, 2020, we had federal and
state tax credit carryforwards of $1.5&nbsp;million and $0.8&nbsp;million, respectively. These amounts expire at various dates through 2035. Due to the degree of uncertainty related to the ultimate use of the deferred tax assets, we have fully
reserved these tax benefits, as the determination of the realization of the deferred tax benefits was not determined to be more likely than not. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Three Months ended March&nbsp;31, 2020 and 2021 </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table summarizes our results of operations for the three months ended March&nbsp;31, 2020 and 2021:
</FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Change</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Revenue</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Collaboration and license revenue</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">General and administrative</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,606</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9,945</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(2,282</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other income:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Interest income</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(2,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Revenue </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We had no revenue for the three months ended March&nbsp;31, 2020 compared to $2.0&nbsp;million for the three months ended
March&nbsp;31, 2021. The increase in revenue was associated with the recognition of the $2.0&nbsp;million of revenue primarily associated with the Novartis Agreement, which has an expected term that ends no later than March&nbsp;2023. The revenue
generated from the Novartis Agreement is expected to increase significantly during 2021. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Research and Development
Expenses </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table summarizes our research and development expenses for the three months ended
March&nbsp;31, 2020 and 2021: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Change</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Preclinical studies</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,384</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Legal and professional fees</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Personnel expenses (including stock-based compensation)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,606</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Facility-related and other</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">818</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">503</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total research and development expenses</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">104
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development expenses were $4.3&nbsp;million for the three
months ended March&nbsp;31, 2020 compared to $7.3&nbsp;million for the three months ended March&nbsp;31, 2021. The increase in research and development expenses was primarily attributable to a $1.4&nbsp;million increase in laboratory supplies,
research material, and preclinical studies. Additionally, there was a $1.0&nbsp;million increase in personnel expenses, including an increase of $0.1&nbsp;million related to stock-based compensation expense and a $0.6&nbsp;million increase in
professional fees, facility-related expenses and other expenses due to the expansion of leased facilities. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>General and
Administrative Expenses </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">General and administrative expenses were $1.3&nbsp;million for the three months
ended March&nbsp;31, 2020 compared to $2.6&nbsp;million for the three months ended March&nbsp;31, 2021. The increase in general and administrative expense was primarily due to a $0.3&nbsp;million increase in legal and professional fees, as well as a
$0.6&nbsp;million increase in personnel expenses, which includes an increase of $0.1&nbsp;million related to stock-based compensation expense and an increase of $0.4&nbsp;million in other expenses. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Other Income </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other income for the three months ended March&nbsp;31, 2020 was $0.1&nbsp;million, compared to $0.01&nbsp;million for the
three months ended March&nbsp;31, 2021. The decrease primarily related to the money market interest rates decreasing due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and a draw down on cash to fund operations. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Years Ended December&nbsp;31, 2019 and 2020 </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table summarizes our results of operations for the years ended December&nbsp;31, 2019 and 2020: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Change</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Revenue</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Collaboration and license revenue</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,085</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,085</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">20,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">11,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">General and administrative</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,741</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">14,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">27,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">13,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(14,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(26,233</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(12,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other income:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Interest income</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(13,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(26,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(12,469</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Revenue </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We had no revenue for the year ended December&nbsp;31, 2019 compared to $1.1&nbsp;million for the year ended
December&nbsp;31, 2020. The increase in revenue was associated with the recognition of the $1.1&nbsp;million of revenue primarily associated with the Novartis Agreement. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">105
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Research and Development Expenses </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table summarizes our research and development expenses for the years ended December&nbsp;31, 2019 and 2020:
</FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Change</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Preclinical studies</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Legal and professional fees</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">859</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Personnel expenses (including stock-based compensation)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Facility-related and other</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,413</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total research and development expenses</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">20,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">11,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development expenses were $9.4&nbsp;million for the year ended
December&nbsp;31, 2019 compared to $20.6&nbsp;million for the year ended December&nbsp;31, 2020. The increase in research and development expenses was primarily attributable to a $4.6&nbsp;million increase in laboratory supplies, research material,
and preclinical studies. Additionally, there was a $3.8&nbsp;million increase in personnel expenses, including an increase of $0.1&nbsp;million related to stock-based compensation expense and a $2.7&nbsp;million increase in professional fees,
facility-related expenses and other expenses due to the expansion of leased facilities. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>General and Administrative
Expenses </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">General and administrative expenses were $4.8&nbsp;million for the year ended December&nbsp;31,
2019 compared to $6.7&nbsp;million for the year ended December&nbsp;31, 2020. The increase in general and administrative expense was primarily due to a $1.4&nbsp;million increase in legal and professional fees, as well as a $0.4&nbsp;million
increase in personnel expenses, which includes an increase of $0.3&nbsp;million related to stock-based compensation expense and an increase of $0.1&nbsp;million in other expenses. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Other Income </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other income for the year ended December&nbsp;31, 2019 was $0.6&nbsp;million, compared to $0.1&nbsp;million for the year
ended December&nbsp;31, 2020. The decrease primarily related to the money market interest rates decreasing due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and a draw down on cash to fund operations. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Liquidity and Capital Resources </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Sources of Liquidity </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have not generated any revenue from product sales and have incurred net losses and negative cash flows from our
operations. We have not generated any product revenue and have incurred net losses and negative cash flows from our operations. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures,
and to a lesser extent, general and administrative expenditures. Under the terms of the Novartis Agreement, we received an upfront payment of $20&nbsp;million. Additionally, Novartis is obligated to reimburse us for costs incurred to perform the
research and development activities of up to $10&nbsp;million. As of March&nbsp;31, 2021, we had cash, cash equivalents and restricted cash of $122.1&nbsp;million. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Funding requirements </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance
our research programs into preclinical and clinical development. In addition, we expect to continue </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">106
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
to incur additional costs associated with operating as a public company. The timing and amount of our operating expenditures will depend largely on: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the identification of additional research programs and product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the scope, progress, costs and results of preclinical and clinical development of any
product candidates we may develop; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the costs, timing and outcome of regulatory review of any product candidates we may
develop; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate
a clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our decision to build manufacturing capabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">investing in next-generation <FONT STYLE="white-space:nowrap">T-cell</FONT> engineering
capabilities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">changes in laws or regulations applicable to any product candidates we may develop,
including but not limited to clinical trial requirements for approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cost and timing of obtaining materials to produce adequate supply for any preclinical
or clinical development of any product candidate we may develop; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the costs and timing of future commercialization activities, including manufacturing,
marketing, sales and distribution, for any product candidate we may develop for which we obtain marketing approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the legal costs involved in prosecuting patent applications and enforcing patent claims and
other intellectual property claims; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">additions or departures of key scientific or management personnel;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to establish and maintain collaborations on favorable terms, if at all, as well
as the costs and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the costs of operating as a public company. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable
us to fund our operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a
combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may
involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through
additional collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates,
or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product
development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have not yet received regulatory approval for or commercialized any of our product candidates and do not expect to
generate revenue from product sales for several years, if at all. We do not expect to generate any </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">107
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
product revenue unless and until we (1)&nbsp;complete development of any of our product candidates; (2)&nbsp;obtain applicable regulatory approvals; and (3)&nbsp;successfully commercialize or
enter into collaborative agreements for our product candidates. We do not know with certainty when, or if, any of these items will ultimately occur. We expect to incur continuing significant losses for the foreseeable future and our losses to
increase as we ramp up our preclinical and clinical development programs. We may encounter unforeseen expenses, difficulties, complications, delays and other currently unknown factors that could adversely affect our business. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Moreover, following the completion of this offering, we will be a publicly traded company and will incur significant
legal, accounting and other expenses that we were not required to incur as a private company. In addition, the Sarbanes-Oxley Act of 2002, as well as rules adopted by the SEC and Nasdaq, requires public companies to implement specified corporate
governance practices that are currently not applicable to us as a private company. Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we will first be required to furnish a report by our management on our internal
control over financial reporting for the year ending December&nbsp;31, 2021. However, while we remain an emerging growth company and a smaller reporting company, we will not be required to include an attestation report on internal control over
financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial
reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control
over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over
financial reporting. We expect these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We will require additional capital to develop our product candidates and fund our operations into the foreseeable
future. We anticipate that we will eventually need to raise substantial additional capital, the requirements for which will depend on many factors, including: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical
development activities, laboratory testing and clinical trials for our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the number and scope of clinical programs we decide to pursue;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cost, timing and outcome of preparing for and undergoing regulatory review of our
product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the scope and costs of development and manufacturing activities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cost and timing associated with commercializing our product candidates, if they receive
marketing approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the amount of revenue, if any, received from commercial sales of our product candidates,
should any of our product candidates receive marketing approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the achievement of milestones or occurrence of other developments that trigger payments
under any collaboration agreements we might have at such time; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other
product candidates and technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the costs of preparing, filing and prosecuting patent applications, maintaining and
enforcing our intellectual property rights and defending intellectual property-related claims; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our ability to establish and maintain collaborations on favorable terms, if at all;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our efforts to enhance operational systems and our ability to attract, hire and retain
qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">108
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our implementation of various computerized information systems;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our clinical development or
operations; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the costs associated with being a public company. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A change in the outcome of any of these or other variables with respect to the development of any of our product
candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational
needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional
covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale
transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Adequate funding may not be available to us on acceptable terms or at all. Our potential inability to raise capital when
needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds as required, we may need to delay, reduce, or terminate some or all development programs and
clinical trials. We may also be required to sell or license our rights to product candidates in certain territories or indications that we would otherwise prefer to develop and commercialize ourselves. If we are required to enter into collaborations
and other arrangements to address our liquidity needs, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which
could materially and adversely affect our business and financial prospects. See the section of this prospectus titled &#147;Risk Factors&#148; for additional risks associated with our substantial capital requirements. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Cash Flows </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table summarizes our sources and uses of cash for each of the periods presented: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Three Months Ended<BR>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Change</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Change</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net cash (used in) operating activities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(12,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(3,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9,499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,129</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(9,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(4,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(4,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(2,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(2,959</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">34,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(34,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">99,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">99,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net increase (decrease) in cash, cash equivalents and restricted
cash</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">21,043</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(6,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(28,016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(6,095</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">86,710</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">92,805</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Operating Activities </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the three months ended March&nbsp;31, 2020, operating activities used $5.1&nbsp;million of cash, due to our net
loss of $5.5&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.3&nbsp;million and net cash provided by changes in our operating assets and liabilities of $0.1&nbsp;million. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the three months ended March&nbsp;31, 2021, operating activities used $10.0&nbsp;million of cash, due to our net
loss of $7.9&nbsp;million and net cash provided by changes in our operating assets and liabilities of $2.9&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.8&nbsp;million. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the year ended December&nbsp;31, 2019, operating activities used $12.5&nbsp;million of cash, due to our net loss
of $13.7&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.7&nbsp;million and net cash provided by changes in our operating assets and liabilities of $0.3&nbsp;million. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">109
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the year ended December&nbsp;31, 2020, operating activities used
$3.0&nbsp;million of cash, due to our net loss of $26.1&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.8&nbsp;million and net cash provided by changes in our operating assets and liabilities of
$21.3&nbsp;million. Net cash provided by changes in our operating assets and liabilities primarily consisted of a $19.4&nbsp;million increase in deferred revenue from the upfront payment in the Novartis Agreement. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Investing Activities </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the three months ended March&nbsp;31, 2020 and 2021, net cash used in investing activities was $1.2&nbsp;million
and $2.9&nbsp;million, respectively, related to the purchases of property and equipment. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the year
ended December&nbsp;31, 2019 and 2020, net cash used in investing activities was $1.2&nbsp;million and $4.2&nbsp;million, respectively, related to the purchases of property and equipment. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Financing Activities </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the three months ended March&nbsp;31, 2020, net cash provided by financing activities was $0.2&nbsp;million, consisting primarily
of net proceeds from the exercise of common stock options. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the three months ended March&nbsp;31,
2021, net cash provided by financing activities was $99.6&nbsp;million, consisting primarily of net proceeds from our issuance of convertible preferred stock and payment of deferred offering cost. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the year ended December&nbsp;31, 2019, net cash provided by financing activities was $34.8&nbsp;million,
consisting primarily of net proceeds from our issuance of convertible preferred stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the year ended
December&nbsp;31, 2020, net cash provided by financing activities was $0.3&nbsp;million, consisting primarily of net proceeds from the exercise of common stock options. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Critical Accounting Policies and Estimates </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our financial statements are prepared in accordance with generally accepted accounting principles in the United States,
or GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and
liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different
assumptions or conditions. While our significant accounting policies are described in more detail in Note 2 to our financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical
to the judgments and estimates used in the preparation of our financial statements. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Revenue
Recognition </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To date, our revenues have consisted of consideration related to the Novartis Agreement.
We adopted the provisions of Accounting Standards Update <FONT STYLE="white-space:nowrap">2014-09,</FONT> <I>Revenue from Contracts with Customers</I> (Topic 606), or ASC 606, on January&nbsp;1, 2018. In accordance with ASC 606, we recognize revenue
when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of
ASC 606, we perform the following five steps: (i)&nbsp;identification of the promised goods or services in </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">110
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
the contract; (ii)&nbsp;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;
(iii)&nbsp;measurement of the transaction price, including the assessment of the constraint on variable consideration; (iv)&nbsp;allocation of the transaction price to the performance obligations; and (v)&nbsp;recognition of revenue when, or as we
satisfy each performance obligation. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As part of the accounting for arrangements under ASC 606, we must use
significant judgment to determine the performance obligations based on the determination under step (ii)&nbsp;above. We also use judgment to determine whether milestones or other variable consideration, except for royalties and sales-based
milestones, should be included in the transaction price as described below. We recognize revenue based on those amounts when, or as, the performance obligations under the contract are satisfied. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We utilize judgment to assess the nature of the performance obligation to determine whether the performance obligation
is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue
recognition. The measure of progress, and the resulting periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement, which are subject to review by the joint steering
committee, or JSC. Such a change could have a material impact on the amount of revenue we record in future periods. We concluded that the transfer of control to the customer for the performance obligation occurs over the time period that the
research and development services are provided by us. We recognize revenue for the performance obligation as those services are provided using an input method, based on the cumulative costs incurred compared to the total estimated costs expected to
be incurred to satisfy the performance obligation. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> method is, in management&#146;s judgment, the best measure of progress towards satisfying the
performance condition. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">At the inception of each arrangement that includes research, development or
regulatory milestone payments, we evaluate whether the milestones are considered likely to be met and estimate the amount to be considered for inclusion in the transaction price using the most-likely-amount method. If it is probable that a
significant reversal in the amount of cumulative revenue recognized would not occur, the associated milestone value is included in the transaction price. For milestone payments due upon events that are not within our control, such as regulatory
approvals, we are not able to assert that it is likely that the regulatory approval will be granted and that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur until those approvals are received.
In making this assessment, we evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone. There is considerable judgment involved in determining whether it is
probable that a significant reversal in the amount of cumulative revenue recognized would not occur. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We
reevaluate the transaction price and our total estimated costs expected to be incurred at the end of each reporting period and as uncertain events, such as changes to the expected timing and cost of certain research, development and manufacturing
activities that we are responsible for, are resolved or other changes in circumstances occur. If necessary, we will adjust our estimate of the transaction price or our estimates of the total costs expected to be incurred. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Accrued Research and Development Expenses </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As part of the process of preparing our financial statements, we are required to estimate our accrued research and
development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers
invoice us in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT> schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each
balance sheet date in the financial statements based on facts and circumstances known to us at that time. At each period end, we corroborate the accuracy of these estimates with the service </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">111
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Vendors in connection with discovery and preclinical development activities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">CROs in connection with preclinical and clinical studies and testing; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">CMOs in connection with the process development and scale up activities and the production
of materials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We record the expense and accrual related to contract research and
manufacturing based on our estimates of the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of the research, development, and manufacturing activities; invoicing to
date under contracts; communication from the contract research organizations, contract manufacturing organizations and other companies of any actual costs incurred during the period that have not yet been invoiced; and the costs included in the
contracts and purchase orders. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the
level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the
performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our
understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not
been any material adjustments to our prior estimates of accrued research and development expenses. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Stock-Based Compensation </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We measure all stock-based awards granted based on the fair value on the date of the grant using the Black-Scholes
option-pricing model for options or the difference, if any, between the purchase price per share of the award and the fair value of our common stock for restricted common stock awards. Compensation expense for those awards is recognized over the
requisite service period, which is generally the vesting period of the respective award. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We use the
straight-line method to record the expense of awards with only service-based vesting conditions. The Black-Scholes option-pricing model uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock,
the expected term of our interest rate for a period that approximates the expected term of our common stock options, and our expected dividend yield. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Determination of Fair Value of Common Stock </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As there has been no public market for our common stock to date, the estimated fair value of our common stock has been
determined by our board of directors as of the date of each option grant, with input from management, considering our most recently available third party valuations of common stock and our board of directors&#146; assessment of additional objective
and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third party valuations were performed in accordance with the guidance outlined in the
American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Our common stock valuations were prepared using either an option pricing
method, or OPM, or a hybrid method, both of which used market approaches to estimate our enterprise value. The hybrid method is a probability-weighted expected return method, or PWERM, where the equity value in one or more of the scenarios is
calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">112
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class
of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount
for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices
based on the value thresholds at which the allocation among the various holders of a company&#146;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeded the value of
the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. These third party valuations were performed at various dates, which resulted in valuations of our common stock of $1.97 per share
as of June&nbsp;30, 2018, $2.46 per share as of July&nbsp;8, 2019, $5.25 per share as of June&nbsp;10, 2020, $5.83 per share as of January&nbsp;15, 2021, $11.57 per share as of March&nbsp;1, 2021 and $13.94 per share as of March&nbsp;19, 2021. In
addition to considering the results of these third party valuations, our board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, including: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the price at which we sold shares, or expected to sell shares, of our preferred stock and
the superior rights and preferences of the preferred stock relative to our common stock at the time of each grant; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the progress of our research and development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our stage of development and commercialization and our business strategy;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">external market conditions affecting the biopharmaceutical and biotechnology industries,
and trends within those industries; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our financial position, including cash on hand, and our historical and forecasted
performance and operating results; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the lack of an active public market for our common stock and our preferred stock;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the likelihood of achieving a liquidity event, such as an initial public offering, or IPO,
or a sale of our company in light of prevailing market conditions; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the analysis of IPOs and the market performance of similar companies in our industry.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The assumptions underlying these valuations represented management&#146;s best estimate,
which involved inherent uncertainties and the application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock- based compensation expense could
have been materially different. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Once a public trading market for our common stock has been established in
connection with the completion of this offering, it will no longer be necessary for our board of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant,
as the fair value of our common stock will be determined based on the quoted market price of our common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">As of March&nbsp;31, 2021, based on the initial public offering price per share of $15.00, the aggregate intrinsic value of our outstanding stock options, was $25.3&nbsp;million, with $5.1 million related to vested stock options.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Recently Issued Accounting Pronouncements </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We do not believe that any recently issued accounting pronouncements will materially impact our financial position and
results of operations. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">113
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Emerging Growth Company and Smaller Reporting Company Status </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Jumpstart Our Business Startups Act of 2012 permits an &#147;emerging growth company&#148; such as us to take
advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#147;opt out&#148; of such
extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or
revised standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth company. We may choose to early adopt any new or
revised accounting standards whenever such early adoption is permitted for private companies.<B> </B> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are
also a &#147;smaller reporting company&#148;, meaning that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less
than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held
by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements
that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Quantitative and Qualitative Disclosures about Market Risks </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are exposed to market risk related to changes in interest rates. As of March&nbsp;31, 2021, we had cash and cash
equivalents of $122.1&nbsp;million, which included restricted cash of $0.6&nbsp;million, which were held in savings accounts at banking institutions and money market funds that invest in U.S. Government securities. Interest income is sensitive to
changes in the general level of interest rates; however, due to the nature of these investments, an immediate 10% change in market interest rates would not have a material effect on the fair market value of our cash balance or on our financial
position or results of operations. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are not currently exposed to significant market risk related to
changes in foreign currency exchange rates. Our operations may be subject to fluctuations in foreign currency exchange rates in the future. We do not believe that inflation has had a material effect on our business, financial condition, or results
of operations during the three months ended March&nbsp;31, 2020 and 2021. Our operations may be subject to inflation in the future. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">114
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_11"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Overview </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We are a preclinical-stage biopharmaceutical company focused on developing a robust pipeline of T cell receptor-engineered T cell, or <FONT STYLE="white-space:nowrap">TCR-T,</FONT> therapies for the treatment of patients with
cancer. Our approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not. Using one of our proprietary platform technologies, TargetScan, we analyze the T
cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system naturally recognizes and eliminates tumor cells in these patients. This allows us to precisely identify the targets of T cell receptors, or TCRs,
that are driving these exceptional responses. We aim to use these anti-cancer TCRs to treat patients with cancer by genetically engineering their own T cells to recognize and eliminate their cancer. In addition to discovering <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapies against novel targets, we are using our ReceptorScan technology to further diversify our portfolio of therapeutic TCRs with TCR-T therapies against known targets. We believe this <FONT
STYLE="white-space:nowrap">two-pronged</FONT> approach will enable us to discover and develop a wide array of potential treatment options for patients with cancer. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are advancing a robust pipeline of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates for the treatment
of patients with hematologic and solid tumor malignancies. Our lead liquid tumor product candidates, <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> are in development for the treatment of
patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation, or HCT. <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT>
target <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2</FONT> antigens, respectively, which are well-recognized TCR targets that were identified in patients with exceptional responses to <FONT
STYLE="white-space:nowrap">HCT-associated</FONT> immunotherapy. We plan to submit Investigational New Drug, or IND, applications with the U.S. Food and Drug Administration, or FDA, for each of <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT
STYLE="white-space:nowrap">TSC-101</FONT> in the fourth quarter of 2021. In addition, we are developing multiple <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates for the treatment of various solid tumors. One of the key goals for our
solid tumor program is to develop what we refer to as multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. We are designing these multiplexed therapies to be a combination of up to three highly active TCRs that are customized for each
patient and selected from our bank of therapeutic TCRs, which we refer to as ImmunoBank. We are currently advancing four solid tumor programs, TSC-200, TSC-201, TSC-202, and TSC-203, through lead optimization, and expect to submit IND applications
for at least three of our four solid tumor TCR-T therapy candidates in the second half of 2022, with the fourth IND expected to be submitted in 2023. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">T cells are an essential component of the adaptive immune system and provide protection against cancer, infection, and
autoimmune disease. Multiple approaches have been and are continuing to be explored to develop effective T cell-based therapies for the treatment of cancer, including tumor infiltrating lymphocyte, or TIL, therapy and chimeric antigen receptor T
cell, or <FONT STYLE="white-space:nowrap">CAR-T,</FONT> therapy. The success of TIL therapy depends on the specific T cells present in the patient. If their TILs do not have appropriate anti-cancer specificities, the therapy is unlikely to be
effective. In addition, TIL therapy has, to date, shown limited applicability for the treatment of liquid tumors. In contrast, <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy has proven effective in certain hematological malignancies of
lymphoid origin, but have not yet shown efficacy or safety in myeloid malignancies. Additionally, this type of treatment is limited to targets on the surface of tumor cells and has not yet been shown to effectively penetrate solid tumors. Both TIL
and <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies, as well as other immunotherapies such as checkpoint inhibitors, harness the power of cytotoxic T cells in fighting cancer. Despite demonstrating compelling efficacy, they are only
effective in a subset of patients. To address a broader patient population, we believe additional T cell-based approaches are needed that more closely mimic the way the immune system recognizes and fights cancer in patients who are responding to
immunotherapy. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our decision to develop <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies for the
treatment of cancer is based on our conviction that we can learn from the natural interaction between T cells and tumor cells and harness this information to treat patients by reprogramming their immune systems. We believe that <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapy combines the benefits of TIL and <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies while uniquely addressing their key limitations. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">115
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The development of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy
requires three key prerequisites: (i)&nbsp;an effective anti-cancer TCR; (ii)&nbsp;knowledge of the precise peptide antigen, a protein or other molecule to which an antibody binds, that is recognized by the TCR; and (iii)&nbsp;confirmation that the
TCR does not recognize problematic <FONT STYLE="white-space:nowrap">off-targets.</FONT> We believe that our approach provides us with the following key advantages: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies are based on highly active
TCRs that are clinically relevant. </I>Many other approaches to <FONT STYLE="white-space:nowrap">T-cell</FONT> therapy rely on specifically expanding T cells that are already present in the patient. Our platform analyzes anti-cancer T cells from a
wide variety of patients who are responding to immunotherapy in order to find the most active and clinically relevant TCRs against each target. We believe this will allow us to develop <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies for a
wide range of patients, including those who do not have T cells that efficiently recognize their cancers. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies are designed to be used in
combination with each other.</I> We are building our diverse ImmunoBank of TCRs to allow for multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy, which has the potential to address the heterogeneous nature of solid tumors and to
prevent resistance developing due to loss of a single target. We believe this approach may allow us to overcome the limitations and challenges of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy development to date.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Our approach is expandable.</I> ImmunoBank has the flexibility to be used with new and
optimized methods of <FONT STYLE="white-space:nowrap">T-cell</FONT> engineering that we may develop over time. We are building ImmunoBank to be compatible with both autologous and allogeneic engineering technologies in order to potentially
transition to generating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf,</FONT></FONT> allogeneic T cells that have been <FONT STYLE="white-space:nowrap">pre-engineered</FONT> with our TCRs for direct administration
to patients. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our proprietary platform is designed to: (i)&nbsp;discover anti-cancer TCRs
from patients with exceptional responses to immunotherapy; (ii)&nbsp;determine novel targets of clinically relevant TCRs; (iii)&nbsp;discover novel TCRs that recognize clinically validated targets; (iv)&nbsp;identify
<FONT STYLE="white-space:nowrap">off-targets</FONT> of TCRs to eliminate candidates that could potentially pose a safety risk; and (v)&nbsp;manufacture TCR-T therapies efficiently and consistently without the use of viral vectors using our
T-Integrate technology. The three central elements of our platform that differentiate us from other cell therapy companies are TargetScan, ReceptorScan, and <FONT STYLE="white-space:nowrap">T-Integrate.</FONT> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>TargetScan.</I> At the core of our proprietary platform is our TargetScan technology that enables us to identify the
natural target of a TCR using an unbiased, genome-wide high-throughput screen. We have developed this technology to be extremely versatile and applicable across multiple therapeutic areas, including cancer, autoimmune disorders, and infectious
diseases. It can be applied to virtually any TCR that plays a role in the cause or prevention of disease. Using TargetScan, we have identified more than 40 shared antigens in patient tumors, and over 90% of these targets have not previously been
publicly identified as targets for <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. We believe this provides us with a competitive advantage, because not only are we among the first to identify these targets as tumor-specific antigens, but we
have already identified highly active TCRs that recognize these targets. TargetScan is also designed to identify potential <FONT STYLE="white-space:nowrap">off-targets</FONT> of a TCR and eliminate those TCR candidates that cross-react with proteins
expressed at high levels in critical organs. We believe this will allow us to reduce the risk and enhance the potential safety profile of our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates early in development before we initiate
clinical trials. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>ReceptorScan. </I>To further expand our ability to discover and develop therapeutic
TCRs, we have developed our proprietary ReceptorScan technology to enable us to identify and clone highly active TCRs that recognize known or clinically validated targets. We <FONT STYLE="white-space:nowrap">co-culture</FONT> hundreds of millions of
CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells from either healthy donors or cancer patients with dendritic cells, also referred to as antigen-presenting cells, that display the target antigen of interest to the T cells. T cells
that recognize the target of interest proliferate, and are subsequently isolated based on their ability to recognize a fluorescently labeled version of the target. We then use single cell sequencing to identify the specific TCR sequences that
recognize the target. Our novel technologies allow us to gene-synthesize hundreds of TCRs simultaneously and to rapidly sort through hundreds of target-specific TCRs in a single high-throughput screen to identify the most active clones. Using
ReceptorScan, we have identified our two lead <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates, <FONT STYLE="white-space:nowrap">TSC-100</FONT> targeting <FONT STYLE="white-space:nowrap">HA-1</FONT> and
<FONT STYLE="white-space:nowrap">TSC-101</FONT> targeting <FONT STYLE="white-space:nowrap">HA-2.</FONT> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">116
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I><FONT STYLE="white-space:nowrap">T-Integrate.</FONT> </I>Manufacturing
cell therapies is highly complex, and associated challenges have led to significant delays or failures in the development of many cell therapies. To enable the rapid, cost-effective, and consistent manufacturing of TCR-Ts, we have developed a <FONT
STYLE="white-space:nowrap">non-viral</FONT> vector delivery system that we refer to as <FONT STYLE="white-space:nowrap">T-Integrate.</FONT> Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates are manufactured using a
transposon/transposase system, in which the DNA encoding the TCR is manufactured as a Nanoplasmid, a <FONT STYLE="white-space:nowrap">non-viral</FONT> vector. The Nanoplasmid, together with an mRNA sequence encoding a transposase enzyme, is
introduced into the T cell by electroporation. After the T cell translates the mRNA into protein, the transposase enzyme inserts the TCR sequence from the Nanoplasmid into the genome of the T cell. This system is highly reproducible, as the only
required components are a Nanoplasmid, which is different for each TCR product, and an mRNA, which is constant for all TCR products. Unlike lentivirus, both of these components are routinely manufactured in a cost-effective manner without the need
for extensive process development. We believe our manufacturing platform will enable us to efficiently develop and manufacture many different <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies, allowing us to deliver customized multiplexed
therapy to patients with cancer. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our Pipeline </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are leveraging our proprietary platform technologies to develop a robust pipeline of
<FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies with the goal of building our ImmunoBank of TCRs to treat a wide range of tumor types. In addition, we are applying our platform to identify targets and TCRs in therapeutic areas outside of
oncology, such as autoimmune disorders and infectious disease, through strategic partnerships. Our current proprietary pipeline is summarized in the figure below. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g06m17.jpg" ALT="LOGO">
 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">TSC-200 will only be developed in HPV-positive cancers, which include head &amp; neck,
cervical, and anal cancers. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">For additional information regarding the targets for TSC-201 and TSC-202, see
&#147;Business - Solid Tumor Program - TSC-200 Series.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Acute myeloid leukemia, or AML; myelodysplastic syndrome, or MDS; and acute lymphocytic
leukemial, or ALL. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Non-small cell lung cancer, or NSCLC. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition to our proprietary pipeline programs noted above, we also are in the discovery phase for our TSC-102
program, which is targeting an additional MiHA target that is presented on HLA-B*07:02. Our overall strategy is to progressively build this program to provide a broad array of therapeutic options for the majority of patients with hematologic
malignancies receiving HCT. Beyond our proprietary pipeline programs, we have also entered into collaborations with strategic partners for applications of our platform technologies. We have a collaboration and license agreement with Novartis to
identify novel cancer antigens from the T cells of patients with one specific type of cancer. Novartis has the option to license and develop therapies for up to three discovered targets. In addition, we have partnered with QIAGEN Sciences, LLC to
develop a highly specific diagnostic test to determine prior exposure to SARS-CoV-2 based on the presence of anti-viral T cells. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">With our differentiated platform as the foundation, we are building a three-pillar research and development strategy to create transformational <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies for patients. </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">1.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Our Liquid Tumor Program.</I> We are developing our liquid tumor program to treat
patients with hematologic malignancies who are undergoing allogeneic HCT. In the first phase of our clinical development strategy, </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">117
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">
we are initially focusing on clinically validated cancer targets that have been discovered in patients with exceptional responses to <FONT STYLE="white-space:nowrap">HCT-associated</FONT>
immunotherapy, including <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2.</FONT> In addition, to further expand our liquid tumor program, we are developing additional product candidates that target other
similarly validated antigens, enabling us to expand the addressable patient population. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We plan
to conduct clinical trials of our lead <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates, <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> in parallel, with patients enrolled in
treatment arms based on their genotype. Patients who are positive for the target antigen, <FONT STYLE="white-space:nowrap">HA-1</FONT> or <FONT STYLE="white-space:nowrap">HA-2,</FONT> as well as the
<FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> allele, which is the HLA type required to display <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2</FONT> on the cell surface for recognition by a T cell, will
be eligible for enrollment. Furthermore, eligible patients will require donors who are negative for either the target antigen or the <FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> allele. We plan to incorporate additional product candidates
into this trial design as they advance into the clinic, which we believe will allow us to provide a broad array of therapeutic options for the majority of patients with hematologic malignancies receiving HCT. In our clinical trials of <FONT
STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> we also plan to evaluate the potential benefit of combining the two therapies as a multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy for
patients who are positive for both <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2.</FONT> </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Through the development of our liquid tumor program, we are building a foundation of manufacturing, clinical, and regulatory capabilities, which will be applied to the future development of our broader portfolio of <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates for solid tumors. </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">2.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b"><I>Our Solid Tumor Program.</I> We are developing a portfolio of autologous <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates that are designed to be used in combination with each
other to treat and eliminate solid tumors. Our <FONT STYLE="white-space:nowrap">TSC-200</FONT> series of product candidates are designed to elicit an anti-tumor response in patients by targeting cancer-specific antigens in their tumor cells. Our <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates include: (i)&nbsp;either well-recognized cancer targets that have demonstrated anti-tumor activity in clinical trials or novel targets that were identified by TargetScan from the T cells of
patients responding to immunotherapy and (ii)&nbsp;naturally occurring TCRs specific to a patient&#146;s HLA type that recognize these cancer-specific targets. Such targets are not only commonly shared among patients with the same cancer type, but
also frequently expressed in multiple solid tumor types, enabling clinical development across multiple indications. Our first four product candidates include a combination of known targets, such as HPV16 for TSC-200 and PRAME for TSC-203, as well as
targets that are novel antigens for TCR-T therapy, such as for TSC-201 and TSC-202. In addition to our four lead product candidates, we have identified over 40 novel antigens based on tumor samples from patients who are actively responding to
immunotherapy using our TargetScan technology. We are in early stages of analyzing these additional novel antigens and plan to advance those that we believe have the best potential as a TCR-T product candidate into preclinical development.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our vision is to create and continuously expand ImmunoBank to enable customized multiplexed <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapy for a wide range of solid tumor patients. For each patient with a solid tumor malignancy, we plan to analyze their tumor to determine which targets are expressed at high levels in their particular
cancer. We will then access ImmunoBank and select up to three TCRs that match their HLA type and address the most highly expressed targets in their tumor. We will use this set of TCRs to genetically reprogram their T cells to recognize these
targets, and the resulting T cells will be infused back into the patient as a multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b"><I>3.</I></FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b"><I>Strategic Partnerships and Collaborations. </I>T cells play a fundamental role in many other therapeutic areas beyond cancer, such as autoimmune disorders and infectious disease. We believe that
our TargetScan technology is well suited to discover novel antigens for the development of therapeutics, diagnostics, and vaccines in these other therapeutic areas. We intend to opportunistically pursue collaborations with strategic partners for
applications of our platform technologies outside our core focus of oncology. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our History and Team
</B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We were founded in early 2018 to discover and develop transformational therapies using a novel <FONT
STYLE="white-space:nowrap">T-cell</FONT> target discovery platform developed by Drs. Stephen Elledge and Tomasz Kula at Brigham and Women&#146;s Hospital and Harvard Medical School. Since then, we have made substantial progress building our target
and </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">118
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
TCR discovery platform technologies, discovering new targets and TCRs, advancing our two lead programs into <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, developing <FONT
STYLE="white-space:nowrap">in-house</FONT> manufacturing capabilities, and, in response to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, identifying the targets of T cells from recovering
<FONT STYLE="white-space:nowrap">COVID-19</FONT> patients. In addition, we have entered into multiple strategic collaborations, including with Novartis Institutes for Biomedical Research, Inc., and QIAGEN Sciences, LLC. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have assembled a highly qualified team with deep experience in <FONT STYLE="white-space:nowrap">T-cell</FONT>
biology, high throughput screening, engineering and manufacturing of cell therapies, as well as in all phases of research and clinical development, from early-stage discovery and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies through
registrational clinical trials. Our team includes industry veterans with prior experience at academic and research institutions such as Harvard University, Harvard Medical School, and Massachusetts General Hospital, and companies such as BlueRock
Therapeutics, LLC, CRISPR Therapeutics, Inc., Editas Medicine, Inc., Human Genome Sciences, Inc., Kite Pharma, Inc., KSQ Therapeutics, Inc., Merrimack Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Repertoire Immune Medicines, Inc., and SQZ
Biotechnologies Company. Our research efforts also benefit from the informal advice and guidance provided by our scientific advisory board members, including Drs. Elledge and Kula, who receive equity and/or cash compensation. Since our inception, we
have raised an aggregate of $160&nbsp;million from leading biotechnology investors, including RA Capital Management, Novartis Venture Fund, Novartis Institutes for Biomedical Research, Longwood Fund, Bessemer Venture Partners, GV, 6 Dimensions
Capital, Astellas Venture Management, and Pitango HealthTech. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our Strategy </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our mission is to create life-changing <FONT STYLE="white-space:nowrap">T-cell</FONT> therapies for patients by
unleashing the untapped potential of the human immune system. Our goal is to use our proprietary platform for the identification of novel tumor-specific antigens and clinically active TCRs to become a leader in the development of engineered <FONT
STYLE="white-space:nowrap">T-cell</FONT> therapies for the treatment of liquid and solid tumors. Our strategy includes the following key elements: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><B><I>Leverage our proprietary platform technologies to build our diverse ImmunoBank of
therapeutic TCRs to treat a wide range of tumor types</I></B>. Our TargetScan technology enables us to identify novel antigens that are broadly expressed across multiple types of solid tumors. In order to ensure that the antigens identified are
clinically relevant, we use TCRs from tumor samples of patients with exceptional responses to immunotherapy. Our platform allows us assess the specificity and cytotoxicity of these TCRs to develop a portfolio of
<FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates with therapeutic potential. As we continue to expand our screening technology, we believe we will be able to generate our ImmunoBank of therapeutic TCRs with the diversity required to
treat many solid tumors using multiplexed therapy. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><B><I>Advance our lead liquid tumor product candidates,
<FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> through clinical development.</I></B> Our two lead programs, <FONT STYLE="white-space:nowrap">TSC-100</FONT> and
<FONT STYLE="white-space:nowrap">TSC-101,</FONT> are designed to target <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2,</FONT> respectively, both of which are antigens with clinically demonstrated anti-tumor
effects in patients who naturally develop T cells specific to these targets. Using our ReceptorScan technology, we generated hundreds of highly active TCRs that recognize <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT
STYLE="white-space:nowrap">HA-2.</FONT> We selected <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> based on their superior potency and lack of <FONT STYLE="white-space:nowrap">off-target</FONT>
effects. We plan to submit INDs for each of <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> in the fourth quarter of 2021. In addition, through our liquid tumor programs, we are building a
foundation of manufacturing, clinical and regulatory capabilities to support the development of our broad portfolio of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><B><I>Apply experience from our liquid tumor program to efficiently develop our solid tumor
program targeting both novel and previously identified antigens. </I></B>Using our TargetScan technology, we have identified over 40 novel antigens based on tumor samples from patients who are actively responding to immunotherapy. We are initially
developing our <FONT STYLE="white-space:nowrap">TSC-200</FONT> series of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies against four selected target antigens that are frequently expressed across multiple solid tumor types. Our first four
solid tumor TCR-T therapy candidates include a combination of known targets, such as HPV16 for TSC-200 and PRAME for TSC-203, as well as targets that are novel antigens for TCR-T therapy, such as for <FONT STYLE="white-space:nowrap">TSC-201</FONT>
and TSC-202. We believe that the treatment of solid tumors will require a combination of several <FONT STYLE="white-space:nowrap">TCR-T</FONT> </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">119
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">
therapies, which we refer to as &#145;multiplexed therapy&#146;. We plan to leverage the foundation built from our liquid tumor programs to efficiently develop a robust portfolio of <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates and expand ImmunoBank to enable multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies for solid tumors. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><B><I>Continue to develop manufacturing capabilities based on our <FONT
STYLE="white-space:nowrap">non-viral</FONT> <FONT STYLE="white-space:nowrap">T-Integrate</FONT> system</I></B>. We believe that <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing capabilities substantially facilitate the successful early
development of cell therapies. For our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates, we have developed a <FONT STYLE="white-space:nowrap">non-viral</FONT> gene delivery system, which we refer to as
<FONT STYLE="white-space:nowrap">T-Integrate,</FONT> based on transposons that are designed to enable cost-effective and consistent cell manufacturing with short development times. We have built an internal good manufacturing practices, or GMP,
manufacturing facility that we expect will provide sufficient capacity to support all of our clinical programs through Phase 2 clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><B><I>Develop next generation <FONT STYLE="white-space:nowrap">T-cell</FONT> engineering
capabilities</I></B>. Our long-term vision is to build an allogeneic repository of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf,</FONT></FONT> genetically engineered T cells and provide multiplexed <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapies to patients with a wide range of malignancies. Although our initial solid tumor programs are autologous, we are developing <FONT STYLE="white-space:nowrap">T-cell</FONT> engineering technologies and <FONT
STYLE="white-space:nowrap">in-house</FONT> manufacturing capabilities to transition our therapeutic TCRs to allogeneic therapies based on T cells derived from healthy donors or induced pluripotent stem cells, or iPSCs. We are also exploring
additional next generation technologies, such as <I>in vivo</I> <FONT STYLE="white-space:nowrap">T-cell</FONT> engineering, to further advance our <FONT STYLE="white-space:nowrap">T-cell</FONT> engineering capabilities. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><B><I>Opportunistically pursue strategic partnerships and collaborations to maximize the
full potential of our platform</I></B>. Our platform represents a powerful tool to identify targets and TCRs in therapeutic areas outside of oncology, such as autoimmune disorders and infectious disease. We intend to seek strategic partners with
proven clinical development and commercialization capabilities for certain targets and/or assets that do not overlap with our internal programs or our core focus. To date, we have established a partnership for
<FONT STYLE="white-space:nowrap">COVID-19</FONT> with QIAGEN Sciences, LLC for the development of a T cell-based diagnostic. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B>Background on <FONT STYLE="white-space:nowrap">T-Cell</FONT> Therapies </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The human
immune system constantly provides a natural and highly effective defense against cancer, which only forms when tumor cells find a way to evade the immune system. The treatment of cancer was revolutionized about a decade ago with the advent of
immunotherapy &#150; therapeutic approaches designed to <FONT STYLE="white-space:nowrap">re-enable</FONT> or <FONT STYLE="white-space:nowrap">re-direct</FONT> immune cells to recognize and fight cancer. Over the past 10 years, a suite of
immuno-oncology drugs has been approved and adopted as part of routine clinical practice. Successes in immuno-oncology came initially from the approval of immune checkpoint inhibitors and more recently from the development of cellular therapies,
such as <FONT STYLE="white-space:nowrap">CAR-T</FONT> and TIL therapies. These therapies all harness the power of cytotoxic T cells in fighting both hematologic malignancies and solid tumors. Although these therapies have demonstrated compelling
efficacy, they are only effective in a subset of patients. To address a broader patient population, we believe additional T cell-based approaches are needed that more closely mimic the way the immune system recognizes and fights cancer in patients
who are responding to immunotherapy. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Overview of <FONT STYLE="white-space:nowrap">T-Cell</FONT>
Biology </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">T cells are an essential component of the adaptive immune system and provide protection
against cancer, infection, and autoimmune disease. T cells are classically divided into two primary types of activating cells: helper T cells and cytotoxic T cells. Helper T cells, which express the CD4
<FONT STYLE="white-space:nowrap">co-receptor,</FONT> function by providing signals to other immune cells for activation and recruitment. Cytotoxic T cells, which express the CD8 <FONT STYLE="white-space:nowrap">co-receptor,</FONT> function by
killing any cells in the human body that are expressing unnatural proteins, including proteins that are not expressed in normal tissue, proteins that arise from mutated genes, or proteins derived from pathogens. By definition, tumor cells are
abnormal and make a wide variety of unnatural proteins.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>T cells are activated and exert their helper or cytotoxic function when their T cell receptors, or TCRs, recognize antigens displayed on the
surface of malignant or infected cells. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">120
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Virtually every cell in the body has a mechanism for displaying on its
surface a sampling of every protein that is being made by the cell. This includes all normal proteins as well as aberrant proteins if the cell is cancerous or proteins from pathogens if the cell has been infected. Cellular proteins are broken down
into short fragments, or peptides, by the proteasome, and these peptides are loaded into Major Histocompatibility Complexes, or MHCs, to be displayed on the outside of the cell. These peptide/MHC complexes are recognized by TCRs on cytotoxic CD8<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP> T cells, as shown in the graphic below. Because the TCR recognizes both the peptide and the MHC, a TCR only functions correctly when both the peptide and the correct MHC are present. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TCRs on Cytotoxic CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T Cells Recognize the </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Peptide/MHC Complexes of Tumor Cells </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g64j63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">MHC proteins, which present different peptides to the human immune system, are highly
variable among people. An individual&#146;s MHC proteins are determined by their Human Leukocyte Antigen, or HLA, type. Although there are many different HLA types, some are quite common. For example, 42% of individuals in the United States are
positive for the <FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> allele, or variant. TCRs are often referred to as <FONT STYLE="white-space:nowrap">&#147;HLA-restricted&#148;</FONT> because they are only able to interact with specific HLA types.
For this reason, <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy harnesses the exquisite specificity of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TCR-peptide-MHC</FONT></FONT> interaction to selectively target tumor
cells. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Current Approaches to <FONT STYLE="white-space:nowrap">T-Cell</FONT> Therapy
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Multiple approaches are being explored to develop effective T cell-based therapies for the treatment
of cancer. One approach is to isolate naturally occurring T cells from a patient&#146;s tumor, referred to as TILs, expand and activate those cells <I>ex vivo</I>, and then return them to the patient via intravenous infusion. Although the targets of
these T cells are not known, it is presumed that T cells isolated from a tumor are enriched in T cells directed against cancer cells. This approach, however, depends on the specific T cells present in the patient. If the patient&#146;s TILs do not
have appropriate anti-cancer specificities or if their TILs cannot be adequately expanded <I>ex vivo</I>, the therapy is unlikely to be effective. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A different approach that has proven effective in certain hematological malignancies is to identify targets that are
preferentially expressed on the surface of tumor cells, such as CD19. Antibody fragments that recognize these targets are used to create an artificial construct that links the antibody to key signaling elements required
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">121
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
for <FONT STYLE="white-space:nowrap">T-cell</FONT> activation. The resulting CAR is incorporated genetically into a patient&#146;s T cells, thereby redirecting those cells to recognize and fight
the patient&#146;s cancer. Although <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies have been highly effective in certain tumor types, leading to multiple approved products, the benefit of these therapies and the addressable cancer
indications have been limited by several factors. First, it is likely that there is a relatively limited set of truly tumor-specific cell surface antigens. In general, most antigens expressed on the surface of tumor cells are also expressed on
normal cells, resulting in therapies that, even if effective, have a narrow therapeutic window and are vulnerable to potentially life-threatening toxicities. Second, <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells rely on antibody fragments that
recognize cell-surface proteins, precluding intracellular proteins as potential targets. Third, <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies generally do not efficiently penetrate solid tumors, which to date has limited their
applicability to hematologic malignancies. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In contrast to <FONT STYLE="white-space:nowrap">CAR-T</FONT>
therapies, naturally occurring TCRs offer two important benefits compared to antibody-containing artificial receptors. First, TCRs are the natural receptors used by the T cell to recognize foreign antigens. As such, they are optimized to stimulate
the T cell appropriately when they engage their targets on a tumor cell. An appropriately stimulated T cell will not only kill the tumor cell, but also produce cytokines that stimulate other immune cells and make copies of itself, or proliferate, to
further augment the immune response. Balancing all the cellular responses of a T cell is something that has been finely tuned over millions of years of evolution and is best mediated by naturally occurring TCRs, rather than by artificial constructs.
Second, TCRs can recognize a much broader set of antigens, including peptides derived from both cell surface and intracellular proteins, whereas CARs are restricted to recognizing only cell surface proteins.
<FONT STYLE="white-space:nowrap">MHC-I</FONT> peptides are predominantly derived from intracellular proteins rather than extracellular proteins, which dramatically increases the universe of potential cancer-specific antigens that can be recognized
by TCRs compared to CARs. We believe <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy combines the benefits of TIL and <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies while uniquely addressing their key limitations, as shown below.
</FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Comparison of <FONT STYLE="white-space:nowrap">T-Cell</FONT> Therapy Modalities </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g11q09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The development of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy requires
three key prerequisites: (i)&nbsp;an effective anti-cancer TCR; (ii)&nbsp;knowledge of the precise peptide antigen that is recognized by the TCR; and (iii)&nbsp;confirmation that the TCR does not recognize problematic
<FONT STYLE="white-space:nowrap">off-targets.</FONT> Each of these prerequisites is technically challenging. Historically, targets of anti-cancer <FONT STYLE="white-space:nowrap">T-cell</FONT> clones were identified through a manual and labor
intensive process, and<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>the identification of each target was often a multi-year project. As a result, only a few dozen targets have been identified to date and most clinical development efforts
are focused on a short list of the most promising targets. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">122
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our Approach </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our approach is based on the central premise that we can <B><I>learn</I></B> from patients who are winning their fight
against cancer in order to <B><I>treat</I></B> those who are not. Using our proprietary platform technologies, we are analyzing the T cells of cancer patients with exceptional responses to immunotherapy to discover clinically relevant targets and
TCRs. We are building ImmunoBank with the goal of delivering customized multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy to a wide range of patients with cancers. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Learning </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">When a patient responds to an immunotherapy drug such as an immune checkpoint inhibitor, their tumor shrinks because T
cells in their tumor become activated and drive an anti-tumor cytotoxic response. The TCRs of their T cells recognize tumor-specific antigens on tumor cells and signal the T cell to kill the cancer cells. Our approach starts with isolating
clinically active anti-cancer T cells from tumor samples of patients who are actively responding to immunotherapy agents. We then use our proprietary TargetScan technology to determine the precise targets being recognized by their TCRs. This
provides us with a novel TCR/target pair that can be developed into a <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidate. The advantage of our approach is that when we identify a new target, we know the target is immunologically
relevant &#150; the human immune system has already used that target to recognize and fight cancer. Furthermore, we have already identified a TCR that recognizes the target and, importantly, is associated with a meaningful clinical response in a
patient. To <FONT STYLE="white-space:nowrap">de-risk</FONT> clinical development of the TCR, we use our TargetScan technology to scan across every peptide sequence in the entire human proteome with the goal of ensuring that it does not have any
problematic <FONT STYLE="white-space:nowrap">off-target</FONT> effects. We then select TCRs that are highly active with no apparent problematic <FONT STYLE="white-space:nowrap">off-target</FONT> effects to be added to ImmunoBank. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition to discovering novel TCR/target pairs, we are leveraging our proprietary ReceptorScan technology to identify
highly active TCRs against previously identified and clinically validated targets. Once we identify these highly active TCRs, we use our TargetScan technology to reduce the risk that they exhibit problematic
<FONT STYLE="white-space:nowrap">off-target</FONT> effects, which <FONT STYLE="white-space:nowrap">de-risks</FONT> their subsequent clinical development. The diagram below illustrates our proprietary discovery process where therapeutic TCR
candidates are discovered using either TargetScan or ReceptorScan and those that we characterize as the best TCRs are added to ImmunoBank. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Our Proprietary Target and TCR Discovery Process </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g06f72.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">123
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Treating </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our discovery process enables us to build and expand ImmunoBank with what we believe represents the most active TCRs
isolated from a large group of diverse patients who are responding to immunotherapy. We are developing <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies that use these clinically relevant TCRs to reprogram the T cells of patients who do not
spontaneously generate effective anti-cancer T cells and thus do not respond to immunotherapy. Our manufacturing process begins with obtaining white blood cells from either the patient or a healthy donor using a procedure called leukapheresis. We
will then transport these white blood cells to our <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing facility, where we isolate the T cells and genetically engineer them using TCR sequences from ImmunoBank. We believe the continued
expansion and diversification of ImmunoBank will enable us to deliver customized multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy to patients, where each patient&#146;s T cells are engineered with multiple TCRs that are matched to
their specific tumor and HLA type. For example, if a patient&#146;s tumor expresses high levels of cancer target X, their T cells will be reprogrammed with a TCR that recognizes target X. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Once the T cells are engineered with a combination of the most relevant TCRs, they will be transported back to the
hospital and reintroduced into the patient by intravenous infusion. Following the infusion, the engineered T&nbsp;cells, which are designed to recognize multiple targets expressed by the patient&#146;s tumor, will proliferate <I>in vivo</I> and
mount an anti-cancer immune response. Our patient treatment and manufacturing process is summarized in the graphic below. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#32406b"><B>Our Patient Treatment and Manufacturing Process </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g71o53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Key Features of Our Approach </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We believe there are three key advantages to our approach: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies are based on highly active
TCRs that are clinically relevant.</I> Many other approaches to T cell therapy rely on specifically expanding T cells that are already present in the patient. Our platform analyzes anti-cancer T cells from a wide variety of patients who are
responding to immunotherapy in order to find the most active and clinically relevant TCRs against each target. We believe we can develop <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies for a wide range of patients, including those who do not
have T cells that efficiently recognize their cancers. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">124
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies are designed to be used in
combination with each other.</I> We are building our diverse ImmunoBank of TCRs to allow for multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy, which has the potential to address the heterogeneous nature of solid tumors and to
prevent resistance developing due to loss of a single target. We believe this approach may allow us to overcome the limitations and challenges of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy development to date.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Our approach is expandable.</I> ImmunoBank has the flexibility to be used with new and
optimized methods of T cell engineering that we may develop over time. We are building ImmunoBank to be compatible with both autologous and allogeneic engineering technologies in order to potentially transition to generating <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf,</FONT></FONT> allogeneic T cells that have been <FONT STYLE="white-space:nowrap">pre-engineered</FONT> with our TCRs for direct administration to patients.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our Platform </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our proprietary platform is designed to: (i)&nbsp;discover anti-cancer TCRs from patients with exceptional responses to
immunotherapy; (ii)&nbsp;determine novel targets of clinically relevant TCRs; (iii)&nbsp;discover novel TCRs that recognize clinically validated targets; (iv)&nbsp;identify <FONT STYLE="white-space:nowrap">off-targets</FONT> of TCRs to eliminate
candidates that could potentially pose a safety risk; and (v)&nbsp;manufacture TCR-T therapies efficiently and consistently without the use of viral vectors using our T-Integrate technology. The three central elements of our platform that
differentiate us from other cell therapy companies are TargetScan, ReceptorScan, and <FONT STYLE="white-space:nowrap">T-Integrate.</FONT> </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>TargetScan&#151;Identification of Novel Targets of Clinically Active TCRs </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">At the core of our proprietary platform is our TargetScan technology that enables us to identify the natural target of a
TCR using an unbiased, genome-wide, high-throughput screen. We have developed this technology to be extremely versatile and applicable across multiple therapeutic areas, including cancer, autoimmune disorders, and infectious diseases. It can be
applied to virtually any TCRs that plays a role in the cause or prevention of disease. TargetScan is also designed to identify potential <FONT STYLE="white-space:nowrap">off-targets</FONT> of a TCR and eliminate those TCR candidates that cross-react
with proteins expressed at high levels in critical organs. We believe this will allow us to reduce the risk and enhance the potential safety profile of our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates early in development before
we initiate clinical trials. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To identify the target of a clinically active TCR found in the T cells of a
patient actively responding to immunotherapy, we mix T cells expressing that TCR with a genome-wide library of target cells where every cell in the library expresses a different protein fragment. In each target cell, the protein fragment is
processed naturally by the proteasome or immunoproteasome and the resulting peptides are displayed on cell-surface MHC proteins. If a T cell recognizes the <FONT STYLE="white-space:nowrap">peptide-MHC</FONT> complex on a target cell, it attempts to
kill the target cell, thereby activating a proprietary fluorescent reporter in the target cell. By isolating fluorescent target cells and sequencing their expression cassettes, TargetScan reveals the natural target(s) of the T cell, as shown below.
This technology was published as a feature article in <I>Cell</I> in 2019. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">125
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Overview of Our Proprietary TargetScan Technology </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g08z43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Central to this technology is the library of protein fragments used for any given
TargetScan screen. Our proprietary libraries comprise hundreds of thousands of specific sequences that collectively include most or all of the targets that a TCR could potentially recognize. For example, our current Oncology Target Discovery Library
(version 3.0) comprises over one million clones, each expressing a unique protein fragment. Collectively, these fragments span every human protein encoded in the human genome, along with all single nucleotide polymorphisms, or SNPs, which are single
amino acid variations in naturally occurring proteins, observed at over 1% frequency in the human population. In addition, the library includes elements that are specific to cancer cells, which are particularly interesting to us as potential
targets: common oncogenic driver mutations, cancer/testis antigens, human endogenous retroviruses, or HERVs, and a large collection of sequences that are not translated in normal tissue but frequently translated in human cancers. We constructed our
libraries using a tiling pattern of overlapping fragments to provide complete and redundant coverage of every targeted sequence, as shown in the graphic below. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">126
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Oncology Target Discovery Library (Version 3.0) </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g69n61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our Oncology Target Discovery Library allows us to precisely identify the novel
targets recognized by TCRs from patients who are actively responding to immunotherapy. In addition, because the library comprehensively covers every <FONT STYLE="white-space:nowrap">non-mutated</FONT> human protein sequence, we are also able to
fully characterize all potential <FONT STYLE="white-space:nowrap">off-target</FONT> interactions for any given TCR, which we believe will help us reduce the risk and enhance the potential safety profile of our
<FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates before we advance them to clinical development. Furthermore, we can use our screen for any HLA type, enabling target discovery across a wide range of patient demographics. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To validate our TargetScan technology, we performed the following proof-of-concept screens using our Oncology Target
Discovery Library (version&nbsp;2.0), which includes approximately 600,000 protein fragments spanning every human protein. In the first screen, we used a naturally occurring TCR that is known to recognize the protein MAGE-A3. As shown below, our
screen correctly identified the primary target of this TCR, and also identified three off-targets, including two that are unrelated at the gene level to MAGE-A3 and would likely not have been identified in a bioinformatic search. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">127
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TargetScan <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Proof-of-Concept:</FONT></FONT> </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Target Screen of MAGE-A3 Specific TCR
Identifies MAGE-A3 and Three Off-Target </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g94z42.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The ability to identify problematic off-targets is critical as TCR-T therapies
engineered with TCRs that recognize off-targets expressed at high levels in critical organs could cause toxicities, thereby limiting their therapeutic potential. To further validate this application of our technology, we used TargetScan to screen an
affinity-enhanced version of the MAGE-A3 TCR described above. Affinity enhancement is a process by which a naturally occurring TCR is mutated in order to generate a more potent therapeutic construct. The affinity enhanced TCR that we screened had
previously entered clinical trials with a different sponsor, but human testing of the TCR was halted abruptly because two patients treated with T cells engineered to express this affinity-enhanced TCR died of acute cardiac failure within 5 days of T
cell administration. Subsequent studies revealed that this TCR recognized an off-target derived from the muscle protein Titin, which is abundantly expressed in cardiac tissue. When we screened this same affinity-enhanced TCR using our TargetScan
technology, we identified a variety of potential additional off-targets which were not seen in our screen of the natural TCR, including the protein Titin, as shown below. This experiment demonstrates why we believe that our TargetScan technology
provides a significant competitive advantage, because it enables us to rapidly and efficiently eliminate from our preclinical pipeline TCRs that are identified as recognizing potentially problematic off-targets. Importantly, this includes
off-targets that may not be identified through standard bioinformatics or <I>in-vitro</I> tissue assays. We believe that TargetScan thereby has the potential to enable us to decrease the risk of encountering unexpected toxicities in our clinical
trials by providing a genome-wide understanding of off-target effects. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">128
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TargetScan Proof-of-Concept: Target Screen of Affinity-Enhanced
MAGE-A3-Specific TCR Identifies Clinically Relevant Off-target Linked to Toxicity </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g80d83.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Using
TargetScan, we have identified more than 40 shared antigens in patient tumors, and over 90% of these targets have not previously been identified as targets for <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. We believe this provides us with a
competitive advantage, because not only are we among the first to identify these targets as tumor-specific antigens, but we have already identified highly active TCRs that recognize these targets. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Overview of Our Proprietary ReceptorScan Technology </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g70r02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I><FONT STYLE="white-space:nowrap">T-Integrate&#151;Genetic</FONT> Engineering of
T Cells Using Transposons </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cell therapy manufacturing is highly complex, and associated challenges
have led to significant delays or failures in the development of many cell therapies. To enable the rapid, cost-effective, and consistent manufacturing of TCRs, we have developed a <FONT STYLE="white-space:nowrap">non-viral</FONT> vector delivery
system that we refer to as <FONT STYLE="white-space:nowrap">T-Integrate.</FONT> Our manufacturing platform enables us to introduce any of the TCRs from ImmunoBank, along with additional genetic elements such as CD8 that further augment <FONT
STYLE="white-space:nowrap">T-cell</FONT> function, into the genomes of patient- or donor-derived T cells. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">129
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Genetically engineering a T cell requires two steps: (1)&nbsp;delivering
DNA encoding the TCR into the nucleus of a T cell and (2)&nbsp;integrating that DNA into the genome of the T cell. These two steps are often accomplished through the use of retroviral vectors, such as lentivirus, by packaging RNA encoding the TCR
into lentiviral particles, which are then used to infect T cells. Although effective, manufacturing lentiviral particles is time-consuming, costly, and often highly variable. In addition, each new TCR requires extensive process development, as the
TCR sequence affects the efficiency with which it is packaged into the lentivirus. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As a more efficient and
reproducible alternative to lentivirus, we have developed <FONT STYLE="white-space:nowrap">T-Integrate</FONT> to genetically engineer T cells using a transposon/transposase system, as shown in the graphic below. In this system, DNA encoding the TCR
is manufactured as a Nanoplasmid and enables DNA delivery using a smaller plasmid footprint. The Nanoplasmid, together with an mRNA sequence encoding a transposase enzyme, is introduced into the T cell by electroporation. After the T cell translates
the mRNA into protein, the transposase enzyme inserts the TCR sequence from the Nanoplasmid into the genome of the T cell. This system is highly reproducible, as the only required components are a Nanoplasmid, which is different for each TCR
product, and mRNA, which is constant for all TCR products. Unlike lentivirus, both of these components are routinely manufactured in a cost-effective manner without the need for extensive process development. We believe our manufacturing platform
will enable us to efficiently develop and manufacture many different <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies, allowing us to deliver customized multiplexed therapy to patients with cancer. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Our <FONT STYLE="white-space:nowrap">T-Integrate</FONT> Manufacturing Platform </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g33z96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our transposon vector includes both the beta and alpha chains of the TCR under the
control of a strong promoter. This is designed to ensure that high levels of the TCR are produced on the surface of the T cells and that the TCRs that are normally expressed in the patient or donor&#146;s T cells, or the &#145;endogenous&#146; TCRs,
are suppressed. We have also introduced specific alterations in the constant region of the TCR to further augment its stability. In addition to the TCR, our transposon construct includes genes encoding the alpha and beta chains of the cell-surface
protein CD8. CD8 forms a complex with the TCR and is necessary for the TCR to recognize its target on tumor cells. Including the CD8 <FONT STYLE="white-space:nowrap">co-receptor</FONT> in our construct enables us to genetically reprogram both major
types of T cells: cytotoxic T cells that naturally make their own CD8 and helper T cells that do not make CD8. Our final <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies are a mixture of both cytotoxic and helper T cells that have been
reprogrammed to recognize and eliminate tumor cells expressing the relevant targets. We also included a short peptide tag at the beginning of CD8 alpha in our construct. This tag does not interfere with the function of CD8 alpha, but provides a way
to easily purify the engineered T cells during our manufacturing process. An illustration of the construct of our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies is shown below. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">130
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Construct of our <FONT STYLE="white-space:nowrap">TCR-T</FONT> Therapies
</B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g97c73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Another important advantage of our T-Integrate manufacturing platform is that its
greater carrying capacity than the commonly-used lentiviral approach enables us to introduce additional genes that augment T&nbsp;cell function along with the gene that encodes the TCR itself. Our current vector co-introduces coding regions for both
the alpha and beta chains of the TCR co-receptor CD8, which we believe will enhance our TCR-T therapy candidates by enabling us to reprogram helper T&nbsp;cells along with cytotoxic T&nbsp;cells. As our programs advance, we intend to introduce
additional elements to our products with the goal of further improving their performance in the solid tumor setting, including features designed to increase the penetration of our T&nbsp;cells into solid tumors, with the aim of keeping our
T&nbsp;cells active for a longer time and rendering our T&nbsp;cells more impervious to the hostile tumor microenvironment. These additional features are expected to increase the amount of genetic material which we need to incorporate into our
T&nbsp;cells to a level which is beyond the limit of the efficient packaging capacity of a lentiviral-based cell engineering system. The limit to how much novel genetic material that can be packaged into a lentivirus is known to be approximately
6,000 nucleotides. Nucleotides are the basic building blocks of genetic material that make up DNA and RNA. We believe that our transposon/transposase manufacturing platform can efficiently deliver into our T&nbsp;cells an amount of novel genetic
material in excess of 6,000 nucleotides, thus allowing us to introduce the desired additional elements into our products. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">131
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our Programs </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">With our differentiated platform as our foundation, we are building a three-pillar research and development strategy to
create transformational TCR-T therapies for patients, as shown below. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g00g01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Our Liquid Tumor Program </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are developing our liquid tumor program to treat patients with hematologic malignancies who are undergoing for
allogeneic HCT. In the first phase of our clinical development strategy, we are initially focusing on well-recognized cancer targets that have been discovered in patients with exceptional responses to
<FONT STYLE="white-space:nowrap">HCT-associated</FONT> immunotherapy, including <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2.</FONT> In addition, to further expand our liquid tumor program, we are developing
additional product candidates that target other similarly validated antigens, enabling us to expand the addressable patent population. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We plan to conduct clinical trials of our lead <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates, <FONT
STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> in parallel, with patients enrolled in treatment arms based on their genotype, as shown below. Patients who are positive for the target antigen, <FONT
STYLE="white-space:nowrap">HA-1</FONT> or <FONT STYLE="white-space:nowrap">HA-2,</FONT> as well as the <FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> allele, which is the HLA type required to display <FONT STYLE="white-space:nowrap">HA-1</FONT>
and <FONT STYLE="white-space:nowrap">HA-2</FONT> on the cell surface for recognition by a T cell, will be eligible for enrollment. Furthermore, eligible patients will require donors who are negative for either the target antigen or the <FONT
STYLE="white-space:nowrap">HLA-A*02:01</FONT> allele. We also plan to incorporate additional product candidates into this trial design as they advance into the clinic, which we believe has the potential to allow us to provide a broad array of
therapeutic options for the majority of patients with hematologic malignancies receiving HCT. In our clinical trials of TSC-100 and TSC-101, we also plan to evaluate the potential benefit of combining the two therapies as a multiplexed TCR-T therapy
for patients who are positive for both HA-1 and HA-2. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">132
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Our Clinical Development Strategy for Multiple <FONT
STYLE="white-space:nowrap">TCR-T</FONT> Therapies </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g99g01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Background on Hematologic Malignancies </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Hematopoietic stem cell transplantation, or HCT, has become the standard of care for many hematologic malignancies. When
a patient with leukemia undergoes HCT, they start by receiving a conditioning regimen of high dose chemotherapy with or without radiation. This regimen is intended to kill both the patient&#146;s leukemia cells as well as their native blood cells
and blood cell precursors, including hematopoietic stem cells in their bone marrow. The patient then receives hematopoietic stem cells from an <FONT STYLE="white-space:nowrap">MHC-matched</FONT> donor. The stem cells engraft in their bone marrow and
start to repopulate their body with new blood cells, which are now genetically identical to the donor. HCT has demonstrated the rare opportunity in cancer treatment to generate long-term remissions or cures. For example, patients with acute myeloid
leukemia, or AML, who receive HCT have a five-year post-transplant survival rate of 41%. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Approximately 7,000
allogeneic HCT procedures are performed yearly in the United States, primarily in patients with AML or acute lymphocytic leukemia, or ALL. As a curative therapy for many hematologic malignancies, use of HCT has been steadily increasing over the last
two decades, as shown below, with increased use driven largely by increasing donor availability, an increase in disease prevalence due to aging populations, and improved conditioning regimens permitting broader use in older patient segments. While
the approval of <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies has significantly impacted the treatment of <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies over the last decade, HCT in
<FONT STYLE="white-space:nowrap">non-B</FONT> cell malignancies is anticipated to remain the standard of care for patients. In addition, adoption of safer and more effective conditioning regimens is anticipated to continue to drive an increasing use
of HCT in patient segments previously deemed too old or unfit for transplant or those who failed to achieve proper remission prior to transplant. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">133
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>The Number of Allogeneic HCT Procedures in the U.S. Continues to Rise
</B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g10g61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">However, despite the increasing use of HCT and the resulting clinical benefits or
cures, up to half of the patients who receive HCT relapse, at which point there are limited treatment options and the prognosis is very poor. Clinical observations have shown that if the T cells of the donor recognize certain minor
histocompatibility antigens, or miHAs, in the patient&#146;s leukemia cells, such as proteins that have single amino acid differences between the patient and the donor, the T cells of the donor drive a specific graft vs. leukemia, or GvL, effect,
whereby the engrafted donor T cells detect remaining leukemia as foreign and eliminate the remaining disease. As a result, the patient often experiences a long-term remission from their cancer, or even a complete cure. If the miHAs are also
expressed in <FONT STYLE="white-space:nowrap">non-hematopoietic</FONT> tissues, the patient may develop graft vs. host disease, or GvHD, but if the miHAs are only expressed in blood cells, a specific GvL effect is observed without an increase in
GvHD. Our liquid tumor program is focused on targeting miHAs that are exclusively expressed in hematopoietic cells in order to induce the GvL effect while potentially mitigating the risk of GvHD. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I><FONT STYLE="white-space:nowrap">TSC-100</FONT> </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap">TSC-100</FONT> is an allogeneic <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy
candidate directed at eliminating all native blood cells, including residual cancer cells, in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">HLA-A*02:01-positive</FONT></FONT> patients with hematologic malignancies who undergo HCT using a donor who is either <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-negative</FONT></FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HLA-A*02:01-negative.</FONT></FONT> Using ReceptorScan, we screened over a hundred million CD8+ T cells and identified and assessed hundreds of highly active TCRs that recognize the <FONT
STYLE="white-space:nowrap">HA-1</FONT> antigen. We selected <FONT STYLE="white-space:nowrap">TCR-100a</FONT> based on its superior affinity, cytotoxic activity, and specificity compared to the others. <FONT STYLE="white-space:nowrap">TSC-100</FONT>
is designed to elicit an anti-tumor response in patients by targeting <FONT STYLE="white-space:nowrap">HA-1,</FONT> which is present on malignant and normal blood cells of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> patients but not on any of the new, donor-derived blood cells they receive from a donor who is either <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">HA-1-negative</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HLA-A*02:01-negative.</FONT></FONT> We believe that donor T cells specifically engineered to express <FONT
STYLE="white-space:nowrap">TCR-100a</FONT> will generate an anti-tumor effect in patients, leading to a reduction in relapse rates and an increase in long-term survival. We plan to file an IND for <FONT STYLE="white-space:nowrap">TSC-100</FONT> with
the FDA in the fourth quarter of 2021. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap">HA-1</FONT> was one of the first
miHAs to be discovered in a patient undergoing HCT.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><FONT STYLE="white-space:nowrap">HA-1</FONT> is a peptide antigen derived from the protein ARHGAP45, which is an intracellular protein expressed
at high levels in all blood cells but not in any other tissue. ARHGAP45 comes in two forms. In <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> individuals, the peptide has the sequence
VL<B><U>H</U></B>DDLLEA and, if the individual has the HLA type A*02:01, the antigen is efficiently displayed on the surface of blood cells. In <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-negative</FONT></FONT>
individuals, the peptide has the sequence VL<B><U>R</U></B>DDLLEA, and the <FONT STYLE="white-space:nowrap">HA-1</FONT> antigen is not displayed. Approximately 60% of people have the VL<B><U>H</U></B>DDLLEA sequence and approximately 42% of people
in the United States have the HLA type A*02:01, which means that approximately 25% of individuals in the United States are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> with the specific HLA type
required for antigen expression. Studies of patients receiving HCT have shown that in cases where the T cells of an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-negative</FONT></FONT> donor naturally develop a response to <FONT
STYLE="white-space:nowrap">HA-1</FONT> in an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> patient, the T cells mediate a specific GvL effect and the patient often experiences a long-term remission. <FONT
STYLE="white-space:nowrap">TSC-100</FONT> is based on this clinical observation and is designed to specifically cause this GvL effect in patients receiving HCT. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">134
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are developing <FONT STYLE="white-space:nowrap">TSC-100</FONT> as a
treatment for patients with cancer who are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> and have been deemed eligible for HCT. For each patient, a healthy donor who is
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-negative</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HLA-A*02:01-negative</FONT></FONT> will be identified. Hematopoietic stem cells
isolated from that donor will be used as the source of transplant material. In parallel, T cells isolated from the same donor will be genetically engineered to recognize <FONT STYLE="white-space:nowrap">HA-1.</FONT> Once engraftment of donor stem
cells is established in the patient, <FONT STYLE="white-space:nowrap">TSC-100</FONT> will be infused into the patient with the goal of eliciting a highly specific anti-tumor effect. The engineered donor T cells are designed to recognize and
eliminate all of the patient&#146;s native blood cells, including residual leukemia cells, which are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive,</FONT></FONT> thereby preventing relapse and potentially promoting
complete cures. Because the patient&#146;s new healthy blood cells are derived from the donor and are therefore either <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-negative</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">HLA-A*02:01-negative,</FONT></FONT> we believe that <FONT STYLE="white-space:nowrap">TSC-100</FONT> should have minimal toxic side effects. A summary of the treatment paradigm for
<FONT STYLE="white-space:nowrap">TSC-100</FONT> is illustrated below. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><FONT STYLE="white-space:nowrap">TSC-100</FONT> Treatment Paradigm </B></FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g69c93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Preclinical Data </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Using ReceptorScan, we screened over 175&nbsp;million T cells from six healthy donors to identify naturally occurring
TCRs specific for <FONT STYLE="white-space:nowrap">HA-1.</FONT> We then extensively characterized over 300 of these TCRs for their ability to specifically recognize and kill tumor cells that express <FONT STYLE="white-space:nowrap">HA-1.</FONT> We
prioritized TCRs with the highest potency in cytotoxicity assays and in their production of cytokines associated with increased <FONT STYLE="white-space:nowrap">T-cell</FONT> activation and function. Through this screening process, we identified <FONT
STYLE="white-space:nowrap">TCR-100a,</FONT> which exhibited superior potency compared to the other TCRs. We assessed the <I>in vitro </I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-specific</FONT></FONT> cytotoxicity of <FONT
STYLE="white-space:nowrap">TCR-100a</FONT> using cell lines with various levels of <FONT STYLE="white-space:nowrap">HA-1</FONT> expression, as shown below. THP1, a cell line that expresses moderate levels of
<FONT STYLE="white-space:nowrap">HA-1,</FONT> was susceptible to cell killing by multiple TCRs we tested. However, TF1, a cell line that expresses less than half the level of <FONT STYLE="white-space:nowrap">HA-1</FONT> expressed by THP1, was
sensitive to cell killing by <FONT STYLE="white-space:nowrap">TCR-100a</FONT> but was resistant to almost all other </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-specific</FONT></FONT> TCRs, including TCRs reported in the literature. Our preclinical studies also demonstrated that SUDHL1 cells, which lack
<FONT STYLE="white-space:nowrap">HA-1</FONT> expression, were resistant to all tested <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-specific</FONT></FONT> TCRs, as expected, highlighting the high selectivity and potential
safety of <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">135
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B></B><B><I>In Vitro</I></B><B> Studies Demonstrate Superior <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-Specific</FONT></FONT> Cytotoxicity </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>of
<FONT STYLE="white-space:nowrap">TCR-100a</FONT> Compared to Other TCRs </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g01a14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Because people inherit two copies of every chromosome, one from their mother and one
from their father, everyone has two copies of the ARHGAP45 gene. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> patients can therefore be either homozygous for
<FONT STYLE="white-space:nowrap">HA-1</FONT> (+/+), with both genes encoding the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> peptide (VL<B><U>H</U></B>DDLLEA), or heterozygous for <FONT
STYLE="white-space:nowrap">HA-1</FONT> (+/-), with one gene encoding the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> peptide and the other encoding the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">HA-1-negative</FONT></FONT> peptide (VL<B><U>R</U></B>DDLLEA). To ensure that <FONT STYLE="white-space:nowrap">TSC-100</FONT> is able to effectively eliminate healthy blood cells and leukemia cells that are either
homozygous <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> (+/+) or heterozygous <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> (+/-), we assessed the
activity of <FONT STYLE="white-space:nowrap">TSC-100</FONT> against blood cells derived from a variety of healthy donors and patients with AML and ALL. As shown below, <FONT STYLE="white-space:nowrap">TSC-100</FONT> eliminates both homozygous and
heterozygous healthy blood cells and leukemia cells. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><FONT STYLE="white-space:nowrap">TSC-100</FONT>
Displays Specific Cytotoxic Activity Towards <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> Cells </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g46c77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Previous clinical studies by others with TCRs that exhibited unexpected <FONT
STYLE="white-space:nowrap">off-target</FONT> effects led to significant toxicities. In order to reduce the potential for <FONT STYLE="white-space:nowrap">TCR-100a</FONT> to exhibit problematic <FONT STYLE="white-space:nowrap">off-target</FONT>
effects, we used </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">TargetScan to comprehensively scan for any other potential targets recognized by <FONT
STYLE="white-space:nowrap">TCR-100a.</FONT> This screen was performed using a subset of our Oncology Target Discovery Library (version 2.0), which includes approximately 600,000 protein fragments and collectively spans every protein encoded in the
human genome as well as all common SNPs. As shown below, all three protein fragments in the library that contain the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> peptide antigen were strongly enriched
in the screen and no significant <FONT STYLE="white-space:nowrap">off-target</FONT> interactions were observed. In contrast, some of the other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-specific</FONT></FONT> TCRs
identified by ReceptorScan did exhibit <FONT STYLE="white-space:nowrap">off-target</FONT> effects, highlighting our ability to select candidates that we believe have favorable risk/benefit profiles. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">136
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TargetScan Screen Reveals No Significant
<FONT STYLE="white-space:nowrap">Off-Targets</FONT> for <FONT STYLE="white-space:nowrap">TCR-100a</FONT> </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g01a15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To further evaluate the potential safety profile of
<FONT STYLE="white-space:nowrap">TSC-100,</FONT> we screened <FONT STYLE="white-space:nowrap">TCR-100a</FONT> against <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">HA-1-negative</FONT></FONT> cells that individually express each of the 108 most common HLA alleles. In the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-positive</FONT></FONT> cells, <FONT
STYLE="white-space:nowrap">TCR-100a</FONT> was able to mediate efficient recognition in cells expressing <FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> as well as in cells expressing two related HLA types,
<FONT STYLE="white-space:nowrap">HLA-A*02:02</FONT> and <FONT STYLE="white-space:nowrap">HLA-A*02:06.</FONT> This suggests that patients with any of these three HLA types could potentially benefit from
<FONT STYLE="white-space:nowrap">TSC-100.</FONT> Notably, <FONT STYLE="white-space:nowrap">TCR-100a</FONT> showed no recognition of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-1-negative</FONT></FONT> cells across all 108
HLA types, indicating low risk of alloreactivity or misrecognizing other antigens on other HLA types, as shown below. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#32406b"><B><FONT STYLE="white-space:nowrap">TSC-100</FONT> Shows No Detectable Alloreactivity Across 108 Different HLA Types </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g01b15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I><FONT STYLE="white-space:nowrap">TSC-101</FONT> </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Similar to <FONT STYLE="white-space:nowrap">TSC-100,</FONT> <FONT STYLE="white-space:nowrap">TSC-101</FONT> is an
allogeneic <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidate directed at eliminating residual cancer cells in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-2-positive</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HLA-A*02:01-positive</FONT></FONT> patients with hematologic malignancies who undergo HCT using a donor who is either
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-2-negative</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HLA-A*02:01-negative.</FONT></FONT> <FONT STYLE="white-space:nowrap">HA-2,</FONT>
which is derived from the protein MYO1G, is another miHA that has been identified to be clinically relevant. In patients who naturally develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-2-specific</FONT></FONT> T cells, a
GvL effect has been observed and these patients experience long-term remissions. Using ReceptorScan, we have identified a highly active TCR, which we refer to as <FONT STYLE="white-space:nowrap">TCR-101a,</FONT> that recognizes <FONT
STYLE="white-space:nowrap">HA-2.</FONT> We intend to file an IND for <FONT STYLE="white-space:nowrap">TSC-101</FONT> in the fourth quarter of 2021. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Unlike <FONT STYLE="white-space:nowrap">HA-1,</FONT> the <FONT STYLE="white-space:nowrap">HA-2</FONT> antigen is highly
prevalent, with approximately 95% of individuals in the United States being <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-2-positive.</FONT></FONT> However, as with <FONT STYLE="white-space:nowrap">HA-1,</FONT> a specific HLA
type, <FONT STYLE="white-space:nowrap">HLA-A*02:01,</FONT> which is present in approximately 42% of individuals in the United States, is required to display the <FONT STYLE="white-space:nowrap">HA-2</FONT> antigen on the cell surface for recognition
by a T cell. As a result, approximately 40% of HCT patients would be positive for both <FONT STYLE="white-space:nowrap">HA-2</FONT> and <FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> and therefore be eligible for treatment with <FONT
STYLE="white-space:nowrap">TSC-101</FONT> using a donor who is negative for </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">137
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
<FONT STYLE="white-space:nowrap">HLA-A*02:01,</FONT> regardless of whether the donor is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-2-positive</FONT></FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HA-2-negative.</FONT></FONT> Such donors are straightforward to identify and should be available to most patients who undergo half-matched, or haploidentical, transplantation using family
members as donors, as patients typically have between two and three potential haploidentical donors. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Similar
to <FONT STYLE="white-space:nowrap">TCR-100a,</FONT> we used ReceptorScan to identify <FONT STYLE="white-space:nowrap">TCR-101a</FONT> amongst a screen of 240 million T&nbsp;cells. We tested <FONT STYLE="white-space:nowrap">TCR-101a</FONT> <I>in
vitro </I>using cell lines and found superior antigen binding and cytotoxicity compared with more than 300 other TCRs assessed. As shown in the figure below, <FONT STYLE="white-space:nowrap">TCR-101a</FONT> had superior activity against DEL cells,
which have high levels of <FONT STYLE="white-space:nowrap">HA-2,</FONT> and <FONT STYLE="white-space:nowrap">THP-1</FONT> cells, which have low levels of <FONT STYLE="white-space:nowrap">HA-2.</FONT> In addition,
<FONT STYLE="white-space:nowrap">TCR-101a</FONT> had no effect against NB4 cells, which do not express <FONT STYLE="white-space:nowrap">HLA-A*02:01,</FONT> indicating that <FONT STYLE="white-space:nowrap">TCR-101a</FONT> should not affect donor
blood cells that are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HLA-A*02:01-negative.</FONT></FONT> We are currently conducting preclinical studies using TargetScan to assess potential
<FONT STYLE="white-space:nowrap">off-target</FONT> effects and performing alloreactivity studies to ensure that other HLA types are not misrecognized. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><FONT STYLE="white-space:nowrap">TCR-101a</FONT> Demonstrates Superior Cytotoxicity </B><B><I>in vitro</I></B><B>
Compared to Other TCRs </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g79n61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I><FONT STYLE="white-space:nowrap">TSC-102</FONT> and Additional Liquid Tumor
Programs </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To broaden the eligible HCT patient population beyond those who have the HLA type A*02:01,
we have identified a third miHA that requires a different HLA type, B*07:02, to be displayed on the surface of blood cells. Like <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT STYLE="white-space:nowrap">HA-2,</FONT> this target was
identified in HCT patients who achieved durable complete remissions from their hematologic cancers with little to no GvHD. This antigen is highly expressed in normal and malignant hematopoietic cells and is not expressed in normal tissues, based on
publicly available databases.&nbsp;We are developing <FONT STYLE="white-space:nowrap">TSC-102</FONT> as an allogeneic <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidate directed at eliminating residual cancer cells in patients with
hematologic malignancies who are positive for both this antigen and <FONT STYLE="white-space:nowrap">HLA-B*07:02</FONT> and undergo HCT using a donor&nbsp;who is negative for either the target or this specific HLA type. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Approximately 25% of the population has the HLA type B*07:02, and the antigen we have chosen is present in about 71% of
these individuals. Therefore, approximately 18% of patients undergoing HCT would be eligible for treatment with <FONT STYLE="white-space:nowrap">TSC-102.</FONT> Using ReceptorScan, we have identified over 1,000 potential TCRs that recognize this
target and studies are underway to identify the most potent TCR candidate. We are continuing to conduct target validation studies and to assess our TCR candidates using TargetScan. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition to <FONT STYLE="white-space:nowrap">TSC-102,</FONT> we are continuing to explore additional miHA targets to
provide a broad array of therapeutic options for the majority of patients with hematologic malignancies receiving HCT. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">138
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Clinical Development Plan for Our Liquid Tumor Program
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Background on Types of HCT </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Patients with acute leukemias who undergo allogeneic HCT have heterogeneous outcomes that are primarily related to two
main variables: (i)&nbsp;the intensity or doses of the conditioning regimen they receive prior to the stem cell infusion and (ii)&nbsp;the type of donor who provides the stem cells. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">High-intensity conditioning regimens are called myeloablative conditioning and associated with higher mortality rates.
They are therefore reserved for young and relatively fit patients. Lower-intensity regimens are called reduced-intensity conditioning, or RIC, and better tolerated, but are associated with higher relapse rates.
<FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> are both designed to substantially reduce relapse rates, and we plan to enroll patients who are eligible for
<FONT STYLE="white-space:nowrap">RIC-based</FONT> HCT with the goal of improving clinical outcomes for these patients. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">There are different types of donors who are eligible for allogeneic HCT procedures. Donors who are siblings of the patient and are perfectly matched for 8 out of 8 HLA alleles are considered the highest priority donor type for
patients undergoing allogeneic HCT, but these types of donor are available for less than a third of patients. For the majority of patients, the choice is between an unrelated donor who is perfectly matched for 8 out of 8 HLA alleles, referred to as
a matched unrelated donor, or MUD, or a family member such as a sibling, parent or child who has a half-match with the patient, referred to as a haploidentical donor, or haplo. Historically, haplo donor transplantation was associated with much
higher GvHD than <FONT STYLE="white-space:nowrap">MUD-transplants,</FONT> but a recent treatment regimen that uses chemotherapy given 3 days after stem cell infusion called post-transplantation cyclophosphamide, or PTCy, specifically kills immune
cells that cause GvHD. As a result, haplo transplants with PTCy have recently achieved equivalent outcomes as MUD transplants and are rapidly increasing in usage in the United States and worldwide. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The use of haplos greatly expands the donor pool for patients undergoing HCT and provides patients with the optionality
to choose donors who are mismatched on specific HLA types, such as A*02:01, as opposed to being mismatched on certain minor antigens, such as <FONT STYLE="white-space:nowrap">HA-1</FONT> or <FONT STYLE="white-space:nowrap">HA-2.</FONT> We are
developing <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> with a specific focus on patients undergoing haplo donor transplantation with donors who are negative for either the miHA or the specific
HLA type. We believe the engineered donor T cells will recognize any residual leukemia cells, which are target-positive, in the patient and prevent relapse with the potential to promote complete cures. Because the patient&#146;s new healthy blood
cells are derived from the donor and are therefore either target-negative or not able to express the target, we believe <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> should have minimal toxic
side effects. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Planned Phase 1 Clinical Trial </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are planning to conduct safety studies for <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT
STYLE="white-space:nowrap">TSC-101</FONT> within a single, <FONT STYLE="white-space:nowrap">multi-arm</FONT> Phase 1 clinical trial. Once safety results are available for the individual therapies, we plan to open a third arm to evaluate the safety
of multiplexed therapy, combining <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101</FONT> in patients who are positive for both <FONT STYLE="white-space:nowrap">HA-1</FONT> and <FONT
STYLE="white-space:nowrap">HA-2.</FONT> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our Phase 1 clinical trial is designed to include the measurement of
early surrogate markers of efficacy, such as chimerism, or the percentage of blood cells that are donor-derived, and whether patients continue to have detectable residual leukemia in their post-transplant bone marrow biopsy, both of which are
predictors of relapse. As shown in the graphic below, we also plan to include a control arm, comprising patients who do not meet the HLA or miHA genetic criteria and are treated with standard RIC haplo transplantation alone. Comparisons of both
safety and efficacy outcomes with this control arm will potentially enable all patients treated with <FONT STYLE="white-space:nowrap">TSC-100,</FONT> <FONT STYLE="white-space:nowrap">TSC-101,</FONT> or the combination to be included as part of the
efficacy analysis in a future biologics license application, or BLA, filing. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">139
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Planned <FONT STYLE="white-space:nowrap">Multi-Arm</FONT> Phase 1
Clinical Trial Design </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g62h01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Anticipated timeline </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As we advance our liquid tumor program, we anticipate presenting pre-clinical data at a major scientific meeting in the
fourth quarter of 2021; filing INDs on TSC-100 and TSC-101 in the fourth quarter of 2021; dosing the first patient in our Phase 1 clinical trial in the first half of 2022; and presenting initial clinical data on our Phase 1 trial in the second half
of 2022. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Solid Tumor Program </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are developing a portfolio of autologous TCR-T therapy candidates that are designed to be used in combination with
each other to treat and eliminate solid tumors. Our TSC-200 series of product candidates are designed to elicit an anti-tumor response in patients by targeting cancer-specific antigens in their tumor cells. Our TCR-T therapy candidates include: (i)
either well-recognized cancer targets that have demonstrated anti-tumor activity in clinical trials or novel targets that were identified by TargetScan from the T cells of patients responding to immunotherapy and (ii) naturally occurring TCRs
specific to a patient&#146;s HLA type that recognize these cancer-specific targets. Such targets are not only commonly shared among patients with the same cancer type, but also frequently expressed in multiple solid tumor types, enabling clinical
development across multiple indications. Our first four solid tumor TCR-T therapy candidates include a combination of known targets, such as HPV16 for <FONT STYLE="white-space:nowrap">TSC-200</FONT> and PRAME for TSC-203, as well as novel TCR-T
therapy targets that have not yet been tested in the clinic, such as TSC-201 and TSC-202. We are currently advancing our four solid tumor TCR-T therapy candidates through lead optimization, and we expect to submit IND applications for at least three
of our four candidates in the second half of 2022, with the fourth IND expected to be filed in 2023. In addition to our four lead solid tumor TCR-T therapy candidates, we have identified over 40 novel antigens based on tumor samples from patients
who are actively responding to immunotherapy using our TargetScan technology. We are in early stages of analyzing these additional novel antigens and advance those that we believe have the best potential as a TCR-T therapy candidate into preclinical
development. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are building ImmunoBank, a collection of highly active TCRs, to enable multiplexed <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapy. Our vision is to expand ImmunoBank with TCRs that recognize diverse targets and are associated with multiple </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">140
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
HLA types in order to provide a broad array of therapeutic options for patients with various types of solid tumors. For each patient with a solid tumor malignancy, we plan to analyze their tumor
to determine which targets are expressed at high levels in their particular cancer. We will then access ImmunoBank and select up to three TCRs that match their HLA type and address the most highly expressed targets in their tumor. We will use this
set of TCRs to genetically reprogram their T cells to recognize these targets and the resulting engineered T cells will be infused back into the patient as a multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Our Strategy to Treat Solid Tumors with Multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> Therapy
</B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g64r13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I><FONT STYLE="white-space:nowrap">TCR-T</FONT> Therapy for the Treatment of
Solid Tumors </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Immunotherapy has reshaped the treatment of solid tumors by demonstrating that tumor
shrinkage, eradication, and long-term durable responses can be obtained by stimulating the patient&#146;s own immune system to attack their cancer cells. Immune checkpoint inhibitors, such as nivolumab or pembrolizumab, work by unleashing
anti-cancer T cells that are already present in a patient&#146;s tumor, enabling those T cells to recognize and eliminate their cancer. For patients who respond to checkpoint inhibitors, these agents have been shown to be very effective. However,
only a subset of patients respond to checkpoint inhibitors, highlighting the need for T&nbsp;cell-based therapies that can treat the majority of patients who do not respond. Despite their efficacy in only a subset of patients, checkpoint inhibitors
generated 2019 sales of approximately $22&nbsp;billion. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">One reason why many patients do not respond to
current immunotherapy treatments is that they lack T cells with highly active TCRs that recognize cancer-specific antigens in their tumors. By reprogramming the patient&#146;s own T cells to recognize these targets, we believe we can expand the
dramatic responses observed with checkpoint inhibitor therapy to the many patients for whom these therapies are ineffective. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Our Solution </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our solid tumor program is based on the premise that if we can
understand how T cells naturally fight cancer, we can use this information to design life-changing <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies for virtually any patient with cancer. Our discovery process begins with identifying patient T
cells that are actively driving their clinical response to immunotherapy. We then use TargetScan to determine the precise targets of these highly active TCRs. Our discovery efforts are initially focused on patients with head&nbsp;&amp; neck cancer
who respond to checkpoint inhibitor therapy and patients with melanoma who respond to TIL therapy. These cancers represent tumor types with a high degree of <FONT STYLE="white-space:nowrap">T-cell</FONT> infiltration and strong responses to
immunotherapy, which provides us with clinically active T cells from which we can discover novel TCR/target pairs. We have found that targets discovered in one type of cancer are often expressed in other cancers as well, enabling broader clinical
development of our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates. The tumor types we are focused on also express several known targets that were previously discovered from patient T cells. We are using ReceptorScan to discover
highly active TCRs for these previously identified targets to complement the discovery of our novel TCR/target pairs. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">141
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Novel Targets Identified from Patients with Head&nbsp;&amp; Neck Cancer
</I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">One of the ways we identify anti-cancer TCRs is by focusing on T cells that clonally expand in a tumor
when the patient responds to checkpoint inhibitor therapy. Some of this work is being performed under collaborative research agreements with various academic institutions. Using single cell sequencing, our collaborators determined the TCR sequences
of thousands of T cells in the tumors of patients with head&nbsp;&amp; neck cancer before and after immunotherapy. This analysis also revealed the frequency of each <FONT STYLE="white-space:nowrap">T-cell</FONT> clone in the tumor samples. As an
example, if a particular TCR sequence is observed at 0.05% frequency in the tumor before the patient receives immunotherapy and then increases to 5% after the tumor starts to shrink, the T cell has clonally expanded
<FONT STYLE="white-space:nowrap">100-fold</FONT> and is likely to have played a causal role in driving the patient&#146;s clinical response. Certain TCR sequences are not detectable in the <FONT STYLE="white-space:nowrap">pre-treatment</FONT> biopsy
but are observed at high frequency in the post-treatment tumor. These emerging clones are also potential candidates for driving the patient&#146;s clinical response. An illustrative example of <FONT STYLE="white-space:nowrap">T-cell</FONT>
sequencing data from one patient with head&nbsp;&amp; neck cancer who had a complete response to immunoterapy. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Clinically Relevant Anti-Cancer T Cells Identified Through <FONT STYLE="white-space:nowrap">T-Cell</FONT> Sequencing
</B></FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g65v32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have performed genome-wide TargetScan screens on over 100 TCRs derived from T
cells that clonally expanded in the tumors of patients with head&nbsp;&amp; neck cancer who are responding to immune checkpoint inhibitors, which has resulted in our discovery of over 20 novel shared antigens. An example of one such screen is shown
below. This screen was performed with our Oncology Target Discovery Library (version 2.0), which comprises over 600,000 protein fragments. Two protein fragments, shown in dark pink, were specifically recognized by the TCR. Due to the redundancy
built into our library through its overlapping tiling pattern, both of the identified clones contain the same nine amino acid-long peptide antigen that we determined to be the target of this TCR. Notably, no
<FONT STYLE="white-space:nowrap">off-targets</FONT> were observed in the screen, highlighting the value of the TargetScan technology in identifying TCRs with clean specificity profiles. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">142
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Identification of a Novel Target from a Patient with Head&nbsp;&amp; Neck
Cancer </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g66x50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Novel Targets Identified from Patients with Melanoma </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Another approach we use to identify clinically relevant anti-cancer T cells is to analyze T cells from patients with
melanoma who respond to TIL therapy. Using single cell sequencing, we determine the TCR sequences of the T cells in the responding patient&#146;s TIL therapy product and focus on the most abundant <FONT STYLE="white-space:nowrap">T-cell</FONT>
clones. We have found that TIL therapy products are often dominated by as few as two or three clones, further increasing our confidence that these TCRs played a causal role in fighting the patient&#146;s cancer. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To increase the throughput of our discovery efforts, we have used TargetScan in a more directed manner to screen <FONT
STYLE="white-space:nowrap">sub-libraries</FONT> of protein fragments that focus on particular classes of tumor antigens. For example, we built a <FONT STYLE="white-space:nowrap">sub-library</FONT> that focuses on cancer/testis antigens, or CTAs,
which are genes that typically play a role in embryonic development but are not expressed in any adult tissues other than testes. T cells do not infiltrate testes and cells in the testes have very low levels of MHC proteins, making testes an
immune-privileged site that will not be targeted by engineered T cells in the context of cell therapy. CTA genes are frequently found to be expressed in tumor cells and often play a role in causing cancer. Several well-recognized targets in
development for <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy are CTAs, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1</FONT></FONT> and <FONT STYLE="white-space:nowrap">MAGE-A4.</FONT> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are focused on the discovery of novel targets within this class of antigens and have built a TargetScan library
comprising 40,000 fragments that tiles across 1,600 CTA genes. Because this library is substantially less complex than our genome-wide Oncology Target Discovery Library, we can screen the library with dozens of TCRs simultaneously. For example, the
screen shown below was conducted with 35 TCRs derived from 11 patients with melanoma who received TIL therapy. In a single screen, we identified three TCR/target pairs that recognize CTAs, including the antigen target for one of our lead solid tumor
product candidates, TSC-201, which we refer to as Target-201, as well as two other antigens that have not previously been identified as targets for TCR-T therapy. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">143
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Three Novel Cancer/Testis Antigen Targets Identified </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>from <FONT STYLE="white-space:nowrap">TIL-Responsive</FONT> Patients </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g67a10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>TCR and Target Validation Process </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">When we discover novel TCR/target pairs, we first determine if the gene that encodes the target is expressed at high
levels in normal tissue. As shown below, Target-201 is exclusively expressed in testis, which is an immune privileged tissue and, as a result, should not pose a significant safety concern. We also examine how frequently the target is expressed in
various solid tumors. As shown below in dark pink, Target-201 is overexpressed in a high percentage of melanoma tumor samples as well as in several other tumor types, including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, or
NSCLC, head&nbsp;&amp; neck cancer, and cervical cancer. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Selective Expression of Target-201 in Multiple
Tumor Types vs. Normal Tissues </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g67b33.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">144
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Next, as part of our discovery process, we test if the TCRs discovered with
our approach are able to kill cancer cells that naturally express the relevant target and specific HLA type. As shown below on the left, when T&nbsp;cells expressing the TCR that recognizes Target-201 are cultured with melanoma cell lines that
naturally express different levels of Target-201, such as A101D and SKMEL5, the degree to which the T cells gets activated correlates with the expression level of Target-201 in the melanoma cells. In addition, the T cells kill melanoma cells
expressing high levels of Target-201, as shown below on the right but do not kill cells that express low levels of Target-201, which highlights the selectivity of the TCR for Target-201. </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g15b64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Finally, to reduce the risk that a TCR discovered in a targeted screen recognizes any
problematic <FONT STYLE="white-space:nowrap">off-targets,</FONT> we <FONT STYLE="white-space:nowrap">re-screen</FONT> the TCR using TargetScan and our genome-wide library. As shown below, when the TCR that recognizes Target-201 was <FONT
STYLE="white-space:nowrap">re-screened</FONT> using our Oncology Target Discovery Library (version 2.0), which includes protein fragments spanning every normal protein encoded in the human genome, only one potential
<FONT STYLE="white-space:nowrap">off-target</FONT> was observed. We subsequently identified several cell lines that naturally express the full-length protein from which the <FONT STYLE="white-space:nowrap">off-target</FONT> antigen was derived and
found that T cells engineered with the TCR do not recognize or kill these cells. Although the TCR recognizes target cells overexpressing protein fragments containing this <FONT STYLE="white-space:nowrap">off-target</FONT> antigen, it does not
recognize cells expressing the full-length protein at normal levels. This shows that our genome-wide screen detects potential <FONT STYLE="white-space:nowrap">off-targets</FONT> with very high sensitivity, and that not all <FONT
STYLE="white-space:nowrap">off-targets</FONT> detected in this manner are problematic. In the event, however, that a TCR exhibits problematic <FONT STYLE="white-space:nowrap">off-target</FONT> effects, we can use ReceptorScan to discover alternative
TCRs that have similar anti-cancer effects but do not cross-react with proteins expressed at high levels on normal tissue or critical organs. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">145
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Genome-Wide Safety Screen of Target-201 TCR Using TargetScan
</B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g67i40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To further expand the pool of addressable patients with our <FONT
STYLE="white-space:nowrap">TSC-200</FONT> series of product candidates, we can also use ReceptorScan to identify TCRs recognizing antigens on the same target protein that are presented by different HLA alleles. Ultimately, we believe this strategy
has the potential to enable multiplexed <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy in which a patient is treated with more than one TCR for the same target protein, presented on two different HLA alleles. This approach could reduce the
risk of resistance arising from loss, downregulation, or mutation of individual HLA genes. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I><FONT
STYLE="white-space:nowrap">TSC-200</FONT> Series </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our first four solid tumor TCR-T therapy candidates
include a combination of known targets, such as HPV16 for TSC-200 and PRAME for TSC-203, as well as targets that are novel antigens for TCR-T therapy, such as for <FONT STYLE="white-space:nowrap">TSC-201</FONT> and TSC-202. All of these targets are
frequently expressed in the solid tumors of interest to us, including melanoma, head&nbsp;&amp; neck cancer, NSCLC, and cervical cancer. In 2021, it is estimated that in the U.S., approximately 100,000 patients are diagnosed with melanoma, 66,000
with head &amp; neck cancer, 200,000 with NSCLC, and 15,000 with cervical cancer. We plan to advance a combination of known and novel targets into clinical development, which will allow us to use the product candidates targeting known antigens as
backbones for our initial clinical trials evaluating multiplexed TCR-T therapy. For example, we plan to evaluate TSC-200, which targets well-known and clinically-validated oncogenic proteins derived from HPV16, in combination with TSC-201 and
TSC-202, which target antigens that have not yet been tested for TCR-T therapy. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I><FONT
STYLE="white-space:nowrap">TSC-200</FONT> </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In parallel with our TargetScan discovery efforts in
head&nbsp;&amp; neck cancer, we are using ReceptorScan to discover highly active TCRs that target antigens in human papilloma virus, or HPV, for our <FONT STYLE="white-space:nowrap">TSC-200</FONT> program. Over 25% of head&nbsp;&amp; neck cancers
are caused by HPV infection, including up to 70% of oropharangeal cancers. HPV antigens are a particularly compelling set of targets due to the fact that HPV proteins drive tumorigenesis in these cancers, which means that these proteins are
(1)&nbsp;present in every tumor cell in an <FONT STYLE="white-space:nowrap">HPV-positive</FONT> tumor and (2)&nbsp;essential to the survival of the tumor cell. In addition to head&nbsp;&amp; neck cancers, HPV is found in more than 90% of cervical
and anal cancers as well as over 60% of vaginal, vulval, and penile cancers. Recent Phase 1 clinical data from the National Cancer Institute showed tumor regression with objective clinical responses in
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">146
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
50% of patients with metastatic HPV-positive cancers who were treated with a TCR-T candidate targeting HPV16, which we believe provides clinical support for the inclusion of an HPV16-targeting
TCR, TSC-200, in our multiplexed TCR-T therapy strategy. We have identified over a thousand TCRs that recognize HLA-A*02:01- specific antigens derived from HPV16, and we are currently identifying the most active TCR to advance to IND-enabling
studies. We also intend to extend our discovery efforts to include additional HPV16-derived antigens presented on other HLA types as the program advances. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I><FONT STYLE="white-space:nowrap">TSC-201</FONT> </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As detailed above, using our TargetScan technology, we have identified what we refer to as Target-201, as one of three
targets from the T cells of melanoma patients responding to TIL therapy. Target-201 is a CTA that is exclusively expressed in testis and is not expressed in normal adult tissues. The testis is an immuneprivileged tissue and, as a result, we believe
that targeting Target-201 should not pose a significant safety concern. In addition, Target-201, which contributes to tumorigenesis by suppressing the cellular mechanisms responsible for controlling cell division, is selectively expressed across
multiple different types of tumors, including approximately 50% of melanomas, approximately 25% of head &amp; neck cancers, and approximately 50% of non-small cell lung cancers. Tumors expressing Target-201 have been shown to be associated with
metastasis and poor patient survival. We have identified two clinically active TCRs that recognize novel epitopes derived from Target-201 presented on two common HLA alleles, and we are currently evaluating which TCR/Target-201 antigen pair to
advance to IND-enabling studies. We are also using ReceptorScan to identify additional TCRs for Target-201 epitopes presented on other HLA alleles to further expand the addressable patient population. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>TSC-202 </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have also identified clinically active TCRs targeting what we refer to as Target-202, which is a protein involved in
cell invasion and migration that plays a role in the metastasis of tumors. Target-202 is a CTA that is expressed only in the placenta, with very low expression in testis and no expression in any other adult tissue. Increased expression of Target-202
is positively correlated with the degree of tumor invasion, lymph node metastasis, distant metastasis, and poor prognosis. Expression of Target-202 is especially high in HPV-positive tumors. Target-202 expression is repressed in normal tissue by the
tumor suppressor protein p53. In HPV-driven carcinomas, however, the viral protein E6 causes degradation of p53, leading to increased expression of Target-202. As a result, high expression of Target-202 is observed in over 90% of cervical cancers
and approximately 75% head &amp; neck cancers. Target-202 is also expressed in HPV-negative tumors, including approximately 40% of NSCLCs, over 95% of melanomas, and up to 80% of primary breast cancers. Using ReceptorScan, we have identified
hundreds of TCRs that recognize multiple HLAA*02:01-specific epitopes derived from Target-202, and we are currently identifying the most active TCR to advance to IND-enabling studies. In addition, we are using TargetScan to discover additional novel
epitopes derived from Target-202 presented on other HLA types. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>TSC-203 </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are developing TSC-203 as a TCR-T therapy candidate targeting a known cancer antigen, Preferentially Expressed Antigen
in Melanoma, or PRAME. Similar to Target-201, PRAME contributes to tumorigenesis by suppressing cellular signals that control cell division, and higher expression levels of PRAME in tumors correlate with increased metastasis and poor patient
outcomes. PRAME is a CTA that, like Target-201 and Target-202, is absent in adult tissues except in the ovaries and testis. Approximately 50% of NSCLCs, approximately 25% of cervical cancers, and approximately 90% of melanomas and head &amp; neck
cancers express PRAME. Moreover, PRAME expression is very homogeneous within these tumors, which we believe make it an attractive target for multiplexed TCR-T therapy. Using ReceptorScan, we have identified thousands of TCRs across multiple
PRAME-derived epitopes presented on HLA-A*02:01, and we are currently identifying the most active TCR to advance to IND-enabling studies. In addition, we are using TargetScan on clinically active TCRs from patients with melanoma and head &amp; neck
cancer to identify novel PRAME epitopes presented on other HLA types. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">147
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition to our four lead solid tumor TCR-T therapy candidates, we have
identified more than 40 novel antigens using TargetScan, of which over 90% have not previously been publicly disclosed as targets for <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. Although target validation naturally results in attrition,
it is clear that tumor-resident T cells recognize many more shared antigens than have been reported to date. Many of the antigens we have identified are expressed across multiple solid tumor types and some have expression levels comparable or
superior to targets currently in clinical development by others such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY-ESO-1.</FONT></FONT> We are currently in the process of validating several of these additional novel
antigens and identifying potential TCR/target pairs using our platform technologies. We plan to continuously expand ImmunoBank with TCRs for both known and novel targets to enable customized multiplexed TCR-T therapy for a wide range of solid tumor
patients. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Clinical Development Plan for Our Solid Tumor Program </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For the initial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> studies
for our <FONT STYLE="white-space:nowrap">TSC-200</FONT> series of TCR-T therapy candidates, we plan to evaluate at least three TCRs in parallel to determine the safety and preliminary efficacy of multiplexed
<FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy. We envision using <FONT STYLE="white-space:nowrap">TSC-200</FONT> as the backbone therapy for patients with <FONT STYLE="white-space:nowrap">HPV-positive</FONT> malignancies, including
head&nbsp;&amp; neck, cervical, and anal cancers. According to the Center for Disease Control, the incidence of <FONT STYLE="white-space:nowrap">HPV-positive</FONT> cancers in the U.S. is approximately 35,000 cases per year, with five-year survival
rates ranging from approximately 50% to 70%. The targets of TSC-201, TSC-202, and TSC-203 are also frequently expressed in the solid tumors of interest to us, as shown below. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Cancer Expression Levels for the Targets of our Lead Solid Tumor Programs </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g97z41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">After establishing single agent safety for each of our initial solid tumor TCR-T
therapy candidates in a multi-arm Phase 1 clinical trial, we plan to test TSC-200 in combination with TSC-201, TSC-202, or TSC-203 in patients who are positive for the respective targets of these therapies. We will also explore three-TCR
combinations in patients who are positive for the three respective targets. Because the targets of TSC-201, <FONT STYLE="white-space:nowrap">TSC-202,</FONT> and TSC-203 are also frequently expressed in melanoma and NSCLC, we will also explore
various combinations of these TCR-T therapy candidates in patients with HPV-negative head &amp; neck cancer, melanoma, and NSCLC. A summary of our planned Phase 1 clinical strategy is shown below. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">148
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><FONT STYLE="white-space:nowrap">TSC-200</FONT> Series Phase 1 Clinical
Strategy </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g13k03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Anticipated timeline </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As we advance our solid tumor program, we anticipate presenting pre-clinical data at a major scientific meeting in the
first half of 2022; filing INDs for at least three of our four solid tumor TCR-T therapy candidates in the second half of 2022; filing an IND for our fourth solid tumor TCR-T therapy candidate in 2023; and presenting initial clinical data on our
multi-arm Phase 1 clinical trial in 2023. As we continue to discover and validate TCR/target pairs, we aim to continue to file additional INDs and introduce those solid tumor TCR-T therapy candidates into this multi-arm basket-style Phase 1 clinical
trial. We believe this trial will serve as the first step towards our long-term goal of building and expanding ImmunoBank to provide customized multiplexed TCR-T therapy for virtually any patient with a solid tumor malignancy. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>ImmunoBank &#150; Flexible Content for Diverse Platforms </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our current clinical development strategy is based on autologous T cell engineering, which is the basis for approved
CAR-T products such as Kymriah and Yescarta. As the field of T cell engineering evolves, a wide variety of additional manufacturing platforms are being developed that may further improve TCR-T cell products. For example, companies such as Lyell
Immunopharma, Inc. are developing methods to enhance autologous T cell engineering to provide improved duration of efficacy, while companies such as Allogene Therapeutics, Inc. are developing ways to engineer allogeneic T cells and companies such as
Sana Biotechnology, Inc. are developing ways to engineer T cells in vivo. All of these engineering platforms require validated &#147;content&#148; &#150; TCRs that recognize tumor-specific antigens on cancer cells without recognizing problematic
off-targets. As we advance our ImmunoBank of TCRs through clinical development, we intend to continue to build our own manufacturing platform, while simultaneously investigating novel T cell engineering platforms once they have established safety
and efficacy. Ultimately, we aspire to build the largest collection of validated TCR &#147;content&#148; that can be used with a variety of T cell engineering platforms. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">149
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Expansion Opportunities Beyond Oncology </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our primary focus is on the development of <FONT STYLE="white-space:nowrap">T-cell</FONT> therapies to treat cancer.
However, T cells play a fundamental role in many other disease areas, such as infectious disease and autoimmune disease. We believe that our TargetScan technology is well suited to discover novel antigens for the development of therapeutics,
diagnostics, and vaccines in these other areas. we intend to build additional corporate value by opportunistically pursuing collaborations with strategic partners for applications of our platform technologies outside our core focus. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for
TargetScan&#146;s applicability and antigen discovery capabilities in infectious disease, we applied our technology to identify the antigens most frequently recognized by the T cells of patients who had recovered from
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> We screened the entire genome of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> the virus that causes <FONT STYLE="white-space:nowrap">COVID-19,</FONT> as
well as the genomes of <FONT STYLE="white-space:nowrap">SARS-CoV</FONT> and the four seasonal coronaviruses that cause the common cold. We found that the antigens recognized by CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells were
largely derived from segments of the virus that are not part of the spike protein, which is the current target of <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines. Additionally, patient T cells were generally not found to be cross-reactive
with seasonal coronaviruses, suggesting that prior coronavirus exposure is unlikely to confer immunity to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We published the details of these studies in the journal <I>Immunity</I> in 2020. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><FONT STYLE="white-space:nowrap">T-Cell</FONT> Targets in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Are Primarily Located </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>In Proteins Other Than the
Spike Protein </B></FONT></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g57g04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have partnered with QIAGEN Sciences, LLC to develop a highly specific diagnostic
test to determine prior exposure to the virus based upon the presence of anti-viral T cells. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We believe that
our findings can also be used to develop next-generation vaccines for <FONT STYLE="white-space:nowrap">COVID-19</FONT> that confer durable immune protection from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> infection and potentially provide protection against future variants. Most current vaccine efforts elicit a response to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> spike protein. While these first-generation vaccines are able to elicit neutralizing antibodies and provide effective protection against infection, it is not clear how durable these responses will
be given that antibody levels have been shown to rapidly decline after a few months and numerous coronavirus variants have now been discovered with mutations in the spike protein. Notably, none of the mutations observed in these variants occurs in
the 29 <FONT STYLE="white-space:nowrap">T-cell</FONT> targets that we identified, suggesting that vaccines delivering these target antigens may be less susceptible to vaccine-resistant strains emerging in the future. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">150
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Other Diseases </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">TargetScan can also be used for novel target discovery in additional infectious and autoimmune diseases. For example,
infections such as tuberculosis, influenza, and HIV have been shown to be T cell-mediated and are associated with high mortality rates. In addition, many autoimmune diseases such as rheumatoid arthritis, psoriasis, and scleroderma are largely T
cell-mediated, but with poorly defined instigating self-antigens. Our TargetScan technology, which provides an unbiased, genome-wide method to discover the natural targets of disease-relevant T cells, is well positioned to identify these
self-antigens. We believe the discovery of these targets could enable the development of novel, more targeted therapeutic approaches to treat these diseases. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>License and Collaboration Agreements </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Collaboration and License Agreement with Novartis </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On March 27, 2020, we entered into a Collaboration and License Agreement with Novartis Institutes for BioMedical
Research, Inc. (Novartis) (such agreement, the Novartis Agreement). Pursuant to the Novartis Agreement, we have received an aggregate of $20.0 million of cash representing the upfront payment and have receivables for reimbursement of expenditures
under the arrangement of $0.3 million as of December 31, 2020. We granted Novartis and its affiliates options to obtain exclusive, royalty-bearing, sublicensable, transferable, worldwide licenses to certain target antigens identified in performance
of the Novartis Agreement and corresponding T-cell receptors for such target antigens to make, have made, import, use, sell or offer for sale, including to develop, manufacture, commercialize, register, hold or keep, have used, export, transport,
distribute, promote, market or have sold or otherwise dispose of such target antigens and corresponding T-cell receptors. Novartis can exercise each option by paying us $10.0 million and can exercise up to three options (each target antigen for
which Novartis exercises an option, an &#147;Optioned Program&#148;). In addition, we granted Novartis and its affiliates an option to obtain a non-exclusive, royalty-bearing, sublicensable, transferable, worldwide license under our intellectual
property corresponding to products associated with such Optioned Program and improvements to our platform created in performance of activities under the Novartis Agreement, in each case, solely as necessary to exploit products associated with such
Optioned Program. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The ownership of inventions (and resulting patent rights) created in performance of the
collaboration will be determined by inventorship (i.e., inventions invented solely by us in performance of the collaboration and inventions invented solely by Novartis in performance of the collaboration will be owned by Novartis and inventions
invented jointly by us and Novartis in performance of the collaboration will be jointly owned). We retain our rights to (i) our intellectual property, (ii) programs that are not selected by Novartis and (iii) our platform improvements, which will
not be considered collaboration technology. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Each party has the sole right (but not the obligation) in its
sole discretion and cost, to prepare, file, prosecute and maintain all patents and patent applications that are owned solely by such party. For any collaboration patents or patent applications owned by us, if we elect not to file a patent
application or to cease the prosecution or maintenance of any of our collaboration patents or patent applications, we must notify Novartis immediately of such decision, at which point Novartis will become permitted to file or continue prosecution or
maintenance of such patent or patent application in our name. For joint collaboration patents and patent applications, Novartis has the first right (but not the obligation) to prepare, file, prosecute and maintain any joint collaboration patent or
patent applications and/or optioned program patents or patent applications. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For each Optioned Program, as
between the parties Novartis is solely responsible for the clinical development of such Option Program. Novartis is required to pay us up to an aggregate of $230.0 million upon achievement of certain clinical milestones and milestones for the first
commercial sale in certain countries with respect to products directed to the corresponding target antigen for each Optioned Program. Novartis is also required to pay us up to an aggregate of $260.0 million upon achievement of certain annual net
sales milestones for products directed to the corresponding target antigen for each Optioned Program. In addition, for each Optioned Program, Novartis is required to pay us, on a product-by-product and country-by-country basis, tiered
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">151
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
royalties in the low-single-digit to mid-single-digit percentage on Novartis&#146;, its affiliates&#146; and sublicensees&#146; net sales of certain products directed to target antigens for each
Optioned Program and a percentage in the mid-single-digits to low-teens on Novartis&#146; net sales of products directed to such antigens and containing a T-cell receptor we identified to Novartis in our performance of the Novartis Agreement,
subject to certain customary reductions. Royalties will be payable on a product-by-product and country-by-country basis during the period of time commencing on the first commercial sale of an applicable product in a country and ending upon the later
of: (a) 10 years from the date of first commercial sale of such product in such country; (b) expiration of the last-to-expire valid claim of patents licensed by us to Novartis under the Novartis Agreement covering the manufacture, use or sale of
such product in such country; or (c) the expiration of any regulatory or marketing exclusivity in such country with respect to such product (the &#147;Royalty Term&#148;). Novartis may terminate the Novartis Agreement entirely or on a
program-by-program basis at any time for convenience upon 90 days&#146; notice; provided, however, that Novartis will be required to fulfill any payment obligations that accrued prior to termination. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For a period of up to 180 days after the end of the collaboration period (which collaboration period will end no later
than March 2023), we agree to notify Novartis if we intend to seek a third party partner to exclusively license or similarly grant rights to patents or know-how developed by us under the collaboration to allow for the development or
commercialization of products directed to any programs that Novartis has not exercised an option to prior to the expiration of such option (a ROFN Notice). Upon receiving such notice, Novartis will have 90 days to provide us with a term sheet to
exclusively license such collaboration technology to develop or commercialize products directed to such previously declined program, which will trigger Novartis&#146;s right of first negotiation. If Novartis delivers such term sheet, then Novartis
will have 270 days following the ROFN Notice to negotiate a license for such collaboration technology. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The
Novartis Agreement will remain in effect until (i) all options expire unexercised or (ii) if any options are exercise, on a product-by-product and country-by-country basis for each Optioned Program, upon the expiration of the Royalty Term for all
products associated with such Optioned Program in such country. Either party may terminate the Novartis Agreement upon an uncured material breach of the agreement or insolvency of the other party. We may terminate the Novartis Agreement immediately
upon written notice to Novartis if Novartis challenges the validity, enforceability or scope of any of the patents we license to Novartis under the agreement. Novartis may terminate the agreement, either in its entirety or on a program-by-program
basis, for convenience at any time with 90 days&#146; prior written notice. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Exclusive Patent License
Agreement with BWH </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On December 5, 2018, we entered into an Exclusive Patent License Agreement with
The Brigham and Women&#146;s Hospital, Inc. (&#147;BWH&#148;), as amended on July 26, 2019 and further amended and restated on April 20, 2021 (collectively, the &#147;BWH Agreement&#148;), pursuant to which we obtained an exclusive, sublicensable,
worldwide license to practice under certain of BWH&#146;s patent rights for identifying T Cell epitopes, which are relevant to our platform for identifying potential therapeutic products. The original 2018 BWH Agreement granted us the right to
practice BWH&#146;s patent rights in a certain field of use (&#147;MHC Class I License Field&#148;). In connection with the amended and restatement of the BWH Agreement in 2021, we expanded the field of use in which we are authorized to practice
BWH&#146;s patent rights to include MHC Class II uses and applications in exchange for certain additional payments to BWH. We are obligated to use commercially reasonable efforts to develop and commercialize at least one product or process that
practices the licensed patent rights and at least one therapeutic or diagnostic product or process directed to an epitope identified through practicing the licensed patent rights. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Upon execution of the amendment of the BWH Agreement dated April 20, 2021, we paid an additional one-time fee of
$466,500. We are required to pay BWH up to an aggregate of $12.72 million upon the achievement of certain clinical, regulatory and sales milestones for therapeutic products and processes. We are obligated to pay a low double-digit percentage of all
non-royalty income we receive under sublicenses of BWH&#146;s patent rights. We are also obligated to pay a low single-digit percentage of all non-royalty income we receive under agreements </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">152
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
with third parties (&#147;Collaborators&#148;) where we practice under BWH&#146;s patent rights in connection with the research or development one or more therapeutic products or processes with
or for such third party (&#147;Collaboration Agreements&#148;). We are also obligated to pay tiered royalties in the high single-digit percentage range on annual net sales of products and processes that practice the licensed patent rights and in the
low single-digit percentage range on annual net sales of therapeutic and diagnostic products and processes directed to an epitope identified through practicing the licensed patent rights (other than those sold by Collaborators), with the royalty
percentage for such products and processes decreasing to lower than one-percent royalties if directed to epitopes identified through practicing the licensed patent rights after December 31, 2019. For therapeutic and diagnostic products and processes
directed to an epitope identified through practicing the licensed patent rights and sold by a Collaborator, we are obligated to pay lower than one-percent royalties of the Collaborator&#146;s annual net sales of such products and processes. For
products and processes sold by us, our affiliates or sublicensees, such royalties only apply to products and processes directed to epitopes in a defined field of use MHC Class I field identified prior to December 31, 2022 and products and processes
based on epitopes in the MHC Class II field identified prior to September 30, 2023. For products or processes directed to epitopes identified under a Collaboration Agreement, such royalties apply regardless of when the epitopes were identified. For
each applicable product or process, the royalty term continues until the tenth (10th) anniversary of the first commercial sale of such product or process. The royalty rates are also subject to reduction upon certain other events. Within sixty (60)
days of each anniversary of December 5th, we are obligated to pay BWH a non-refundable, mid five figure minimum annual royalty, which amount is creditable against royalties subsequently due on net sales of products and processes in such calendar
year. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The BWH Agreement will terminate upon the later of (a)&nbsp;the last to expire or abandoned valid
claim within the licensed patents, and (b)&nbsp;one year after the last sale for which a royalty is due. The current expected expiration date for the last-to-expire licensed patent right is June 8, 2038 (absent any adjustments or extensions of
term). We also have the right to terminate the BWH Agreement in its entirety or on a country-by-country basis, for any reason upon 90&nbsp;days&#146; prior written notice to BWH. BWH may terminate the BWH Agreement: (1)&nbsp;without notice if we
fail to maintain insurance required by the BWH Agreement; (2)&nbsp;upon notice within 60&nbsp;days of our bankruptcy; (3)&nbsp;upon notice within 60&nbsp;days after notice by BWH of our default in the performance of any obligation under the BWH
Agreement that is not cured within such 60-day period; (4)&nbsp;if we fail to make any payments due under the BWH Agreement and do not cure such failure within 10&nbsp;days after receiving BWH notice thereof; or (5) if we or any of our affiliates
challenge the validity, enforceability or scope of any of the patent rights licensed to us under the BWH Agreement. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Option and Exclusive License Agreement with Qiagen </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On November 5, 2020, we
entered into an Option and Exclusive License Agreement with QIAGEN Sciences, LLC (Qiagen) (such agreement, the Qiagen Agreement). Pursuant to the Qiagen Agreement, Qiagen paid us a one-time non-refundable, non-creditable $150,000 option fee (Option
Fee) in exchange for an option to obtain an exclusive, royalty-bearing, sublicensable, worldwide license under our rights to patents and patent applications related to certain SARS- CoV-2 peptides to use, make and otherwise commercialize products
containing such SARS-CoV-2 peptides (the Option). Qiagen exercised the Option on April 14, 2021 and is required to pay us an additional $150,000 option exercise fee. Qiagen may freely sublicense its rights through multiple tiers so long as it binds
each sublicensee to terms consistent with the Qiagen Agreement and remains responsible for any breaches of such terms by its sublicensees. We expressly reserved the right to conduct research or develop or commercialize products for or related to the
treatment of SARS-CoV-2. To date, we have not received any payments from Qiagen under the Qiagen Agreement other than the Option Fee and we are not owed any payment from Qiagen under the Qiagen Agreement other than the option exercise fee.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, Qiagen is required to pay us a one-time, non-refundable, non-creditable $300,000 milestone
payment upon launch of the first in vitro diagnostic product containing the licensed peptides. Qiagen is also required to pay us, on a product-by-product and country-by-country basis, royalties in the low-single-digit to mid-single-digit percentage
on Qiagen&#146;s and its affiliates&#146; net sales of products containing the licensed peptides, </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">153
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
subject to certain customary reductions, for as long as such products are covered by a valid claim of the patents licensed by us to Qiagen under the Qiagen Agreement. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are solely responsible for managing patent maintenance, prosecution and enforcement during the term of both the
Option Exercise Period (defined below) and term of the Qiagen Agreement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Qiagen Agreement will expire
upon the later to occur of (i)&nbsp;expiration of the last to expire valid claim of patents we license to Qiagen under the Qiagen Agreement or (ii)&nbsp;15 years from the effective date of the Qiagen Agreement. Should any patents issue from any
non-provisional patent applications claiming priority to any of the licensed U.S. provisional patent applications, the current expected expiration date for the last-to-expire licensed patent right is June&nbsp;17, 2041 (absent any adjustments or
extensions of term). Qiagen may terminate the Qiagen Agreement for any reason upon 60 days&#146; prior written notice to us; provided, however, that Qiagen will be required to fulfill any payment obligations that accrued prior to termination.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Non-Exclusive License Agreement with Provincial Health Services Authority </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On October 15, 2020, we entered into a Non-Exclusive License Agreement with the Provincial Health Services Authority of
British Columbia (PHSA) (such agreement, the PHSA Agreement). Pursuant to the PHSA Agreement, we obtained a non-exclusive, perpetual, non-transferable, sublicensable, worldwide license to practice certain of PHSA&#146;s patent rights for identifying
T Cell epitopes, which epitopes are relevant to our platform for identifying potential TCR-T therapies. Any sublicenses we grant to PHSA&#146;s patent rights must also include a license of our own IP; we are not permitted to sublicense PHSA&#146;s
rights on a standalone basis. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Pursuant to the PHSA Agreement, we paid PHSA a one-time, non-refundable
upfront fee of $500,000 as well as a reimbursement for previously incurred patent prosecution costs of approximately $50,000. Starting on the first anniversary of the effective date of the PHSA Agreement and continuing for five years thereafter, we
are required to pay PHSA a mid-five-figure annual license fee. In addition, we are obligated to pay a mid-six-figure fee for each sublicense and each further sublicense granted by one of our sublicensees or a sublicensee of our sublicensee (through
multiple tiers) of the rights granted to us under the PHSA Agreement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The PHSA Agreement will terminate upon
the last to expire patent licensed under the PHSA Agreement. We also have the right to terminate the PHSA Agreement at any time, but such termination will not be effective until the later of (a) October 16, 2023, and (b) the date we have paid PHSA
total aggregate fees equal to the upfront fee plus five years of annual license fees totaling $750,000. PHSA may terminate the PHSA Agreement upon giving us two separate written notices at least 30 days apart if: (i) we or any of our affiliates
challenge the validity, enforceability or scope of any of the patents licensed to us under the PHSA Agreement; (ii) we owe unpaid fees due under the PHSA Agreement in excess of $100,000; or (iii) we breach material terms of the PHSA Agreement
regarding sublicense restrictions (such as failing to pay the sublicense fee or sublicensing PHSA technology on a standalone basis) or our obligation to indemnify PHSA for damages resulting from our research or commercialization of PHSA&#146;s
patent rights and, in each case described above, such termination will be effective only if we fail to cure such breach after receiving PHSA&#146;s two separate notices. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Royalty Agreement </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In connection with our incorporation in April 2018, we entered into a royalty agreement with one of our founders. We
amended and restated this royalty agreement in June 2018 and our founder assigned his rights and obligations under the royalty agreement to one of his affiliated entities in January 2021. Pursuant to the royalty agreement, we are required to pay him
a royalty of 1% of net sales (as defined in the royalty agreement) of any product sold by us or by any of our direct or indirect licensees for use in the treatment of any disease or disorder covered by a pending patent application or issued patent
held or controlled by us as of the last date that the founder was providing services to us as a director or consultant under a written agreement. Royalties are payable with respect to each applicable product on a country-by-country and
product-by-product basis, beginning on the </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">154
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
first commercial sale of the first royalty-bearing product and ending on the later of (i) the date on which the exploitation of such royalty-bearing product is no longer covered by such patent in
such country or (ii) the 15th anniversary of the first commercial sale of the first royalty-bearing product in such country. We may not assign our rights and obligations under the royalty agreement except in the event of a change in control relating
to our company. The term of the royalty agreement continues until expiration of the last applicable royalty term. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Manufacturing </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are building <FONT STYLE="white-space:nowrap">in-house</FONT> cell therapy manufacturing capabilities as one of the
key components of our platform. The manufacturing of cell therapies requires the integration of several distinct components. Primary human blood cells are the source of T cells, along with a vector that delivers the desired genetic elements into
these T cells. As a more operationally flexible and cost-efficient alternative to lentivirus, we have developed a manufacturing platform to genetically engineer T cells using a transposon/transposase system, which we refer to as <FONT
STYLE="white-space:nowrap">T-Integrate.</FONT> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are designing our programs to use a transposon vector and
corresponding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectively inserts our TCRs and other exogenous genes, such as CD8, at random locations in
the genome. The transposon will be delivered as a Nanoplasmid, which was developed by Nature Technology and has no antibiotic selection element, reducing the risk of inadvertent transmission of antibiotic resistance into T cells. The transposase
will be delivered as mRNA. mRNA is transiently expressed in the cell, reducing exposure of cells to prolonged transposase activity, which could result in multiple transposition events where the transposon would be moved around the genome. Aldevron
has a license from Nature Technology to manufacture research-grade and GMP-grade transposon and transposase. The initial batch of research-grade and GMP-grade transposon and transposase which we intend to use in connection with our near-term
pre-clinical studies and clinical trials will be manufactured by Aldevron pursuant to a non-exclusive, fee-for-service supply arrangement pursuant to which we may purchase materials from time-to-time, subject to normal market pricing. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are developing our manufacturing process using industry standard instrumentation to enable direct transfer of methods
from process development to manufacturing. These devices also allow for functionally closed processes in a small footprint. For product manufacturing, we use <FONT STYLE="white-space:nowrap">single-use</FONT> bag and tubing kits, supplies, and
process reagents that are available from well-established vendors who specialize in supplying clinical grade reagents for the cell and gene therapy industry. Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies will be characterized and
released using well-developed analytic methods. The final product will be cryopreserved, simplifying logistics and reducing risk of delivery failures. We plan to have controls and safeguards throughout the entire process to ensure product identity,
integrity, and chain of custody. A clearly defined and documented manufacturing process, performed by trained operators using specialized instrumentation in an appropriately designed, commissioned, and operated manufacturing facility, are all
critical for the manufacturing of safe, effective, and well-characterized cell therapies. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our cell product
manufacturing facility in Waltham, MA was designed and built to support multiple programs through Phase 1 and Phase 2 clinical development, with a projected capacity to support treating over 200 patients per year. We believe internalizing our
manufacturing process enables us to better control this key aspect of clinical development and reduces the risk of program delay due to third party reliance. We expect to revisit our manufacturing process prior to commencing registrational trials
and may use third-party CMOs to manufacture product candidates for our registrational trials. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Competition </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We believe our novel and proprietary platform technologies, TargetScan and ReceptorScan, and our <FONT
STYLE="white-space:nowrap">in-house</FONT> cell therapy expertise constitute a meaningful competitive advantage in successfully developing novel and highly effective treatments for cancer. However, the biopharmaceutical industry in general, and the
cell </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">155
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
therapy field in particular, is characterized by rapidly advancing and changing technologies, intense competition, and a strong emphasis on intellectual property. We face substantial and
increasing competition from many different sources, including large and specialty biopharmaceutical companies, academic research institutions, governmental agencies, and public and private research institutions. Competitors may compete with us in
hiring scientific and management personnel, establishing clinical study sites, recruiting patients to participate in clinical trials, and acquiring technologies complementary to, or necessary for, our programs. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the
development of <FONT STYLE="white-space:nowrap">TCR-T</FONT> or other cell therapies for the treatment of cancer. We expect to compete with a number of other <FONT STYLE="white-space:nowrap">T-cell</FONT> therapy companies, including those with
target discovery platforms, such as Adaptive Therapeutics, Inc.,&nbsp;Immatics N.V., Enara Bio Ltd., Regeneron Pharmaceuticals, Inc., Sana Biotechnology, Inc. and 3T Biosciences Inc. In addition, we may face competition from other TCR companies such
as Adaptimmune Therapeutics, Plc., Medigene AG, Bayer AG, and Ziopharm Oncology, Inc., as well as TCR<SUP STYLE="font-size:85%; vertical-align:top">2 </SUP>Therapeutics Inc. We may also face competition from companies focused on <FONT
STYLE="white-space:nowrap">CAR-T,</FONT> TIL and other cell therapies, such as Kite Pharma, Inc., a subsidiary of Gilead, Inc. (including Yescarta, which is approved for the treatment for large B-cell lymphoma or follicular lymphoma, two types of
non-Hodgkin lymphoma), Juno Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb, Inc., Iovance Biotherapeutics, Inc., Instil Bio, Inc., Achilles Therapeutics plc, Geneos Therapeutics, Inc., Lyell Immunopharma, Inc., Allogene Therapeutics, Inc.,
and PACT Pharma, Inc. There are also companies utilizing other cell-based approaches that may be competitive to our product candidates. For example, companies such as Celyad, S.A., Fate Therapeutics, Inc., and Nkarta, Inc. are developing therapies
that target and/or engineer natural killer, or NK, cells. In addition, for our lead liquid tumor programs, <FONT STYLE="white-space:nowrap">TSC-100</FONT> and <FONT STYLE="white-space:nowrap">TSC-101,</FONT> we may face competition from HighPass
Bio, Inc. and Kiadis Pharma U.S. Corporation, who are also developing cell therapies in the <FONT STYLE="white-space:nowrap">post-HCT</FONT> setting. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Furthermore, we also face competition more broadly across the oncology market for cost-effective and reimbursable cancer
treatments. The most common methods of treating patients with cancer are surgery, radiation, and drug therapy, including chemotherapy, hormone therapy, biologic therapy, such as monoclonal and bispecific antibodies, immunotherapy, cell-based
therapy, and targeted therapy, or a combination of any such treatments. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates, if any are approved, may compete with these existing drugs and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our <FONT
STYLE="white-space:nowrap">TCR-T</FONT> therapies may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third party payors may also
encourage the use of generic products or specific branded products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapies that we successfully
introduce to the market may pose challenges. In addition, many companies are developing new oncology therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We could see a reduction or elimination in our commercial opportunity if our competitors develop and commercialize drugs
that are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive, or receive a more favorable label than our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates. Our
competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The
key competitive factors affecting the success of all of our <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidates, if approved, are likely to be their efficacy, safety, convenience, price, and the availability of reimbursement from
government and other third party payors. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Intellectual Property </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our success depends in part on our ability to obtain, maintain and protect our proprietary technology and intellectual
property and proprietary rights and operate our business without infringing, misappropriating and </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">156
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
otherwise violating the intellectual property and proprietary rights of third parties. We rely on a combination of patent applications, trademarks, trade secrets, and other intellectual property
rights and measures to protect the intellectual property rights that we consider important to our business. We also rely on know-how and continuing technological innovation to develop and maintain our competitive position.&nbsp;We also seek to
protect our proprietary rights by entering into confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to our proprietary information.&nbsp;The steps we have taken to
protect our trade secrets, trademarks, patent applications and other intellectual property and proprietary rights may not be adequate, and third parties could infringe, misappropriate or misuse our intellectual property. If this were to occur, it
could harm our reputation and adversely affect our business, competitive position, financial condition or results of operations. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">As of April 16, 2021, we do not own or exclusively in-license any issued patents and all of our owned patent applications are provisional patent applications. In addition, although we plan to file patent applications with respect to
TSC-102, TSC-200, TSC-202 and TSC-203, as of April 16, 2021, we have not filed any patent applications with respect to these product candidates. As of April 16, 2021, we have filed sixteen U.S. provisional patent applications, nine of which are
jointly owned by us and AHS Hospital Corporation (&#147;AHS&#148;). AHS has exclusively licensed their interest to us in such patent applications. Conversion of such patent applications to utility patent applications is expected to occur between
June 2021 and April 2022. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As set forth in detail below, our provisional patent applications are drawn to
subject matter in the following main technology areas: certain compositions of matter directed to SARS-CoV-2 immunodominant antigens, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-SARS-CoV-2</FONT></FONT> TCRs,
anti-SARS-CoV-2 vaccines, anti-HA-1 TCRs (including the TSC-100 TCR-T therapy candidate, anti-HA-2 TCRs (including the TSC-101 TCR-T therapy candidate), TCRs targeting the antigen of TSC-201, and certain therapeutic and diagnostic uses thereof, as
well as a phospholipid scrambling reporter-based T cell antigen screening platform and certain screening methods thereof. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><I>SARS-CoV-2 technology </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We filed four U.S. provisional patent applications (U.S. patent
application serial number 63/040,267, filed June 17, 2020; U.S. patent application serial number 63/050,930, filed July 13, 2020; U.S. patent application serial number 63/056,462, filed July 24, 2020; and U.S. patent application serial number
63/056,849, filed July&nbsp;27, 2020) drawn to SARS-CoV-2 immunodominant peptide compositions of matter and certain therapeutic and diagnostic uses thereof. Any patents issuing from any non-provisional patent applications claiming priority to these
provisional patent applications would be expected to expire in 2041 (absent any adjustments or extensions of term). </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We also filed four U.S. provisional patent applications (U.S. patent application serial number 63/056,511, filed July&nbsp;24, 2020; U.S. patent application serial number 63/056,945, filed July&nbsp;27, 2020; U.S. patent application
serial number 63/069,926, filed August&nbsp;25, 2020; and U.S. patent application serial number 63/111,448, filed November&nbsp;9, 2020) drawn to anti-SARS-CoV-2 TCR compositions of matter and certain therapeutic and diagnostic uses thereof. Any
patents issuing from any non-provisional patent applications claiming priority to these provisional patent applications would be expected to expire in 2041 (absent any adjustments or extensions of term). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We also filed a U.S. provisional patent application (U.S. patent application serial number 63/113,024, filed November
12, 2020) drawn to anti-SARS-CoV-2 vaccine compositions of matter and certain therapeutic and diagnostic uses thereof. Any patents issuing from any non-provisional patent applications claiming priority to this provisional patent application would be
expected to expire in 2041 (absent any adjustments or extensions of term). </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Each of these nine U.S.
provisional patent applications is jointly owned by us and AHS. AHS has exclusively licensed their interest to us in such patent applications. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">157
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>HA-1 technology </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We filed four U.S. provisional patent applications (U.S. patent application serial number 63/110,851, filed November 6,
2020; U.S. patent application serial number 63/111,462, filed November 9, 2020; U.S. patent application serial number 63/129,804, filed December 23, 2020; and U.S. patent application serial number 63/175,350, filed April 15, 2021) drawn to anti-HA-1
TCR compositions of matter (including the TSC-100 <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapy candidate) and certain therapeutic and diagnostic uses thereof. Any patents issuing from any non-provisional patent applications claiming
priority to these provisional patent applications would be expected to expire in 2041 (absent any adjustments or extensions of term). </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>HA-2 technology </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We filed a U.S. provisional patent application (U.S. patent application serial number 63/174,818, filed April&nbsp;14,
2021) drawn to anti-HA-2 TCR compositions of matter (including the TSC-101 TCR-T therapy candidate) and certain therapeutic and diagnostic uses thereof. Any patents issuing from any non-provisional patent applications claiming priority to this
provisional patent application would be expected to expire in 2042 (absent any adjustments or extensions of term). </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><I>TSC-201 technology </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We filed a U.S. provisional patent application (U.S. patent
application serial number 63/174,808, filed April&nbsp;14, 2021) drawn to anti-TSC-201 TCR compositions of matter and certain therapeutic and diagnostic uses thereof. Any patents issuing from any non-provisional patent applications claiming priority
to these provisional patent applications would be expected to expire on 2042 (absent any adjustments or extensions of term). </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><I>Screening technology </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We filed a U.S. provisional patent application (U.S. patent
application serial number 63/055,766, filed July&nbsp;22, 2020) drawn to a phospholipid scrambling reporter-based T cell antigen screening platform compositions of matter and certain screening methods thereof. Any patents issuing from any
non-provisional patent applications claiming priority to these provisional patent applications would be expected to expire in 2041 (absent any adjustments or extensions of term). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our provisional patent applications may not result in issued patents and we can give no assurance that any patents that
might issue in the future will protect our future products or provide us with any competitive advantage. Moreover, U.S. provisional patent applications are not eligible to become issued patents until, among other things, we file a non-provisional
patent application within 12 months of filing of one or more of our related provisional patent applications. With regard to such U.S. provisional patent applications, if we do not timely file any non-provisional patent applications, we may lose our
priority date with respect to our provisional patent applications and any patent protection on the inventions disclosed in our provisional patent applications. While we intend to timely file non-provisional patent applications relating to our
provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patents that provide us with any competitive advantage. For more information regarding the risks related to our intellectual
property, please see &#147;Risk Factors&#151;Risks Related to Our Intellectual Property&#148;. We rely on certain technology and intellectual property rights that we in-license from third parties. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have an exclusive patent license from The Brigham and Women&#146;s Hospital, Inc. (BWH) to a patent family directed
to a granzyme B (GzB)-based antigen screening technologyplatform compositions of matter and certain screening methods thereof (consisting of one pending U.S. patent application (U.S. patent application serial number 16/619,859, filed December 5,
2019) and six pending foreign patent applications in Australia (patent application serial number 2018279728, filed December 5, 2019), Canada (patent application serial number 3,066,645, filed December 6, 2019), China (patent application serial
number 201880051295.1, filed February 6, 2020), Europe (patent application serial number 18812782.3, filed January 7, 2020), Hong&nbsp;Kong </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">158
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
(patent application serial number 62020017383.4, filed October 9, 2020), and Japan (patent application serial number 2019-567577, filed December 6, 2019)). Any patents issuing from the U.S. and
foreign patent applications are expected to expire in 2038 (absent any adjustments or extensions of term). We also have a non-exclusive, perpetual, non-transferable patent license from the Provincial Health Services Authority of British Columbia
(PHSA) to a patent family directed to granzyme-based antigen screening methods (consisting of one issued U.S. patent (patent number 10,627,411, granted on April 21, 2020 and expected to expire August 4, 2035), one pending U.S. patent application
(U.S. patent application serial number 16/841,943, filed April 7, 2020), and one issued foreign patent in Canada (patent number 2,943,569, granted on February 23, 2021 and expected to expire March 25, 2035)). Any patent issuing from the U.S. patent
application is expected to expire in 2035 (absent any adjustments or extensions of term). We do not have any additional material licenses to any technology or intellectual property rights. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of April 16, 2021, we own or have rights to two pending U.S. trademark applications, 14 foreign trademark
registrations, and three pending foreign trademark applications. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Government&nbsp;Regulation</B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries,
extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion,
marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third party contractors, will be required to navigate the various preclinical, clinical and commercial approval
requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The process required by the FDA before biologic product candidates may be marketed in the United States generally
involves the following:</FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">completion of preclinical laboratory tests and animal studies performed in accordance with
the FDA&#146;s current Good Laboratory Practices regulation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">submission to the FDA of an IND, which must become effective before clinical trials may
begin and must be updated annually or when significant changes are made; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">approval by an independent Institutional Review Board, or IRB, or ethics committee at each
treatment site before the trial is commenced; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">performance of adequate and well-controlled human clinical trials to establish the safety,
purity and potency of the proposed biologic product candidate for its intended purpose; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical
trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">satisfactory completion of an FDA Advisory Committee review, if applicable;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a determination by the FDA within 60 days of its receipt of a BLA to file the application
for review; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT>
inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s continued
safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices, or GCP; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">FDA review and approval of the BLA to permit commercial marketing of the product for
particular indications for use in the United States. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Preclinical and Clinical
Development</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Prior to beginning the first clinical trial with a product candidate, we must submit an
IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">159
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the
toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND
must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or
questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND
therefore may or may not result in FDA authorization to begin a clinical trial. In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or
synthetic nucleic acid molecules had historically been subject to review by the Recombinant DNA Advisory Committee, or RAC, of the NIH Office of Biotechnology Activities, or OBA, pursuant to the NIH Guidelines for Research Involving Recombinant DNA
Molecules, or NIH Guidelines. On August 17, 2018, the NIH issued a notice in the Federal Register and issued a public statement proposing changes to the oversight framework for gene therapy trials, including changes to the applicable NIH Guidelines
to modify the roles and responsibilities of the RAC with respect to human clinical trials of gene therapy products, and requesting public comment on its proposed modifications. During the public comment period, which closed October 16, 2018, the NIH
announced that it would no longer accept new human gene transfer protocols for review as part of the protocol registration process or convene the RAC to review individual clinical protocols. These trials will remain subject to the FDA&#146;s
oversight and other clinical trial regulations, and oversight at the local level will continue as set forth in the NIH Guidelines. Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment
by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public
health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH
funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Clinical trials involve the administration of the investigational product to human subjects under the supervision of
qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among
other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during
product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the
clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to
an&nbsp;unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring
board, which provides authorization for&nbsp;whether or not&nbsp;a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety
risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may
overlap.</FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Phase 1&#151;The investigational product is initially introduced into healthy human
subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">160
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">
absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Phase 2&#151;The investigational product is administered to a limited patient population
with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information
prior to beginning larger and more expensive Phase 3 clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Phase 3&#151;The investigational product is administered to an expanded patient population
to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the
overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is
approved to gain more information about the product. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal
studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing
process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety,
purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>BLA Submission and Review</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the
results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent
preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things.
The submission of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies, and the sponsor of an approved BLA is also subject to an annual program fee.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Once a BLA has been submitted, the FDA&#146;s goal is to review standard applications within ten months after it accepts
the application for filing, or, if the application qualifies for priority review, six months after the&nbsp;FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA
requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards
designed to assure the product&#146;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or
facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities&nbsp;are in compliance with&nbsp;cGMP requirements and adequate to assure consistent
production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more treatment sites to assure compliance with GCP. If the FDA determines that the application, manufacturing
process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA
ultimately may decide that the application does not satisfy the regulatory criteria for approval.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">161
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">After the FDA evaluates a BLA and conducts inspections of manufacturing
facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing
information for specific indications. A Complete Response letter will describe&nbsp;all of&nbsp;the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to
support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend
actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied,
require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If regulatory approval of a product is granted, such approval will be granted for&nbsp;particular indications&nbsp;and
may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS
is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication
plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of
adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may
require one or more Phase 4 post market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these
post-marketing studies.</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Expedited Development and Review Programs</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track
program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease
or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast
track product has opportunities for frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review,
where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA
and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough
therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or
more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes&nbsp;all of&nbsp;the&nbsp;fast track&nbsp;program features, as well as more intensive FDA interaction and
guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track
designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">162
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a
significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#146;s goal is to take
action on the marketing application within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date (compared with ten months under standard review).</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or
conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible
morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of
alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible
morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing
of the commercial launch of the product. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In 2017, FDA established a new regenerative medicine advanced
therapy, or RMAT, designation as part of its implementation of the 21st Century Cures Act. The RMAT designation is intended to fulfill the 21st Century Cures Act requirement that FDA facilitate an efficient development program for, and expedite
review of, any drug that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or
products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical
needs for such a disease or condition. Like breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for
rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data
obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical
evidence, clinical studies, patient registries, or other sources of real world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the
therapy prior to approval.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Fast track designation, breakthrough therapy designation, priority review,
accelerated approval, and RMAT designation do not change the standards for approval but may expedite the development or approval process.</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Orphan Drug Designation</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or
condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making
available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA
grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory
review or approval process.</FONT></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">163
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If a product that has orphan drug designation subsequently receives the
first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the
same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different
drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application
fee.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is
broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the
manufacturer is unable to assure sufficient quantities&nbsp;of the product to meet the needs of patients with the rare disease or condition.</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Post-Approval Requirements</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing
regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval,
most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each
product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state&nbsp;agencies, and&nbsp;are subject to periodic unannounced inspections by the FDA
and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the
significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third party manufacturers
that we may decide to use. Accordingly, manufacturers must continue to&nbsp;expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the product reaches the market. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Later discovery of previously unknown problems with a product,
including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of
post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">restrictions on the marketing or manufacturing of a product, complete withdrawal of the
product from the market or product recalls; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">fines, warning letters or holds on post-approval clinical studies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">refusal of the FDA to approve pending applications or supplements to approved applications,
or suspension or revocation of existing product approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">product seizure or detention, or refusal of the FDA to permit the import or export of
products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">consent decrees, corporate integrity agreements, debarment or exclusion from federal
healthcare programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">164
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">mandated modification of promotional materials and labeling and the issuance of corrective
information; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other
communications containing warnings or other safety information about the product; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">injunctions or the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those
claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of
off label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products
for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across medical specialties. Physicians may believe
that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict
manufacturer&#146;s communications&nbsp;on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products.</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Biosimilars and Reference Product Exclusivity</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an
abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> reference biological product. To date, a number of biosimilars have been licensed under the
BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the
reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product
must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be
alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex,
structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the
date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#146;s own preclinical
data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture,
it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if
granted, adds six months to existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the
voluntary completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">165
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The BPCIA is complex and continues to be interpreted and implemented by the
FDA. In addition, recent government proposals have sought to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have
also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Other U.S. Healthcare Laws and Compliance Requirements</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the United States, our activities are potentially subject to regulation by various federal, state and local
authorities in addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (such as the Office of Inspector General and the Health
Resources and Service Administration), the Department of Justice, or the DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs may have to
comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended, as
applicable.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from
knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or
order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The federal Anti-Kickback Statute has
been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers and purchasers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities
from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for
an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of
the arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of&nbsp;its facts and circumstances. Our practices, including our
arrangements with physicians, may not in all cases meet&nbsp;all of&nbsp;the criteria for protection under a statutory exception or regulatory safe harbor.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to
violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
of the federal False Claims Act, or FCA.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The federal false claims and civil monetary penalty laws, including
the FCA, which can be enforced by private citizens through civil qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by,
the federal healthcare programs, including Medicare and Medicaid, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#147;any
request or demand&#148; for money or property presented to the U.S. government. For instance, historically, pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with
the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of the product for unapproved, <FONT
STYLE="white-space:nowrap">off-label,</FONT> and thus generally <FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">166
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">HIPAA created additional federal criminal statutes that prohibit, among
other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of,
any healthcare benefit program, including private third party payors, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material
fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute, the ACA amended the intent standard for certain
healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Also, many states have similar, and typically more prohibitive, fraud and abuse statutes or regulations that apply to
items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign
laws.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We may be subject to data privacy and security regulations by both the federal government and the
states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements relating to the privacy, security and
transmission of individually identifiable health information on certain healthcare providers, healthcare clearinghouses, and health plans, known as covered entities, as well as independent contractors, or agents of covered entities that receive or
obtain individually identifiable health information in connection with providing a service on behalf of a covered entity, known as a business associates. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly
applicable to business associates. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file
civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs&nbsp;associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health
information in specified circumstances, many of which differ from each other in significant ways, are often not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating
compliance efforts.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, many pharmaceutical manufacturers must calculate and report certain price
reporting metrics to the government, such as average sales price and best price. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future
relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. It is difficult to predict how Medicare coverage and reimbursement policies will be applied to our products
in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additionally, the federal Physician Payments Sunshine Act, or the Sunshine Act, within the ACA, and its implementing
regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) report annually to
CMS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and
to report annually certain ownership and investment interests held by physicians and their immediate family members. In addition, many states also govern the reporting of payments or other transfers of value, many of which differ from each other in
significant ways, are often not <FONT STYLE="white-space:nowrap">pre-empted,</FONT> and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">167
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In order to distribute products commercially, we must comply with state
laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or
distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and
others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance
programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare
entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to
federal and state consumer protection and unfair competition laws.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Ensuring business arrangements with third
parties comply with applicable healthcare laws and regulations is a costly endeavor. If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other current or future governmental
regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government programs,
such as Medicare and Medicaid, injunctions, private &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm,
administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Coverage, Pricing and Reimbursement</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may
obtain regulatory approval. In the United States and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third party payors provide coverage and
establish adequate reimbursement levels for such products. In the United States, third party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. Coverage and adequate
reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial payors are critical to new product acceptance.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Third party payors decide which therapeutics they will pay for and establish reimbursement levels. Coverage and
reimbursement by a third party payor may depend upon&nbsp;a number of&nbsp;factors, including the third party payor&#146;s determination that use of a therapeutic is:</FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a covered benefit under its health plan; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">safe, effective and medically necessary; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">appropriate for the specific patient; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">cost-effective; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">neither experimental nor investigational. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and
reimbursement are available, we cannot be sure that the level of reimbursement will be adequate. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Limited
coverage and less than adequate reimbursement may reduce the demand for, or the price of, any product for which we obtain regulatory approval.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">168
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Third party payors are increasingly challenging the price, examining the
medical necessity, and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may be particularly difficult because of the higher
prices often associated with branded drugs and drugs administered under the supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products,
in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a product from a third party payor is a time-consuming
and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. A third party payor&#146;s decision to provide coverage for a product
does not imply that an adequate reimbursement rate will be approved. Additionally, in the United States there is no uniform policy among third party payors for coverage or reimbursement. Third party payors often rely upon Medicare coverage policy
and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, one third party payor&#146;s determination to provide coverage for a product does not assure that
other payors will also provide coverage for the product. Adequate third party payor reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. If
reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Certain of our products, once approved, may be administered by a physician. Under currently applicable U.S. law, certain
products not usually self-administered (including injectable drugs) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits
to the aged and disabled, and covers outpatient services and supplies, including certain pharmaceutical products, that are medically necessary to treat a beneficiary&#146;s health condition. As a condition of receiving Medicare Part B reimbursement
for a manufacturer&#146;s eligible drugs or biologicals, the manufacturer is required to participate in other government healthcare programs, including the Medicaid Drug Rebate Program and the 340B Drug Pricing Program. The Medicaid Drug Rebate
Program requires pharmaceutical manufacturers to&nbsp;enter into&nbsp;and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for
the manufacturer&#146;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities that participate in the program.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Different pricing and reimbursement schemes exist in other countries. In the European Union, governments influence the
price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list
systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a
particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become intense. As a
result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a
country.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The marketability of any product candidates for which we receive regulatory approval for commercial
sale may suffer if the government and third party payors fail to provide coverage and adequate reimbursement. In addition, emphasis on managed care, the increasing influence of health maintenance organizations, and additional legislative changes in
the United States has increased, and we expect will continue to increase, the pressure on healthcare pricing. The downward pressure on the rise in healthcare costs in general, particularly prescription medicines, medical devices and surgical
procedures and other treatments, has become very intense. Coverage policies and third party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">169
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Healthcare Reform</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and
regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates
for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving
quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For example, the ACA has substantially changed healthcare financing and delivery by both governmental and private
insurers. Among the ACA provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">an annual, nondeductible fee on any entity that manufactures or imports certain specified
branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs that began in 2011; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid
Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the average manufacturer
price; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to
offer 50% (and 70% starting on January 1, 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for the manufacturers&#146; outpatient drugs to be covered under Medicare Part D; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to
individuals who are enrolled in Medicaid managed care organizations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">expansion of eligibility criteria for Medicaid programs by, among other things, allowing
states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid
rebate liability; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">expansion of the entities eligible for discounts under the 340B Drug Discount Program;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and
conduct comparative clinical effectiveness research, along with funding for such research; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">expansion of healthcare fraud and abuse laws, including the FCA and the federal
Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate
Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">requirements to report certain financial arrangements with physicians and teaching
hospitals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a requirement to annually report certain information regarding drug samples that
manufacturers and distributors provide to physicians; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">establishment of a Center for Medicare Innovation at CMS to test innovative payment and
service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a licensure framework for follow on biologic products. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">170
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Some of the provisions of the ACA have yet to be implemented, and there
have been legal and political challenges to certain aspects of the ACA. Since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA.
Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA
have been signed into law. In December 2017, the Tax Cuts and Jobs Act of 2017 was enacted which repeals, effective January 1, 2019, the tax penalty for an individual&#146;s failure to maintain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT>
health insurance, commonly referred to as the &#147;individual mandate.&#148; Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain <FONT
STYLE="white-space:nowrap">ACA-mandated</FONT> fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain&nbsp;high cost&nbsp;employer-sponsored insurance plans, the annual fee imposed on certain health
insurance providers based on market share, and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA, effective
January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; More recently, in July 2018, CMS&nbsp;published a final rule permitting further collections and payments to and from certain
ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, President Obama
signed into law the Budget Control Act of 2011, which, among other things, included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and, due to subsequent
legislative amendments to the statute, including the BBA, will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things,
reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Further, there has been increasing legislative and enforcement interest in the United States with respect to specialty
drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of
prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#146;s budget proposal
for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain
drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. Additionally, the Trump administration
released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize
manufacturers to lower the list price of their products and reduce the&nbsp;out of pocket&nbsp;costs of drug products paid by consumers. The U.S. Department of Health and Human Services has already started the process of soliciting feedback on some
of these measures and, at the same, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning
January 1, 2019, and in October 2018, CMS proposed a new rule that would require <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> television advertisements of prescription drugs and biological
products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product. Although a number of these, and other proposed
measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At
the states level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on
certain product access and marketing cost disclosure and transparency measures.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">171
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additionally, on May 30, 2018, the Trickett Wendler, Frank Mongiello,
Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have
completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA
expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>The Foreign Corrupt Practices Act</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Foreign Corrupt Practices Act, or the FCPA, prohibits any U.S. individual or business from paying, offering, or
authorizing payment or offering of anything of value, directly or indirectly, to any foreign official,&nbsp;political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or
business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all
transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Additional Regulation</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances,
including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and
radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe
that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future
operations.</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Other Regulations</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions,
manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future.</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Employees and Human Capital </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of March&nbsp;11, 2021, we had 60&nbsp;full-time employees and 1&nbsp;part-time employees, 25&nbsp;of whom have
Ph.D.&nbsp;or M.D. degrees. Of these full-time employees, 50&nbsp;employees are engaged in research and development activities and 10&nbsp;are engaged in finance, business development and other general and administrative functions. None of our
employees are represented by labor unions or covered by collective bargaining agreements, and we have not experienced any work stoppages. We consider our relations with our employees to be good.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We recognize that attracting, motivating and retaining talent at all levels is vital to our continued success. Our
employees are a significant asset and we aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing, expanding and retaining our workforce to
support our current pipeline and future business goals. By focusing on employeeetention and engagement, we also improve our ability to support our clinical trials, our pipeline, our platform technologies, business and operations, and also protect
the long-term interests of our securityholders. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">172
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
Our success also depends on our ability to attract, engage and retain a diverse group of employees. Our efforts to recruit and retain a diverse and passionate workforce include providing
competitive compensation and benefits packages and ensuring we listen to our employees. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We value innovation,
passion, data-driven decision making, persistence and honesty, and are building a diverse environment where our employees can thrive and be inspired to make exceptional contributions to bring novel and more effective therapies to cancer patients.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining,
motivating and integrating our existing and future employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through grants of stock-based compensation awards
and payments of cash-based performance bonus awards, in order to increase stockholder value and the success of our company by motivating our employees to perform to the best of their abilities and achieve our objectives. We are committed to
providing a competitive and comprehensive benefits package to our employees. Our benefits package provides a balance of protection along with the flexibility to meet the individual health and wellness needs of our employees. We plan to continue to
refine our efforts related to optimizing our use of human capital as we grow, including improvements in the way we hire, develop, motivate and retain employees. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Facilities</B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Our facilities are located at two adjacent leased sites, both located at 830 Winter Street, Waltham, Massachusetts, 02451. The first site consists of 25,472&nbsp;square feet of office and laboratory space and is primarily used for
research, clinical, manufacturing, and corporate activities. Our lease expires September&nbsp;30, 2024, with an option to extend three years. The second site consists of 14,447&nbsp;square feet of office and laboratory space and is primarily used
for preclinical and clinical research. Our lease on this facility expires in March&nbsp;31, 2026. We believe that our facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will
be available to accommodate any such expansion of our operations. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Legal Proceedings </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal
proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other
factors.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">173
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_12"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Executive Officers, Directors and Key Employees </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Executive Officers </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table sets forth the names and positions of our current executive officers, including their ages, as of
July&nbsp;1, 2021: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Age</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">David Southwell</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">60</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">President, Chief Executive Officer and Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Brian Silver</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">52</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Senior Vice President and Chief Financial Officer</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Gavin MacBeath,&nbsp;Ph.D.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">51</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Chief Scientific Officer</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">William Desmarais, Ph.D., MBA.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">51</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Chief Business Officer</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following is a biographical summary of the experience of our executive officers.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>David Southwell&nbsp;</I>has served as our President, Chief Executive Officer and as a member of our
board of directors since October 2018. Prior to joining us, Mr. Southwell was President, Chief Executive Officer and a member of the board of directors of Inotek Pharmaceuticals Corporation from June 2014 until Inotek&#146;s merger with Rocket
Pharmaceuticals, Inc. in January 2018. Previously, Mr. Southwell served as Executive Vice President, Chief Financial Officer of Human Genome Sciences, Inc. from 2010 until its merger with GlaxoSmithKline plc. in 2012. Prior to Human Genome Sciences,
Mr. Southwell served as Executive Vice President and Chief Financial Officer of Sepracor, Inc from 1994 to 2008.&nbsp;Mr. Southwell is a member of the Board of Directors of PTC Therapeutics, Inc., and Rocket Pharmaceuticals.&nbsp;He previously has
served on the boards of Spero Therapeutics from 2017 to 2019; Inventiv Health, Inc. in 2016; THL Credit Inc. from 2007 to 2015; Human Genome Sciences Inc. from 2008 until his appointment as Chief Financial Officer in 2010; and Biosphere Medical Inc.
as Chairman from 2005 to 2010.&nbsp;Mr. Southwell received a B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College, where he has served as head of the M.B.A. Advisory Board from 2008 to 2011, and served on the Board of
Advisors from 2011 until 2020. We believe that Mr. Southwell is qualified to serve on our board of directors because of the perspective and experience he provides as our President and Chief Executive Officer as well as his broad experience within
the life sciences industry, together with his historical perspective on our operations. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Brian Silver
</I>has served as our Senior Vice President and Chief Financial Officer since May 2021. Prior to such time, Mr. Silver was a member of our board of directors since December 2020. Mr. Silver served as the Chief Financial Officer and Head of Corporate
Development of Freeline Therapeutics Holdings plc (Freeline), a systemic gene therapy company focused on inherited rare disorders, from November 2018 to April 2021. Before joining Freeline, Mr. Silver was a partner in the healthcare group of Perella
Weinberg Partners, a leading independent global advisory firm, from August 2013 to November 2018. Prior to that, Mr. Silver held a variety of positions in Morgan Stanley&#146;s investment banking division, most recently as a managing director in the
healthcare group, from March 1998 to July 2013. Before that Mr. Silver was an investment banking associate at Salomon Brothers from August 1997 to March 1998 and a corporate associate at Sullivan &amp; Cromwell LLP from August 1994 through July
1997. Mr. Silver received an A.B. with honors from Harvard College and a J.D. with honors from the University of Chicago Law School. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Gavin MacBeath, Ph.D.</I><B><I> </I></B>has served as our Chief Scientific Officer since December 2018. He has two
decades of experience in academia and industry, founding companies and driving research from early-stage discovery through drug approval. Prior to joining us, Dr.&nbsp;MacBeath served as the Chief Scientific Officer at Abpro Corporation from March
2017 to July 2018, where he advanced T cell-engaging bispecific antibodies through <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development. Previously, Dr.&nbsp;MacBeath served as <FONT STYLE="white-space:nowrap">Co-founder</FONT> and SVP
of Discovery at Merrimack Pharmaceuticals, Inc. from February 2014 to October 2016. Dr.&nbsp;MacBeath began his career in academia, where he served as the first fellow at Harvard&#146;s Bauer Center for Genomics Research, as an Assistant
Professor&nbsp;and later Associate Professor&nbsp;in the Department of Chemistry&nbsp;&amp; Chemical Biology at Harvard </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">174
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
University, and as&nbsp;Lecturer and Principal Investigator at Harvard Medical School.&nbsp;Dr.&nbsp;MacBeath received his undergraduate degree from the University of Manitoba, his Ph.D. from The
Scripps Research Institute, and postdoctoral training with Dr.&nbsp;Stuart Schreiber at Harvard University. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>William Desmarais, Ph.D., MBA </I>has served as our Chief Business Officer since March 2021. Prior to joining TScan,
Dr. Desmarais served as Vice President of Business Development of Momenta Pharmaceuticals, Inc. from September 2017 until Momenta&#146;s acquisition by Johnson &amp; Johnson in February 2021. Before Momenta, Dr. Desmarais spent 11 years in roles of
increasing responsibility within business development and research and development at Eli Lilly &amp; Co. Dr. Desmarais received his Ph.D. in Biophysics and Structural Biology from Brandeis University, an MBA from Massachusetts Institute of
Technology and a B.S. in Cell and Developmental Biology from Purdue University. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table sets forth the names and
positions of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, including their ages, as of July 1, 2021: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Age</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Timothy
Barberich<SUP STYLE="font-size:85%; vertical-align:top">(1),(2),(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">73</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Chairperson of the Board</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stephen Biggar, M.D.,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(2),(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">50</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Katina
Dorton<SUP STYLE="font-size:85%; vertical-align:top">(1),(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">63</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Gabriela
Gruia<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">65</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Ittai
Harel<SUP STYLE="font-size:85%; vertical-align:top">(1),(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">53</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Andrew
Hedin<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">36</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Nandita Shangari,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">40</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Director</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Christoph Westphal, M.D.,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">53</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Director</FONT></P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #32406b;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Member of the audit committee. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Member of the compensation committee. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Member of the nominating and corporate governance. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Appointed to the board of directors on May 3, 2021. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Resigning as a director immediately prior to the effectiveness of the registration
statement of which this prospectus forms a part. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Resigning as a director immediately after the pricing of this offering.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following is a biographical summary of the experience of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Timothy Barberich</I> has served as a member of
our board of directors since March 2019 and as the Chair of our board of directors since March 2021. Mr. Barberich is founder and former Chairman and Chief Executive Officer of Sepracor Inc., a publicly traded, research-based, pharmaceutical company
based in Marlborough, Massachusetts, which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009. He founded Sepracor in 1984 and served as Chief Executive Officer from 1984 to May 2007 and as Chairman of the Board from 1990 to 2009. Mr.
Barberich has been Chairman of BioNevia Pharmaceuticals since June 2008 and Chief Executive Officer since 2014. He currently serves on the board of directors of Frequency Therapeutics, Inc. and Verastem, Inc. He also previously served on the boards
of directors of Neurovance Inc, Inotek Pharmaceuticals, Inc., HeartWare, International, Inc., Tokai Pharmaceuticals, BioSphere Medical, Inc. and GeminX Pharmaceuticals until each company was acquired. Mr. Barberich has also served on the board of
trustees of Boston Medical Centre and the board of the Pharmaceutical Research and Manufacturers&#146; Association (PhRMA). Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Bedford, Massachusetts-based Millipore
Corporation. Mr. Barberich is a graduate of Kings College and holds a Bachelor&#146;s of Science degree in Chemistry. The Board of Directors believes that Mr. Barberich&#146;s qualifications to sit on the Board include his significant experience in
the development and commercialization of pharmaceutical products, his leadership experience at other pharmaceutical companies and his service on other boards of directors. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Stephen Biggar, M.D., Ph.D. </I>has served as a member of our board of directors since March 2021. Dr.&nbsp;Biggar is
a partner at Baker Bros. Advisors LP, a biotechnology-focused investment advisor to fund partnerships whose </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">175
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
investors are primarily endowments and foundations, Dr. Biggar joined in April 2000. Dr.&nbsp;Biggar serves on the boards of Kiniksa Pharmaceuticals, Ltd., and Acadia Pharmaceuticals Inc.
Dr.&nbsp;Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester. We believe that Dr.&nbsp;Biggar is qualified to serve as a member of our board of directors due to
his extensive experience in the life sciences industry. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Katina Dorton, J.D., M.B.A.</I> has served on our
board of directors since March 2021. She currently serves as Chief Financial Officer of Nodthera Limited, a company developing medicines to inhibit the NLRP3 inflammasome. She also serves on the board of directors for Fulcrum Therapeutics, Inc.,
Pandion Therapeutics, Inc., and US Ecology, Inc.. Previously Ms.&nbsp;Dorton has held CFO positions at several biotechnology companies, including Repare Therapeutics Inc., a synthetic lethality and DNA repair-focused oncology company from 2019
through 2020, and AVROBIO, Inc., a lentiviral gene therapy company from 2017 through 2018 and Immatics GmbH, a biotechnology company from 2015 through 2017. Earlier in her career, Ms.&nbsp;Dorton served as a Managing Director in investment banking
for Morgan Stanley and Needham&nbsp;&amp; Company and as an attorney at Sullivan&nbsp;&amp; Cromwell. Ms.&nbsp;Dorton received her J.D. from the University of Virginia School of Law, her M.B.A. from George Washington University and her B.A. from
Duke University. We believe that Ms.&nbsp;Dorton is qualified to serve on our board of directors due to her extensive leadership experience in multiple publicly-traded and privately-held pharmaceutical and biotechnology companies, and expertise in
developing, financing and providing executive leadership in numerous biopharmaceutical companies. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Gabriela Gruia, M.D. </I>has served as a member of our board of directors since May 2021. Dr. Gruia founded Gabriela
Gruia Consulting, LLC in January 2021. Prior to that, Dr. Gruia served as the Chief Development Officer at Ichnos Sciences Inc. from February 2020 to January 2021, where she oversaw several key functions including Regulatory Sciences, Clinical
Operations, Clinical Pharmacology, Biostatistics and Drug Safety. Prior to her time at Ichnos Sciences Inc., Dr. Gruia served as Senior Vice President and Head of Regulatory Affairs for Novartis Oncology from February 2008 through February 2020,
where she was responsible for leading the oncology regulatory affairs organization. Dr. Gruia has served on the board of directors for Tessa Therapeutics, Inc. since January 2021. Dr. Gruia received her doctorate in medicine from Bucharest Medical
School in Romania and has a Masters in Breast Pathology and Mammography from Rene Huguenin/Curie Institute Cancer Center in Paris, France. She received her training in oncology and hematology from Rene Descartes University in Paris, France. We
believe that Dr. Gruia is qualified to serve as a member of our board of directors due to her extensive leadership experience in the life sciences industry. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Ittai Harel</I><B><I> </I></B>has served as a member of our board of directors since August 2019. Mr.&nbsp;Harel has
served as the Managing General Partner of Pitango Venture Capital since 2006 and has extensive investment experience in the biotechnology and healthcare industry, including digital health, medical devices, diagnostics, and specialty pharma. Before
joining Pitango, Mr.&nbsp;Harel headed up Corporate Development at Nektar Therapeutics (Nasdaq: NKTR) and served as Executive Vice President at IDGene Pharmaceuticals, Inc. He also served as head of business development at IDEXX Laboratories, Inc.
Mr.&nbsp;Harel currently serves on the board of directors of DouxMatok, Intensix Ltd., LifeBond Ltd., EarlySense, Medisafe, Vertos Medical Inc., and Click Therapeutics, Inc. and serves as Chairman of the Board at LifeBond Ltd. and EarlySense.
Mr.&nbsp;Harel holds a B.Sc. in Chemical Engineering and Biotechnology from Ben Gurion University, and an M.B.A. from the Sloan School of Management. We believe that Mr.&nbsp;Harel is qualified to serve as a member of our board of directors due to
his extensive experience in the life sciences industry as a venture capitalist. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Andrew Hedin</I> has
served as a member of our board of directors since July 2020. Mr.&nbsp;Hedin has served as an investment professional at Bessemer Venture Partners, a venture capital firm, since 2015 and has been a partner since 2021. Mr.&nbsp;Hedin serves as a
director or observer of the board of directors of several privately held life sciences and healthcare companies. Mr.&nbsp;Hedin holds an M.B.A. with Honors from The Wharton School and a B.A. from the University of Pennsylvania. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Nandita Shangari, Ph.D.</I> has served as a member of our board of directors since September 2020. Dr.&nbsp;Shangari
has served as a Principal at the Novartis Venture Fund since 2018. Prior to joining NVF, she was part of the Novartis Oncology Business Development and Licensing team from 2017 to 2018 where she managed key alliances for the Oncology Portfolio.
Before that, Dr.&nbsp;Shangari held the Global Program Team Director position as part of the Kymriah<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Global Program Team from 2015 to 2017 where she helped bring this novel cell
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">176
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
therapy to market, for two indications, in the US and EU. Dr. Shangari has also held strategic and group head roles in the Novartis Preclinical Investigative Toxicology organization.
Dr.&nbsp;Shangari received her B.Sc. in Biochemistry and Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><I>Christoph Westphal, M.D., Ph.D.</I> has served as a member of our board of directors since our founding. Dr.&nbsp;Westphal is one of our co-founders and served as our Chief Executive Officer from our founding through October
2018, at which point Dr. Westphal transitioned to our Chair. Dr. Westphal has been a partner of Longwood Fund, LP, a venture capital investment fund, since 2010. Dr. Westphal co-founded Verastem, Inc. in August 2010, served as Verastem&#146;s
Chairman since March 2011, and Executive Chairman since July 2013, and was Verastem&#146;s Chief Executive Officer from September 2011 to July 2013 and its President from September 2011 until January 2013. Dr. Westphal served as the President of SR
One, the corporate venture capital arm of GlaxoSmithKline plc, from 2010 until 2011. Dr. Westphal co-founded Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline plc in 2008, and served as its Chief Executive Officer from 2004 to
2010. He also co-founded Alnara Pharmaceuticals, Inc., Concert Pharmaceuticals, Inc., Acceleron Pharma, Inc., serving as its Chief Executive Officer in 2003, Alnylam Pharmaceuticals, Inc., serving as its Chief Executive Officer in 2002, and Momenta
Pharmaceuticals, Inc. serving as its Chief Executive Officer in 2001. Dr. Westphal is also co-founder of Longwood portfolio companies, including Immunitas Therapeutics, Inc. serving as its Chief Executive Officer and also as Chairman of the board,
ImmuneID serving as executive chair and Pyxis Oncology, Inc. Dr.&nbsp;Westphal has served or currently serves as a member or director of the Boston Commercial Club, the Biotechnology Industry organization&#146;s (BIO) Emerging Companies Section
Governing Board, the Board of Fellows of Harvard Medical School, and the Board of Trustees of the Boston Symphony Orchestra. He earned his M.D. from Harvard Medical School, his Ph.D. in Genetics from Harvard University and his B.A. from Columbia
University. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Board Composition </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our board of directors currently consists of nine members, who were elected pursuant to the amended and restated voting
agreement that we entered into with certain holders of our common stock and certain holders of our preferred stock and the related provisions of our amended and restated certificate of incorporation, as currently in effect. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The provisions of this voting agreement will terminate upon the completion of this offering, after which there will be
no further contractual obligations regarding the election of our directors, except as described below. Our directors hold office until their successors have been elected and qualified or appointed, or the earlier of their death, resignation or
removal. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In connection with our Series C convertible preferred stock financing described in the
&#147;Certain relationships and related party transactions&#148; section of this prospectus, we entered into a nominating agreement with Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the BBA Funds) which was subsequently amended
and restated on April 22, 2021, pursuant to which, among other things, we agreed to support the nomination of, and cause our board of directors (or the nominating committee thereof) to include in the slate of nominees recommended to our stockholders
for election as directors at each annual or special meeting of our stockholders at which directors are to be elected, one person designated from time to time by the BBA Funds, subject to the requirements of fiduciary duties under applicable law and
the terms and conditions of such nominating agreement. The agreement only applies during the period beginning at the closing of our initial public offering and for the three years thereafter, as long as (1)&nbsp;the BBA Funds and their affiliates,
collectively, beneficially own at least 75% of the Series C convertible preferred stock purchased by the BBA Funds in such Series C convertible preferred stock financing, or such number of shares of our common stock issued upon conversion of such
number of shares of Series C convertible preferred stock (in either case, as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification or similar transaction), and (2)&nbsp;the BBA Funds and their
affiliates, collectively, beneficially own at least 2% of our then outstanding voting common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In
accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect upon the completion of this offering, our board of directors will be divided into three classes with staggered
three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will
be divided among the three classes as follows: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the Class&nbsp;I directors will be Timothy Barberich and Stephen Biggar, M.D., Ph.D. and
their terms will expire at the first annual meeting of stockholders to be held after the closing of this offering; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">177
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the Class&nbsp;II directors will be Ittai Harel and Katina Dorton and their terms will
expire at the second annual meeting of stockholders to be held after the closing of this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the Class&nbsp;III director will be David Southwell and Gabriela Gruia and their terms will
expire at the third annual meeting of stockholders to be held after the closing of this offering. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Directors in a particular class will be elected for three-year terms at the annual meeting of stockholders in the year in which their terms expire. As a result, only one class of directors will be elected at each annual meeting of
our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Each director&#146;s term continues until the election and qualification of his or her successor, or the earlier of his or her death,
resignation or removal. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our amended and restated certificate of incorporation and amended and restated
bylaws that will be in effect upon the completion of this offering provide that only our board of directors can fill vacant directorships, including newly-created seats. Any additional directorships resulting from an increase in the authorized
number of directors would be distributed pro rata among the three classes so that, as nearly as possible, each class would consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the authorized number of directors. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The classification of our board of directors may have the effect of delaying or preventing changes in our control or
management. See the section titled &#147;Description of capital stock&#151;Anti-takeover provisions&#151;Certificate of incorporation and bylaw provisions&#148; elsewhere in this prospectus. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Director Independence </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Upon the completion of this offering, we anticipate that our common stock will be listed on Nasdaq. Under the rules of
Nasdaq, independent directors must comprise a majority of a listed company&#146;s board of directors. In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and
nominating and corporate governance committees be independent. Audit committee members and compensation committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> and Rule <FONT
STYLE="white-space:nowrap">10C-1,</FONT> respectively, under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Under the rules of Nasdaq, a director will only qualify as an &#147;independent director&#148; if, in the opinion of
that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To be considered to be independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange
Act and under the rules of Nasdaq, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&nbsp;accept, directly or
indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act
and under the rules of Nasdaq, the board of directors must affirmatively determine that each member of the compensation committee is independent, including a consideration of all factors specifically relevant to determining whether the director has
a relationship to the company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: (i)&nbsp;the source of compensation of
such director, including any consulting, advisory or other compensatory fee paid by the company to such director and (ii)&nbsp;whether such director is affiliated with the company, a subsidiary of the company or an affiliate of a subsidiary of the
company. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our board of directors undertook a review of its composition, the composition of its committees and
the independence of our directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">178
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined
that, other than Mr.&nbsp;Southwell, our Chief Executive Officer, all of our directors, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of
these directors is &#147;independent&#148; as that term is defined under the rules of Nasdaq, including in the case of all the members of our audit committee, the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT>
under the Exchange Act, and in the case of all the members of our compensation committee, the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In making these determinations, our board of directors considered the current and prior relationships that each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock
by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director, and the transactions involving them described in the section titled &#147;Certain relationships and related party transactions&#148; elsewhere in this prospectus. There are no
family relationships among any of our directors or executive officers. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Board Leadership Structure </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our board of directors is currently chaired by Mr.&nbsp;Barberich. As a general policy, our board of directors believes
that separation of the positions of chairperson of our board of directors and Chief Executive Officer reinforces the independence of our board of directors from management, creates an environment that encourages objective oversight of
management&#146;s performance and enhances the effectiveness of our board of directors as a whole. As such, Mr.&nbsp;Southwell serves as our President and Chief Executive Officer while Mr.&nbsp;Barberich serves as the chairperson of our board of
directors but is not one of our executive officers. We currently expect and intend the positions of chairperson of our board of directors and Chief Executive Officer to continue to be held by two individuals in the future. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Role of the Board in Risk Oversight </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">One of the key functions of our board of directors is informed oversight of our risk management process. In particular,
our board of directors is responsible for monitoring and assessing strategic risk exposure. Our executive officers are responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of the
material risks we face. Our board of directors administers its oversight function directly as a whole. Our board of directors will also administer its oversight through various standing committees, which will be constituted prior to the completion
of this offering, that address risks inherent in their respective areas of oversight. For example, our audit committee will be responsible for overseeing the management of risks associated with our financial reporting, accounting and auditing
matters; our compensation committee will oversee the management of risks associated with our compensation policies and programs; and our nominating and corporate governance committee will oversee the management of risks associated with director
independence, conflicts of interest, composition and organization of our board of directors and director succession planning. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Board Committees </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our board of directors has previously established an audit committee, a compensation committee and a nominating and
corporate governance committee. Prior to the completion of this offering, our board of directors may establish other committees to facilitate the management of our business. Our board of directors and its committees will set schedules for meeting
throughout the year and can also hold special meetings and act by written consent from time to time, as appropriate. Our board of directors expects to delegate various responsibilities and authority to committees as generally described below. The
committees will regularly report on their activities and actions to the full board of directors. Each member of each committee of our board of directors will qualify as an independent director in accordance with the listing standards of Nasdaq. We
plan to amend and restate the existing charters for each committee of our board of directors prior to the completion of </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">179
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
this offering. Upon the completion of this offering, copies of each charter will be posted on the investor relations portion of our website, www.tscan.com. The inclusion of our website address in
this prospectus does not include or incorporate by reference the information on our website into this prospectus. Members will serve on these committees until their resignation or until otherwise determined by our board of directors. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Audit Committee </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The members of our audit committee are Katina Dorton, Ittai Harel and Timothy Barberich. Ms. Dorton is the chair of the
audit committee. Each member of our audit committee can read and understand fundamental financial statements. Each member of our audit committee is independent under the rules and regulations of the SEC and the listing standards of Nasdaq applicable
to audit committee members. Our board of directors has determined that Ms. Dorton qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of Nasdaq. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Effective at the time of the offering, our audit committee will assist our board of directors with its oversight of the
integrity of our financial statements; our compliance with legal and regulatory requirements; the qualifications, independence and performance of the independent registered public accounting firm; the design and implementation of our risk assessment
and risk management. Among other things, our audit committee is responsible for reviewing and discussing with our management the adequacy and effectiveness of our disclosure controls and procedures. The audit committee also will discuss with our
management and independent registered public accounting firm the annual audit plan and scope of audit activities, scope and timing of the annual audit of our financial statements, and the results of the audit, quarterly reviews of our financial
statements and, as appropriate, initiates inquiries into certain aspects of our financial affairs. Our audit committee is responsible for establishing and overseeing procedures for the receipt, retention and treatment of any complaints regarding
accounting, internal accounting controls or auditing matters, as well as for the confidential and anonymous submissions by our employees of concerns regarding questionable accounting or auditing matters. In addition, our audit committee has direct
responsibility for the appointment, compensation, retention and oversight of the work of our independent registered public accounting firm. Our audit committee has sole authority to approve the hiring and discharging of our independent registered
public accounting firm, all audit engagement terms and fees and all permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> engagements with the independent auditor. Our audit committee will review and oversee all related person transactions
in accordance with our policies and procedures. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our audit committee operates under a written charter that
satisfies the applicable rules of the SEC and the listing standards of Nasdaq. We believe that the composition of our audit committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Compensation Committee </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The members of our compensation committee are Stephen Biggar, Timothy Barberich and Katina Dorton. Dr. Biggar is the
chair of the compensation committee. Each member of our compensation committee is independent under the rules and regulations of the SEC and the listing standards of Nasdaq applicable to compensation committee members. Effective at the time of the
offering, our compensation committee will assist our board of directors with its oversight of the forms and amount of compensation for our executive officers (including officers reporting under Section&nbsp;16 of the Exchange Act), the
administration of our equity and <FONT STYLE="white-space:nowrap">non-equity</FONT> incentive plans for employees and other service providers and certain other matters related to our compensation programs. Our compensation committee, among other
responsibilities, evaluates the performance of our chief executive officer and, in consultation with him, evaluates the performance of our other executive officers (including officers reporting under Section&nbsp;16 of the Exchange Act). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Effective at the time of the offering, our compensation committee will operate under a written charter that satisfies
the applicable rules of the SEC and the listing standards of Nasdaq. We believe that the composition of our compensation committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">180
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Nominating and Corporate Governance Committee </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The members of our nominating and corporate governance committee are Timothy Barberich, Stephen Biggar and Ittai Harel.
Each member of our nominating and corporate governance committee is independent under the rules and regulations of the SEC and the listing standards of Nasdaq applicable to nominating and corporate governance committee members. Mr. Barberich is the
chair of the nominating and corporate governance committee. Effective at the time of the offering, our nominating and corporate governance committee will assist our board of directors with its oversight of and identification of individuals qualified
to become members of our board of directors, consistent with criteria approved by our board of directors, and selects, or recommends that our board of directors selects, director nominees; develops and recommends to our board of directors a set of
corporate governance guidelines and oversees the evaluation of our board of directors. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Compensation Committee Interlocks
and Insider Participation </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">No member of our compensation committee is currently or has at any time during
the past year been an officer or employee of our company. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee (or other board committee performing
equivalent functions or, in the absence of any such committee, the entire board of directors) of any entity that has one or more executive officers serving on our board of directors or compensation committee. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Code of Conduct </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our board of directors will adopt a Code of Conduct prior to the completion of this offering. The Code of Conduct will
apply to all of our employees, officers, directors, contractors, consultants, suppliers and agents. Upon the completion of this offering, the full text of the Code of Conduct will be posted on the investor relation portion of our website,
www.tscan.com. We intend to disclose future amendments to, or waivers of, the Code of Conduct, as and to the extent required by SEC regulations, at the same location on our website identified above or in public filings. Information contained on our
website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase shares of our common stock. We have included our website
address in this prospectus solely as an inactive textual reference. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">181
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Director Compensation Table for the Year Ended December&nbsp;31, 2020 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table sets forth information regarding the compensation of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors who served as a director during our year ended December&nbsp;31, 2020. Other than as set forth in the table and described more fully below, during our year ended December&nbsp;31, 2020,
we did not pay any fees to, make any equity awards or <FONT STYLE="white-space:nowrap">non-equity</FONT> awards to or pay any other compensation to the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors. David
Southwell, our President and Chief Executive Officer, receives no compensation for his service as a director, and is not included in the table below. The compensation of Mr.&nbsp;Southwell as a named executive officer is set forth below in the
subsection above entitled &#147;&#151;Executive compensation&#151;Summary Compensation Table.&#148; Katina Dorton, Stephen Biggar, M.D., Ph.D. and Gabriela Gruia, M.D. are not included in the table below since these directors were appointed to our
board of directors in 2021. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Fees<BR>earned&nbsp;or<BR>paid in<BR>cash ($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Stock<BR>awards</B></FONT><br><FONT COLOR="#32406b"><B>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Option<BR>awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>All other<BR>compensation<BR>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total<BR>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Christoph Westphal, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Andrew Hedin</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Nandita Shangari, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Ittai Harel</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Timothy Barberich</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Douglas Fambrough,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">117,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></FONT>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">117,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Brian
Silver<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Hannes
Smarason<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Lea Hachigian,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #32406b;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">The amounts in this column represent the aggregate grant date fair value of option awards
granted to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director in the applicable fiscal year computed in accordance with FASB ASC Topic 718. See Note 7 of the notes to our audited financial statements included elsewhere in this
prospectus for a discussion of our assumptions made in determining the grant date fair value of our equity awards. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">As of December&nbsp;31, 2020, our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors held outstanding stock options as follows: Mr. Barberich (options to purchase 47,890 shares) and Dr. Fambrough (options to purchase 47,890 shares) </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Dr.&nbsp;Fambrough resigned from our board of directors on March&nbsp;1, 2021.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Mr. Silver resigned from our board of directors on May 3, 2021.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Mr.&nbsp;Smarason resigned from our board of directors on January&nbsp;15, 2021.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Dr.&nbsp;Hachigian resigned from our board of directors on January&nbsp;21, 2021.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">On February&nbsp;26, 2020, Dr.&nbsp;Fambrough was granted an option to purchase 47,890
shares of our common stock, with an exercise price of $2.46 per share. Such option vested over four years, with 25% of the shares vesting on the first anniversary of February&nbsp;26, 2020, and
1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares vesting upon the completion of each month of continuous service with us thereafter. At the time of Dr.&nbsp;Fambrough&#146;s resignation, he was vested in 11,973 shares
subject to this stock option. The 35,918 unvested shares subject to this option were forfeited in connection with Dr.&nbsp;Fambrough&#146;s resignation. On March&nbsp;3, 2021, Dr.&nbsp;Fambrough exercised the vested portion of this option for 11,973
shares of our common stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On January&nbsp;27, 2021, Mr.&nbsp;Silver was granted an
option to purchase 48,780 shares of our common stock, with an exercise price of $5.83 per share. Such option vests over four years, with 25% of the shares vesting on December&nbsp;14, 2021, and
1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares vesting upon the completion of each month of continuous service with us thereafter. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On March 16, 2021, in connection with her appointment to our board of directors, Ms. Dorton was granted an option to
purchase 48,780 shares of our common stock, with an exercise price of $11.57 per share. Such option vests over four years, with 25% of the shares vesting on March 1, 2021, and 1/48th of the shares vesting upon the completion of each month of
continuous service with us thereafter. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On May&nbsp;4, 2021, in connection with her appointment to our board
of directors, Dr.&nbsp;Gruia was granted, subject to the execution of the underwriting agreement for this offering, (i)&nbsp;an option to purchase 9,146 shares of our common stock with an exercise price equal to the initial public offering price in
this offering (First Option) and (ii)&nbsp;an option to purchase 9,146 shares of our common stock with an exercise price equal to the initial public offering price in this offering (Second Option). The shares subject to the First Option vest over
three years, with 1/36th of the shares subject to the First Option vesting upon the completion of each month of continuous service thereafter. The shares subject to the Second Option vest over one year, with 1/12th of the shares subject to the First
Option vesting upon the completion of each month of continuous service thereafter. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">182
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We entered into a services agreement with Dr.&nbsp;Westphal on
October&nbsp;9, 2018, which was amended in June 2019. Pursuant to the terms of the services agreement, as amended, Dr.&nbsp;Westphal received cash compensation at a monthly rate of $15,000 per month from October 2018 through October 2019. Following
October&nbsp;31, 2019, Dr.&nbsp;Westphal&#146;s service to us has been provided for no cash compensation. Dr.&nbsp;Westphal currently directly owns 914,634 shares of our common stock. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Prior to this offering, other than as discussed below, we had not implemented a formal policy or agreements with respect
to compensation payable to <FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors.</FONT> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We
reimburse our directors for expenses associated with attending meetings of our board of directors and its committees. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Director Compensation </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our board of directors adopted the following compensation program in March 2021 for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors following completion of this offering. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director will be paid an annual cash retainer of $40,000. The chair of the audit committee will be paid an additional $7,500 annually, the chair of the compensation committee will be paid an additional
$6,000 annually and the chair of the nominating and corporate governance committee will be paid an additional $4,000 annually. In addition to any fees received as chair of our committees, members of the audit committee will be paid an additional
$7,500 annually, members of the compensation committee will be paid an additional $6,000 annually and members of the nominating and corporate governance committee will be paid an additional $4,000 annually. All retainers will be paid in quarterly
installments. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, the compensation program for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors will include both an initial equity award upon joining our board of directors and an annual equity award in connection with each annual meeting of our stockholders. </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Annual Equity Award&#151;Following the conclusion of each regular annual meeting of
stockholders, each continuing <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an option to purchase 9,146 shares of our common stock under our 2021 Equity Incentive Plan. The option will vest in twelve equal monthly
installments following the date of grant, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous service. All <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as of the offering will be granted
this annual equity award. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Initial Equity Award&#151;Our board of directors intends to provide for an initial option
grant to purchase our common stock for any new employee directors following this offering. It is expected that such initial equity award will vest in three equal annual installments on each anniversary of the date of grant, subject to the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous service. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Any <FONT STYLE="white-space:nowrap">non-employee</FONT> director equity awards will also
vest in full in the event of our &#147;change in control&#148; (as defined in our 2021 Equity Incentive Plan) or a director&#146;s death or disability. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">183
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_13"></A>EXECUTIVE COMPENSATION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following discussion relates to the compensation of our Chief Executive Officer, David Southwell, our Chief
Scientific Officer, Gavin MacBeath, Ph.D., and our former Chief Business Officer, Henry Rath for the fiscal year ended December&nbsp;31, 2020. Mr.&nbsp;Southwell, Dr.&nbsp;MacBeath and Mr.&nbsp;Rath are collectively referred to in this prospectus as
our named executive officers.<B> </B> </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Summary compensation table </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table shows information regarding the compensation of our named executive officers for the fiscal year
ended December&nbsp;31, 2020. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Name and principal position</B></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Salary<BR>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Bonus<BR>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Option<BR>Awards<BR>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>All Other<BR>Compensation<BR>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total<BR>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">David Southwell</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Chief Executive Officer</I></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">466,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">275,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">750,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Gavin MacBeath, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Chief Scientific Officer</I></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">350,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">171,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">11,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">532,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Henry Rath</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>former Chief Business Officer</I><SUP
STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:6.5pt" COLOR="#32406b"><I>(1)</I></FONT></SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">355,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">12,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">367,516</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #32406b;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Mr.&nbsp;Rath&#146;s employment with us terminated as of January&nbsp;31, 2021.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Represents bonuses earned in 2020 and paid in 2021. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">This amount represents certain benefits paid to the named executive officers, including
reimbursement for long term disability insurance, payment of domestic partner medical benefits, and Company matching contributions to 401(k) plan in the amounts of $10,404 and $11,400 to Dr.&nbsp;MacBeath and Mr.&nbsp;Rath, respectively.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Narrative explanation of compensation arrangements with our named executive officers </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Base salaries and annual incentive opportunities. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The base salaries of all of our named executive officers are reviewed from time to time and adjusted when our board of
directors or its compensation committee determines an adjustment is appropriate. For our 2020 fiscal year, the base salary for Mr.&nbsp;Southwell was $466,700, Dr.&nbsp;MacBeath was $350,200 and Mr.&nbsp;Rath was $355,350. For our 2021 fiscal year,
Mr.&nbsp;Southwell&#146;s base salary is $550,000 and Dr.&nbsp;MacBeath&#146;s base salary is $400,000. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Each
of our named executive officers is eligible to earn an incentive bonus each fiscal year, with such bonus awarded based on individual performance goals, as well as achievement of corporate goals related to our product development and advancement of <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies established by our chief executive officer and approved by our board of directors. During our fiscal year ended December&nbsp;31, 2020, our named executive officers were eligible to earn cash
incentive bonuses based on a combination of corporate and individual goals. We require that participants continue to be employed through the payment date to receive a bonus. For our 2021 fiscal year, Mr.&nbsp;Southwell&#146;s annual bonus target is
55% of his base salary and Dr.&nbsp;MacBeath&#146;s annual bonus target is 40% of his base salary. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Pursuant
to agreements with us, Mr.&nbsp;Southwell and Dr.&nbsp;MacBeath are each eligible to receive certain acceleration benefits in the event of our change in control, as described in the footnotes to the &#147;Outstanding equity awards at the year ended
December&nbsp;31, 2020&#148; table and under the &#147;Agreements with Our Named Executive Officers and Potential Payments upon Termination or Change of Control&#148; section below. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">184
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Equity compensation. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We offer stock options to our employees, including our named executive officers, as the long-term incentive component of
our compensation program. Our stock options allow our employees to purchase shares of our common stock at a price equal to the fair market value of our common stock on the date of grant. In the past, our board of directors or compensation committee
has determined the fair market value of our common stock based on inputs including valuation reports prepared by third party valuation firms. Generally, our stock options granted to new hires have vested as to 25% of the total number of option
shares on the first anniversary of the award and in equal monthly installments over the following 36 months. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Employee benefits and perquisites. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our named executive officers are eligible to participate in our health and welfare plans to the same extent as are
full-time employees generally. We generally do not provide our named executive officers with perquisites or other personal benefits. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Retirement benefits. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have established a 401(k) <FONT STYLE="white-space:nowrap">tax-deferred</FONT> savings plan, which permits
participants, including our named executive officers, to make contributions by salary deduction pursuant to Section&nbsp;401(k) of the Internal Revenue Code. We are responsible for administrative costs of the 401(k) plan. We match 100% of every
dollar contributed up to 4% of salary, subject to certain limitations under the Internal Revenue Code. In fiscal year 2020, Dr.&nbsp;MacBeath and Mr.&nbsp;Rath received a Company matching contribution of $10,404 and $11,400, respectively.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Outstanding equity awards at the year ended December&nbsp;31, 2020 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table sets forth information regarding each unexercised option and all unvested stock held by each of our
named executive officers as of December&nbsp;31, 2020. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The vesting schedule applicable to each outstanding
award is described in the footnotes to the table below. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options<BR>exercisable<BR>(#)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options<BR>unexercisable<BR>(#)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Option<BR>exercise<BR>price<BR>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Option<BR>expiration<BR>date</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">David Southwell</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">40,449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(1),(2),(3)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">80,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">10/8/2028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">David Southwell</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">23,277</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(1),(2),(3)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">46,554</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2/4/2029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">David Southwell</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">50,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(1),(4)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">150,616</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">12/17/2029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Gavin MacBeath, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">18,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(1),(2),(5)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">38,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1/23/2029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Gavin MacBeath, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">13,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(1),(4)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">41,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">12/17/2029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Henry Rath</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">27,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(1),(2),(6)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">38,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5/7/2029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Henry Rath</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(1),(4)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">22,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">12/17/2029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #32406b;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">25% of the shares vest on the first anniversary of the vesting commencement date, and
1/48th of the shares vest upon the completion of each month of continuous service thereafter. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">If we are subject to a change of control, then 100% of any unvested shares subject to this
option shall immediately vest. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">The vesting commencement date is October&nbsp;9, 2018. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">The vesting commencement date is December&nbsp;5, 2019. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">The vesting commencement date is December&nbsp;3, 2018. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">The vesting commencement date is April&nbsp;22, 2019. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Mr.&nbsp;Rath&#146;s employment with us terminated as of January&nbsp;31, 2021. As a
result of this termination, 37,540 of such unexercisable options expired as of such date. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">185
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Mr.&nbsp;Rath&#146;s employment with us terminated as of January&nbsp;31, 2021. As a
result of this termination, 21,476 of such unexercisable options expired as of such date. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On January&nbsp;27, 2021, Mr.&nbsp;Southwell was granted an option to purchase 518,504 shares of our common stock, and
Dr.&nbsp;MacBeath was granted an option to purchase 166,577 shares of our common stock, each with an exercise price of $5.83 per share. The option shares vest over four years, with 25% of the shares vesting on the first anniversary of
January&nbsp;25, 2021, and 1/48th of the shares vesting upon the completion of each month of continuous service thereafter. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Employment agreements </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Agreements with Our Named Executive Officers and Potential Payments upon Termination or Change of Control
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We currently maintain employment agreements with each of Mr. Southwell and Dr.&nbsp;MacBeath, as
summarized below. The employment agreements provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment and, other than in the context of a termination without cause or a resignation for good reason (as such terms are defined in the
employment agreements), may be terminated at any time. The severance benefits that Messrs. Southwell and Rath and Dr.&nbsp;MacBeath are entitled to and the acceleration benefits that Mr.&nbsp;Southwell and Dr.&nbsp;MacBeath are entitled to, each
pursuant to their offer letters and award agreements, are summarized below. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Agreements with David
Southwell </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We entered into an employment agreement with Mr. Southwell on October 9, 2018, which was
amended in December 2019 and then replaced with a new employment agreement effective as of April 23, 2021. Pursuant to the terms of the new employment agreement, Mr. Southwell receives a base salary at annual rate of $581,532 per year. He is also
eligible to receive an annual performance bonus of up to 55% of his annual base salary, subject to his achievement of certain performance metrics to be approved and updated by our board of directors on an annual basis. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The employment agreement also provides Mr. Southwell with severance benefits if the Company terminates his employment
without cause or if Mr. Southwell resigns for good reason, equal to (i) salary continuation at his base salary for eighteen months following the separation and (ii) payment of the employer share of COBRA premiums for up to eighteen months. If such
separation without cause or for good reason occurs within the 3 months prior or 12 months following a change of control, then Mr. Southwell will be entitled to a lump sum payment equal to 1.5 times his base salary plus annual target bonus, plus his
pro-rata target bonus and payment COBRA premiums for up to eighteen months. Such severance payments are conditioned upon Mr. Southwell executing a general release of all claims that he may have against the Company. The Company&#146;s obligation to
make severance payments during the applicable severance period will cease immediately upon Mr. Southwell&#146;s (i) breach of his restrictive covenants (described below) or (ii) acceptance of any paid employment or consulting engagement during any
period in which the Company is obligated to make such payments. Mr. Southwell is obligated to inform the Company in the event that he has accepted any such paid employment or consulting engagement. If the Company is subject to a change of control
and in the three months prior to or twelve months following Mr. Southwell is terminated without cause or resigns for good reason, then 100% of any unvested shares or equity awards shall immediately vest and be non-forfeitable. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">&#147;Cause&#148; is defined in the offer letter as (a)&nbsp;any material breach by Mr.&nbsp;Southwell of any agreement
to which he and the Company are both parties to and that is injurious to the Company; (b)&nbsp;substantial negligence in the performance of, or substantial failure to perform, his services to the Company, which breach, negligence or failure, as
applicable, is not cured within 30 days following written notice by the Company; (c)&nbsp;commission by Mr.&nbsp;Southwell of a felony or other crime involving moral turpitude; or (d)&nbsp;willful misconduct by Mr.&nbsp;Southwell which has, or could
reasonably be expected to have, a material adverse effect upon the business, interests or reputation of the Company, </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">186
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">&#147;Resignation for Good Reason&#148; is defined in the offer letter as a
separation as a result of Mr.&nbsp;Southwell&#146;s resignation after one of the following conditions has come into existence without Mr.&nbsp;Southwell&#146;s consent: (a)&nbsp;a material diminution in his compensation (except for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> reductions affecting the Company&#146;s similarly situated employees generally), (b) a material diminution in Mr.&nbsp;Southwell&#146;s title (it being
understood that the removal of the President title shall not in and of itself constitute &#147;Good Reason&#148;), duties, authority and responsibilities within the Company, or (c)&nbsp;a material breach of the Company&#146;s obligations under any
agreement between the Company and Mr.&nbsp;Southwell; provided in each case that &#147;Good Reason&#148; shall not exist unless Mr.&nbsp;Southwell has given written notice to the Company within 60 days of the initial existence of the event(s) giving
rise to such Good Reason, including specific details regarding such event(s), and unless the Company has thereafter failed to cure such event(s) within 30 days after delivery of such written notice. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Mr.&nbsp;Southwell also entered into our standard <FONT STYLE="white-space:nowrap">Non-Disclosure,</FONT> <FONT
STYLE="white-space:nowrap">Non-Competition</FONT> and Assignment of Intellectual Property Agreement, which contains <FONT STYLE="white-space:nowrap">12-month</FONT> post-termination <FONT STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT
STYLE="white-space:nowrap">non-competition</FONT> provisions, provided that such <FONT STYLE="white-space:nowrap">12-month</FONT> period will automatically be extended for the amount of time, if any, during which Mr.&nbsp;Southwell engages in any
activity in violation of such provisions. In the event of Mr.&nbsp;Southwell&#146;s termination without cause or resignation for good reason in the 3 months prior to or 12 months following a change in control, then the restrictive covenants are no
longer enforceable. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Agreements with Gavin MacBeath, Ph.D. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We entered into an offer letter with Dr. MacBeath on November 28, 2018 that was replaced with a new employment agreement
effective as of April 23, 2021. Pursuant to the terms of the offer letter, Dr. MacBeath joined the Company as its Chief Scientific Officer. Dr. MacBeath received a one-time signing bonus equal to $10,000. The Company entered a new employment
agreement with Dr. MacBeath in April 2021 that provides for current base salary of $400,000 per year. He is also eligible to receive an incentive performance bonus of up to 40% of his annual base salary, which bonus amount shall be determined by our
board of directors and dependent on the achievement of specific company, team and individual performance objectives. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">The employment agreement also provides Dr. MacBeath with severance benefits if the Company terminates his employment without cause or resigns for good reason, equal to (i) salary continuation at his base salary for twelve months
following the separation and (ii) payment of the employer share of COBRA premiums for up to twelve months, subject to Dr. MacBeath executing a general release of claims against the Company. If such separation without cause or for good reason occurs
within the 3 months prior or 12 months following a change of control, then Mr. Southwell will be entitled to a lump sum payment equal to one (1) times his base salary plus annual target bonus, plus pro-rata target bonus and payment COBRA premiums
for up to twelve months. If the Company is subject to a change of control and in the three months prior or twelve months following Dr. MacBeath is terminated without cause or resigns for good reason, then 100% of any unvested shares or equity awards
shall immediately vest and be non- forfeitable. The Company&#146;s obligation to make severance payments during the applicable severance period will cease immediately upon Dr. MacBeath&#146;s (i) breach of his restrictive covenants (described below)
or (ii) acceptance of any paid employment or consulting engagement during any period in which the Company is obligated to make such payments. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">&#147;Cause&#148; is defined in the offer letter as (a) any material breach by Dr. MacBeath of any agreement to which he
and the Company are both parties to and that is injurious to the Company; (b) substantial negligence in the performance of, or substantial failure to perform, his services to the Company, which breach, negligence or failure, as applicable, is not
cured within 30 days following written notice by the Company; (c) commission by Dr. MacBeath of a felony or other crime involving moral turpitude; or (d) willful misconduct by Dr. MacBeath which has, or could reasonably be expected to have, a
material adverse effect upon the business, interests or reputation of the Company. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">&#147;Resignation for
Good Reason&#148; is defined in the offer letter as a separation as a result of Dr. MacBeath&#146;s resignation after one of the following conditions has come into existence without Dr. MacBeath&#146;s consent: (a) a
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">187
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
material diminution in his compensation (except for across-the-board reductions affecting the Company&#146;s similarly situated employees generally), (b) a material diminution in Dr.
MacBeath&#146;s title, duties, authority and responsibilities within the Company, or (c) a material breach of the Company&#146;s obligations under any agreement between the Company and Dr. MacBeath; provided in each case that &#147;Good Reason&#148;
shall not exist unless Dr.&nbsp;MacBeath has given written notice to the Company within 60 days of the initial existence of the event(s) giving rise to such Good Reason, including specific details regarding such event(s), and unless the Company has
thereafter failed to cure such event(s) within 30 days after delivery of such written notice. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition,
on December&nbsp;31, 2018, Dr.&nbsp;MacBeath entered into our standard Proprietary Information and Inventions Agreement, which contains <FONT STYLE="white-space:nowrap">one-year</FONT> post-termination
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> provisions, provided that such <FONT STYLE="white-space:nowrap">one-year</FONT> period will automatically be extended for an
additional year following the separation date if Dr.&nbsp;MacBeath breaches a fiduciary duty to the Company or unlawfully takes, physically or electronically, any property belonging to the Company. In the event of Dr. MacBeath&#146;s termination
without cause or resignation for good reason in the 3 months prior to or 12 months following a change in control, then the restrictive covenants are no longer enforceable. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Agreements with Brian Silver </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We entered into an Employment Agreement with Mr. Silver. Pursuant to the terms of the employment agreement, Mr. Silver
joined us as our Senior Vice President and Chief Financial Officer on May 3, 2021. Mr. Silver received a base salary at an initial annual rate of $457,500 per year. He is also eligible to receive an annual performance bonus of up to 40% of his
annual base salary (pro-rated during the first year of employment), subject to his achievement of certain performance metrics to be approved and updated by our board of directors on an annual basis. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The employment agreement also provides Mr. Silver with severance benefits if the Company terminates his employment
without cause or if Mr. Silver resigns for good reason equal to (i) salary continuation at his base salary for 12 months following the separation and (ii) COBRA premiums coverage for up to 12 months. If such separation without cause or for good
reason occurs in the three months prior to a change of control or within 12 months at or following a change of control, then Mr. Silver will be entitled to a lump sum cash payment equal to (i) one times (x) his base salary plus (y) his annual target
bonus plus (ii) his pro rata target bonus for the number of days worked in the fiscal year of such separation. Such severance payments are conditioned upon Mr. Silver executing a general release of all claims that he may have against the Company.
The Company&#146;s obligation to make severance payments during the applicable severance period will cease immediately upon (i) Mr. Silver&#146;s material breach of the proprietary information and inventions agreement between him and the Company or
(ii) Mr. Silver&#146;s acceptance of any paid employment or consulting engagement during any period in which the Company is obligated to make such payments, and Mr. Silver is obligated to inform the Company in the event that he has accepted any such
paid employment or consulting engagement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Pursuant to the employment agreement, Mr. Silver was granted an
option, subject to the execution of the underwriting agreement for this offering, immediately following the effective time of the registration statement of which this prospectus forms a part of, to purchase 250,441 shares of our common stock
(subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization), subject to the approval of our board of directors or its compensation committee. The exercise price per share of such
option will be initial public offering price in this offering. Such option will be subject to the terms and conditions applicable to options granted under our 2021 Plan, as described in such plan and the applicable stock option agreement. Such
option will vest with respect to 25% of the shares subject to it after 12 months of continuous service following Mr. Silver&#146;s employment start date, and the balance will vest in equal monthly installments over the next 36 months of continuous
service, as will be described in the applicable stock option agreement. Additionally, Mr. Silver was also granted an option to purchase 48,780 shares of our common stock for his service as a director that is described above in &#147;Director
Compensation&#148; and that will continue to vest during his continuous service as an employee. If Mr. Silver&#146;s employment is terminated without cause or for good reason within the three months prior to a change of control or within 12 months
at or following a change of control, any unvested shares or equity awards shall immediately vest. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">188
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">&#147;Cause&#148; is defined in the employment agreement as (a) any
material breach by Mr. Silver of any agreement to which he and the Company are both parties that is injurious to the Company; (b) gross negligence in the performance of, or a willful failure to perform, Mr. Silver&#146;s services to the Company,
which breach, negligence or failure, as applicable, is not cured within thirty (30) days following written notice by the Company; (c) commission by Mr. Silver of a felony or other crime involving moral turpitude; or (d) willful misconduct by Mr.
Silver which has, or could reasonably be expected to have, a material adverse effect upon the business, interests or reputation of the Company. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">&#147;Resignation for Good Reason&#148; is defined in the employment agreement as a separation as a result of Mr.
Silver&#146;s resignation within 12 months after one of the following conditions has come into existence without Mr. Silver&#146;s consent: (a) material diminution in Mr. Silver&#146;s compensation (except for across-the-board reductions affecting
the Company&#146;s similarly situated employees generally); (b) a material diminution in Mr. Silver&#146;s title, duties, authority and responsibilities within the Company, including without limitation no longer reporting to the Company&#146;s Chief
Executive Officer; (c) the relocation of Mr. Silver&#146;s principal workplace by more than 50 miles away from any Company office; or (d) a material breach of the Company&#146;s obligation under any agreement between the Company and Mr. Silver. A
&#147;Resignation for Good Reason&#148; shall not be deemed to have occurred unless Mr. Silver gives the Company written notice of the condition within 60 days after the condition comes into existence and the Company fails to remedy the condition
within 30 days after receiving the Mr. Silver&#146;s written notice. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Mr. Silver also entered into our
standard proprietary information and inventions Agreement, which contains one-year post-termination non-solicitation and non-competition provisions, provided that such one-year period will automatically be extended for an additional one year if Mr.
Silver engages in any activity in violation of such provisions. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Agreements with William Desmarais
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We entered into an offer letter with Mr. Desmarais on March 16, 2021 that was replaced with a new
employment agreement effective as of April 23, 2021. Pursuant to the terms of the offer letter, Mr. Desmarais joined the Company as its Chief Business Officer on March 2, 2021. Mr. Desmarais&#146; current base salary is $360,000 per year. He is also
eligible to receive an incentive performance bonus of up to 40% of his annual base salary, which bonus amount shall be determined by our board of directors and dependent on the achievement of specific company, team and individual performance
objectives. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The employment agreement also provides Mr. Desmarais with severance benefits if the Company
terminates his employment without cause or resigns for good reason, equal to (i) salary continuation at his base salary for twelve months following the separation and (ii) payment of the employer share COBRA premiums for up to twelve months, subject
to Mr. Desmarais executing a general release of claims against the Company. If such separation without cause or for good reason occurs within the 3 months prior or 12 months following a change of control, then Mr. Southwell will be entitled to a
lump sum payment equal to one (1) times his base salary plus annual target bonus, plus pro-rata target bonus and payment COBRA premiums for up to twelve months. If the Company is subject to a change of control and in the three months prior or twelve
months following Mr. Desmarais is terminated without cause or resigns for good reason, then 100% of any unvested shares or equity awards shall immediately vest and be non- forfeitable. The Company&#146;s obligation to make severance payments during
the applicable severance period will cease immediately upon Mr. Desmarais&#146; (i) breach of his restrictive covenants (described below) or (ii) acceptance of any paid employment or consulting engagement during any period in which the Company is
obligated to make such payments. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Mr. Desmaarais was granted an option to purchase 119,688 shares of our
common stock with an exercise price of $13.94. The option shares vest over four years, with 25% of the shares vesting on the first anniversary of March 22, 2021, and 1/48th of the shares vesting upon the completion of each month of continuous
service thereafter. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">189
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">&#147;Cause&#148; is defined in the offer letter as (a) any material breach
by Mr. Desmarais of any agreement to which he and the Company are both parties to and that is injurious to the Company; (b) substantial negligence in the performance of, or substantial failure to perform, his services to the Company, which breach,
negligence or failure, as applicable, is not cured within 30 days following written notice by the Company; (c) commission by Mr. Desmarais of a felony or other crime involving moral turpitude; or (d) willful misconduct by Mr. Desmarais which has, or
could reasonably be expected to have, a material adverse effect upon the business, interests or reputation of the Company. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">&#147;Resignation for Good Reason&#148; is defined in the offer letter as a separation as a result of Mr. Desmarais&#146; resignation after one of the following conditions has come into existence without Mr. Desmarais&#146; consent:
(a) a material diminution in his compensation (except for across-the-board reductions affecting the Company&#146;s similarly situated employees generally), (b) a material diminution in Mr. Desmarais&#146; title, duties, authority and
responsibilities within the Company, or (c) a material breach of the Company&#146;s obligations under any agreement between the Company and Mr. Desmarais; provided in each case that &#147;Good Reason&#148; shall not exist unless Mr.&nbsp;Desmarais
has given written notice to the Company within 60 days of the initial existence of the event(s) giving rise to such Good Reason, including specific details regarding such event(s), and unless the Company has thereafter failed to cure such event(s)
within 30 days after delivery of such written notice. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, Mr. Desmarais entered into our standard
Proprietary Information and Inventions Agreement, which contains one-year post-termination non-solicitation and non-competition provisions, provided that such one-year period will automatically be extended for an additional year following the
separation date if Mr.&nbsp;Desmarais breaches a fiduciary duty to the Company or unlawfully takes, physically or electronically, any property belonging to the Company. In the event of Mr. Desmarais&#146; termination without cause or resignation for
good reason in the 3 months prior to or 12 months following a change in control, then the restrictive covenants are no longer enforceable. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Agreements with Henry Rath </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We entered into an offer letter with Mr.&nbsp;Rath on April&nbsp;8, 2019. Pursuant to the terms of the offer letter,
Mr.&nbsp;Rath joined the Company as its Chief Business Officer on April&nbsp;23, 2019. Mr.&nbsp;Rath received a base salary at an initial annual rate of $345,000 per year. He was also eligible to receive an incentive performance bonus of up to 35%
of his annual base salary, which bonus amount shall be determined by our board of directors and dependent on the achievement of specific company, team and individual performance objectives. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The offer letter also provides Mr.&nbsp;Rath with severance benefits if the Company terminates his employment without
cause, equal to salary continuation at his then current base salary for six months following the separation, subject to Mr.&nbsp;Rath executing a general release of claims against the Company. &#147;Cause&#148; is defined in the offer letter as
(a)&nbsp;a material breach by Mr.&nbsp;Rath of any agreement to which he and the Company are both parties to and that is injurious to the Company; (b)&nbsp;negligence in the performance of, or substantial failure to perform, his services to the
Company, which breach, negligence or failure, as applicable, is not cured within 30 days following written notice by the Company; (c)&nbsp;commission by Mr.&nbsp;Rath of a felony or other crime involving moral turpitude; or (d)&nbsp;willful
misconduct by Mr.&nbsp;Rath which has, or could reasonably be expected to have, a material adverse effect upon the business, interests or reputation of the Company </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, on April&nbsp;23, 2019, Mr.&nbsp;Rath entered into our standard Proprietary Information and Inventions
Agreement, which contains <FONT STYLE="white-space:nowrap">one-year</FONT> post-termination <FONT STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> provisions, provided that such <FONT
STYLE="white-space:nowrap">one-year</FONT> period will automatically be extended for an additional year following the separation date if Mr.&nbsp;Rath breaches a fiduciary duty to the Company or unlawfully takes, physically or electronically, any
property belonging to the Company. As noted above, however, the <FONT STYLE="white-space:nowrap">non-competition</FONT> restrictions were waived by the Company upon Mr.&nbsp;Rath&#146;s execution and
<FONT STYLE="white-space:nowrap">non-revocation</FONT> of his separation agreement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On January&nbsp;26,
2021, we entered into a separation agreement with Mr.&nbsp;Rath. Such agreement was amended on February&nbsp;3, 2021, and, subject to the terms and conditions thereof, provides for (i)&nbsp;the continuation of his base
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">190
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
salary for six months, equal to an aggregate amount of $172,500 and (ii)&nbsp;a transition bonus in the amount of $32,000, to be paid in two installments, each subject to Mr.&nbsp;Rath&#146;s
full cooperation and support of his transition and compliance with the separation agreement. The first installment of the transition bonus in the amount of $15,000 was paid on February&nbsp;28, 2021, and the second in the amount of $17,000 was paid
on March&nbsp;31, 2021. Further, the Company waived the post-termination <FONT STYLE="white-space:nowrap">non-compete</FONT> restrictions contained in Mr.&nbsp;Rath&#146;s Proprietary Information and Inventions Agreement with the Company. The
separation agreement contains a <FONT STYLE="white-space:nowrap">one-year</FONT> <FONT STYLE="white-space:nowrap">non-solicitation</FONT> covenant. In addition, the Company agreed to use its best efforts to seek the approval of the Company&#146;s
board of directors to allow Mr.&nbsp;Rath to exercise the options that were vested as of his termination date to be exercised on a cashless net exercise basis at any time before the expiration date of the applicable option. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Equity plans </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>2021 Equity Incentive Plan </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our board of directors adopted our 2021 Equity Incentive Plan, or the 2021 Plan, in April 2021 and our stockholders
approved the 2021 Plan in May 2021. Our 2021 Plan become effective upon the effectiveness of the registration statement of which this prospectus is a part. Our 2021 Plan is intended to replace our 2018 Stock Plan, or the 2018 Plan. However, awards
outstanding under our 2018 Plan will continue to be governed by their existing terms. Our 2021 Plan has the features described below. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Share Reserve.</I><I></I> The number of shares of our common stock available for issuance under our 2021 Plan will
equal the sum of 3,278,048 shares plus up to 150,889 shares remaining available for issuance under, or issued pursuant to or subject to awards granted under, our 2018 Plan. The number of shares reserved for issuance under our 2021 Plan will be
increased automatically on the first day of each of our fiscal years, commencing in 2021 and ending in 2031 by a number equal to the smallest of: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">4% of the shares of common stock outstanding on the last day of the prior fiscal year; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the number of shares determined by our board of directors. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In general, to the extent that any awards under our 2021 Plan or our 2018 Plan are forfeited, terminate, expire or lapse
without the issuance of shares, or if we repurchase the shares subject to awards granted under our 2021 Plan, those shares will again become available for issuance under our 2021 Plan or our 2018 Plan, as will shares applied to pay the exercise or
purchase price of an award or to satisfy tax withholding obligations related to any award. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Administration.</I><I> </I>The compensation committee of our board of directors will administer our 2021 Plan. The
compensation committee will have complete discretion to make all decisions relating to our 2021 Plan and outstanding awards, including repricing outstanding options and modifying outstanding awards in other ways. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Eligibility.</I> <FONT STYLE="white-space:nowrap">Employees,&nbsp;non-employee&nbsp;directors,</FONT> consultants and
advisors will be eligible to participate in our 2021 Plan. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Under our 2021 Plan, the aggregate grant date
fair value of awards granted to <FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors</FONT> may not exceed $750,000 in any one fiscal year, except that the grant date fair value of awards granted to newly appointed <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors may not exceed $1,500,000 in the fiscal year in which <FONT STYLE="white-space:nowrap">such&nbsp;non-employee&nbsp;director</FONT> is initially appointed to our board of directors. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Types of awards.</I><I> </I>Our 2021 Plan will provide for the following types of awards: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">incentive and nonstatutory stock options; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">stock appreciation rights; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">191
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">restricted shares; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">stock units. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Options and Stock Appreciation Rights.</I><I> </I>The exercise price for options granted under our 2021 Plan may not
be less than 100% of the fair market value of our common stock on the grant date. Optionees will be permitted to pay the exercise price in cash or, with the consent of the compensation committee: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">with shares of common stock that the optionee already owns; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">by an immediate sale of shares through a broker approved by us;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">by instructing us to withhold a number of shares having an aggregate fair market value that
does not exceed the exercise price; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">by other methods permitted by applicable law. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">An optionee who exercises a stock appreciation right receives the increase in value of our common stock over the base
price. The base price for stock appreciation rights may not be less than 100% of the fair market value of our common stock on the grant date. The settlement value of a stock appreciation right may be paid in cash, shares of our common stock or a
combination. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Options and stock appreciation rights vest as determined by the compensation committee. In
general, they will vest over a four-year period following the date of grant. Options and stock appreciation rights expire at the time determined by the compensation committee but in no event more than ten years after they are granted. These awards
generally expire earlier if the participant&#146;s service terminates earlier. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Restricted Shares and
Stock Units.</I><I> </I>Restricted shares and stock units may be awarded under our 2021 Plan in return for any lawful consideration, and participants who receive restricted shares or stock units generally are not required to pay cash for their
awards. In general, these awards will be subject to vesting. Vesting may be based on length of service, the attainment of performance-based milestones or a combination of both, as determined by the compensation committee. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Corporate Transactions</I>. In the event we are a party to a merger, consolidation or certain change in control
transactions, outstanding awards granted under our 2021 Plan, and all shares acquired under our 2021 Plan, will be subject to the terms of the definitive transaction agreement (or, if there is no such agreement, as determined by our compensation
committee). Unless an award agreement provides otherwise, such treatment may include any of the following with respect to each outstanding award: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the continuation, assumption or substitution of an award by a surviving entity or its
parent; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cancellation of an award without payment of any consideration;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the cancellation of the vested portion of an award (and any portion that becomes vested as
of the effective time of the transaction) in exchange for a payment equal to the excess, if any, of the value that the holder of each share of our common stock receives in the transaction over (if applicable) the exercise price otherwise payable in
connection with the award; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the assignment of any reacquisition or repurchase rights held by us in respect of an award
of restricted shares to the surviving entity or its parent (with proportionate adjustments made to the price per share to be paid upon exercise of such rights). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The compensation committee is not required to treat all awards, or portions thereof, in the same manner. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The vesting of an outstanding award may be accelerated by the administrator upon the occurrence of a change in control,
whether or not the award is to be assumed or replaced in the transaction, or in connection with a termination of service following a change in control transaction. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">192
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A change in control includes: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">any person acquiring beneficial ownership of more than 50% of our total voting power;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the sale or other disposition of all or substantially all of our assets; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">our merger or consolidation after which our voting securities represent 50% or less of the
total voting power of the surviving or acquiring entity. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Changes in Capitalization.
</I>In the event of certain changes in our capital structure without our receipt of consideration, such as a stock split, reverse stock split or dividend paid in common stock, proportionate adjustments will automatically be made to: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the maximum number and kind of shares available for issuance under our 2021 Plan, including
the maximum number and kind of shares that may be issued upon the exercise of incentive stock options; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the maximum number and kind of shares covered by, and exercise price, base price or
purchase price, if any, applicable to each outstanding stock award; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the maximum number and kind of shares by which the share reserve may increase automatically
each year. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the event that there is a declaration of an extraordinary dividend payable
in a form other than our common stock in an amount that has a material effect on the price of our common stock, a recapitalization, <FONT STYLE="white-space:nowrap">a&nbsp;spin-off&nbsp;or</FONT> a similar occurrence, the compensation committee may
make such adjustments to any of the foregoing as it deems appropriate, in its sole discretion. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Amendments
or Termination</I>. Our board of directors may amend, suspend or terminate our 2021 Plan at any time. If our board of directors amends our 2021 Plan, it does not need stockholder approval of the amendment unless required by applicable law,
regulation or rules. Our 2021 Plan will terminate automatically 10 years after the later of the date when our board of directors adopted our 2021 Plan or approved the latest share increase that was also approved by our stockholders. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>2018 Stock Plan </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our board of directors adopted and our stockholder approved our 2018 Stock Plan, or the 2018 Plan, in April 2018. No
further awards will be made under our 2018 Plan after this offering; however, awards outstanding under our 2018 Plan will continue to be governed by their existing terms. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Share Reserve</I>. As of March&nbsp;31, 2021, we have reserved 2,902,738 shares of our common stock for issuance
under our 2018 Plan, all of which may be issued as incentive stock options. As of March&nbsp;31, 2021, options to purchase 2,525,506 shares of our common stock, at exercise prices ranging from $1.97 to $13.94 per share, or a weighted-average
exercise price of $4.98 per share were outstanding under our 2018 Plan, and 150,889 shares of our common stock remained available for future issuance. Unissued shares subject to awards that expire, are forfeited, or are cancelled, shares reacquired
by us and shares withheld in payment of the purchase price or exercise price of an award or in satisfaction of withholding taxes will again become available for issuance under our 2018 Plan or, following consummation of this offering, under our 2021
Plan. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Administration</I>. Our board of directors, or a committee thereof, has administered our 2018 Plan
since its adoption; however, following this offering, the compensation committee of our board of directors will generally administer our 2018 Plan. The administrator has complete discretion to make all decisions relating to our 2018 Plan and
outstanding awards. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Eligibility</I>. Employees, <FONT STYLE="white-space:nowrap">non-employee</FONT>
members of our board of directors and consultants are eligible to participate in our 2018 Plan. However, only employees are eligible to receive incentive stock options. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">193
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Types of Awards</I>. Our 2018 Plan provides for the following types of
awards granted with respect to shares of our common stock: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">incentive and nonstatutory stock options to purchase shares of our common stock;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">direct award or sale of shares of our common stock, including restricted shares; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">restricted stock units. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Options.</I> The exercise price for options granted under our 2018 Plan is determined by our board of directors, but
may not be less than 100% of the fair market value of our common stock on the grant date. Optionees may pay the exercise price in cash or cash equivalents or by one, or any combination of, the following forms of payment, as permitted by the
administrator in its sole discretion: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Surrender of shares of common stock that the optionee already owns;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Delivery of a full-recourse promissory note, with the option shares pledged as security
against the principal and accrued interest on the note; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">An immediate sale of the option shares through a company-approved broker, if the shares of
our common stock are publicly traded; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Surrendering a number of vested shares subject to the option having an aggregate fair
market value no greater than the aggregate exercise price, or the sum of such exercise price plus all or a portion of the minimum amount required to be withheld under applicable law; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Other methods permitted by the Delaware General Corporation Law, as amended.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Options vest as determined by the administrator. In general, we have granted options that
vest over a four-year period. Options expire at the time determined by the administrator, but in no event more than ten years after they are granted, and generally expire earlier if the optionee&#146;s service terminates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Restricted Shares</I>. Restricted shares may be awarded or sold under our 2018 Plan in return for cash or cash
equivalents or, as permitted by the administrator in its sole discretion, in exchange for services rendered to us, by delivery of a full-recourse promissory note or through any other means permitted by applicable law. Restricted shares vest as
determined by the administrator. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Restricted Stock Units</I>. Restricted stock units may be awarded or
sold under our 2018 Plan. No cash consideration shall be required of the recipient in connection with the grant of restricted stock units. Settlement of vested restricted stock units may be made in the form of (i)&nbsp;cash, (ii) shares of our
common stock, or (iii)&nbsp;any combination of both, as determined by the administrator. Restricted stock units vest as determined by the administrator. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Corporate Transactions</I>. In the event that we are a party to a merger or consolidation or in the event of a sale
of all or substantially all of our stock or assets, awards granted under our 2018 Plan will be subject to the agreement governing such transaction or, in the absence of such agreement, in the manner determined by the administrator. Such treatment
may include, without limitation, one or more of the following with respect to outstanding awards: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">The continuation, assumption or substitution of an award by the surviving entity or its
parent; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Cancellation of the vested portion of the award in exchange for a payment equal to the
excess, if any, of the value of the shares subject to the award over any exercise price per share applicable to the award; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Cancellation of the award without payment of any consideration;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Suspension of the optionee&#146;s right to exercise the option during a limited period of
time preceding the completion of the transaction; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">Termination of any right the optionee has to exercise the option prior to vesting in the
shares subject to the option. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">194
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The administrator is not obligated to treat all awards in the same manner.
The administrator has the discretion, at any time, to provide that an award under our 2018 Plan will vest on an accelerated basis in connection with a corporate transaction or to amend or modify an award so long as such amendment or modification is
not inconsistent with the terms of the 2018 Plan or would not result in the impairment of a participant&#146;s rights without the participant&#146;s consent. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Changes in Capitalization. </I>In the event of certain specified changes in the capital structure of our common
stock, such as a stock split, reverse stock split, stock dividend, reclassification or any other increase or decrease in the number of issued shares of stock effective without receipt of consideration by us, proportionate adjustments will
automatically be made in (i)&nbsp;each of the number and kind of shares available for future grants under our 2018 Plan, (ii)&nbsp;the number and kind of shares covered by each outstanding option and all restricted shares, (iii)&nbsp;the exercise
price per share subject to each outstanding option and (iv)&nbsp;any repurchase price applicable to shares granted under our 2018 Plan. In the event of an extraordinary cash divided that has a material effect on the fair market value of our common
stock, a recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar occurrence, the administrator at its sole discretion may make appropriate adjustments to one or more of the items described above. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Amendments or Termination</I>. The administrator may at any time amend, suspect or terminate our 2018 Plan, subject
to stockholder approval in the case of an amendment if the amendment increases the number of shares available for issuance or materially changes the class of persons eligible to receive incentive stock options. Our 2018 Plan will terminate
automatically ten years after the later of the date when our board of directors adopted the plan or the date when our board of directors most recently approved an increase in the number of shares reserved thereunder which was also approved by our
stockholders, provided, however, that in any event, it will terminate upon the completion of this offering, but as noted above, awards outstanding under our 2018 Plan will remain outstanding and will continue to be governed by their existing terms.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>2021 Employee Stock Purchase Plan </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>General. </I>Our board of directors adopted our 2021 Employee Stock Purchase Plan, or 2021 ESPP, in April 2021. Our
2021 ESPP will become effective as of the effective date of the registration statement of which this prospectus is a part. Our 2021 ESPP is intended to qualify under Section&nbsp;423 of the Internal Revenue Code. Our 2021 ESPP has the features
described below. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Share Reserve.</I> 254,390 shares of our common stock have been reserved for issuance
under our 2021 ESPP. The number of shares reserved for issuance under our 2021 ESPP will automatically be increased on the first day of each of our fiscal years, commencing in 2022 and ending in 2041, by a number equal to the least of: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">243,902 shares; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">1% of the shares of common stock issued and outstanding on the last day of the prior fiscal
year; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the number of shares determined by our board of directors. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The number of shares reserved under our 2021 ESPP will automatically be adjusted in the event of a stock split, stock
dividend or a reverse stock split (including an adjustment to the <FONT STYLE="white-space:nowrap">per-purchase</FONT> period share limit). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Administration</I>. The compensation committee of our board of directors will administer our 2021 ESPP. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Eligibility. </I>All of our employees will be eligible to participate in our ESPP, although the administrator may
exclude certain categories of employees from an offering period, as permitted by applicable law, including employees employed for less than two years, working less than 20 hours per week, who are employed less than five months per year, or are
highly compensated employees. Eligible employees may begin participating in our 2021 ESPP at the start of any offering period. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">195
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Offering Periods. </I>Each offering period will last a number of months
determined by the compensation committee, not to exceed 27 months. A new offering period will begin periodically, as determined by the compensation committee. Offering periods may overlap or may be consecutive. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Amount of Contributions. </I>Our 2021 ESPP will permit each eligible employee to purchase common stock through
payroll deductions. Each employee&#146;s payroll deductions may not exceed 15% of the employee&#146;s cash compensation. Each participant may purchase up to the number of shares determined by our board of directors on any purchase date, not to
exceed 914 shares. The value of the shares purchased in any calendar year may not exceed $25,000. Participants may withdraw their contributions at any time before stock is purchased. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Purchase Price. </I>The price of each share of common stock purchased under our 2021 ESPP will not be less than 85%
of the lower of the fair market value per share of common stock on the first day of the applicable offering period or the fair market value per share of common stock on the purchase date. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><I>Other Provisions. </I>Employees may end their participation in our 2021 ESPP at any time. Participation ends
automatically upon termination of employment with us. If we experience a change in control, our 2021 ESPP will end and shares will be purchased with the payroll deductions accumulated to date by participating employees, unless the rights to purchase
our common stock under the 2021 ESPP for an offering period then in progress are continued, assumed or substituted by the surviving entity. Our board of directors or our compensation committee may amend or terminate our 2021 ESPP at any time.
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">196
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY
TRANSACTIONS </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following is a description of transactions since our incorporation on April&nbsp;17,
2018 to which we have been a party in which the amount involved exceeded the lesser of (i) $120,000 or (ii) one percent of the average of our total assets at year end for the last two completed fiscal years; and in which any of our executive
officers, directors or beneficial holders of more than 5% of our capital stock (or any immediate family member of, or person sharing the household with, any of these individuals or entities), which we collectively refer to as a related person, had
or will have a direct or indirect material interest, other than compensation arrangements which are described in &#147;Management&#151;Director compensation&#148; and &#147;Executive compensation.&#148; We believe that all of these transactions were
on terms as favorable as could have been obtained from unrelated third parties. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Sales of Securities </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Series A Convertible Preferred Stock Financing </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In June 2018 and December 2018, we issued and sold an aggregate of 3,209,240 shares of our Series A convertible preferred
stock at a cash purchase price of $7.79 per share for an aggregate purchase price of approximately $25&nbsp;million. Each share of Series A convertible preferred stock will convert into one share of common stock upon the completion of this offering
The table below sets forth the number of shares of Series A convertible preferred stock sold to our directors, executive officers and holders of more than 5% of our capital stock: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Investor<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares&nbsp;of&nbsp;Series&nbsp;A<BR>convertible<BR>preferred stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total&nbsp;purchase<BR>price</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with 6 Dimensions Capital</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">641,848</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with Bessemer Venture Partners</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">641,848</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with GV</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">641,848</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Longwood Fund IV, L.P.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">641,848</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Novartis Bioventures Ltd.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">641,848</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #32406b;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">See &#147;Principal stockholders&#148; for additional information about shares held by
these entities and individuals. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Series B Convertible Preferred Stock Financing
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In July and August 2019, we issued and sold an aggregate of 3,325,937 shares of our Series B
convertible preferred stock at a cash purchase price of $9.02 per share for an aggregate purchase price of approximately $30&nbsp;million. Then, in November 2019, we issued and sold an aggregate of 527,927 shares of our Series B convertible
preferred stock at a cash purchase price of $9.48 per share for an aggregate purchase price of approximately $5&nbsp;million. Each share of Series B convertible preferred stock will convert into one share of common stock upon the completion of this
offering. The table below sets forth the number of shares of Series B convertible preferred stock sold to our directors, executive officers and holders of more than 5% of our capital stock: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Investor<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares&nbsp;of&nbsp;Series&nbsp;B<BR>convertible<BR>preferred stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total&nbsp;purchase<BR>price</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with 6 Dimensions Capital</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">665,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with Bessemer Venture Partners</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">332,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with GV</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">332,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Longwood Fund IV, L.P.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">332,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Novartis Bioventures Ltd.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">332,594</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Novartis Institutes for Biomedical Research, Inc.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">554,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Astellas Venture Management LLC</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">527,927</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with Pitango Healthtech</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">723,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,525,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #32406b;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">See &#147;Principal stockholders&#148; for additional information about shares held by
these entities. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">197
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Series C Convertible Preferred Stock Financing </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In January 2021, we issued and sold an aggregate of 8,553,168 shares of our Series C convertible preferred stock at a
cash purchase price of $11.70 per share for an aggregate purchase price of approximately $100&nbsp;million. Each share of Series C convertible preferred stock will convert into one share of common stock upon the completion of this offering The table
below sets forth the number of shares of Series C convertible preferred stock sold to our directors, executive officers and holders of more than 5% of our capital stock: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Investor<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares&nbsp;of&nbsp;Series&nbsp;C<BR>convertible<BR>preferred stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total&nbsp;purchase<BR>price</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with 6 Dimensions Capital</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">256,594</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with Bessemer Venture Partners</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">171,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with GV</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">102,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Longwood Fund IV, L.P.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">171,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Novartis Bioventures Ltd.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">273,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with Pitango Healthtech</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">256,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with Baker Bros. Advisors LP</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,960,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">46,308,065</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">JMD III Holdings Limited</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,282,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">15,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #32406b;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">See &#147;Principal Stockholders&#148; for additional information about shares held by
these entities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Agreements With Stockholders </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Investors&#146; Rights Agreement </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In connection with the sale of our Series C convertible preferred stock, we entered into an amended and restated
investors&#146; rights agreement with certain investors, including entities affiliated with 6 Dimensions Capital, Bessemer Venture Partners, entities affiliated with GV, Longwood Fund IV, L.P., Novartis Bioventures Ltd., Pitango Healthtech, entities
affiliated with Baker Bros. Advisors LP, and JMD III Holdings Limited and including entities with which certain of our directors are affiliated. Under our investors&#146; rights agreement, certain holders of our capital stock have the right to
demand that we file a registration statement or request that their shares of our capital stock be covered by a registration statement that we are otherwise filing. See the section titled &#147;Description of capital stock&#151;Registration
rights&#148; elsewhere in this prospectus for additional information regarding these registration rights. Other customary investor rights under this agreement, including rights of information, observation and first refusal, will terminate
immediately before the consummation of this offering. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Voting Agreement </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In connection with the sale of our Series C convertible preferred stock, we entered into an amended and restated voting
agreement with certain investors, including entities affiliated with 6 Dimensions Capital, Bessemer Venture Partners, entities affiliated with GV, Longwood Fund IV, L.P., Novartis Bioventures Ltd., Pitango Healthtech, entities affiliated with Baker
Bros Advisors LP, and JMD III Holdings Limited and including entities with which certain of our directors are affiliated. Under our voting agreement, certain holders of our capital stock have agreed as to the manner in which they will vote their
shares of our capital stock on certain matters, including with respect to the election of directors. The voting agreement will terminate upon the completion of this offering, at which time there will be no further contractual obligations regarding
the manner in which shares are voted with respect to the election of our directors. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Right of First
Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In connection with the sale of
our Series C convertible preferred stock, we entered into an amended and restated first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement with certain investors, including entities affiliated with 6 Dimensions Capital, Bessemer
Venture Partners, entities affiliated with GV, Longwood Fund IV, L.P., Novartis Bioventures Ltd., Pitango Healthtech, entities affiliated with Baker Bros Advisors LP, and JMD III Holdings Limited and including entities with which certain of our
directors are affiliated. Under our first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement, certain holders of our capital stock have the right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> relating to the
shares of our common </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">198
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
stock held by the parties to the agreement. Upon the consummation of this offering our first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement will terminate. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>License Agreements </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Collaboration and License Agreement with Novartis </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On March&nbsp;27, 2020, we entered into a Collaboration and License Agreement, or the Novartis Agreement, with Novartis
Institutes for BioMedical Research, Inc., or Novartis. Pursuant to the Novartis Agreement, we have received an aggregate of $20.0 million of cash representing the one-time, non-refundable, non-contingent and non-creditable upfront payment and have
receivables for reimbursement of expenditures under the arrangement of $0.3 million as of December 31, 2020. We granted Novartis options to obtain exclusive, worldwide licenses to certain target antigens identified in performance of the Novartis
Agreement and corresponding <FONT STYLE="white-space:nowrap">T-cell</FONT> receptors for such target antigens. Novartis can exercise each option by paying us $10.0&nbsp;million and can exercise up to three options (each target antigen for which
Novartis exercises an option, or the Optioned Program. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For each Optioned Program, as between the parties
Novartis is solely responsible for the clinical development of such Option Program. Novartis is required to pay us up to an aggregate of $230.0&nbsp;million upon achievement of certain clinical milestones and milestones for the first commercial sale
in certain countries with respect to products directed to the corresponding target antigen for each Optioned Program. Novartis is also required to pay us up to an aggregate of $260.0&nbsp;million upon achievement of certain annual net sales
milestones for products directed to the corresponding target antigen for each Optioned Program. In addition, for each Optioned Program, Novartis is required to pay us, on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;product-by-product&nbsp;and&nbsp;country-by-country&nbsp;basis,</FONT></FONT></FONT></FONT> tiered royalties in the <FONT STYLE="white-space:nowrap">low-single-digit&nbsp;to</FONT> <FONT
STYLE="white-space:nowrap">mid-single-digit</FONT> percentage on Novartis&#146;, its affiliates&#146; and sublicensees&#146; net sales of certain products directed to target antigens for each Optioned Program and a percentage in the <FONT
STYLE="white-space:nowrap">mid-single-digits</FONT> to low-teens on Novartis&#146; net sales of products directed to such antigens and containing a <FONT STYLE="white-space:nowrap">T-cell</FONT> receptor we identified to Novartis in our performance
of the Novartis Agreement, subject to certain customary reductions. Royalties will be payable on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">and&nbsp;country-by-country&nbsp;basis</FONT></FONT> during the period of time commencing on the first commercial sale of an applicable product in a country and ending upon the later of: (a) 10 years from the date of first
commercial sale of such product in such country; (b)&nbsp;expiration of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;last-to-expire&nbsp;valid</FONT></FONT> claim of patents licensed by us to Novartis under the Novartis
Agreement covering the manufacture, use or sale of such product in such country; or (c)&nbsp;the expiration of any regulatory or marketing exclusivity in such country with respect to such product. Novartis may terminate the Novartis Agreement
entirely or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis at any time for convenience upon 90 days&#146; notice, but Novartis will be required to pay any payment obligations incurred
prior to termination. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Royalty Agreement </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In connection with our incorporation in April 2018 we entered into a royalty agreement with Christoph Westphal, M.D.,
Ph.D. who is one of our founders. We amended and restated this royalty agreement in June 2018 and our founder assigned his rights and obligations under the royalty agreement to one of his affiliated entities in January 2021. At the time the original
royalty agreement and the amended and restated version were executed, Dr. Westphal was our chief executive officer and the chairman of our board of directors. Pursuant to the royalty agreement, we are required to pay the aforementioned affiliated
entity a royalty of 1% of net sales (as defined in the royalty agreement) of any product sold by us or by any of our direct or indirect licensees for use in the treatment of any disease or disorder covered by a pending patent application or issued
patent held or controlled by us as of the last date that the founder was providing services to us as a director or consultant under a written agreement. Royalties are payable with respect to each applicable product for a defined period of time set
forth in the royalty agreement. We may not assign our rights and obligations under the royalty agreement except in the event of a change in control relating to our company. The term of the royalty agreement continues until expiration of the last
applicable royalty term. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">199
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Nominating Rights and Registration Rights Agreements with BBA Funds
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In connection with our Series C convertible preferred stock financing, we entered into a nominating
agreement with Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the &#147;BBA Funds&#148;) which was subsequently amended and restated on April&nbsp;22, 2021, pursuant to which, among other things, we agreed to support the nomination
of, and cause our board of directors (or the nominating committee thereof) to include in the slate of nominees recommended to our stockholders for election as directors at each annual or special meeting of our stockholders at which directors are to
be elected, one person designated from time to time by the BBA Funds, subject to the requirements of fiduciary duties under applicable law and the terms and conditions of such nominating agreement. The agreement only applies during the period
beginning at the closing of our initial public offering and for the three years thereafter, as long as (1)&nbsp;the BBA Funds and their affiliates, collectively, beneficially own at least 75% of the Series&nbsp;C convertible preferred stock
purchased by the BBA Funds in such Series&nbsp;C convertible preferred stock financing, or such number of shares of our common stock issued upon conversion of such number of shares of Series C convertible preferred stock (in either case, as adjusted
for any stock split, stock dividend, combination, or other recapitalization or reclassification or similar transaction), and (2)&nbsp;the BBA Funds and their affiliates, collectively, beneficially own at least 2% of our then outstanding voting
common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Also in connection with our Series C convertible preferred stock financing, we entered into a
Registration Rights Agreement with the BBA Funds, pursuant to which, among other things, we agreed to provide the BBA Funds with certain &#147;resale&#148; registration rights and related &#147;piggy-back&#148; rights. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additionally, we agreed to use commercially reasonable efforts to cause the underwriters of this offering to provide the
BBA Funds the opportunity to participate in this offering in an amount equal to such the BBA Funds&#146; pro rata share of an aggregate of at least 25% of the total number shares of common stock being offered by us, excluding in such calculation any
shares offered for sale pursuant to the underwriters&#146; option to purchase additional shares in connection with this offering. Despite our commercially reasonable efforts, the underwriters may, in their sole discretion, determine that the BBA
Funds&#146; participation in such proportion is not advisable and designate a reduced number of, or no, shares for purchase by the BBA Funds. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B>Equity Grants to Executive Officers and Directors </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have agreements with and have
granted stock options to certain of our executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, as more fully described in &#147;Executive compensation.&#148; </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Indemnification Agreements </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have entered, and intend to continue to enter, into separate indemnification agreements with each of our directors and
executive officers, in addition to the indemnification provided for in our restated certificate of incorporation and amended and restated bylaws. The indemnification agreements and our restated certificate of incorporation and amended and restated
bylaws that will be in effect upon the completion of this offering require us to indemnify our directors, executive officers and certain controlling persons to the fullest extent permitted by Delaware law. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Employment Agreements </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have entered into employment agreements with our executive officers. For more information regarding these agreements,
see the section entitled &#147;Executive compensation&#151;Employment agreements.&#148; </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Consulting and Other Agreements
With Our Directors </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have entered into consulting and other agreements with certain of our directors.
For more information regarding these agreements, see the section entitled &#147;Management&#151;Director compensation.&#148; </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">200
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Directed Share Program </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">At our request, the underwriters have reserved up to 333,333 shares, or up to 5% of the shares offered by this
prospectus, for sale at the initial public offering price through a directed share program to certain of our directors, officers, employees and business associates and other parties related to us. If purchased by these persons, these shares will be
subject to a <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction. Morgan Stanley &amp; Co. LLC will administer our directed share program. See the section titled
&#147;Underwriters&#151;Directed Share Program.&#148; </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Related Party Transaction Policy </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Effective upon the completion of this offering, we intend to adopt a formal written policy providing that we are not
permitted to enter into any transaction that exceeds $120,000 and in which any related person has a direct or indirect material interest without the consent of our audit committee. Our audit committee will have the primary responsibility for
reviewing and approving or disapproving such &#147;related party transactions.&#148; The charter of our audit committee will provide that our audit committee shall review and approve in advance any related party transaction. In approving or
rejecting any such transaction, our audit committee is to consider the relevant facts and circumstances available and deemed relevant to our audit committee, including whether the transaction is on terms no less favorable than terms generally
available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#146;s interest in the transaction. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">All of the transactions described in this section were entered into prior to the adoption of this policy. Although we
have not had a written policy for the review and approval of transactions with related persons, our board of directors has historically reviewed and approved any transaction where a director or officer had a financial interest, including the
transactions described above. Prior to approving such a transaction, the material facts as to relationship or interest of the relevant director, officer or holder of 5% or more of any class of our voting securities in the agreement or transaction
was disclosed to our board of directors. Our board of directors took this information into account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our stockholders.
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">201
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_15"></A>PRINCIPAL STOCKHOLDERS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table sets forth information with respect to the beneficial ownership of our capital stock as of July 1,
2021 and as adjusted to reflect the sale of common stock offered by us in this offering, for: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">each of the named executive officers; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">each of our directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">all of current our executive officers and directors as a group; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">each person, or group of affiliated persons, who is known by us to beneficially own more
than 5% of our common stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have determined beneficial ownership in accordance with
the rules of the SEC. Except as indicated in the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common
stock that they beneficially own, subject to applicable community property laws. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Applicable percentage
ownership is based on 17,299,057 shares of common stock outstanding as of July&nbsp;1, 2021, after giving effect to the conversion of all outstanding shares of preferred stock as of that date into an aggregate of 15,616,272 shares of our common
stock (including 5,139,633 shares of our non-voting common stock). For purposes of computing percentage ownership after this offering, we have assumed that (i)&nbsp;6,666,667 shares of common stock will be issued by us in this offering;
(ii)&nbsp;the underwriters will not exercise their option to purchase up to 1,000,000 additional shares of common stock and (iii)&nbsp;none of our executive officers, directors or stockholders who beneficially own more than five percent of our
common stock will participate in this offering. In computing the number of shares of common stock beneficially owned by a person or entity and the percentage ownership of that person or entity, we deemed to be outstanding all shares of common stock
subject to options held by that person or entity that are currently exercisable or that will become exercisable within 60&nbsp;days of July&nbsp;1, 2021. We did not deem these shares outstanding, however, such shares were included for the purpose of
computing the percentage ownership of any other person or entity. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table does not reflect any
shares of common stock that may be purchased in this offering pursuant to our directed share program described under &#147;Underwriters&#151;Directed Share Program.&#148; If any shares are purchased by our existing principal shareholders, directors,
executive officers or their affiliated entities, the number and percentage of shares beneficially owned by them after this offering will differ from those set forth in the following table. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Upon the closing of this offering, each outstanding share of our Series A convertible preferred stock Series&nbsp;B
convertible preferred stock and Series C convertible preferred stock, will automatically convert into shares of voting common stock in accordance with the provisions of our amended and restated certificate of incorporation, or our current charter,
with the exception of certain outstanding shares of our preferred stock owned by entities affiliated with or managed by Baker Brothers Life Sciences, L.P., 667, L.P., and Novartis Bioventures Ltd., which shares will automatically convert into an
aggregate of 5,139,633 shares of non-voting common stock. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">202
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Unless otherwise indicated, the address of each beneficial owner listed in
the table below is c/o&nbsp;TScan Therapeutics, Inc., 830&nbsp;Winter Street, Waltham, Massachusetts 02451. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares Beneficially Owned Prior to This<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares Beneficially Owned Following This<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Voting</B></FONT><br><FONT COLOR="#32406b"><B>Common Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Non-<BR>Voting<BR>Common<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>% of Total<BR>Outstanding<BR>Capital<BR>Stock Prior<BR>to This<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Voting Common<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Non-Voting<BR>Common Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>% of Total<BR>Outstanding<BR>Capital<BR>Stock<BR>Following<BR>This<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>%</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>%</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>%</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>%</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>5% stockholders:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with Baker Bros. Advisors LP<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,276,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">24.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">24.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,276,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">83.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">17.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with 6&nbsp;Dimensions Capital<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,563,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,563,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with Bessemer Venture Partners<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,145,504</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,145,504</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Longwood Fund IV,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,145,505</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,145,505</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Novartis Bioventures
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,802,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">10.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">10.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">916,101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">863,045</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">16.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">JMD III Holdings
Limited<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,282,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,282,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with
GV<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,077,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,077,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Entities affiliated with Pitango Healthtech Fund<SUP
STYLE="font-size:85%; vertical-align:top">(8)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">979,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">979,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Directors and named executive&nbsp;officers:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">David
Southwell<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">299,016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">299,016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Gavin MacBeath,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">74,523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">74,523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">William Desmarais</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Henry Rath</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Timothy
Barberich<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,585</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">58,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Andrew Hedin</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Nandita Shangari, Ph.D</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Ittai Harel</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Christoph Westphal, M.D.,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,182,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">12.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">12.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,182,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">11.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Brian Silver</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Katina Dorton</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stephen Biggar, M.D., Ph.D</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#32406b">All current executive officers and directors as a group (11&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(13)</SUP></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,615,214</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">14.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">14.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,615,214</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">13.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">10.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #32406b;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Represents beneficial ownership of less than one percent. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consists of (i) 315,777 shares of non-voting common stock held by 667, L.P. (667)&nbsp;and
(ii) 3,960,811 shares of non-voting common stock held by Baker Brothers Life Sciences, L.P. (Baker Life Sciences and together with 667, the BBA Funds). Baker Bros. Advisors LP, or BBA, is the management company and investment adviser to the BBA
Funds and has complete and unlimited discretion and authority with respect to the BBA Funds investments and voting power over investments. Baker Bros. Advisors (GP) LLC, or <FONT STYLE="white-space:nowrap">BBA-GP,</FONT> is the sole general partner
of BBA. The managing members of <FONT STYLE="white-space:nowrap">BBA-GP</FONT> are Julian C. Baker and Felix J. Baker. <FONT STYLE="white-space:nowrap">BBA-GP,</FONT> Felix J. Baker, Julian C. Baker and BBA may be deemed to be beneficial owners of
the securities directly held by the BBA Funds. The address for the above referenced entities is 860 Washington Street, 3rd Floor, New York, NY&nbsp;10014. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consists of (i) 1,485,450 shares of common stock held by 6 Dimensions Capital, L.P. and
(ii) 78,180 shares of common stock held by 6 Dimension Affiliates Fund, L.P. The general partner of each of 6 Dimensions Capital, L.P. and 6 Dimensions Affiliates Fund, L.P. is 6 Dimensions Capital, LLC, which is in turn ultimately controlled by
Dr.&nbsp;Chen Lian Yong (Leon). Wei Li, Ph.D., is an affiliate of 6 Dimensions Capital GP, LLC and a member of our board of directors. The address of 6 Dimensions Capital, L.P. and 6 Dimensions Affiliates Fund, L.P., is Unit 6706, 67/F, The Center,
99 Queen&#146;s Road Central, Central, Hong Kong. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consists of (i)&nbsp;635,985 shares of common stock held by Bessemer Venture
Partners&nbsp;IX L.P. (BVP&nbsp;IX) and (ii)&nbsp;509,520 shares of common stock held by Bessemer Venture Partners&nbsp;IX Institutional L.P. (BVP&nbsp;IX Institutional, and together with BVP&nbsp;IX, the BVP Entities). Deer&nbsp;IX&nbsp;&amp; Co.
L.P. (Deer&nbsp;IX L.P.) is the general partner of the BVP Entities. Deer&nbsp;IX&nbsp;&amp; Co. Ltd. (Deer&nbsp;IX Ltd.) is the general partner of Deer&nbsp;IX L.P. Robert P. Goodman, David J. Cowan, Byron&nbsp;B. Deeter, Jeremy&nbsp;S. Levine,
Robert&nbsp;M. Stavis and Adam Fisher are the directors of Deer&nbsp;IX Ltd. and hold the voting and dispositive power for the BVP Entities. Investment and voting decisions with respect to the shares held by the BVP Entities are made by the
directors of Deer&nbsp;IX Ltd. acting as an investment committee.<B> </B>Andrew </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">203
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">
Hedin disclaims beneficial ownership of the securities held by the BVP Entities, except to the extent of his pecuniary interest, if any, in such securities by virtue of his interest in the BVP
Entities.<B> </B>The address of each of these entities is c/o Bessemer Venture Partners, 1865&nbsp;Palmer Ave., Suite&nbsp;104, Larchmont, NY 10538. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">These shares of common stock are held by Longwood Fund IV, L.P. (Longwood). The general
partner of Longwood is Longwood Fund IV GP, LLC (Longwood GP). Longwood GP may be deemed to have sole voting and dispositive power over the shares held by Longwood. Each of Richard Aldrich and Christoph Westphal, M.D., Ph.D. are managers of Longwood
GP and may be deemed to share voting and dispositive power over of the shares held by Longwood. The address of Longwood and Longwood GP is 800 Boylston St., Suite&nbsp;1555, Boston, MA 02199. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consist of (i) 385,098 shares of common stock held by Novartis Bioventures Ltd., (ii)
863,045 shares of non-voting common stock by Novartis Bioventures Ltd., and (iii) 554,323 shares of common stock held by Novartis Institutes for BioMedical Research, Inc. (referred to as &#147;NIBR&#148;) (collectively referred to as the
&#147;Novartis Entities&#148;). Novartis Bioventures Ltd. is a Swiss corporation and an indirect wholly owned subsidiary of Novartis AG. NIBR is an indirect wholly owned subsidiary of, and controlled by, Novartis AG. As a result, Novartis
Bioventures Ltd. and Novartis AG may be deemed to have shared voting and investment power over the securities held by Novartis Bioventures Ltd. and NIBR and Novartis AG may be deemed to have shared voting and investment power over the securities
held by NIBR. The address for each of Novartis Bioventures Ltd. and Novartis AG is Lichtstrasse 35, CH-4056 Basel, Switzerland. The address for NIBR is 250 Massachusetts Avenue, Cambridge, MA 02139. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">These shares of common stock are held by JMD III Holdings Limited. JMD III Holdings
Limited is incorporated in the Cayman Islands and is wholly owned by Hillhouse Venture Fund V, L.P. Hillhouse Capital Management, Ltd. (&#147;HCM&#148;) acts as the sole management company of Hillhouse Venture Fund&nbsp;V, L.P. Mr.&nbsp;Lei Zhang
may be deemed to have controlling power over HCM. Mr.&nbsp;Lei Zhang disclaims beneficial ownership of all of the shares held by JMD&nbsp;III Holdings Limited, except to the extent of his pecuniary interest therein. The registered address of
JMD&nbsp;III Holdings Limited is 89&nbsp;Nexus Way, Camana Bay, P.O. Box&nbsp;31106, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-1205,</FONT> Cayman Islands. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consists of (i) 641,848 shares of common stock held by GV 2017, L.P. and (ii) 435,232
shares of common stock held by GV 2019, L.P. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the managing member of GV 2017 GP, L.L.C.), XXVI Holdings Inc.
(the managing member of Alphabet Holdings LLC) and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of the shares held directly by GV 2017, L.P. GV 2019 GP, L.P. (the general
partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the managing member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the managing member of Alphabet Holdings LLC) and Alphabet Inc. (the
controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of the shares held directly by GV 2019, L.P. The principal business address of GV 2017, L.P., GV 2017 GP, L.P., GV 2017 GP, L.L.C., GV 2019,
L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc. and Alphabet Inc. is 1600 Amphitheatre Parkway, Mountain View, CA 94043. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consists of (i) 952,682 shares are held of record by Pitango HealthTech Fund I, L.P., and
(ii) 20,499 shares held of record by Pitango HealthTech Principals Fund I, L.P; and (iii) 6,804 shares held of record by Pitango HealthTech Fund I &#150; Israel, L.P (collectively, the Pitango Entities). The Pitango Principals (as defined below)
possess shared voting and dispositive power with respect to all shares of common stock held by all Pitango Entities. The general partner of the Pitango Entities is Pitango HT Fund I, L.P (the GP). The general partner of the GP is Pitango GP Health
Holdings Ltd. (the GP of The GP). The partners in the GP are, either directly or via holding companies and intermediary entities formed for tax purposes, the following individuals: Guy Ezekiel, Ittai Harel, Aaron Mankovski, Zeev Binman, Isaac
Hillel, Eyal Nic, Nechemia (Chemi) Peres, Ayal Itzkovits and Rami Kalish (the Pitango Principals). The shareholder of the GP of the GP is the Pitango Entities&#146; management company, Pitango HealthTech Management 2019 Ltd. (the Management
Company). The Pitango Principals are the shareholders of the Management Company . The Pitango Principals therefore possess shared voting and dispositive power with respect to all shares of common stock held by all Pitango reporting persons. The
address for the above listed entities is 11 HaMenofim Street, Building B, Herzeliya 4672562, Israel. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consists of (i) 86,899 shares of common stock held by Mr.&nbsp;Southwell and (ii) 212,117
shares of common stock issuable upon exercise of outstanding stock options held by Mr.&nbsp;Southwell, which are exercisable within 60 days of July 1, 2021. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consists of (i) 44,767 shares of common stock held by Dr.&nbsp;MacBeath and (ii) 29,756
shares of common stock issuable upon exercise of outstanding stock options held by Dr.&nbsp;MacBeath, which are exercisable within 60 days of July 1, 2021. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consists of (i) 33,259 shares of common stock held by Mr. Barberich and (ii) 26,326 shares
of common stock issuable upon exercise of outstanding stock options held by Mr. Barberich, which are exercisable within 60 days of July 1, 2021. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consists of (i) 914,634 shares of common stock held by Dr. Westphal, (ii) 121,951 shares
of common stock held by Dr. Sylvia Westphal and (iii) the securities held by Longwood as set forth in footnote 4 above, for which Dr. Westphal may be deemed to share voting and investment power. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">Consists of (i) 2,347,015 shares of common stock and (ii) 268,199 shares of common stock
issuable upon exercise of outstanding stock options held by our current directors and executive officers, which are exercisable within 60 days of July&nbsp;1, 2021. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">204
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_16"></A>DESCRIPTION OF CAPITAL STOCK </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following descriptions of our capital stock and certain provisions of our amended and restated certificate of
incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws that will be in effect upon completion of this offering. A
description of our capital stock and the material terms and provisions of our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect upon the completion of this offering and affecting the rights of
holders of our capital stock is set forth below. The forms of our amended and restated certificate of incorporation and our amended and restated bylaws to be adopted in connection with this offering will be filed as exhibits to the registration
statement relating to this prospectus. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Upon the completion of this offering, our amended and restated
certificate of incorporation will authorize shares of undesignated preferred stock, the rights, preferences and privileges of which may be designated from time to time by our board of directors. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Upon the completion of this offering, our authorized capital stock will consist of 320,000,000 shares, all with a par
value of $0.0001 per share, of which: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">300,000,000 shares are designated common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">10,000,000 shares are designated non-voting common stock; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">10,000,000 shares are designated preferred stock. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of March&nbsp;31, 2021, after giving effect to the conversion of all outstanding shares of preferred stock, into an
aggregate of 15,616,272 shares of our common stock (including 5,139,633 shares of our non-voting common stock), there were outstanding: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">17,271,699 shares of our common stock held of record by 45 stockholders; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">2,525,506 shares of our common stock issuable upon exercise of outstanding stock options.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Common Stock and Non-Voting Common Stock </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The holders of our common stock and non-voting common stock have identical rights, provided that, (i)&nbsp;except as
otherwise expressly provided in our amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our common stock are entitled to one vote per share of
common stock, and holders of our non-voting common stock are not entitled to any votes per share of non-voting common stock, including for the election of directors, and (ii) holders of our common stock have no conversion rights, while holders of
our non-voting common stock shall have the right to convert each share of our non-voting common stock into one share of common stock at such holder&#146;s election, provided that as a result of such conversion, such holder, together with its
affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 4.99% of our common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in our amended
and restated certificate of incorporation. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of non-voting common stock upon 61 days&#146; notice to us. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Dividend Rights </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding
shares of our common stock and non-voting common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that
our board of directors may determine. See &#147;Dividend policy&#148; for more information. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">205
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Voting Rights </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The holders of our common stock are entitled to one vote per share. Stockholders do not have the ability to cumulate
votes for the election of directors. Our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect upon the completion of this offering will provide for a classified board of directors consisting of
three classes of approximately equal size, each serving staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective
three-year terms. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>No Preemptive or Similar Rights </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our common stock and non-voting common stock are not entitled to preemptive rights and are not subject to conversion,
redemption or sinking fund provisions. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Right to Receive Liquidation Distributions </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Upon our dissolution, liquidation <FONT STYLE="white-space:nowrap">or&nbsp;winding-up,&nbsp;the</FONT> assets legally
available for distribution to our stockholders are distributable ratably among the holders of our common stock and non-voting common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment
of liquidation preferences, if any, on any outstanding shares of preferred stock. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Preferred Stock </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Upon the completion of this offering, no shares of preferred stock will be outstanding, but we will be authorized,
subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the
shares of each series and any associated qualifications, limitations or restrictions. Our board of directors also can increase or decrease the number of shares of any series, but not below the number of shares of that series then outstanding,
without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common
stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our
company and may adversely affect the market price of our common stock and the voting and other rights of the holders of common stock. We have no current plan to issue any shares of preferred stock. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Options </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">As of March&nbsp;31, 2021, there were options to purchase 2,525,506 shares of our common stock outstanding, at a weighted average exercise price of $4.98 per share, of which 411,959 were vested and exercisable as of that date. All
of such options were granted under our 2018 Plan. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Registration Rights </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Following the completion of this offering, the holders of 15,616,272 shares of our common stock (including 5,139,633
shares of non-voting common stock) issued upon the conversion of our preferred stock will be entitled to contractual rights to require us to register those shares under the Securities Act. These registration rights are provided under the terms of
our amended and restated investors&#146; rights agreement between us and the holders of these shares, which we entered into on January&nbsp;15, 2021. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We will pay all expenses relating to any demand or piggyback registration described below, other than underwriting
discounts and commissions. The registration rights terminate upon the earliest to occur of: (i)&nbsp;the </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">206
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
fifth anniversary of the completion of this offering; (ii)&nbsp;a liquidation event; or (iii)&nbsp;with respect to the registration rights of an individual holder, such time after consummation of
this offering as Rule&nbsp;144 or another similar exemption under the Securities Act is available for the sale of all of such holder&#146;s shares without limitation during a three-month period. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Demand Registration Rights </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The holders of the registrable securities will be entitled to certain demand registration rights. At any time beginning
180&nbsp;days following the effectiveness of this offering, the holders of 35% or more of the registrable securities then outstanding may make a written request that we register at least 35% of the registrable securities (or a lesser percent if the
anticipated aggregate offering price, net of selling expenses, would exceed $10&nbsp;million) some or all of their registrable securities, subject to certain specified conditions and exceptions. We are required to use commercially reasonable efforts
to effect the registration and will pay all registration expenses, other than underwriting discounts and commissions, related to any demand registration. We are not obligated to effect more than two of these registrations. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Piggyback Registration Rights </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In connection with this offering, holders of our registrable securities were entitled to, and the necessary percentage of
holders waived, their rights to notice of this offering and to include their registrable securities in this offering. If we propose to register any of our securities under the Securities Act either for our own account or for the account of other
stockholders in another offering, the holders of shares having registration rights will, subject to certain exceptions, be entitled to include their shares in our registration statement, provided that the underwriters of any such offering have the
right to limit the number of shares included in the registration. These registration rights are subject to specified other conditions and limitations as set forth in our amended and restated investors&#146; rights agreement. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I><FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;Registration</FONT> Rights </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">At any time after we are qualified to file a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3,&nbsp;and</FONT> subject to limitations and conditions specified in the amended and restated investors&#146; rights agreement, the holders of registrable securities then outstanding may make a written
request that we prepare and file a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;under</FONT> the Securities Act covering their shares, so long as the aggregate price to the public is at least $3,000,000. We are not
obligated to effect more than two of these <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;registrations</FONT> in <FONT STYLE="white-space:nowrap">any&nbsp;12-month&nbsp;period.</FONT> Such holders will pay pro rata all expenses related to
filing a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3.</FONT> </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Anti-Takeover Provisions
</B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Delaware Law </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Upon the completion of this offering, we will be governed by the provisions of Section&nbsp;203 of the Delaware General
Corporation Law regulating corporate takeovers. This section prevents some Delaware corporations from engaging, under some circumstances, in a business combination, which includes a merger or sale of at least 10% of the corporation&#146;s assets
with any interested stockholder, meaning a stockholder who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of the corporation&#146;s outstanding
voting stock, unless: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the transaction is approved by the board of directors prior to the time that the interested
stockholder became an interested stockholder; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">upon closing of the transaction that resulted in the stockholder becoming an interested
stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">207
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">
transaction began, excluding for purposes of determining the voting stock outstanding those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans
in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">subsequent to such time that the stockholder became an interested stockholder the business
combination is approved by the board of directors and authorized at an annual or special meeting of stockholders by at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested
stockholder. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A Delaware corporation may &#147;opt out&#148; of these provisions with an
express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or amended and restated bylaws resulting from a stockholders&#146; amendment approved by at least a majority of the
outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Certificate of Incorporation and Bylaw Provisions </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Upon the completion of this offering, our amended and restated certificate of incorporation and our amended and restated
bylaws will include a number of provisions that may have the effect of deterring hostile takeovers or delaying or preventing changes in control of our management team, including the following: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Board of Directors Vacancies</I>. Our amended and restated certificate of incorporation
and amended and restated bylaws will authorize our board of directors to fill vacant directorships, including newly-created seats. In addition, the number of directors constituting our board of directors will be set only by resolution adopted by a
majority vote of our entire board of directors. These provisions will prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Classified Board</I>. Our amended and restated certificate of incorporation and amended
and restated bylaws will provide that our board of directors will be classified into three classes of directors, each of which will hold office for a three-year term. In addition, directors may only be removed from the board of directors for cause
and only by the approval of 66 2/3% of our then-outstanding shares of our common stock. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for
stockholders to replace a majority of the directors on a classified board of directors. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Stockholder Action; Special Meeting of Stockholders</I>. Our amended and restated
certificate of incorporation will provide that stockholders will not be able to take action by written consent, and will only be able to take action at annual or special meetings of our stockholders. Stockholders will not be permitted to cumulate
their votes for the election of directors. Our amended and restated bylaws will further provide that special meetings of our stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors
or our chief executive officer. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations.</I> Our
amended and restated bylaws will provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at any meeting of stockholders. Our amended
and restated bylaws will also specify certain requirements regarding the form and content of a stockholder&#146;s notice. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making
nominations for directors at our meetings of stockholders. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><I>Issuance of Undesignated Preferred Stock</I>. Our board of directors will have, the
authority, without further action by the holders of common stock, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">208
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">
the board of directors. The existence of authorized but unissued shares of preferred stock will enable our board of directors to render more difficult or discourage an attempt to obtain control
of us by means of a merger, tender offer, proxy contest or otherwise. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Choice of Forum </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Upon the completion of this offering, our amended and restated certificate of incorporation will provide that the Court
of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware
General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim against us that is governed by the internal affairs doctrine. This provision would not apply to claims
brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our amended and restated certificate of incorporation provides further that the federal district courts
of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These choices of forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum
that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#146; certificates of
incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are
facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive-forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other
jurisdictions. If a court were to find the exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such
action in other jurisdictions, which could harm our business. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Transfer Agent and Registrar </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The transfer agent and registrar for our common stock is Computershare Inc. The transfer agent&#146;s address is
150&nbsp;Royall Street, Canton, Massachusetts 02021, and its telephone number is (800) 942-5909. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Listing </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have been approved to list our common stock on The Nasdaq Global Market under the symbol &#147;TCRX.&#148; </FONT></P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">209
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_17"></A>SHARES ELIGIBLE FOR FUTURE SALE
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Before this offering, there has not been a public market for shares of our common stock and a liquid
trading market for our common stock may not develop or be sustained after this offering. Future sales of substantial amounts of shares of our common stock, including shares issued upon the exercise of outstanding options, in the public market
following this offering or the possibility of these sales occurring, could cause the prevailing market price for our common stock to fall or impair our ability to raise equity capital through sales of equity securities in the future. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Following this offering, we will have outstanding 23,938,366 shares of our common stock, based on the number of shares
outstanding as of March&nbsp;31, 2021, after giving effect to the automatic conversion of all outstanding shares of our preferred stock, into an aggregate of 15,616,272 shares of common stock (including 5,139,633 shares of our non-voting common
stock) upon the completion of this offering. This includes 6,666,667 shares of common stock that we are selling in this offering, which shares may be resold in the public market immediately unless purchased by our affiliates and assuming no
additional exercise of outstanding options other than as described elsewhere in this prospectus and the conversion of all outstanding shares of our preferred stock into an aggregate of 15,616,272 shares of our common stock upon the closing of this
offering. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Of these shares, all shares sold in this offering will be freely tradable without restriction
under the Securities Act, unless purchased by our &#147;affiliates,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act. The remaining shares of common stock that are not sold in this offering, will be &#147;restricted
securities,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act, and we expect that substantially all of these restricted securities will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below. These restricted securities are eligible for public sale only if they are registered under the Securities Act
or if they qualify for an exemption from registration under Rule 144 or Rule 701 under the Securities Act, which are summarized below. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, we, our executive officers and directors, and substantially all of our security holders have entered into
market standoff agreements with us or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters under which they have agreed, subject to specific exceptions, not to sell any of our capital stock until at least 180 days after
the date of this prospectus, as described below. As a result of these agreements and the provisions of our investors&#146; rights agreement disclosed in &#147;Description of capital stock&#151;Registration rights,&#148; subject to the provisions of
Rule&nbsp;144 or Rule&nbsp;701, 23,938,366 shares will be available for sale in the public market as follows: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">beginning on the date of this prospectus, the 6,666,667 shares sold in this offering will
be immediately available for sale in the public market, unless purchased by our affiliates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">beginning 181 days after the date of this prospectus, 17,271,699 additional shares will
become eligible for sale in the public market, of which 8,426,069 shares will be held by affiliates and subject to the volume and other restrictions of Rule&nbsp;144, as described below; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the remainder of the shares will be eligible for sale in the public market from time to
time thereafter, subject in some cases to the volume and other restrictions of Rule&nbsp;144, as described below. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We cannot estimate the number of shares of our common stock that our existing stockholders will elect to sell under Rule
144. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Rule 144 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In general, under Rule 144 as currently in effect, a person who has beneficially owned shares of our restricted common
stock for at least six months would be entitled to sell their securities provided that such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale, and we are subject to the
periodic reporting requirements of the Exchange Act, for at least 90 days before the sale. In addition, under Rule&nbsp;144, any person who is not an affiliate of ours and has held their shares for at least
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">210
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the completion of this
offering without regard to whether current public information about us is available. Persons who have beneficially owned shares of our restricted common stock for at least six months but who are our affiliates at the time of, or any time during the
90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">1% of the number of shares of our capital stock then outstanding, which will equal 239,383
shares immediately after the completion of this offering, assuming no exercise by the underwriters of their option to purchase additional shares; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the average weekly trading volume of our common stock on Nasdaq during the four calendar
weeks preceding the filing of a notice on Form&nbsp;144 with respect to such sale. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">provided, in each case,
that we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale,
current public information and notice provisions of Rule&nbsp;144. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Rule 701 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any of our employees, directors, officers, consultants, advisors or service providers, other than a person who is deemed
to have been one of our affiliates during the immediately preceding 90 days, who purchased shares under a written compensatory plan or contract prior to this offering may be entitled to rely on the resale provisions of Rule&nbsp;701. Rule&nbsp;701,
as currently in effect, permits resales of shares, in reliance upon Rule&nbsp;144 but without compliance with certain restrictions, including the holding period requirement, of Rule&nbsp;144. Rule&nbsp;701 further provides that <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> may sell such shares in reliance on Rule&nbsp;144 without having to comply with the public information, volume limitation or notice provisions of Rule&nbsp;144. All holders of Rule&nbsp;701 shares are
required to wait until 90 days after the date of this prospectus before selling such shares if such resale is pursuant to Rule&nbsp;701. All Rule&nbsp;701 shares are, however, subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and
will only become eligible for sale upon the expiration of these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In connection with this offering, we and all directors and officers and the holders of substantially all of our
outstanding stock and stock options have agreed with the underwriters, subject to certain exceptions, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, shares of our common stock or any securities convertible into or exchangeable for shares of our common stock or enter into any swap or other arrangement
that transfers to another any of the economic consequences of ownership of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written
consent of Morgan Stanley &amp; Co. LLC, Jefferies LLC, Cowen and Company, LLC, and Barclays Capital Inc. These agreements are subject to certain exceptions, as set forth in &#147;Underwriters.&#148; </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Certain of our employees, including our executive officers, and directors may enter into written trading plans that are
intended to comply with <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> under the Exchange Act. Sales under these trading plans would not be permitted until the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
relating to our initial public offering described above. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">211
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Registration Rights </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Under our amended and restated investors&#146; rights agreement, after the completion of this offering, the holders of up
to 15,616,272 shares of our common stock (including shares of non-voting common stock) will, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements referred to above, be entitled to certain rights, subject to certain conditions,
to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. The registration of these shares of our common stock under the Securities
Act would result in these shares becoming eligible for sale in the public market without restriction under the Securities Act immediately upon the effectiveness of such registration, subject to the Rule 144 limitations applicable to affiliates. See
the section titled &#147;Description of capital stock&#151;Registration rights&#148; for a description of these registration rights. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B>Equity Plans </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of March 31, 2021, we had outstanding options to purchase an
aggregate of 2,525,506 shares of our common stock under the 2018 Plan. Following this offering, we intend to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all of the shares of
our common stock subject to options outstanding or reserved for issuance under our equity plans. We expect to file this registration statement as soon as practicable after the completion of this offering. This registration statement will become
effective immediately upon filing, and shares covered by this registration statement will thereupon be eligible for sale in the public markets, subject to vesting restrictions, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described
above and Rule&nbsp;144 limitations applicable to affiliates. For a more complete discussion of our stock plans, see &#147;Executive compensation&#151;Equity plans.&#148; </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">212
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES
FOR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR COMMON STOCK </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following is a
general discussion of the material U.S. federal income tax considerations applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued
pursuant to this offering. For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock (other than an entity or arrangement that is treated as a partnership for U.S. federal
income tax purposes) that is not, for U.S. federal income tax purposes, any of the following: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">an individual citizen or resident of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a corporation (or other entity treated as a corporation for U.S. federal income tax
purposes) created or organized in the United States or under the laws of the United States, any state thereof or the District of Columbia; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">an estate, the income of which is includable in gross income for U.S. federal income tax
purposes regardless of its source; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">a trust if (i)&nbsp;a court within the United States is able to exercise primary
supervision over the administration of the trust and one or more &#147;U.S. persons,&#148; as defined under the Code, have the authority to control all substantial decisions of the trust or (ii)&nbsp;such trust has made a valid election to be
treated as a U.S. person for U.S. federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">This discussion is based on
current provisions of the Internal Revenue Code of 1986, as amended, or &#147;Code&#148;, existing, temporary and proposed Treasury Regulations promulgated thereunder, judicial opinions, published positions of the Internal Revenue Service, or
&#147;IRS&#148;, and other applicable authorities, all of which are subject to change or to differing interpretation, possibly with retroactive effect. This discussion assumes that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds
shares of our common stock as a capital asset (generally, property held for investment) for U.S. federal income tax purposes. This discussion does not address all aspects of U.S. federal income taxation that may be important to a particular <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances, nor does it address any aspects of the unearned income Medicare contribution tax pursuant to
the Health Care and Education Reconciliation Act of 2010, any U.S. gift taxes, any U.S. alternative minimum taxes or any state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes. This discussion may not apply, in whole or in part, to
particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders in light of their individual circumstances or to holders subject to special treatment under the U.S. federal income tax laws (such as insurance companies, <FONT
STYLE="white-space:nowrap">tax-exempt</FONT> organizations, financial institutions, brokers or dealers in securities, &#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148;
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders that hold our common stock as part of a straddle, conversion transaction or other integrated investment, holders who own, actually or constructively, more than 5% of our common stock, and
certain U.S. expatriates). </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If a partnership (or other entity or arrangement treated as a partnership for
U.S. federal income tax purposes) holds our common stock, the tax treatment of a partner therein will generally depend on the status of the partner and the activities of the partnership. Partners of a partnership holding our common stock should
consult their tax advisor as to the particular U.S. federal income tax consequences applicable to them. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>INVESTORS CONSIDERING THE PURCHASE OF OUR COMMON STOCK SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE
APPLICATION OF THE U.S. FEDERAL INCOME AND ESTATE TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE CONSEQUENCES OF <FONT STYLE="white-space:nowrap">NON-U.S.,</FONT> STATE, OR LOCAL LAWS AND TAX TREATIES. </B></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Dividends </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We do not expect to declare or make any distributions on our common stock in the foreseeable future. If we do pay dividends on shares of our common stock, however, such distributions will constitute dividends for U.S. federal income
tax purposes to the extent paid from our current or accumulated earnings and profits, as </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">213
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and
reduces, but not below zero, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s adjusted tax basis in shares of our common stock. Any excess will be treated as capital gain and such gain will be subject to the treatment described below
under &#147;&#151;Gain on sale or other disposition of common stock.&#148; Any such distributions will also be subject to the discussion below under &#147;&#151;Backup withholding and information reporting&#148; and &#147;&#151;Foreign account tax
compliance act.&#148; </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any dividend paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder on our
common stock that is not effectively connected with a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a trade or business in the United States will generally be subject to U.S. withholding tax at a 30% rate. The withholding
tax might apply at a reduced rate, however, under the terms of an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence. You should consult your own tax
advisors regarding your entitlement to benefits under a relevant income tax treaty. Generally, in order for the applicable withholding agent to withhold tax at a lower treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must
certify its entitlement to treaty benefits. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally can meet this certification requirement by providing an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate form (or any successor or substitute form thereof) to the applicable withholding agent. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder holds the stock through a financial institution or other agent acting on the holder&#146;s behalf, the holder will be required to provide appropriate documentation to the holder&#146;s agent. The holder&#146;s agent will then be required to
provide certification to the applicable withholding agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty, you may generally obtain a refund or
credit of any excess amounts withheld by filing an appropriate claim for a refund with the IRS in a timely manner. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Dividends received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that are effectively connected with a U.S. trade or business conducted by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, and if required
by an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence, are attributable to a permanent establishment maintained by the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, are not subject to U.S. withholding tax. To obtain this exemption, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must provide the applicable withholding agent
with an IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> properly certifying such exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same U.S. federal income tax rates applicable to U.S.
persons, net of certain deductions and credits. In addition to being taxed at U.S. federal income tax rates, dividends received by a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that are effectively connected with a U.S. trade
or business of the corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable tax treaty. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Gain on Sale or Other Disposition of Common Stock </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Subject to the discussion below under &#147;&#151;Backup withholding and information reporting&#148; and
&#147;&#151;Foreign account tax compliance act,&#148; <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders will generally not be subject to U.S. federal income tax on any gains realized on the sale, exchange or other disposition of our common
stock unless: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the gain (i)&nbsp;is effectively connected with the conduct by the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of a U.S. trade or business and (ii)&nbsp;if required by an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of
residence, is attributable to a permanent establishment maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States (in which case the special rules described below apply); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is an individual who is present
in the United States for 183 days or more in the taxable year of the sale, exchange or other disposition of our common stock, and certain other requirements are met (in which case the gain would be subject to a flat 30% tax, or such reduced rate as
may be specified by an applicable income tax treaty, which may be offset by U.S. source capital losses, even though the individual is not considered a resident of the United States); or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">the rules of the Foreign Investment in Real Property Tax Act, or FIRPTA, treat the gain as
effectively connected with a U.S. trade or business. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">214
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The FIRPTA rules may apply to a sale, exchange or other disposition of our
common stock if we are, or were within the shorter of the five-year period preceding the disposition and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, a U.S. real property holding corporation, or USRPHC. In
general, we would be a USRPHC if interests in U.S. real property comprised at least half of the value of our worldwide real property and our other assets held for use in a trade or business. We do not believe that we are a USRPHC and we do not
anticipate becoming one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will not be subject to U.S. federal income tax if
our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market, and such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder owned, actually and constructively, 5% or less of
our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period. If any gain from the sale, exchange or
other disposition of our common stock, (i)&nbsp;is effectively connected with a U.S. trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and (ii)&nbsp;if required by an applicable income tax treaty between the
United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence, is attributable to a permanent establishment maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States,
then the gain generally will be subject to U.S. federal income tax at the same rates applicable to U.S. persons, net of certain deductions and credits. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a corporation, under certain
circumstances, that portion of its earnings and profits that is effectively connected with its U.S. trade or business, subject to certain adjustments, generally would be subject also to a &#147;branch profits tax&#148; at a rate of 30% or such lower
rate as may be specified by an applicable income tax treaty. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Backup Withholding and Information Reporting </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The applicable withholding agent must report annually to the IRS and to each
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the amount of dividends paid to, and the tax withheld with respect to, each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder. These reporting requirements apply regardless of whether
withholding was reduced or eliminated by an applicable tax treaty. Copies of this information reporting may also be made available under the provisions of a specific tax treaty or agreement with the tax authorities in the country in which the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder will generally be subject to backup withholding for dividends on our common stock paid to such holder unless such holder certifies under penalties of perjury that, among other things, it is a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder (and the payer does not have actual knowledge or reason to know that such holder is a U.S. person) or otherwise establishes an exemption. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Information reporting and backup withholding generally are not required with respect to the amount of any proceeds from
the sale or other disposition of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder outside the United States through a foreign office of a foreign broker that does not have certain specified connections to the United
States. However, if a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder sells or otherwise disposes of its shares of common stock through a U.S. broker or the U.S. offices of a foreign broker, the broker will generally be required to report
the amount of proceeds paid to the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder to the IRS and impose backup withholding on that amount unless such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder provides appropriate certification
to the broker of its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (and the payer does not have actual knowledge or reason to know that such holder is a U.S. person) or otherwise establishes an exemption. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Backup withholding is not an additional income tax. Any amounts withheld under the backup withholding rules from a
payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally can be credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, or refunded, provided that the
required information is furnished to the IRS in a timely manner. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Foreign Account Tax Compliance Act </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Under the Foreign Account Tax Compliance Act, or FATCA, withholding tax of 30% applies to certain payments to foreign
financial institutions, investment funds and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons that fail to comply with certain information reporting and certification requirements pertaining to their direct and indirect
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">215
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
U.S. securityholders and/or U.S. accountholders and do not otherwise qualify for an exemption. Under applicable Treasury Regulations and IRS guidance, this withholding currently applies to
payments of dividends, if any, on, and, subject to the proposed Treasury Regulations discussed below, gross proceeds from the sale or other disposition of, our common stock. An intergovernmental agreement between the United States and a foreign
country may modify the requirements described in this paragraph. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">While, beginning on January&nbsp;1, 2019,
withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of our common stock, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers
generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Prospective investors are encouraged to consult with their own tax advisors regarding the possible implications of FATCA
on their investment in our common stock. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Federal Estate Tax </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Common stock we have issued that is owned (or treated as owned) by an individual who is not a citizen or a resident of
the United States (as defined for U.S. federal estate tax purposes) at the time of death will be included in the individual&#146;s gross estate for U.S. federal estate tax purposes unless an applicable estate or other tax treaty provides otherwise,
and therefore may be subject to U.S. federal estate tax. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>PROSPECTIVE INVESTORS SHOULD CONSULT THEIR OWN
TAX ADVISORS REGARDING THE POTENTIAL APPLICATION OF WITHHOLDING UNDER FATCA TO THEIR INVESTMENT IN OUR COMMON STOCK. THE PRECEDING DISCUSSION OF U.S. FEDERAL TAX CONSIDERATIONS IS FOR GENERAL INFORMATION PURPOSES ONLY. EACH PROSPECTIVE INVESTOR
SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, GIFT, ESTATE, STATE, LOCAL, AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE
CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </B></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">216
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_19"></A>UNDERWRITERS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the
underwriters named below, for whom Morgan Stanley&nbsp;&amp; Co. LLC, Jefferies LLC, Cowen and Company, LLC and Barclays Capital Inc. are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them the number of
shares indicated below: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><FONT COLOR="#32406b"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>Number&nbsp;of</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><FONT COLOR="#32406b"><B>Shares</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Morgan Stanley&nbsp;&amp; Co. LLC</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,733,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Jefferies LLC</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,800,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cowen and Company, LLC</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,466,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Barclays Capital Inc.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">666,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,666,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The underwriters and the representatives are collectively referred to as the
&#147;underwriters&#148; and the &#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides
that the obligations of the several underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The
underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146;
over-allotment option described below. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The underwriters initially propose to offer part of the shares of
common stock directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $0.63 per share under the public offering price. After the
initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up
to 1,000,000 additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may exercise this option solely for the purpose of covering
over-allotments, if any, made in connection with the offering of the shares of common stock offered by this prospectus. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about
the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of shares of common stock listed next to the names of all underwriters in the
preceding table. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table shows the per share and total public offering price, underwriting
discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional 1,000,000 shares of common stock. </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Per<BR>Share</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>No&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Full Exercise</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Public offering price</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">15.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">100,000,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">115,000,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Underwriting discounts and commissions to be paid by us</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,050,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Proceeds, before expenses, to us</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">13.95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">93,000,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">106,950,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The estimated offering expenses payable by us, exclusive of the underwriting discounts
and commissions, are approximately $2.9&nbsp;million. We have agreed to reimburse the underwriters for expense relating to clearance of this offering with the Financial Industry Regulatory Authority up to $45,000. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">217
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The underwriters have informed us that they do not intend sales to
discretionary accounts to exceed 5% of the total number of shares of common stock offered by them. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have
been approved to list our common stock on The Nasdaq Global Market under the trading symbol&nbsp;&#147;TCRX&#148;. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">We, our directors and our executive officers and the holders of substantially all of our outstanding stock and stock options have agreed that, without the prior written consent of the representatives on behalf of the underwriters,
we and they will not, and will not publicly disclose an intention to, during the period ending 180 days after the date of this prospectus (the restricted period): </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares
of common stock; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">enter into any swap or other arrangement that transfers to another, in whole or in part,
any of the economic consequences of ownership of the common stock, whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In addition, we and each such person agrees
that, without the prior written consent of the representatives on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares
of common stock or any security convertible into or exercisable or exchangeable for common stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">In relation to the Company, the restrictions described above do not apply to: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(a)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">the shares to be sold under the underwriting agreement: </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(b)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">the issuance by us of shares of common stock upon the exercise of an option or warrant, the settlement of restricted stock units or share value award, or the conversion of a convertible loan, note
or other security outstanding on the date hereof as described herein; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(c)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">the grant of options, restricted stock units, share value awards or any other type of equity award described herein pursuant to employee benefit plans in effect on the date hereof and described
herein, or the issuance of shares of common stock by us to employees, officers, directors, advisors or consultants of us pursuant to employee benefit plans in effect on the date hereof and described herein; provided that each recipient shall execute
and deliver to the representatives a lock-up letter in the form of this section; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(d)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">the filing by us of a registration statement on Form&nbsp;S-8 relating to issuance, vesting, exercise or settlement of equity awards granted or to be granted pursuant to any employee benefit plan
in effect on the date hereof and described herein; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(e)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">the issuance of or entry into an agreement to issue shares of common stock or any securities convertible into or exercisable or exchangeable for common stock in connection with one or more mergers,
acquisitions or securities, businesses, property or other assets, products or technologies, joint ventures, commercial relationships or other strategic corporate transactions or alliances; provided that the aggregate amount of common stock that we
may issue or agree to issue pursuant to this paragraph shall not exceed 5% of the total number of shares of our common stock issued and outstanding immediately following the completion of the transactions contemplated by the underwriting agreement
determined on a fully diluted basis, and provided further, that each recipient shall execute and deliver to the representatives a lock-up letter in the form of this section; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(f)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">facilitating the establishment of a trading plan on behalf of a shareholder, officer or
director of ours pursuant to Rule&nbsp;10b5-1 under the Exchange Act for the transfer of shares of common stock, provided that (i)&nbsp;such plan does not provide for the transfer of shares of common stock during the restricted
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">218
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">
period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by us regarding the establishment of such plan, such
announcement or filing shall include a statement to the effect that no transfer of shares of common stock may be made under such plan during the restricted period. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In relation to our directors and our executive officers and the holders of substantially all of our outstanding stock
and stock options, the restrictions described above do not apply to: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(a)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">transactions relating to shares of common stock or other such securities acquired in the offering, if the holder is not an officer or director, or in open market transactions after the completion
of the offering; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(b)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">transfers as a bona fide gift: </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(c)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">transfers or distributions to (1)&nbsp;direct or indirect limited partners, members, stockholders, or holders of similar equity interests, (2)&nbsp;to affiliates (as defined in Rule 405 under the
Securities Act), or (3) to any investment fund or other entity controlled or managed by certain holders and their affiliates: </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(d)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">transfers to any immediate family member (&#147;immediate family&#148; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin); </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(e)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">transfers or dispositions by will or intestacy; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(f)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">transfers or dispositions pursuant to a court order or a settlement agreement related to the distribution of assets in connection with the dissolution of a marriage or civil union;
</FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(g)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">transfers or dispositions to the Company in connection with the exercise or settlement of options, warrants or other rights to acquire shares of common stock or any security convertible into or
exercisable for shares of common stock in accordance with their terms (including the vesting or settlement of restricted stock units and including, in each case, by way of net exercise and/or to cover withholding tax obligations in connection with
such exercise, vesting or settlement) pursuant to an employee benefit plan, option, warrant or other right disclosed herein, provided that (i)&nbsp;any such shares issued upon exercise of such option, warrant, restricted stock unit or other right
shall be subject to the restrictions set forth in the lock-up agreement, and (ii)&nbsp;any filing under the Exchange Act reporting a reduction in beneficial ownership shall indicate in the footnotes thereto that the filing relates to the applicable
circumstances described in this clause, and no other public announcement shall be required or shall be made voluntarily in connection with such transfer; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(h)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act; provided that no sales or other transfers occur under such plan, provided that (i)&nbsp;such plan does not
provide for the transfer of common stock during the restricted period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company
regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such plan during the restricted period; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(i)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">any sale, disposal or transfer of shares of common stock to a bona fide third party
pursuant to a tender offer for securities of the Company or any merger, consolidation or other business combination involving a Change of Control (as defined below) of the Company occurring after the settlement of the offering, that, in each case,
has been approved by the board of directors of the Company; provided that (i)&nbsp;all of the shares of common stock subject to the lock-up agreement that are not so transferred, sold, tendered or otherwise disposed of remain subject to the
agreement; and (ii)&nbsp;that it shall be a condition of transfer, sale, tender or other disposition that if such tender offer or other transaction is not completed, any of the shares of common stock subject to the lock-up agreement shall remain
subject to the agreement. For the purposes of this paragraph, &#147;Change of Control&#148; means the consummation of any bona fide third party tender offer, merger, consolidation or other similar transaction, the result of which is that any
&#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, other than the Company or its subsidiaries, becomes the beneficial owner (as defined in Rules&nbsp;13d-3
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">219
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">
and 13d-5 of the Exchange Act) of at least 75% of the total voting power of the voting share capital of the Company; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(j)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">in the case of each of our major investors, the placement of any charge, mortgage, lien, pledge, restriction, security interest or other encumbrance in respect of any shares of common stock or any
securities convertible into or exercisable or exchangeable for shares of common stock in connection with bona fide margin loans entered into by the major investors or their affiliates in the ordinary course of business; provided, that (i)&nbsp;any
beneficiary of such transaction that forecloses or enforces following a default shall sign and deliver a lock up letter substantially in the form of this section, and (ii)&nbsp;no filing under the Exchange Act or other public announcement shall be
required or made voluntarily in connection with such pledge or subsequent foreclosure, enforcement or transfer of such shares or securities, subject to certain exceptions; </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">provided that in the case of any transfer or distribution pursuant to clauses (b), (c), (d), (e), or (f), each donee,
transferee, heir, beneficiary or distributee shall execute and deliver to the representatives a lock-up letter in the form of this section; provided further that in the case of any transfer or distribution pursuant to clauses (a), (b), (c) or (d),
no filing under the Exchange Act shall be required or shall be voluntarily made in connection with subsequent sales of shares of common stock or other securities acquired in such transactions; and provided further that in the case of any transfer or
distribution pursuant to clauses (e) or (f), any filing required under the Exchange Act shall indicate in the footnotes thereto that the filing relates to the circumstances described in the relevant clause and no other public announcement shall be
required or shall be made voluntarily in connection with such transfer, disposition or distribution. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The
representatives, in their sole discretion, may release the common stock and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize,
maintain or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short
position is no greater than the number of shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short sale by exercising the over-allotment option or purchasing shares in the open
market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the over-allotment option. The underwriters may
also sell shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this
offering, the underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels
or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the
Securities Act. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A prospectus in electronic format may be made available on websites maintained by one or
more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet
distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The underwriters and their respective affiliates are full service financial institutions engaged in various activities,
which may include securities trading, commercial and investment banking, financial advisory, </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">220
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time,
performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In addition, in the ordinary course of their various business activities, the underwriters and their respective
affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers
and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment
recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Pricing of the Offering </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Prior to this offering, there has been no public market for our common stock. The initial public offering price was
determined by negotiations between us and the representatives. Among the factors considered in determining the initial public offering price were our future prospects and those of our industry in general, our sales, earnings and certain other
financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Directed Share Program </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">At our request, the underwriters have reserved up to 333,333 shares, or up to 5% of the shares offered by this
prospectus, for sale at the initial public offering price through a directed share program to certain of our directors, officers, employees and business associates and other parties related to us. If purchased by these persons, these shares will be
subject to a <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">The number of shares available for sale to the general public will be reduced to the extent that such persons purchase such reserved shares. Any reserved shares not so purchased will be offered by the underwriters to the general
public on the same basis as the other shares offered by this prospectus. Other than the underwriting discount described on the front cover of this prospectus, the underwriters will not be entitled to any commission with respect to shares sold
pursuant to the directed share program. We will agree to indemnify Morgan Stanley&nbsp;&amp; Co. LLC against certain liabilities and expenses, including liabilities under the Securities Act, in connection with sales of the shares reserved for the
directed share program. Morgan Stanley&nbsp;&amp; Co. LLC will administer our directed share program. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Selling
Restrictions </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Canada </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The shares of our common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that
are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National <FONT
STYLE="white-space:nowrap">Instrument&nbsp;31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of our common stock must be made in accordance with an exemption from, or in a transaction
not subject to, the prospectus requirements of applicable securities laws. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Securities legislation in certain
provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised
by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable restrictions of the securities legislation of the purchaser&#146;s province
or territory for particulars of these rights or consult with a legal advisor. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">221
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Pursuant to section 3A.3 (or, in the case of securities issued or
guaranteed by the government of a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI
<FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>European Economic Area </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In relation to each Member State of the European Economic Area, each a Member State, no shares have been offered or will
be offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Member State or, where appropriate, approved in
another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Member State at any time under the following
exemptions under the Prospectus Regulation: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">a.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">b.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the representatives; or
</FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">c.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the
Prospectus Regulation or supplement a prospectus pursuant to Article&nbsp;23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to
and with each of the underwriters and us that it is a &#147;qualified investor&#148; within the meaning of Article&nbsp;2(e) of the Prospectus Regulation. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the case of any shares being offered to a financial intermediary as that term is used in the Prospectus Regulation,
each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor
have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Member State to qualified investors as so defined or in
circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer
and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129 (as amended). </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>United Kingdom </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In relation to the United Kingdom, no shares of common stock have been offered or will be offered pursuant to this
offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares that has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the Financial
Services and Markets Act 2000 (FSMA), except that offers of shares may be made to the public in the United Kingdom at any time under the following exemptions under the UK Prospectus Regulation and the FSMA: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">a.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">to any legal entity which is a qualified investor as defined in Article&nbsp;2 of the UK Prospectus Regulation; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">b.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">to fewer than 150 natural or legal persons (other than qualified investors as defined in Article&nbsp;2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the
representatives; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">c.</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">in any other circumstances falling within Section&nbsp;86 of the FSMA, </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">222
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">provided that no such offer of shares shall require us or any of the underwriters to
publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article&nbsp;23 of the UK Prospectus Regulation. Each person in the United Kingdom who acquires any shares in the offering or to whom any offer is
made will be deemed to have represented, acknowledged and agreed to and with us and the underwriters that it is a qualified investor within the meaning of the UK Prospectus Regulation. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares in any
relevant state means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression
&#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have not authorized and do not authorize the making of any offer of shares through any financial intermediary on
their behalf, other than offers made by the underwriters with a view to the final placement of the shares as contemplated in this prospectus. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further
offer of the shares on behalf of us or the underwriters. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Any person in the United Kingdom that is not a
relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively
by relevant persons. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Japan </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">No registration pursuant to Article&nbsp;4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law
No.&nbsp;25 of 1948, as amended) (the FIEL) has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common stock. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accordingly, the shares of common stock have not been, directly or indirectly, offered or sold and will not be, directly
or indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or <FONT STYLE="white-space:nowrap">re-sale,</FONT> directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration
requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><I>For Qualified Institutional Investors (QII) </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Please note that the solicitation for
newly-issued or secondary securities (each as described in Paragraph&nbsp;2, Article&nbsp;4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary
distribution&#148; (each as described in Paragraph 1, <FONT STYLE="white-space:nowrap">Article&nbsp;23-13</FONT> of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article&nbsp;4 of the FIEL, has not
been made in relation to the shares of common stock.&nbsp;The shares of common stock may only be transferred to QIIs. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><I>For <FONT STYLE="white-space:nowrap">Non-QII</FONT> Investors </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Please note that the
solicitation for newly-issued or secondary securities (each as described in Paragraph&nbsp;2, Article&nbsp;4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;small number private placement&#148; or a &#147;small
number private secondary distribution&#148; (each as is described in Paragraph 4, Article <FONT STYLE="white-space:nowrap">23-13</FONT> of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of
the FIEL, has not been made in relation to the shares of common stock.&nbsp;The shares of common stock may only be transferred en bloc without subdivision to a single investor. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Singapore </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this
prospectus and any other document or material in connection with the offer or sale, or </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">223
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
invitation for subscription or purchase, of the shares of common stock may not be circulated or distributed, nor may the shares of common stock be offered or sold, or be made the subject of an
invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the SFA),
(ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance
with the conditions of, any other applicable provision of the SFA. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Where the shares of common stock are
subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(a)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by
one or more individuals, each of whom is an accredited investor; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><FONT COLOR="#32406b">(b)</FONT></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT COLOR="#32406b">a trust (where the trustee is not an accredited investor) the sole purpose of which is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,
securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has
acquired the shares of common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">i.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of
the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">ii.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">where no consideration is or will be given for the transfer;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">iii.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">where the transfer is by operation of law; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">iv.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">as specified in Section&nbsp;276(7) of the SFA; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">v.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">as specified in Regulation 32 of the Securities and Futures (Offers of Investments)
(Shares and Debentures) Regulations 2005 of Singapore. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Kuwait </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Unless all necessary approvals from the Kuwait Ministry of Commerce and Industry required by Law No.&nbsp;31/1990
&#147;Regulating the Negotiation of Securities and Establishment of Investment Funds,&#148; its Executive Regulations and the various Ministerial Orders issued pursuant thereto or in connection therewith, have been given in relation to the marketing
and sale of the shares, these may not be marketed, offered for sale, nor sold in the State of Kuwait. Neither this prospectus (including any related document), nor any of the information contained therein is intended to lead to the conclusion of any
contract of whatsoever nature within Kuwait. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Dubai International Financial Center </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial
Services Authority (DFSA). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility
for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this
prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should
consult an authorized financial advisor. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>China </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">This prospectus may not be circulated or distributed in the People&#146;s Republic of China (PRC) and the ADSs may not be
offered or sold, and will not offer or sell to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any resident of the PRC except pursuant to applicable laws and regulations of the PRC. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">224
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Saudi Arabia </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">This prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the
Offers of Securities Regulations issued by the Capital Market Authority. The Capital Market Authority does not make any representation as to the accuracy or completeness of this prospectus, and expressly disclaims any liability whatsoever for any
loss arising from, or incurred in reliance upon, any part of this prospectus. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not
understand the contents of this prospectus you should consult an authorized financial adviser. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Qatar
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the State of Qatar, the offer contained herein is made on an exclusive basis to the specifically
intended recipient thereof, upon that person&#146;s request and initiative, for personal use only and shall in no way be construed as a general offer for the sale of securities to the public or an attempt to do business as a bank, an investment
company or otherwise in the State of Qatar. This prospectus and the underlying securities have not been approved or licensed by the Qatar Central Bank or the Qatar Financial Center Regulatory Authority or any other regulator in the State of Qatar.
The information contained in this prospectus shall only be shared with any third parties in Qatar on a need to know basis for the purpose of evaluating the contained offer. Any distribution of this prospectus by the recipient to third parties in
Qatar beyond the terms hereof is not permitted and shall be at the liability of such recipient. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Israel
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The shares of our common stock have not been approved or disapproved by the Israel Securities
Authority (the ISA), nor have such shares been registered for sale in Israel. The shares of our common stock may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus that has been approved
by the ISA. The ISA has not issued permits, approvals or licenses in connection with this offering or publishing this prospectus, nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an
opinion as to the quality of the shares of common stock being offered. This document does not constitute a prospectus under the Israeli Securities Law and has not been filed with or approved by the ISA. In the State of Israel, this document may be
distributed only to, and may be directed only at, and any offer of the shares common stock may be directed only at, (i)&nbsp;to the extent applicable, a limited number of persons in accordance with the Israeli Securities Law and (ii)&nbsp;investors
listed in the first addendum to the Israeli Securities Law, or the Addendum, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock
Exchange Ltd., underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as
qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written
confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Hong Kong </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">No securities have been offered or sold, and no securities may be
offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance (Cap. 571) of Hong Kong (SFO) and any rules made under that Ordinance; or in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong (CO)
or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for
the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">225
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made under that Ordinance. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to
members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus
and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Switzerland </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (SIX) or on any
other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material
relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Neither this prospectus nor any other offering or marketing material relating to the offering, the Company or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this
prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on
Collective Investment Schemes (CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">226
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_20"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The validity of the shares of our common stock offered in this prospectus will be passed upon for us by Gunderson Dettmer Stough
Villeneuve Franklin&nbsp;&amp; Hachigian, LLP, Boston, Massachusetts. Certain investment partnerships comprised of partners of Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP, own an interest representing less than one percent
of the shares of our common stock. Davis Polk&nbsp;&amp; Wardwell LLP, New York, New York, has acted as counsel for the underwriters in connection with this offering. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_21"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The financial statements as of December&nbsp;31, 2020 and 2019 and for the years then ended included in this prospectus have been
audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements have been so included in reliance upon the report of such firm given upon their
authority as experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_22"></A>WHERE YOU CAN FIND ADDITIONAL
INFORMATION </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT>
under the Securities Act, with respect to the shares of common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement
or the exhibits, schedules and amendments to the registration statement. Please refer to the registration statement and to the exhibits and schedules for further information with respect to the common stock offered by this prospectus. Statements
contained in this prospectus regarding the contents of any contract, agreement or other document are only summaries. With respect to any contract, agreement or document that is filed as an exhibit to the registration statement, you should refer to
the exhibit for a copy of the contract, agreement or document, and each statement in this prospectus regarding that contract, agreement or document is qualified by reference to the exhibit. The SEC maintains an Internet website that contains the
registration statement of which this prospectus forms a part, as well as the exhibits thereto. These documents, along with future reports, proxy statements and other information about us, are available at the SEC&#146;s website, www.sec.gov. The
information on the SEC&#146;s web site is not part of this prospectus, and any references to this web site or any other web site are inactive textual references only. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We are subject to the information and reporting requirements of the Exchange Act, and, in accordance with this law, are required to file
periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be available on the SEC&#146;s website referred to above. We also maintain a website at www.tscan.com, at
which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that can be accessed through, our website is not a part of
this prospectus. Investors should not rely on any such information in deciding whether to purchase our common stock. We have included our website address in this prospectus solely as an inactive textual reference. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">227
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="index"></A>TSCAN THERAPEUTICS, INC. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="rom107876_23"></A>INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Audited Financial Statements</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_1">Report of Independent Registered Public Accounting Firm
</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_2">Consolidated Balance Sheets</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_3">Consolidated Statements of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_4">Consolidated Statements of Convertible Preferred Stock
 and Stockholders&#146; Deficit</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_5">Consolidated Statements of Cash
Flows</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_6">Notes to Consolidated Financial
Statements</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Unaudited Condensed Consolidated Interim Financial
Statements</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_7">Condensed Consolidated Balance
Sheets</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_8">Condensed Consolidated Statements of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_9">Condensed Consolidated Statements of Convertible Preferred
 Stock and Stockholders&#146; Deficit</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_10">Condensed Consolidated Statements of Cash
Flows</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><A HREF="#fin107876_11">Notes to Condensed Consolidated Financial Statements
</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">F-30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-1
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">To the stockholders and Board of Directors of TScan Therapeutics, Inc. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Opinion on the Financial Statements </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have audited the accompanying consolidated balance sheets of TScan Therapeutics, Inc. and its subsidiary (the Company)
as of December&nbsp;31, 2019 and 2020, the related consolidated statements of operations, convertible preferred stock and stockholders&#146; deficit, and cash flows, for the years then ended, and the related notes (collectively referred to as the
financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2019 and 2020, and the results of its operations and its cash flows for the years
then ended, in conformity with accounting principles generally accepted in the United States of America. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Basis for
Opinion </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">These financial statements are the responsibility of the Company&#146;s management. Our
responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulation of the Securities and Exchange Commission and the PCAOB. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control
over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control
over financial reporting. Accordingly, we express no such opinion. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our
audits provide a reasonable basis for our opinion. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT COLOR="#32406b">/s/ Deloitte&nbsp;&amp; Touche&nbsp;LLP</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Boston, Massachusetts</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">March 19, 2021 (May 14, 2021, as to the effects of the reverse stock split discussed in Note 14)</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">We have served as the Company&#146;s auditor since 2020. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-2
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TScan Therapeutics, Inc. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_2"></A>Consolidated Balance Sheets </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands, except share and per share data) </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Current assets:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">41,764</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">34,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total current assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">42,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">36,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Right-of-use assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,769</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Long-term deposit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">49,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">49,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146;
Deficit</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating lease liability, current portion</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred revenue, current portion</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">10,627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,396</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">17,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred revenue, net of current portion</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating lease liability, net of current portion</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">32,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Commitments and contingencies (Note&nbsp;10)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Convertible preferred stock (Note 6)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stockholders&#146; deficit:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Common stock, $0.0001 par value; 86,000,000 shares authorized; 1,466,082 and
1,574,138 shares issued; and 642,903 and 1,135,858 shares outstanding as of December&nbsp;31, 2019 and 2020, respectively</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(17,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(43,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(17,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(42,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total liabilities, convertible preferred stock and stockholders&#146;
deficit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">49,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">49,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>The accompanying notes are an integral part of these consolidated financial statements
</I></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-3
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TScan Therapeutics, Inc. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_3"></A>Consolidated Statements of Operations </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands, except share and per share data) </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Revenue:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Collaboration and license revenue</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"> &#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"> 1,085</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">20,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">General and administrative</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,741</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">14,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">27,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(14,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(26,233</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other income:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Interest income</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(13,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(26,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(35.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(28.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Weighted average common shares outstanding, basic and
diluted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">385,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">916,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>The accompanying notes are an integral part of these consolidated financial statements
</I></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-4
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TScan Therapeutics, Inc. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_4"></A>Consolidated Statements of Convertible Preferred Stock and&nbsp;Stockholders&#146; Deficit
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands, except share and per share data) </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Convertible</B></FONT><br><FONT COLOR="#32406b"><B>Preferred Stock</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Common Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Additional</B></FONT><br><FONT COLOR="#32406b"><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B></FONT><br><FONT
 COLOR="#32406b"><B>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Accumulated</B></FONT><br><FONT COLOR="#32406b"><B>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total</B></FONT><br><FONT COLOR="#32406b"><B>Stockholders&#146;</B></FONT><br><FONT COLOR="#32406b"><B>Deficit</B></FONT></TD>

<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Balance at January&nbsp;1, 2019</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">24,874</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">68,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"> 23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(3,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(3,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Issuance of Series&nbsp;B Preferred Stock (net of issuance costs of
$193)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">34,807</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Issuance of common stock upon exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Vesting of restricted common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">571,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(13,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(13,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Balances at December&nbsp;31, 2019</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">642,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(17,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(17,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Issuance of common stock upon exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">142,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">287</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Vesting of restricted common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">350,606</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">515</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">515</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(26,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(26,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Balances at December&nbsp;31, 2020</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,135,858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"> 1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(43,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(42,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>The accompanying notes are an integral part of these consolidated financial statements
</I></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-5
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TScan Therapeutics, Inc. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_5"></A>Consolidated Statements of Cash Flows </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands) </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Cash flows from operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(13,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(26,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Adjustment to reconcile net loss to net cash used in operating
activities:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Depreciation expense</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap">Stock-based</FONT> compensation
expense</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">515</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Loss on sale of property and equipment</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Changes in current assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Prepaid expenses and other assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets and lease liabilities, net</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued expense and other liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">19,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(12,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(3,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Purchases of property and equipment</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(4,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,247</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(4,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Proceeds from issuance of convertible preferred stock, net of issuance
costs</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">34,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Proceeds from exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">34,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net increase (decrease) in cash, cash equivalents and restricted
cash</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">21,043</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(6,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash, cash equivalents, and restricted cash&#151;beginning of
year</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">21,316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">42,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash, cash equivalents, and restricted cash&#151;end of year</FONT></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">42,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">35,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Supplemental cash flow information:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Purchase of property and equipment in accounts payable and accrued
liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Right-of-use-assets</FONT></FONT></FONT> obtained in exchange for operating lease liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,981</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>The accompanying notes are an integral part of these consolidated financial statements
</I></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-6
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TSCAN THERAPEUTICS, INC. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_6"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>1. Nature of Business and Basis of Presentation </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Nature of Business </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">TScan Therapeutics, Inc. and subsidiary (the Company) is a biotechnology company that was incorporated in Delaware on
April&nbsp;17, 2018 and has a principal place of business in Waltham, Massachusetts. The Company is a biopharmaceutical company focused on developing a pipeline of T cell receptor-engineered T cell <FONT STYLE="white-space:nowrap">(TCR-T),</FONT>
therapies for the treatment of patients with cancer. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Risks, Uncertainties and Going Concern
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company is subject to risks common to companies in the biotechnology industry, including, but not
limited to, successful development of technology, obtaining additional funding, protection of proprietary technology, compliance with government regulations, risks of failure of preclinical studies, clinical studies and clinical trials, the need to
obtain marketing approval for its product candidates and the ability to successfully market its therapies any products that receive approval, fluctuations in operating results, economic pressure impacting therapeutic pricing, dependence on key
personnel, risks associated with changes in technologies, development by competitors of technological innovations and the ability to scale manufacturing to large scale production. Product candidates currently under development will require
significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and
infrastructure and extensive <FONT STYLE="white-space:nowrap">compliance-reporting</FONT> capabilities. Even if the Company&#146;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from
therapy sales. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The accompanying consolidated financial statements have been prepared on a going concern
basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has primarily funded its operations with proceeds from sales of convertible preferred stock and
with payments received under its license and collaboration agreements. Since its inception, the Company has incurred recurring losses, including net losses of $13.7&nbsp;million and $26.1&nbsp;million for the years ended December&nbsp;31, 2019 and
2020, respectively. As of December&nbsp;31, 2020, the Company had an accumulated deficit of $43.5&nbsp;million. The Company expects to continue to incur additional losses and negative operating cash flows in the foreseeable future. The Company
expects that its cash and cash equivalents as of December&nbsp;31, 2020, along with the net cash proceeds from the sale of shares of its convertible preferred stock in January 2021 (see Note 14) will be sufficient to fund the Company&#146;s
operations for at least the next twelve months from the date of the issuance of the accompanying financial statements. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">The Company is seeking to complete an initial public offering (IPO) of its common stock. Upon completion of a qualified public offering on specified terms, the Company&#146;s outstanding convertible preferred stock will
automatically convert into shares of common stock (see Note&nbsp;7). In the event the Company does not complete an IPO, the Company expects to seek additional funding through private equity financings, debt financings, strategic alliances and
marketing, distribution, or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely
affect the holdings or the rights of the Company&#146;s stockholders. If the Company is unable to secure funding, it could be forced to delay, reduce, or eliminate some or all of its research development programs, therapy portfolio expansion or
commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the
Company to fund continuing operations, if at all. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-7
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT>
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In December 2019, a novel strain of coronavirus, which causes the disease known as <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> was reported to have surfaced in Wuhan, China. Since then, <FONT STYLE="white-space:nowrap">COVID-19</FONT> coronavirus has spread globally. In March 2020, the World Health Organization declared the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak a pandemic. The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> global and national health emergency has caused significant disruption in the international and United States economies and
financial markets. The spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> has caused illness, quarantines, cancellation of events and travel, business and school shutdowns, reduction in business activity and financial transactions, labor
shortages, supply chain interruptions and overall economic and financial market instability and business disruptions for the Company and many of the Company&#146;s vendors. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company
has taken a series of actions aimed at safeguarding the Company&#146;s employees and business associates, including implementing a flexible <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-at-home</FONT></FONT> policy. These
disruptions could result in increased costs of execution of development plans or may negatively impact the quality, quantity, timing and regulatory usability of data that the Company would otherwise be able to collect. While these disruptions are
currently expected to be temporary, there is considerable uncertainty around the duration of these disruptions. Therefore, the related financial impact and duration cannot be reasonably estimated at this time. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>2. Summary of Significant Accounting Policies </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Basis of Presentation </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company&#146;s consolidated financial statements have been prepared in conformity with accounting principles
generally accepted in the United States of America (US&nbsp;GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards
Updates (ASUs) issued by the Financial Accounting Standards Board (FASB). </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Principles of Consolidation
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The accompanying consolidated financial statements include the accounts of the Company and its wholly
owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Use of Estimates </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The preparation of the consolidated financial statements in accordance with US&nbsp;GAAP requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting
period. The Company bases its estimates on historical experience, known trends and other <FONT STYLE="white-space:nowrap">market-specific</FONT> or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis,
management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Cash and Cash Equivalents </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash includes cash in readily available checking and money market accounts. Cash equivalents include all highly liquid
investments maturing within 90&nbsp;days from the date of purchase. The cash equivalents consisted of money market funds. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Restricted Cash </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In connection with the Company&#146;s facility lease
agreement, the Company is required to provide a letter of credit of $0.6&nbsp;million for the benefit of the landlord to serve as a security deposit. As of December&nbsp;31, 2019 and </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-8
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
2020, the cash securing the letter of credit was classified as restricted cash <FONT STYLE="white-space:nowrap">(non-current)</FONT> on the consolidated balance sheets. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Concentrations of Credit Risk </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and
cash equivalents. The Company&#146;s cash deposits on hand at one financial institution often exceed federally insured limits. The Company places its cash in a financial institution that management believes to be of high credit quality. The Company
does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Deferred offering costs </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company capitalizes certain legal, professional accounting and other third party fees that are directly associated
with the proposed IPO as deferred offering costs. The deferred offering costs will be offset against the IPO proceeds upon the consummation of the IPO. In the event the IPO is abandoned, the deferred offering costs will be expensed immediately as a
charge to operating expenses in the consolidated statements of operations. The Company had no deferred costs capitalized for the year ended on December&nbsp;31, 2019 and an immaterial amount of deferred offering costs as of December&nbsp;31, 2020.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Property and Equipment </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Property and equipment are stated at cost and depreciated using the <FONT STYLE="white-space:nowrap">straight-line</FONT>
method over the estimated useful lives of the respective assets as follows: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><FONT COLOR="#32406b"><B>Estimated useful
life</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Laboratory equipment</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3&nbsp;&#151;&nbsp;5&nbsp;years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3&nbsp;&#151;&nbsp;5&nbsp;years</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Office and computer equipment</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3&nbsp;&#151;&nbsp;5&nbsp;years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">Shorter of the asset&#146;s estimated useful life or the remaining lease term</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Major additions and betterments are capitalized; expenditures for repairs and
maintenance, which do not improve or extend the life of the respective assets, are charged to operating expense as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are
removed from the accounts and any resulting gain or loss is included in loss from operations. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Impairment of <FONT STYLE="white-space:nowrap">Long-Lived</FONT> Assets </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap">Long-lived</FONT> assets to be held and used, including property and equipment, are
tested for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be fully recoverable. Evaluation of the recoverability of the asset or asset group is based on an estimate of undiscounted
future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, an impairment loss
would be based on the excess of the carrying value of the impaired asset over its fair value. The Company did not record any impairment losses on <FONT STYLE="white-space:nowrap">long-lived</FONT> assets during the periods presented. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Fair Value Measurements </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Certain assets and liabilities are carried at fair value under US&nbsp;GAAP. Fair value is defined as the exchange price
that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-9
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
measurement date. Valuation techniques used to measure fair value must maximize the user of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried
at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><B>Level</B><B></B><B>&nbsp;1</B>&#151;Unadjusted quoted prices in active markets that are
accessible to the reporting entity at the measurement date for identical assets and liabilities. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><B>Level</B><B></B><B>&nbsp;2</B>&#151;Inputs other than quoted prices in active markets
for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability. Level&nbsp;2 inputs include the following: </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">quoted prices for similar assets and liabilities in active markets
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">quoted prices for identical or similar assets or liabilities in markets that are not active
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">observable inputs other than quoted prices that are used in the valuation of the asset or
liabilities (e.g.,&nbsp;interest rate and yield curve quotes at commonly quoted intervals) </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b">inputs that are derived principally from or corroborated by observable market data by
correlation or other means </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#32406b"><B>Level</B><B></B><B>&nbsp;3</B>&#151;Unobservable inputs for the assets or liability
(i.e.,&nbsp;supported by little or no market activity). Level&nbsp;3 inputs include management&#146;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Lease Agreements </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company records leases under ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02</FONT> Leases (Topic 842)<I>
</I>whereby the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company has elected to not recognize a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset or lease liability. The Company&#146;s operating leases are recognized on the consolidated balance sheets as other noncurrent assets, other current
liabilities, and other noncurrent liabilities. The Company does not have any finance leases. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets represent the Company&#146;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#146;s obligation to make
lease payments arising from the lease. Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities are recognized at the lease commencement date based on the present value
of lease payments over the lease term. As the rate implicit on the Company&#146;s leases are not readily determination, the Company uses an estimate of its incremental borrowing rate for secured borrowings with terms similar to the lease term based
on the information available at the lease commencement date in determining the present value of lease payments. Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets also include the
effect of any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a
straight-line basis over the lease term. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Research and Development Costs </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development costs are expensed as incurred. Research and development costs that are paid in advance of
performance (if any) are capitalized as a prepaid expense and amortized over the service period as the services are provided. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Accrued Research and Manufacturing Contract Costs </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company has entered into
various research and development and manufacturing contracts. These agreements are generally cancelable, and related payments are recorded as the corresponding expenses are incurred. When evaluating the adequacy of the accrued liabilities, the
Company analyzes progress of the research </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-10 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in
determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#146;s estimates. The Company&#146;s historical accrual estimates have not been materially different from the actual costs. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Patent Costs </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">All <FONT STYLE="white-space:nowrap">patent-related</FONT> costs incurred in connection with filing and prosecuting
patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Revenue Recognition </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company accounts for revenue under ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-19,</FONT> <I>Revenue from
Contracts with Customers </I>(ASC 606). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, certain collaboration arrangements and financial instruments. ASC
606 provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those
goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">identify the contract(s) with a customer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">identify the performance obligations in the contract; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">determine the transaction price; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(iv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">allocate the transaction price to the performance obligations in the contract; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT COLOR="#32406b">(v)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#32406b">recognize revenue when (or as) the performance obligations are satisfied.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company only applies the five-step model to contracts when it is probable that the
Company will collect the consideration that it is entitled to in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses
whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until
a distinct combined performance obligation is identified. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company then allocates the transaction price
(that is, the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation
is satisfied. The allocation is based upon standalone selling price. The standalone selling price is the price at which an entity would sell a promised good or service separately to a customer. Because the Company have not sold the same goods or
services in our contracts separately to any customers on a standalone basis, the Company estimated the standalone selling price of each combined performance obligation by taking into consideration internal estimates of research and development
personnel needed to perform the research and development services, estimates of expected cash outflows to third parties for services and supplies and typical gross profit margins. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company enters into collaboration and licensing arrangements that are within the scope of ASC 606, under which the
Company may exclusively license to third parties&#146; rights to develop, manufacture and commercialize its product candidates as well as options to acquire additional rights. The terms of these arrangements typically include payment to the Company
of one or more of the following: nonrefundable, upfront license fees; development, regulatory and sales milestone payments; and royalties on net sales of licensed products. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-11 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Revenue is typically recognized using a cost-to-cost input model as the
measure of progress. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete the Company&#146;s performance obligations under an
arrangement. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be
recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Amounts received prior to revenue recognition are recorded as deferred revenue in the balance sheets.
Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as the current portion of deferred revenue in the balance sheets. Amounts not expected to be recognized as revenue within the 12 months
following the balance sheet date are classified as deferred revenue, net of current portion in the balance sheets. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B><I>Customer Options </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">If an arrangement is determined to contain customer options
that allow the customer to acquire additional goods or services, the goods and services underlying the customer options that are not determined to be material rights are not considered to be performance obligations at the outset of the arrangement,
as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material
right, the material right is recognized as a separate performance obligation at the outset of the arrangement. To date, none of our arrangements have included any material rights. The transaction price is allocated to each performance obligation on
a relative standalone selling price basis. The observable price of a good or service sold separately provides the best evidence of standalone selling price. However, when standalone selling prices are not readily available, the Company is required
to estimate the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price. Amounts allocated to a material right are not recognized as revenue until the option is exercised or terminates.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Milestone Payments </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For each arrangement that includes milestone payments upon the achievement of performance-based milestones, such as
development and regulatory milestones, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that
a significant reversal of revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#146;s control, such as regulatory approvals, are not considered probable of
being achieved until those approvals are received. Upfront and ongoing development milestones per the Company&#146;s collaboration and license agreement are not subject to refund if the development activities are not successful. The Company
reevaluates the probability of achievement of such milestones and any related constraint at each reporting period, and any adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues
and earnings in the period of adjustment. To date, the Company has not recognized any milestone revenues. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Royalties </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the
license to the Company&#146;s intellectual property is deemed to be the predominant item to which the royalties relate as it is the primary driver of value, the Company recognizes revenue when the related sales occur in accordance with the
sales-based royalty exception under ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">606-10-</FONT></FONT> <FONT STYLE="white-space:nowrap">55-65.</FONT> To date, the Company has not recognized any royalty revenue resulting from
the Company&#146;s collaboration and licensing agreements. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-12 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The estimate of deferred revenue also reflects management&#146;s estimate
of the periods of the Company&#146;s involvement in its collaboration and license agreements. The Company&#146;s performance obligations generally consist of the performance of research and development services and sharing <FONT
STYLE="white-space:nowrap">know-how</FONT> through participation on steering committees. If these estimates and judgments change over the course of these agreements, it may affect the timing and amount of revenue that the Company recognizes and
records in future periods. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Income Taxes </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been
included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the consolidated financial statement and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax asset to an amount, which, more likely than not, will be realized. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company recognizes the tax benefit from any uncertain tax positions only if it is more likely than not that the tax
position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit
that has a greater than fifty percent likelihood of being realized upon ultimate settlement. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. As of December&nbsp;31, 2019 and 2020, the
Company has not identified any uncertain tax positions for which reserves would be required. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Segment
Information </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating segments are defined as components of an entity for which discrete information
is available for evaluation by the chief operating decision maker, who is the CEO, in deciding how to allocate resources and in assessing performance. The Company manages its operations as a single segment for the purposes of assessing performance
and making operating decisions. All of the Company&#146;s assets are held in the United States. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Convertible Preferred Stock </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As the preferred stock contains redemption features in a deemed liquidation event that are not solely within the control
of the Company, the outstanding preferred stock has been classified outside of stockholders&#146; deficit. The Company&#146;s convertible preferred stock is subject to a dividend when and if declared by the Board. From inception through
December&nbsp;31, 2020, no dividend has been declared. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I><FONT STYLE="white-space:nowrap">Stock-Based</FONT> Compensation </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company accounts for stock option awards at fair value, which is measured using the
<FONT STYLE="white-space:nowrap">Black-Scholes</FONT> <FONT STYLE="white-space:nowrap">option-pricing</FONT> model. The measurement date is generally the date of grant. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company recognizes stock-based compensation expense over the requisite service period, which is generally the
vesting period of the respective award. For awards that include performance-based vesting conditions, stock-based compensation expense is recognized using the accelerated attribution method when the performance condition is deemed to be probable.
The Company accounts for forfeitures as they occur. The Company determines the fair value of restricted stock awards in reference to the fair value of its common stock less any applicable purchase price </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company classifies <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation expense in its consolidated
statements of operations in the same manner in which the award recipient&#146;s salary and related costs are classified or in which the award recipient&#146;s service payments are classified. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-13 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Comprehensive Loss </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Comprehensive loss includes net loss as well as other changes in stockholders&#146; deficit that result from transactions
and economic events other than those with stockholders. For the years ended December&nbsp;31, 2019 and&nbsp;2020, there was no difference between net loss and comprehensive loss in the accompanying consolidated financial statements. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Net Loss Per Share </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Basic net loss per share is calculated by dividing net loss by the weighted average common shares outstanding during the
period. During periods of income, the Company allocates to participating securities a proportional share of income (the two class method). The Company&#146;s convertible preferred stock participates in any dividends declared by the Company and are
therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, the Company allocates no loss to participating
securities because they have no contractual obligation to share in the losses of the Company. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Diluted net
loss per share is calculated by adjusting weighted average common shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the <FONT STYLE="white-space:nowrap">treasury-stock</FONT> and <FONT
STYLE="white-space:nowrap">if-converted</FONT> methods. For purposes of the diluted net income (loss) per share calculation, convertible preferred stock and stock options are considered to be common stock equivalents. All common stock equivalents
have been excluded from the calculation of diluted net loss per share as their effect would be <FONT STYLE="white-space:nowrap">anti-dilutive</FONT> for all periods presented. Therefore, basic and diluted net loss per share were the same for all
periods presented. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>3. Property and Equipment </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Property and equipment consist of the following (in thousands): </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Laboratory equipment</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,836</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Office and computer equipment</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Construction-in-progress</FONT>
</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Property and equipment</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Less: accumulated depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Depreciation and amortization expense for the years ended December&nbsp;31, 2019 and
2020 was $0.5&nbsp;million and $1.2&nbsp;million, respectively. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-14 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>4. Fair Value Measurements </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table sets forth by level, within the fair value hierarchy, the assets (liabilities) carried at fair value
(in thousands): </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Fair value measurements<BR>at December&nbsp;31, 2019 using:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Assets:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash equivalents&#151;money market funds</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total financial assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table sets forth by level, within the fair value hierarchy, the assets
(liabilities) carried at fair value (in thousands): </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Fair value measurements at<BR>December&nbsp;31, 2020 using:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash equivalents&#151;money market funds</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">33,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">33,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total of financial assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">33,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">33,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The cash equivalents are comprised of funds held in an exchange traded money market fund
and the fair value of the cash equivalents is determined based upon quoted market price for that fund. There were no transfers among Level&nbsp;1, Level&nbsp;2, or Level&nbsp;3 categories in the periods presented. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The carrying value of accounts payable and accrued expenses that are reported on the consolidated balance sheets
approximate their fair value due to the <FONT STYLE="white-space:nowrap">short-term</FONT> nature of these assets and liabilities. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B>5. Accrued Expenses and Other Current Liabilities </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued expenses and other
liabilities consisted of the following (in thousands): </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued employee compensation and benefits</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued consulting and professional services</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued legal services and license fee</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">578</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>6. Convertible Preferred Stock </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Series&nbsp;A Preferred Stock </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In 2018, the Company entered into the Series&nbsp;A Preferred Stock Purchase Agreement with its founding investors
providing $25&nbsp;million in Series&nbsp;A Preferred Stock equity financing and issued 3,209,420 shares of Series&nbsp;A Preferred Stock. Issuance costs associated with the transaction were $0.1&nbsp;million. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Series&nbsp;B Preferred Stock </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In 2019, the Company entered into the Series&nbsp;B Preferred Stock Purchase Agreements providing $35&nbsp;million in
Series&nbsp;B Preferred Stock equity financing and issued 3,853,864 shares of Series B Preferred Stock. Issuance costs associated with the transaction were $0.2&nbsp;million. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-15 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of each balance sheet date, the preferred stock consisted of the
following (in thousands, except for share data): </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>December&nbsp;31, 2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Preferred<BR>Stock<BR>Authorized</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Preferred<BR>Stock<BR>Issued and<BR>Outstanding</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Carrying<BR>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Liquidation<BR>Preference</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Common<BR>stock<BR>issuable<BR>upon<BR>conversion</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series&nbsp;A Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">26,315,790</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">24,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">27,622</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series&nbsp;B Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,601,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">34,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">36,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">57,917,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">63,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>December&nbsp;31, 2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Preferred<BR>Stock<BR>Authorized</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Preferred<BR>Stock<BR>Issued and<BR>Outstanding</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Carrying<BR>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Liquidation<BR>Preference</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Common<BR>stock<BR>issuable<BR>upon<BR>conversion</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series&nbsp;A Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">26,315,790</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">24,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">29,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series&nbsp;B Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,601,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">34,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">39,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">57,917,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">68,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The terms and conditions of the Series&nbsp;A Preferred Stock and Series&nbsp;B
Preferred Stock (collectively the Preferred Stock) are as follows: </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Dividends</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Dividends shall accrue at the rate of 8% compounded annually and are cumulative in nature (Accruing Dividends). Dividends
are payable only when and if declared by the Board. The Company shall not declare, pay, or set aside any dividends on shares of any class of common stock, unless the holders of the Preferred Stock shall first receive dividends on each outstanding
share of Preferred Stock in the amount of the accrued dividends unpaid as of such date. No dividends have been declared or paid as of December&nbsp;31, 2019 and 2020. The cumulative dividends at December&nbsp;31, 2020 totaled $8.9&nbsp;million.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Liquidation </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the event of any liquidation, dissolution, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, which
would include the sale of the Company, the holders of the Preferred Stock are entitled to a liquidation preference. The amount to be paid to the holders of Preferred Stock is an amount equal to the greater of (i)&nbsp;the original purchase price per
share, plus all Accruing Dividends accrued but unpaid thereon applicable to the series of Preferred Stock (which Accruing Dividends shall be paid out in cash), whether or not declared, together with any other dividends declared but unpaid thereon or
(ii)&nbsp;such amount per share as would have been payable had all shares of Preferred Stock been converted to common stock prior to such liquidation, dissolution, or winding up of the Company. The original issue purchase price per share of the
Series&nbsp;A Preferred Stock was $7.79 per share, and the original issue price of the Series&nbsp;B Preferred Stock was $9.02 per share. The holders of the Series B Preferred Stock are entitled to receive their respective liquidation preference
with respect to the Series B Preferred Stock in full before any liquidation preference is paid upon the shares of Series A Preferred Stock. Any assets remaining following the preferential distribution to the holders of Series&nbsp;A Preferred Stock
and Series&nbsp;B Preferred Stock would be available for distribution ratably among the holders of common stock. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-16 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Voting </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The holders of the Preferred Stock are entitled to the number of votes equal to the number of shares of common stock into
which the shares of the Preferred Stock held by each holder are then convertible. The holders of Preferred Stock are entitled to vote together with the holders of the Company&#146;s common stock, as a single class, on all matters submitted to a vote
of stockholders. In addition, the holders of Series A Preferred Stock are entitled to elect four (4)&nbsp;directors and holders of Series B Preferred Stock are entitled to elect two (2)&nbsp;directors. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Conversion</I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The holders of Preferred Stock shall have the right to convert, at the option of the holder, at any time, into shares of
common stock by dividing the preferred stock original issuance price by the conversion price in effect at the time. The initial Series A Preferred Stock conversion price is $7.79 per share and the initial Series B Preferred Stock conversion price is
$9.02 per share, subject in each case to certain adjustments to reflect the issuance of common stock, options, warrants, or other rights to subscribe for or to purchase shares of the Company&#146;s common stock for a consideration per share less
than the conversion price then in effect. In addition, each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert into shares of common stock at the applicable conversion ratio in effect upon the earlier of
(a)&nbsp;the closing of a Qualified IPO (as defined in the Company&#146;s certificate of incorporation) or (b)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least fifty-nine percent
(59%) of the then outstanding shares of Preferred Stock (voting together as a single class, and not as separate series, and on an as converted to common stock basis). </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Redemption </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Preferred Stock is not redeemable at the option of the holder. However, upon certain change in control events that
are outside of the Company&#146;s control, including liquidation, sale or transfer of control of the Company, holders of the Preferred Stock can cause redemption of the Preferred Stock. Shares of Preferred Stock must be redeemed by the Company in an
amount equal to the liquidation preference for each series of Preferred Stock. The Company classifies its Preferred Stock outside of stockholders&#146; deficit as certain change in control events are outside the Company&#146;s control. As there is
no certain redemption date and the redemption feature can only be triggered in the event of a liquidation, sale, or transfer of control of the Company or similar event, the Company has concluded that it is not probable that the Preferred Stock will
become redeemable and as such does not accrete the Preferred Stock to the redemption value. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>7. Stock Based Compensation
</B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On April&nbsp;20, 2018, the Company adopted the 2018 Stock Plan (the 2018 Plan). The 2018 Plan, as
amended, provides for the issuance of up to 1,474,335 shares of common stock to employees, officers, directors, consultants, and advisors in the form of nonqualified and incentive stock options, unvested stock awards, and other <FONT
STYLE="white-space:nowrap">stock-based</FONT> awards. At December&nbsp;31, 2020, there were 28,867 shares of common stock available for issuance under the 2018 Plan. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Stock Options </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In general, stock options typically vest over four years and have a maximum term is 10 years. Also, the Company typically
grants stock options to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> at exercise prices deemed by the Board to be equal to the fair value of the common stock at the time of grant. The fair value of the common stock has been
determined by the Board at each measurement date based on a variety of different factors, including the results obtained from third party appraisals, the Company&#146;s financial position and historical financial performance, the status of
development of the Company&#146;s services, the current climate in the marketplace, the illiquid nature of the common stock, the effect of the rights and preferences of the preferred stockholders, and the prospects of a liquidity event, among
others. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-17 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company utilized the
<FONT STYLE="white-space:nowrap">Black-Scholes</FONT> <FONT STYLE="white-space:nowrap">option-pricing</FONT> model to estimate the fair value of stock options awarded to employees. The <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> <FONT
STYLE="white-space:nowrap">option-pricing</FONT> model requires several key assumptions. The key assumptions used to apply this pricing model during the years ended December&nbsp;31, 2019 and 2020, were as follows: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap">Risk-free</FONT> interest
rate</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Expected term (in years)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Expected volatility of underlying common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The <FONT STYLE="white-space:nowrap">risk-free</FONT> interest rate was based on rates
associated with U.S. Treasury issues approximating the expected life of the stock options. The expected term of stock options granted to employees was determined using the simplified method, which represents the midpoint of the contractual term of
the stock option and the <FONT STYLE="white-space:nowrap">weighted-average</FONT> vesting period of the option. The Company uses the simplified method because it does not have sufficient historical stock option exercise data to provide a reasonable
basis upon which to estimate the expected term. The expected <FONT STYLE="white-space:nowrap">dividend-yield</FONT> assumption was based on the Company&#146;s expectation of no future dividend payments. The expected volatility of the underlying
stock was based on the average historical volatility of comparable publicly traded companies based on weekly price returns as reported by a pricing service, as the Company does not have a trading history for its common stock. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table summarizes the stock option activity under the 2018 Plan: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Stock<BR>Options</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Weighted<BR>Average<BR>Remaining<BR>Life<BR>(in Years)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Intrinsic<BR>Value</B></FONT><br><FONT COLOR="#32406b"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Outstanding January&nbsp;1, 2020</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,290,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Granted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">363,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3.77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Exercised</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(142,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Canceled</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(66,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Outstanding December&nbsp;31, 2020</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,445,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,799</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Options vested or expected to vest as of December&nbsp;31,
2020</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,445,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,799</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock options exercisable as of December&nbsp;31, 2019</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">163,632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8.87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock options exercisable as of December&nbsp;31, 2020</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">362,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The weighted average grant date calculated value of stock options granted for the years
ended on December&nbsp;31, 2019 and 2020 were $1.32 and $2.38 per share, respectively. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Restricted Common Stock
</B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company has granted restricted common stock with service based vesting conditions. Unvested shares of
restricted common stock may not be sold or transferred by the holder, except for transfers for estate planning purposes in which the transferee agrees to remain bound by all restrictions set forth in the original common stock purchase agreement.
They are legally issued and outstanding but only accounted for as outstanding when vested. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-18 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
These restrictions lapse over the four year vesting term of each award. The purchase price of each share of restricted common stock was $0.0001 per share. A summary of the activity for the year
ended December&nbsp;31, 2020 is as follows: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Number<BR>of Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Weighted</B></FONT><br><FONT COLOR="#32406b"><B>Average<BR>Grant<BR>Date Fair<BR>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Unvested restricted stock as of January</B><B></B><B>&nbsp;1, 2020 </B>.
.. . . . . . . . .</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">823,179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . .</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . .</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(350,606</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Forfeitured . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . .</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(34,293</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Unvested restricted stock as of December</B><B></B><B>&nbsp;31, 2020
</B>. . . . . . . . . .</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">438,280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The aggregate fair value of restricted stock awards that vested during the years ended
December&nbsp;31, 2019 and 2020 was nominal. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Stock-Based Compensation Expense </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock-based compensation expense was as follows (in thousands): </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">General and administrative</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">267</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">515</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of December&nbsp;31, 2020, there was $1.7&nbsp;million of unrecognized stock-based
compensation expense related to unvested stock options and restricted common stock, which is estimated to be recognized over a period of 2.76 years. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>8. Income Taxes </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the years ended December&nbsp;31, 2019 and 2020, the Company did not record an income tax provision due to the
losses incurred and a full valuation allowance provided on the net deferred tax assets. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">A reconciliation of
the federal statutory income tax rate to the effective tax rate is as follows: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Tax at U.S. statutory rate</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">21.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">21.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Changes from statutory rate:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">State taxes, net of federal benefit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Tax credits</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Change in valuation allowance</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(32.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(32.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Effective income tax rate</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-19 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred tax assets and liabilities reflect the net tax effects of net
operating loss carryovers and temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#146;s deferred tax assets and
liabilities were as follows (in thousands): </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Deferred tax assets:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net operating loss carryforwards</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Tax credits</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,087</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Start up costs</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">617</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap">Stock-based</FONT>
compensation</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Lease liability</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Total deferred tax assets</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">15,611</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Deferred tax liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Right-of-use assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,320</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Valuation allowance</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,295</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(13,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Net deferred tax asset&nbsp;&amp; liabilities</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In determining the need for a valuation allowance, the Company has given consideration
to its cumulative losses. The Company has assessed the available means of recovering deferred tax assets, including the ability to carryback net operating losses, the existence of reversing taxable temporary differences, the availability of tax
planning strategies and forecasted future taxable income. The Company maintains a full valuation allowance against its net deferred tax assets. The valuation allowance increased by $4.3 and $8.4 million during the years ended December 31, 2019 and
2020, respectively. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of December 31, 2020, the Company had U.S. federal net operating loss carryforwards
of approximately $17.6 million. The U.S. federal net operating losses have an indefinite life carryforward. As of December&nbsp;31, 2020, the Company had Massachusetts net operating loss carryforwards of approximately $16.7&nbsp;million that expire
at various dates through 2040. As of December&nbsp;31, 2020, the Company had U.S. R&amp;D federal credit carryforwards of approximately $1.5&nbsp;million that expire at various dates through 2040. As of December&nbsp;31, 2020, the Company had U.S.
state R&amp;D tax credit carryforwards of approximately $0.8&nbsp;million that expire at various dates through 2035. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">Under Sections 382 and 383 of the U.S. Internal Revenue Code, if a corporation undergoes an ownership change, the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss
carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> attributes, such as net operating losses and research tax credits, to offset its post-change income and taxes may be limited. In general, an ownership change generally occurs
if there is a cumulative change in ownership by 5% stockholders that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under U.S. state tax laws. The Company may have experienced an ownership change in the past
and may experience ownership changes in the future as a result of future transactions in its share capital, some of which may be outside the control of the Company. As a result, if the Company earns net taxable income, its ability to use its
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-20 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
<FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards, or other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes, to offset U.S. federal and state
taxable income and taxes may be subject to significant limitations. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company accounted for uncertain tax
positions using a more likely than not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax
positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates uncertain tax positions on an
annual basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. The Company accounts for interest and penalties related to uncertain tax positions as part of its
provision for income taxes. For the years ended December&nbsp;31, 2019 and 2020, there were no accrued interest or penalties in the consolidated statements of operations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company is subject to taxation for federal and Massachusetts purposes. At December&nbsp;31, 2020, the Company is
subject to examination by these taxing authorities for all years since inception. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>9. Collaboration and License Agreements
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Novartis </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In March 2020, the Company entered into a Collaboration and License Agreement (the Novartis Agreement) with Novartis
Institutes For Biomedical Research, Inc. (Novartis) to collaborate on their research efforts to discover and develop novel TCR-T. Under the Novartis Agreement, the Company will identify and characterize TCRs in accordance with a research plan,
transfer data arising from the research plan. and Novartis will have the option to license and develop TCRs for up to three novel targets identified in performance of the collaboration during the collaboration period of the Novartis Agreement.
Novartis will also have rights of first negotiation for certain additional targets and TCRs identified in performance of the collaboration during a defined collaboration period of the Novartis Agreement and for 180 days after such collaboration
period ends (which collaboration period will end no later than March 2023). If during such <FONT STYLE="white-space:nowrap">180-day</FONT> right of first negotiation period, the Company notifies Novartis of the Company&#146;s intent to grant a third
party a license to a target or TCR identified in the collaboration, then Novartis may obtain the exclusive right to negotiate a license to such target or TCR for an additional 270 days by providing the Company with a term sheet to license such
target or TCR within 90 days of the Company&#146;s notice of such intent. The Novartis Agreement provides for payments of an upfront fee of $20 million, research funding totaling $10.0 million and potential milestone payments contingent on clinical,
regulatory and sales success. In addition to payments upon achievement of certain clinical and regulatory milestones, Novartis will pay the Company <FONT STYLE="white-space:nowrap">mid-single</FONT> to low double-digit royalties on net sales for
each product directed to a target licensed by Novartis. After the end of the collaboration period and the expiration of Novartis&#146; first right of negotiation, the Company is free to develop TCRs against targets not licensed by Novartis.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company concluded that Novartis meets the definition of a customer, as the Company is delivering
research and development activities and <FONT STYLE="white-space:nowrap">know-how</FONT> rights. The Company identified performance obligations for research and development activities, data reporting and participation in joint steering and research
committees. The Company determined there is a single performance obligation due to the services being highly interrelated and are therefore not distinct in the context of the contract. The Company combined the
<FONT STYLE="white-space:nowrap">pre-option</FONT> research services and data reporting into a single performance obligation Novartis has an exclusive option to obtain a commercial license for up to three Targets (as defined in the Novartis
Agreement) to pursue further development and commercialization of the respective Target. Pursuant to the Novartis Agreement, the option for Novartis to license, develop, and commercialize Targets is not a performance obligation at the outset of the
Novartis Agreement as it is a customer option that does not represent a material right. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company looked
to the promises in the arrangement to determine the method of recognition that best coincides with the pattern of delivery. The Company concluded that the performance of the research services over the expected research term was the predominant
promise within the performance obligation. The Company </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-21 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
is recognizing the revenue associated with the performance obligation using the input method, according to the actual costs incurred as a percentage of total expected costs to complete the
research services. As costs are incurred, the Company will recognize revenue over time. Any change in the estimated percentage complete due to a revised cost forecast will be adjusted in the period in which the change in estimate occurs and the
revenue recognition will be updated accordingly. The Company expects the research term to last approximately three years, which is inclusive of the option to extend the arrangement. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of December&nbsp;31, 2020, the Company determined that the $20.0&nbsp;million upfront payment, together with the
$10.0&nbsp;million of estimated research costs to be reimbursed by Novartis to be the entirety of the consideration to be included in the transaction price as of the outset of the arrangement. The potential milestone payments that the Company is
eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the assessed probability of achievement. The Company will <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the transaction
price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust the estimate of the transaction price. During the year ended December 31, 2020, the Company recognized
$0.8&nbsp;million of revenue associated with the Novartis Agreement based on performance completed during that period. Additionally, during the year ended December&nbsp;31, 2020, the Company incurred $0.2&nbsp;million of costs associated with the
Novartis Agreement that were recorded within research and development expenses in the statements of operations. Additionally, as of December&nbsp;31, 2020, the Company had current and long-term deferred revenue of $10.6&nbsp;million and
$8.8&nbsp;million, respectively due to Novartis Agreement. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Qiagen </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On November&nbsp;5, 2020, the Company entered into an Option and Exclusive License Agreement with QIAGEN Sciences, LLC
(Qiagen), pursuant to which Company licensed to Qiagen intellectual property relating to specific, identified peptides to enable Qiagen to develop and commercialize diagnostics related to <FONT STYLE="white-space:nowrap">COVID-19.&nbsp;The</FONT>
Company has not identified any performance obligations under this agreement other than the delivery of certain intellectual property that was delivered at the inception of the agreement. Qiagen paid the Company a nominal upfront <FONT
STYLE="white-space:nowrap">non-refundable</FONT> payment of $0.2 million with the potential for additional payments that become payable upon successful achievement of certain clinical and commercial milestones achieved by Qiagen. The initial payment
is included in revenue for the period and the additional payments will not be recognized until the milestones are probable of being achieved. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b"><B>Poseida Therapeutics </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On October&nbsp;19, 2020, the Company entered into an
arrangement with Poseida Therapeutics, Inc. (Poseida), pursuant to which Poseida paid the Company a nominal fee in exchange for certain data. The Company does not have any remaining performance obligations under this arrangement and does not expect
future revenues to be significant. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>10. Commitments and Contingencies </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Leases </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company leases for laboratory and office space with a term that expires in September&nbsp;30, 2024, subject to
certain renewal options, which are not deemed highly probable of renewal. The Company provided a letter of credit in the amount of $0.6&nbsp;million as security for the lease which expires January&nbsp;31, 2025. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additional, laboratory and office space was secured through a sublease that commenced in June 2020 and will continue
through March 2026. The Company provided a cash deposit of $0.2&nbsp;million in conjunction with the execution of the lease which is recorded as a long-term asset. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Summary of lease cost </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company lease costs is $0.6&nbsp;million and $1.3&nbsp;million for the years ended December&nbsp;31, 2019 and 2020,
respectively. These amounts include short-term and variable lease costs, which were not significant in any period presented. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-22 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Supplemental disclosure of cash flow information related to leases was as
follows (in thousands): </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year ended<BR>December 31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash paid for amounts included in the measurement of lease
liabilities:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating cash flows for operating leases</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">679</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The weighted-average remaining lease term and discount rate were as follows: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Weighted-average remaining lease term (in years)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4.5&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4.4&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Weighted-average discount rate</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table represents the maturity of the Company&#146;s
operating lease liabilities as of December&nbsp;31, 2020 (in thousands): </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#32406b"><B>Year Ending
December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Operating</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">2021</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"> 1,948</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">2022</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">2023</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,131</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">2024</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">2025</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Thereafter</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total future minimum lease payments</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Less: imputed interest</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Present value of operating lease liability</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b"> 7,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Brigham and Women&#146;s License Agreement </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company obtained the worldwide exclusive license to its foundational technology from The Brigham and Women&#146;s
Hospital, Inc. (or &#147;BWH&#148;). The license grants worldwide exclusive use to the patent underlying the TargetScan technology in exchange for fees including development milestones and various royalties on product sales should they occur in the
future. The Company is negotiating an amendment of the license agreement with BWH. The potential amendment would include an exclusive license to new technology and certain changes to the fee and royalty structure that the Company does not expect to
have a material impact on the financial statements. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Royalty Agreement </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In June 2018, the Company amended and restated an existing royalty agreement with one of its founders. Under the amended
and restated royalty agreement, the Company agreed to pay the founder an aggregate royalty of 1% of net sales of any product sold by the Company or by any of its direct or indirect licensees for use in the treatment of any disease or disorder
covered by a pending patent application or issued patent held or controlled by the Company as of the last date that the founder was providing services to the Company as a director or consultant under a written agreement in perpetuity. Royalties are
payable with respect to each applicable product for a defined period of time set forth in the royalty agreement. The founder assigned his rights and obligations under the royalty agreement to one of his affiliatedentities in January 2021.
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-23 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>11. Retirement Plan </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company initiated a defined contribution plan under Section&nbsp;401(k) of the IRC (the Plan) covering all qualified
employees effective January&nbsp;1, 2019. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. The Company made contributions to the Plan of $0.1&nbsp;million
and $0.2&nbsp;million were recorded for the years ended December&nbsp;31, 2019 and 2020, respectively. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>12. Net Loss Per
Share </B></FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Net Loss Per Share </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):
</FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Numerator:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(13,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(26,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Denominator:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Weighted-average common shares outstanding, basic and
diluted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">385,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">916,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(35.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(28.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company excluded the following potential common shares from the computation of
diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Year ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series A Preferred Stock (as converted to common stock)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series B Preferred Stock (as converted to common stock)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Unvested restricted common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">823,179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">438,280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Options to purchase common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,290,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,445,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9,177,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,946,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>13. <FONT STYLE="white-space:nowrap">Related-Party</FONT> Transactions </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Certain employees of Longwood Fund, a stockholder of the Company, including board of directors member Christoph Westphal,
provided management services to the Company. Personnel and consulting expenses of $0.6&nbsp;million were recognized in general and administrative expenses for year ended on December&nbsp;31, 2019. No such expenses were incurred for year ended on
December&nbsp;31, 2020. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company has received professional services from founders of the Company.
Consulting expenses of $0.3&nbsp;million and $0.2&nbsp;million were recognized in general and administrative expenses for the years ended December&nbsp;31, 2019 and 2020, respectively. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Novartis and its affiliates held shares of the Preferred Stock and entered into the Novartis Agreement discussed in Note
9. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-24 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>14. Subsequent Events </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For the year ended December&nbsp;31, 2020, the Company evaluated subsequent events as of March&nbsp;19, 2021, the date
the audited consolidated financial statements were issued and May&nbsp;14, 2021, as to the effects of the reverse stock split discussed below. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Series C Preferred Stock financing </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On January&nbsp;15, 2021, the Company entered into the Series&nbsp;C Preferred Stock Purchase Agreement and completed the
sale of $100&nbsp;million in Series&nbsp;C Preferred Stock. The Company authorized and sold 8,553,168 shares of Series C Preferred Stock with an issue price of $11.70 per share. In connection with the issuance of Series C Preferred Stock, the
Company increased the authorized number of shares of common stock, resulting in 165,210,543 authorized common shares as of January&nbsp;15, 2021. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Increase in shares available for issuance under the 2018 Plan </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On January&nbsp;15, 2021, the number of shares of common stock authorized for issuance under the 2018 Plan was increased
from 1,474,335&nbsp;shares to 2,902,738&nbsp;shares. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Grant of stock options under the 2018 Plan
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On January&nbsp;27, 2021, the Company granted options with service-based vesting criteria for the
purchase of an aggregate of 1,025,647 shares of common stock, at an exercise price of $5.83 per share. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On
March&nbsp;16, 2021, the Company granted options with service-based vesting criteria for the purchase of an aggregate of 77,439 shares of common stock, at an exercise price of $11.57 per share. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Reverse stock split </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company&#146;s board of directors and stockholders approved a 1-for-8.2 reverse stock split of the Company&#146;s
issued and outstanding common stock and outstanding shares of Preferred Stock, which became effective as of May&nbsp;13, 2021. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes
thereto have been retroactively adjusted to reflect the reverse stock split. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-25 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TScan Therapeutics, Inc. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_7"></A>Condensed Consolidated Balance Sheets </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands, except share and per share data) </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>December&nbsp;31,</B></FONT><br><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>March&nbsp;31,</B></FONT><br><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Current assets:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">34,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">121,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total current assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">36,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">123,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred offering costs</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,651</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Long-term deposit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">49,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">140,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146;
Deficit</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating lease liability, current portion</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,530</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred revenue, current portion</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">10,627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">11,382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">17,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">18,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred revenue, net of current portion</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,756</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating lease liability, net of current portion</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">32,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Commitments and contingencies (Note 8)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Convertible preferred stock (Note 5)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">159,411</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stockholders&#146; deficit:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Common stock, $0.0001 par value; 165,210,543 shares authorized; 1,574,138
and 1,655,427 shares issued; and 1,135,858 and 1,304,789 shares issued outstanding at December&nbsp;31, 2020 and March&nbsp;31, 2021, respectively</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(43,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(51,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(42,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(49,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total liabilities, convertible preferred stock and stockholders&#146;
deficit</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">49,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">140,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>The accompanying notes are an integral part of these unaudited condensed consolidated
financial statements </I></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-26 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TScan Therapeutics, Inc. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_8"></A>Condensed Consolidated Statements of Operations </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands, except share and per share data) </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Three Months Ended<BR>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Revenue:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Collaboration and license revenue</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">General and administrative</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,606</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">5,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9,945</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other income:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Interest income</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(6.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Weighted average common shares outstanding, basic and
diluted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">776,769</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,218,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>The accompanying notes are an integral part of these unaudited condensed consolidated
financial statements </I></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-27 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TScan Therapeutics, Inc. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_9"></A>Condensed Consolidated Statements of Convertible Preferred Stock and&nbsp;Stockholders&#146;
Deficit </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands, except share and per share data) </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Convertible</B></FONT><br><FONT COLOR="#32406b"><B>Preferred Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Common Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Additional</B></FONT><br><FONT COLOR="#32406b"><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B></FONT><br><FONT
 COLOR="#32406b"><B>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Accumulated</B></FONT><br><FONT COLOR="#32406b"><B>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total</B></FONT><br><FONT COLOR="#32406b"><B>Stockholders&#146;</B></FONT><br><FONT COLOR="#32406b"><B>Deficit</B></FONT></TD>

<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Balances at January&nbsp;1, 2020</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">642,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(17,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(17,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Issuance of common stock upon exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">111,764</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Vesting of restricted common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">88,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Balances at March&nbsp;31, 2020</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">843,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(22,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(22,343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Balances at January&nbsp;1, 2021</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,135,858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(43,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(42,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Issuance of Series&nbsp;C convertible preferred stock (net of issuance costs
of $270)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,553,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">99,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Issuance of common stock upon exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">81,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Vesting of restricted common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">87,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Balances at March&nbsp;31, 2021</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">15,616,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">159,411</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #32406b">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,304,789</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(51,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(49,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>The accompanying notes are an integral part of these unaudited condensed consolidated
financial statements </I></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-28 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TScan Therapeutics, Inc. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_10"></A>Condensed Consolidated Statements of Cash Flows </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(in thousands) </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Three Months Ended<BR>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Cash flows from operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Adjustment to reconcile net loss to net cash used in operating
activities:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Depreciation expense</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">222</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">469</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Changes in current assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Prepaid expenses and other assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets and lease liabilities, net</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">469</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued expense and other liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,129</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(9,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Purchases of property and equipment</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(2,959</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(1,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(2,959</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Proceeds from issuance of convertible preferred stock, net of issuance
costs</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">99,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Proceeds from exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Payment of deferred offering costs</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">99,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net increase (decrease) in cash, cash equivalents and restricted
cash</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(6,095</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">86,710</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash, cash equivalents, and restricted cash&#151;beginning of
period</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">42,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">35,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash, cash equivalents, and restricted cash&#151;end of
period</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">36,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">122,096</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Supplemental cash flow information:</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Purchase of property and equipment in accounts payable and accrued
liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Deferred offering costs included in accrued expense</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">911</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>The accompanying notes are an integral part of these unaudited condensed consolidated
financial statements </I></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-29 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>TSCAN THERAPEUTICS, INC. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B><A NAME="fin107876_11"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><B>(Unaudited) </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>1. Nature of Business and Basis of Presentation </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Nature of Business </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">TScan Therapeutics, Inc. and subsidiary (the Company) is a biotechnology company that was incorporated in Delaware on
April&nbsp;17, 2018 and has a principal place of business in Waltham, Massachusetts. The Company is a biopharmaceutical company focused on developing a pipeline of T cell receptor-engineered T cell <FONT STYLE="white-space:nowrap">(TCR-T),</FONT>
therapies for the treatment of patients with cancer. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Risks, Uncertainties and Going Concern
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company is subject to risks common to companies in the biotechnology industry, including, but not
limited to, successful development of technology, obtaining additional funding, protection of proprietary technology, compliance with government regulations, risks of failure of preclinical studies, clinical studies and clinical trials, the need to
obtain marketing approval for its product candidates and the ability to successfully market its therapies any products that receive approval, fluctuations in operating results, economic pressure impacting therapeutic pricing, dependence on key
personnel, risks associated with changes in technologies, development by competitors of technological innovations and the ability to scale manufacturing to large scale production. Product candidates currently under development will require
significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and
infrastructure and extensive compliance-reporting capabilities. Even if the Company&#146;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from therapy sales. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis,
which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has primarily funded its operations with proceeds from sales of convertible preferred stock and with
payments received under its license and collaboration agreements. Since its inception, the Company has incurred recurring losses, including net losses of $5.5&nbsp;million and $7.9&nbsp;million for the three months ended March&nbsp;31, 2020 and
2021, respectively. As of March&nbsp;31, 2021, the Company had an accumulated deficit of $51.4&nbsp;million. The Company expects to continue to incur additional losses and negative operating cash flows in the foreseeable future. The Company expects
that its cash and cash equivalents as of March&nbsp;31, 2021 will be sufficient to fund the Company&#146;s operations for at least the next twelve months from the date of the issuance of the accompanying financial statements. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company is seeking to complete an initial public offering (IPO) of its common stock. Upon completion of a qualified
public offering on specified terms, the Company&#146;s outstanding convertible preferred stock will automatically convert into shares of common stock (see Note&nbsp;7). In the event the Company does not complete an IPO, the Company expects to seek
additional funding through private equity financings, debt financings, strategic alliances and marketing, distribution, or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and may not be able to
enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#146;s stockholders. If the Company is unable to secure funding, it could be forced to delay, reduce, or
eliminate some or all of its research development programs, therapy portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance
that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-30 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT>
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In December 2019, a novel strain of coronavirus, which causes the disease known as <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> was reported to have surfaced in Wuhan, China. Since then, <FONT STYLE="white-space:nowrap">COVID-19</FONT> coronavirus has spread globally. In March 2020, the World Health Organization declared the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak a pandemic. The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> global and national health emergency has caused significant disruption in the international and United States economies and
financial markets. The spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> has caused illness, quarantines, cancellation of events and travel, business and school shutdowns, reduction in business activity and financial transactions, labor
shortages, supply chain interruptions and overall economic and financial market instability and business disruptions for the Company and many of the Company&#146;s vendors. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company
has taken a series of actions aimed at safeguarding the Company&#146;s employees and business associates, including implementing a flexible <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-at-home</FONT></FONT> policy. These
disruptions could result in increased costs of execution of development plans or may negatively impact the quality, quantity, timing and regulatory usability of data that the Company would otherwise be able to collect. While these disruptions are
currently expected to be temporary, there is considerable uncertainty around the duration of these disruptions. Therefore, the related financial impact and duration cannot be reasonably estimated at this time. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>2. Summary of Significant Accounting Policies </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Basis of Presentation </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company&#146;s condensed consolidated financial statements have been prepared in conformity with accounting
principles generally accepted in the United States of America (US&nbsp;GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting
Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB). There have been no changes in the significant accounting policies in the period ended March 31, 2021. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Unaudited interim financial information </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The accompanying the condensed consolidated balance sheet as of March&nbsp;31, 2021, the condensed consolidated
statements of operations, condensed consolidated statement of convertible preferred stock and stockholders&#146; deficit and of the condensed consolidated statements of cash flows for the three months ended March&nbsp;31, 2020 and 2021 are
unaudited. The unaudited interim financial statement have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments,
necessary for the fair statement of the Company&#146;s financial position as of March&nbsp;31, 2021 and the results of its operations and its cash flows for the three months ended March&nbsp;31, 2020 and 2021. The financial data and other
information disclosed in these notes related to the three months ended March&nbsp;31, 2020 and 2021 are also unaudited. The results for the three months ended March&nbsp;31, 2021 are not necessarily indicative of results to be expected for the year
ending December&nbsp;31, 2021, any other interim periods, or any future year or period. The condensed financial statements should be read together with the annual audited financial statements. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Deferred offering costs </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company capitalizes certain legal, professional accounting and other third party fees that are directly associated
with the proposed IPO as deferred offering costs. The deferred offering costs will be offset against the IPO proceeds upon the consummation of the IPO. In the event the IPO is abandoned, the deferred offering costs will be expensed immediately as a
charge to operating expenses in the condensed consolidated statements of operations. The Company had no deferred costs capitalized as of December&nbsp;31, 2020 and $1.1&nbsp;million of deferred offering costs as of March&nbsp;31, 2021. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-31 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>3. Fair Value Measurements </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table sets forth by level, within the fair value hierarchy, the assets (liabilities) carried at fair value
(in thousands): </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Fair value measurements at<BR>December&nbsp;31, 2020 using:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Assets:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash equivalents&#151;money market funds</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">33,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">33,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total financial assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">33,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">33,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The following table sets forth by level, within the fair value hierarchy, the assets
(liabilities) carried at fair value (in thousands): </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Fair value measurements at<BR>March&nbsp;31, 2021 using:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Assets:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Cash equivalents&#151;money market funds</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">121,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">121,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total financial assets</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">121,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">121,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The cash equivalents are comprised of funds held in an exchange traded money market fund
and the fair value of the cash equivalents is determined based upon quoted market price for that fund. There were no transfers among Level&nbsp;1, Level&nbsp;2, or Level&nbsp;3 categories in the periods presented. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The carrying value of accounts payable and accrued expenses that are reported on the condensed consolidated balance
sheets approximate their fair value due to the short-term nature of these assets and liabilities. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>4. Accrued Expenses and
Other Current Liabilities </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued expenses and other liabilities consisted of the following (in
thousands): </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>December&nbsp;31,</B></FONT><br><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>March&nbsp;31,</B></FONT><br><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued employee compensation and benefits</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued consulting and professional services</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Accrued legal services and license fee</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">578</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,365</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Other</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Total accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>5. Convertible Preferred Stock </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Series&nbsp;A Preferred Stock </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In 2018, the Company entered into the Series&nbsp;A Preferred Stock Purchase Agreement with its founding investors
providing $25&nbsp;million in Series&nbsp;A Preferred Stock equity financing and issued 3,209,240 shares of Series&nbsp;A Preferred Stock. Issuance costs associated with the transaction were $0.1&nbsp;million. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-32 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Series&nbsp;B Preferred Stock </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In 2019, the Company entered into the Series&nbsp;B Preferred Stock Purchase Agreements providing $35&nbsp;million in
Series&nbsp;B Preferred Stock equity financing and issued 3,853,864 shares of Series B Preferred Stock. Issuance costs associated with the transaction were $0.2&nbsp;million. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Series&nbsp;C Preferred Stock </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In 2021, the Company entered into the Series&nbsp;C Preferred Stock Purchase Agreements providing $100&nbsp;million in
Series&nbsp;C Preferred Stock equity financing and issued 8,553,168 shares of Series C Preferred Stock. Issuance costs associated with the transaction were $0.3&nbsp;million. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of each balance sheet date, the preferred stock consisted of the following (in thousands, except for share data):
</FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>December&nbsp;31, 2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Preferred</B></FONT><br><FONT COLOR="#32406b"><B>Stock</B></FONT><br><FONT COLOR="#32406b"><B>Authorized</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Preferred</B></FONT><br><FONT COLOR="#32406b"><B>Stock</B></FONT><br><FONT COLOR="#32406b"><B>Issued and</B></FONT><br><FONT
 COLOR="#32406b"><B>Outstanding</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Carrying</B></FONT><br><FONT COLOR="#32406b"><B>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Liquidation</B></FONT><br><FONT COLOR="#32406b"><B>Preference</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Common</B></FONT><br><FONT COLOR="#32406b"><B>stock</B></FONT><br><FONT COLOR="#32406b"><B>issuable</B></FONT><br><FONT COLOR="#32406b">
<B>upon</B></FONT><br><FONT COLOR="#32406b"><B>conversion</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series A Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">26,315,790</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">24,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">29,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series B Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,601,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">34,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">39,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">57,917,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">59,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">68,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7,063,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>March&nbsp;31, 2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Preferred</B></FONT><br><FONT COLOR="#32406b"><B>Stock</B></FONT><br><FONT COLOR="#32406b"><B>Authorized</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Preferred</B></FONT><br><FONT COLOR="#32406b"><B>Stock</B></FONT><br><FONT COLOR="#32406b"><B>Issued and</B></FONT><br><FONT
 COLOR="#32406b"><B>Outstanding</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Carrying</B></FONT><br><FONT COLOR="#32406b"><B>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Liquidation</B></FONT><br><FONT COLOR="#32406b"><B>Preference</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Common</B></FONT><br><FONT COLOR="#32406b"><B>stock</B></FONT><br><FONT COLOR="#32406b"><B>issuable</B></FONT><br><FONT COLOR="#32406b">
<B>upon</B></FONT><br><FONT COLOR="#32406b"><B>conversion</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series A Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">26,315,790</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">24,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,126,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series B Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">31,601,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">34,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">41,080,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series C Preferred Stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">70,136,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,553,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">99,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">101,643,836</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,553,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">128,053,586</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">15,616,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">159,411</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">173,850,409</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">15,616,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The terms and conditions of the Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred
Stock, and Series C Preferred Stock (collectively the Preferred Stock) are as follows: </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Dividends
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Dividends shall accrue at the rate of 8% compounded annually and are cumulative in nature (Accruing
Dividends). Dividends are payable only when and if declared by the Board. The Company shall not declare, pay, or set aside any dividends on shares of any class of common stock, unless the holders of the Preferred Stock shall first receive dividends
on each outstanding share of Preferred Stock in the amount of the accrued dividends unpaid as of such date. No dividends have been declared or paid as of December&nbsp;31, 2020 and March&nbsp;31, 2021. The cumulative dividends at March&nbsp;31, 2021
totaled $13.9&nbsp;million. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Liquidation </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In the event of any liquidation, dissolution, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, which
would include the sale of the Company, the holders of the Preferred Stock are entitled to a liquidation preference. The amount to be paid to the holders of Preferred Stock is an amount equal to the greater of (i)&nbsp;the original purchase price per
share, plus </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-33 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
all Accruing Dividends accrued but unpaid thereon applicable to the series of Preferred Stock (which Accruing Dividends shall be paid out in cash), whether or not declared, together with any
other dividends declared but unpaid thereon or (ii)&nbsp;such amount per share as would have been payable had all shares of Preferred Stock been converted to common stock prior to such liquidation, dissolution, or winding up of the Company. The
original issue purchase price per share of the Series&nbsp;A Preferred Stock was $7.79 per share, the original issue price of the Series&nbsp;B Preferred Stock was $9.02 per share, and the original issue price of the Series&nbsp;C Preferred Stock
was $11.70 per share. The holder of the Series C Preferred Stock are entitled to receive their respective liquidation preference with respect to the Series C Preferred Stock in full before any liquidation preference is paid upon the shares of Series
A and B Preferred Stock. Then the holders of the Series B Preferred Stock are entitled to receive their respective liquidation preference with respect to the Series B Preferred Stock in full before any liquidation preference is paid upon the shares
of Series A Preferred Stock. Any assets remaining following the preferential distribution to the holders of Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock, Series C Preferred Stock would be available for distribution ratably among the
holders of common stock. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Voting </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The holders of the Preferred Stock are entitled to the number of votes equal to the number of shares of common stock into
which the shares of the Preferred Stock held by each holder are then convertible. The holders of Preferred Stock are entitled to vote together with the holders of the Company&#146;s common stock, as a single class, on all matters submitted to a vote
of stockholders. In addition, the holders of Series A Preferred Stock are entitled to elect four (4)&nbsp;directors, holders of Series B Preferred Stock are entitled to elect two (2)&nbsp;directors and holders of Series C Preferred Stock are
entitled to elect one (1)&nbsp;director. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Conversion </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The holders of Preferred Stock shall have the right to convert, at the option of the holder, at any time, into shares of
common stock by dividing the preferred stock original issuance price by the conversion price in effect at the time. The initial Series A Preferred Stock conversion price is $7.79 per share, the initial Series B Preferred Stock conversion price is
$9.02 per share and the initial Series C Preferred Stock conversion price is $11.70 per share, subject in each case to certain adjustments to reflect the issuance of common stock, options, warrants, or other rights to subscribe for or to purchase
shares of the Company&#146;s common stock for a consideration per share less than the conversion price then in effect. In addition, each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock will automatically
convert into shares of common stock at the applicable conversion ratio in effect upon the earlier of (a)&nbsp;the closing of a Qualified IPO (as defined in the Company&#146;s certificate of incorporation) or (b)&nbsp;the date and time, or the
occurrence of an event, specified by vote or written consent of the holders of at least fifty-nine percent (59%) of the then outstanding shares of Preferred Stock (voting together as a single class, and not as separate series, and on an as converted
to common stock basis). </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Redemption </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Preferred Stock is not redeemable at the option of the holder. However, upon certain change in control events that
are outside of the Company&#146;s control, including liquidation, sale or transfer of control of the Company, holders of the Preferred Stock can cause redemption of the Preferred Stock. Shares of Preferred Stock must be redeemed by the Company in an
amount equal to the liquidation preference for each series of Preferred Stock. The Company classifies its Preferred Stock outside of stockholders&#146; deficit as certain change in control events are outside the Company&#146;s control. As there is
no certain redemption date and the redemption feature can only be triggered in the event of a liquidation, sale, or transfer of control of the Company or similar event, the Company has concluded that it is not probable that the Preferred Stock will
become redeemable and as such does not accrete the Preferred Stock to the redemption value. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-34 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>6. Stock Based Compensation </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">On April&nbsp;20, 2018, the Company adopted the 2018 Stock Plan (the 2018 Plan). The 2018 Plan, as amended, provides for
the issuance of up to 2,902,738 shares of common stock to employees, officers, directors, consultants, and advisors in the form of nonqualified and incentive stock options, unvested stock awards, and other stock-based awards. As of March&nbsp;31,
2021, there were 150,889 shares of common stock available for issuance under the 2018 Plan. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Stock
Options </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In general, stock options typically vest over four years and have a maximum term is 10 years.
Also, the Company typically grants stock options to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> at exercise prices deemed by the Board to be equal to the fair value of the common stock at the time of grant. The fair value of
the common stock has been determined by the Board at each measurement date based on a variety of different factors, including the results obtained from third party appraisals, the Company&#146;s financial position and historical financial
performance, the status of development of the Company&#146;s services, the current climate in the marketplace, the illiquid nature of the common stock, the effect of the rights and preferences of the preferred stockholders, and the prospects of a
liquidity event, among others. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company utilized the Black-Scholes option-pricing model to estimate the
fair value of stock options awarded to employees. The Black-Scholes option-pricing model requires several key assumptions. The key assumptions used to apply this pricing model during the three months ended March&nbsp;31, 2020 and 2021, were as
follows: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>March&nbsp;31,</B></FONT><br><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>March&nbsp;31,</B></FONT><br><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Expected term (in years)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">6.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Expected volatility of underlying common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The risk-free interest rate was based on rates associated with U.S. Treasury issues
approximating the expected life of the stock options. The expected term of stock options granted to employees was determined using the simplified method, which represents the midpoint of the contractual term of the stock option and the
weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical stock option exercise data to provide a reasonable basis upon which to estimate the expected term. The expected
dividend-yield assumption was based on the Company&#146;s expectation of no future dividend payments. The expected volatility of the underlying stock was based on the average historical volatility of comparable publicly traded companies based on
weekly price returns as reported by a pricing service, as the Company does not have a trading history for its common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">The following table summarizes the stock option activity under the 2018 Plan: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Stock</B></FONT><br><FONT COLOR="#32406b"><B>Options</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Weighted</B></FONT><br><FONT COLOR="#32406b"><B>Average</B></FONT><br><FONT COLOR="#32406b"><B>Exercise</B></FONT><br><FONT
 COLOR="#32406b"><B>Price</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Weighted</B></FONT><br><FONT COLOR="#32406b"><B>Average</B></FONT><br><FONT COLOR="#32406b"><B>Remaining</B></FONT><br><FONT
 COLOR="#32406b"><B>Life</B></FONT><br><FONT COLOR="#32406b"><B>(in Years)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Intrinsic</B></FONT><br><FONT COLOR="#32406b"><B>Value</B></FONT><br><FONT COLOR="#32406b"><B>(in<BR>thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Outstanding January&nbsp;1, 2021</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,445,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,799</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Granted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,272,798</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">7.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Exercised</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(81,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Canceled</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(111,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Outstanding March&nbsp;31, 2021</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,525,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">22,635</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Options vested or expected to vest as of March&nbsp;31, 2021</FONT></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,525,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">22,635</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock options exercisable as of March&nbsp;31, 2021</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">400,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">4,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-35 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The weighted average grant date calculated value of stock options granted
for the three months ended March&nbsp;31, 2021 was $4.68 per share. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Restricted Common Stock </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company has granted restricted common stock with service based vesting conditions. Unvested shares of restricted
common stock may not be sold or transferred by the holder, except for transfers for estate planning purposes in which the transferee agrees to remain bound by all restrictions set forth in the original common stock purchase agreement. They are
legally issued and outstanding but only accounted for as outstanding when vested. These restrictions lapse over the four year vesting term of each award. The purchase price of each share of restricted common stock was $0.0001 per share. A summary of
the activity for the three months ended March&nbsp;31, 2021 is as follows: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Number<BR>of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Weighted</B></FONT><br><FONT COLOR="#32406b"><B>Average</B></FONT><br><FONT COLOR="#32406b"><B>Grant</B></FONT><br><FONT
 COLOR="#32406b"><B>Date Fair</B></FONT><br><FONT COLOR="#32406b"><B>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Unvested restricted stock as of January&nbsp;1, 2021</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">438,280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Vested</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(87,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Unvested restricted stock as of March&nbsp;31, 2021</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">350,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The aggregate fair value of restricted stock awards that vested during the three months
ended March&nbsp;31, 2021 was nominal. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Stock-Based Compensation Expense </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Stock-based compensation expense was as follows (in thousands): </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Three&nbsp;Months&nbsp;Ended</B></FONT><br><FONT COLOR="#32406b"><B>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Research and development</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">General and administrative</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of March&nbsp;31, 2021, there was $7.1&nbsp;million of unrecognized stock-based
compensation expense related to unvested stock options and restricted common stock, which is estimated to be recognized over a period of 3.31 years. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>7. Collaboration and License Agreements </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Novartis </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#32406b">In March 2020, the Company entered into a Collaboration and License Agreement (the Novartis Agreement) with Novartis Institutes For Biomedical Research, Inc. (Novartis) to collaborate on their research efforts to discover and
develop novel <FONT STYLE="white-space:nowrap">TCR-T.</FONT> Under the Novartis Agreement, the Company will identify and characterize TCRs in accordance with a research plan, transfer data arising from the research plan. and Novartis will have the
option to license and develop TCRs for up to three novel targets identified in performance of the collaboration during the collaboration period of the Novartis Agreement. Novartis will also have rights of first negotiation for certain additional
targets and TCRs identified in performance of the collaboration during a defined collaboration period of the Novartis Agreement and for 180 days after such collaboration period ends (which collaboration
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-36 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">
period will end no later than March 2023). If during such <FONT STYLE="white-space:nowrap">180-day</FONT> right of first negotiation period, the Company notifies Novartis of the Company&#146;s
intent to grant a third party a license to a target or TCR identified in the collaboration, then Novartis may obtain the exclusive right to negotiate a license to such target or TCR for an additional 270 days by providing the Company with a term
sheet to license such target or TCR within 90 days of the Company&#146;s notice of such intent. The Novartis Agreement provides for payments of an upfront fee of $20&nbsp;million, research funding totaling $10.0&nbsp;million and potential milestone
payments contingent on clinical, regulatory and sales success. In addition to payments upon achievement of certain clinical and regulatory milestones, Novartis will pay the Company <FONT STYLE="white-space:nowrap">mid-single</FONT> to low
double-digit royalties on net sales for each product directed to a target licensed by Novartis. After the end of the collaboration period and the expiration of Novartis&#146; first right of negotiation, the Company is free to develop TCRs against
targets not licensed by Novartis. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company concluded that Novartis meets the definition of a customer, as
the Company is delivering research and development activities and <FONT STYLE="white-space:nowrap">know-how</FONT> rights. The Company identified performance obligations for research and development activities, data reporting and participation in
joint steering and research committees. The Company determined there is a single performance obligation due to the services being highly interrelated and are therefore not distinct in the context of the contract. The Company combined the <FONT
STYLE="white-space:nowrap">pre-option</FONT> research services and data reporting into a single performance obligation Novartis has an exclusive option to obtain a commercial license for up to three Targets (as defined in the Novartis Agreement) to
pursue further development and commercialization of the respective Target. Pursuant to the Novartis Agreement, the option for Novartis to license, develop, and commercialize Targets is not a performance obligation at the outset of the Novartis
Agreement as it is a customer option that does not represent a material right. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company looked to the
promises in the arrangement to determine the method of recognition that best coincides with the pattern of delivery. The Company concluded that the performance of the research services over the expected research term was the predominant promise
within the performance obligation. The Company is recognizing the revenue associated with the performance obligation using the input method, according to the actual costs incurred as a percentage of total expected costs to complete the research
services. As costs are incurred, the Company will recognize revenue over time. Any change in the estimated percentage complete due to a revised cost forecast will be adjusted in the period in which the change in estimate occurs and the revenue
recognition will be updated accordingly. The Company expects the research term to last approximately three years, which is inclusive of the option to extend the arrangement. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">As of December&nbsp;31, 2020, the Company determined that the $20.0&nbsp;million upfront payment, together with the
$10.0&nbsp;million of estimated research costs to be reimbursed by Novartis to be the entirety of the consideration to be included in the transaction price as of the outset of the arrangement. The potential milestone payments that the Company is
eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the assessed probability of achievement. The Company will <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the transaction
price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust the estimate of the transaction price. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">During the three months ended March&nbsp;31, 2021, the Company recognized $2.0&nbsp;million of revenue associated with
the Novartis Agreement based on performance completed during that period. Additionally, during the three months ended March&nbsp;31, 2021, the Company incurred $0.4&nbsp;million of costs associated with the Novartis Agreement that were recorded
within research and development expenses in the statements of operations. Additionally, as of March&nbsp;31, 2021, the Company had current and long-term deferred revenue of $11.4&nbsp;million and $6.8&nbsp;million, respectively due to Novartis
Agreement. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-37 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>8. Commitments and Contingencies </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Brigham and Women&#146;s License Agreement </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company obtained the worldwide exclusive license to its foundational technology from The Brigham and Women&#146;s
Hospital, Inc. (or &#147;BWH&#148;). The license, as amended, grants worldwide exclusive use to the patent underlying the TargetScan technology in exchange for fees including development milestones and various royalties on product sales should they
occur in the future. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>Royalty Agreement </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">In June 2018, the Company amended and restated an existing royalty agreement with one of its founders. Under the amended
and restated royalty agreement, the Company agreed to pay the founder an aggregate royalty of 1% of net sales of any product sold by the Company or by any of its direct or indirect licensees for use in the treatment of any disease or disorder
covered by a pending patent application or issued patent held or controlled by the Company as of the last date that the founder was providing services to the Company as a director or consultant under a written agreement in perpetuity. Royalties are
payable with respect to each applicable product for a defined period of time set forth in the royalty agreement. The founder assigned his rights and obligations under the royalty agreement to one of his affiliated entities in January 2021.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>9. Net Loss Per Share </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Net Loss Per Share </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):
</FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Three Months Ended</B></FONT><br><FONT COLOR="#32406b"><B>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Numerator:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(5,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Denominator:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Weighted-average common shares outstanding, basic and
diluted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">776,769</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,218,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(7.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">(6.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company excluded the following potential common shares from the computation of
diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>Three Months Ended</B></FONT><br><FONT COLOR="#32406b"><B>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#32406b"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series A Preferred Stock (as converted to common stock)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,209,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series B Preferred Stock (as converted to common stock)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">3,853,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Series C Preferred Stock (as converted to common stock)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">8,553,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Unvested restricted common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">731,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">350,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Options to purchase common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">1,367,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">2,525,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">9,162,087</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#32406b">18,492,416</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#32406b">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>10. Related-Party Transactions </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">Novartis and its affiliates held shares of the Preferred Stock, including the newly issued Series C Preferred Stock, and
is the customer in the Novartis Agreement discussed in Note 7. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-38 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B>11. Subsequent Events </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">For the interim period ended March&nbsp;31, 2021, the Company evaluated subsequent events as of May&nbsp;14, 2021, the
date the unaudited condensed consolidated financial statements were issued. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>2021 Equity Incentive Plan
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The 2021 Equity Incentive Plan (the &#147;2021 Plan&#148;) was approved by the Company&#146;s board
of directors on April&nbsp;22, 2021 and will become effective on the date immediately prior to the date on which the registration statement for the Company&#146;s IPO is declared effective. The number of shares of common stock available for issuance
under the 2021 Plan will equal the sum of 3,278,048 shares plus up to 150,889 shares remaining available for issuance under, or issued pursuant to or subject to awards granted under, the 2018 Plan. The number of shares reserved for issuance under
the 2021 Plan will be increased automatically on the first business day of each fiscal year, commencing in 2021 and ending in 2031, the aggregate number of common shares that may be issued under the 2021 Plan shall automatically increase by a number
equal to the lesser of (a) 4% of the total number of shares of common stock actually issued and outstanding on the last day of the preceding fiscal year or (b)&nbsp;a number of shares common stock determined by the Company&#146;s board of directors.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>2021 Employee Stock Purchase Plan </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The 2021 Employee Stock Purchase Plan (the &#147;2021 ESPP&#148;) was approved by the Company&#146;s board of directors
on April&nbsp;22, 2021 and will become effective on the date immediately prior to the date on which the registration statement for the Company&#146;s IPO is declared effective. A total of&nbsp;254,390&nbsp;shares of common stock were initially
reserved for issuance under the 2021 ESPP. The number of shares reserved for issuance will automatically be increased on the first business day of each of the Company&#146;s fiscal years, commencing on January&nbsp;1, 2022 and ending on
January&nbsp;1, 2041, the aggregate number of shares of common stock that may be issued under the 2021 Plan shall automatically increase by a number equal to the least of (i)&nbsp;one percent (1%) of the total number of shares of common stock
actually issued and outstanding on the last day of the preceding fiscal year, or (ii)&nbsp;a number of shares of common stock determined by the Company&#146;s board of directors. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b"><B><I>Reverse stock split </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#32406b">The Company&#146;s board of directors and stockholders approved a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-8.2</FONT></FONT> reverse stock split of the Company&#146;s issued and outstanding common stock and outstanding shares of Preferred Stock, which became effective as of May&nbsp;13, 2021. Accordingly, all share and
per share amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted to reflect the reverse stock split. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">* * * * * * </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b">F-39 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>6,666,667 Shares </I></FONT></P>
<P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>COMMON STOCK </I></FONT></P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #32406b;width:21%">&nbsp;</P></center> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107876g78x09.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #32406b;width:21%">&nbsp;</P></center>
<P STYLE="font-size:200pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13pt">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#32406b"><I>MORGAN&nbsp;STANLEY</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>JEFFERIES</I></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>COWEN</I></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#32406b"><I>BARCLAYS</I></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g107876g00g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g00g01.jpg
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M>)>8L[2VMS)!6%DC)$)1TR56U"8S-5-A_\0 '0$!  $$ P$
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M83I12E\./24U="!TU0/H&ODB!-A+$_IUFN@<2 ) UI:[J)&-);FU?]UCHO\
MTC1O[;+WZLSPG_$75?JI#_&7_P"UKU?X'(/T])_#1_7)[K'1?^D:-_;9>_5F
M/^(NJ_52'^,O_P!K3\#D'Z>D_AH_KD]UCHO_ $C1O[;+WZLQ_P 1=5^JD/\
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M;N[15JOLJ^6Z#KTFOU44B&-F=N:\K. Q3,F@XD"PK!!9T1<6J:C4$7"WGGN
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M+P.YM@ZK8UWVATGI^PQU3F9.$%"5?,(MJFSAD40?.HYFZS\YBU\V:2-OXR0
MNPR*0/>'#-$R0NS2R-+@'7 )-SNN1G9G1ZZ6\C&@/> 3A\;P]X(S1LD+KRR
MN%]ER;G=<J%ZB7"BT[GQ9[;8[9K(U!:[;W<#BW[*2V=R5UC)Q$NG?(R/D)E[
M4E:MM#;T;/"_:%C+<7VHE; ]?Q]LL3)-HI*,1RKV/?1-:ULF<Q0]3'JZ>0$9
M"0 [-'$18W9M#0"UIO8K(O:]U&UH:_.8HNI9JX'@C(2 'AT<9%C=I!  +1R%
M23<_-8:YI7$0MT"-X!TB;V.[K#O6]:UYQ5WKH7DA9H-&R1B[VRU:)VGL62EX
M2EJ1Z3L[ZQS]*1A)^(*YC862,]DHY53HT<CWU.2]:\,S![GU,,T#3E(RN,;
M'.!(ZEKRYKK%PL"NE1R/?4Y+U;PP.#R^HAFA:<IL'&., NO:P:^[38D;"IQ/
MJ>C\73"?+#M'^:B,Q&-]G'O4?\UB\8[-=WN/Q%3CYB%BTPB81,(F$3")A$PB
M81,(J@6Q_P (=\_3.T?/C[/G#C/;C%?A*N\JE6Y6%]K<.]XTGD\:D5U!L"W/
MX#6=.;U'G$U:/(JHUY&Q4[9LVUJK9LNU81Y)BMQ*M%4C&M>12,#R+9*2JC-O
M&%12,_,B07 S-HYC&)34F"8:S#^BK'')3X=1LK,,QZJ90,8^.&$5-#3.PAT$
M=&UIUM/$ZI=$R -:92P9U&V,X?1QU&*5KJW0-[V35E2ZFK<*IWU;G-?)(8*J
M85XE?4N(R2O$(D=*7$1AQRJ.[9D8M"[(V##N9M:S.(F[VN,7L;E05G%@683S
M]JK-KK"HJ*JTJ=(S]5055!.=P8PJ'Z]H8;QR!U+C6,4SZIU<^GQ3$('UKW9G
MUCHJN:-U4YQ+BYU06F9SLSKEY-SO4DX7*V?#,.F; VE;-04DK:5HLVF;)3QO
M$#186;"#JP+"P;:P4M/DC_N3?GY1K+^'?\V&^YVZS2_W6 ^+&5#_ $8>OT>]
MSBOCPY3(9LLH53")A$PB81,(F$7!6C[V;%^8I?YO<9<A_*Q=\9\X*S4=CS]Y
ME^8Y><)FUBT-5C..Y(J[^B:/IF#WWP;V/9).+B*I1M16/2/+>J5Z8G3LDFT=
M655W,_'T!I*2+H"1WMBNU3:O'RA/^**:J>14_"1ACZFODPS2*DA8^2>HKHL0
MP2:5D8<2Z4 1.J7,8WJL@<7-:#LV%3LS'W8W%1X3#C6A]?/)'%34>%U&$Z44
MT$LQ8&QTY+IXZ%DDCK1ZQS0USR-MB%73=(K-W3E!PEW"Z"ZR*Z'3IW*R:AB*
M)=.ING=G*8G3J/3L].H_;R5&D$ @W! (/$$;#\>]0406D@BQ!((X$&Q'Q'8K
M7'D"OBT[A^7-U_0-)R%^B7VVH/@X>4U"V4Z"OYO8I\,O\AHU.SD<*8TPB81,
M(F$3")A%J[SA^)7R_P#U7=__ -I[;G8I.RZ7WQ#](U7Z7LFG[_#](U5,8K:T
MG"Z$B:IL'A]HG94+,<;.!-!V';/= \A*G*7/75]446T PFX6K'@&4=(PDK6U
MI&YMJT"3<BQ4D#25G:"0A?1NC!F<YE5-&1/6/8T0PN#7Q@:XASKGJ@0&EW_:
M5GW19IBYE3+&1-5O8W4Q.#7LMK2'.)/5!P#;WXV:0%&IKR0B.,?E%IX\O/ZZ
MTI'Z8WIN:!3FGU M/(C7&O7M6=WBNP[>*I\RNQN=ZCHJ5;L8RI3<PNVLC!T6
M'N,F8DE&+@&0D!J*%H#7S&6&(EH>V![P[(77>+L82"2X#J2+L&PKOO!GHFV:
M^4R11.L'MA>^^1Q)>.I:2+EP&P[6C85O%S.OE?Y/:%WOMZ@[DXH;]L=+?:[L
M&Z;)"\))K0.]&$%9[Q#5."LD%LRS.9M]/(JVEU!5V?C$91L[""DU$S HR[2)
MNI2L=3S0Q/BJ86O#VQ--6)H26L+BUT;0 +-N02+7'%=6F88)H8W15$+7!XC:
M:H31$M826F-MK6;<@VM<;[J?+ZGH_%TPGRP[1_FHC,-C?9Q[U'_-8C&.S7=[
MC\14X^8A8M,(F$3")A$PB81,(F$3"*H%L?\ "'?/TSM'SX^SYPXSVXQ7X2KO
M*I5N5A?:W#O>-)Y/&MZ;3]9T+!ZTBW7+K9^I_9^E-32+^A1D+L^VQ#9:8HD,
M\=N$'C.ZMHU)M)*+'<%B&;-NQC$S@R;-D6Z1$RROB'J;2TF!T[^B+CVCXFT7
MT>GFPB"FQW$:9CZG"::25[)(\5C@;'.YQ?TM%$R& '5,8UK0T>"I!63U&*3,
MT.PK%]7CF,11XC+-A5),]L-?,QC7,?0NE+X@W(9GO=)*1G<XN)*CSET&#65D
MVL7(FF(QM(/4(Z7.S5CSRC!%RJFTD3QZZBRS$SYN5-R9FLJJJV%445%#G()A
MARH9#'43QT\QJ8&32L@J#$Z$U$+7N;',87N<Z(RL#7F)SG.CS92XD$J1X72/
MAB?+$(971L=+"'B012.:"^(2- ;((W$MSM #K9@ #93(>2/^Y-^?E&LOX=_S
M93[G;K-+_=8#XL94*]&'K]'O<XKX\.4R&;+*%4PB81,(F$3")A%P5H^]FQ?F
M*7^;W&7(?RL7?&?."LU'8\_>9?F.7G"9M8M#58,N-'Y2:PN+EGH[6/D_J[[1
MQD*-)VH$-Q>UWM^)5D:O'+FG4DIZYI3-=LK5=\Z*W>O8U-X82)ON[_XX",84
M]1@U7 '8C6:3RZQ\G3%%K,9JJ!X;,\:HF. QRPN#1=K7ENTMOL4VU=)I'AU4
MYF$8?H3!J8XNE,2U6C=!BD9DIF$S 3U8F@J&E[LKGQA^P/L;[:^ZHJ"JJ*QA
M.J*AQ5.8_>&.H)A$YC*=3=L3&ZB)^T/:$>UU'KUR3A:PMNL+;+;.39R>TH2-
MR22;F^TWO<\;\OMJUWY KXM.X?ES=?T#2<A?HE]MJ#X.'E-0ME>@K^;V*?#+
M_(:-3LY'"F-,(F$3")A$PB81:N\X?B5\O_U7=_\ ]I[;G8I.RZ7WQ#](U7Z7
MLFG[_#](U5G^&%ZD]U:"KT;$[:X1>T6K]3:DC]KV;=?"#;3J H+73\2!J!"[
M3WS8;)7M9S%CI3AV[)6%$)9-5Y(.7;RKQYDW!Q#/53!%,XF.LS222F-L-5#F
M?K39YCA:UT@:\ 7N+@6#BLW5-$4KB65-WR2&-L55'F=K#U99$UCG@. !-QL
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M<S2Y^3O="Z"\<=/_ +2Z7Z[S.ZN3UM_[+O,L7T]1>S*7Y1%]=/="Z"\<=/\
M[2Z7Z[QJY/6W_LN\R=/47LRE^41?73W0N@O''3_[2Z7Z[QJY/6W_ ++O,G3U
M%[,I?E$7UT]T+H+QQT_^TNE^N\:N3UM_[+O,G3U%[,I?E$7UT]T+H+QQT_\
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)3")A$PB81?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g107876g01a14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g01a14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X66]:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<P,6$Q-#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S Q83$T+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @($1E;'1A,28C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,38M36%R8V@M,C R,2 Q.3HS,#HQ,"8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" Q-BU-87)C:"TR,#(Q(#$P.C P.C$P)B-X03M38W)I<'0@5F5R
M<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @
M(#(S+C N,R8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!,:6YE($-H87)T
M)B-X03LF(WA!.^* HB Q,30@0TU92R!B;&%C:R!C:&%R86-T97)S(&-H86YG
M960@=&\@9W)A>7-C86QE+B8C>$$[)B-X03OB@*(@,3,P(&)L86-K('1E>'0@
M8VAA<F%C=&5R<R!C:&%N9V5D('1O(&]V97)P<FEN="XF(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z
M)B-X03L@(" @(" @(" @07)I86PM0F]L9$U4)B-X03L@(" @(" @(" @07)I
M86Q-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @
M(" @(" @("!#/3DS($T]-SD@63TP($L],"8C>$$[(" @(" @(" @($,]-S @
M33TS-R!9/3 @2STP)B-X03L@(" @(" @(" @0STQ,# @33TY-2!9/34@2STR
M,R8C>$$[(" @(" @(" @($,],3 P($T].3,@63TV($L]-#4F(WA!.R @(" @
M(" @("!#/30Q($T],S0@63TS,2!+/3$F(WA!.R @(" @(" @("!#/38R($T]
M,S,@63TP($L],"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @
M(" @(" @("!G,#%A,30N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @
M1&5L=&$Q)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q-BU-87)C:"TR
M,#(Q(#(P.C X.C0X)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#$V+4UA
M<F-H+3(P,C$@,3 Z,S@Z-#@F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,C,N,"XS)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($QI;F4@0VAA<G0F(WA!.R8C>$$[XH"B
M(#8@0TU92R!B;&%C:R!O8FIE8W1S(&-H86YG960@=&\@9W)A>7-C86QE+B8C
M>$$[)B-X03OB@*(@-B!W:&ET92!P871H(&]B:F5C=',@8VAA;F=E9"!T;R!K
M;F]C:V]U="XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"8C
M>$$[(" @(" @(" @($%R:6%L+4)O;&1-5"8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@
M(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#/3DS($T]-SD@63TP($L]
M,"8C>$$[(" @(" @(" @($,]-S @33TS-R!9/3 @2STP)B-X03L@(" @(" @
M(" @0STQ,# @33TY-2!9/34@2STR,R8C>$$[(" @(" @(" @($,],3 P($T]
M.3,@63TV($L]-#4F(WA!.R @(" @(" @("!#/30Q($T],S0@63TS,2!+/3$F
M(WA!.R @(" @(" @("!#/38R($T],S,@63TP($L],"8C>$$[)B-X03LM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF
M(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G,#%A,30N86DF(WA!.U5S
M97)N86UE.B @(" @(" @(" @(" @<G(R.38T,3DF(WA!.TQO8V%L(%1I;64Z
M(" @(" @(" @(" @(#$Y+4%P<BTR,#(Q(#(S.C,Y.C,R)B-X03M%4U0@5&EM
M93H@(" @(" @(" @(" @(#$Y+4%P<BTR,#(Q(#$T.C Y.C,R)B-X03M38W)I
M<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I
M;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!,:6YE
M($-H87)T)B-X03LF(WA!.^* HB Q,S @8FQA8VL@=&5X="!C:&%R86-T97)S
M(&-H86YG960@=&\@;W9E<G!R:6YT+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG
M(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @
M(" @("!!<FEA;"U";VQD350F(WA!.R @(" @(" @("!!<FEA;$U4)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D
M;V-U;65N=#HF(WA!.R @(" @(" @("!#35E+)B-X03L@(" @(" @(" @0FQA
M8VLF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @
M9S Q83$T+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R,CDV-#$Y
M)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" R,"U!<'(M,C R,2 P,#HS
M,CHQ-28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q.2U!<'(M,C R,2 Q
M-3HP,CHQ-28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M)
M;&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP
M93H@(" @(" @(" @3&EN92!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI
M9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C
M:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[
M5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE
M;G0Z)B-X03L@(" @(" @(" @07)I86PM0F]L9$U4)B-X03L@(" @(" @(" @
M07)I86Q-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0TU92R8C>$$[
M(" @(" @(" @($)L86-K)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO
M;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^
M"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,#0M,C!4,# Z,S(Z
M,C4K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D
M:69Y1&%T93XR,#(Q+3 T+3(P5# P.C,R.C(U*S U.C,P/"]X;7 Z36]D:69Y
M1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#0M,C!4,# Z
M,S(Z,C4K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R
M96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM
M<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @
M(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'
M26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @
M(" @/'AM<$=);6<Z:&5I9VAT/C$P,#PO>&UP1TEM9SIH96EG:'0^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O
M<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!
M05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!
M-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT
M041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*
M0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU4
M1D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&
M4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%:045!07=%4B8C
M>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W
M24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W
M449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))
M>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%
M;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&
M4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M
M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S53
M5FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!
M44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C
M>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE
M2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*
M4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E
M6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N
M6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q
M;&5O96%F3#)N6'8Q2RMV-"8C>$$[<F$V2TQ,-E5H;V5$=G=5,39B="]8<&EQ
M2S!Z5F1.,5,Q1C-P,7=L,6)&:6]L:DY25E11:D955FER0R]-=FMR5DPO>D0K
M;&1.=59T2"8C>$$[2S)L6E1*25=74T<U5C5(15)R1S,W;$%+2%EN<C0T<%-7
M=R],2'I-=')Q8VPS<D5G=G!R5C=E>D5%,&=6;4U#2W9R3W<K>#9I;C11=B8C
M>$$[=EAT:%<P+S%V>3<U;'5.5&EU-T]A3C5)-U=/2S!U2F)M94E7;'=N4#%*
M4D1'<%-C4SAL<4I0-6%(8D%H:F<X:V9M:GI.,F1::E<O3B8C>$$[<C91:T4X
M:"M,,6\R06(Y,D%F,V%%16IQ92]F0VPV8EIR8W!A44QD3TI,;%DQ13=R.6QP
M06\U16),<U0W645,-5I9;UEN;6QC4GA2<28C>$$[6&MD:E)65E)5:VLY9TU6
M4V4R.#8K5DQQ-6ET;TY59VMU2FEI>%)"=FE9>7)Y4550:5!X,C8T<6Y72V],
M5SE/1W!A4F574%$S151):"8C>$$[-4UG1#!Q:$Q*.%%O,4]M2W-!4#5887E,
M83EA3%579W5'<UDW87IJ:FUL<#8S;W%*;61Y3U%6<&57=W)52'1H5&%E*UEF
M3'9M4S8Q>28C>$$[5RMS2EEZ>71W;6YZ>5A%.% Q2UI68TU21$=R2DU*1UI3
M969H46<W645-8U!K=CA!3E-V,7!.6FE7*V5(,#-K.5HO1T-L9C-62S!H3B8C
M>$$[5T9#9G!/1DPP*S-%>7=2:5IG,'=64DEW-D9Q8FMB1'9G479X5D-A;'$K
M;#980W,R;UA59')%-T95959G;TI#;&E".&Q5;D951&)E8R8C>$$[+TMT>F-2
M5S!'<'=08U1.1W-546%J35I6-6]+2'A(-#=D9'-65&Y&6&UT-35).#<O04MA
M,5,K=')Q3C1B<6%:-&]P3'595E=E1V5"0R8C>$$[04EY<65I2C%016AV<S=-
M0E1#;%)T9GDY.#=26&9+3%56=%%L>3AS;'ET>$Q),7=P:V1O,V%.;$MO63!B
M:G@S<EAR=&EQ3S!J>6XU,"8C>$$[9S!29$IU<&M$=S-.;F1X,SAD,TE3+V]M
M05-1=6AJ<G<T>'5W*TPW5DYS5E)E=2M7=DXP=7!A;F5A6%!';'IC1"]18CDW
M<61':&DY3B8C>$$[1F$R1G-&84AD;%IH265H879567%L35AK=CAZ24QX8G5,
M5UE28U!,0S%Y+W%Y1EA#:CDU.$)J-#!,9'%F,'A6-F)G43=&6%EQ-T98628C
M>$$[<3=&5U V3#5R+U-E<UA/;FDS:E%124I/8V1Z1$TT5G9S1U)%4'<X:'8X
M1$XW,')I<3=7=DDS;')7=%%854Y1=&UL=6QJ5TE/2EI%2"8C>$$[0E<U8V5+
M<T)V56<K,DMP0C5Z.&XK6#E-.&@S=W-R9&]M,#)#86%Y8U-Y.&\S64QU1'DS
M;T550W911$-R4&-#=7A6,DMU>%8R2W5X5B8C>$$[5'5R84,V='!B83114U%4
M;S!C<4=T1U)X>%EB94E/2W-A,#<X<W9*,FY8548Q83)B<%!B=6MK8D=A56IL
M2#EK:T9Q9F%O,WI!>'164"8C>$$[>71P;&QP9FTS>D)9,DM'2S!7,S K4EE3
M-W5!-VTT1$5C>3-8:4U66F)I<G-69&ER<U9D:7)S5E%'=&%(<&UT5V8Q4%5O
M9EAT<3AI;B8C>$$[2FPS-&QE<6M(;WAX5DIB9CAS+TIS13A5-E=41U-(,'=V
M2U=6:'AH6&EI;%,Q0W1F:7 O3G9J87)02F5M,D]M-C,U;W-R0T)B83!I=B8C
M>$$[3&-X=U)I:4QY<V]786<Y>6$T<7EZ1EA9<3=&6%EQ-T9867$W1E5V,7IZ
M0F\R9S)1=F18=6QT3%9N15%L8TU2>EE%9V9#1#%O8VYJ>"8C>$$[>6UA:4Q7
M,'!M+TUZ>49#<VI383-B05)-<4]!4WA$3W)-0E)14V%"1W)4;U)1-S593DQK
M4%)&:$U,+WI:-6%S134S97!7.%-M,BMU9R8C>$$[.'<Q8EEU:V%Y:FI7<7,X
M:7%P+V%*,G)K231:;FM02F)B<R].;FQM.75:8F$P,5,Q;FUH84Y(5DI54'A4
M:7-953%O,U!T>'AL:&U"6B8C>$$[0E1B2'9*+VQF5'1".'@V:$AB86]T>F-8
M4W1C>E<T:EE31D=K255Z4S@S:F-O,5%/2TLS:EA)2WIB07)(4'I'+S516%A0
M*UE35#E72R8C>$$[<VIX5C)+=7A6,DMU>%8R2W5X5C)+<V,P;B]L3W9-4"]!
M1$-A8BMU-7A6:V5+=7A6,DMU>%8R2W5X5C)+=7A6:FYL,R]!2E-F>E@O>B8C
M>$$[1C)V+T%&05%9<7E01EA9<3=&6%EQ:$Y5,4],5')6<FU73U=65C9R0W9*
M=#EU-4%(,&Y*=VAX1VM%<3%P8T,U=&]R9TDP66Q53T5F:B8C>$$[>4%95D9E
M2EEF:FM:0VI35EA!<5)E9&]D3G503# Q=G%8,6=78S!K26MA,55.27!35EI&
M-F=G07-G2%1V;"MN0C0O5%8K8D-C>$575R8C>$$[0C9R-6,X;7HV54QA*W9T
M5V9Y*VPS2DQ9,EAP;VM%8VMQ6%!Q3$9,-E-U,T9P6D16;DHR03-'6G-$:S1T
M:$AI<F8W1W%784E&;3948B8C>$$[>E U9CAO,UIS5W5R>31J=G)F5$EK=$HW
M84M.6$MR9%=Z=U-"4%0T1B]7:5%#4&IX;U1S37%W>7E#-D%R:2]18BMX;%!*
M16,K-6I$+R8C>$$[04IE9FQH2T9T-&19=F],65!!3%II545A:%EP1T9(84]P
M5715<U=/>#(R1UI(:35X=G=I,E!J43<P*R]+<5-38GI"<G)V2&)6:D-2:28C
M>$$[4S!G9VAJ*S)X234R>4UJ+T%$85ET-V5'<$QK=E1-0T=/9FU.+W=!;TQR
M;B]!1$-39G%X5FME2W5X5C)+=7A6<&U65DQ-84%B:VY&528C>$$[<W1.5VAV
M3EAE,FE$56=I3$UW63A45F="5F5N:E-U2W!P:7)S5EDU<% O2V1E668K6514
M9C$S3TMS:GA6,DMU>%8R2W-7.#9E8V)04B8C>$$[-T]72E-R,TA!;'=3449(
M:6%%2#9/+U1*-#1'4F])2G!/4$QT=SEX;VQN3S166&MI5FY29'5*27%19FEF
M8V0Y.%IX;S!O5$A)2F1I<B8C>$$[2%!,=B]+5"MA+SA!;4QT9BMO0T1&5U(T
M<3=&6%EQ-T98:4@U=2ME-S)B5T4X=F%%<3-.-GA646="5C!D4WA0>&Q9;EAT
M<T-14V%$3B8C>$$[;G!-3S$X;7)*341M.6(X<71D=#5B,'<S;E V,F)A4#$O
M54-+,U!I2S=*.$Y01#(Y.'=-;SE2.3=91'-M;59P4TQZ='%3861O16QZ3"8C
M>$$[64YQ1G5*26QM9U-14D5"<$%&8FMF*TQ/26]-=C P94MD03!712M7-T)T
M5C@P*U@W8E-V,'!C*U@W:#E0=4QL,71K93=5>$9W;'=*>28C>$$[<TEK67AQ
M1U-4.6=!,7)T,'I/:&EM6F-):TQR=3DQ8B]!0V%*4F@Q2#0S5'9Z4G(R9S(W
M,FQV96%:9'HS375N<$IA8VY-5#%K=7)E3B8C>$$[275F4&%66E=2;6%V=S V
M;755-$E43FM%5GAF;U R335X:659-F9Q4V)49DUN-61A:DXV86%B95%15$=%
M5W)*-G)C,&5.,&-E;D,W1R8C>$$[3D98;4A(-U$S,WDV95!.16-W=T=01V5I
M<BM55V\R.3-Q=7-P0D)"0VM22$5#2S%3-$$U;6=A5T51=DE0.6%,63=C<35Q
M>35:96XT128C>$$[36,O36(O;$)D8R\U:$I0,5EQ>5!&6%EQ-T9867%K=FU0
M5U9S-%!1:$Q'-VQ01T)56E(X6"M6=GE!03,R1TMT95=T24YP0V)M5C-E928C
M>$$[87)/5RM'<%!E9TIR-U9X5D\X5F1I<DA.2B\U5')Z1"]!37=M;2]R=6-6
M6DAI<G-69&EQ42M9.69.;W8Q4WID1&5306QN3$%I1D)S6"8C>$$[8T1C93-J
M,CEJ15=6960V0G!J*UHO37=)6F)N4CE.;35V3E9!6C=L9C)I2E5,=6MF:'AP
M>3A+6G-I0FAX+W="3U14.5(X9SEH:E)),"8C>$$[5D5!5E9&04%!04%065IR
M0U<U=D9867%X>GDW+T%-<% U<B\U:3=8+T%+9TE-5EI(:7)S5F1I<D@O4&YM
M83 X=656-S=5<#5!:DI%=R8C>$$[:%@T0WI/4E%55GE/5S4S03-Y>D9!>6M!
M145V4&9Y:#AG>3-6=DPU<#%L-54Q3R]C4U)H94MT1T99;%%$=T9+1&)9*THW
M-6YA;DYW928C>$$[:5!X85E$:4XO2C8O8G=2,CA+47A!:4]-0E5"2EEG1'!U
M>$IZ6$4R8F(Q*T)74#A!;F9653 O4UEV56=T<&MU-VU/,TQ8-V-B4TMT6B8C
M>$$[0DI/84Y245EW0B]L15E9:V<R1G!H1G@U-SAL=UAS.' X=%%Z,W-H33EZ
M4$-S1$-2;'1P2DIP0WI"6&]53&-#-FHQ05-F2$Q01FY65R8C>$$[85)W0G1V
M>D4X=%A69W$S+T%*8E=3,FEJ87I:4UE':E-(;3=#04=4:4-E3F]'5D]R3T%&
M,W=$2DE'=V9.5$5-=#AU85@U8C%Z4F)B5B8C>$$[<#E&<V\U8G-P3DEG:%%J
M;D%7:FI.4W8W2VIB=W<K4%!V2VU)4TPX<V)8>D1&<FUS4V%L650R1G,V<4E%
M8C%6:%IH23E44UHU0WHP-R8C>$$[<6%5*UE*<EI&3F9.;FY(6'1),7%#># O
M4WIF=WE2>'E3>4EK-TUV3UAG9G-P=TY2.6XT=797;4)5;3AY*V%D9#%$.'1B
M*V4W.'8S528C>$$[8W0Q1F-2>FU)=V]L<W$X85!-='I*0DM2.%)(-W1(*WEF
M15E54%-S0W5X5C)+<&1R97-W85IA;5)I<E-N84]):V=S5#!!;T1I<54K6"8C
M>$$[.4IE-FYB5G11:B]E>6)W<%=Q278X;T)Q5#=M=4975#1&57)Q5C1B5V%6
M13E2-#!:,6I(23AI;TI!;V]:="]9131Q=TA29GI%.#)8,B8C>$$[<#)D<E U
M8VQG=#=I4T)*3&=P3V]!:U=R<T]38V%$9'A5+UI&1'5C2U5Z.' S.3%F96-0
M354Q,7!T>G!C9W1T3U@V=&1T8G1)441C+R8C>$$[1E<Q;759-D=V.#%F8D%H
M;4=+=7A62SED,653>5-/,W165U,O=4LK:6I%0E959F%K8SEK56(Q=V=+.'4Q
M6%5.53%B57!03"MK4W1C,R8C>$$[5G=61W$V:E%-44(P5D]1*T$X5#A.3C%'
M-7I:64U)>'@T-715<%=A1#%$>3$U9G-T1#!Y2WIT;TDT94MG4#9F2VA)2&EX
M635G-7-P;B8C>$$[2WDR4D9"3F-Q4VAD5W5R:3 P=3AU-V5%,TYX8G=34W<R
M-C%R239)5U9"444O15)465EQ=V)4=GI#.#,S1B]A,CAV;'%54GIM,T1Y028C
M>$$[4W)1>7@X;E=R;T9"6#=D4V%"9&IV=FA3;3-K<39U-W)84$Y-,3-:=EE4
M;3AT9S%T23AC:D%#>&A!4$M*;E1F-31%371X5C)+=7A6-"8C>$$[>"M9;'IC
M*V,O=T%W9% X04IL;7I.<"MN3W1Z<5AP-VIM1%91,B](-&%%,% X=$\K8DA3
M>$5);DE7;DME9S9V67)3,FAT8F%+,FA52B8C>$$[1$-G4TY",$-Q2T%$3F9+
M4DIS=&]&0VQ806PR2W1/:75P5G='53=&4TMG-'$P66\R2DI116YQ4T)V<U(K
M;S1Q-S!O-E4T0VQE5DM$<B8C>$$[6&Q8-SDX5EA!04-G,D%X5F=N:S-Z3E!R
M4&TV*U%A;6(K,6AT0GA23&53,&E6=E<O:VME5&UE2DAX:G1H4WIV06AJ;C5J
M9CA!2T,V-28C>$$[+W=!=VMN-G-66DAI<G-64WI79&5S.4YJ;U<Y4S5F84LS
M5#1N2B\Q8U93-U)T1G5B=35'<F%T.%5X,W0W8S=R1T0K<RLO=T1$0W)*328C
M>$$[0W5X5C)+=7A6:FUK+W=$2V1E668K65149C$S3TMS:GA63&1D,7%,5$Q9
M348Y4S5L4$<S9W%!5V%N53$O6DAC-%%,5C5F9C9V9#8S9B8C>$$[=F\K:%-I
M.3%A-4DO4T]Q250V8T%",VA62&I7=DAT4G5)-FY.:FAW1$=/3V9Y87!3=EE0
M42]*+VLO5"],9&=)65(V;#%*.%9X8W1U>B8C>$$[<V5P-456>D5Z-7IK4&MZ
M:D=K+WEH:S=&6%EQ-T973V589CA!;$HO3F8O35AA+SA!54)":7)).%9D:7%4
M96-F371T-6$X=#,R<WIJ:R8C>$$[=')'5U)"*S U*WE0=GEE3TA&24)"3$-0
M>5,X<C-%3VY84&U85EEG3E8Q959P:GE#.&M5;EEB2VQ.9T9P,#)Q3W5:;7-Y
M5E5">414:B8C>$$[1FYI96]:9TXW<U9D:7)S5F1I<G-69&ER05!Y,C!4-G!Q
M3CEE>#).=&)1>7A"1&-7.7DQ=W-R;5IZ>6E(<E0X62]40T0T9W)62%1#;"8C
M>$$[;BM"1$A0>D<O=T-51C%Z+T%*:$I0,5EQ;F0Y<4YH65%.8UAT>$AB47%+
M;5-69V\R*V5%06YK='-$=CA!.#102W0U9G)P3VDV>%IM-28C>$$[:U!%,T4P
M9VIJ0DIP4E=9<4-F;&PS-6)*5C!74$5'539.-6)T3&-I.'5(*W98:V]$1S1C
M:'AV=4]"239:4WE4=D%R<U9D:7)S5F1I<B8C>$$[2$Y*+S54<GI$+WI#86(K
M=35X5F8U<S@Y*U=V2SEU6#%/.&E3-4ER1%HX,45R*T9&2G)4,R]J;'501$MF
M24E*<&=%5FYQ,VY3-48Y<28C>$$[=7 R;6LV6% Y;4]+-FEL=4HT:E=K64U,
M.%DP-T9E6$MV6$TV26II1W=-<&4W64Y*;&9-,#E(,&UW.'1E6$Y05S%S:D):
M,G%G8G1);R8C>$$[<C=L;4]95354>4=Z6DQ:8UEH9% U<SAU4DUI9E@T<'!*
M1%))<F-M-&-N+U9H1'1I3E!K4%0U-V9E>$]A039Q5#9J<C$K=D148DDR528C
M>$$[8D-H=F(T8U-V63A,8TAM5#1C*TEY46A#4#%'+TEF<E)X4VQY1F4O.5-B
M5W-5.%9U:V,X>'5*5D9(;4MQ:%DK4$9104UP:U%4<TMB428C>$$[3FQ827!D
M:7)(4$QV+TM4*V$O.$%M3'1F*V]#1$974C1Q-T98:2]N<E5*+U S;G4P.&TV
M62]Q84QP8VE83W)Y<#9B<3!I;EEF=&9:*R8C>$$[6'HR8DYJ<&]J2$$U1'HV
M3D]5,S92,65X,FQR1&%7<U9R06]31T)&:FI18D%+;V]!33$X<$5M>3)G54M6
M8T-867$W1EA9<3=&6%EQ-R8C>$$[1EAM6#5587%T>')/<#)#851P*VYI>6E5
M4$YA25!6;$Q.549P1$I),&EN8S$K5T5P3# S06AJ6#5L0U$K471C15I!8C9Q
M*S4S,C<O:"8C>$$[:V]692]*0F5C,T@U1RMB3F5U2&LX,&$X='IZ4$PQ1VQU
M3&]H=D))85=L=7$K,T$U<U)Q.&-0<$(K=V9R4#)T6$))<'9*+WIJ.35C3R8C
M>$$[:5,R274U5VYC9D,T5TY)=5%'>$5D1TLO-T9H:U(R:DLK47!4:$AX63<U
M6"]!1$0X=V9L.7%1.'$K8S1Z3'!Y3GAS=%9*231P6%E.<R8C>$$[46$Y=6<K
M5U=:9%!(2T]/0W=N4F]V8G10,4Q4.5)T574W0S1J=7)A5&1:66U$3#!R5&)O
M9"MM87554T128FM29U8R2W5X5C)+=DTO328C>$$[5&5F-79/*W)A9C52:6=T
M,W5R5W=&-W)6,'E&8E9&*W-&9450>$Y)-S%)0C0P1DXK=3$K25EW3&PX:T<P
M=SAV+T%*3BM5-T=74RLQ<28C>$$[32M:9%IU3C=R54Y60S-"62]W0U)'+TI&
M1U-N<7!N665K95-/14QT6B]*5#AV.5%D<#=7>&)2<G=I9W5D2V,R:' O>&I4
M.3!F<%1$1"8C>$$[5UI).6(Y-D1J:6594W5(.'5F3S)I;T8P<E5.2#%Y269#
M<T]T-F5S8VE,5V\O=T)*=&9I9'9D,'EW-F]3-3A1.7@O5W@X1U!C4&MM5B8C
M>$$[;C5Q."MA8D@V96]E46Y3>FA(>'DV4F57='A8,VIT;DYU-7%E,UA+-5DT
M4S54,SAW5UDR-DYJ.#)%<E(O2TAM9$0S<G!J3B]X0C)W9B8C>$$[;'8V569M
M;3)9-EIQ0S9H67A887=4,GEY:6]H=6\R:&Q(*W1',WA,.4]54VI2<$M+>4MU
M>%9J;FPS+VQ*+TYF+T%$1C)V+U5"0FER228C>$$[.%9E92]M3C4Y=3=A4F9+
M+VQ92F4K6C<V<V)O3U1#,6I),VQK-$1R,E56-C5L8694.%AQ;'1%3F,U.%!V
M5% X04Q8>49A*U4Y15-*,28C>$$[4CE5;DA/*W513C-C-VYF<C,O,G5M1%4U
M*TTP4'!#-#16=65B3#AX;7@R2W5X5C)+=7A6,DMU>%8R2W9-9GEN:30V-W)J
M+UA93"\W4"8C>$$[-S(Q16=I:C53369455!"0T%+,4E#3U9(:%=P=VQ*96Y9
M14UC+TUB+T%*45A84#A!;45K+U9I<DDX5F1I<51E6F9+2&PO=T%Y5VAT.28C
M>$$[5W1%;D%"16-H035P6'5P24]7-',X<UHR651G2F,S;'-N-51F;48U4FUE
M-#AG838S,61J539D8T9$1V5V*S8U0C9F,UIN+VUC5U0V>"8C>$$[4F$K1V-E
M5S18:C@U4'I',$=)2C5Q.&UY4VUO5F)U,%IO;&%M>%!",6MR6#)/4B]*46PY
M16LK3#-H;#-K,S@T4$PS;6Y653!M,W,W-B8C>$$[>3%";WI)63=U2EDQ*T56
M64MW8SAV=7I(>F%/94U7951/3U--=5):,6U+>F1I<DA.2B\U5')Z1"]!37=M
M;2]R=6-66DAI<G-69&ER<R8C>$$[5F1I<G-69&ER<U9E9DYR6&UF5"]!1%HU
M;E129DQJ-C)R,T9Q>GER9#(Y<7%0.5-H2$$K<V52,C-Q0FQS25)),VQ8=U%3
M5CDS669M,28C>$$[-6I14GDS9' U4# K5"LX:G1#8C=52V1#=G)%4G=P6'A1
M16IX>3!(1DAV;CEG62MO*U-D*U5024AL>GER07<P-D5Y6&MU.7IQ334Y4R8C
M>$$[-6U9.5,X;% Q6EAL>GEN>C5D>7AG0G8Q6DAL3$XR2W5X5C)+=7A6,DMU
M>%8R2W5X5FHS;&9Y9$9O56MT=S$W3&989'=V0V%A5T]&4R8C>$$[44=,1#1L
M5#%4,2]B:V)&5U$T<3@V,7IY94Y0+T%#.'5D3#%06#-75FA,2$9E>7I3=U%S
M.#5!55-G1U9M1E8U2'(Q63E-2W-Q+W=!2R8C>$$[=V8X059Y,4PO<$UM+W)G
M5C,K1EE0*W)L<5@O4UI.+UA&541R3VQA6G!L:UIR<E=R*S$Y5FA$0DI*951C
M5$Y*=$=.<3E4:%94.'1A3B8C>$$[8C9H;U9L8VY83'DK;4U3<F,S5G9E5&5K
M.#9$:DM6*WIT>D)P<TU65$PO0W-(+U9Y,4PO<$UM+W)G5D,V:G!/:C9B0W,K
M;V$S9E=S3"8C>$$[=4DP95<K;%5&,C9+2VXR2G=Q-WE0<71R4%E35T@V6&DQ
M5SEG;75:9S931U)X87I836ML;W)L9W)C,'0R:E(O02]14T92974V1&0V;"8C
M>$$[<5=K6&-&.#ER2' P-6UM:%AL4U94>$Y.;55F<VQD=V9H6G-667IP,VQ#
M,E!M-U=56'I,9G1.-D9M<G=2,UHK<TQW.5)I6F%P5&I35B8C>$$[94Y$=%AE
M;%)5<6YV*T,O*S$W<D@O4U@O04TR63)R=CA&+SA!83DQ:B]P3"]!3V)-8E9J
M,'1L62\T;G0W1U!Z:&5R8F]S,7)D,FI8:"8C>$$[.6,S<G1#,7-%+V0X84-0
M,5$O>&9A6D)I=$UH+W=8+S)V9%DO-E,O*V)-8E8S*T,O*S$W<D@O4U@O=T$R
M63)Q4UAK;6PV4G$Q:S9E8B8C>$$[6BM6<F1-3E)T3#(W36EV16QU>E!'159$
M.%E-:UHW94A79WA7;617,7A"8S(X5GIB>4Q,0D]I>5%Y<6%Q>4]/4W-$-$5(
M07%4*UEV3"8C>$$[=#%Q,3=P8SA.+TI:>%=->E-4>'A&,4UI<T)S1U9L;V9H
M2S%.9&U/2W-D,%!Y6'!%;71A.#!/=3,X-4YZ14AJ:#%+-CE737!!:UI%>"8C
M>$$[-6ER8VM.3W9H,DEW<6YF*T)R2"]!2W5M<B\X06-3=2\K<6U"6&8T1W-F
M.$%Q-F%V+W=">$LW+S9Q67%K1G)P96A82&UE5WAI.#!8."8C>$$[:V9!,C!D
M9TY3=2]71C-B<WI81E1Y-D--<G18<V9F0W%F+S1'<V8X07$V878O=T)X2S<O
M-G%91F0O9V%X+W=#<G!Q+R]!2$5R=B]Q<"8C>$$[:7%39E=V3&5I-B]B>DHU
M;VPY1S!-.%=P5V0W9E0S05IQ2W%G23=/=DI(8F9V,3A$:%9N<7-R2T=5:&Q9
M5D)'-$E/0E<X5F1I<G-69"8C>$$[:7)S5F1I<4$Q>E%T33%Y=TYH<552;'1M
M64U51$UH<4YU<6M(8T5G*S)+;R]&6%EQ;"MT-D1P970R83)E<%)'83-74EI1
M;UIK*TIA.28C>$$[,4E.0T-18U9884IO;6YA3' V869P,%II=&]Y>DMR37IM
M<D=P2EII4V-64C)+;TQ73D8P,U=,4#9N<4U8<E=X9%A+8VU89$158G%18R8C
M>$$[5E%79RM49$$P2V57-# R0F\U<#!62EAA4C5/5DM68C1I4GEB:4]2-S!X
M5D]S5E%&=&]7;5<R<C-E<G=X1F(K*U9&=4I/5$5%27%Q2R8C>$$[2U1X2'=O
M;TY",D=+;U184$]0;#-1<FE+,S%7-6$S:VU4,4EZ-DTX:49E45-V3TY'455:
M9T15.7@T:D953EIF;4PU3G9R-D-W<SE1.28C>$$[939U0V]I4DE:>4-85EA&
M5S1C5C)C5G%D=6@S>%9+66]0>71U9&-N,5E8;'5U<'<S84=:<&)L;W8S-$A+
M34)*1U5-<DXX83A2>%EJ8B8C>$$[<&A6:V-V;3=Y=$AY0C%E>EHQ4C5$16LX
M8GE&67=3-5=.0UAB:GA.841T9U9.561854]H1$MW0E9G86=G.4-$:7%1870U
M13AT87)D=B8C>$$[95AL=3=83&QM85)*6D5.5VI34#EL9T]K4T@U:75+<#%9
M,F1T63)6=EI7<65N8E=S85%W4C%*-'!';U9253%/=T=+<3)+;T149$(P>B8C
M>$$[5&)U*W5R4TEX>C9J2C9T,'A:;7$R-3)"2D-J:S=.461Y8U92*TMU>%9)
M8EAY4C5C=&1B3W1W,C=,<4IM;'5$25I:0U!5;E5Q-V-#,R8C>$$[2&\W53(R
M<6-65#=&6%EQ>')5+WDU.'!A;F1Z,V0S84TP.7=X959L;&Q3<D=N>%56:'5/
M4#1N1E=2>'AP2$=S841I:4%+<6IS0G-":28C>$$[<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%X5'HS+V=R:$(O:69L=SE+5#!U
M4')F,V9R,C-0*S8O-'0Y2"8C>$$[+T]U2W-9.'8O=T1+;2\P.7 O-D4Y6#E)
M*W4O,5@P=G)F2&Y8.79L.%!(=W(Y3T9+;F)F.'%M;W90-C$V;C%P858K<U8K
M=U!3<C97,R8C>$$[<"]6*U K>"LQ.%9C5E=,+T%-<6LK<'<O5E!R9C%R:F1F
M5G50<BMV>C13970O92]">7)8-U<Q8U9E<%=(,5@V:F(O5E Y-5!35#9V,28C
M>$$[+W4K231F83,K>C0T14LK2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=B\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.C@T1$9!-T9&,T5!,45",3%!139"13)%0T-!.3%"-D1!/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED
M.C@T1$9!-T9&,T5!,45",3%!139"13)%0T-!.3%"-D1!/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L
M87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \
M>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C@S1$9!-T9&
M,T5!,45",3%!139"13)%0T-!.3%"-D1!/"]S=%)E9CII;G-T86YC94E$/@H@
M(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C@S1$9!-T9&
M,T5!,45",3%!139"13)%0T-!.3%"-D1!/"]S=%)E9CID;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R
M,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.45#-D0W13 T-S@V14(Q
M,3DY03!$-39$0D4P-44X0C4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#,M,394,3DZ,3 Z-3,K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C@T1$9!-T9&,T5!,45",3%!139"13)%0T-!.3%"
M-D1!/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(Q+3 T+3(P5# P.C,R.C(U*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R871O<CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @(" @(" @
M/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O
M<CI3=&%R='5P4')O9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O
M<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X
M;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB
M;&5/=F5R<')I;G0^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L
M<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \
M>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP
M5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T1&EM.G<^-3DU+C(W-C,V-SPO<W1$:6TZ=SX*(" @(" @
M(" @(" @/'-T1&EM.F@^.#0Q+C@X.38T.#PO<W1$:6TZ:#X*(" @(" @(" @
M(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \
M+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*
M(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF
M;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^
M4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N
M,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;"YT=&8\+W-T
M1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86PM0F]L
M9$U4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86UI;'D^07)I86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP
M93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN
M9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO
M<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9I;&5.86UE/F%R:6%L8F0N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^
M"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L
M871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L
M;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%10
M9SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O
M=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO
M>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R
M86YT<SX*(" @(" @(" @(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,].3,@33TW.2!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT:6YT
M/C$P,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.3,N,#@Q-3DV/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M-SDN,S R-CDV/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STW,"!-/3,W(%D],"!+/3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1I;G0^,3 P+C P,# P,#PO>&UP1SIT:6YT/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXV.2XY,3@T
M,#0\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XS-BXW,C@U,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P,"!-/3DU(%D]-2!+/3(S
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT:6YT/C$P,"XP,# P,# \+WAM<$<Z=&EN
M=#X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDT+C8V-30P-3PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M-2XQ,C Y,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXR,BXY.#8R,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y'4D%9/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIG<F%Y/C \+WAM<$<Z9W)A
M>3X*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/DL],3 P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^1U)!63PO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)A>3XR
M-34\+WAM<$<Z9W)A>3X*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],3 P($T].3,@63TV($L]-#4\+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1I;G0^,3 P+C P,# P,#PO>&UP1SIT:6YT/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^.3(N-CDP.#DU/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXV+C,X-S0P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C0T+C<R-S(P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-#$@33TS-"!9/3,Q
M($L],3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z=&EN=#XQ,# N,# P,# P/"]X;7!'
M.G1I;G0^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C0Q+C(Q-S<P,3PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C,S+C<Q,#(P,3PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,S N.3@T.3DW/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,"XU,# U,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/38R($T],S,@63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z=&EN=#XQ,# N
M,# P,# P/"]X;7!'.G1I;G0^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C8R+C Y.38P,CPO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C,R+C8Y
M,#@Y.3PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @
M(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A
M=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @
M/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R
M;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&
M/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K
M970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_\  $0@ [0)= P$1  (1 0,1 ?_$ !X  0 #  (#
M 0$            '" D&"@$$!0,"_\0 11   00# 0   P0%"0<"!04!!0(#
M! 8  0<("1$4$A,5>!89(3FW,3<X67>8M+;6"A<B45>XUR,D&"5!87$R@9'!
M\+'_Q  < 0$  04! 0               @$#!08'! C_Q ! $0 " @(! @,%
M!04'! ,  P$! @ #!!$%$B$&$S$B05%A<0<4,I&Q%5)R@:$C0F*RP='P))+2
MX18S\1<E-$/_V@ , P$  A$#$0 _ ._QB(Q$8B,1&(C$1B(Q$8B,1,6>KM>W
M@GMCDWG@![QM FJ=MJ77NBQ92?/? )LBC0Z7(;EB:M 3.J4B0<BIBS&X"BI.
M>B>M$9,A[3[[KBLF.GI)UZ=O4]_3_>)_0GXA"N+>F/;/'/0O3[@=&<UC<2'<
M6_ >*%[']$0(\@V9O9,G)Y;0"FH:SUHEC#"8]PG/1(VW9$0!ID7#EL-.G84@
M>N]_+OV]?].\2J\[W3Z$F<=^&,<O'KQ'GZ%Z*KOJ.?W/M+_+>46-MV7S8I#;
MH#CE>*TM\*-^\EJ8K*45^&';D*,ZEST3)##3B9!1M^V] :&]>NM_ZF):?S7Z
MO]A='\Y>@C]%_1;TV9H_9#]!XYZ"LP.%Q*GV[G\2NR29'J1^K0!K+1J!22$=
MJ&L131C4JQR248:PXE0\F2U0JH8=78$;('<_(;W[_G\/G$O)X"Z?>NT>.>"=
M1Z8=59KW<J<Z4LIY8\2*43GI.EX>I&QX. ,$Q=ZC1F&_NX,",S_Z?VON_MJ6
MI4#ZGZG]8E(><6KW7[.!]A[WQ#TO7>)!*MUJ]T#AW%I_+JG8J=9A7."K8I1'
MK=P*BR]SBRKL^A]B<FMM*35V]?6B(\EQQ##<ST+H%2>VR=D>OP'OUZCTWZ'4
M2P?8OB& >#68ESVT<QM71[ERKF%6Z5Z4)\J(55NH\K&&X6WY+HC70;'4;'=7
M?L1B!R"""BGC7Z*H8)RVVWDS8\2@0GT]#O7O)^&]1*H^H?;':JV4]NEN/]/1
M%IO/?)/G?L?%);%5IQ%D46Z9;8K,^S,K.UJ;++-G*_+9T@?8]D1\-#FG8D")
M)UMS50HT-COL@]_AO_:):,Q\1BM@>QRN$">4=!Z7:J5&Y?%Z,0JYSET$Y%(]
M) A#<"94.8GKL#Z)T48.A&X<VRD*75YD(&A;WVOMM-(6Y0)L;V!OTWOOWT>^
MM#T[=^_H.\32?(1&(C$1B(Q$8B,1&(C$1B(Q$R,^(::]:<DL_(+IR'UL=H-0
M[9Z2XEP!GF[/&N.66#2XE_B3QQFU0;-:JR7L)F;]<%>+(&$7VXJ7"+D-F1'B
MQF$Y->D[VN] GU(W_P $2"O4_>/0/G+NW >#7SWE<Z-6C/%;S<KMV83Y=YYT
M&P6RV,=!+-UJ,]SRJ\VM2@\>)7WXM?W)"1(@Y309DB33LD0?>=JH# D*/7L.
MK7N'O)_G$E'TIZ$]4<I\#0.I<$Z(SW21*J=MNMG]8=!IU<Y25JM<BV<3'KL(
M5PEVH#]$[6<:,2P079.LPA(J)6IAFSM/RB0U$@%'40W;X*#OOKXCMK^?O[1-
M+;1U'?.O.MA[2?8=-;HW%BW4#49G;45\LJLT9^UD6&MM,_<QW9^X3S:-MQ_N
MF5NZVAG["=(R &R!\2!^<3/;@ GXBO4J+P7U'&]/T LSU9VH]!N'G.Q<R UW
MEH?D%Q928_ JI>0(8[TA%S$5Z5"=&D"DB4U+,O*C&);P^"YLC(]'<:(UL;!V
M=_,$Z]?7Y?.)*D_XEW*(/62E&W0[\_SD!VZ+YO/]U:D4M-+%=FE2HXY0)RN/
M6EKH,FLP3$N.!)WJ-5W*]"+K^Z6\N%MJ>ZZ#K>QW!.OE_N?</>/GVB53C^P?
M1CA&.PKHJMM+^."7\A*1^BE'U\_.T42_)8YY]K5:^UI*'T)7^E6MZNROE]E=
MD4C>T[J5 UV]:PW\SOO$M_QGXAE2[IU^3S:C\DZ#/K3%UN-!7T2*>YB4T(-4
ME^?$(DKKS43>)O5*#4R4P>[& V*T5*"R05*&NO1H;$M3K$2A V2/CKO_ $.M
M$^OH?<??VB:&9&(Q$8B,1&(C$1B(Q$8B,1&(GR+ ^9B@#DJNP8Q.P1A!)\$-
MF2/I8A RS"?<&094K>TZC1I<U+$=^1]I/W+3BG/GK[/SQ$P"\N>O?1)[N?&Z
M=V+U3.J'7[3<9P;L?E#T7Y]C<A N#)+TN-'A\!OU:I\YPM8A:_HFZM!M%M@J
MNSCS&Y2WI"]1I-U@NB0O;0T0V^^N_8^[?KZZB6.IWJ3NY3R!\3;J!"]J?O?G
MSOWKNE<A.[K50:W4*US$&$F489H:S7VQ!W\#DS)#FI=E'F9Y+[S[!>5/0E"4
MQ(&T[>J@GYDDB)P<%U+V#Z ]'<7XS2/593B0TU\.+C_I>S%!G'./WQ=AZ38;
M1%KM@FR(=JK.E#XQ9)>/+<@B9T$7$4.0R/&Q$RGW,KI0&)7>GT!L@:[GZ^[Z
MQ(XL'Q#>]TGEW,W>C7."-MW'?B=1/(WHRX4N@P2L3J_+:K -&+"8$TU(.RD@
M\ZS"6XVG8%)BQ[$B>-7H!N#LD@<@%&^W<%"P'?L==OAZ'^7Q)]8G.;/\0^U]
M#ZY[#5P3H9]GF?)?AR]"['2Q]EY2NJ30?<JN5)_<6I,+I%&%VDM&C#G!3:(!
M))&F3%(=1^'2)+4S[(+H#8[]:CU]Q![=C[]?7YQ-2//5]N-V\I<.Z@=;<N70
M+;Y[YI?3#,=(D$[:[B>YN%L)!ME+#$ $&<.FY;R6TLQH0D<J4G3;$:&SIM$6
M #,!V 8@?3?YQ*K>'^Y^E>I=]]KT;T:S6ZY.Y0;X1JI\TJ<D8;"\W']"H!BV
M206KC'#C"=P,+B*"*LA:<[*&;L+!/58;A 5Q6-F  7I^?<]B='UULZ^7R]>\
M3\N[]+[YUCV.'\;<-ZPWP /6N#N=[Z?U"!2ZY>+B701N.J97:+5QUN9E A+"
M7MH-%S:X,F6ZRO4*,[%VPXW.J O26(V=@ ;U\]^F_P"OPB?7D=]['XYY&#&>
ML# CT-UFZ=EE<PX6YR8>'J%FZL*)-.3:S.OHVP?HA0*";@PH9.7;B,$L[4A
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MPGU.:GT?@U!Y?6+/.$BRH>+0 U.HDL-'K@:) GQV(-B/$[Y9&FXBF94F9"5
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M0XA6DXRM<OG!'K<U=0L$'P;[ER++&J7(MLQ[*PG6:T.,-("2 YZP6#:'L[!
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MB+D2E,[D.5(U^0/YC<2;,I$8B,1&(F/?QT?Z !3\R7C7_NIY+B27U/\ "_\
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M)V:P51/.ROL(A(*R93$!.HC360;N3H[^>M;[?#W1+:Y2(Q$8B,1,>_CH_P!
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M7&A[5:JVO[]CY>,+&0GRS>E+UZ;1K9E+Z ,XG:?+G>.KP?0G7SM3KU%ZK?\
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M@;($2T>0B,1&(C$1B)1GXGW[MCX@GY)_4W\#[QB23\:_Q+^HDC>(?Z%WD/\
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M '<GX#WSJ[?&=]85BU<A:D5R*$36:W8E6>X0+;03=*M9L6NI3*]$HQ$J6'7
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MS\3H>_43X/(.!VN57Y86OJ*38,G</],ST6S4P2?L V^\(J:- V/T@I%I5"'
MF;,3B!F6'&TCAQ.<VWM1%N--CF8;[D'W@'9T0S#?LD>H&SZ]_E$U1J@HN($M
ML'+(<LY!Y>I3LL^W5T3(>W8\=*QC2JE6ZJ,?BQ7FW5M2%C-RW5O.[<D*9^G9
M8LGY#7Y_GW)B<ERD1B(Q$8B,1*,_$^_=L?$$_)/ZF_@?>,22?C7^)?U$D;Q#
M_0N\A_E?X#_"BIXE&]3]3^LM!B4C$1B(Q$8B,1&(C$3C]FL@ZJBG"A)QUMK[
M>H['W4 J0^W+=;<5';=:##RDUIE:F]Z=D)ANH93^W>E*VA"VM_\ Z!^L3(/N
M_>;9T\D=!T8Q*J0*#'^OZ1UVN=&["9Y+7*['K9=LG7[ ';H<&'7?JFHK+DXD
MBOJ8U+3O<MW[J26E1_7CT6W654TU/?=<ZUTT55"R^VQV 1*T4,]CL3I47;'8
MUZ@&+NE:L[LJ(@+,[L%55 V69B0% '<DD #N9FUZ4L_(J?19[8J\>+NG(_1:
M['^=54.=F]7Z"P8A$N810M&VI4T">'WOH#EB5]D?'K<)45BMEY\L2IM!'8_N
M_P!GOASDJ[J#9Q_C3AT;*PDSWM88?%6U7XW(&_DK$OXZL#%P?NP)\S(<E[Z4
M\_S&4/I'/<CCLKZOX?+(KN:@*#;DJ]=E'1C*R9#;MO\ ,_NUCV4<]! )$N^
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M@: ]G(248B,1&(C$1B)0CXE_&.@=T\AWRH<P#_I1<Q!RBWP;3-O-LZNS%$N
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M7XJC!;GSNK=GKO3^66F]=#NM^KXWH<-4 97U5KSQPP"5*Q[02B=+@L08]_#
MHS-&9'W*T;>T?Z'8G8 B8WTGU((/8>G;?M'Z>X^O;X1*L"'1-<K1L53[!R_J
ML:Y5@/<O1_2Z!S@[S[J_.*KKU!QEWL-0[5+EVRPV",Y<^86CK,DA7+) I]I
MM\QLSC8=P6T[%KM??WV/W03L?A.B-_/7?OO?TB:%>>&_JZQZEA^?"=.&T!?2
MR<3S>5@1&B_)14QWAW,-%Y55'U^5%'D.>#NTN7!XJ.K4V+!=L#5Q@#Y$5S6]
MM1;?;?KKOO>][/KOWZU_+43$3XJ%#^*.#\IQ27IGT)Y"OW'6/1/D]-CJ_)^#
M]%H]YGRWO2',F@#@NR6#IED%0F(1U8^82;?$2%RQ[$F(RMAYY#S<9<4KLZ!W
MTOZL#_=/N"C]9VF,2W&(C$1B(Q$8B,1&(D"]LOP.MAWAU@)7^J"W5-)(66MT
MX,>$2H<R'.:?#3Y5GKUD!)BO,_;?G:5"9?:U&;TJ8U&7(:?DH)/8 GZZ_P!0
M?^?&)CI&I=E[@V/T$K$K5?.JB(C2(H3F%*LLWH$/D#Y:2/&1TOT(>/Y@4(KD
MR5OKD2W20R,Q,90HXX[HEZ.H#>SV&SW+$%2^AOU.]>@'?8.]")I]R3SV+0],
M.7.F"(VY! E*V)/T>CQ":GB;8^2Y(#EJ7T&ZP(H+4AA"&A[JH\EQV+]M;#;*
M(KKEAFWV#$C7Q)&N_;NJDGY_.)<?(1&(C$1B(Q$H)[N:Y1.J"AEWLE#J=^D<
M[Z:KE!KKT8](YW$,?<5U!.0 U&*B0K';(R=C5\S)Q5D.@ V7+(3IP<K ;LX^
M3)=[[ D;&P/7MOW_  ]=^[X^Z)6L::9-72*9)PIH/UF3]"^79O.*[<IJ'^NB
M. %.7</F=(#HVAJ&3E<\A@7^YHZ-(@0F*J]TB':GR;+-@B0VX]>^B!^'3;UZ
M;V=?S]->_P"$20O%CU>7=.*_H5(B/VE[R07?]CZ@OMNG->CDV?CB 2^P(86I
MQGJVRZO0[,O1S2#WT<>9'UK\&ABVVC>AW^][/PZ>^]>_7IKW?SB4V^(U7?C
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MAK?G(@K*/3XC,]#F<X/A\KF<H5TXN3DT5V!+DP;<2O,+6I8*5HKRKZTL9[%
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M_&?MY0HR<+,.1;GU8UJ)X#\28UV(^5B9E.'>@7E,_%X_&LQ\=L6K(\LNU%)
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M%2*^3DVUK94BY%G4O4_M.11;JNIFL\M0+%[QODOBB^.\[&"I)2^.S(^B<>5
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M] -G?P&M_#7UV/K$Q$Z7V>?P2Q6;JOHDE$D]2%BBT(B,.5CAMI!JB1QS$V+
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MJUO01)#>E;^UK[M&]?;=W]K325[2KY9&GP+XPO\ P>'>47N!_;8S8_KO7_\
MH-7;MW/HO;J(V-^*WQ=X9I_'S> >Q/\ 97"_T]?_ *!9W^ ]3[@=&1>6]Y\\
M)0''^,T#KW=Y:)C</;='YS<(XI"U)<^]4^9*@F&F?IE_2Z>UN*K_ -*8T\WM
M:4KUK,4_9QRE-H7GN3X/PXA0OOD>5P6N(V.D+CTY+,W6.OI]L>U6RG1(WC+?
M'&!;66X? Y7G'#!=87'Y:U G>^JZV@=/2>G8Z#V8$$Z,X2]?_B#=:G#%TKDM
M3\\U22]_ZA>_%P]LL*(SC/TK[DL'M+)!ER'.CR)4=IVNCEOQ)47Y)G-)V^Y[
MQQGV9<)7<,_F\WQ1FHO:CC*+\+%+ANM0F3MJF#ULJ.RY5H5T?_ZS[(\9S_'G
M*O4</BL;@,5CWMSK:LK("D=)+TD+8"CJSJ#CUDHR]G ZCS2'XH@WLV N?I[H
MUC[S: L!EF,%E1!%3Y^/>=2S(GL, :R.%2"D/\21MV/J?)9CR8Z&FR(V1\W$
M[\%GC^SCL?)P/"'%8OAO#R+&9\A'OS>3M52RU,V3EVW+39Y1TWEHSHQ8U7+V
M,]B^#:\Z['S/$O(9'.95%85:62G%P:V8*UBK3C5U-8GF D=;*KJ +*SW!MY3
M*)3.=!4URAU@)40*93\U(@ /CC(&I<K['U$GZ:,AMO[Y[[M'WCGV?M+^PG6]
M_).LTC/Y'/Y3(.5R69D9V246LWY-K6V]";Z$ZW)/2NSH;T-GXS;,/!P^/I^[
MX.-3B4!F?RJ*UKKZVUU-TJ .IM#9]3H3EF>*>J,1&(C$1B(Q$8B1=W#^97K_
M /9=T#_*9;$2CGP9OW5WA#\NM&_PKN).S\;?6::8D(Q$8B,1&(E)O>/JP5Y3
MX-<KK%FR'+]$$Q"M3KX^"W-)E(<2R 8=FFQM3AI ,ED&!G$"\_9+2$I@0I+C
M.OO6TK1E^$XK]K\ACX;7C$JO=JCEV5O937<:;7QZ6Z63V\JY$QJAUKNRU3W
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M^[E?+14K++2@K9:R%Z>G6YU?O9/P$>^</A/W4#N0=K34YF*W+=G;L\-*UP;
M;D(<*5YARS"HNM0'5R)ARG#J\/2ZXZ1N&Y;D5,GMGA_[1/"_B&S[MB9PQ\QD
M+G%S:VQ+".NJD>7;9_TMKL]R)735>][C9%'2C$8EK_$O"J/VMQ R,13TG-XE
MTR$!T2#9@LXR$1*JG=[0!6IZ$506$S>Y&[Z_\*V^/U6CTNQNHC/1Y+A&I7#H
MGZ($&Q8 N&5+.S^%=#I4QN/"<L3KT!RP;2I1!N0EF>XW^,L%=@YKA,'G,9L/
M.12A!4%L?#OM3JLJL/1]^Q<I4)-2J>E "I.P2M93(<=XGXK*L"TY]-=Q]:,@
MVXEVRS!$"7>6;&*[9O+M8KI3T*'(&TO$O]JE[Y4?I0G>?,7,KN,#PM"T/<_M
M=^HMJ<5 B0X,79B=?2?6EDRFGV9<HQ/F*C2""W-)4EB4VZ_*Y-R7V'\7>7LX
MSF<[%L=BY7+Q\7)I!9V9@B8J8 K3154100FO>I 7;*^3;I!*5NI4$,C$ C6P
M0Q+A@0-['KZS6'E?^TS>%KH BS[[2>U\R-N:<7*$(&4J]1F&52BJ(RX[M>N3
M5FE*T/$ODB:7*=#;%(<C,O.N[(B'">B9WV->)L>UEQ<GC<VL=E?S,G&8D+66
MZA=CFE1UV!$UD,;"&( Z; GI7D:"/:5U/?W CM\-$$_E^<O5R+XT7PS.R042
MA/JV@T23_P"W0^,[2DOQ63'?DPU3TL-S>ECJT"*_=1=-.2)0 P7'L*EP&G)F
MGB$)M_6,_P"SKQGQS$6<%EY*]]/QWE\B& 8)LIA/=:FVV MM=;GI<A=(Q%],
MS&?TM4?Q[3^K #\B?4?$;T$H?7.4]3@-E.8]-Y]T48[]K[LA1;E7;;"7M+$:
M4K29( D09VI$:9$D+3]O[2694=U6M(?;4K5<K SL%S7FX67AN/5,K'NH8=V7
MNMJ(?56'IZJ1Z@R^KHXVK*P^*L&']"?B/SDA9Y)*,1&(C$1B)1GXGW[MCX@G
MY)_4W\#[QB23\:_Q+^HDC>(?Z%WD/\K_  '^%%3Q*-ZGZG]9:#$I&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(Q[:A3O&>N-HUK:W.8WY"-;4E.MJ7
M52R4ZVI6])3K>]Z^:E;TG7\N]ZU^W$3KW_#9^+Q\/WS=X#\E\3[)VXK4ND\U
MXS6:C= ?^YSN!B$+L AIYF=!B68)S@C5; TV[K[+1*M&S J3K>G(TYUK_CS>
MJ/LU\:9-->11PZVU6UI;6:^2XIRU=BAD;I7.)3:D$BP(P/8@'M/+;R.$+'!O
M4$,0>I771';WJ/?V[2RMD^/GY,G17VO/W+O4?IL\EW3447S3@G0(L.9O3RVU
MH03/A83[;RT)2[&2H4IEW3C:7I$7?WFV_?7]E/BL:.<O%\57V+6\ARN(JHI&
MRS?=WR&TH]= GX CO/(_-<:AZ3E5%N^E%B!C\@K,I)/N_P!Y77H'7OCI^X(3
M-<X3P*%\/_GQ1#J#-^Z;9:_)Z%. $@Y ;(8&"9@24; 3W%3F2<"4&3!."Y\*
M(XP<':2MQ>8P>#^SGPV[9'B#Q%C^);TZ17QO%TY+T)=7:C,SY%%S59"=*LAK
MO--5BLP*OVZ?)9R>=D@K@<;F$]/4+;D&'4>I3T@OF+5;HG6VHHO9?76NQX5Q
M?_9L:19;.2ZO[F]']5[]T.Q2=%2D&%-CQ4O%783D*7)L]KLOZ7D+6Z\GZ9UG
M;4,0Y%7#CH7-G-_:1K*9WVQIQ]=>#X3X' Q<3' 1+<NNQ:VK!)"U8.+91Y !
M)[OE6[V3T)+*\3R&;43G9C<>]BGJKXYJ[;ZVZE8'[[DTNC'2E6"XB@ACIIV$
M.*^9>&>>Q447R?G0&M.1HB8.S>V%$K,_&^D'0WH[MB)KEEFX4E J$\\*B2HP
M?4IM4E@>RZZXI7*N;\4\_P"(GWRW)9&14""F*K"G#K*M8R%<6H)2;*Q:Z+?8
MKY!K(1K6 &O?QG \3Q'4V#A55W/U&S*<>;EV%PGF=619U6A;&17:I&2D/MEK
M4DR>,U^9>,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)A=\
M1+E7Q";<6['(KDWI/0?/I*E$H_)Z%YGZ$ YW<:S:5UOZ5J7V&NSJI&NG6J])
MLF_J7*]2[XO>H"&OM Y.ER867%*:[@;]_5W'\NXT?KV[^AU$TL\7M\EC^;N<
MP>*THOSND#89$8JFV&K6&G6 ':(!6;&ND<Z#M331UHLY:FRS\Z9-5(_$7G53
M69<EA]MU4&WL[.S\?C\XEI<I$8B,1/&MZ5K2D[UO6]?/6];UO6];_DWK>OV;
MUO\ YZQ$Q\^.C_0 *?F2\:_]U/)<22^I_A?_ "--A,2,8B,1&(C$1B(Q$8B,
M1*_]7\K>>>WN;D].Y/5K&2VI]?X\RS+KUG2[(9BQW'T6FL2PUC;DZCPHK#,E
M!1,B.RREN.XTC:M*V'B/%?B/@>W%<OF8B */)ZUOQM*78*<7(6['*]3NQ4U=
M+%B6!,QF=PW%<F-9^!C9.]^U96 _M  GS%Z; 2%4;#;   ,S=[K\#GREV#?V
MPY _3TZ:;:;&F18#IPI*4$7)NOM2KG$?NF_NFW-1XZ6[HTWM;:)D]!"4[+7)
MZ%Q?VT^(\-/+Y'#X[E@3LVLCX%YT@4=\,IC=W!L<G%))9E0HG2%UNSP+QE=G
MF\9E\CQ+;8]&)E6&G;$@GRK6;OT'H73 !57L2)DETG_9BS2-K7S:Y<J)MI0V
MK3:K#TWFKCFVF7W?L:''1O?Q<OY2U(^[C2Y,2-)6O[Y^1$90[%D;YA?;CX=M
MU]_XCF<(GM_TS8/)(#L %B]G%MT].V;5;,"-!6ZMCSOX>\3T]Z.:P<W6R?OV
M%Y#]U (5\,(P;0"*W6I ).P=$49O?^S@^UP+K4*EUY\U%=^O:<D5_I/+C$)A
MM<: Q]I[5DL7$I&]34HVEU38:<[,5#UJ=J*AEG9'8L;[5_ &0C/;RM^&X"%4
MS>)Y NQV_8' IY!!Y?9N[J-LI7K]L(^[^+*2!9QN#E@[V<3.7'7L=G:YGFL>
MO?2H##H ;8[KK<'X./C+W!Y#N+5/[YR>@1N;QPM[GL]6G5KB,SL#ARPS0LN)
M7IW0ZAT^[7\J#=?:)R-1B;,N*A'W,1R;'BPQT='+OM+YWP3S?'_>.#YG)R>3
M-^(AP:QSF/Q_W>I;@]RXF;A8^$EJ@UKNMD8CV@A<V,<KP_[?&;K/XY,3"\IS
MUG*P\FT7>R%4-2J6]+#J;V@P!W[7255>QIG#YM48B,1&(GC6];^>M;UO>M_+
M>M;^?RW\M;^6_P#EOY;UOY;_ /IO6_Y-ZQ$HU\3[]VQ\03\D_J;^!]XQ))^-
M?XE_421O$/\ 0N\A_E?X#_"BIXE&]3]3^LM!B4C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1/'SU\_L_/7VOEO?R^>OG\M;UK>_E_+\M;WK6]_P GSWK$
M2+^X?S*]?_LNZ!_E,MB)1KX-+:'?A5^$D.(0XA7G2C:4A:=+2K7TSO[-I5K>
MMZ__ #K*@D'8)!'H0=$?S$E: 7;8![^\;FFJ4I1K24ITE.M:UI*=:UK6M?LU
MK6M?+6M:U^S6M90DGN3L_$R( '8#0^ GG$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)DQ5^7>Z_P#?Q["-<>Z'SODU!LG>1Q4+
M%Z[QZTVZ3:TM\;Y8-D6:HF8]KK4-ZK[DP'0ND0X\ME!L082J7]]IUAF9Z=#>
M_3W:_KOY[_.)HYR,7U8/1!0_M5KJ=UZ(R^349L5(K4RHUR9'=(RG1+<("0*F
MY41R(+7$BRUN$7M29;+TE"6D.I:1$ZWVWKY^L22\I$8B5I]>-3'N"69#+4U\
M/^E')UWYF"W)>=>Y$UUZB.]H:?9AI7)?&N<F1=$&&&4+4\)5-:^RK2]ZW)?7
M^1UZ>NCKU^>HD<^>*W6;16O4U9YF5>JW#K9TTH%X]8.3SHM?&!0IGAW,!=VL
M/%RPEAP0*A0>J/7H@*+@8[PMB_1[$2B(?W]M3H^[?KKOZ[WL^N_?K7\M1,,_
MBX?#>8X_XU(75/NOXDG3MM]S\O@/T4[#ZM(WJE+U:O0O.*YLRY7WJG 0H_7=
M$_QVJDOJ-*#6. ,*H:>5$TTN,N*W?\*_A;W?!3_PS3/]4=&_K+?BZ_WW2W^A
M\2/5_A7\H_5'1OZRWXNO]]TM_H?$=7^%?RC]4=&_K+?BZ_WW2W^A\1U?X5_*
M/U1T;^LM^+K_ 'W2W^A\1U?X5_*/U1T;^LM^+K_?=+?Z'Q'5_A7\H_5'1OZR
MWXNO]]TM_H?$=7^%?RC]4=&_K+?BZ_WW2W^A\1U?X5_*4!\&>*;YZ5(>X8O0
MOB1_%.BM^=???=?,M"W6O9=D&JD\[YO7N;%:_*L>YM<*:(V=V3;2B21*'H9"
MDM(B)9%15-.+>23$#ITJ]U!/;W[(_P!)?[]4=&_K+?BZ_P!]TM_H?$CU?X5_
M*/U1T;^LM^+K_?=+?Z'Q'5_A7\H_5'1OZRWXNO\ ?=+?Z'Q'5_A7\H_5'1OZ
MRWXNO]]TM_H?$=7^%?RC]4=&_K+?BZ_WW2W^A\1U?X5_*/U1T;^LM^+K_?=+
M?Z'Q'5_A7\I3_P!">9K[XK](_#6*T/WC\1'I8SLON"G\IZ%2NY^I[!T"C'Z6
MYS[H-RD#9M<8"@8\Q,PI51L>6T0<FPWQSDR,N)]MYM]E*@@AO97LNQH:[]2C
M_6=C7$A&(GXR/O\ Z=_Z;:-2?N7?I]N_/[O3_P!A7W6W/E^W['WGV?M_+]OV
M?G\OVXB9<^+8U?:NG%-TN+%CVACR07C>Q5PHS;!Q?HW=GXXL$CK[C+:''^JI
M,(]#R):C:EG=Q)<R7\U!IHIUV;>_?[WL_#I[[U[]?AU_O$II\1KX;IBN^,_=
M'5U_$4^)=86 GFOTIT!7++)Z%I9#DIIH=S.Y6+=".5=GCT0A-YX00U^CY$$T
M=C3)%<=>'H+-/+U+3"7%;VE'2OXE&]'?J/GZSD/E#X7)NV^6O-5J;^)M\5.J
MHLW >.6!%7J/I6B"ZG6T&>=UPBD!6!DCB4^0.KP?4G0X+ ?G37H8V/&CNRY*
MVU/+06T2.A#H^NCW^?XI/WZID]_6J?%T_O2<_P#_  1B4ZQ^XGY'_P H_5,G
MOZU3XNG]Z3G_ /X(Q'6/W$_(_P#E'ZID]_6J?%T_O2<__P#!&(ZQ^XGY'_RC
M]4R>_K5/BZ?WI.?_ /@C$=8_<3\C_P"4?JF3W]:I\73^])S_ /\ !&(ZQ^XG
MY'_RC]4R>_K5/BZ?WI.?_P#@C$=8_<3\C_Y2A7(O'?7K[\07V/Y4,?$_^*-'
MYWY\Y/YCO5++#O2E69N)$OV:%T*1:6+*1D\EEAYHZ$NJ#= F1@ 1(BI=FZGR
MR>W6=QTKU#I!Z$V2P]#KL%]._P _?N7U_5,GOZU3XNG]Z3G_ /X(Q*=8_<3\
MC_Y1^J9/?UJGQ=/[TG/_ /P1B.L?N)^1_P#*/U3)[^M4^+I_>DY__P"",1UC
M]Q/R/_E'ZID]_6J?%T_O2<__ /!&(ZQ^XGY'_P H_5,GOZU3XNG]Z3G_ /X(
MQ'6/W$_(_P#E'ZID]_6J?%T_O2<__P#!&(ZQ^XGY'_RE#?B9^1>O^)/%'7/3
MO+/B<?$^LMZYH7XZ@*#Z-Z0JYJED6KMW+FO.S+)P97^458O+:2"MI-V(F(>@
M?8(-Q'7]R8S;T.0DT(9@I1-'?H#OL"?C.S5B68Q$8B,1,K2L8+_\0Y7:XL+?
MIK?LBDRJY+5&3N\Z\V)YS4DGEBI>V_Q%/&-4E-Q@E4QW=4K7372;$I/Z>2/D
MY<'I[]=!^G5_OL_7TB<2]1?"NX)>!GH#L)7KGLN!9+*&Z;?YH6N^P.YU^B12
M\X89-NCA-(&6MBO"JRW*7N/&K<.$T*CCM)'M1TQDZ;RW)A]#72G\U!/YRBOP
MN_A3<![!\/3R%T^Q]>]H!3MXXE4K 4%47V)W6DU"!,G,.*=C5VI5ZV0@E?%M
M[UK4<:,BL1(Z?GIMM.M[Q).VG8=*GN?503\?A_SWR^GZE[S/_P!<???]^WT=
M_K;$CUG]U/\ L$?J7O,__7'WW_?M]'?ZVQ'6?W4_[!'ZE[S/_P!<???]^WT=
M_K;$=9_=3_L$?J7O,_\ UQ]]_P!^WT=_K;$=9_=3_L$?J7O,_P#UQ]]_W[?1
MW^ML1UG]U/\ L$?J7O,__7'WW_?M]'?ZVQ'6?W4_[!,[6_AU\W5\6:9Y'WZ"
M]T?[EV?AVCO1J!/_ ,:OH+\9UU"3Z4*<S=([/_II^(;&;JD1F-H/]OZ-,O2I
MND_?JWO*>\#Y'^FO]Y+J]@-TIOJ(_"NM:!^$T2_4O>9_^N/OO^_;Z._UME9'
MK/[J?]@C]2]YG_ZX^^_[]OH[_6V(ZS^ZG_8(_4O>9_\ KC[[_OV^CO\ 6V(Z
MS^ZG_8(_4O>9_P#KC[[_ +]OH[_6V(ZS^ZG_ &"/U+WF?_KC[[_OV^CO];8C
MK/[J?]@C]2]YG_ZX^^_[]OH[_6V(ZS^ZG_8)2SXC/PRN2>;_  KZI[QRWOWN
MP=T3E'&;?=*=/*>VO0ID=%/!X7W\%Z8*F7146>PAS]JXSZ=MN:_8K7RQ*JVV
M4%4T2 ?9'O,WMX [)D<(XH_,F32$Q[DG-W91 C+?GD)TERG!EOS)\Z4MV3,F
MR75+>E2Y#CC\A];CSJUN+4K:6Y+>(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1*?>H;U0G(L_FMTX0)]" J]2U][OM5L<6J3PH"J<YL4(D".P0UNB3A]
MBOB+$(D&J&(2V.;21J,Z<[9 ,Z,'_$*@;]^MG0^O^WS^8C_GY^LMF+)P30P<
M8&2$2QI:#$)CI;>E:;E09\=N5$D(TO25:0]'=;<3I24JTE6OM:UOYZRD3WL1
M&(C$1B(Q$JKW?U$&XM>Z'SK\.JI*QWH%8#\7]+^J4WE8R.R'-U:OCAD6?;W-
M:-GK(1LCJ0X@6T[)<9!E75_+:&4.R"[!.]=]>A/Z?#_6)QBA],YK1.CV:NT+
MAP:B4GIWHFW5.U]-JL6J@6KSZ2>J2C-NM%LK8B'$)EW3*JDNC3>C%9<P^6MX
M&&+FB] =#K NFNV]C?KKY'_7WZ^$;)]3Z=A\A\)='*1&(C$1B(Q$A/KG;A7)
M2G-0TRK6ZQ3.E7ZIT:+,"!Y2Z[6DVBRAZRDW:K.\RD,+99FFX;8X+]2[8;!(
M6O0L8X,'G2P:H&]_($Q*\])[KQPI: EDZWQ@0=YQR7K5^&\][+9H-7LTFG]J
MY%S^[G[38:Q79T.2;J?T >L=$I8B\C)S)B581\\'L=#$&AQ4C7I^??MV^IU_
ML?Y_$1_KZR=^2=K(="/F:C:N?D^;VP=3*1TB"'GFQ5A01HW09%D@@Y2YXG2&
M(=B&$ZF8&6NOZ3*8#ROPYV :-P"4>;E"- '8.]_'W:^('QB3WE(C$1B) WH@
M[66Z1$YK9>>0.M-=^*$N)Q.8FWH$:LW=BR4BX'K<&MTLG&GPXU33SJK70A8/
MMC"SLP=!>&Q1<^7-8C.5 WOW:&X]/2?:X+9:K:.455RF535" UC\;YHW0D-0
M&F:*2Y+8BW+SU+B)%..#%CZJ=J!($,D#E?02QT&++A)3%?:3H1HZ^A_D1L?T
MB2_E(C$1B(Q$8B05Z$[J$\_4@;<#489,4:MX"F"HYJV Z,&V2.*E/KDEK79'
M&PP4<-%#BA67*F*WK;,%3+:=NNHRH&S_ "W\8E9G.X<SHUEO/=P'"*Q-N9'A
M]"ZSZ6ZA1+32S<R)Q$68Z"'YQ-8N0MG;?6DB!%4Z19A0<?*@PQH$651"(OE2
M0L63KT_/U.AV/<@>GR[D#^?PC_G_ #\A-#=;UO6MZWK>MZUO6];^>MZW^W6]
M;U^S>MZ_DWD8GG$1B(Q$8B<!Z?T&#RVC6"\D =ILS(*$N0V I@&;8K$6D[UM
M,>%!@PT;:CI==^SJ47+2!P +%T\5/%18F)+G,!W_ /<2G7<^S\NZAR)VO=$X
M!%[7R\EP>C^F^V4FRNUXB'J_,5DDVZM2-A#,=UB]6H>8HYVQ! 4=H:TZ]0)4
MILI%*N QY&079UL=V*CU]?\ ;N)4$@[!(/Q'8R8@/IJ >O@8$Q3"3?/K7TZZ
M\6J'3=&1;\4WTSGX2T&K&.>K;>OQ ;7-N46[@!-D=EO+GV.MO07A,&&3"$2-
M-=CW] #KY$_^P?Y_(RDM#E(C$1B(Q$BWL-_'\[INB$RO.W"99+#6.?U^HM.0
MF$V:Q7T["JXH7,E$M*@0@^G22YUAG26I28-?A%);4 E(99'2J@;^7Q/P$3X_
M!;17#U'?!URAC^6_[M;&:YF9YN'9$,@Z<8J[C/\ \N ?@,:"(>KL\5.%'Z](
MACQJG0IB J:*$D?K!D01K^?<?\_6)-64B,1&(C$1B)$'=^P!^$<R,]+.1F)L
M,86IP%B)+-C*W#?*WBYU^C!=3[ :<:$A!C):QPY)4N16F&,&,S)TE6F8Z]ZJ
M!LZ_]^G<_P!(E;E>BZ_)E NG5;B%1O\ TXIR2]6DK8Z!>N<VF9$X;SRSC]2Q
M0;JPZ,J/9WCMG*NR:M08T^(!D'1AY\P9 R82),NO3\^V];(UWUON/4#YQ+KU
MT^*M=?!6@%)U-"60,+/AYFD+;U+%&(3!$?)TVYI*T:?B267=(6E*T_;^RK6M
MZWK(^D3[.(C$1B(Q$X]:[)$J%=*V2; /%8XJ-I]0RK@2MGL!!UQUN/'A"006
M+,(SYDJ2\TRVAIG3+.EJDS7XL)F1*9#O_P"XE0B_I$+T[EW.T0N$RNG:[7QJ
MU==.\GL\VI?1P>9UG59C6$78?QILE7#UA($+>%"@JPIO8DY._$US#@L6,?([
MET^NSH ZWHZ]?I[AW^/R[Q/L5_UE4BDL&Y3:1/E<83:.0\P7T:)-$BX(6V]C
MJ5&LO-Q(^F?83-E5M<+I7. !$O%DQMB#UIBC(P>;$$FYPQTG^??M[]#>_P M
M'UUZ?,1+C9&(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2KO;.#V[H-@,
M6&A7H)2YEVY&?XC>E'JI,M"EU(S/>GCC]7^CLE>;'6JLK*V9,%!5LL&)*-L.
MSHJ$B$L$) Z]V]$'UUW'\O?$L<##0:Z$#U\6VIH8"%#PPYI:]N+:@C(C,*(V
MI>]:VM2([#:5+WK6U;UO?RU\\CZQ/J8B,1&(C$1B)6GO'&;[U1JQ"*S=:2 K
M-]YA8N470?;.9Q;>2BB+(X^B78*J<B&ZZ1:(H@39L5=<L;QRI29K88PD=$?'
M$X]AJ"!Z[['8[_3U]?A[O_Q.&USRV9KELKT-B]CY7'JKU^=W,15Y5=G/7QZZ
M3ZJ3#.""UT<L:ADVN-6<T4ONGT5:.;?(.00CLO0^'(E$:EMCW[T!O?;0^6OY
M=CKY1+D9&(Q$8B,1&(D7=7YRYTL541K9= ?=7ZCS+HRGEPE3M36^>W(3:W!"
M4)E1-QUE4#-P43=K>3#4]J0J+)TWME=0=;^8(_.)6ZT^/IEVD':98[P-=X:6
MZ'UGJC54@UF5&O*;-V*F7JLV,1,MSMADAWZV/-]+N-T%[CU2*540> "),I0\
M-.>/U#:[@=] ;W\"/]M>L26.0<@NM1MAF_=,NM?NEME\\H'*QCU6JD^HB8U8
MH,ZUEOQ>9")6:TR7[):R]MERS&F)S H=$&!QPV*MQF>1)4)'N&NY/KOUU\OE
M$L5E(C$1B)#G8.;&KZGG1VIG1=>N_)^@M]$J$P^(EG:]*G2*5=><'!!T:/+
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$C$3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g107876g01a15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g01a15.jpg
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M=WB9*#)"D=@8)4F!)#-65VB5EJ&QU.'_Q  ; 0$!  ,! 0$
M 0(%!@0#!__$ $,1  $# P$%!04' P(% P4    ! @,$!1$A!A(Q05$38:'1
M\!0U<8&1!Q5UL;6VP2)VX3)20E56E?$6(Y.4TM/5UO_:  P# 0 "$0,1 #\
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M>N1TVUOO:G_MW8_]HV,M"MT<R* 4 H!0"@% * 4!\Q.<4:U4GM33QJ;H\9X
MN>B^R6>6YMZZV/2*R!<._P!;Y!(A]=XUL75BFO,2@QR<=L9F7D3M5@X#)AA&
M+7Z7>#SV;<X7&\NJ:(O/7"\%S\.8-Q.-$?"1G2T1&1]6!.1N;B5%;$=9R^13
MV&&'AR8'S)$V,ETL(%I$9<F2#]R3,J%"I19F<=$1J1%\U9H.5<7<5X\N*87A
MW ]VV)'M<(_B#;7<3L8#/GA2TU/>"R(N(^,2"D56C@>&R-C2+]XD]22<IH-&
M)3(@X29A4V^&9/-TT)C7/=A.O7P!J?R$G&_%.(/)MS*-8X%BJO'Z9(/!#!V.
MB:(3,KK[9.$G?MR1HH^;GF0@,RB!E5DRS4=HE9&5!).W*X=PW8%QR7/_ (3N
MZY!] (Y^'@/[F%_P*%0&9H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H"KX/^-MS_P!](Y^6$%K26SWGM'^(T?Z+;#I[W[DV-_!K
MC^YKX6A6[.8% 5?J#\(/_P#$;<GYOSJM+8/=\GXMM!^O7(Z;:WWM3_V[L?\
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M/NX\7&+==);)#)?6$@=(XK8IYY72R6;+(N$K9VQNH@JDMA:Z:F&5P+TCGX>
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MH @[X$\P#X.G!5STXYT[\>01<:_FB+X+H;[QS\/ ?W,+_@4*@,S0"@% * 4
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M33<$,""3>RB+?%=43IW^:I_!;- * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MF\7CH9L5)%R:+LJ\!5SQ]>N/Q+EH04 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% ?/:?2U[L.= 5AQR2:UV!
M%N34LXSQ>=Z[)1W)^QB)[5++:A?ZUQB=Q6=165#C+^&B&ZPMR''/63AB/,Q\
M\'<(/426:)IR7+5<J+U153DJ*BXU^>N@-R-7Z\9:OAS2)M#9R3+6+2:1&9-)
M,A=SLCDTSDQ>82@X23!C H1JL4D!PD[3'A0XL0-;J(CQC!JR;((X8JN5SP[D
M[OCE?$%@U :]\M_Y*7)O_+WNC\MY+0%UQS\/ ?W,+_@4* S- * 4 H!0"@%
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M-/-<42+-CDX20;/FEW#-VDK:JF,=_P#A?R5"HBKP-T8Y^'@/[F%_P*%0AF:
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MMJEPCAXW377$%5 .B#810D,4SR:/LPYDL+R<)*7'DG[:Z;A04R=^VEX.VO\
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MREU;9->7R-DE.YCDKV>W.R]E[>&FIXJ7A<>%;^'WE,DOUUDL_$24^QX?AJ*
M=E^VFX.VO:UD>765KVO>^5NSVYW],?M8X]+]>.MLNM[97SMTM>W=PRZWMEW<
M<@]>O7\G[?MI>#EK]/#Y<WMUQMUMV>W/#I[;]+W]O'2U^F/WY>SKT_W;97]E
M!Z]<O$7[:3@Y;IT3Y<Y=?YNSVYX>S[OO[W'3'^?]G7[K_P!74#\Q[:7@[EUZ
MI<NL.F5\?M=GMSO^U:WW96[O'7+[.7[.O3+^?&U =:O;4\'D[6OBUY?+7ODE
MC>R79[<Z^N-E%<4\LK^+QY2MW4<<KK*]+WOX6.7AV44[J>0F?C],_D<\NVFX
M.VOA:R'+O+O=>M\>SVYW=,.F.67V^]QVQ^^^-L+=SO6[V>/7ICWLL1<^?!?7
MRXG/]-)P<_H<N/\ 3VYX_P#3G0'6GVT_!W/O=Y#EXEW<U,+>)V>W.[[=L,KX
MXJ8^'QW4^PK:W?3[W=S[M[>)@GEUQL 4[:?@\FFKGBWY>*W3PSSQ23[/;G=X
MBU\<>]9-+Q..Z>'?4O\ 8P\3-/#O?[^>&/VJ [+=M)P<O:U^YRXMUM:][7[/
M;GCUMU_9?IQSO;K;]O2][?S7O0'F=]M7P@;-5W";'F"]412S4P9M.SWYT6=.
M<L+=;(H7=<>VK6RJGW877<H)6O?[:N%NM[ =^';2\'<\,<[I<ND[Y8VRNGGV
M>W/#OX7O:U[XY=SCKGAWL>O3+NYY8];7Z97MTO<#]MVTO!SK>WA\N;6MT]M^
MSVYX=+^RU_9_LZ=?9UZ7ZVM[;7Z=;=+W X*=M/P>PP5SQ;\O%;IX9Y8II]GM
MSM[ZU\<.];!+Q..^&'?SO^KP\7-/#OV^WGAATSH/7KU_)P:]M5P?<-FSA1GR
M_9*+H)+*,W79[\ZKN6F:B6*F39S=KQZ=-;KH99715NV<N4+JXY72752[JN0$
M*V'VYW$2)0T_(8AK/FWM&1BL6]Q<"CO [F  -2;)5ZQ;KXC2\UTK'HNS\JU=
M.2&>1DR.LJD.<MT>^Z59I.!,]R_3'YDJ%]MEPD(,&CQR%YE!5W+=LNJ+*=GQ
MS>S?L5%VJ3A1H[R%:%*#LG#113)DYR9D';6[I%6[5RY:72=*B\L_^3]']MEP
MC>M6CA<-S)%J.<5+JLB'9\<W\G3&Z=\K8XN[CM"$&E\E;8VNGY1T[QZ9X^)=
M._?MB)GXZ]WYF1MVTG!R_P#P<N+?V]GMSQ]GL^[V<<[_ -GLZVZVO[>G2]Q1
M^FCX.>W[/+C_ $]N>7M_JM_LY_\ YZ6_KH#H;=M3P?7;HKYM.7[3-5+!3-JY
M[/;G7YAOEGC;*Z*WE^/+AOXJ=[]W/P5UD^]:_<4SQZ97 XY=M7P@Q3>9V8\P
M<LFM\[))8]GMSI\1_P!UNFO:[/O<>\4[64SSR;8>;4:7\PDIW[8(>&OF'KUZ
M^!R;]M5P?7;MU\V?+]KFNDFIFU<=GMSJ\PURS3LI=%Q=OQZ7;^*EE^J4\NNN
MGXEK]Q3-/]90';?MIN#MK7OX/+J_3'O6M;L]N=_7*_2]^[;KQUM;O6Z=/;>V
M/7*WVNG6]@.6/;2<'+VM>^'+C&][6O>V79[<\>N/6WW7[O'.]NMONOTO>W7[
MKWM0'[^FCX.?T>6_^GMSR_Z<O_/_ /OLH#Z.ZKV;%MRZ[B6T81:1XQ.;"$3@
M&TOADOUY)?(+YJ)IW,0J? XW,8ZZODEG>[ ^#&OK)W36NW\%5+/,"P* 4 H!
M0"@*8WMKQS.=)[YAL1&BDI?LW5&P(DS<*8MQUBAX[!R\; W,$L4O$R215=M6
MOFG5UO)M+=,+623MA0%>"MQ;L8"QK%7AUN+-5DP9M%,D]B<:+IY*-VZ:.>6%
M\MX8Y7PRRPO?&^6..7=O;KC:_LH7"=4\?(]_K9NGW.-R_$/C-\\:#"=4\?(>
MMFZ?<XW+\0^,WSQH,)U3Q\B*33D]L^! ,Y(?X<[RL,3+1H+E<?-N-I!SYV5R
M41%!/1LWWADK="Y8VQL[7Z>&T:77=K7LB@I>P8[T\?(E?K9NGW.-R_$/C-\\
M:#"=4\?(>MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]SC<OQ#XS?/&@PG5/'R'K9NG
MW.-R_$/C-\\:#"=4\?(>MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]SC<OQ#XS?/&@
MPG5/'R'K9NGW.-R_$/C-\\:#"=4\?(>MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]S
MC<OQ#XS?/&@PG5/'R'K9NGW.-R_$/C-\\:#"=4\?(BDOY/;/A#(20.<.=Y6;
MFI7$X:R\C-N-KY3Z:FD@'QD)9=-#>&62#*Y0FUL]>YVL@R:^*Z7RQ22RO8,)
MU3Q\B5^MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]SC<OQ#XS?/&@PG5/'R'K9NGW.
M-R_$/C-\\:#"=4\?(>MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]SC<OQ#XS?/&@PG
M5/'R'K9NGW.-R_$/C-\\:#"=4\?(>MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]SC<
MOQ#XS?/&@PG5/'R'K9NGW.-R_$/C-\\:#"=4\?(>MFZ?<XW+\0^,WSQH,)U3
MQ\B*2+D]L^+EX&$*<.=Y6?;&E;R&QORLVXVND+FF,'F6PE[$ETMX73&LOJ[!
M#UTWKF^**A&S =C?S#]OCD&$_P!R>/D2OULW3[G&Y?B'QF^>-!A.J>/D/6S=
M/N<;E^(?&;YXT&$ZIX^0];-T^YQN7XA\9OGC083JGCY#ULW3[G&Y?B'QF^>-
M!A.J>/D/6S=/N<;E^(?&;YXT&$ZIX^0];-T^YQN7XA\9OGC083JGCY#ULW3[
MG&Y?B'QF^>-!A.J>/D/6S=/N<;E^(?&;YXT&$ZIX^0];-T^YQN7XA\9OGC08
M3JGCY#ULW3[G&Y?B'QF^>-!A.J>/D10KR?V>&E<2AKWASO+Z:FB$C<A+(S;C
M:LRNE%FK%V5\Z]PWA=!CE9$BV\KBO>UW>?B8)=;IY= QSRFGQ\B5^MFZ?<XW
M+\0^,WSQH,)U3Q\AZV;I]SC<OQ#XS?/&@PG5/'R'K9NGW.-R_$/C-\\:#"=4
M\?(>MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]SC<OQ#XS?/&@PG5/'R'K9NGW.-R_
M$/C-\\:#"=4\?(>MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]SC<OQ#XS?/&@PG5/'
MR'K9NGW.-R_$/C-\\:#"=4\?(>MFZ?<XW+\0^,WSQH,)U3Q\B*.^3VSV4X :
M]7X<[R^L4DBDNF0RV$VXVYCKA827A(0Y=R1QWAY=L]L^G\>\DR5RLL^0R(+H
M6R3'N;XACO3Q\B5^MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]SC<OQ#XS?/&@PG5/
M'R'K9NGW.-R_$/C-\\:#"=4\?(>MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]SC<OQ
M#XS?/&@PG5/'R'K9NGW.-R_$/C-\\:#"=4\?(>MFZ?<XW+\0^,WSQH,)U3Q\
MAZV;I]SC<OQ#XS?/&@PG5/'R'K9NGW.-R_$/C-\\:#"=4\?(>MFZ?<XW+\0^
M,WSQH,)U3Q\B*->3VSWDX.:]1X<[R^L4>BD4F1&V<VXVX#K!9D7F00+=N1RW
MAY=R]N^@A[SK)+*ZS)"S!=>V*;]O?(,=Z<^O+'=WDK];-T^YQN7XA\9OGC08
M3JGCY#ULW3[G&Y?B'QF^>-!A.J>/D/6S=/N<;E^(?&;YXT&$ZIX^0];-T^YQ
MN7XA\9OGC083JGCY#ULW3[G&Y?B'QF^>-!A.J>/D/6S=/N<;E^(?&;YXT&$Z
MIX^0];-T^YQN7XA\9OGC083JGCY#ULW3[G&Y?B'QF^>-!A.J>/D/6S=/N<;E
M^(?&;YXT&$ZIX^0];-T^YQN7XA\9OGC083JGCY$4%\GMGEY7*X8SX<[R^FH8
MTC;TU9:;<;465D)4@2<"?)/<]X60>YW3%._-X(97R:962Q6M:ZV'4,)U3Q\B
M5^MFZ?<XW+\0^,WSQH,)U3Q\AZV;I]SC<OQ#XS?/&@PG5/'R-FZ$% * 4 H!
M0"@*VVJ+G1>)+L]>$L!<@R7RR37N\Q'YWZL'R3#/![DU>8HHL#JH<N21NW5L
M2$#B(BZ2]B'EU:F,Z^NOA\ 634 H!0"@% * 4 H!0$5G(^0E8;*1L2+*@I0\
M E$(Z71NSMDQ-YLU?HQ;+)\P*-L$?.>#@Y4S8.%$V^2N:&.#C%)3 G%,\.8-
M:C$*Y/N##Q4).!XUHK+)(['KOG]B+)D&<Y=1V;P,FP9+$6"B=V6 ^.)E&"X;
M,>3R4/./IC')+++>B\->]?KIW]>B80&R\*:2!A$P#*5N;/9,T&MVQY_BZL\3
M)%D<;IOB:*V+0?A@W).,<W[=JFP8I,D'";))FV3;XH88KQ7'#D"44 H!0"@%
M * 4 H" [/9RPA!S;&#W6PE#NS!$:N@4P#J,^^39><?6=Y8]5;,6/F7>0S!P
M-4-61N'P,@[OOIAC4QG77UZ_R#7->#<J%7:=V,_8L>LO0=I$"3M HU:@,6Z&
M!K,@ 9L!:91 P4LU)AHZV(C;A1[ J*2/,,#6&"5RWHO!=$7GR\/C\.HVFA[8
MXRBL?9R97S$B:B63<ZZL]L1Q>%D4,$R#U-Y9D-LLB]=8JND;XC1V."2V">(]
MCCA9JECZ]<022@% * 4 H!0"@% 5_M(=,"L#D0^ N\A\O=,[) 7^+_$=9B0N
MJG=N]57R07LJW:*VP<.V7ZKS[5-9G=7HO=-2IQUU3F#75S!N5:Z^-F$_%"7&
M<FC;E,DZ=8FQ@\.V;(ISW)>/69#%"[62G[-CL4!W),E 8!B0C^)B/XE,V2]R
MWHO/\].?)/2@VKBB!=K&8^VD%[Y'FP<<@:4^D+E;*E46J29!;$E=B,N^36=8
MJJINKC!EUD\\<[CF'7RB./KUQ!GZ 4 H!0"@% * 4!7NTF.P2<(-L-8$!8J8
MN6RF Q^6<9M$$,K)*Y8V2=8"3F+=99?%!"ZR@MS9-LJXR1R;NK-W2%3&=> -
M=7D$Y6+WLF+V(,#.\RT.S1+D%TS[!@P9(II[*6<1ZS(;]*XRN0^7D<2&9$&V
M(2/,GL;3>19!^H%=W+>B\^??ISY<P;8QE$HWC@%N;QO@90##$2V-R.1B]B:3
M-%-]_P![9,AN9.UW6*M\2&8T=F\QO9QFP99*7;)8@S= * 4 H!0"@% * K;:
MHN<EXIFTUZ^18R'$@T<)9N7CI@W73;V642:O'+%9J_P&JD+,/IFP]ZS(9!L2
M%F6;IU=(<]J8Y^O7?E.O5!KP[@?+!PC=$3L48"(*.(39 R272D;(>@Q42QV:
MJL"\@/Q)JRHU9.11%)1W@B%CK9Q&>['FSQ0(O<MZ=?\ '/Z@VYCZ9!$"$1*I
M9(E$A U,DCF2R,Y)/\&:.+Q/(OFT89E;X.+*8W(YL66;[IYG)HVR5NAACZZ
MR] * 4 H!0"@% * J_; O8Q8 -1UF58"S"!U)T1N0S<))O!N DPFT;8N&JS=
M=!)"3*QTF3R36RNL$'%&EV)JSFX,G4QS\/BG\9!KVY@7+1PU\ 3L<6!(J,H:
MB@6*.$I(U'N&1-#/8BZHBXUE@2<25W90W%EEE+M08''ZL*#F*"F8U2Y;T7G_
M (_S_(-P0F#Q,,(3((YMWZ8QA@^;J$<R^:#S!JEBY1S+*(-5">:2UL\,B*C9
MOF]OC=SD@EDK=/'$&3H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MV>V,M2I&9KR(2<?.]H.A<<:PE^3R0?*2 >*8%1$U7.,)IP7*IGCCAC7AKD$
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I((IXXII(I)XXIIIIXXX888XXXXVQM:U0';0"@% * 4 H!0"@% * _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g107876g01a22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g01a22.jpg
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M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<V)E<G1I;F]
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M 0$! 0$! 0$! ?_  !$( 1H"70,!$0 "$0$#$0'_Q  ?  $  @,!  ,! 0
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M$X1.$3A$X1.$3A$X1.$5"WIU/_@SKM_2?8?^55;GNH?/R?V1\:TO;+^2H/\
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M1IYVO:Z2862\O*ENODD.N//.KSE;CBU*5G.<YSSBER:UMQKVM :UM;5-:T#
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MD;5I;K)"LW,D'8T#$]C;[J>'/B]ZE-#Q$(1)14CN*"3$TAPJV@1 UBC1QF[
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MVIOWK+8#)(&'KVDW"KQM^8N]@KE7BI!%BW+9]D[MM(S;IHS<B3-1%T:K@$%
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MRYW#UK1^"?ZY/OP=O_:YL?\ X>]?QI/<']8?QM[Y_.6O?L!QY<[AZUH_!/\
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M ! Y^D]!17-Z[_D_HO\ 0ZL?Y(#RMO =P?$BK&U-\L-V@^C?5/\ !T=RAO\
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M,<1T'QS^Q?FW<;?1\8'OM029#H^]^[77@9,C&MHQG_WTW4\)=L$*E+:5.$$
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M;_1A2?V'QN,_%;[T?N1/WNG7S\1.F_T84G]A\;C/Q6^]'[D3][IU\_$3IO\
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MJ*^4DX1.$6)-GX*-?0+(S42 2YX9;'-D0Q7UX5_W<H:?>;<5YO\ 1Y4Y\?\
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M"#O 1,P=,:9.8_=FE/Q(;L_N_5OMES+>:Q</ZH.J]_T+9S_NQ6?(6/V<L?\
MB:O[$G[LTI^)#=G]WZM]LN/-8N']4'5>_P"A;.?]V)Y"Q^SEC_Q-7]B3]V:4
M_$ANS^[]6^V7'FL7#^J#JO?]"V<_[L3R%C]G+'_B:O[$G[LTI^)#=G]WZM]L
MN/-8N']4'5>_Z%LY_P!V)Y"Q^SEC_P 35_8D_=FE/Q(;L_N_5OMEQYK%P_J@
MZKW_ $+9S_NQ/(6/V<L?^)J_L2C[N%(KENDG9J3=C9*'<.ZW;>)7%3#3#$H
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M(X$@^$%>-64Z[_D_HO\ 0ZL?Y(#RMO =P?$BK&U-\L-V@^C?5/\ !T=RAO\
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MC072-L=7UL"V-LL+XIJFDJJ>,EL1DHJJHBA<61R&-SF-/5G-@7I3A%S!W:_
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M5EL3659GZX>_ RRG,^+KSH>$^I(=SC.?%U;2O4OKSG.721WW?BPO&,2X8.G
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MBUDPE2L87L7725XQG.,+3B6>7A*L8_[R<+0E7AGQQYDI5_'C&<;3LGZ,1_\
M(G_17T9]RP >JW09 .+)>R,C.#ULT9'0<$CN$C@5:'3%*53ZHI2LJ4JM02E*
M5G.5*5F+%SE2LY\<YSG.<YSG.?'.?CSS7I?Y67_F/_2*X#<P!<K@   *ZK
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M;KI9NR5<U)7:]-P,.+2-W4S8UE:G\R&&9*NP0DT%(B1Z8\,S+\MZF65D(0O
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M+,9'*/R>R+MP%S8]QKG ROZ5&P#VWT?Y=J$!E8L6S2VIK -&3P*HR<CAYF1
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MXK V4-O,EMIRXC&'6D--H5AO*'"GB"''?)67!NC0-.)/.?'_ ,*@-WM7$Z\
M.99BIDV#7]_%UU+S!5@K\_'D'5D\]67#@716R'G0GG595G*,-BO-J;PK+/FR
M(\,@;UQ _(.'-WL8(.O;\<J1D.W<DC&GCWB/V+H'E"K3A%7!Z7#Y/3L+_-:N
M_73KCF=V:]&Z'NU'R6==O^YP]6C8O^W?O]+WM3ST=_ UZL_U ZH^I4-SQW?T
M5N/Y;4_KGK4>JSZI_5!_/':+YUJEU-S'+GRU>[72KZZJ<_>+I+CP56K$:_*S
M4J2EUQ PC&,8\K0X[;Q9IA+JFA (\)@@^1.?'  &(,(88<O00354T=/3QNEF
MF>&1QMQESCVR0  ,ESG$-:T%SB&@D>>JJJ>BIYJNKE;!3T\;I9I7YW6,;Q.
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M45P/)TNT.P("@EM33Q N1B"G#'6VU+RQE2!TI7E#RTN81D=8,UU(Q\:%^1@
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M)0VVVA.5+<<6K.$H0A.,J4I6<)2G&<YSC&,YY: )( !))P -22>  YR5Z"0
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M^MFR.;QMGZ'[)>XL7ZBC7,.IMZ+]4+\Z*CY5<%\^E!_"1]%M]*Z)^NFH?_\
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MD?\ G6Z?[\0GV.XY%O2? WZ*)[F7J1_YUNG^_$)]CN.1;TGP-^BB>YEZD?\
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M\N'8%]0@]2LIQZSVQ+^'$^*5X4E6<9@M!Y@I#B.<^/1T=Y;M%0\3! LQD)&
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M,54.0,X'@I;##K=.2,:CCJ,<PXYQQ(YT6MZ?[X]9=\7M.M=7VZY3MOP5) E
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M#='8(^S@UK96H=MZAE9JOQ1D='RTK76-J4BG8L@L0;+Q0\OF!7(KBE20"I!
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M-F3%[ANZW7>J:PVU4MFO2.M*9UUQ/:NA:3HZ5&&V HENP1+T?)"RVOY2JEV
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M,-SC#;D[XU_M ]X-(_:BVFP=1NV]HD]X[#@=,==-33]\ZVZ4U+ :]$FZM?H
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@G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g107876g01b15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g01b15.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ M0)= P$1  (1 0,1 ?_$ !X  0 " P # 0$            '" 0%!@(#
M"0$*_\0 11   @(" @ #! <$" 0%! , ! 4#!@$"  <($102$Q46(517DY;1
MTS$V.+<)%R)!479W>!@CLK8D)31SLR8S8;5"8KC_Q  < 0$! 0$! 0$! 0
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MGSZ+#I%"H,/_ (I,Q7$Y,N=,DS,5G4\$B3*L#SU9X < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
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M9%B>:$9P. . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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MZZH!0-^80=R]P]:5:[KJY? 2:/%5Z4HM%R.6(>MSK@ 8_<9999+W5DWIL"=
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M2(1_4$]-:Q#0>^DUC]\1)\PY]W!%[7MR[^6?8CUVV\L^7ESR$OE.4R9!+_\
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M>9[L3]]\IO\ OJ7]&[(FC[=_<G);[OG]:[9%B>:$9P. . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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M)_FK>\Q3%2Z1ZR1S"W222V 2C;P2+[%)(Y!V'82;D;7G199O+3PM\LNS(&T
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M-'.YOMJ2HG4TWF/G0^UD3(I4SFQ67.AY\#YKLKJSLC8<_0?G' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M5* 8UA&2,$J(&'.:9+EF:M=#F!,DI)$LTG+U>O?KIO!//(#2B5Q" Y:V$-0
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MJ:.Q@A*.]^##"+"1F, "*O$#;:X7O3CB+ S#QWY^LNS7KSNC1PVJPXZIZ58
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M 8P]T1%!O7K+];Z:[^LAU7>;G_479;$=V;,VL*V]Z+];5G-,Q)K$+E'#LM4
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MULXD%L\ *:L3@P 1YP9H,QG&SI))9W^S<K7R6A:[#3#1#QR6!@9 1NU<1K<
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MOM9W_ M=_5Y;P]'S,EHNEY4/E/LK[6=_P+7?U>+P]'S,6BZ7E0^4^ROM9W_
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M G*<%-Z:'&F-<P>Y VVCF\]\9D]YOY;X]KV<?1C'([;E;ON57WN_=8Z+D*.
M. . . . . . . . . . 5;[,I+5^[[&B,Z[DN[*T5I<DZRL9&Z/9-2,[K)QB
MLSE,&4#:JEK+-)O;&+M"NE:,PL)854K)P@"7B=)V2SM9YK>^S<\EOT>NIRUF
M_P"6^66GQO:V;W;NPY!7UQVEJZ(?X)MX;M?9+#B)D2S3R8;#W7N*NJ9V.())
MS==5-;ZGZ[KSS=3IL/&9JXG7QQDS[2A16ZLNSY+YMMK3KRU)9WOGJWKQ=K.S
MS5DGKNMGH;RJJ/$$W*&'M;JP)A7#I3%:IP1Z^)E-H,/;73G%3+PZ=R?!))PZ
MS2X2H52\@H!H*['CT=#/#\'S5IGPZ\UKDNM_JK(B45[.Z6][]&\M4ENRZNLW
M?9M'[*>M^S'=0;L4L^>KE5&J,$(J [9VV*DLYK4[<EKB6=<+'.VK\!<L>XA,
MOP>>:/:3;0;.(FLD^+;UZK;M<GQ6>XZ:;O;@DM-,[\>/4:]$!V"EIMTIU1IC
MRN6RR7&RBJ[2SW215Q%7LL_E6L6.,D5LP/F)3=9HD!2X+91)M*Y'#6DPQCYF
MDC99-NZX9WXO=;5O?H+-)V23;=N"W?+MSUX&PI-?[7ZUZ]+J];KM8WRD>746
MO*]RSR8YH[19#&U7/&8SF0;15BNRV+7X]@^'=Y(I1L(UPI!^X6A)M-W=]V=E
MNURSS>[17U(E$E96ZM;Y]VZ_@CRZ[I_8?6=&[;5:+_C%BF8DV2K%JV@GO;*Y
M8T.MBM6."W@<HT#YM=ECRP,]F:O*W=HXDVT$E"V]WPVFUP[-%=\."X!)I-6\
M-^2TO^GB1B52>\+)N%$W7GM85-A,,036:9:-IH!\6ZL="X9QP/6YWI6&*9>E
MY.DYI!L %[B#]*LB&PJ7])PJ^=K\/_Z7"V5UFN&\EF]U[:7?8_C9JSTNN!Y2
M5[Q&LDBHJ:9R0Y2E[60,IRMK4+,%]%6)*D_+7@:6EHN*G-$O3YI6DTTBQ#"]
MI&=QHA5#5;N3+P]UK97SWJ^2WI)ZNSO=V*E%OUO=:.V[CO3;MDDUUG;JP^\-
M&5 B-GMLRV)W,4STS\ 6Y^!'6F+.L3MC*_LY&\R&NK)9I%C41F0_36O4 !JA
MNB+X@//Y<]-,M7GX*U^ZS7!V%HLM=UUDOC=M_FNLM?SD[' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' (H[0K5CMA?7BQ$9.I$ NNMD?.X1UIGH!$5=?R*(\!,L2P
MDS3VDA!-%C(T^(M YYL^ZDCBDQ4TKWX9=MUKH]+Z?(C5[=N?II[[$-]?IKU3
MKTUL-LJ%NLY9B^U[B/5<%6\R2K3V(XQ/HQ&U=K8@2(Z#0^H_/04>0;VMY!]-
M]=PY(M.FTU9-+3CN79Q;ZSE)J[:>][KYZ_)<-^1L*!2^Y*_;[?;6(M4TL/9=
M=4LW!DYK-FH3N$+YCLKK144&P)&V5%5LV*\M+5:9#/UJ^S-AOJ:;O@DW#DL[
M+QS6M^U7SXVW!7NVUFUW:[\LFDTEQ.<H'7MPSVNMN+>I&+R,7_M"S/F[))3%
M^T2AM!:4=/$"LZIN;;K!MA*:@'PB8"ZH8((23RI1F*9' 2NN;;J6]ZW3>3R6
M_2_QR)/G7?7N76EGJ^]?$]]@6]W6"R6& I/89J<Q.*%-0EE5[<"=8K[0I<P&
MBLR%E#G,+;K95;)/8U2KI(YK,*N<LK"S7RS+7\MMU[=?!W6:UNUOME=6OF_F
M;SO;2V5K<Y=>>5]V9S =&[_T2&THB5A"KFJFE6(T$'383$ V.B*T3AC$QS9=
M"?CFE]>OKJ:;E!(Q@C0'*HS,*#U&K.WAUZ[KBK-M;EE:RU2X+)DM%I9V:W]:
MSOUIW?'N.H'"\06H-H]7._"VE)C#B%6*D4@@6FEMD-#TK6@]S&.V0"5)='5S
M2U<"1U*#9@K!'H7:$+6".?RY:<>/Y9N^>>67!E_F_FUX++7XZ;LLW>^I:&FZ
MN=*C6-;'&9#8/@"C9Y Q.7M#AFVP$&S$4MFI!6K&1 I>91Y3P !!3-HLDPP1
MZ2XUYP]78Z5[*^ML^TZ7@HX X X X X X X X X X X X X X X X X!Z"I9
M(!29X1Y"Y88)I8A8LZ:RDR1Q[;Z#Q;2;:1ZR3;:XCTS)OIIC;;&=]M=?/. *
M+N>I.T1Z73DC+9O<PX.O68ED2!!U<21;:;^ZIM?N.ZN?$X$S0@:G6'M<R20X
MW;WVN88XBI"S,:R=N)-MZ9Y/J5[7OUJ'AV<.%"TDM<LT[97:O\&R0>U4G9G9
MDBIDCJDZI+U]NJNR=%9#107MDOZ9Y$R6Y$'5G,%^L2-8HF%!B;L(%[%C;M2I
M<#S5X>?$5EOO?+):)Y/7MW+=;>'=Z7277:[3W:]U[:I[CJ;LCM)]HJ[.Y4T3
ML:GJH[SB*L5H1>7%"\-DJ>*.Y<J+>X! 8&A+!KJJ^(1S>D5%.Q2-AH899F*T
MK6=G9Y:]][-:;NTKZU=9Y:\+/.W7V&#V !V,GZXJ*'K:KM$1HJ8Z<A/5G@#.
M-(P 0R;I:9&:V*KY!*:1L3[H5L$S1AK]480I \Z<W*8@K7;;3[;Y]>^[ZNOJ
M)%>R25NS=U;NO/BNLC NE]VCV!G;!Q#H61C' SILNC53MCDS',%:>2IE\+I1
M@>9L'TSU0P(R,<O+ 2W-E.MD&;KR8Q>KPZ>%_@GD]+OCIG=,6BO??W=_#7FK
ML3/T^L>(S0[!XY30=LR0@5P]\O!KLS(DZOUFM'TXIB/BUA!#+%]JNG:>[OW1
MIRU@>@#S.,:K9C!,"<&FZ_%Z-N^Y[DK<.-\R-1:[WD_"R^+?5?,G2@:=C[7V
MZ$6K5]I7<XFU3>OE3#J\RX9;##CA+0BF\L\4*X#1HN<AFI,2@6#*NSI#;$LR
MP'X=K+CZ\.SJNK)Y]*]W?3]].O+?W//2;>0Z' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M)<$F-HYQ2Q9I1R(=]<Z2Q2;Z;8SKMG' .#N'374_8 %=5W?KFFVI;4]-H:V
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1 X X X X X X X X X!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g107876g06f72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g06f72.jpg
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M 0$! 0'_P  1" $: EX# 1$  A$! Q$!_\0 'P !  (# 0 # 0$
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MY!#[BWGWWWEJ<>>>=<RIQUUUQ2EN.+4I:UJRI6<JSG//K, - :T -:   ,
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MC3,+(6.,B@I)U\=H1]UPAE*]BAUW2)[+Z<-^%]AG2@L&_AQ@&9FQR%HCF=$
M3(V)[W,P=X#!6HV-E]?J48]2L:79BIRB B5W1Y8VT0*SYX0\S5X[!(;#)8CB
M9(XAK'$D [P=T![@1AY<7(:2G0I&.#S(R89,Y3VB(F,Q-#0'NM,-KL>,Q,1F
M1+'4F5D?98]48O,XDG,(V[(H\S=J-!>UKV:C&YKG;K'"*P1(_HW2[D?\#_"/
MW&GTC-YV_P#P>.D(8?:_8?:J-[HI-'F9(QG22,=/4#HH^F;!TLH-C^"BZ1S?
MX63=CZ,]-O="#(-,V5U![*:>J\Q<]EZDLE2K=?GA:Y.2,@[$.JBI.0=)8BUG
M@A214B-$3+PA#<%87!$U^<6C"8B4-RXWY_14U[2+\\=>G>AGFEB=-&Q@D&^Q
M@!?NN<QK#)&' R1!W2QCU;&X./'J&RVT&E5I;>H:78JUX)VUYI)#$3%(\N;&
M7L9(Z1L4I8X0SEG03$?P4C\C/-W,NL G"+<:1;K12Y8B4J<]*UV1(CG@'C8@
MU\ ET)TD0AP5;PZT+4PM\49Y3><Y3EQAI6<>*$YQY+D$,\363Q,E8) X-D:'
MM#@UP#@"",@.(SV$]J]=.W9IRNEJSRUY'1F-SXGN8XL+F.+26D$M+FM)'++0
M>I?Z,_/E)?>J_*UZ?/\ I_TG]#Q/ZZSW.C;%_25O\*'Q+%^A7[COZS=J_P"T
MT?\ I5-4.<W)?7R<(G"+I?K!N^#T58-J3$]#RTTS?M ;=U%'M1"@TN@S&Q*]
MB'CI0SVQ]A&8T!['K34L*<*RU_T#+B_N>>#4*C[C*[&.:TPW:MIQ?G!9!)ON
M:, ^F<. S@=I6A[?[)V]KZ6SU6G:K57:/MELWM+,ZR)2V6MHEPV9Z\71,>>G
MF:=V(O#8P[U;FCBNJ>F'<[176> H!L]JZR&;&INR;#9YNQ5NOZSF2;U6)R'"
MBH^(7;;P ;;-?9JZFRBDQU!<BV;9YDCS<N*EY3@^-U;2;FH/F#+$8@EKLC9'
M(^PP0R,<7E_1PD1S])D#,V]T7-C20%SSNI=R[:_;R[K,5/:"A%H>J:'2H5*5
M^[KU5FD7ZEF6Q-9;INDRQ:=K/F@',C,^L"P[3L%]6M(6!K_EISMG#+WGT'(A
MAXR$8Z]UB6UQ/2.T;"U4Z=(YML]>%R<LNPQ@T_FKLO0%L8#9FCH]8\7-"C&2
M&6XH9PQN+6F/[SUH/+GF](V=C:T9EE;T3(=UHC<6=(=^+.X'9<PD#+CA1M-W
M.+3=D>[%':?/;=MIJ%;7*<&S])VI:I --J:2*]84K$E,:@YES3G2OJQ3A]BI
M))'#O6)&Q.ZPL>_-'=+*EU^HU393=(@2>[0!W.KC[0TYNZXQ5&VU7*S7(^T$
M'U8*=U0Q($DLN%PM)GA)$.<A8<INT,,9L!K8V-CI6]6EO2R'HG&/3S#*:]JI
M$Z:K))(Z/$A99P 0'RL(+'N!B)Z,9YS1V.VM[JFI;9ZMJ+_,NS)3V DTO4'[
M/[3;*:98U;9R[>NS:?'#?EJ;1.ACC>V.UJM.2"2I:LQG3W.%.)TG+\EWAU+.
MS6PJU.Q&TSM56?JNYU[KY4=5M&4JRPDG]G<?L'$G&4C7%9I=#K]4(EQRF,P:
M2[%) Y))D&I4K)GN>'D&Z-98R"1CZS;,>I"\\.DN2QO;T1AW733R2S/D#<'?
MPQKL %HQD[_7[DNTE.KHM^G9V=AVAH=T-NVEV.?4-K=4H6JXTF;1N]Y]6UN_
MJFL7=196>Q_?3HZ4$VY'"Z"/HNFER%'[T:.UQK2PQ]+IV^8>=M.E)C5\YH9S
M80$SU0,M4[7%UR5V3B GGI.SL%&.NNV5R 8&;5B5>>"1/I$=<(5$VC7+$[#+
M+3>R.VVPR[T#FZD(F2;[:_2,#8R  &!Y/J0#N9X*SJW<CVNUS7:4VJ:IL?9J
M:?M56V@J;8-T6:KW18M.J76W:^A=^5&P:>Z.)K6T6W'R.!KL9*:9D:&",MA=
MG^N>RZ_6K=:]8[6D]SQVJM2:BEZ^-=P:]ILF)UB3"!EV%AR%PU;"W[+6H3V%
M-4D150L+*2+TJV;(/@B*SZ(-.O5WR116*PJNLVK3'NA+[0=8#BUAWOX(='([
M>Z5I#WM:&[K02%G]%[G^W&A7+^F:=K^SL&RTVT.TFTE6[)I,MW:B.SK\=N6.
MD\6LZ=&RA?M=,=1@D%JU7A;6=#"R60+I,KTCF@(>3URW1]8WJ(JM$[6UOL2)
M "U/4-,#C*[&TBVU,JA1@E':C534@ Y/"%#7:WR,S8K*A!"IPH-UACU_@&@W
M7-GZ:Q"Z2;37T7/,MJ8ND,T4HF<9L[C7;A!AB:QD9(+0[)6B1]P[;*U!K;M7
MU[2+.HZOW.[VQ,ER34MIM4EGO3ZMIVI,UF>35G3BK#,VF^.32M,@JTJ)+.](
MY6O?N5_[$W]"W7KQ4-.L1$TS/5[>NU]KES1KHCD<3%["CJX(%',^0APS,D(_
M#$O'+<:2.OU[:F775Y<\N;@I/BO2VBYA8^E6K!@SO!T#I"7'@!ND/ ''(QQ"
M[-HFQMO2MMM2VG?9J.J7=D=G=G8ZL391/'8T6:[)+.XN8V+H)&66,A#7%XW#
MO-:,*3[[WQVF3IC1FFM17S9NLZ[K[4;VO]@1D/8EPT7<)DB?G#R)0;W&,27D
M-^&DQ8MY)2QGW$,.LK:4QG&5^:#1:XMW+5J&O8?/:Z>!SF;[HF[K0&G?&,AS
M2X8R..>:P&C]R#9YFU.UNU&TNCZ#KUW6MI&ZSHT]JD+5C3*K*=2)E>3OJ,Q=
M*RU!)8:8P]C2]K@X.SC>-?\ <'1H-;T]6]A:RGYDC5W72YZEC++]CNO[S]C=
M[L&SC;Q'76$HU_R73+(*Q$&/0;H]J%]8"02[( C.NLLJ59GTJXY]I\%B-HLW
MXK3H^DGAZ2%E<1&%\T&)8R7 /S$[TP&Z3Q.,1K7<RVMFO;37M%UZE59M!MOI
MFTD]#OW6=)[^TBGH,6E3:7;U;1A'JE&1]F)EMK]/DQ*Q@AED:US@M@W!WAT_
MM^&[3PLC4-F1 ^\]?];@JD^,JF/$P=[Z]P$M&C,V5 V8N.>JEB//'()-@(T$
MX49I]H* $PZPV-15T>U5?ISQ+7>:<U\R@]* ^&\]CB8\ASA(P-( >XM)(R\X
M)/BV9[DNTVS-ON>W(-3T&R_9+6=N9=29(-4:RWI&VERM/(^B9!8G;J-*&%[(
MXKD\T,DCF.EN2X>7_P O/=K2.X;7VDAME4K:D7J;L/9=-W6//HAU3:V+69_4
M=6'KB 9$&:<=K<W!SR%G.>K7(LNQ#R!#F6BWUN,LHM(MU8]/?7FK.LTH[<+F
MS"3H)([4ADWFE@WV/8<?R2'C+3@ $SI'<HVLV8T[N>VM"U79VQM'L50VGTJ>
M'5X=1=HE^GM)J$EXS0356MO5+=,B%N\('-LM,L+G1L <_1^R'=^%WSKW<=1$
MILY6#-A[OU5?(+ULF)*#!T75.H2-51<78Y'Q'-E+3)('AYL\I 60<E(*0VZE
M#(J57J&D/I3U93*R005+,3\-+2Z>S9%ASHV\6MB;ES&C.]C&1DE9;8;N36]C
M];V8U.35*FH1:+LGM#H]O=@DKR2ZOM#M*W:&Q8HP>GBKZ? 9+%6&,R]-T987
M-)=(1F=O]XJ=L9SN$N-JMOC\=D)GJE(UW!I$5G,$+U]C6@YP:=]G.<PYF8>9
M;=A$@^TMMX;1DSV=2<>%%;1Y86Z6'2Q.-!NI->0'>G-YQ+"S+1C<!P_.">K*
M\VS7<EU30V]S,3ZAIDQV'J]T6"\8F61WY)MG.^6H^IOPC=%9KRVV9NC<[)Z+
M?'/E'M5N"'W]V'VON.OQ4E"0VP+0[.Q\3,*%7)@CK"#%PR:H)Y\7+V%#*5GU
M#SB/*I.,*SGQYD]-JOI4:U5[FO?!'N.<S.ZX[Q.1D XX]871>YYLS:V-V*V=
MV8NV8+=K1J J36:PD%>5XEEDWHA*UD@;B0#T[6G(/#"Y^Y[5N:<(G"+]V/HX
M_B.=:/HTCOST_G'==^K&H?A#O@"_(ONW^NSMY[?3_%0KM?F)7*TX1.$3A$X1
M.$3A$X15_0_I!=:1LMM*$V?&3M<EJCV$W)I&BPM)JE[VC/7\335)HUXL5@:A
MJ9590Z-)8B;BLLT%QIP0..C"9%4BH5@Y8=6Z>KCP!/( 9[23[Z+9 _2)]3#:
M[8;8B_V :NUVLT"ZNR<EJ_:44B;INS;F'KRHVNHBR5.%/M]?-O!S59)DJX))
M#Q\F@A!BFFF''L-QW#AS.!Q',<>/'APX\<<$63JG??K7<+1&4V.L%ZC9^3L]
MHHN1[3IW;=/$BK]4821LTO09Z5L]+BHJ#O'V,Q1MB$JLD:/-DQ"!R4AX4?'M
ME"TCGCD#S!X'AD8/$9[,HLA)=Z.L<15(F[2.P"1JU-Z2;[$1TBJH7)7K=1N6
MFLTQ-G<&1 J*'<Q8;? !*A"&6YU#9BS%1V Q"WV6Z[LZ\=7,C./(B^O[>GKF
MF L<X]8+H(;6=@0&K2Z.?J7:<=M*0OMMA$6:H5V!U:=3Q[].F6JM+^R*#5&U
M\ADF%:)D7'6!@C%CMQW4 >&]G(Q@<^.<<.1XHN9]V>DPK-6L&G0M3R>CGJMM
M*L;0F2[OV'V-;M%0U7G]76."K$U0I<%[7%FLD7=TR<J8.179V!B3A'8DK#J,
M(RTMR0WGG(QCD [.>SB 1X044LU'TA.JUZ"U3O':]?NVO6=CTZ:O,C&UVD;!
MVI#4VJ5ZPJKDA<[!:J92R0XBCEO+CY6'G;")!/G0\L&3[FMN-'-"BPY(&#C'
M,AIXCE@GGX!E%)SW=CKLQLM&J%VJP*M&=D0>HGS6M=[">I8.QK3!1]CJ=4/V
M U6%TD64M47)#N5]IR>QB1=2^RVK"V'/"-TXSCAC/,<O%G*+ =1.Y=+[3UB+
MR".F-V,U 2%BN]3@VIJP0=%$Q=+)5:_'SMT]QPX .QV$. S/@U4LH>QKB'\R
MJ(M</AJ0=%I'BY>/@#RY]?/DBV61[I=>XS8\AJY^TV%^QQMH*H#\C'ZZV'*4
MI[9H<(Y8G=4@7^/JY-,DMGN1#:GA:*!.$6$PS*(44%Z=<1&*;IQGAY1G';CG
MCP\D6,Z5=DK#VNU$=MZ8I35$BS[Q:X*J0RA[DU(.P%?D,QXY\F3;:I51Y,PE
MQ#F"#:HB8KHYC9<*J43/0\W&1QS=TXSGAX/S$^_QZ^M%UYRE$X1.$3A$X1.$
M3A$X18"U_P UK+_W!,?HXGEV#Z/#]]C_ "VJS8^EY_O,OY#E_G#<^LU\"IPB
M<(K=]K^DLC=VVKL[4=C1^SYOK?O"NPF:!4'IT5ZTZ;OU6KL()!6*ML.2^(5,
M 9/@2)EIJ8QXT=.#&MDN9;.P6DO1*6Q[].AT:>H^E'JVFS2=]3B)PAU"M-+(
MZ2*4AG2=*V)S&PSEA?&6D#+=W'4=2[H,>KV=HJM]FI3;/ZQ7A[QJ&=ILZ3>K
M00MAL5P9>A$#YV2/LU6O;'.UX<</WP_ZMF>D@K5MH[AM9JEB@=IV"&T5#6^&
MS2M#BZ^,QI@^M22GC;X+0B-WW"(G#*A#%1-8E[1$-T\A3C8,W(108T2N*>R,
MT%G=FGBDI12:E)!)WSJ;K31J#9F8;5=9;IU>2-L\C9)F0R=..+HVO<7IJ.W]
M>U3+Z]:Q!J<\6C16XN\]%;1?YD/KR9?=;2=K%N*5U6)T5>6S$*KB0R:2)C8C
MXT=Y>NU-[$PW9S7.K=PGWZQ[FG]J[+A[W=H-=3A8ZZ5*R5JVU:@Q42,\!.%^
MU6R0E8"U6Z,#*C&8V/B,QBAB2GVJSLWJUC2GZ/;NT&58=/BI5)*U>3IY'UYX
M9H)[,CR'Q-W8&QRP0/<UY<Y^_D *@;9:#4UZ+:*AINJR7;&K3ZGJ$5VY#WK"
MRW5L5[5:E%$TLF=O6GRP6;4;71B-D1C+7.<):U?VYTC=K/;Z^=*V6#U'0^EO
M;"NA@V2+Z[Z,E;!/[.Q!2$E5];U_4=)K55C;-.!Q(H4.R81;#IVPMO2HT. H
MB1#.\%W0=1K05Y&LADO6MH=$E+H9-5U)D45/I6LFMRWK$T[H8W2%TA:(&QQ$
M,+W8:YN3T[:C1[=FU ^2Q#I5+9+::NR.Q'H.C2SSZCT+Y:VGP:73KUH[$S(F
MLB:]UI\TX=*V*/>D8^&A>[FAA6G-6M4W;N-'@].[3U@B)QXFG$[8)EK5L&*V
M0;;I(-1357&C&Y0!4.#!C21BH^.RDM!)#CB@6LD=G=4<>_38H>:+M>AUE\8;
M8%$,@J24VP,=@S%YC>)'R%C=Y^6X PY8INV&BM!TT5-5\QV;*6=G(IBZJ[4W
M2V;T6H/M2,+A6;$)(^A9"U[S''AX<XGHVXZS=YM32T#?[[&T'8S'83:/5H#J
MM9P#9NNN:4BJ^BOP%3F+M7Q6!TVE4H9"5P,B*JY;+43"311,@J3DEMLYS5#L
MU>CEJUGVJCM+I:T[6H7MBE&HR2F66=E>5Q)A#&R2D/F:XODC ;N,XA6[&V6F
M2P7KS*5\:[J.S<>S5ACYH#I$< @@K2W(6@=\](^&NUT59S1%#,YSS)(0"M2L
MO;K35_[<;#WE>=?['=I-UH-5J5;.J=M15-NZFL59U[2JD+?Z-* 2'N&],!GU
MF44-%RKRXTJ-FUN%>K+:RTN_%H.H5M"JZ;6M4Q8KVIYYFSP&:A>AFM6)S6LL
M<PR!CF3,WGL&^'QX;EIRO+8VITF[M3?UFY1U T[E*M6KR5;0K:KI<]>A3JMO
M4I&/Z RL?7DW8Y28W1S$NP\8,S67TBFKK'.1-1FZWNV[:P?ZT;+ZWW3:-ZLE
M6D^R5EC]D6N(N2;(_)MM*KAGV'R$"#%P$%*2131,.;*>Z,HX4_YW,=#LG=BC
MDGCFTZM=&L5-6KTZT,[-)A=4A?!T083TP[X9(7RR,8W$C6;K-T8&6L;>:;8F
MBJS5]8N::=GM1V?MZE=GK2;06(]0LPVQ8=(!WN\U)(&1P0RRO#HGR])(7'C&
MFM>TW4[6,W=WZ_J/9BVFHS3X>L[K:_X.-H7MK.NO;7+8/(1VQH^>IVOOL_=?
M#;$EJ1'2IU"8CVDUP=:5J:Y[+FB:Y=BK"6_3R7WW7*\/?=.L>^]T0.:^HZ*>
MUWJ [++#F-LEQZ4]:Q^G;2;,:;-<=!I>HX$>DMT^Y9\S]1NCS/WS:;)'?CGJ
M41>)8&RTXY7TA&WH&D<%L-U[^T"Q7"LV".I]W'!A?2'N]S"ABG(1M]^IN@T@
M?%492/)NLYLK#E;DD-$.+1&J8+'5DI"UOMMVJ^R]J*O-"^Q6+I-E1L^UP$A
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MW9D5ND=$>]_,.)D<_3;KSD3%I,/1[V ?3[O%5M\VY<_3A%[X[_IU_P#Z2O\
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MA%D8Q"UOKPA*EY]2K/@E.59\/.WCQ\,8SGP\<X^'_P"?+,_J!_6'P%5Q@DG
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M?]#>_P#*[R)N_P#F;Y?^%_7]S5(-#KLE&WV+:90IQYT_6]Z::;0C&5+4MQ$
MZA*4XQG*E>;RXQC.<Y\,9SR=X>'R']"C!\'E'Z5ME-O-7V!%+FZE)YE8QLMP
M%PGV*0!PDMEMIUUGU<B*(ZO+:'V_.I"%-I7E365^M;<0@"#Q"$$<UMG)4)PB
M<(G")PBH\[%_?O.E'T#3/YCV4YT;2?6[VB]LHORM)7'->]>+9'VDE_(VA5X?
M.<KL:<(G"*D'M+]^3Z+_ $6R?^+=/-NT[ZUM8_"&_P#:KZO[GO\ %B[KGM_7
M^#9=7?<U%?*"<(G")PBC;8M]<IS$8!$QV9JT6$G(<'%8RK#:W$Y;0LDKR*2O
MU#2W6DX0E;67EJSCUS+3;SS531G.> '$_/RJEQQC'$G@/GY%H1DEONN"+L4D
MQ59V/';R5(0("7$'#"(QYR/5.('9RIQEO"L^9HJ2RGRY7ADA.,XS/I#P&0>0
M/A_Y\0]Q0=\<>'B[/_KQJ9*I9H^WP$?8(S*\#'M*5EESR^N&(:6IHD5["<YQ
MZQAY"T95C[EQ.$NH\6W$9S21@D=BJ!R >U;%R%*<(N8-HSK.Q2T4ND0AEAG8
M,]LM5C#)2$# $MK\CB6SE92V[ZSR*;=6M\=C#S3:A5DDLI]5<:-T$NX C&/T
MCY]:MN.\< 9(//Y]7+BOY*UGL0=7W(Q^P0A+3H^6"&1"&!I<EA2/*H=T]4:,
MUC*T_<..-F-+>QYL//N)6OS@69SC'AXX\G_"$/(_Y'O]OEZULNI;9$13(FMI
M*%*J-DC6UYP#(+PXB9=7YGB#1C,H:PZ02KUC^&?+EK+&,8!>?89REJ' ^JSD
M'WO!\^OFI:1ZG&"/?\/SZN2GOE"K3A%\''$-(6ZZM+;;:%...+5A*$(1C*EK
M6K.<82E*<94I6<XQC&,YSGPX1<^#W39NQ"CG]=#0T)6 27!!YR?0XIZ5>9\/
M.IEKV<O*&\XRE6&T@Y]5YO*Z7Z[SL-5X:WU623U=GO\ YU;RYWJ> ';\S[RS
MU1OMF'LZ:)L2.#!G21UE0LM&Y5[FS++27%K0G"E*2A_*&GEH4GU.%9:6PZ*.
M]ZO#\$#&\WEU^!2''.'#CU?//P*:.4JM.$7&WI"_B1]F_HFLG^4WS*Z']5]/
M_"8_SKI_<6]=?8+^T='\IRU/T8'Q"^N'S2F?UTL_+FT/U9O_ 'UOQ4:R/=]]
M>#;CVRK?Z707>O,,N/IPB<(G")PB<(JS?2Y?$EO/SLUY^M8'+4WJ#XPBL!UW
M_1_1?F=6/T(#RXWD/$/@15B:R^_&]A_ZL,'_ )^CN6F_1G_U1\#472/I'+!.
MU;I5O6<K4S*5^9%A:RR++0IY49)#-2%\JL:<@<X-UDEC!8!90;_JG49<&(>:
M5G*'%8S[:X!FC! (R>!X_P DK#Z\]\>D77QO<QX9& YA+7 .GB:[!&",M)!P
M>1*G'K9*24YUUT%-S)Y<K,3&E=62DK*2!#I9\E)2%&@BSCS2GU+>)+,*>=()
M(>6MUYYQ;CBE+5G.;<G"1X'+?=\)7MT]SGT*3WN+GOJ5G.<XY<YSH6%SB3Q)
M))))YE<1=3+K<)SOAWYK<S:+!+5Z"DJ!B#@Y*7.-B87#8\@(G$1'DON"1B5#
MI0TZD)IC#R4-^NPYEM&4WYFM$%<@ $AV2  3RYGK6'TN:5^LZVQ\DCV,? &,
M<]Q8P#?'I&D[K>& =T#.!G.%_/2M76X4C4VC#J;:+!5#3NS.OPC2Z[+GPQ)@
M*("Y'8!*?CWQW2 LFAB%+$>4L=P@4=U;2EL-Y2J-:Y[PX CHG<" >MO'Q^%1
MM--+#6INAEDB)OP@F-[F$C<E."6D9;D X.02 2. 5I'/*MD56GHFKM<;UI/<
M<E=+38+9(!]E+^"(=8I<Z9+%!<K5%DE!#$'OONL!>Z$@<8D1I2!VR#"74-I6
M^YE7JMM#9&!H '1-. ,#FX=7@ 6N;-32S5+9EDDE+=0G:#(]SR&]'"[=!<20
MW>).!PR2<9)7J[5W2WPG?7H17(:T3\57YXK9&)R#CI<X.(FL+ $'SB7CAWVP
MY+"&<Y0U@UE_#/BI3/D4K.<H6M,%@D D!N"0,CGR/,*=3FE9K.B,9)(UCW6
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M#22T^*L?_P RAI*%8PKS)SC&<"YO+GGJ'%2 [F.'ASA075-@:;$DJU-!ZXO
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MK5 J&;7>M?:WURU@&/I\.VQ78B!KE .B8? ()I[(=TG2Y4B>F,.R,A)=G@?
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M -VE+_8G(W&?8M_NC]")]KUH+\!VG_[M*7^Q.-QGV+?[H_0B?:]:"_ =I_\
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MBY\:*B++*8A%R4.:V<$\N(D79$!KRNM^K7[&P(O+*W4(6C+BE<IW1XL'//\
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M?; C(J<DZ3'UV-Z_'S!VP[97C;1&6.UVDBRUJA4NPES+%CKH=56SQZN7/TW
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M@^F>^^CW?2 =]'AVK7]9;!W5TXWM2NN._;N?MC3.W27(K2&X)WUN;)"6)#K
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M+>?G9KS]:P.6IO4'QA%8#KO^C^B_,ZL?H0'EQO(>(? BK$UE]^-[#_U88/\
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MQXY\,<NX'8/(B\_V.5[_ %%#?DL'_P!#C [!Y B?8Y7O]10WY+!_]#C [!Y
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MY[5.PT3=)-(R&RZ9@DZ6:)F^2>R>;$KZ<(M/V'_,"\_,^S?H4WE^K],U_O\
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M=&TGUN]HO;*+\K25QS7O7BV1]I)?R-H5>'SG*[&G")PBI![2_?D^B_T6R?\
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MZB)C6]B<Q:Y@G")PBXM[]:0&W7UNNR V5-WC70).R]>RPN5-28%@J0SLF^(
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MD9-#*P\G1R1ES'M.",M)&00O$U>*6_<2M>,VZLO7X&#9LYE(:G8M=M$K9!6
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MZV.Q;ZSE3S[+(SSR5"MS4:Z^5@#VS"!2QCBA"7FT9;\:2#G(X]1':/G\^HU
MCD>'6#V'_GY]JB-)<&P-BOL%=BHF)RUEE.O&*K(/9;%QXM9B0;'B",/9B_+A
M3#?LUNPPT,G*&#66$I\M.?Z_/B,9\AYX]U3U_P CQY&/'C./>]Q251ZC*'S<
M3:IR":J,+58M^'US1T.LNE0HIK*1Y":G5C*='Q,'"-MB#A,$$( $<(P0\\:0
MZM%0''E@#@!V=I/A/C4$]6<YXD]O@'@"F_E2I5?5Z^Q+,6VF=RQFT?;$SBK4
MG.4^[.*AF3-]OR:E/_*<5W[%,0WAEW&([V;V;.,^3.<\M''7SWSGMQ[GS[%<
M&>K[#AV9X=O#.2NF=3Y#58]N*@,CYJ6;F!F'R#E&8W,I]C,3]D^0,M>+66O=
M7_I_49]3@OVCR>"O/RMO7CEGA^<#P#\ZI=_)SSQQ\6>"FSE2I7*6Y55[%NN'
MV6Y%P+G0LSBL^Z&6L-9F,S4A[H8BO7>&,S&5XKODPQG)/EPSE'@CS>-#L$G/
M+=./'GJ\/BXJMN<#'V7''/'5[G/FL)IW,-[K:437LL^[6*%>?L_PC*,R>/\
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M(]D0?+(Y\P<\*R2<(JS?2Y?$EO/SLUY^M8'+4WJ#XPBL!UW_ $?T7YG5C]"
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MI@"OCCFJ*((99:6R$AQ;@3B6#"!EDI]0\A"VTI<Q0[JZR"#@<3CYX530>/'
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MX3WX>[?($[#_ .R6_=_QYUHONU1_R_MD_>S:5_3'L3Y:W^\)[\/=OD"=A_\
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M"0OE3;C:>7;/:[:#:B6'O<ZUJ4]N*N7!SJ]8D1U('O'![X:L<,3W@ />QS@
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M")PB<(G")PB<(L5.S496X28L4T3['#P$5(34L7AE\C(L9%"/''D^SBM/E/\
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M^CR6NS-IPI%BLE/"(G!%N56CW>TV(HJN64^H3(T72:]7I*Z3#X4_&'B*:BH
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M8>&*^**0ZW):1GEPYX<TD<<<0"3SX(ND.4HHXKFUJ=;;W>]=5]Z;D+!K0B,
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M*Z>%K%BHNM-CRU\@92#UC,&'51^!,C2F58EYN%@1XN04]&$LPMC='&7('SD
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MF#@$#E@'\R+4)_13U<V=MBV36G[/+:<L_=4BV;4K].JTS,2>P==/=3:*!5+
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M/]4;P95JE",J@X"5'[G]H-XSMABBT8DPJ7N,7L[$5F;!?0.RZ9:!HK:=%9+
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D<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g107876g06m17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g06m17.jpg
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M 0$! 0$! ?_  !$( ,$"70,!$0 "$0$#$0'_Q  >  $  00# 0$
M    !@0%!P@" PD!"O_$ &$0  $$ @$!  H," D'"08' 04" P0& 0< " D1
M$A,4%1875M08&3556':4E9:7U=<A,5-7D[6VTS,T-E1T=;*TUB(D05%9<G,C
M,C=Q=[&SQ><E.(:1H<%#2&%F@;?'\/_$ !T! 0$  @,! 0$            !
M @,$!0<&" G_Q !A$0 ! @,$ PH*!@0)"P$%"0 !  (#!!$%$B$Q05&A!A-2
M87&!D9.QT105%A<B4U64TM0',E16DM.5P=7P(S,V0E=ULK36)#1#1&)R<W2"
ML^'Q-3=D=H1%1F5FA:*UPL7_V@ , P$  A$#$0 _ /W\<(G")PB<(G")PB<(
MG")PB<(G"*,VC^+A_C-7OUDSRC/F=V%0Y<[>T*3<BJ<(G")PB<(G")PBC-3]
MSIWQFN'[5&.4Y\S>P*#+G=VE2;D53A$X1.$3A$X11DA_*FM?U?8__)N%-(Y#
MVM4FX53A$X1.$3A$X11BH]OQ5+[?X_*>[?\ R\LS_:_^G:Y3GS-[ H,N=W:5
M)^158>.;0=#;VU]J)R!#P/NNI]N[&>./RU-28<W6MOTI6H8AB+E'>7V2S.U9
MTM]Y3J7F' T9MIIQ,EY35I@3J('2'=R+549V2331:M +9$H>XDB+)80PP9B4
M I\,@_6#[55?&;*C"Y-Z:($Z-WNY O&KXB.0L%<=E-1[)7Q+TX0@GEO;JD85
M&>W"M*5PPUZ--"R]H+J?B;_OVP 8*G&:[4*QKS55ZK!RQ/!$EK=#V+;=VUQ1
M1D8".GD"P2F-4PI@B,=6'M>'"4]HY7166(F'X6T QQJ1T!O?R:D6UO,449F?
MRP ?%VU_K&G\N@\H['*:1R'M:I-R*KIDNY8COO8QA66677<)S^#"LMH4O&,Y
MQ^'&,YQVL\(O' %V4NRSPT-XMJ(8**G:J!M=3D^.B+M>LC>>A6#U:7T-&E8B
M]_BF*/8K%1ZT\Q*[CQK5KC%,P$NS1!AJ/L+ ,C7$@\7IW1TC'E"+='2?4]*M
MMC,Z]VC!K86[PYU&9!RZ"NSV.K6!N^T6/>(4"3)?"X75SX2+F3',0C$Q4%R,
MX&)Q".<F,#X>);D1734&@(H::\46XG,47!S^#<_W%?V<\(H_3OY(U;XN _U9
M%Y79GE/:HW(<@[%(^15.$3A$X1.$49$>[]M_I@G]2Q.4Y-Y/UE8CZSO^GL4F
MY%DG")PB<(G"*-'<YP4I>,9SC&;+*QGM9_'CR.MF>UG_ %X[>,9[6?\ 3C&?
MQXY1D[D_6%#FWE_45)>15.$3A$X1.$5"3_ -(=K^8R__  '.49CE':H<CR%4
MU>SG( 'G.<YSD.-SG.?PYSG,)GMYSG_3G/!S/*>U&Y#D'8JHD1AB!T\L1>Q&
M'BX4HC.D90Z[AB'"8<DRGLMLH<><PTPTM?<--N.K[GN6T*5G"<Q58@H_4=H[
M8XR$:IVRJX4#D:Q0KA!*/O20P^4"V=,LHZCN-3#D8;'43-D:=9AV:_WS%@&$
M1$B 8%CY:V&7:016H.%:\V?:BE9/;&L@Y2L!"-]JD8O<SZ:M5QOCR [,-6!;
M%D?0*AL,/.K5)7BGVAA.',(0J:"(CDKS/CJC<4..!P%>;#O'2BHL;GU=YQK)
MJ5=T$,;!J%,@["LM?E9DQ,AZ<1FN0(YJ64DQV@N&FY"&LSHC9)<\7&G"9Q.)
M$A&A,B:H: TP)H.7]^G'445*]O7431X36&+\!*V Y%$3Q8FO//6:7*&';9BB
MCB^$5YDGAD,NV]V$EF)"FA@R2Q+63EPX\.4\RH=6O/#(5T\6A%=%;;UHB6U%
M\MJ^IMT<;)Y+-3D/5J-'KID#7S#$^UM8761I2*9LP6 D(0+1C,MV4ZJ% D-0
M2#D50ZC^OHYD739MRZFIPJ4;LVR*4'&0@8ZS2),JQB\Y372\^&+$G4,,R79+
MX@F2(08(\@PRY%F2YD:/'=<=>;2I0ZCJRTZD5>;VAKBNAK#8#-YJL$15'E1;
M',4<'O)$3L1O#$"YC,=]Z0@O(C]RY##X:43G96TB'$?<=;0M0GGR128$;&64
M('L825B<&/BAYL1-PR_'Q,&%8C,Z!*PQ*:8E,8D1'VG<,R667V^[[AYIMQ*D
M8F2*Z\(G")PB<(G")PB<(G")PB<(G")PBC-H_BX?XS5[]9,\HSYG=A4.7.WM
M"DW(JG"+RW-=9^V-)O[_ #&YTZ^V2 U'M,CK )6=0ZXLE'NAIH-T_P!*ZC3U
MU?=LVY=E>&P =4LA0!-!B:SWJ-*&QK<=M5;K"RV!&8:'4 J*YDD$9T&@:>-%
M+;?V1.OU,1:+ YI^XRP=?E[NS!GOVFB!\6 +T]C5D=DE(#1,VQEF8QB4#BUZ
MORE(+V%^<37$8;B WI,H&5IC2M-!.>5=O[E%;C'9#T3R1<+K_3-T(R!.XZ#J
M]H]:FE *D9:*]0-7T%>GX!QY#<!LJ)L9Y;=;BXF3&B<?&#9#$&(/(CT@WC'U
M2::<&EP_\Y41>EG,$3A%&:G[G3OC-</VJ,<ISYF]@4&7.[M*U/VUU46#5F_X
MVI(]%1=H5AIVI7*G!$3(H>P2+ULNX;@!906-&RS(.-580_6\)Y66AN2D9^7.
MD)<)XS&'-T-J*UI0FM=5 = S[>)5:Y6[LEKA,%3[%JV@.P:^6"23=E.WM LI
M+&.SNB/9/5P% B*<%O  L3FP6@]%A%C2R+59((<MM9B$QA3 VP1LKE*@G$&@
MIQ.#34].&>1R19M;ZZ0RA%J)LZ\*SV@)I5-K^4VJDP#5\NPJ[5?7ED%!->(L
M!?8K46)9+1'=$/#JY9GS(QC&(K*B9:L#[!C=RQXS@<!G6N7_ )18<@=DJ:GQ
MVK].H$VMZC;55CW?W(L:RW@Q4RW1GM[JH.0D#(5I$1JZ?$.:\B"8<]QFRCB3
M:9(SP".X838JQE<S%:G$<X>&\=:UXN\IX=[(F$K:"T0GIFZ+/5"'L0OL$6,M
M-"*PJP UM7="W0P6@6&$<<#VK,JH]0E/F0QX=_,Y!N$6!SF8B&6RBY<PK44-
M*8'&I<!R8M/,>9%L!I'J=!;JOVUM>QZE8Z>9UB2D1THLZ,1'K0'CVNUT_P I
M0D=;+*2 *22J<E^&9!R3P!Z,0A0W#3-@C&@0G$B@!U[-./[USPI0DL[D/Y4U
MK^K['_Y-R*:1R'M:L7]2FSCVGM.V"^UE%>R<@G=> H+ML9F2*Y"\MMD5*CR2
M99@>3#3'HHF)8Y!/+3)6!WQ<1"')3365JY0*G3IRSP"JTU8[(1,J\>S)NU-3
M=9%/GV<!(G:=%3BH2W2Z_LARF8MU9=D'BY5NNHAH>P<#Q!=HE C0PREZPR10
MR;,C9W"<J:,SEA4@X9HLFM]?5!(-S)%?IAPU#DV&NU&GR4W+5(]=LL9^=2X"
ML8'SKTT5"5F"[>@[F;L1@>3,]I/<#Y\B:;IL*TXW3K&5=.6/%Q99\2*.O]DC
MU>@-XTCZZVC*ENT^G7Z*&8%")1!^H[#(:OJM(.)R.+D([T&P;&V=BA1'1SI#
M,J?1;\9$)+ 0D6>2MPZQ2I%:Y4J3L%><#,HN]79$Z/'K!J^E-3[3#4&LKK@V
MR6,G&KL>4(M%MUD_L2N5ERM>.U6!Z<8G>** -DM0<PR-SM-7B#W9<(F]-AKA
MRJ*XTQU''13#,UT Z<$7H' ??E084J5#='2I,2,_)'O.,O/07WF4./0WGHRW
M([KL5Q2F''&''&7%HRII:D92K."+"EXV?!TYJ:RWZ:'GV%4"Z3@8H ,>B19A
MRS7?;JJ/4@Z)L]UF".9)6BQAX4LI,7X,+B/OD'TN-QE-JRI4C1@-C05!ESN[
M2L1P>MS7@,R=I.X QW6VQZG8S &TU\0//[+KHJ$'%:;.R+BNZ52MXA0J4V+W
MYK%<PW9A]96-FF)L2="92,?DJ73@1B" =6=12AT^B<JY*K$!WJ\Z/-F#@=TW
M1J]B9"K]8C7>GJV%I@I?;G7()%>YRQXBT#123[]5ACZ[TXV2VSRXPF^U(@B&
M5RL1EPP[I6W7# ''EIJIB2.$BJB>[^A@9%-DY^GZEY*U*5,N9E]OIX*R+$"O
M1:Z$=?%)\^C(UKDT/.EC-;@C\G\IR8-R9( ?X.ZN8)5) /T$XX?6';7E12)7
M5;THZIN5JKNO:$Z-V"4O@RL;&B534!*FD$F28O;EK'V2]36ZN/G$0_AM V&I
MXTJ.9E1GYLBQ9CJ!F<FI2ZX@:<#3'40"!T@\G&*(LBP>N7I^?@1I4L^?9D2(
ME=RPU H>P2\ R:/']<5)ZMTXK&JC;%T- K7MBA@3@T"U()#9AU.)L",H::;&
M2Z=6O,@9 FN>H'BX\D6:*5?:SM!-!OM.F2)U;LE2MTP:_,'$!$U.&3-6A2HT
MX65C0R(^=!G1I,*9#F1F7X\F.ZVI/^3C.5" 0=8["II'(>UJRJZOO;;CF<=O
M#:%K[7;[7;[A.5=KM_Z.WVNUV^8JKSWUCV0K7UNU4(VWL*J&:!6K7 %SJN/#
M#K[L@X08EZXM6U339(:(UH*Q%37:/43)<E/$O6$$MJ'+2V7_ ,F'X?F6$&Z"
M">8:0-)TDC]ZT+IM'4=T@5XQ%UD!U@)MY,5<Z=7IM-K^F9:W1T:Z44SKT59J
MV!337,V2+Y"UM&NDH QEN/TAV$*9>S3L-=U*.S).-<:Z1CB:X8XXZ47S6G5[
MTOT]V=5]<TT)1]:N$(,NKRM;TF<Q'NTBW!.D*952H+7]+I;<KPNT$^KK7];=
MCS41ST:<-PX\/DQ'9K@&EKJ5-2::<Q2_48G1<*+/%+ZO=%;!LU+J54L1XD6O
MKD.& =71+O"$)-S:%8=G(JY@[. 1PP*U,T:KE[!*KI>;#*L16F$+C=_DLM*Q
MNG/4*YC(D"N>LA%LNY_!N?[BO[.>1%'Z=_)&K?%P'^K(O*[,\I[5&Y#D'8M2
MNK3?FY=1V'6%2TG1!FP+1?:]MDXQ7Y=</V&85(:]B4QT-7XKX6R5R+58EAF6
ME4$C<SJR(BN83%F2Q[[.74*K0#6IH!3;6N@UY-*JQJCL@C5:AWUC86K3<<_6
MK=M 16(M9* 9<.YBJ!O"T:D=9%M/FGCCAT:P$CD2T=(?#A-;1F<'&MB8:7<4
M,K2AZ:X8 Z!^_&<$7!79,M7*8*N1M:[4=EXCT"14A:@\'QC=&KZL TQ)#HBS
M9D:5!"/6,>R<EAY1S V8K @@U"/RAXB8+"*8C&M>*FO_ ,TXJBI1;"6/?=AP
MCI2/T^G,*I'4/9@H\]-N,J8%MU.&6;6AV_5V"U5(\:0AVP2<B78IKPXO'C5_
M,"3%\%*R9[#L'&GUJYC5EF <46T/(BC(CW?MO],$_J6)RG)O)^LK$?6=_P!/
M8K)MJWS=?:JV9?AL6+-(TC7USM\"%.[[X%+FUJN$C46+,\'<9?\ !9#\)MJ1
MWEUIWO2U][<0ON58#$@:R%DO/ %US;KJ\6KG-Q:4RBI'0E[MV#=>$R*4;G4J
MIAM%3'[3 IEVNA&=#'AS6S[0!D-2"DPA;% !10' &CYDASF1:,@=0UXFN& S
MP')QHI?/[)9K =).MO:]V$Y KUU@5P@>BMA)M>:K9&/8Y,:^N%X1*3$9K&6:
MN16^:<7BK04N0U$K3"0^I32X=8RKIY]''R\2++-$ZOZ_MBL;]*T\!/I#NF1!
MLA'M&Y6)=1UP5CP2.P@$>P3[!#:(2H==@&=;G95F\'B2)P@$X/?=2@G)F#AD
MNTNZ:Z!B=&'0136BRKTW[,L.X-/UK85FAAXLX]-L^8#X*/.'#C=:'VHR,J-I
M0!*SRABJNVVKPQ%E?J1LE--UATJL*8=22AR6&H0 :#BZ:8CF-172BR:>]U:5
M\9I?[&VW@9.Y/UA0YMY?U%2;D57F3NCJ_P!_4'8W4@,I.KZ];-?Z JUG-&#$
MP%9(;0IL3TO2=W#31V[8L[(.9X5>70-)711-=:L#X<VD^T8CM0I"^9M:"&U-
M"2!_^X#+DJ:G"HHBEI7LAM(KA,,!L6L[_#/OVTY2[,(ARZ82E58N-FL#Q3TQ
M42SN0<C;'(DMH'DI<\>.PZU/B-S9DP=*82N'8",\:]W(B^4GLBNN;O8-8U>#
MK;:C)O8)M(,K$S75+<U])EVD%412[C&=S%)"4R2-D%32#1$>/?$ W%&)#;L6
M0)R5ETBN(P',=.!TX"N%>XLT =X'YO5/8=&3G:!/K/F\.W*N3:T2D3[2*)U
MGK@58ZY<D-D)<>&93C8HLT\+F!ZWXL!DJG(%$;HZ</MTM3T:XY@'GKW:]:+9
M0I[FD?Z#+_N[G(W,<H[5'9'D/8J6O>X /^IQG]R8X=F>4]J-R'(.Q<CXAFP
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M0L5N65[?C24 Q&@-X#R27;SX>^.\&=F=O/A"G.WQ4ZSCGQHKY&KE>AFR-EB
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M5]I>HD>JF/F4]NUZJ?0'07T7V#]Z''@4+A1.EOP)Y7VEZB1ZJ8^93V[7JI]
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MPY:_%8T%SWP9SPF+#+'11"$)X#7,B,:R*V(RX0Z&\W81N7J&H-^UR&%U@E:
MMK!0%Q8\:124L./OKV39;5A]F]0-K)0.C-B#[:L1<Z[(25$H;D7!%MB4U.A9
MLAN:ZIH0<Z.R] #%I;0XC,.&!Z=4W:$"/+M9#=%9%8" #  ))F8D:HCMFO1
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MK^Y-[1*%8.J0?2JZ2UH(MK$S7&Q78I>KD]XZ3C[7M/3R1$:SCUD>+U9IU>P
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M)_I;L#W62_Q GEONH^X%J];-_LI/87]-7P\=7?-%:^]+CS8[B?Z6[ ]UDO\
M$">6^ZC[@6KULW^RD]A?TU?#QU=\T5K[TN/-CN)_I;L#W62_Q GEONH^X%J]
M;-_LI4+G1STXH(Q(:>N;62XTB&0DO3L":YWJ,]$>'-QXJ\8V=E.5S43)+K><
MNH5A,%W"4.8RI33S8[B:?^]NP-'^JR7'_P#F#]ZIY<;J*_\ N_M73_I9OB__
M  K]Z*N]A?TU?#QU=\T5K[TN/-CN)_I;L#W62_Q GEONH^X%J];-_LI/87]-
M7P\=7?-%:^]+CS8[B?Z6[ ]UDO\ $">6^ZC[@6KULW^RED/5/1STZ#M@5<K
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M7YN:B,EG,C1I@0Y:'$C.AP(!CS$:*Z!":V$YSF@M+(4%L/,4"B5D;>;+L:'
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M2/3JW>H9R)0!@N$+A0!E4GR0"G,YBK-$768LX\5+$WG)F<#2C<!IKTZ=./\
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M&# A1;5+M=U#1=9TA_6#TVT@2H<H#&QI3DED+!*K#CJ'8% 0<J@#2!HT:S7
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M"E<14:JTVXJKRIU[V0"WU.MZ28VZU6]CVS<L ;8Y2JE"(T)ZDB;.<M52JD5
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MA$X1.$3A$X1.$7NSV&O.?$G4!CMY[6"NM\XQV_P8SF)=<9SC'XNWG&,=O/\
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MX1.$3A$X1.$6".HS<I/0>L2NSX= G["'5]^*H^-&6 /7Y@\5*<Q$23:<,_\
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MRG.<94&H="+>:O>X /\ J<9_<F.:79GE/:M[<AR#L6 =_=,E7Z@B52)6*P'
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B"+_%H_\ P&?_  T\(N_A$X1.$3A$X1.$3A$X1.$3A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g107876g08z43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g08z43.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %= E\# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            <(!@D#! 4! @K_Q !3$  !! (" 0($ P,&
M" P$ PD$ @,%!@$'  @1$A,)%!4A%B(Q%T%1&2,R5V&7&"1QD9;5UM<*-SEV
M>(&AL;6VP? T0D/1,U*"\25B<G>2M+?A_\0 ' $!  (# 0$!
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M"24.PD9TUUH-M>25H:5)4Y. 3CJ ?#/U4J2=[[UC-%-:A=DX ^?QMS>^M=%
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MH!24=5ZK"0($QC&)42,!9%8/QAIQC&"FVTX2[X9==:_-C/Y%J3^F>,GQ/QH
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MH-*@#3O>C==8BJ1L*^DV_<D5'?#"IG8&P4."C(EB3M6SY3>YM+/MBGHB =,
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MJ>Y';4E+CK*#B[%L4<>@*CV9\4.D14P$[92Y0:/Q&$N?3WF_GU-#.1P'K@;
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M4SLVDW429OS>N]3ZVA]B3RH6N2Q\2?)]EH#9Y!L76X@2+#328K;VO-D0 (8
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M+_D\.VO_ /265_\ \^-Y%A_TRV_[U?KK&P_Z9;?]ZOUU<C6/_%MKW_F/4_\
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MA4CV/VU9;%3HAT9MQ\HJ.UQ!DUK74;&MM^^O !%<-%8:4YE65JRIS+TV4>K
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M&L(>7!&"0>AQ\*5FO(I3BE.*5K"[_(5I39/5#N['H<&"TUM(74F[36/4E"]
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M:<4IQ2G%*<4IQ2O'G+# 5@#ZI99R'KT9\R(']1G),*) ^</(0("+\X>^./\
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M7%C>D2WAN+>ZP!++!&DT<Y4<(D:)Y(FCE( [QE=E=@7X59C4M+!<$//WD<V
M'>-5=9<#'$49D*N1@$ABI(S@$FL2NEQ!ZVQEB[,=EIV-F[[)A1VM->T76T7(
MGONJFI)!<+JG6,.6KZ[>+U>;$T.1(R#@HBR&XX5Q0D17X$HE&#R).B65BCI;
MHQGFDF9>.60 J9Y>'U(HXD/"B*2!Q,2S.^T[3<-M;*5C#&1WE(!) X3+(1ZJ
M(BD@*"<9.Y9JQ2);^)Q?8P&=)F^HVAF9IC$@W39*B[-V]<:F,6KWA8:?G MC
MT>JR<]'C+0/*D0XF8E9[3OR2G!LI5RN?0D) 6XEQMQAXXU8CJ%[MV .^ 6R
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M%.S+:_9Q=L)=3M=$E[V*>\TIHUN[":2-EM;[@DAG[Z"UG*2SPQH97B5N[XV
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MU3L;3'96=JDM$@*)Q32XG8<:$LPMG#I1VNFVQV<J=?RC"<XYLC@B,B-%=1,
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MUKNFNE#LY&%)#OE;R,?))$'RID4"RM3L4PA:O: 0OTK39ANIH1PJP>,_.AD
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MQ.6^NFR<J-AR/)M30+=K99?=(%F63DL%,;9+Q)(C$;=6V(6261Y)4\.%SPG
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M1^HY95GUU9XGN) V8+5!?3%&<O[.E]S2@SCD+%UK+8[GU?6TVVTN=#V<(*_
MM5A+A3F7)-+,83M-@_> AU-LRF07)V3N@=\YY2#D8R>+BVY;UM]!8R##J;8J
M9/2?Q!&,9)W&)!G'=D@EMN62)FZC]6[?2)NP]DNS$U'[![=[5CVA[1-A^IZK
M:AIF7,%QFE-2C.K=:B:G K5C,U)B^DVWS:7I64)-5[3[NJXG5P(804MXR2BG
MYTC<C+)XN>G15]48&:UW$ZN!#""EM&?54_.D;K))XNW0<E&PJ^?*M5*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4J*]J4^9N ].:AE"I7!V]4V=\T^L?&0<T^W0>,,Y
M0VY[CWSTV#GV\^C'LX><]?EO"%2.OF/M%01G'7??X&I4Y%33BE.*4SC&<9QG
M&,XSCQG&?OC.,_KC./WXSQ2O"&EH\J:DJZV#(H*@PXF0=?(@Y(:%<;EUR*!4
M14T^&W$21HV8Y_,B'&ED%Q27PE'M#I/%R[&!RP,+@C;8>&/9Y<JG?GGGY[^_
M]=>[R:BG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2L7%H]
M+"MTG?PZA6!+W-Q(,#,W4: BF+9+0<8ZX_'0TG8FA$2YT4 ^ZX\''E&.B#.K
M4XRRA6<YYEQ,5"%FX020N3P@G8D#D"0!DXR<5D68J$+,5!)"DGA!/,A<X!/4
M@9-91S&L:\:OS\;9XD:;B%&+CRG#&F5'QDG#E96 :3'D^Y'3 @,@PG!0KV&E
M/BMI(9PV4/ET9YEYP#FA&*]GBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*5AH5:#&OU@MJ)+#I\O5ZS!/Q'I:QD,6#DK*:,?E6'<O9P<Y-DL8P
MME#:?DLY;<<5EQ*)SMCS)^./T5&-R?''T5F7(J:<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4J-C-.ZJD-GQ6ZC=>U$K;<'73*E$;%?@P'+='UP]
M[#Y40--*9R8V(M>7<(Q[F5L,E'CCK:8D#FR,^\<(8P[=V6#%,GA+#D2.6:S[
MR0(8@[=V6#%,GA+ 8!(Y9_5X"I)YA6%.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M45[5;N#@U._!^93#J+>I4Y]+=4TK,)^#[<G&#/2M&5B?7%0F?1GU8^;P(OT^
M484F1U]FWQ'V9J#T]N_P-2IR*FG%*<4IQ2L$B6WT[#N3JFI7 SE?IB672+AF
M2B%NH?M'OHCJ3\PO\+%H2IG,C-?+LXM"5!-86[F!7Z8ZGGR'7;KR&=OAOCRW
MGH.7,]-^G,]?L]]9WR:BG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4K!]<LG,4^-:DFK,R8DF;RZW<)R)LEAPA<])K8R;,09!482R
MH=32HYH=]:P8S(8!.$%BOH3 Y#G[SD_&I//I[N59QR:BG%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*P,"JG";*LUT<?$5'35/J5=&&0I[)K1=?E
M;8>6\^A3*6,#/-3XJ!U-ON.J<:(PXTTE+:G)Z >9^G'Z*@#!)\<?16><BIIQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*BO:EGL-8'ISE>PG*Y>WJB9/U!X,\1N*?;I;&<8RE7L9^
MIQ,;CW_M]LY8\_S_ (S(Z^0^T5!.,=-]_@:E3D5-.*4XI3BE1U#9"SLZ]>UB
M ^?Q6:)\WD2H2,=8_E\DV[(F)JZ/.9C;/'85@G,-#@MH(K+F9-PY2L3@OB.I
MY=/;UY^/+:IZ#W_9TJ1>344XI3BE.*56*P;IV;*6K94#I?5$#L$#3Q <-=)&
MS;$)HI,[="JQ$W5RAZ[#'I-L#F9<*L6&OOG3%DE:G7F)R; KZ3G5CV"0KV6!
M@$G&02,#/7&^XQN#RR?*E9 3V9U&"=(Q<A,R\>=$MV1@YTRJV5NNMV"G521N
MMNI@U\1%.:_D[G6:[#3ATW6XFU'R(/T&P-.-9=@I= 48/Q\QU..7.E151NZ%
M2DH@H[9-<EZ#)C-1ROH4#&W+:!^?I^H]2;+VA)/LT^DNE@5?5\KMN*I,Y99
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M/6%NBO1;JM&(@X>P/$P:[4D/$8-#X@&(VW"7A1Y>Q32:U@I"R-IG!8\9L/1
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M-C*VC(KT*N^5Y0J.D/4B!Q)CXPO+UO+KGG[OUTV\^GA[_P!7TU\<>VIA+WM
M:_RO U(R/[DO8TI46Y(>-CI>RF%5E P<5^>DK1AQV1D/YN=;C!OYSC?RZ>/O
M_5]--O/KT'NZ^S/T9KG:=V9\\QA\&BXC/KUF02MJ5G\G8K* W54Y]AI<.D?,
MZ0?[#=F$<=Q'AB9=>BS#WL(94];RZ^/+I]/.FWGR'ASZ^[PK#X6R;?FPIUMF
MO4L&:@(^#A7TRZ[O%0\CL!I0AUO>A##*XV1+:Z1#R(C56LH0[I1\Z/* 'AC-
M@N.8C??&/?GGU]W@:G;KGW8Y=/?XBLS2[LCZBG"PJ1B)_&;[:EIDY[,C^SS%
M<RH8Q+68G WXSS;?##\=EWZ(FNXR2W**DLX%Q._ES^C]-1MY\OIS]6/IKQ/?
MW7])QGZ;J[$Y^#3G,M_6K7F)_:#@Y"8T7#OT'!F:<Y&>XZ<?EG$TT=A#+$<\
MQE3^'K>7+SY_H^ORIMY\_+E^G]MZ]EYW9>)-_ X5&5#_ (IA4#./2D^B3S25
MPK*K$2^RB(6+BTL6+WVX4)M]425"X:>./#.RL?#?RYCQY=??GE3;SY'PY]/=
MXUT$O;>^43E4=K?!WT2ZJ6A,S9\B8L;<HG&NF4NY@L/*A#(7UN74C+23H^4]
M+,&+)B8R]EZWER\^?3W4V\^8^'7QW\*[2W=H^X_[8%!RS\[2L#97*V'#F8]Q
MUG]HBWL8AO3@T-CYC-+;1G+$B[AG$X[%I4OTM_+IX^_]7*FWGUSR]WZZ_33N
MS_6/[P%#PC)MRP7EJ6L"EICFW2/V?.#I5#)PLPMG N+BTXIMB/=4_F$=DD);
MPH.+KCKG&?=^NFWGR'QZ^[PKJ*>V[\MY1':X^<^ATQ7I5,6; WXD<E%IV$QZ
M\0>7?H@L+[;E-*]'SYTIZV9L2/$PE_+?RS@>//K[O"FWGC)\.73W^-=YIW97
MU)E+X-'Q$?BF8;?=:E)[,EBE)AG50!3+"X=(JK0[8?99F 5D)B1X;+I(4@2;
MA(N6_ES^CI[Z;>?+Z>ONKQ_?W5]*RKZ9J_ZY^#17,-?6[7]*_:#\^Y@T3+_T
M#YS\'8B_:<%/P/\ 6LG^XR[')']+_'K>7+SY_H^FGJ^?/RY?I^BO94[LGZDO
M"0J/F(_&0S;;BI.>Q)?L^S74*++6UB)R-^,4VSW&AH]+WT1=>]!#LDB2]0_&
M_ES^C]/U^5-O/E].?JQ]-?K75?,J].BH20C82(-%=E72(^N24U+PS#A\S(2/
MJ"D+ VU+O_,)+P20DIM"6"WGQQL9$:8SD!@ ?5^NA.23]?ZJS;DU%.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5@8%J.+V59J6XP(F.A:?4K$,2
MA+V#72[!*VP IE]2GE,9'9:@!5CI;8;=2X\1EQUQ.6TMST!\S]&/TU .21X8
M^FL\Y%33BE.*4XI3BE0U8][T&J7:.HLWBUC'R-AKE13.HH]L?I8MLM[3;U7K
MAER9B%UYJ4FL$!M,-H.=8%)D(T22(!*D V7YP?+XC.WEG-*CJ#[FZ*L4(//1
MLE=,!RL!2[-4AS=9[ CI2_PVPIAFNU(N@11U='/MN)2>)'C<XB6'_DDD#2Y^
M1:\4++O.$^'B.8V(Y@^'OI7H5#L]3I/3^R=W79@VA4C6]RV77I=Z7B;"U+CQ
M6OK.;7/GI"MDPXUB$F)!T5*55]$6^:V<\@,;YO*FW'-L,$MQ-'!"O'+*RJBY
M4 LPSNQ(4 =22  "3BNIHNC:EVAU6PT32+8W>IZG<):V=N)(HN]FDS@-+.\<
M,2* 7>261(XT5G=E4$U@D7V+ZO4UL*]P5'L5;L^XK5/5UL6 Z\7H#9>PK56H
M-5OD&R8>'I";-:L?1B%RPD^I$C#$(68XB5PL.3^5MC3+MGD0& B&-)9)#=VX
MAC21^Z4M*90B'C'"58A@0,KNN?6Q_)EVHENM1MD.@E-)L;/4M1OSVG[/II=G
M97UX;""6XU&344M8'%X#!);2R)=H_!F#$T)DRDSNGU_#B*#9$V&SG5+8H5</
MAKG&:XV#(4^)8MMG72Z^U<+(-6EQ-/D#K:T]7W8FPD@2L;(LNIE@@&<8>4&E
M7I>:/NXQ+"9 T33PK*YBC[U^ZC,@:4"(APR!E8$<))VK*+Y+>V4MSK%B;*PA
MU+1);V&ZTNXUO1H-3N'TZP&J7C:98R7RW&IPQ:<R7BW%E'-;W$+J;:69B5'K
M4WMOI&^;##UA79NR.6>2G=BU6*>D:#>(:M3%IU.:4)?ZW#VZ5@!*U*S%>0$0
M>4,!*$87')P2RXYY]',9=-NX8#<2)&(PD$K!9HGD2.Y4-#(\:N757R%!91ZV
MQ%5M4^3CM7I&BRZ_>VMBMA!::)J%PL&L:3=7]KI_:**.71KZZTVWO)+^WM;T
MRI#')-;IB<]VZKSKOSW:735=V21JF1FYQ=K#E8JMFN@4NWR58!N<_7W;57:&
M;<@85^K"WBQ5YKZG"5A^61*2"" !F6<G2<<*5":==20"Y5$[HJT@XI8ED,2.
M(Y)A$7$IAC<\+R!.%<,<X5B--I\G_:>]T).T4-I:#3I;:XOXEFU338+^72[.
M]73[W6(M+ENDU"32;*];N+K4$MC;PF.:1W$5O/)'C3_=;KFS#0<XS=3I(2R4
M"H;'@AX:I6R9E92%V!;$46D10D/&0Q4FY<;1;LDP433/E<65XR,F5.QK(T/)
M/C9C2KXLZ]R%,<TL#EI(E57@B,TS%V<*(HHL.\N>[ 9,,2Z@WU^2SMLUU=VC
MZ5%!)8ZSJ>AW;W6I:;:V]O=:-IQU;5KB2ZN+J.W&F:?IO=WESJG>>@K%<6H6
M=GN8$DZ;W=[02'*P&'(WV:FK4+;BA*S :GV7-6F(S0+(/4;T-;:Y'U=^6IQ5
M0GB$A3[5F%BT@IQ\SE:Q71WG\AI%[B0E842(Q R/<P)&W?1]Y"8G,@642IZR
M&,MGES! V)\E/;%EOY9(-(M;73Y-.CDO[SM%H5KI]S]V+%]2TA]-O9M02WU.
M/4[-#+9-827!FSP8$BNJ2MKS?6KMJRH</0;$JQ%&ZSI.W6W1(R30"Q2-BN2C
M=.+-/?$:$!E)G$+*O-5\MUJ;''">(+ 8:]*E5I[*YME+S1]V!<36N[+DS0</
M>@*"253C4%P"A) #&O/:UV0[0=GK>6ZUBR%E'%KVJ]FV66> S/JNB+;G5(HH
M4D:2:WM3=6Z->1JUH\DJ)',[9 JWIKO1I$FB&9LT(7J)ZM1O82R9@8ZC6Y-+
M?J>@KO9HRZ&TVQCU2.KEGE@X$&,MD_ UEPXX F?<C_04>*;AOHW>CW8G C<7
M0D:QCXVFB[X2WL,;1++&96DC4N6C1Y %8)Q; BO?]I_DF[5QZO$+&[B[2+?S
M]B[(7D^K::=434>V6DV%QI<6J6+ZC/?6%M+>2W&G6=Y?+%#-'9B;,<4D69KL
M_;[151.(C)>PSKDFP1J<-,9#4BY6&3-.W='V>2UG'Q<;!0<B?*R%D'J$XVT%
M'CDDBEL#AF-,$G"-O5(],O)5#*B!2+EN)YHD4+:-&MPS,[J%6,RINQ ()(R
M2/+6'R;=K=2B2>VLK18'C[13&XNM6TNRMXH>RDUA!KT]Q/=W<,-O#8OJ5HS2
MSO'')&[RQ,\<4K+X%3[Q=>;HI],)-W;U-4^X71E,AJ?:$8N5C]>204/?HNO-
MFU)EVS6>FR\B!%S]:KR).7%D2DA-BODLE-L9RZ1?0_/2+^%BB/#<V[<+3J7A
M9R)<1QRJK,DC\*%1G(!!-S4?DH[::6$-W::7AM2TS2V,/:+0)UMYM:@ENM'N
M+UHM29;"PU2V@FN+.^O3!;201F4R*C1L_P"VN[FAG@ GT%[#S,GWV?U<U2$:
MCV8]L)O8%;J35YD:P11V*N[9&3<U4D68'(4!].=%(2K)J/8+^7'2;P,01!P"
M".Y[[TFW[@P22]RL@F,G=\/> H1Q9!'+!&8;Y*NUZRRJ8M%]%BT>S[0-JI[2
M:"NBG1K[4FTB"_35GU!;%XONBDEJZ";OED0@1'CCX\[.[-Z9C](P?8EZT%NZ
MFL::MF)L -;LL@<2NXV&/JL(/^&@8DBRI-=GY(:,)!S$Y,#)]U!#"/97XTKI
M]TUV]B(P+F/O.-&DC4#NHVD<]X6$> BE@>+!&,'>N3#V"[43]J[OL2FGQKVC
MLCJ N+*6^L(84&F64VHW;^GRW*6!B6SMY)XYO2>ZE3A*.>)<X(WW<T(]FNAC
MGWXFR6>Y6K7P-&&U-LM_8 EPI0,),6>%FZ4U5UV*#=B8"Q1-E()E0!0?PZ0N
M924H$8EUK;]R;P<9*PB..*.<S&Y@$#12LRQNDO><#\3HT8"DMW@X,<1 /6;Y
M*NV""]E>'1X[&PTS3]9EU:3M'H2:-+IFJS75M875IJK:@+*[6YO+*YL4CMYI
M)O34%J8Q,\:MBEQ^(%H.O5'8EF@R+=;7Z53+[<J\(+1;O$PVT@];EHB[?^S6
MXR=:;K=NCZW+O,#V:;@3)./@(O)=F+4NNQQLBSLAT6\DE@C?NHA-+#$Y,T+O
M;F<%HN_B60R1F103&KA6=L1C$A"GHZ9\C?;"^U/1+"[33=.35=4T?2[V635]
M)N;GL_+KD9N--^[NF07QOM-FOK9'DL+6[B@FO)Q'8Q@7L\4#YQ7>X^EIR>I]
M2).M,)9[4S0Q2!)2@WP.'JMKV5"IGJ71;=93:T'#5BX66/S@B#@)\B+DY!HB
M-S@1EV9B63-3Z7=HDLH$3QQF8@K/"7DCMVX)IHHQ(7DBC/SW0,HPVY",1R+W
MY,NU%I9ZEJ4<6GW=AI[ZPZ2V^L:1+<ZAI^A71L]4U?3;"*_ENK_3+&8%+J\L
MTN+>%H[@&5EM;EHHWA/B":2#I%:L>P98L&5EJ*]LR910*5M6]5FO4)%^LFO_
M ,72<VG7\4;$P(4Q6RAY<RP1$-D(C*,-M$C$@$F;VT6[,KI H91-Z.AFEMH9
M'F[F.?NE3OV#.4D4J$9N(>!# =VZ^1KM5+JM]9:-;136]OJZ:#:G6-5[/:3?
MWNL-H]CK(TVWM#K-Q%<WDMM?1O;165S==Z@)8QR)-'%?!"T.H0XVI*VW$I6A
M:,X4A:%XPI*DJQYPI*DYQE.<9SC.,XSC[<X_+G7R(@@D$$$$@@C!!&Q!!W!!
MV(/*OUQ45X-BJM8MX3,;;*Y VB.'.$E!X^Q0\?-!,28"\N R+(LD.2PT<$XK
M+@A:&TD#KSE3+B%9SGF<<DD1+12/&Q!4M&[(2IYJ2I!(/4<CUJY9:A?Z;*\^
MG7UY83O#);O-97,UK*\$PX9H'D@>-VAE4 21DE' PRD5[W,*ITXI3BE1[L+%
M%RQ6?QUE6&?Q*K\.^GZM][#^&K)YQGZ3C*O'X>_$&?\ '? 7G&/&?G?D\9G?
M?V;^S(^W%1MM[=O;@_9FI"Y%33BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*5'E#0E!^Q\I9]K*]AGK4K\=&W7WU?ARKI][Y0Q:\43SA.&_P "B80$![?U
MIE&%3[F50.OM\<_\O94GI[/#'_/VU(?)J*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*PT*R!$WZP5)$9A
MJ0B*O69TB7\M>3!9N2LH0H&4X;P_C +L(4_C*W5MY^>S[:$*PYE<XVSYD?#'
MZ:@'<CPQGWUF7(J:<4IQ2G%*<4JH5QZ=4JZ;A5N.3L\ZF:QL'6NR!1UP5#DC
M8R4UFBK,1]9A+?,520ND!KV8156)&8IT'/1PCMEEI^?:):<F3Q'L@Q P/ @^
M8/ERSYGR'2E?/\#FEL5[4T/&7"YQ<GI/6.N=;:_LH^:\_)Q^=82U?EJ]9C13
M8(F)D90Q5?1&SH3P"8D^(E)84<,$AX4P-QG?8;DD^_F*5G$9UZCQ-0;!U+(7
MNX36-ERU[G;'=#1:=^(OJFP94J8F5B1N*LJG?(#DEN"A1!U9/C51:4QT@.>U
MEU3NR"8P3QSJJL8G5PK%PI*\@2C*X]JLK [@@BNKH>JRZ%J^G:Q#!!<RZ;=Q
M7<<%RURD,KPMQ*KR6=Q:7<>^ZRVUS!/&P62*5'56%0QOA[R- L6F'=.[-FJ@
M-6=M;-VA<;3%Q.O8$BN&VS31VNXD37.M(^A+U>!$%'-1S=CAUUQG!HLA.2?S
MOU%8*@NT=;6=+H75NDIDM;>WBC9IW$@CNUG8SW!G%PS@%BC=X<%47&,\7VB3
MY9X=9L>U*]IM!M-2DO\ LYH.@:9I]Q<:U>)?1:=VGBUJYEUO79M8&ORW,<33
M&QN1?/W3PVMN(A )1+[LI\,G49X=.C&+]L5B-I]8JD".R>/K^QFOR55V+);2
M5:(^9L=)E)6GR]KMTP>7>440JLAV<7 ,:4PW'!Y$?P77[D&5C# 6EDD<E3/&
M )(%MN[94F"S+'$JB'OA(8SQ,"6;(IV_R\=I(9=3N&T?1'GU/4-0O)&A?6+&
M)8-0T2W[/BPFMK'5;>WU.VT[3;6"/23J\=_)82=[/&S3R]XL^U+J92*?9==V
M<"PVHDS6^TM];8B6#'8A0QTWV"S9,VB.D<,Q3+JHJ'S9C/H*!G1RT?+B_42C
M_2[[M.34I98YXVCC GMK*V8CBR$LN[[MERQ]9^Z''G(W/"!MCQ^I?*+JVIV6
MM6$UEI\<6N=G^R'9VY:-;GCBM.QBV*Z?-!Q7#*+BY%A$;PR*\;%Y.XCARO#C
MI_235QO8@CL3@M]N=D;56[W+P!-0UC-#E7&IU\>N0TG'6V?H\IL.L@X%!C)$
MV&K=LBPB9Z,$EVOE7W#D&;%U:X%B+' *+')"KB6X4B*1S(RF))E@D.2RAI(F
M(1BN^Q%Z'Y5>T$78I.Q)C1K.#3K[2+:\CU+7K5X],U&]>^NH)]-L]6M]%OYC
M)+/!%=7^G7$L=G<26S=XHA:+$R_AV:,(J>W:JT39&F]K;3A=LM&EIK<XU1Y6
MLV0ZX5NK5J L%?E*P7KZ+L<Y;"U4ZR0TW&'"7"PQY25,$CY&V#7+P2VTA$?[
MVMWML#O$[U)(UBDDD=)%D$[1I&.^C9&4QHPW&_0C^6KM:FH]F]0:.Q8]GNSU
MUV<:*/TZT;5;>_L8M,OM1OKRSO+>_CUJXL;33HAJ=C=6D\4FF64T>'C<29UJ
MKJ-3-)3U=O-0--E[14==[,IHT=]'H5&KMB(V1<:W>Y0XR)H5+@(6#(9DZG%0
MD4N)B6Q8^!SELT26,906K3<:G+=QO#* L<D]O*6XIII$$$4D*@--*[N"LK.W
M$V6?D5!Q7)[0_*1JG:NSO=(U***VT_4M;T'5))_2=8U:]LDT/3+[2+>&.YU?
M5+RZNXV@U&XN[@7-PTDUX 8I+>-C&/'Z2]:I'KO3=@/V4&+C+;L[9%AM[L!#
MSI5HC*%1T%OBZYU?%6$N+A').*I$ MQ#+K<0",B0EI1 K:Q\-/.9ZM?K?2P"
M,L8K>!(@[((VFF(!GN&0,X5IG&_K,2%4G!) L_*KVZ@[:ZGHR6$MQ/IN@Z'9
M::+RZLX]/N-8U8QI)KG:"YLHKB[6WN-6O "ZFYF<PV]N9&#\2C@(Z(ZM-J-7
MI)]DNY,)68#M-6T>DN%8,D(WMG)2LC?/F2&X7TMD02Y<EFJNC,M)';0RJ5;E
M5I6I;[L7 FDG"1!Y'TZ38-A6TU56' +'(?@!D!)R<\/"-JS3Y7.T$.I:AJL-
MCI4=U?WGR?7S9BNGBAG^3FWMK?1^[1KK+)=BUC?45D9B[,XMVMP0!Y]:Z)5>
M)L,=;K%MC9EXLH%KT!;/J4XU10&W'^N8%VBZ1%(!KE/AA&(HL"[F-3?I0N2,
M?!%,;D627C%D92:Q(R-%';6\,;17L7"AF;:^:%IFXI)7)8-".#\4!B.$@#&Z
M^^5O4+FSGTZR[.Z#I-C-IW;+3NXM&U:8JO;>;2KC5K@S7VIW4CW$4VE1-:;K
M!$DLD30.BQ!.":Z :XF*G$U--^V7$LPM>[$UX&5AY*#"E<,=D-BQVR[6^Z^F
M"6TY](F(QF,BA,LX#+@'S(Z=9E,DK>Q*:U.LK2&&W?CDL9"KJY7-A;M;Q@#C
MR.)&+,<\2R ,A7&*SM?ECURVU&YU$Z/H-RUW>]B+V:WN8+N6W+]AM$GT+3D5
M3>!AZ5;7#3W,G$98KQ(IK1[?NPM>GJOHIKO5%JJUOB+593#ZKM6R;?$CFH37
M]7KR[):M-8TK*1P]>I5/KD/$UQF PF3C(R)$#>%E4)60<:TLA+^-SK$]S')$
MT4862V2U+%YY).[CN_2U8O-+(S2=YZI9B<J=@"!C1VA^5O6^T.G:AIESIUA%
M#J'9VQ[-23-=:SJ%Z+'3^U'[JK>=[W5=3OKFXOFO,P3SW,LJR6Y(2*)E0ITM
ME=1SL=1JQUDU39)!K-6N6K)2-L\\>"%-C1-5W17=BSL@P8+!%1F)T.."DE02
M'(1P)Z09 9,:RRMYSBWU)1J4E_<Q@]Y%<JT:*2A:6UD@12"X;@+,H?#Y )(/
M*MFA?*1#]\B_[>=HK&%_NAI?:&WGT^SAEEM)+G4>RU]HEI \4EW'.;26>6 7
MA%VLJP-,T3<01:RR@=.:G2=AUO;,A?+S=-C1%VV9?YVR3Z:J)^+K!LVEUK7Q
MF)&+KU<AHR,C:_5JE"!0 $"-&MM.LD$FJ-64O&-<^J230O;+##% T-O D:=X
M>Z2"9YP59W9F:221V=G+;'"X %<_6?E-U'5=%ONSD&CZ3I6AW.E:%HUI869U
M"3[FV>A:K?:U&8+B]OKJXGGO=0U&[EO)KR2=F5T2(1",$Q^S\/+6RH,ZFRNQ
M=GS=!C=?;BUMJRFG$4]D#4,!O(5\*[NUN3CZD'.V"08"(5&5E^\25D:@XG*@
M?8,4O)/-WW;N ZRI!;I,T]K/<2@2DW3VA!A$BM(4121Q2"%8R[>MD<J[#?+1
MKHNXM4MM$T"TUB?6>S.N=H-3B34WF[27G9*1)=)6^@GU*6TLH'E03WZ:3!8F
M[N<2\<841UW(7H!KF-VO7-PR=LE[-:XPG74S82)^B:;/)M%IU=7Q*U5I]J<(
MUR[9*9C,?%PCLK%T:8KX)LC!QLFTD0_YX@X^M3M;26HC2.)A.B!)KM1''<2&
M21"@N.[E]9G"F9'*J[+NO"%UW7RQZW/V=O>S4&G6UAITZ:W;626>K]IX8]/T
M_M!>RWVH69M$UQ;'5/P]Q=K;W&K6M[-%!=SV[&6'N4A_('P^=7 46QT%NXWU
M<99NOTCUU,,<?KOS[%4DM@V_8KTT,I,"D?%A;E;E(!-N.L.QN(\4-*H]1*7B
M'AUJX,L<QBAXHKU;Y1A\&1888. ^OGNRL*L0"&XBWK8P E^677Y=7L=8.F:.
M+BP[90=M8H@E[W+ZA;Z-IFB+:R WG&;)K?2X96576?OI)2)A&41;W"#(#$&$
M;4I2!1V1D*7X]:D,-I:2I7IQC'JSA.,J\8QCSY\8QC[<XY.22>I)^-?(Y',L
MDDK !I'=R!G +L6(&23@$[9)..M=CD5A3BE.*4XI3BE1]L&M5ZRL5ENPS6(5
M$3952L8O)8(GS\EFM62*R!C)R58>SB-E)(_V1_!'@'+WGY=E_&9\?9O\14>'
MMV^!J0>14TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE1W0E-J/V1Z%!*
MRG8AZ7?DZ-(4M27/PW5\^DTL]QQ-[-PC*/<O('HCSFLL0C+:7:^_Y@=?;X8_
MY^VI/3V>.?\ E[*D3DU%.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE86&95E7^>!&']%R:J]:(F"\MNI]^
MOOR5E1!#I=4YEES(YS$ZYEMMM+C6'\*<6I+C>$ST'AD_9G[*@8R?';/[?MSK
M,<NMX5Z,N(PKSC'IRM/J\Y_3'I\^?.?W8\>>13(SC(SX=:*=;1GPMQ"<^//A
M2TISX_CXSG&?'%,@<R![Z*<0CQZUH1Y\^/4K"?/CQY\><X\^/.//C^..*G('
M,XIEQ&$X7E:,)S^BLJQA.?/Z>%9SXSY_LSQ3(YYV\:8<1E.5X6C*,?JK"L93
MC_*KSXQ_GXID<\[>-$N(7C.4+0K&/URE6%8Q_E\9SX_3/Z\4R#R.:)<;7GPA
MQ"\^//A*TJSX_3SXQG.?'G./O_;Q49!Y$&F'6\J]&'$95YSCTX6G*O.//G'C
M&?/G'C/G[?;QGBF1XCXTRZVE7IRXC"OMCTY6G"O.?TQXSGS]_./'V^_GBF1X
MBBG&T9\+<0C.<><84I*<YQ_'QG./MQ0D#F0/;7U3B$8QE2T)QG],J5A.,_Y,
MYSCS_P!7%3D#F<5\]Q&$^O*T>C/Z+]6/3G[^/Z7GQ^OV_7]>*9'/.WC3#B%)
MRK"T93CSY5A6,IQXQYSYSC/C'C&<9SYS^G%,CGG;QKZEQ"_/H6A?CQY]*L*\
M>?/CSXSGQY\9\?Y,\5&0>1!KXEUM>?"'$*SX\^$K2K/C^/C&<Y\<4R#R(/OI
M[K>5>C#B,J\YQZ?6GU><?KCT^?/G'[\>//%,C.,C/AUHIUM.?2IQ"5?;\JEI
MQG[_ *?;.?/W_=Q3(\113C:/'K6A'G]/4I*?/^3SG'GBA(',@>VF7&TXPI2T
M)2K^BK*DXPKSCSCQG.?&?./O]OW<5.0.9Q7WW$>GU^M'H_\ S^K'I_7Q_2\^
M/U^WZ_K]OUXID<\[>-?,.(4G*DK0I*?/J5A6,IQXQYSYSC/C'C'WSY_3'WXI
MD'D<T2XVOSZ%H7X_7TJ2KQ_E\9SXXJ,@\B#1+K:L^E+B%*_@E:<Y^WZ_;&<Y
M^W%,CQ%/=;]7H]Q'J\^/3ZT^KS_#T^?/G^SQYXID9QD9\.M%.MHSX6XA.?U\
M*6E.?'\?&<XSQ3(\113B$>/6M"//Z>I6$^?'Z^/.<>?'%"0.9 ]M,N(2G"LK
M1A.?'A658PG/G'G'C.<^,^<8SG'C/Z<5.1SSMXT]Q&4^O"T>C'ZK]6/3C[^/
MZ7GQ^OV_7]>*9'/.WC1+B%8SE*T*QC]<I5C.,?O^^<9SC'V_CQ3(/(YHEQM>
M?"'$+SC'G.$J2K.,?Q\8SG[<5&0>1!J.-C4MV],U8<23$"77K0J?=P\A3V26
MLU:SU_(S:6E8RAS#L^T3E:L93[8SB/'J6G.)'7S'V@_938D8(V._P(^VI*Y%
M33BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5@]-8/9-O>3AY]A#]X,?CU
M3EC$L#! "H&NI;(KPXKKJJU *(02VQ7"\-%CR#<E)K:2S*LJ5 Z\^?7[/*I/
M3ERZ?;YUG')J*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*QUVI5A^R"W%Z!BW;4$$J-$L"PV52PT>O!&%
M!LFY3[R!U8+)\M)5A.??=^WY\^51@9S@9\>M>&3JS7!=C3<"J16B+2@\643/
MNQ(BY5,B"IE09N#,MY>P2,H=A3+OJ]:,M(RG./3CDY/+)QX9I@<\#/CBOMFU
M;KFYR"):V4FMV&3;%;";/EXH4TI C+CSK0R7GFU+PRVZ0^XA&,^E*G5YQCRK
M/&2.1(]], \P#[J[MIU_2+NB/;M]5@K(B)P1B,3,1PYR0<%X'P3@7#Z%X9P_
M@0;#OH\>O##7GSZ,>&2.1(H0#S /MI(:_I$M70*C)U6"/J\7D;,= E1P[T6%
MD-MQD7(P:T99:R.T\ZVUZ$X]"'%IQXPK/&3XFF!RP,#ITH)K^D 5HJFAU6#%
MJAN7LEUYF/';B2<ON(=>R\$E&&5^ZXVA:_4G/J4A.<_?'&3SR<^.:8'+ QX8
MI7-?4BGB20-6JD% !S&$XE!HJ.'#9D,(;=91@MME"4O82T^\VG"\9\(<6G'V
M5GD9)YG-  .0Q75J^L=>THY^3J-,KM<D"1%@D&0\6*"0\&MYDA8SCK#:5*94
M^,PZIO.?3EQEM6<>4XY.2>9)]], <@![JXX_5>MXJP_BV-I%:!L_S1IWUX6*
M%9E/G))!#9Y/SB&\/>\8@LE)#GJ]3J7W<*SG"\^63RR<>&:8'/ SXXI)ZLUQ
M,V'\62M(K4A9OF 2_KI<2(])_-1K8[4>_P#-K;R[[H;8@R!U^KU-)8:PG.,(
MQX9/+)QX9I@> KFM&L]?78P>1MU-KMC.%&P$,7,18IS[ F'77\#M./MK4AG#
MSSKN$8SZ?6XM7CRK/&2.1(]], \P#[:[%BU_2+<%&QMGJL'/ 0^/$6'*1PY@
M\?CV4,>!6WD*2S_,M-M?DQC\B$I_3&.,GQ/QI@> VY4)U]2"ZP/2RJK!$5(3
M+:AJZ['#KB&,M/+):RT$I&649;?<6\CPG'I<6I6/OG/&3SR<^.:8'+ QX8I&
M:_I$-7I"IQ-5@HZLRV2LR<$)'#L19^3F&A3,E"(1AE[)([+3+WK3GW&VT(5Y
MPG&.,GQ-,#E@8\,4JNOJ/1_G_P 'U2"K7U3 R9'Z-'#@?.I#^8^5P3["$>[@
M?YHGVL*\^CWW?'CUYX))YDGVTP!R %=&M:LUQ39%4O5*36J]**&=#4?$Q0H1
M2A7EMN.CY>9;2O+3BV6E+1Y]*E-HSG'E..,D\R3[Z8 Y #W4:U9KABQYN#-(
MK35I4>]**GT1(J97,B2IQ3YN3,-^]\R\IUS+COJ]:LK5G.?OGC)\3\:8'@/&
MDWJS7%EF<6*?I%:F)W'RWB6D(H4D_'R6$X$_QEUM3G^+X0C#/YOR83CT^/'&
M3XGXTP/ 5VK3KFAW=\0FWU& LA #3C 3TS&C'."LNKPXZTRI]"\MH<6E*U)3
MG&,JQC.?OQDCD2/?3 /, ^VN2;U]2+)#Q=?GZK!3$'"X'3$14A'#D@QV!!<A
M#8#'=0IMC# F<C->C&/0SG*,>$_;C)\33 \!3.OZ1FJ?@7-5@OP=C/G%9^G#
M_1?/U#ZMY^0]'L>?J?\ C_\ 0_\ BOY[^G]^,G.<G/CUI@8QC;P^FD+KZD5R
M%E*Y U6"B(&;P2F7B (X<8"2P8(D$K!@S:$MOX(#2D9WUISZV<8;5Y3CQQD^
M)I@> ^%<=6US0Z.\613ZC 5M\]IMDUV&C1@7"F65J<:;?4PA&7$-K6I2$J\X
M2I6<X_7C)/,D^^F .0 ]U=6"U9KBL3&;!7:16H6;S@E.96.B113LI,QG!6/F
M&FTN>",*SAW'G\_G/GSQD^)^-,#P'PHYJS7#UCQ<':16G+3@]J4Q/JB1,RN)
M%A2%,FX,RW[WS+:FT*0[ZO6G*4YQG[<9/B?C3 \!XTLFK-<7"2Q,6JD5JP2J
M1VA<2$M$B&EX&84XIEC#SS:E^TTIUQ2$>?"<K5G&/OGC)'(D>^A /,"N]:M?
M4>\J!5<:I!6549@E,>J9CAS\AI,RQDK ^7T+]K!&1A\NX3X]?LM^KSZ<<9(Y
M$BA /, ^VDIKZD3=?C:G+U2"DJU#Y$S%P1D<._&1^01G0P\B"+1EIG(PK[P[
M.4)Q[;3JT)\)5G'&3XFF >G*C&OZ0+6'Z4/58-FI$Y<R17&XX=,.]ETA);F7
M <(]A7K)0E]7E'W=3A>?S8\\9.<Y.?'K3 QC QX4KVOJ14P)*+K55@H*.F<9
M3*A1D<.(-(8RRL?."VFD)0]C+#CC.?7C/EM:D_IG/&3XGXTP/ ?"NO5]::_I
M)9!]1IU>K9I8WR9)4/&# OOB^ZV]\NZXPA"EM>ZTVYZ,YSCUH2KQYQCC)/,D
M^^F .0 ]U=,/4FL8^:78P:)6 YYQ\LE<N-$BLR"B#\/)->44VVEW+A6'WL/J
M]7ES#J_5Y]6>,GEDX\,TP/ ? 5(G(J:<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4JG?8*D;AJML [%:#-DK':*["LP>P=)R4H2JM[6H@!)4A\M7AWOF1Z[L
M.'=**)@96/8:5)Y<7'')*;<4%(8,&'K+N>J^(\O CI[ZR&",'W'P/Z/V\Q K
MW9%_L(M&KNDT6JIVG8:D6[>FUI*KIB4:5P<AJ F,3H"VFT2^Z3&(%N(C@''"
M,H9CQY'!S@K+<@!'%Q#";9&2<8QY?TOCC%3C&[;XV \?U?MY'8+K2A1NKZ'6
M*#$R<]- UB-0 W,6>6*G+!*O*==*,D9:4,6MXDLTP@@E:4^V,/AQ(H3 X;+
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MIM ;N6'X7K30)O9,8,[YRA*I'8:416JXH?W<8;6_(WD?",J]6$*QC/+ LYL
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M*4831DNKE2T>?1\$AHXT$)!&Q5L 2''4.Q.>>]5'NK@<2 ]P,D%(D$6.>02
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M][S5_P H:)^>S_X2GWWNSWY*[2_U;;?\0I_+6]9_ZH>U/]UU7_WC<?>\U?\
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M5+$?=6MQ,3$2\87*0P;BE*CHV?'!;7D5@9*+FH'OX+&]< 3W"3QSL  )7MI
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M<G6ALP3$FMJJYI$!L#8TK98(;5FJ]K2$XJ$J5&.-#2!7=KP$J^U'9GH]NL$
MV$B8'=<G(:MSPG_G@=2/'Q'QI63I[-:0=L4)61KMD\^Q253A8>0BZU;Y6J%3
MUZA0++4:ZY>8V *I8=DGJU*1EE!KIT^--JKD@%/. -Q)3)BXX3OMRSG.QVY[
M<_UTJ>.12G%*T]V3_EL]?_\ 0W-_\R7;GO8?\G=U_P"/K_96]?*[C_*_8_\
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M!O?#,8\H>8>;5ELN.D15^'X^4CR$K%/ )0A\4AM:%I\>E2I!!&14$$'!K/\
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M.*SGSZG+303:U8'<X5^;'N22\85YSX\YSYNC4;PQ]S+,+J#&/1[V.*^M\?\
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MM! 4P^U7UN$XR.A$LL12W\9:3C+F,IXP? [\MCO2LWDK75H<QZ.E[+ 14@/
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MA( 1(1,E*'!QL<$TI\P^0)9#"$81CRMXDHA;;##2,?=3CKB$)Q]\JQRJ 2<
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M9A:A8[!7;4D!GKA;]':UI/73<.F]R(M<!7JFT?#;)K56J\1J"J9AY&1_&L9
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MG-L:V'<SG.<X7K_? &RX]H;.<_86&.A$(Q^1E32/R\U>E<?\-!!-XL4[I_\
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M/&IV2LCJEKK6O7LFJZG97,%[9V.FSS6NF6ES;RK-"]S?H([V^DBD16,=D;.
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MG"6%^V..XTV)CWL2HR7$05K5)!;R)Z/[J;4]/U I=L_HTK;7BQA<38R3*BY
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MKRPO(L%[>XB9XI$DB<2V\\;,A8(RL0*H2HQXD(9)$?!5@59)$."KKS!!V92
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M-*PS;Q,#MO\ PT@_BC\13\\[_-!-7XHM%I^LJ?7*!0*[%U.F5**%A*Y7889
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M;&PZ'SY>&YS6/E=.;2WC/I:<SG'Z>$Y_ACQ]LYQG]/'V_P F/W<T/V=L&S^
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MJ=>??IM==>=<7G*EN.NN1REN+5G.<J6M65*SG.<YSGED7MX  +NY  P )Y0
M/  /@"J+:9IK$LVGV+,Q)9FM+<DD[DDF/)).Y)W-<7[(=3?U7Z[_ -"JU_JS
MD^G7O\LNOSB7_?J/N5I?Y-L/S.W_ +NG[(=3?U7Z[_T*K7^K./3KW^677YQ+
M_OT^Y6E_DVP_,[?^[I^R'4W]5^N_]"JU_JSCTZ]_EEU^<2_[]/N5I?Y-L/S.
MW_NZ?LAU-_5?KO\ T*K7^K./3KW^677YQ+_OT^Y6E_DVP_,[?^[I^R'4W]5^
MN_\ 0JM?ZLX].O?Y9=?G$O\ OT^Y6E_DVP_,[?\ NZ?LAU-_5?KO_0JM?ZLX
M].O?Y9=?G$O^_3[E:7^3;#\SM_[NG[(=3?U7Z[_T*K7^K./3KW^677YQ+_OT
M^Y6E_DVP_,[?^[I^R'4W]5^N_P#0JM?ZLX].O?Y9=?G$O^_3[E:7^3;#\SM_
M[NG[(=3?U7Z[_P!"JU_JSCTZ]_EEU^<2_P"_3[E:7^3;#\SM_P"[I^R'4W]5
M^N_]"JU_JSCTZ]_EEU^<2_[]/N5I?Y-L/S.W_NZ?LAU-_5?KO_0JM?ZLX].O
M?Y9=?G$O^_3[E:7^3;#\SM_[NG[(=3?U7Z[_ -"JU_JSCTZ]_EEU^<2_[]/N
M5I?Y-L/S.W_NZ?LAU-_5?KO_ $*K7^K./3KW^677YQ+_ +]/N5I?Y-L/S.W_
M +NG[(=3?U7Z[_T*K7^K./3KW^677YQ+_OT^Y6E_DVP_,[?^[I^R'4W]5^N_
M]"JU_JSCTZ]_EEU^<2_[]/N5I?Y-L/S.W_NZSD$ &+$8CXP(2. %;PT*$",R
M((,UC.<X;8&'0VRRWC.<YPAM"4XSG.?'WY79F=B[LSLQRS,2S$^))))/M-74
M1(T6.-%C11A410B*/!54  >0 %=OF-94XI3BE.*4XI3BE.*4SC&?MG'G'\,\
M4KBRRTK]6T9_ZL8_[N*5^,B#9_5E&?\ +Y_^_%*XLQXBOU81_;^5/_JG/%*P
MZUT:(L,>^,^*TK"VUI\^A'JQYQG&/W>,X\Y_=X\?P^^>*9(W'/I6H[L5UN*B
M2B92'$5Z<J4YE+:<9]7WSGS]L?\ O],^,_?G)U+2X+^%XI$#!@1RSC8C8?\
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M'/'3IM2HQM?3C8-G'ERW-SP0MQM-SOMXF+O'Z\F(.?K-EM0E9K5=G=='P>R
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MVSZUHW55'C(NZ/O S%@@]6%N$6]UVR.1)MLI,(BDW2:D#IL^2HVQG<XY@X(
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>Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g107876g10g61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g10g61.jpg
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M.T=R87!H:6,@='EP93H@(" @(" @(" @0F%R($-H87)T)B-X03LF(WA!.^*
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "^ <4# 1$  A$! Q$!_\0
M'P !  (" P$! 0$           @)!@<$!0H# 0L"_\0 6A    8#   !! H-
M!PD$"04  @,$!08'  $("1(3%E@1%!<8&5:6F-;7%3<X4U=W>)*5E[>XT2$Y
M=;;4U=@*(S915':1TM,B-#6T)"4Q04B'D[7')B<S66C_Q  < 0$  04! 0
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M*QNB\],EV>863I0<6 K9HP%Z'Y8@AV!L? & , 8 P!@# & , 8 P!@# & ,
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MRG1*3/.MI*P@GS7D*#"C!EA&*&FM/Y$I\$# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8!U3L\H65.6>L$>,9YY:5&C1)5"]P7*31:"
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MQ(:P3T7OZ+:-['9W\63[P0:FO6YHASU4%@W5.P.Q\7KN.JWY>WQ]#ISD3XH
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M6-N5;J7OVZ[1MG1U#WEIGFAL4-<-QI J9['KJ)FF.^F\!PE;F6 X[6E(S0X
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MJ^$"42]X=U*-N1A4KE29&GVH4%Z.5J2$Y?E''%@%ZZ%J&JE.)J%+/NVTDO\
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M*X;*J2@'[F:5UA&TKK;5U0"'&6@GLBIXU:(GN-L4H6Q]8E0QT,E(CR[9:AW
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MQ5!*,*4$*D9AB99$6\0#P//FS=DC^R3J%$R"+-(4MP9(1M203\3T'?-;"W-
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MU)_B/]K_ "#KA_@_^1_@'ISVC^%KE_YK=K_XRL=2?XC_ &O\@ZX?X/\ Y'^
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M%FVL\S;H%KD\T<DZ-(H=O13H*S8JU +1H$R1&C1-[,S(&YN2$$ "F0I$Y/\
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M*1[5.9>C@EN[HH4N[N6!22D(4E$.;F:J6I4RD"%+L]&E.(1C&2$S9&A^SO<
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MW4/W+9)^)5>W5)Q[T4.[K+OQLG?A- :)S*S 1@# & , 8![>_"/_ )NWFO\
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MXZ7SAK&MW'5>;S>8>U?PG9M#&OP^.<4#G+HPW+D[+-@J$2Y_:DBL@0[1G!@
MG)U"LLXK8BQ@,#H8 [$ 81:]D(M;WS#EMIY9RNTTT\IU[33NFG536FFL&FL4
MUI.W-3:<.IS4_#$G#%#D/),,4,2:<,4.3Z=.%IXIIIIIXIJS+$O=%K[X]PWY
M3LG]NRV%Z'NBU]\>X;\IV3^W8 ]T6OOCW#?E.R?V[ 'NBU]\>X;\IV3^W8!2
MYX[$MBCWQY"4C-)X\[JP=$P-0-*UO3:O4!(!#;) ,\1*12:8$D S"PC,V'0
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MOV5 E7DIEY:E,3#PW^ %I. , 8!H_H3_ $"8/QX<R?O)5/DK3Y(OL8-X9 &
M, 8!YX?%3N6X++NY#QIKF?M15QXK8V!\ZDN3FGF"PK1E-WIQ;1OK30%?R]J;
MDD>98@<F4$:L:9)'IQ=0*1.,.1H47M!Z3O<[&_[^^Q;8OL"(O8E(W4:_^)51
M=<<O7J])O$MC?AXJ.8'IEJY\/@4':JI:8E'IW%[IDJ8![13BVKT3,::8URA2
MG&F1)RQ;V2GV6H&PLO+M;2W]Y;6T@<WI7G;H0J==Q<<L]&W5+GSLCLWDRYJF
MO-B@;P[4\AK6,*(.YV#(YK9R8!C!"UM<&PY:VN#*^*TCPJ-7HS&=&N2KD9RE
M;9NN#9V.7[0<-PH'I^ENO>AV:LH)V2DZ'L[Q,&?H:D;+A"RQ]<<+>:+2D;$\
MVQ[JA[:[%T^:>CBZ5?&)VAFC6HF!AC/"&F->P04:0K>CELK[^+T?EB#UKY &
M , 8!H^-?=%6_P#BEH7^M%_Y.PN%_9"#>&0!@# -<7#.15E55B6$7")?99T,
MALAD::NX#'E\KFLZ5M;8H5)(E%XZV)%RQU>I"I+*:D"<M*:7H]4$U3Y"4LXP
M 'EAC\'Z#[OJ7OF67!SAUU#>Y;NY6E,)K!AL/G*9TWSC4-+P2>1^71OF6HYS
M,PM?I7/+!=RD#T^.CZB:S7]S3K=(D[6TLSBM=9WKX>B_OP@G-P_6;SU%UC<-
MZ6ES78D%H?WCW.'*SI!.E:F7PT-@V)$GL<UFJ4B"35"$4CC$&7HDT?4/"IO-
M8G)<,!3::N( H\T^CD_+'>N#CT1*;PXEXT\1"<Q_D>X;1LMP\1KJU^HRDFFH
M)VO6S9KFTS8"(#/$D;:(Z:[JZB2I"#I$*4L:3[$N3.T#0L3L4M6(3@0#>WA
M(EZJ,WW85GU_U8T=26Y+898/2=F]-4#(*";9W)EC&ZL\8AM*,CZ/V5U9TZR,
MQL::R %%K&].Z(%BPI 2^(&1H< +D< 8 P# K5^U?9'^X4P_J\XX!RJX^UY
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MP$*0 /T8WE:";H82Q& UHP5>8W9JVA?8MX':?"[\V_$B\/DW OK+QF/;7IY
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M+ZR\9CVUZ>0#X7?FWXD7A\FX%]9>,Q[:]/(!\+OS;\2+P^3<"^LO&8]M>GD
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$X'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g107876g11q09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g11q09.jpg
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M 0$! 0$! 0$! 0$!_\  $0@!$P)> P$1  (1 0,1 ?_$ !X  0 !!0$! 0$
M           (! 4&!PD# @$*_\0 41   00" 0$#!@40" 0& P$!!0(#! 8!
M!P ($1(3"105%E64%R&5T]4Q-38X5%98='5VD9>TM]+4&!DB.5&UUM<C)$%Q
M,C.RL[;!)4)A)D3_Q  = 0$  @,! 0$!            !08" P0!!P@)_\0
M6!$  @(! @0!!0<."P@" 0(' 0(#!  %$082$R$4%2(Q05,'451SD]'2%B,R
M,S9A<7*1DK*TT]0D-$)258&4E:&CL1=68[.UP=7P-4,E8O$(@H2BX8/"_]H
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M*OZ5/]BT_P#=,?[+N!/Z"']Y:O\ ^0Q_5&>3R_!Y:_6ENK_<?CZNN*OZ5/\
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MX/5L\0JQEJNYI]YLL03#LHB3"+ O6:UUNM5I^<-G0ICL<LZ-9D(7/QC,AIX
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M(4AEI*WY4EQ*/!B0HS;LN;*<9B1&7I+S32X&M7FMSPUJZ&2:>18HD&PYG<[
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M+O9K1S3LD$=RM;91,\<5FN(92PL=XN=L,4ROZ8W 3:/'=4=8W3A1-D6942/
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M-*;4M"U>A7V-BWIUR" ,=E,[P.(58GMRM)RAM^W*3OVR, _;XL??:EU@,AK
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M%4TG,VFZ@]/2*\T3<C2G2(Y>M=JRC<!J^HV98J\Z[[3T>HNZJI.O+E7;; (
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MUMH5GTN1AZ;MMGL5;%5^Z59E^F K-1 X6TA3,E3ESB3QLH:# ;$[G8J??]
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M.^VP!]?H)/HW'O[^GT_EQF#5_H5V)6SU09:-UDI6&$]-,LN\J]6\4JEOZ$R
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M-,C")$^" #C*[=;E9CL_TS'1!;%U%58'Y9<Q;K;5G)P!LWZ!O_\ MO\ ^_\
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MLB8,#1.OK]-,"WB\.48I=3=L%PH4\6P]?**"BS\L!B<(C4;%<93\47*]Y#N
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MS"<H0MYI*LXRXC&?=CMOL=@0"=NP)W(&_HW(!('KV/O9YN-PNXYB"0NXW(!
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M>M)8C 3=-C9H _:C&]C]XCWWHD.5A 2NV"%0)%7K5_U-9=M&=GB:?(-:S#7
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M'2YT#%?=B8,!=TU>'3)]'@@YFD;Z,(%"A =[,]69KS.U/>1YW2<-5=BC5HS
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M&,<8RQ6C[&;%^0B_^7R.;(?ML7QB?I#--C^+S_$R_H-D2?)W?:9:,_(EB_\
MG%HY-<3_ /SNH_&1?J\.5S@K[E])^*G_ %NQDT^0.6G-#]2@+;EBU!9A^D+
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M*ZZMB(^4(NQVVW)LE3N1=RH0LQ169U0L>57<*'8+OL&8(@9@-V"*"2%&V(1
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ME?M<>&3X95_+8_=\>AXGWR OT'/H7CJM[";_ "OVN/#)\,J_EL?N^/0\3[Y
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M[T&0YN9@#IMVT:KK,BC6"V5[4@^AW6 ##76-K^I" Q"I[.>AQ*K=+78*A/V
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MD8$, <@GUD=8\C7C^-+:6[]@W-8ELBI$@2SDFY3ED\H9BQ(D5E#WGURG^,C
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M$9!;AAH&%H(;$IN&4).)^5$Z(3G!BEB4DL-N5R_8?8['O/V=/LV-4%A+-FI
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MI))Z)#DRF1T-<1N7/=CLK=;A17"$J# 1)E+1AAA<V;#B)=<2J3*CLX6ZBIJ
MS*I(4$@%CN0H)VW(4%MAZ3L"=O0">V?E>&-99HHGE2!9)$C:>42-'"KL%,LB
MPQRS%(P2[B**60J"(XW;93%?675>!MVJJW?+55[!6C<O773_ 'BQ@H[8DA'B
M*Z@B;@"JI#2XQR2B8/45CO3W%378A&( DP'9L-HSF<'A2-C37CLR0Q2)(@GN
MPQN2REO!*'DY@4!#<I"]@5+AN4\FS'Z%KWN=W--XAO:1I^H4K]6/6N,=)I6W
M:S \@X-KK<U'Q44E2,Q3"NZ0J(EE@DN),L4K51%9EML_K0J$%DE,1JK<\X7
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MG2)NT8D0V/$/$8@LNPB2LMIIOM7-L(FYV0J)0!RB,R;H.Q_<GU5%2BM^G)Q
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MOEE7T?QRS>U3Y(_M,=2K\&?^T']ECSP#[$E?+*OH_CEF]JGR1_:8ZE7X,_\
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M+O)B:[KYGH2Z>B<S,_$F77[.MWP9*$-]J-@6UK'=1EE6<8[K:>W^UGX^W/\
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MOB/Y?CRG8_FQ?FM]/'D.E_QOE!]#'P457_$G[XC^7X\IV/YL7YK?3QY#I?\
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M:96DYJ:KYP6,D%0_-OUBH#K&4',K#E8D@&DW^-*^E\0^1M0J25JI2$IJ3O\
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M2I(5&>S*CZ*]:*9))))VB5)Z\"[0]0LU@3E68=1 JH("7V+ML?-5B-C"</\
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MHYD(YAVP +OK:^ = FV:W5<?#V;K_2%X+VY57C#1&JHVQ)5D8-NH3+*2(LF
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M/B(;7E.5(0OL[R4*RE.5)3G"<Y2GMQGLQQN=B-SL3N1OV)]\CW\;#<'8;@;
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M<86PSX*#8:E 6)VUKS5XG6\H0J5<+&!O >GRR6Q8<K)QB4MBO9LQPZVW$#2
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MF5/?LH0?(U:\(:HT)T:0F>GF9QZ!(-IM>.!G)DYQ&\H8EW"NEIH1"[1P&L0
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M3(XM6(?FB7&Y#(Y6&.^W$SX>/3M$N>G.2A;J'DD)4J?.Y^WFE2_G<VQ!?O\
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MAL2GVF6'Y+,9AJ0\S'3W([+KR$)<<:81C"66UJRAI..ZC"<?%P7=@ S,0"2
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MJQW>S+3"G%J9;SVH:4M>483E6<Y\YF_G-V)([GTMZ3^$^L^OUYER)MMRKL0
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M3K;*,2,9 ,MN8FS0C32,/X]')<@(0G#GQ)3A6,"LY5R5E**_UTD/RK)Z//\
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MAR4:8MSHLVJ)+G.0F843TF@HZ689B.<3:H#!+&C3(7T]:J*I"HDIU);;D!6
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M]7R(4L9( /BWC&;8_$)P8BYC@]8AG,MXA'GH0.5C#K$,.GK60V$L+IMBF)$
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M)M0/.D<IL#=8HW8B6-H]WA,BJW/OO*J3(WG-R2@]S*SZ),_#M;25Z4DU9:A
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M6@BDE64-9EB>>2,2.TDN)]5G3SMO=!2RMTF51(X4_J5JEPGC).+6RT"SLG;
M6=E'R;&J+W9CE86B97W0@FOVJF-AC$ R2)QK$HB.P+V:;>K5%C,PF+I9,Q"*
M9%:,HB;(ILPQI)VD#N\<I9"BJ8]FYN[W/>-.'.%Z]!M5CU=[5/B-]4E2K!)>
MKS4&ITZR1TX'XBTBA4OAHKBV[-S3M4:S6FJPP24A!/XBAM72(</5\O!@^H,
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M[?JY^+..60ZA4!VZN_X$<C\O+E+71[[ 'I*-_4TB C\(WST^"^W?<D7WZ/\
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-8XQCC&.,8XQCC&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g107876g13k03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g13k03.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!60(_ P$1  (1 0,1 ?_$ !X
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M%5_SIY=S_%KDCP4:/[=,5_2FR9CD&ANB'@:&:^2ME9U2@UMS2$VK"&K%DO"
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M=QC=!F,9S==MQY(QK&MN9K7,5BVW"J,^79BI>_K1N'A!T)LX 9=I(0_0VSG
M>->H>'.Q5![RW)JYF/\ OC&3IQ_E])]@=?=R/8&TE=B_=6MHG7_P4^[TG20%
M.R'90X.AMG ?EY8>JRE^AP[V2E]<VY-W0AP]P0CIY+T^G_M)W\1#W?=Z?OX[
M ^D[,86ZO;0-,/\ @[09Z6Z1DTYM?C=D.R3@_0RSB-F_2Q]=E4V+V%XP\@8\
M>]$<JKPD<O[02RUUCO<]SZYM;G E^Q[@#DAN.;H\MC);KUN-(R_XNW9;TPK8
MBT\13W\:+Q<(^A%G$'/^:L^+\^097T+E)ZHYMPP]Z%Y,N9#N?M"SEHMCGO=/
M< 2R41.IB(^YT.(E'[)NF3&@>[S)8R&ZFZ9NXM$_:ULQ"ZF0(F9&T&U.QSB*
MYFF*C[XMSN/A,:'B%7,RTI)-IMH84Q+'#BH==*KGI3G:/5D0!O<JQ<D4_<;J
MH410%.G[[F3@Z^^'O?\ S/"_O^@?3EK8GNG[*IO=L63;;&8[TYNCSK]-1BS<
MA9LP:\<<'C!4"W<EG.%(3UGN.;@;1%*Z[D&9FX8IQ,/(5VB/+#G!4A MMT)"
M65NE_G58.$FEWIP+^V'QFM6&=8@7IU'O$C>Z'I-U$H=,N;NK;OMC=K;.YU)V
MI#9PWV?9\]%C. S.^V5:4_+@:[PE:#$G 85G0_<XGL9'2B8E'NR;,QX#88)R
M%R;E9:)XXQV9D+(HOM-HV,739[,TA<ZFX >ZJ,9)(2"YN@@!SDCI^.JJB?3_
M /I&>*"'N"J/7-Z6]U)+2D5L#2G0.W+&B#!_4TRR8B&F;FRMHRMD.;^(8SJ=
MVJ(NY'%CM,2Q](K.GV4JW?8;H3<<@8LK%G0<?O@P<BV$J'/?C);1214N[FJ/
M%N[W6EO@Y.+ HC[OA9-JC(P2/=$0 PJ2I0^R43% 1#Z+8WN@]RVV"QCK=BV1
M&?2D&V9":E /QYJ$R9D&4UWIL;14 E>8GMS72^1!<+.;.PVUJ^1F(4<FFR"Y
MT.9=752"3SX+:6M7*H7-G[(5"TUVTL>A3"[KLU'3+<H&]SOK1SEP0@_8[IS%
M, ]0$ $!#/K%F6U8UMP>J+&M:S;6@4!,:S9Z6G88KE>?+18C6D['$&H(I4%>
M.FY"=D(F]3TG-2<2I%R:@18#\-C8K&D\VK%9)G36HF$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%K]OWE5Q
MUXN5\+)OW<%*UFP51478,YZ5*>QS9$>\"I:Y4HXCZTV15,2B!T8*'D%"=![Y
M2@ B%T&7CS#KL&$^(1G=':MKE><:-;7^T0KH,O&CNNP8;HAR-!VHKW3C1K>5
MQ 5%.V/\H22N=B<:YX%\7-A[]N*OA$F%BM<3,-XLQRF[A)%CKRF)RMOF8@QC
M%$ZTQ-45P@4#&<()E#O9V(5B%K=\G)AD%@S:P@NY+[J-!Y ]=6'8Y:+\U'9"
M;F6M()Y"]U&@TKD'!00_UEVYO-3O.-R;[C^)VO93Z\U/ILNG3Y-.-=!U.V2B
M-7*/K3)(F(82KQ6P=B-W()]Y%P0.IDQV0;)E?L<$S#Q]\\7Q4:ZO[0;:L9T+
M8!LR6^QP3'>/OG"^*\KZ-'*QBS_6'8+\:H1T$YNS9&U-XV-PMXS*"M(HT6O2
MCE0P'<+NFL6>6MYUEC]>\L-[[XE,83=5!!0L7VM&(I"APX30*#"^1R5HVG%=
M6'VG%(I#8R$W5A>(Y*T;_D5D&LN"W#W3Q6YM?\<M4Q3QH!0;34E5F5KLB/<]
MP26>W!.V(IA$ $QO9/J<P 8XF, "&D^;F8G#C1#Q!UT>)M!Z%J/F8\3AQ7G/
M &Z,<\&T'H6U:2*3=)-!!)-%%$A4TD4B%3223( %(FFF0"D(0I0 I2E "E
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ML:Z.)MVF8H0"M?YG@O7&;P)?6FP[?1Y=$QE&JJJA)(C<_NE(U>1ZD%*M"B(
M JG>O%"_MNA^@%SYG:'N=K*@QNK-%-)[:L"=82Z"Z*YLVR&[4V%'EG6?.06G
M*^Z-'>,Z.R7JY;=-G'P]XMFR9"TX#L'AH,%SAA4O9%;,P'G,W1"AM.6&:][&
M;Y^Z4Z&CK%';HKK4.\+.64)97AT2>YX4\D,)=55C%#N^ CY:0(41Z@"G0#95
M#B>Z,T$[:6M"6TZLR#B8,R\6I'<P97^JNH+=?$(%+DM-S+037MLU-S=S#2'"
M-*QM'9M^%^"#*P@X[-YZHD T'&]%@033.@4LT?M)JNF_)7MW:YL^M)M(2).W
MK-LZE8Y$X_MEWT.\;1]CC$OVW=0;M9U7ZW]N;J/=]-87NF[+9,BS=.]&;6T6
MGV$,CQH,*+-RT-VN),24>%+6E*,SI#AP9]XIPC7#DVAN43CH1FM';6DK8EG5
M+&.>R#%<.YAQH;XTK&(PJYT27&/!PQW[H>S]>[/C?9;7]Q@;6R*4AEQB7Z2S
MIEX0.I$Y*.,))&,6,'000D&K9?H("*8=0S]"Z/Z5:.:52O5FCMM6?:\  &)U
M',,?&@7N"V:EC=F95Y[W,P842F-VA"^:6E9%IV1&WBTY&9DHE2&B/"<UD2F9
MA1<849O]J$][>-9WG?7.3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81:S<G>87'7A[3!NV_P#94+2VCE-P,# =\TG<K:Y;
ME#O,JI4V +S4RJ"ADDG#M%J6*C!726F)".:F%P78EY6/-.N0(9>1PCDUHVN<
M: <E:G4"KX$M&F77(+"[:[)K1M<XX#;3,Z@3@OG>N_:H]H5V@\Y+:_[.;3$E
MIW5Q'2D7*[QMR48K8TFYQ[JBSRU29'5%H[D[505%:_6$;I>$.X1Y"3)5 \&7
MN0[-DY,!\]%$6)F(3:W=7WH[=_*;K2,P5V66?*2@#YR((L3,0FUN^3@]V.MQ
M:W405D6E>Q'I#N?/M#FMMNZ<F-H2ZR<A/,5+#8F=8<OA !4),V=^]/L*Y&3.
M4O@7RLI54%$A,@YA54P <S%M-P&]RL-L"&*@&ZV]3+!H%UOB)XU*):+@T0Y:
M&V## H.U%1R-':-Y*.VUU*YG7&J=9Z?KR-3U70:CKVN( 00B*A 1L"S64(7N
M Y=DCVZ!GSTX"(K/GIG#QP<QU%UU%#F,/-?$B177HCW/=M<2?%7(<0P6@^(^
M(;T1[GG:XD^+8.(8+/\ (*"81,(F$3")A$PB81,(F$3")A$PB81,(L/LUZKM
M4(8LB\\*][O>3C6@%7>GZAU*)B=XI&Y#!Z0.Y42*8.O<[XAW1XMJV_9MD-(F
M8UZ/2K96#1\=U14$MJ!#:<PZ*YC2 ;MXX+H2=F3<\?YF'=AZXT2K88Y#0EYX
MF!Q&N@Q42+6K8=Y$4X%J%:AE!$/'14,FLHF(].OCYDP74'T#T]C6Z?<'ZU14
M0^N'R#K5TFM\TLZ#ULDG5'5!<6N<TX5ZI<W?''892$TM.#G'-=P2=D66 9I_
M5DR,=Z ! /Y(&Z!J_GG&N8 *\/J+U&58NV-V9MKLUDDQ3DHR=:(O(5\0_03I
M/(YT#@C],QOVY7AU4E>@"=$/2&;]FZ*R\I%;-S,S,34XUV^;XV)$@-;$)J7
ML?OSG5S<Z+1V98*T6M,VY'BM,*78R6A4H  U[RW#"I%QHXFM!%<U7-R([&3B
MMMX[FP:P0D^.]\%07;23H!?&J::0*;OHKO*&\=(-&2:!@(**-/E*B5,Y05,"
MIP$#?0)>V)J" R*1,PJ4+8N+[M*$")2IKKWR_7):,.>C,P?2(W7>P=3B</\
MU K4I';O:L=F48I=HQ@<P>-D0( I9!?2MAD8&&1$!%0]Q\37OM*.@W*@@8]Y
MBK32V/H80[A0P@OE<Q9-AVQ4P/\ PZ<=4T8UK8;W8YPJB$^I)/\ -.AQ#F[
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M'I<QT43=-*ZR8]]*_P!GBB$6</7 +)T>MG1\/,OYSQ*8A&G:DK)+VB8G#O,
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M5\6MX]L&-*HG+:CQAO4L.I8 %T!E!$+:4H7-H&#^S#I3(N<%(X
M  !T  #T   'H  #W SU(      % !@ !D -0"XI))))J3B2<R=I7[F43"+\
M,4IBB4P 8I@$IBF !*8HAT$! ?0("'H$!] AZ!PBJ.Y==D;I?>3MQL?2#E/C
MQO%HY"9CYZHHJQU,FIMNIXTV=3<!$"V4@9,[PA%2VFHBQD&[A162D(VPNBI)
MAU92U8L$;U''5,N1=<Q]'/#3F&EV#A0D7'U!% "T!;L&=?#%R(-]AY$&A<!Q
M$\(<3O&%KMHCM+^1G"W8$9QK[3"L3;F'$2-*CR":-E)EZM%)*$:H2TN^CDC-
M]D5DA#("[L,6F6]PY_")6:*FY==5%AHVEHU*ST-\[8CFMB8NB21(:TG,MA _
M87URAN.]'"XYC0*[+H$.,W?98CC9QYT%>"?[)[4ZB!G]$U8M%;NM>A[;4)V)
ML]7L,>WE8*P03]M*0\O&NR HW>Q\@S46;.FRQ!ZD514,7J E$0,40#P<2'$A
M/?"BL=#B,<6O8]I:YKA@0YIH01L*TB"#0@@C,' CF7>Y!83")A$PB81,(F$3
M")A$PB81,(F$3")A$PBXKYBQDVCB/DF;608.TC(.V+YNB[:.D3AT.BX;."*(
MKI'#T&35(8A@]T!RF9EI><@196;@09J6CL,.-+S$)D:!%AN%',BPHC7,B,<,
M"US2#K"G#BQ(,1D6#$?"BPW!T.)#>YD1CAB',>TAS7 X@M((U%:4;!XB^QLN
M2_\ 'VPO=<76.5.\:QC60=M(I=;H(G3BWZ)S/(0[@!.F=HH+R&<$.5F9LP:"
MH?/S_I1N'MEYP:1[FMI1]%[=EG&/"DX4S&@R42)6KFRDRPF-(&(+S70';_(Q
M&D03"EH)>5](LG3\Q8!LO2J59:]G1@(;X[X;'S#&G &-#(#)@,P(B#>YAM"\
M/BQ*!29I'G5*PL\EJKE/$&I5N;'19M[PHT(QB'YCCX-!:QM4.K-@1T8.\E8X
M<5*ZY*?PJJ,8U2.[4Z^@V[U.V?:+=$-UN2=85M0G-@P[=?!;+R<P7&Y#=:4*
M&-XEVQ2"66G)%UF10;[V2L)CHSM'2#<[EYF5=;>ADP+1D'@O?9[7F),0@,7M
ME7.I$B%@X4I' FV4H#&>0P6<(+HN447+99)PW<))KH+H*$51715("B2R*J8F
M(HDH0Q3IJ$,8AR& Q1$! <_4D.(R*QD6$]D2%$8V)#B0W![(C'@.8]CVDM<Q
MS2'-<TD.!!!(*^1N:YCG,>TM<TEKFN!:YKFFA:X&A!!!!! ((H5[<FL)A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81>M55)!)1==1-%%%,ZJR
MRIRII)))E$ZBBBAQ A$R$ 3'.80*4H"8P@ ".$7RL<Y.T&W?VA.X)/@/V=+U
MPGKWONHW=6_8UXY81D]"H+@QGDF%D9$45@]4,S',R?S##PDSLUV<D'745Z\[
M(A;O1R4C"DX8G)[AX&%!.)!S:2W[Z(<PW)@[9V(JWT$I)0Y2&)N<';_]."1B
MTG*H-*Q,R <&#MCVP[6P;A-P%TMPDI9(VEL$[)LB88HHWG:\RR1+9+$L'@U5
MV$83O+A6JJFY(4[*NQZYR&!%LXF'DQ)I>R!M>:G(LTZKC=8#VL,9#83W3J9D
M\P P5$S-1)EU7=JP<&&#@.,Y7G;21R4&"WES46LF$3")A$PB81,(F$3")A$P
MB81,(F$3")A%UDQ,1\#'N)23<%;M&Q>IC#Z3G./H(BB3W55E3?6IIE])A'J/
M0H&,&K.3DM(2T2:FH@A080JYQQ+B<&L8T8N>XX-:,2=@!(NEY>+-1608+"][
MS@-0&MSCDUK<R3Z20#KPJK8-L2 K.#+1%09K#X% @_7+F(/0>GH[CIZ(=0.L
M<#-V0&$B13'$Y5OG)-I:83-^(7R=BP(AN,&;R,.2-,$8%Y!A2X)#07%PB>J_
MX2P85U@;,6A$;VSCDT';C5D/8T&_$I4D"EV6HN*80S--C&MDVS=,/VI ZG4/
MT #*K*#U.JJ;H'>4.)C"  '4"@4 ]M)R4M(06R\K";"AMU#%SW4H7O<:N>\T
MQ<XDZA0  >=CS$:9B&+&>7O.W)HU-:W)K1J Y34DE=AFTJ4PB81,(F$3"*&M
M[: U/R2U_)ZTW!4F-JK4@!E6QE2@A+P$H"1TVT[6I=,OCD)-,P4-X%ZT.4%4
M3K,GJ3N.=.V:]T"8BRT018+RQP\3AK:X9.:=AUT(H0"+(<5\)UYCJ'6-1&PC
M6%05 6;D=V)>W64%8G$]NG@CL>PJ$9N$R =Y6'CLYUEU8Y(YRLJOL:/:D4=O
M(<%FM6V7&M7#EL9A*MU7%4Z$[(2FD<N7L#)>U(+,'9"*!DV)3%\)QP#Z%\%Q
M&;3=?TP8<ZPD49':,1M_:6'('-ISPX7TUZVV11]OT6L;+UO8XZV4BXQ:$Q7I
M^,4$[9ZS6$Q#$.FH5-PS>LW":S*2C7B3=_&2+9U'R#9L];+H)_-H\"-*QHDO
M'ANA1H3BU['#%ISY"""'-<"6N:0YI((*T7-+26N!!!H0=7\>E9OE2PF$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PBB_:FH*3M^"-"VV-*==$B@Q,XT B,S".
M% ]*S!V)##X,Q@*+ADN59DZ[A/#H'.FD=/Q^F.@^C^G%G&0MJ5#HC&N,E:$$
M-9/R$1PX<M'+7&X2 8LO$#X$:@WR&7-8YO:L.W[2T?FA,R$8M:X@1Y9]72TR
MP?>Q8=0*BIN1&EL6'4W'@.<#JMJ[<NS.%-N8:TVTH]MNCY=R=.MV5NDNY4KR
M)E $[N'*8RJR;=MX0JD[4%%%#MA$TA!'5\(8)CX?HUICI7N$6U+Z*Z9.CVSH
M%.17-LJUH3(D4V?#+L8LD"7O8R'>#K0L5[W.@U,S9[GAQZM]_:MB6/NAR$2V
M+#;#D=(Y=@,[).+6B:=3!L8@-#G/H1+3P #_ +%,AI ,"X^&F8JQ1,=.P4BT
MEH:79MY",DV"Y'+-\R=)E5;N6RZ8F(HDJF8#%, _9Z" & 0#]G24[*6E)RUH
M2$S!G)*<@PYB5FI=[8L&/ BM#X<6&]I(<US2"".0T((7PN/ C2L:++S$)\&/
M B.A1H41I9$AQ&$M<Q[30AS2"""NRS:5281,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(OFT[97FILC8.P*WV7W$9PO(;8VR=A';LG(=T=NI UR<9
MA((Z]4DF_?4BFTA73*6O9DET(2-HH-HU0[EO-SK5KW;*E&-:ZT)B@APJF$#]
M\\87Z:Z'M6#,OJ?O17MV9*L:UT],"D.'4P@?OB,"^FNA[5@UOQS KN;PJX<:
MXX6:=C=;TM%&3LD@5K*;'OJS4B,M>+25 2+/%AZG5:0<:*BS.LP8*G0B8\QS
MG.YE7TM)2%<U,OFHI>[!HP8RM0UO2<W'6>( *N8F'S$0O=@!@QNIK>DZSK/$
M MOLUE0F$3"+TN7+=FW7=NUT6K1JBJY=.G*I$&[9N@0RJRZZRIBIHHHIE,HJ
MJH8I$R%,<Y@* B!%'M%W'J+:#F59ZTVEKK8;N#$I9IK1[K6[6XB!.<4R>R2$
M%)/U6('4*9,AG)4RG4*8A1$Q1 '(0>0@Y[:9<BP'-=6ZX&F="#3EHI(PLIA%
MUB4W#+S#VNHR\8M8(V.CI>1@DG[52881,NXDFD3*/8PBHO6L=*.X:7:QSU=!
M-L]<14DBV5548NBI$_C^/$5V>$76/)N%CY"(B7\O%L96P+/&\#&/'[1M(3;B
M/9*R3]"(9K*D<R2S&.07?O$F::QVS)%5TL4B"9U"DJ-N>7&NSPB81,(F$3")
MA%ZUE4FZ2JZZA$D44SJJJJ& B:::91.=0YA$ *0A0$QC"(   (CD7O;#8Z(]
MP8QC7/>]Q :UC07.<XG -:T$DG  $G!9:USG-:T%SG$-:T"I+B:  :R2: +6
MMVY>;7LIP[ZS:H0JH@F4.I#.1$1 #B ^Z[> 7KU$!\2:>@ \*<17^917Q]+[
M4(!B0K%D7X4JW?3E>QSCQQ6F'_#P#3ADF+Z]HAV%)C!K[0F6XDXAE*5&W>X=
M?_V1!L':S"V;-V;=%JU130;H)E2112*!2)D*'0"E /\ :(CU$1$1$1$1'/=P
MH4.!#9!@L;#A0VAC&-%&M:!0 #UG,G$DDKS3WOBO=$B.+WO)<YSC4DG6?XH!
M@,%[\L4$PB81,(F$3")A$PBP':&L*+N:A6;66R:\QM%+MT:K%S4.^)U(JD<2
MJ(.FJY1*NPDX]R1%_%2;11%[&R#=L^9KHN4$E"V0HKX,1D6&XM>PU:X:CLXP
M14$' @D' J3'NAN#V$AP-01ZCQ'(C6%\_P!QQV'>NR'Y?K<7-P3[Z9XB[QEO
M977-XE3=QA6'TBY2CHZU'5Z%91Z[%R9G6=KQR7BJ**/L5=D4T8]-FA*[ML2,
M.W9#JZ68&VC*-I$AMX46&VI=#PQ=A6) ..)=")J26]5UV;@B*P 168/:-=,Q
MMXV'95N>7U# (" " @(" " @/4! ?2 @(>@0$/2 A[N?-EH+]PB81,(F$3")
MA%CL;;JI,3]DJD398&3M%.]B/*VNL)9@[G*QY0,C24$,_%(+J/H@)F/(=[%"
M_00"0:$.X:BJD4Q@D6N#6N+7!KZW7$$-==-'7210T.!I6AP*P' D@$$MI>%<
M145%1JJ,MJP^Q;PTU4:@2_V?:FOH"D*S,C7$+7+6Z"90#JPQ$I(PDI M)-=\
M1H[FHZ8AY:+>Q3955^V?Q<BU5;D69.2)R;!BO=<;"B.?=#BT,<7!I <'$4J&
MEI!!R(((P(43$AM;>+VAM2*DBA()! VD$$4&-05W-?V=K>UTPVQJS?J9/Z_(
MT>/E;M$6:&?U1!G' <9)PYL#9XI%MDHWP2H2)EW2?B)DE2._ F3.!<.AQ&OW
MMS'M?4"X6D.J<NU(KCJPQU+(>PMOAS2W.\"+O.:T'&L:I/(#1FR6=BD-?[@U
MK<V519GDK2YK5TK\PE7HQ-)5P,K,&8OUO8^*,@W762E'/@V"R2"RB+@Y$E!+
M)\"-#+0^%$87&C0YC@7'# 5&)Q& Q!-"%AL2&X$M>UP:*D@@T%*U/%QY9[%*
M$7*1LW&1TU#/V<K$2[%I*14I'.47D?)1K]NF[8OV+QN=1!TS>-54G#9R@H=%
M=!0BJ9S$,4PUD$$@@@@D$$4((P((.((.84P00",014':"HLA.0NA[+>%]:5W
M<NL)S8+==ZU5ID3>*X_LGCD84QY-DG$M9%5XL^C"$.>38HI*.X\I#F>(H 0P
MA88$=K-\=!B-AX=N6.#:'(U(I0ZCD=2@(L,NN"(PN[D.!/BJIARI33")A$PB
M818?>Z+6MCUB2J5K8$?Q4BGT]'0CIDZ(!O%I&/<"4QFK]H<WA$%R@(#U.BL1
M9NJLBIP](]'+)TJLB:L6V983$G--S%!&EXS0=ZFI6(0XP9F"XWH<0 CA,>U\
M)[V.Z%F6G.61.P9^1BF%'@NY61&&E^#%94!\*(!1[3Q.:6O:UPU,XW;1LW%/
M;)N/&T9([O6EK? M0K*Z$Q&40\DW)DV+Q$ZAC%91$RZ$64\P$YD(>=Z2)%",
MUI!Z\^"[F^DUK;CVF3MS32V9=&T7M>8$31VU8M6R\I&FXKFP(['.)$&3GHM8
M%H2Y<8<C:'_$AS8+YF/'^AZ463)Z;V$-*[&@B':\E#++4DF &)&9!8'1&D 5
MB1H#/YV6B4O1Y:L(@Q&0X;+B\_9R^&)A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A%K3S#Y&P/$OC1M_D#/IMW1->5)T^@XIRH*:4_<))5"$I5>.8A
MBK%2FK5)1$>Z61[RK5DNY> 0Q6YLOE8#IF/"@-PON )[EHQ>[_RM!/&<-:OE
MH+IB/#@MPON )[EHQ<[F:">,T"^?OL8>/4]*0.P^>FZ5'%BW)R.L5F<P$Y,)
ME/(-JHXGG#FS6%(#%(+1W>;8@Z^M32*FE7H&(&,43CY=PBIWK2C-!9*0NUA0
M&M!:,KP #1QW&[<R23B*KMVA%#2R5A@-AP0VH&50WM1_Y6GQDUQ I>UG*7-3
M")A$PBTUYSBC]1RMDGC@362N\-'(;K%4W<CAU$OLB!2MB<^<! 2U14YXU*WB
M80;C5SRY7P^QXN\P?VBM<J5%:TU4SXE")P<<KS;W)>%>;;JI6N"Y6Y;#H_7=
MDI=IBZW$R^]8/5VWY?2D35&\@1T_KD!0W4]-1\JC5%4&JE$?^Q<3'L!L22\
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M-VZQ056ADE44%9>QR\?"1B:[@_@VZ*C^3<-6A%5S_6(IF5 ZI_K2 8?1A8)
M%20 ,R30#G*[E%9%RBDX;JI+MUTDUD%T5"JHK(JE Z2J2I!,11)0ABG34(8Q
M3E,!BB(" X65US6=A'K5^^93,4[913J18RCQK(M'#6->Q"ATI9F_<)+'19NH
MQ5)1.1;N#IJLE$SD<D2,0P 2HV[?1GXM:YK1VT?M6S]@Y;O6+UNB[9O&BR;E
MJ[:.4RK-W+9PB8Z*[==$Y%45DCG353.4Y#&*8!$F>2Y&$7#9R,?(^-A'OV;X
M6#Q:.?>)ND'7B4@V @N&#OP!S^+O&X*)BLU6[BZ0*$$Y"@8O4BYF$7S^\5$_
M:M]M?O;2D>'B5(Y&UJP66#C4_P!A8#*R$(AN5HX;H% ")D@G++8=;CD0Z))-
MG*J:)0 4BANV]#ZLT=EYHXQ)**P.=F;CG]3D$GNRZ"\\875>=]DX<0\)E =N
M!N''C[5WK7TE9\Z6DF$3")A$PB81=8SA(:.?R\K'Q$8QE+ NT<STDS8-6S^;
M<L&2,8P<2[Q%(CB2791K9O'M%7BBRC9D@BT1,1!(B9<ESB "20VH:"20T$U(
M R%2233,FJQ0 D@ $YFF)I@*[:!8?)ZBU/-5!/7TSK#7DM0DG;B02I$G2JV_
MJ"3]V]>23MZG6G4:K#$>.9&0?OW#DK(%EGKYXZ4.9=RLH>8BQ0\Q!$B!Y%"\
M/<'D4 H7 UI0 4KD -2P6,(#2QI:,0TM% 3B2!2F>*[:!H%$JU6\AJS2JE7:
M5XL[9^1\%6X>(JWBC\#E?-?)^/9MXGQ9Z510KM#Q3P3D%#@L4X'-UBY[W.ON
M>YS\#><XEU1D;Q).&K'!9#6@70UH;W(  \62Z.H:9T_K]A.15"U3K:DQEG3.
MC9(ZHT:L5MA84E4ED%$IQG#1;)O+)*(N%T3IOTW!#)+*IB D4.49/C18A!?%
MB/+>"7O<XMY"22,ADHMAL:"&L8T.S#6@ \M!CSKAU/16D*',I6*C:;U53+ @
MBNV0G:GKRHUV91;NDQ2=()2</$,WJ:+E(1372(N!%DQ$BA3%]&'1HSQ=?%B/
M:<VN>YPPRP)(P00X;35K&-.T-:#XP*KE0^E].UZXO-AP&I]:P=_D3.CR%YAZ
M+5XRX/CO@,#TSRRLHM":<F> <X.C+/3BX Q@6$X".#&BN8(;HL1T,4HPO<6"
MF5&DW1350((; Z\&,#CFX- <><"OI4EY6IIA$PB81,(F$3"+2OC.X'4G.+9&
MM6X^ K^RX>0DXQF0/!H"^3:$N\>*) Z!X.+:'M,4B3IT*0Q^Z/0O4WYSW-C[
MR]WW2G1:%6'9NE$I,SDI ;VL+?MY;;TL6-I2[*076K)PQA1I< 305^FZ4CK[
MN<6/:[^WFK(CPY>/$.+][+S9\2\:U)C/$E&<<R:$C$JWS/V(OB281,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB^7#M:A]ENU_P"S2@GX]8MBGK>;:D4Z
MBE[)_5MG'(]"CU+WSK0$24?1]<()@;T=,]%98I9L\X9G?!4;!!%/65W[-PL^
M=.LEXYMZ'25>?G-6@F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81:X:N_9
M']Q<']*JDBW[XC[H=5I,X^[Z?KC&'K_W!USYOHAVTS;D1V+W3,*IUB]$FW'Q
MG/:1Q+U=O80[.8."(3Z##N8(&6&0U8*/N;/[C_DW^ W9GY)RF>Y;F.4>M>8C
M?8HOY-_S2M=-JGY"&DN)H;,;::2JGMD]4^ /17UW<6'Q_P G;;XD"R<_'MHT
M&@H>,>-&(J*P*@B")3$$XA@4IA6E!3T9\VS6H/OUA7KM-];D3G1VT9<ZQS6G
M(/D;;9C76Q7,;=D*C?-XR&OY.N6-?B_7M-1E./<[%3DF=3E3[ ;<@9':%;2B
M4Y-ZPDF3]2R2\9/PL?0X]%6.6:,.>@%>VSSRIA6NL#"F.W#7Q"6NH:.>6T)A
MAH;4@4[:^7 "I&-34!H&7HKG)#;9KOHZWL;/LN^ZYW'L*Z5Y,)BB::IVJ+/7
MD:'LNX5E33L<S=K<ADWK96HPZ24U>C2<#.,W#I==1BXDX1F.0,#M'+7,#'5X
MJ8\Z![[S""YS7N<,6L:P]H]PN_\ 4!JT"KL",1F%R*3)[#NUX[/';MVVZ6XF
MVV[O=Z5H9*]3XJ$IDC8>-FP9H(RC.H.(CK,O"U=O(GK4\%UE[;*NI0L<]!_#
M*G=1SC/=#Q9UX0S_ /8#CJC;SC >Y];Y+KM&T%8;C1M!4AN1)+B30U&2SCF>
M%_OE^UIK?2L/79';NO*Q>-_,!OBT<O3I.NHPTGJUU5&M;E(Z18V2V3Z]Q5+$
MOGZL-%4Y9LUD):54:2HQ<A@4%:Y98"IKB?V<9..&L9BWG.:UE+S07]MD12[2
ME,2:G6 T@$YT,Q\)M@Z[V!QXI1-4L;BSH5!:M]70"U[%@%ED4J+%1<4[>2"+
M!TX*V72?@ZC'"*J,>3QR.<JQK$D(K%+N,&M37//#+''#^#RG-3@N:Y@N5NM[
M05I7M0!C3+9S5&!"T KKV6T)2N1FV_&7SS3>X]U\OZ/MYB=19PVU]L -O[,J
M^M]JM4SBH1E 3Z816N+\"8MT&IRTFPJ?L$?,JFD<2!KH*<>%:<N)(YQK%*6_
MS8>\GM'OBAXQ[5V^O#7\0([5W'=.U9A6MP[V<UNKT36R>R8>&U'Q+X\VEJ\H
M$?QP<QLG/V_7[^0&8V>[W]<JT_1UZP2KJ481MKY.+D#*M+.Z?W&/60C&J4<-
M>WCR%,J9G/;JJ#K-<^C6M#@&0H9[40\2X'A7R.U[6G:T/"[84%)KAMJ;CVP&
MQK$KN"!X^(:AU1I^Y/(MI':[N] ?3MWUFALNT3][M,DWL*\QK&/57<U:,?:W
MMU8\9;5^<FVMLDC*-!;9PPUXYFHV@4 (Q.!QKF!0%3#G.J;X9<:QQ':EM2V\
M2XFM6:@6N;DXWCJP?1NT[F'(JX:S%RI0M=6;D3NNQ,;R1E"3"&XKA#0]1D5-
M1PCA\+_R1:MZ\Z<W!Y).H]*>M;.&DHVI/HOV"F7SC&-/7M&>.(QQIJPUY@+#
M'.WPMX+3$>;V!OD =J.YSK7,TH-:M.PMA4"\I_\ T)VXG".0C/V-Y+:\IQ)#
MP?0#J%?6+=M==**" @(@>(*"!@'W4D1+Z0]&=1X#M&;4#L@YQ'*!+N'B< >=
M=.7QDHP.I[J<P8[UE?2%GS-:B81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PBT<M C']H+H=RT]"SR C <B7KU$'1K[%+][IZ?2Q*!1^QW.G7T>C/SAI'
M_P /[I'<^BP<'Q[,D]]IF=]=I%*/K_\ \X /]G!?4++_ )W<MTF9$X,.<C7*
M_P!AMEQFTK_]TDX:^-7%Y^QU\/3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$7R\=OHV6U'R:[.GE;X)08:E7Q:*L;LA#B1LG1;S2+_&,UA*41-[+1KV
MW 1(O4QTH]R'=](=?0V*1$@3LOK<P.:/QFO83S$,\:[UCD1(,Y UN:"!MO-<
MP^(W<>//)7AHK).$DET%4UT%TR+(K)'*HDLDJ4#IJI*$$2*)J$,4Y#E$2F*(
M&*(@(#G.RS6CEFO9A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6N5-+[$7
MNZP:GUGA7*SI IO1WDD'BJB'=#T>DS60(IT#W2@)@]!<^;V#_P %I#;L@[M=
M\B1(L,'6R''<Z%SF#,A]-@.H+U=I_P#$679TT!6ZQK'D:B^&T.KKH'PJ<IQQ
M*D.R5R!N$!-56T1+&>KEBC'L-.PLF@1U'RL5(H':OH]ZW4 2+M73=11%=(X"
M4Z9S%'T#GN%YL@$$$5!!!!R(.!!Y5Z9>J5J?+ DFH2.DR5>:C['72O&Q%@AI
MV*0<-HV6CP, ^+OF2#MRDW7)T.F1=0I1Z&'&2$ TJ :&HJ*T.T;#QK!F>B--
MQU[5V:QUI3VM\5D'LP:RHPS4CXDY)-C,I*?0*!/%FUADF:BK21GVZ"4P_;++
MH.WJR2ZI#JG:?&L7&5O76WLZT%:G,\O'FNM@^.&AZU.,K) :GI$5.Q<RM/P\
MFSA&J3J!E70O#.W%>-W1+7TWAW[P[UG#%8LGBBYU'3=4_=,! Q@-0UH(RPRY
M-G-1<F!X^:1J]N2OM=U;2X6XMI&5EF5@CH1HVD(V0G6LDSG'$4HF0"10S:$Q
M*#,)QI&J,HN^<.WZ;AT<5L(&,!O!K0<<:"N-:T.JM36FU=OL;36J]NI1:.S*
M%6KH$(=X>(5G(Y)RZC2R*1$)-NS>!W':+*50211E6!%@92:***3]NX(BF4K+
M+^*9>)'-:ZEYH-,JC+;S'6,CK7<U#7="U\653HE,K%-2FW+%W+(5B$CH-N_<
MQD2Q@H]5PWC6[9 QF4/&,(UJ )@5%HU223 H /5^Q9  R '( ,A09;!AR+\#
M75$"L6.EC4H U2M[FTO+17%(ULK#S[F[OW\I;UY5BH0R#Q2Q2,I(O)85B&\;
M</%U%.IE!Q_[:ZY9>*B710B@H:U%,#>)+JC74DUVU*PRS\=]&W1O6VMJU72Y
MQO4H%M5*^B_A6RA&%49E1*VJI@*4OCE83!NB/DZ_\:ACF3 ZC(QQ$PE@L8:5
M:TT%!4# #(<G%DN=;=$Z;ODQ#S]QUG3;%+P+-E'1CV3@V:YTXN-=^R$;$.4_
M!E1D8>-?]7T?$2*;N-8O#'=-6J2ZAU#$+&N-7-:32E2 <-F.JN/*N\<ZOUV\
M2,@YIM?63->6^S.AXY'ODV"T71<-[DBH!040L22K=(2RB)TW7=*9(5!244(<
MLW6[!PKV7WVWEXUGF%E4 F.&]>WRJR$</C\+QTUV<DPX1_9$D!A=>34B  <
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M=X5UCG7<^%0&F1SV'8LE[&TO/:*Y5<!7DJ<>99V @( (" @( (" ]0$!]("
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M")A%TM@LM<J44YG;5/PM9A&9>^\F+!*L8:*:DZ"/><R$DNV:(%Z (]Y58@=
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M  %)%;!4$A>A/&REZERX3MD1_LL!\!VLM::>.$XD\[%<)RRXWV2"^"2<2&D
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M$)HTF8>YP)RK+R$A/.<<NU$9M:T#LBNAV-(<J ^U=)+/DFC%W\VVG-$F9F6
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ML&>MF';\6:M>3?,GK?%DS":Z$]K7@MCF$Y@-]MT Q*XU(P![+RHYZ?;OC?\
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MT\J.>GV[XW_B5W_5F.K?="^$-S#S-O\ U--XW-/@VEWG+,^G3RHYZ?;OC?\
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MMHC];L)2;B#JDDHALG?U:T\&2:E047.R,V*X,S[CU-,[-5)<\W,>QQ:YI#@
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MM9.-!M Y$@D4H*BG;5QP(/+Z=JJ,.(ZC7-AU!'\Z#VV!!)NT%'$ @T-*DY#
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MG6D)%0!H1"#4V331UG=+\]G%W+Z>LYIIJTK990[!&$@6Q(E-^\I,:'"+>IV
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MSWR7\Z?93S[7%CXC^9_T"-_7;'6>9[[*^>/L)UHF>^2_G3[*>?:XL?$?S/\
MH$;^NV.L\SWV5\\?83K1,]\E_.GV4\^UQ8^(_F?] C?UVQUGF>^ROGC["=:)
MGODOYT^RGGVN+'Q'\S_H$;^NV.L\SWV5\\?83K1,]\E_.GV4\^UQ8^(_F?\
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M'Q TEC+H>[4"XT:.,DZA4TJ<@2I%[0YK"1>=4M&L@8D\@VGD6:B(  B(@
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M1XA3]JF"^@-UK64JYIJ' 8U% *<QIQK2J)V!4N7AI]S$V&*J,VQT_N:C<5-
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M:YL+=4O 5X&MS@'E1C;'.74DE8U'VO+%%2S>6*P4L5E@YPD&0WLA3&^--'P
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MN0VDHYXX>LV<@R=.XU1-*1:MG2"[A@JJ05$DWJ"2AE6JBJ8"=,BY4S'( F*
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MZ5K^91N6V1C]B.E(Y"/8R,ABHH0#F<CA05XA2NTZA@%D#(D' 9X$UI3:33B
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M3JV9[[_DA^PGF8^SG^(F0^EG<?K[CKE.]^_TX7T:=6S/??\ )#]A/,Q]G/\
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MQ04=.UEG+DZ2!3+N%5%E1,H<QAE%FXL=YB1G1HT0@ Q(KW1'D-  JYQ+C0
M5. %%NVG:MJ6U.1;1MBT9ZU;0C!@C3UHS<>=FXHA,;#AB),3,2)&>(<-K8;
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M;<.]9%^?;;IQ.3CXNQR7O0>W-J2L3,Q*\@LS4;TVX5.!5JJ"#9$M3C(4T%%
MSC73IJLRH[6<SG44)IL&6',H#!L&+4A[JE]34NJQSB*'# @4PP& H*K.=*0R
M%*<=GQL. EYM_<.2%9D2;PFGM@F90VR5++QWLNYW=HGFCQ\XCU7T/?*[&D@'
MJ39$]?AYEU6XL[:*> R$!2Z=;LSMPKELKXL%)HNF 14NB WS7$@L+ZG"F!&&
M5, MB^7^Y]JZ@I;!_K76MKL2CNX:A8.KI#R>KDXF+3LFY:15I.INHF\6J,EU
MY*WPTHZKD;)L()Y&Q#R>9R3N8ABL7,G'9<2!4?QCKY>)617N8VK6DXM[8%M!
MVP%""03488 YZEL%')&V=KU5EL.@2M13MD9+1-DH%EE:_(R;2/<+O(U5F_E*
M-8)Z#5+*1Y2/DCP\^Y.BU?))+J-GZ3ALA+,8C/5_V4^&VCFD5&+203SEI(\1
M6BF@>/\ I2"Y'\IWQ*@Q8M]0[$U.XHBSJ;GA:4Y!WHZBVJ35: \F#MDVZLT_
MD)=R+P%D06764-W4_K0@&B\[#*E,\,%2R&P1(G:@7"R[GA5H)U[<5!U4I:.I
M&NM;]M:BV1XX"^TB;+SVT7MMC>6NQVUNN,>,)*;-KTR]:V)OKO93.<9UVPP\
M3#WVG0D?,%6KK^.9MXF48J4QQS'; BAJ<:Y4'H'KK#0T-<X&EYI$=K@002*%
MPJ" 30$ $ ;,UL3JW4%#Y,RO(&Z[QC'MULT-R VOJNLM7T]/L4]84[7<L2NU
M%K1VD9)L4JE,3$2FVOCNS1*;6Q23ZS)/%I11JC')-\@ U)Q-=>JF5-FW;KKE
M2UK&Q#$<\5(>]HJ3VK0<*;#3MJYXYJ<*/N#64/$ZYT_&[3OVS9^9J4;&UK:C
M>CVZ\L+,0J3Z(;6*9VI5*,]U.$V1S%.O9-:7FFI@?M^_-("N[[SG.P5)XZ5]
M-*>/G4FN: U@>YQ(H'T+JUR)<!=KRGE6FIX9C0IRS6SC$]M<XWX]:9W<&]=S
M35AF9UAN?:4?0WAJ[3Y!=^[<16P=@0EV8C<[A/Q['V,HKEOY$M7;5>:D*['1
MVW:F@-3@:G4,\3KV:M:JH&DF%7M&/OOQ(>ZAH#4T)#A6HK3@B@*RRKTR$UG9
M.,S>JW.T59+?/'W:C;<=U)<7KJ3G'\=K^FVUEN9^_M*\U$(WFNS;^2<,[:[8
M*)()6=5B_1<Q2;%BW:VTKBTU\0QV5KKIKXUD -,.A+=\8Z^:XGM00XDX7@30
M&E<=BS#3U93TURS#7K& FZ%1K;I":"E%6NCN],=WV&A6RM#8]CV91P^.K6KY
M!0UCBDUE';)R\NC"W/'CZ<.M7&L<CD8.V"F''E4GCQICGM4F"[%N@$-+#0UJ
M'D%M7$UP=B,ZEPQ)P5B&25Z814C[\Y*5WBIVQ%"VC9]>[=V9&J<#?)@*WI2F
MH7FY%<RVX[VX2D3PCB9@DRP[4L<HF^>^/"9!5PT("*GAA$G19 =,V8Z&U\*&
M1.7KT9]QE!":*5H<37 4VK9= =,2#H;7PV'JD.O177&X0P*5H<<<!3:MT//;
MZ;^X[[1+_P#&R*_Q*S2ZU1?A4C\8_P#@M#K9%^$2?G__ ()Y[?3?W'?:)?\
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MF7530(JX6>.EUW3M9R^?OW[YRYD).3D'+J1E)%TZD)!TY>N5UU,@4P"FUH:
MUHH!_'C4$ZXXA:OU1)1C^DV7=\:UBYR0L:=<<;\V[(4Y[,2\@ZE9=W+U![;E
MJY+C+2;UW(RB<C&N$Y!ZX5<NBJK',<8AM-9VTKA_%<56V"UI!#HF!K0O==).
M=1D:K)J;QFU11+@QN4 PL7C$$YM#VG5Z4N-GF*5K][=5%U+8[H=/DI1S U=:
M;\;?-U!C6:98V/D9.)@RQ<3)/V+C-!6O\"N=-E5D0F U .N@)):"[,AIP!/J
MYU^Z^XSZHUG96%GK#&QBM7V$W$TB%FKC9[!5M<15E=(/)^-UY69B4>0]3:2:
MC9LV,2-:D.PB6Z4!$J1\"48P0 &7'K.%<339C_%$;"8TU%<*@ DD-!S#1D!R
M*<9"-CI9MXE*L&4FS\89._%)!J@];>-QKUO(QSKP#E-1+QAA(-&K]DMW/"-7
MK9NZ0,FNBFH7*L(!S%>5<W"+"H#7M5K-GV!<(A@HA/;/DX.7N3E5XZ<HR3ZN
MUB+I\4HDT<*J-F)$("&8-%$6:2*3A1([E<IW"JBAL4Q)V_L40T N.MU*\=!0
M>A05#\--(P<A%&8M[\-1@; TM4!J=WM+83W3D'/QTH2<C'L9K)W8E:J@TB9M
M,DQ#P!F"E:B)--!Y&0S1=JU.BNC9KK2II4&N5:>A1WIF'"H#4-O.NU_%K3#,
M:@<LEW=XXKZKO5FL5L<+[#JDG=T&;782&N=HW_7D3L-NP9)Q;7RQB*C8(IA*
M/21"1(8\RF@UG5X<B<4O**L$&[=(0#MX\2*\J.A-<2>V%[A77%H=JQH14\>>
M 4RQ])K4-2FVO*_&IUJHQ];+4HF*KBBL(6$@DH[V*:M(5>/.@XC#LF8%(R<M
M%4W+51--=)4JQ /F:84YE,- ;= H * #"@I3!0;JSB7J[3@PC:ES6W@KM>C7
MT/%T6P;KVC:=<I1<@Q=QZ[!;7]@M,A4G+4J+U=5N@XB%$VSP4WJ!2.DDU2Q#
M:4Q.&JN'B_C%5L@M9DZ(0 1=+W%M#AP<O_?'-<ZH<4],4WV01;0L[8HUU1IC
M5\9!WBX6B[P55UE8!;>SFOZC$V:5DF=?JTJFQC6C]BS3!5U&Q,-%+.31<1&L
MVN:#T4QV;/X]2RV$QN0)%VZ XD@-U@ X '7XL@ NYUMQTUQJZ>2L\&:XS<\P
MK0TFO2=[OENOCFI4HSED\4JE5-:I>3"%B7+F,BU) [8/9.6]BHHDO(ODXQ@1
ML  V\53D.)&PVM-14D"Z+SB;HV-KD#05IL&H!3KF58F$5:=8]_5HW_VZ97^V
MNU9M1?N2[\^'Z$*<S]S3^=M_1*^3.*N(F$3")A$PBJ,Y3^^4<+?O(K_6ULR8
MX#N7H5;N&WF]95N>05BJ)X\>^I\NOP;H_P#'U#EKOL8Y6_-<JV\-W/ZPK<5U
MT&J"SERLDW;-TE%W#A=0B*""")!456654$J:22293'44.8I"$*)C"!0$<K )
M( !))   J23@  ,22< !FIN<UK2YQ#6M!<YSB UK0*DDG  #$DX 8E8_4;G3
M[_ M+31+76[K6) SDC"Q5*<C+'!/3LW"K1V1I+0[IXP<F:NT5FS@J+@XHN$E
M$5 *H0Q0LCR\>6B.@S,&++QFT+H4>&^%$:' .:7,B-:X5!!%0*@@C JB5FY6
M>@LF9*9EYN7B7@R/+1H<>"\L<6N#8L)SV.+7 M< XW7 M-""%D@F* @43 !C
M (E*(AU$"].\(![H@'4.O3W.H=?=RI;" 8HB)0, F* "8H"'4 -U[HB'N@ ]
M!Z=?=Z#T]S"+]PB81?G4.H%ZAU$!$ ZAU$ Z=1 /=$ ZAU'['4.ONAA%^X1,
M(F$7X(@'3J(!U$ #J/3J(^X ?RC]@/LX1?N$50V^_?9>*'X)%/\ ?WIDQP'<
MO0H'AMY.E6\Y!350O$3WQ7F[_JUOREBLL=P&\WJ*K;PW<_K"MZRM6)A$PB81
M,(JU];_NI.8'W\U?^3TYGYKT._YK;M7]X:*?[?:2^IVW_0[0+\VMK];E5LQG
MUQ>,3"+$)RA5.R6>D7*:B0>V77+N=?4R3%[(MQA75F@W-;FU2M&KM!B_\>A'
MCED))-L]3;@IXPU(@Z*1<LVO>UKV--&Q T/%!VP:X.;B144< <"./!1+6ES7
M$5+*W34X7A0X5H:C;7B48;$XQZ=V?:37BQPUGB[@XB6L!)V77VR]F:JF+! ,
ME7"K2$M#W65NJ2MHC&AG;DK-M/C(E9)N%TF8H)JJ%-9#F(L-MQKFEE2X-?#A
MQ UQ%"6B(QUTF@J6TK3%0?!AO=>((=2A+7.82!D'72*@<=5R;#QITE9*52:
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MBF4J:2**92II))E*1,A2D(4"@  SS18N[H=3?7J#V6ZB2JW>N5>QTR%G/')
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MGOF5#>L&-_'<GQA%X*=K;K]4"@KQCY-J 0Y%2 I2(0X%43,!DU"@:?'NG(8
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MQT9O(-X="Y='9Q2>QDQ&I-%960E)A^2-9C.2+Y%@V,W3%\L97OE!1P1<75%
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g107876g15b64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g15b64.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( ,@"7P,!$0 "$0$#$0'_Q  >  $  @(# 0$!            !P@&"00%
M"@," ?_$ #P0  $$ P$  0(#!P$&!@(# 04#! 8'  $"" D3%!$2%187&2%9
ME]<V&#%V>;6W(B,D.7BV08$E)C1A_\0 &P$! 0 " P$               $"
M! ,%!@?_Q  _$0 !! $# @,&! 4# P0" P !  (#!!$%$B$3,09!410B87&1
M\ >!H<$5(S*QT4+A\18S8B0T4I(7<B:"PO_:  P# 0 "$0,1 #\ ]_&$3")A
M$PB81,(F$457G<,/\^4Q:MZ6 [^RA515_++$DRW/?'*_8B)!'AITT9Z4WK2Q
M%_RS^Q&->?S*O"#ELU1X466XXZ*@$D =RO,9Y%^5WT=15+>P'GJ)I:%B7'Q7
M=7^OZ=C]]US:E#CX\E=TSA=3VY4 YY8L'CQ E27EZSYE#2JTPAHPZ#[@LD+*
M"B_7 WCM(N0L!(P1C)!((/ &0>,^\X X'J,*T=O^Y?8;6YZ(@O5M^0G<<5$>
M^1%O)>>)S(Y".DYRC*4KV<Q-BJ6,#NY#5EH!QMB)/A,":221I<$%1\F,E2;9
MX'$ G/WZ8_S^BQ '/!\L9X[G'EW_ '\L=UDE'?)_<:+[Q[YT.U\%)V5Z&IOP
MY<=:S"3G)2;Y->;)YY_-V%ZKM6P9&IVG]_-Z8-5=+P:KCMR-XDABPZI?O1VN
MCA%/HA9C=SPTD9QW(. /S[_D?152L3YBO7=B55:Z-8\T-!R@QCX@MVOKBCPV
MR$XJ2IWT;ZZ:404&<C[7""904'DV>A:G%DE8-6+]S#RTH* 88 ,HQ0YA9!@S
MSGNX$>?#<CMVYX(Y['E61#_(]>\>G,UIJ(=4[Q.I3ZR][#VMF>FK0ES>E8U"
M?*,8J V[AT3=#T&Y5JXE;BQ>',5!)$N1<+B8.425P@?TA]AT6( (R?( 8 Y.
M21^W/S7$"?,CZ G0+][\2H:L(]343CGQFRZQ([-Y#,]VJN/^0>7M((J)A3D<
MP:QE3J!%7>CHR2G&39M)(]IEK0!NX(]+CR;1D@DY&\<=O=&5<CWK[WM'S;:3
M.J*I T8V(!?+5S^N99*_14T/PR+R6)TX9CP1Q4];*Q]LHJZL8ZJ<4)/2Y)1P
M+B(9%B^< 3VR?*34HT9]>X''Q^OIV\RHH^/NW[^]0^R?:UE6%+I !J-I4_E9
M&I:92D\P8_NK&W[0D!NY'EW$EU$HENPV34TJVEDO7&JR!K).B L(NUBZFA_)
M5P :W'?G/Q(..#Z?#^ZY7@:NYZ/]P^^XU*/4WJZU(CY;LVHZ_K2'6I<3F7QA
MT%M#S'7-DGW4M%*AFB9TNQE,L*N@#_GME^F(<M$=HN.F_P!3LCOZ6G R0<\>
MCB,_HH,!72M.KT]*V9>OR'6AYAL6C_D6$^;*D\Y@3(!W 3%5(G*Y#UC%COG3
M0!]*;1?>G1<H)&^K(4[=$ #<\B<BY,$#@1+CDF.!AN06Y)Y[\DG.>-OZ@<A5
MUO\ ^8'T=9_GOVEJ'P5K38T94/K$O3E@P^0& MN5B=\T78$J?E:8<&G"#:0N
MYJDY?EG#^ #4&]8%TV$.DVRZYX>:PJ&@%OGZ^G()'[?,'(X4D6!\FGISS<=]
M1) 0X6W! GW;[ !K%IV]-S5]4-24G3GFB4! @:J81(!UJNZQX?3N6$I?8<'C
ME@L:C212=FX28ZE@SC@H&@X[^7;XDCN>/AR1GU\E>GWIZ#/E81\?C*)W07H.
MC/8=ZPR.VUZ&@)M.,%8]7TAI6<V?"HQ%IY,8^P<P-6W9@%B\38S!\# 29JS=
MJ#FC<,8+:10*-']7F0. ?7(';X#)QZ^1&5!S#V>=I1K5/G/S7ZDK_P!8$K&N
MKUI'6'I3V+*28R"5.*\X1.'3&0TC(;&APH.[N:8-74S;L(]/DR*G'0,=+GI1
MZ>7A2HSLA'<D8QC@8'?MGT[9['DCME1$G\SWI6;4S>7HRNZ%J"/UEY]\3^?_
M %7,XU89^=.9X9D/H"/6C^S\,BCH*W&@W<99R2N52/$O)(CERD+>,G3,+M^4
MXZ&%=@SC/.XC@>@]#@Y.<8^"F S\GWJJO/6@3S!8=*4X5(0Z7^9(5=!"$F)L
MR0+/?5$D-I C%3'IDJ+$ILJSBWZ)I^&D[1V;MN5A9X'AZ486'BVCHF&XR"><
M]_AY<9Y/Y <%5&@OR[WS2?GNAUG"T&O4^DZDDJNU.=N[+>VMJ&3WY"+6\X09
M?F5-Q@JLX<*8@P'8V'N24CG<K/D8]T$[KD&!8(2DD5+>3CMSCD 9#<]R?T_5
M=[S\LGLBI>I[#9**IRV+#D?M'Y#(-$BSQG*&<9KRLO'#QEKB!F!4:_2'2"TA
M0)C$XA+"KY/L-#0DNG<UXE;]FX26)M'?L,#XG)SCR_L%:RL_EAM69^MJ=J>9
M5+!*QIJX%:<CH(ZL6,V87ZGEN^<1%U-X*^LBIGTPAD*LP/)B3V+M:TLZ&PEI
M*88%[LL%8ZHTR'%KOOY_)8[1@G.2,_+&0.,\G/?/Y87:>W?EFF?B_P!-]T;(
M:D"'(UHM0=K.)@DJ?UV'\92%*? ?35OD=->UVJ\IHR<0L6FD%1Y00(1^<1U9
M=KVORHX7*M;N&?F!_P#MP0/S&?+R_-49L_Y'O:Y]Q#9M"'<4H^568#^)^=$8
MY-C)TO7$7K'UMZIO.--A#R./T'7,5.GX*,K0;<DI9NFYG8)>4M0*H(L&CKAL
M5#1SDY ZGECEK1SW[9.0..W/?"MKY&]K>G6GI[FH[*ZA]@4Y>OR/?)+Y\@\C
M(R"5.[4@+?S]Q9%G1%JVX7;\Q3FNF "$.H$'BZ'"A,?Q]D=Y.=(** FY8D#'
MF#M!]0<G!^7?].WFM^F%BF$3")A$PB81,(F$3")A$PB81,(F$54_;$+*3+S1
M:ZH.S[8J0W"89+;$#2NG)DI!Y3T6A\0D!(<+>EDF3_MS'7CS2*I85I)/[W;9
MM_ZA+:6M[*M[CXD#MGS5!J(F5W4Q\*[OU+&['M_T#Z'EGA$;ZG'O;BDRUEO6
MMK&O-X:9]#(P.48-5N(<RDB79IG"^/O%72BKQDFZ55?:WHLN"_!  W8X],JK
MJ'KV(>+:1DU_P+WK9?NVQS/D>J[6,>>;(F@JQ8MN2V1;E75DT] -Y;#8S]6E
MX4&DEE=LSM5BUV(XC&VSU0,'1)1WLHTG;G*8R>6[><<9'8$D<D\_J/-1'Z$^
M13U//80H;2*/J/ED&\W?,X$/<UB>(#(Y-)IYW\X4I.JDM)K'2!$M)(3((85G
M+U)K%961>2&)2L><6TZ<L'H]PK4P >.02WN.><Y!R/A^8PKET/\ )I;Q/UI5
M/FFRHG!A%82U6(5A&;/[6E,W,6!82_FL);RS9S84!>2R&0^TGQ?D_P#JM+6U
M&*U-,X@P_;)C-CB[Y@">%,>[D>F3\.<=O/RY&>>,<956?>_KWU[6OL[V%6T2
MEMDPWR#%HS\?13T7?D))BBDI\@U!8,AM0!9$IJ6$$MJN$I59:JPMQ*K!'##^
MZVA%?R.5Z OS;>/*-BS :6M.,N)=@8[D8QD^@]//..%F5G^JK4%>I'E;5S:U
MA-H+%?<K>JFSO]YAJ8L)A7O7Q!2"\ J'#LBJZ[Z$JSG0>:J]<D2>CDK9_M>Y
M>K$""W6%CC@GC^C(XQ@]3']L_EPN+ZANKUR>^%3XY9O2UV6!&/3][-?%XIS9
M@HLMN63"7V%4) P^;GWF^>U"J,PE:3'H\BKSU]_M7O?6OS;UA4!H>[(X!=Q\
M ?+Y#MGS50:E^8;T4ZM+T;Z]8KR6<4W>M<>=N/+5)2IX<0JJK^Y=Z6'^/2U@
MDQ8U'LUH?W8,*L"2F>!_:!&2O7+".,GPGHGP1:DVC(:>"-V3W)P-V.YYQQQV
M.>ZMQOY2KK3L0+;D]6A]8#H+XS]R*R2"F9%.'%$R^W*D]7^;*>K2PWH>"@+$
MLL8N52F;@.E"=Q\Q/(L=D)V OUN7**Q[10-!!QD^\W!QS@M<3P2/3U&<96<U
M[\L'KNTG<;K*+5#0@BWW-W^TZ;D9F:K6('AC77E6D*ANX;(4H<*,'I,)(21K
M9JL/-1 E*G;H,4':**F&W:3L!J9YQ\_TQ_?/T3: ,Y/8'R\R01\>W!X]>1C/
M 1^:ZUSL1"6R"J.F \&AE*^"K3MJN);8$B0NNRR/MSH1QL-YI'M!B8HRSK?L
MKIHV=R-F]7G,@9$(TDC&EVG1'NILP<$^;N?(;?7YGCX=^>R_!_Y8?:G_ *TC
M%Z?\P; ' 7R<2"$JGI!:GZLR&?&M9:,:D3B4LQZ.FCQY:0<@/#A10E^R1CI;
MAW+WQHBQVC",*[1CN?\ 1GX[QD8[]AWSW^"E*,?+G/9AZG\X5K'X/5ABH+NG
M5.U/)_TAQ8ZU@5G8%L>5N_2>V1N7G0L8K\H4CR:PX>O$80)G#;J-$!QL]/(K
M)B7[#L"FW =G.0,CM@C<&]N_GW_PN)ZNM1Q+O9/K6M[O]U6;X,JOS)Y3IJWZ
M->5W-([ N)R4G#BV7-G71(AI<.2*78+K4S"8E"4ZO;=O(^Z4>.!Z@16021JZ
MV\^_Y?N@QAN&@DN(.?RP!Z9SW[Y'PY^//RL6P[]1N//49@8*:5=')74-(&;3
M)HF('9LND=K^;&-UL;Q"BB6Q42! N5# WM"IN1CR9$P+242H8_8) .H]M]_I
MG[^"F!C.>2"?RR1CMWX^'<#'/%'_ #O\CGKV!5I&IJD6(^@Y;)/$GQ7/FT:L
M*3MBCGF;WH2]1<V=8<5@SV7P4Q;MF2)I!P":M>Q"4#IA*TQR9%A]TA'G31<L
MG-'/EA\@X![#;@>> ,GE7U]<>U;$LWX199Z[JF9_L#9YQ.KQ7<EJHI-Z^4CD
MG9^L8/3UBA@I*RHO&YE#G":[2418S^T !70190FW1?R04W;'"K]5  '@=QWP
M<'C&1V./U^BB8A[.MSP)Y'G?H\PD3NQP*NVN8E(*BLSW. ]96)*HO+!A,:Q0
MHR60*%QUA'IPF;4[/DH&;C9G1^%1.62!N1']A..5"!NX@=L^9;CZX.,#U^/R
M7967\O?H&M-2<ML#Y$FP*IO,?C/TQ.VT;GTV;FK?&^FYA(8Q((EYL^JJ1;R3
MJ/\ #,0I&90914X+$'@<>]CB7<S:=1H@:"!R<DN X'D >>1Z\_8/<37Y5O5\
M<"&I$UJ"DOT69_()=/A6DG:7%HR5^R4HN37@E)+$LL**58?J+V3 ZL& H;!(
MD49N'TB>FY ^D+,6S;QW9-@]>S0X\>1V\>?;)YP>W;NN''?F1N8K9'F%M+*8
MK*N*FMD'YT1L:4\R4S<*,=FMYSR1U[T(7DM//I(\JEH1,"PRU-/K.K-6+6PD
M;TF\G4%X9/W;1_LA:,<9)R>/@!G/Q\P>V"#P5$DI^76[)[3OK 1-HG&ZHF4+
M@4?L^JF%826:-3IJ%CO54'I>0'(??,56GE-VK$$$I0 :$YC"Y9$CG!DH0C#J
ML^6&GI@>^_O[^:NT9'.>><_4<=^<%3^6^63T%#+!EA*4TE5Q^E1=\_)30L;%
M0P],]7&:+>"ZPMJW0Q]?3]F[BJ?%CB:L=PQ>/LVKMVQ./VTC:D5&:VXTV+';
M\><-(_,X_3C_  K"_'Y[\M7U-<,KJJQD/.1)(-Y7\Z^DF<E\\R^1RL<S=WZ3
MGO6X!)]G5UN1IV("(R)TX32[[5*I/VTD^F+:G&P 00C !Y[N&",'W<<_#OVY
MQCN5MQPL4PB81,(F$3")A$PB81,(F$3")A$PBQV60^)3Z/$XC.HO'9I$S2:*
M)B,2P(,D<>+(MW*#U!(F%,-7@U^F@\;-G:/#ILKRDY;H+\:Y523[Y(NJE%95
MO.'K<E-:^A$O(M8_)(FU(2B)@9 ];1:9(-6LOC3=T68.UT8_*FS%DWD@9-3D
M<<09M42C9TFW1YX(L :>6_,H^/0Z(L/.E$L8I7A4H=@$8:5%7[:/08V;05:F
MC$."HQ[@;&2I=LX7;E" 5LR=OT%E47:RJ:G?/17)]3]?3LL_'5E6X=[$B0BO
MH0+(P&*JP6"OQT4 L7L+A*Z0Q!>'1)TV8)+QR*K(! R*L>#J,Q"B0@8GVSWP
MP:Z2**+V'D/R<+!RB,#/,'G<=&INR5&S2/,*4K9F#EXY<TA)%A\H$MXTFP/L
MEI"U;'E6I5N[04--D"G:>WR*:_)7)]3]2J.;]$?'M:%TNO#IOR--3\P0F:4X
M)U_-/CXL3NMV))_("D%'WL6(R&I-P9E$#9>,$Q >\'JR4=,)"%N&$G<HM>M)
MO^.RN'8W9[^>X9^7?/Y+8 ZBGG0RRDA5[&J5+#B[V)#I>2=!H*^9%"54.-FX
M(PDCQ9LJ@]>UJZ;]%XDU)J*KPUPAM^&X'*);5Y+%?NPZ]\\W2XCP>V(/3%LN
MXP38'XH*L.,P>>.(\8(ME7@LU'F,E9%51)-\T&K.F!$:DW=.FS!5=NMVDU[Z
M3)D^JZ>66EYOI1;4\D<BKB%/K>M.!5$\E0]J-_59W:Q==I!X)%#Y0"T<$"IM
M@E]N&;J'5>T8N#:J=OW(H(P750*\G\LGY>JC'T3ZB\M>)'Z4GLH<1 RRZ=R6
M5EOW4TM-+'GDP#4[$Q'4VL:;,ZJA\AD+F+57">P*)Z8R?G;*. NQ Q%UKCID
MRV0 G@>7J0 ,G'F<<E0XV]1_&S8GKF# DAE:2[THY$ 6T!O%U13LDU9O9%52
MEV1RO@GI9]!^X\'FA:EW*MDC8*C.69A:'N.G?#'2KC350KAV//'IGXXSC.<9
MXSC&>.ZD#SR7^/SUMOT;8-!0*@;0;.++D-">@;#!U5#'3&U9;&P\0EYP-();
MW'OIV]&T&\KCKE,TN]D,<(O^%.F#QWTR^MHAW# .1P" 3Y<X^7FH)K#T+\=_
MMU\/"C?*Y^P(5)9=-;(:6C;G@R;,//Y"=QU!<+*Y\K<MA56E5O<L<]P_F,[E
M2LCV8,$ ["/)/W#ILU:<3S^7P_?LA#F^>/DX?V!^*V-3H33DVB9F V8,K.70
M5ZR:M)#"ITRBQ^)NQW#3HTR:F8X?2=AUV7# ;V6:HOF?:'+1AT_2YTBUVJG5
MB"1R#@^H6"&*/\GGJ^B-+GZ@\\&:I8+C2<#J8Q7];$:^9.E=D'8@A$8(]$K1
MQNNKOHJY&NPPKA3O?1!9JIO>W/6RN3G.3GU\_3O^B[LE#_.1"-2TD8BU)O8?
M-A &#3M^2"01S&I<!B"C\9&(=+73IKV+/B(NJ2)CP,?,*.V011^_:#VC;ITX
M34*9/K\?S]5RI'6WG^26G"9Y+8#3IZ[(Z.<?NYF<CBT**6F"$<=.5G7[$R(F
MP7EHL=QTY>*N/T)X@VYZ<.>U/PVJKOHKDC(!(![C/?Y^JA6*UEXGN*,5[/G7
MG6EVS?MS,X?7#6UJ!B,.EXKI.=23]J@D<C<[B8Z1!VLBE[4[*=LQ[-LA*.B7
M[7))ODC"9!P3D>?IV.?EV]/T6=R'SOY!FKV1Q^549YMEI&;S#JP):$D-95@>
M>RZ?@6B;3N;2,:2".US\P#,""3;J2$T79H<T?)H[>HHN>>>R9/J?JLY_<)1>
MK)87+JEZGU;XH6F#%VK^[F'_ +R1H5%AT*1$,)S^C_M.S%I"^NAJ8]N43:<,
M.NF?*.F^]IX3)QC)QZ>2[N4U76$Y>.2,VKB!3$@]B1R O'\IA\>D#QW!).JV
M6DD*<NBPYVNO$I"LR9JG(XKWV'+*M&RC]FXZ02WP471RF@Z*G(XV'FU+5+,1
M,F 1B*R07*:YA\A'2"+P@@X+PN-FV18,[;%0$1*NW9.,!WZ3@< (.G#T4W:.
M5E%>BH)'8D8[87<#ZEJH0_%E!59U\,)A)3)YP%(CX9'&3\1-9LS?#YG,!;QL
M-2<#Y3+F!,DQD\@:*(EC[,@^;%7;M%VXX4**0<(F$3")A$PB81,(F$3")A$P
MB81,(F$7$(,&!5@]%E&30D,)-'+ B.(-D7C!^P>(]MW;)ZT<<*-W31TW440<
MMETU$5T5.TE>.N.NN=D7# @ ,6!!XO& @B.1F.BF */QT"-9AP0(&*:),!88
M.('HMQXP4-8H(,F YDW0:,VB*39NBFBGQQHBBR,>;/.L)&SL-#:#I6)"+2Y<
M<6:*C%608"-L7AVFZ2=<3MB*!-&LNY<I/7B3CF0)$-+)NW7"FNN5U==E22>Y
M)QVR5_1?F[SL$C(B%!:$I81#8^$F<9 Q(75L&81D)&[&02:V%'Q %H"2%#0D
M[:H(MIF)9M$6$H0121-MWR:?'.B9/J5S6'G^AA=BM[?&4E48ZVF8="/-+185
MM#6=BM0#4;P%; V\V;A4Y*@';ATTQ* Q(GRR2&I\,$T.6O'*6BF3Z_'\_55A
M'^I_%$YAT&M%(6%-@?:=J23R2Q*/JE<."=MR^LN[LCI.O[!:NP'9$I%0Z=9V
MX-%?M?PO'.V:SI =^+>2I</2RP[Z#=W[ XY_4?%2A603R?)X-74]C%2UE!A,
MN$"9["P\OJ./5?,!R3."MJW'D7$+DT?!R2,FP=<.&E=J)/!K(F$ARJ$/4Y:A
M>TQVRASSS\.^?/U\^>?U7*I^<>8;O!KPZMPL%(@_.]LRVL@\(=PL2&:UY8/G
M*4.:_(.()%" ULF(900\S5$1B41E@W'-$])Z ODT5$_Q(01W\P#\P>1]>ZZ"
M'!O&DUG-V^9HM4=1N3M,0FO(9;L!W34>8QAE7MN=R6R87#>^',80C4BB9@BE
M)94ZC(_I^)82!Z^($F+<L2457)SP>>3D<^8\_FL]0I3RJB!W FU2>?4HQ&XT
M_J3<+0@5<< 0$/FY$>9)UEN.)BM#Q<:EY9D+*OX9]F@+/D6@]\X&NW+=LKP3
M)[Y.>^<^?JOK':;\N5ML6C$ZJH* [$F7P8*E'8-7<6V,D$HC :+$Q(M,:+8[
M9&9%#0D?CKYBTTD]+Q@0&$.$G I@R;I%%%$2UX<G4X/:&UK2#:9>*)R#H<;(
M)'5<-CSJFY+W!HE84?B%5R4V"9[!#$HK.(\Z'(P9ZU&H+NEV#?GATT<I)E?>
MQW.'<]^_<$GZ'NIX(U)0X@8H]+5E48L,*8V(DJ[(PN&LA@T;;+M-_;":B[D:
MDU9L;,?II/;$XZ[3;S-VFFYDNB2W//>BBK#)ROA&O_5-)5E^Y2KR'IRV(GU+
MJ\.PJA(Z?DH&O:@:!8\(EQVQ T84[AD1BB1H)&8<^>&FR#+ARB. I),D5=I%
M1G!YX&!W]<\8_(_115:WJWPS9?J&*>8+B\S6A:M[Q,ZN]@G,Y\'6G80F.BTI
MH&@Y"WH?/3E5EP(JJF$J( VI6Y0I5O!V'UF#M[(TDOH*8S_CL?O\^RHW $@X
M'&<. ^(XSGR5X'5?^;3]A]W*]A-(&K8BR*D'[M9U&X&1L..-WJ:PU6(=SE9D
MM)!"+M)^X8*1_91NFNF\6:]-.^7':?98Y/;/'HL?=TIY$D(#N"/ZD\X'(O)8
ME!X^I#7<"K(F /P2./""M;!.X\L*7'%8D!($2JL'&[9KAA;Q\0[ HH+.G.^R
MN3WR?/GX^?\ NNIM<QX]JVB7D4M<?2(7SJ%/0>JGD )Q2,%ZR''S\P  X)!%
M:]8""01NY4F)&/\ (P+L%RD+>;:E5$F2#/MZW(,D\=^3W_,G/R[J&+>>?'[X
M480.2DZ K>(FIA+R'[M8_0GEI*;6,?E,>@LH,2 _&(G3E>F9/^,5K7B8/I!*
MTV;=H%BK@LT=DDD2W+-\3D_N2<>?F2<=U4B 2SX?N?6T!DD*&PN53^]*^\J-
MJ=VWH;96@JI57&7'97FQ*$2A*JT8?1%PVV&E=B2 (!*2D%+I(F'8Z:!Q9'I!
M(P61#L<^1/S\@?C@8'V#B\=9S?PCZ^2]"417T=I"[8A4MGIL[QBG%>125U4[
MMF7Z6G15\ZX>!7D*FLK4+.'KZ6'&>BKUK+^2;<R^T?;ON$RQY&#R,C(^7;]E
M/3GSCYY>2:!S5Y0U,.YE58L<$K"6N:N@Z\FK@*'_ #:$"(&>5!]E8@+%Z[ZT
M.'QYV.:,?S=?;(I?FW^),GU//?E<,;YA\U!U9VN(\\T:*7M)TW?6:L-J6 L5
M;&>LRG!MH\G:C6/I=RYTU-)\%V[B0;(*H%..'Z7?+OG2NB9/J5WA2CZF)LGC
M=& Q4$^<%)Y(F<CBX$5&Y: F-FB"H.>3V+R@.S:&HY/Y0.-E43,U$/&DD([?
M.>WI%?:ROYRF56/QW\>5,^+3\WED"E%C3J63J)PJ OI#8W=;(.Q<'@!27G8_
M'!0^K*UJ\"MTJ?G4G/2&3G@YR<2PT2[)2>4EG7'"FBI<3\LDX^)P,_0#X#R5
M\L*)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+77-?+UPD?9_H;TA$B
M%=(A+&^/F*>9X"WE2QI_TVMV-V7=DU1(3*/L1B7"U>;;V#'.'BHTXH9?:1,,
MN!K72;9VX*Y&,?'/Y86G6E/A3O\ 0?C&5U0[S0I6IJ__ (_[6L.K!16+$X4;
M">9H+Z-AUS#%H' O,E)5LX:35:RX1S'(R\BI=0_$6+H39$T.%6"KPL_59E_)
M(SDYY(YY(^)[#)\L'L/-0P=\GV&<][KT?7%1,XQ(.?=OIRU&OJT13=VQ>U*]
MIFR?)=I0Z""W\Q*TZ!I[BE:8-FX=$:E7A_H"2]2-5C"A$>@T.)!Y%PJ5W>[D
MGNT #(QD.&>,YY SR!W/*E.MOA-OZ(5( :R6N?.TUF=>7)X4F"=7R2?PAU4U
MMB?+3J6LK+/NOV-\5UFUAAVT $Q=AMF)G&KBL*61I#@3:<VDBXL9VZ??^5"_
M)SSSN\N?>[#EQR >0.,'D+83[-\B_(),X%JFJ5O+J_ZDMVQY/(?2 R_;5#4-
M-=4ZNR:MQOFNH9U2/FZ0O %<S)5X4:6+(BPM]8B\58\Q<-*FO,F*E&)1I;G)
M&,#C )Y]2'.QQ]/@HZA_QJ7\T]10PR3!43$_,K;U=7GN@R/C,SDIF61.=13Q
M)KRJ[\UQN'NZU"1\]7#*0]Z.!Y\[/@>W$&:\B',&:%.^4-$+ACS)V[>0,8W;
M@?GCC]<K8CXO\TR/S:7]B:+MX<PC5W>OY1=M8!H7VKPR 5L1I6BJX"!"0W8<
M0R!E&)*LS?/(81I^*9B.A/39_P!=K+-&98DY#?@,?J3_ &(6J#QA\<'IKS)
M"U>R_P L><;+?O*Z]!Q M-COO_U.?@MA<67^W1B/1N2>6#M,*4R C!UX: 0V
M9N@*RA(4"[.RL2B6.+*"2)9N<#V+O+C:.,#DY!S^GS]565;XR_2'F>JO'E"2
MNH*1]D/V/R,P2U2<H./+$<@;6AS+Q=<$9=QGT8]DT(M5S!XE4YH2,J2HI&3Y
MF<1=Q+BMF9N-A2RIMD6*AX.X_P!/N$ 9\RX=NV2>Y[>?DK UG\*=J(Q@VSL4
MG2C"7:^/B\_/5+R()V9E?/F"[;B]#W]:\8ZJ5<W$QA05#Z<@-M@ZUC,[!KQ^
M9<"!)H: #QX0^0;86._D=R,@N\MP &<\GO@DY)R2HK:_"SZ%U0SB/.HE6[:7
M)7-6T]'5X#NZK!\)$]0'SW):6>SD$!8_'N(\^O3,K>R%)O(XU8'GB8%9%! H
MDB_LAA8;=9X[F._]O+^W^5=PSQG&".1R><X.'9QP#PX<_#@R]'OBK]? ?1GC
MVY^]^9^Y-5,6\@@;AFH[4:=P38V@Q[H5.@U>4A*O-Q@Y!#7Z(Y7#U+*:0N*C
M02#EZN8E$%%]I=-'M3<,$<\EQ'?(SG'O;N>_.0<J-9/\-/J)W6HF%.XUY;MT
ML=\WW7Y^#&[+F\R8]>/Y[8OK*ZKU#>GJ)VWJB1K'IMJ)61$DC#,?U6TJ;S"L
MXHR:S1Y&=N^F[[^_T3>,YY[Y^8P!M//8X^. 3P<X5LH3\5EAQ&]8Q?*_[IC-
MH!?E =^FRER.E7:5KGO*[KR2\I=]!'DB3BFR7)L[9KI:5F*[3+:A*R+MT;[-
M+ENMM.V//[^2A=Q@9_I#2#VR#GC_ #WRM\>%@F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB\ZM3_#/+JW ^.Y<D]"_OTJ+VY<][7.3[O.\
M3=;DJBG1;U$ZC Z 5F;<N*Q$SE!E9]7\&'(>O8>[VX8S)3J4D5'Y%:2ER;^"
M/(L#1P.X#1D_0^IQC\M6OH3PW>%%Q2"^:9!2T5]"W#*/('@.FH3,6U97W-G]
M+3*CKJ.?O '>:;(!44?KA,+.QYU0W:*TULVAW\9!,G)^2CI0 =#A)8L@X$DY
M(!<\D9 R"!C(S\.PSD\>BW6TM\8,XJ[U?6OI;0>F6$C&>_/D+]"V5,P:KSBP
MI51/IV(6D*J*$N3.XDU?&G8"02>)%9!#219*,1]T/>E@C\L21XZ>%B7@@CG^
MEK1\"W&?/S4W(T_[7ISW7ZIOFH*J\]VE4GI]GYC'N7<[]!S:K)O"$:5AAV*2
M%PA%PWGRSA,C4(=29X\%H=RP%SWH:@BX60^_[49%CEI: 201GR!!S\<C'T*U
MNTQ\)%XB!'HZ-VA-8TE()13UK12NKKCDTB;@K/KF,^A1_HJE+PL*( /,5>37
MF2UG-(O&#JQFRKPO*5"C+R7 (<6:PTVHELLB_M@=B#SY #&T')X/P \CR>W
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MV;I<(MV[="O3*2*""*?/*:2**?/*:22?//"?'//'/.N=:UAW8_(_V17IA/\
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M-M&J\*C5J'GDF/=$721+O]K2#0JJP1&.=HQ_A(2*0:.$'#YP[*+4Z@2Z%XB
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MEN0TR/<\@'N!N)QGSPN\S87&F$3")A$PB81,(F$3")A$PB81,(F$6AJQJH]
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M^*1T<C&R-+H96LEC=M>PN9(QDC"X->UKLA<$D;XGOC> '1O=&_#FO:'M<YI
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M0/-PS&"3*HXS0LCJ>2'>(/R <5^_J"&1:&\M6,98'FG(5L::'T3BCH@XF/\
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M/?3A\%XFRJ9IZU1%]<_0)L1_Z6^W^508L0YUM3/C'CY_XIV]=T&3\/\ J_P
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M??"?.^U.^4^.=?CUWWUKGGG7^[\=]=;UK6OQ_E_/>0D-!<XAK0,DD@ #U)/
M'S5 ). "2>P')/Y*J_H3U3'O/[^*L2$9(RKJ4MBCE)4038-N66ABS%'OA?3C
ME3\_2VWW/7&^=\_ETGUK>M_CK>OF7CW\4M(\ SZ/7O4;NHNUGVGH.HOK;(O9
MI*\;NH9969+G6&[=H( :[<0<9]7X=\(W?$<=Z6O8@K-H]/J"PV7+^JV1PVAC
M'< 1G.?48!41TI1M[IVZ<E]Q2!21UJ50D!,1%"$_/RD6W($C+(G'N>XX_P"$
MQ"G AG]?E#ZS;Z#1=-%1LARJFAVGU/A3PAXXI^-M>USQ'KC=0\-Z@-0DTO13
MJ^IW8Z;[-^&Q3#J-BO%28*U9LD0Z;GMB<0(FD8<-W6=:\/S:#IU#2Z!K:K6]
MF9;OBE5KNG;%6?%.18BE?8/5E+7D.#2\9+SG@[!O]W^[/LB\,F$3")A$PB81
M,(F$3")A$PBX1$:P,,'@HJS;$1I!LLS?,7B*;AJ[:K\;360<(*\])JI*<=;Y
M[XZYWK>MYP6:U>Y7FJ6X8K-:S$^&>"9C9(IHI&EKXY&.!:YCFDAS2"""N2*6
M6"6.:&1\4L3VR1R1N+7L>TY:YKA@@@C((7'# A$=9:'!![8:RTLNYZ1;<?E^
MJZ=*=+.73A3K?2KATX5ZVHNY7[476[W^913K><=&A3TV 5J-:*M!ODE+(FXW
MRRN+Y99'$E\LLCB722R.=(]W+G$K*Q9GM2=6Q*^63:U@<\YVL8-K&- PUC&-
M #6- :T< !=KFVN%,(F$3"+AMQ[%JY?O&S5!!T461<$7":?/"KU=NU19(*N.
M]:_%7M)HW0;<==?COE%+CC7\N=:SACKP12V)HHHXY;3V269&M ?/)'$R"-\C
MAR]S(8HXFD]F,:T<!9NDD>V-CWN<R)KFQ-));&USW2.:P=F@O>YY [N<3W*Y
MF<RP3")A%Q5V+-RX9.W#9)9P.4668*J\:[Z:++MU&BR[?\WXZ27[:K+MMK<Z
MTIINX<(ZZTFNMSWQ/@AED@FDB8^2LY[Z[WM#C"^2-T+Y(\YV2.B?)$7C#^E)
M)&"&2/#LVR/8V1C7N:V4-;(T' >UK@]K78[M#VM?M/N[VM<1N:TCS^?+L'/R
M3T)2P =Z=4JYZXJ(F]KND^/8UF>(U+EG;6X(.A)(ZQLR+BN8>>.R.K7TL2BR
M9PX0+0R5Q4']*&$P4[,D6'*C3@$[0?4EN[''&>^!GZ\^BW0>:(A.:^\X^?X%
M9Q-D:LF$4G540L(P-,FI$.+3>-04"&E9)A()(NYD1UF^.LG[IL9/.7!DHBKP
M^*+*OEU^^BP/<_?]E-N$3")A%IRL?XD6\N@/4<B'I"55Q,_WU>UK'3GH^O(O
M(_P@GNU])OWQ5CW&9 0<,.EFH4^U81J:INT2 XB%;%MBE.'+@=DQ^_EW!.2/
MO_99$YQ\ !].Q^_KRL#^4[P+XW$_'1ZLGCOS=3<DM*HO%DLCD&MV3UU$C5I!
MVM45*M'X&\;S=V)[.HD8Z/##^!KM!VDHRZ;I[:_1UQSSS' 8/ X!QQV6*V_5
MC,8A(0 T( E4;.&HS'XXUD@@.<&$RD?=+"D/I-C@]DZ7=B5U?I*_31?I-U._
MIJ?EYW^3K\,RUP ):0#V)! /R/G^2I:X $M(#AEI((#AZ@GN/B%\S=TU/&U+
M"1.S^,BUJH8 "=CH.R22:T/92M%1>,JFD=?BHW[/II=?I#?GGMR_[[12;)**
MN$.%,@QYVX:X[R0SC^HCOCUQY^GFLA&\[,,<>H2&<?U;?ZL? >9[#G/8K%&'
MJ+SP4?0D:PN*!N7]C,G;^%M.3C;E<XW8O2@UWI%-3?&VKE(F#."_LG_VCWLH
M$,C4V_;X4_;MZ8I '$L=AN XX/&0",_,$'/;!'J%D890'$QOPS&[@\9 (S\,
M.:<]L.![$+IFOL'S*[#@I!Q<D0;AI-(%(Q'R!%9Z*;EC*+<6Z729[)LFG2K-
MN@;#]N"_Y=!V^R@]-9^FH[0X[=&7)&QQ+1D@#. <XSCUP>._"O0FRX=-Q+1N
M<!@X&2.<$\\'COP>%9/_ '_[LXUPIA$PB818LR@\*&R4E,QT0C#"7F&_+4O*
MF8$6VD11MQM/?+<@:1:\$GB.OI)?^6X<J<?^2C^.M_23_+D7O+0PO<6-)+6%
MQ+6D]R&DX!/G@+;DU"_+4AH2W;<E&N]TE>E)9F?4@>_.Y\-9SS#$]VYVYS&-
M)W').2L??4W4Q,V4DI&M8,^D!Q!\V,&G47#+DR:!,=^CDN'SQ1GTNY^_$[V,
M>]*]]=NA^^F:W7;?K:>\A+*&AHD>&M.6M#G;000X$#.!AP!''!Y[K9CUO6(J
MT-./5-0CJ5Y&2P5F6YVPPR1RB>-\<8>&L,<P$S, ;)0)&X?[RY1VJJSE!-^9
MD< AYTL5$K@29(M'A;]Z0"N6+H8X%/7+EJHJY8+#GKQ@JV6Z[2[9N5VW7.T5
M.N-P2/: &O<T-.YN'$8=D'(P>#EH.1R" >X7%7U74ZK(8JVH7*\=>868&0V9
MHFPSB2*431!CQTY!+#%('MPX21L>#N:"NN*4E3YMUI\6K*#D'FMK[TZ=1H4J
MXU]SM#;C_P [IM^?\%MMF^U=?F_#O:"6^OQ^GS^&39YF ADLC0<9 >X#C..
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M)ZPA3DO7SXZ<HJ5LQE:G%BS#1-^[?L71)YD+$8)X<?Z27&.,%Y!><$ @-X<
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M9F9U<1!\M5CIXHR\22L'\MCB0#]D?1M-]?2[5DSX8W<,NB2S\W"YS'A;!/\
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M*1&,L?NHH[F@%NUG#3[N'.)R#"QW;!?K5WC2[;@.(P<XW;>//&<?W/R6Z7S
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MXR:YJLM,49+DIK"4RAGNAV\N+\=1K1)L#G%P87[03@   #*+PYHD-]VIQZ?
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MQ$\22-A<7N<S:""UG969[]?5EZ'J^AS'F^VN%+!X;*+FNN@)0@T;.R3H=T3
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M/BZ=J&5TL9F9+%U(V,<]@DBD87M <Q[26G<H3QUK<<TK0^-C9@YAW%K]\,C
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MZ?)R!]TJ)"])Z>DFZ[9/M/9%:#^'5(OZC'R3_P!\*M_P1A$_AU2+^HQ\D_\
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M+^HQ\D_]\*M_P1E43^'5(OZC'R3_ -\*M_P1A%5;S?X^O:R)MZX"61[U^2(
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7B81,(F$3")A$PB81,(F$3")A$PB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g107876g21x97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g21x97.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $L ET# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            @)!@<$!0H" P'_Q !9$  !! ("  0!!0<1
M!08$ PD$ @,%!@$'  @)$1(3%!46&"%8%R(C,3B5MADR-T%767)W>)26E[?4
MU=;7)%%VM-$*0F%B<9$E)CE2,Z&S)R@T-39S=8&X_\0 ' $!  $% 0$
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M;6MC!2]9"K%9BJ:F1FA_E=BTR:9EX.(!!"RB1>>"LLS]PJ<ATIC7GVI5@KJ
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M*TN%(SC(MI%CE!;HI!4GV;UH_-L=:@^(+&:_QS1VXYI8I4G2/8!DY%=&0$]
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MP-FXGZ<R]>L2$J7WY$E5;>E9CTKK?"'9#G.(,?\ OBSEY9\&\(1J)).(,Z1
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MFRPKJ-6/FP0$^9J<L,)B,9(\UACK6VGD7EDN$B#7,B#J$>Y?FG= ?!&D*CR
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M1ETDLD !+@B#%GB2.-L/3YG#RB"W@B::XF(WR1K[!T!8^6SH ,W77*>@=G?
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MM/\ Q?!_\+I\YO%8_<[Z>?G/8O\ F_CN^'/Y1E/P(/\ 94^#_P!SK_/G:?\
MB^#_ .%T^<WBL?N=]//SGL7_ #?QW?#G\HRGX$'^RI\'_N=?Y\[3_P 7P?\
MPNGSF\5C]SOIY^<]B_YOX[OAS^493\"#_94^#_W.O\^=I_XO@_\ A=/G-XK'
M[G?3S\Y[%_S?QW?#G\HRGX$'^RI\'_N=?Y\[3_Q?!_\ "Z?.;Q6/W.^GGYSV
M+_F_CN^'/Y1E/P(/]E3X/_<Z_P ^=I_XO@_^%T^<WBL?N=]//SGL7_-_'=\.
M?RC*?@0?[*GP?^YU_GSM/_%\'_PNF;+XJ^<9QG7?3S.,_5G&9+8OEG'^[/\
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MI3BE.*4XI3BE5N=Z?V9N@7\IN(__ %(7D_AO\%S?_NZ3\SUW7LA_Z+=LW_X
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M#'J/R/:D/15>$K#Z,VM5Q&C)!V!@%.4>_P"XWKKOF /0>T;Z>.ZP^H>,AO\
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MR&B)$K"<Y3DV4+]^1.7C.?<,*?<_[W(FYG>ZGFN)/CS2-(WL',=A1[E&E'N
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MJ*E9V<E"18N$A8YDF3EY,H:/CA22R&F5W)/B-\U5 ).AU/[&O/%VNU9<]@^
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M'.XCQ/S_ *!6OGXJ_P"M^>I]=>=2V#4T7=0K 9%F.V"X&3 &8MTAU"8[++3
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M'2>W8KJ_WELU<Z_;IT831.V>S]J6JGZ!E=B[X8VAKW8M.V!(:VL&PMO2>O\
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M,$,>(LFYH+9N:YE&MW%S]T21XJAV -D; 4=(U)ZIVH\18C"XK']E'!TXFP>
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MV4Y01U5&&P?#F!8GEC;?>^R_AC'<.XR;M;XVA*X+"R?\U\7* DW$G$"%O1#
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M/'>?&9?.=$!>0(T\2.TX^IM#C[*,J<3B6\+W,\-O'H//+'"A8Z4-(X12Q )
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M'0>J"!T UH"LKY:J.IQ2G%*<4IQ2G%*CKNC>9=)EX?5>KZ\/LKL'=HYV1J5
M4>['P=:KR"5 %;1VY/BC'.4?5D*:E;#DED,N?M\LPNIT&&L-D4\*&I].OV\*
M[#2FC!-7*G[?:+"1LK=NP4@/;/VW+@-QY\]F-R2Y$52JPJ"3F*'JJH*//8HV
MNXHTH2)2;)3L])VB^V.X72R*J3]7[?E_;PU6^N*I5.GA<?LP>(1_*!S^E&U.
M6(?&3YQ^=J5-GO;^1UV-_BKLW_*XY<D^(WS4K%?#A_(DZ^_\*ROZ76+E(OM:
M_3_:-*K*\2W8YUD[^^']3]$Q,;MO:FO]EELV&!'E30Z=1)PJ>U_8HP';%UA(
M6S_,G*H4%VP&PP\/.75JL^B?'JA$2\T=G:</<+%BLY%R,[RP*-C01%[N=2[N
MQ"CJP5$7FDD8@*I 9E^C>R3.0X_LN[:L=Z//<7.1P=N R&&&VM+;T++VSW5U
M<W,L,0)FN(H+6TA,U]>W#K';VS1I/-!L;K37-CUSQKNS#>U]B#;(NTMX=_7^
M:DY&'JH%+J, DO>NU&&:I1J^P1*S0M4B<"*=$?N-IN-K./-DC)"Q*$?CXF)U
MJOG0_%77RF_,E5\0L#-PG@Z>,DB9AY.)6IC<XB420!0*E%1U1%8D!TI)::RI
MX)Y:&2V\8RL=U6&W<)7GRYMG%;H\V.Y'5M6"$\K!M!F/*>A/0Z.O;KI7U'^Z
M?O+2[S?9^;6ZM[D#@FQD)@FCF 2:ZE:%R8V8!95!:-CT=02I(ZU-'Q2(*;G>
MA?2IF$AY28>3<]),*9BP"CW4O2&HIL$%I38K3J\+,->9#%3G&,OE/-#M84ZX
MA"G"+HE[>%W5 ;"0@L0-A98B?'V#9/N!/@*\_N5;NUM.,N+6NKFWME;@G(L&
MN)HX5*Q9+%RRD-(R@B.)6DD.])&K.VE4D>@'FIU\N52WT3@YH#Q'/$C..B),
M,)VQ0?M%E %#C._*4Y+2,?EM]UI#2\'1^<'"90K/Q(><$L^MG.%\VO,.C8'
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M31\1O][_ #/Y_/<=Y)][/U-^JE/IH^(W^]_F?S^>X[R3[V?J;]5*?31\1O\
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M>UY76-?RL*Q+^\AQUC>7]P>6"RM9[N8^&H[>)Y7\?/E0Z]IT*@OX8%2EHGK
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MI@=AIQY]]YQ+3+++2<K====7E*&VFT)4MQQ:DI0E.5*SC&,YYY )( !))
MV23T  '4DGP%>R0H+,0% )))   &R23T  ZDGH!7$C)2,FX\26AI$"7BI!E!
M($G&&#GQYH[GZP@0T1QT8EE?EGT.LN+;5^TK/*NCQNR2(T;J=,CJ5=2/$,K
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M RF3A!31LK4.8.P4QEUEX=S+)#27FLN#D(:?87E"TY6R^TV\TKS0ZA"TJ3C
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M_P#5[6_[AQW:?)%*?0IZB_9LTO\ U>UO^X<=VGR12OA72;J$K/FKK3I16?\
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M; PLK*(LS&TLY(4D)WMZEU/&A"E8)8M#E(9IQ<AZY+3BE==,2T? 1$K.RQ*
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ML!=H/S"3_@?'P-:_SWCOPQ_?I_!!PO\ Y9NS_P#&T_WNGT[=Q_8"[0?F$G_
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M>\=^&/[]/X(>%O\ +-P!^-+_ +U7;5;Q H]%TJE/W;H#=/7EB]2K%?J=MV)
MK9J1T^2I*!HDV54P#D!TEQ;;;;R&"V&,N)?D5@ I<,;\R81C%++9WMI?&%2\
ML4#@RA!XLJ[;F Z[&P3K2\S>K6-D>QB8XK)9/A/C/A3C9L/;/>Y+&X2]#9.&
MRC!:2YBM@\PF2-59BI>)WY2D"S3<L36&\@JXG3BE.*5@&U[)*T[5VR;=!,MD
M3=6H5PL<.PZRLAIZ4A*](R0#3H[?X1]M98S27&6\9<=1G+;>,K4G&;]M&LMS
M;Q.=)+/%&Y!T0KR*K'9\- D[J9X=L;?*<08+&W;%+3(YG&6-TZL$9+>[O8+>
M9E=O51ECD8AFT%(!) !J!Y] JK>O=S70NS01DM0I:>&>K5FJVO+2N^R,"(R1
M7)#94W-5>5V'8;)N+UQ\W6RZK:(!47#62J1%!C1G8M&)*96>7O[2$(ZK,J$2
M1RSQB!7)$BP1I*L"1VOK)()(WYF21IV/-ZO8(<UD3F^%L5%87D-MF;>SD2_L
M,CFL>,/!>2LE]#@;2UO[;"6-APO]FL[^/(8^\%Q=6.1N<U/(MP?1]QAPT_:M
M;' J=F[$)2+7M/6N#'5YL-E*I9;1T"@E.27\N6V?H!:Q*W,X(+>E;2Q6+$AU
MZ0L$CEHSE_:1AI\E:03VL,LJ^A7]MD+:SA6>Y2RS>,DLY[RRLB8UNYK6;T6^
M./#(UWCVO;2V62>6""73;^:TL<U!.J6MG)E<;@<VT*(+.QCR0[JZ955$"X^T
MRT:OD+41QI;V)O[0(D5I"K1]E8).S[;;&KF(<%HG,78(;+\,'<U#".6J#,JL
MK-V(ZUTZIC5T"&A)22D!J?EZ:GIR=^2ADX'&B29!W0\G=Y?C58<9Z#;I-Z)D
M[$RV$&>,4#9G'SX>\R&4N,S@L+%C+:QQ]Y>7,6#,E_DLCD19Q#NHK.6XDC[6
M*SPA:Z[^1D[ZUGY9WQX=ULKF.\AM[6*SO[U[J2XN8(HFO@MO;6UL)G/.TZQ+
MCVT92V['VPO64/-9AHJ-G!JF(&5)6B,A")8:@A;+LUIL[%+L=.LUT89AK!5Z
MU4J*Q;J[!/FN7.R6-V;3"1<>%](6,=O9V O)(N\=XFG9E2!Y0ANFLH((&N8;
MF"V8R133SW1MYI0OH\,(B,CL_$<K->9++G&13=Q%'.MJBM+=0P-,MA'D[JZN
M5LKFRN;U5AN+6VL[!;NV@+F]N;DSB"*./\M:F62C[/?U-9)%FRUZ9EI"ERT0
MHVQSM<S(&:_?V- 6&OA7FP7.Q5../K\5:*Q<M?GVNRP#)C5/GZ\[#LSTI'GU
MO5@NK$7T4?<RQQK<HX2&.;D6[%G-#,UM%;PW#++)!/;W:P0RLIN(I1(8D=/>
M&NK_ !&:2Q-T[ 71@!BGO&2*Z%B<K9WUBUW<W=Y8?8H+FWNK(WMQ%'*EE=6C
M0=_*CX3#]QO#JU?OG:N@*39-8P^^=90U7?OE#U)KDFPWTG-G)F<C52%KNKJM
M-6JZ6."S#-FVJI5J+F)&IMSE<<F@PGYD9OD!+<W$PU-/-*H.P))9) #[0&8]
M?>.M=-R.>X@S$4466S67RD,;F2*/(Y*\O8XY".4R(ES-(J.5/*7 #%>F]5M[
M[NF^;W]YIGJY8PHYW[X6\]E;?':-K1@B_O<&1E+@HO:>[_C6?K<S!7O5VLUD
M^2&,RX6'5DCV:A]#S/7V#K^7P^K=/N(]@;Y]_N+M#-0T:[]Z11^LU+C--P10
MCGWR@)B]VV0VQN%\MC.<-IL&O[UJ=\CT9>3% X=R,VIL>SZ^OU#I^7=8EL[J
MGU\UYI7?%EKFLH%^\E:2VF 7M*YO2FR=O&ADT><;='D]N['D+5LN4'\E*5AB
M1M13*%*6I*$Y6O*LNP)%]9$>(N[8C7CL3)6T\"R/%QMP=(A/-'Q5P\ZZZ>LF
M6LV7H/>!62] R72NG&@'7LYRM-'0-CU?C]H.6E!&,?7^UAAAO"?_ "XQY?5S
M)S8 RM[K[]OZ2BD_E-;'VS(L?:AQFJZT<NSG7RI;:WE?Z>=VW[ZF!R+KF5.*
M4XI3BE4LN^''VIIFR]OW'1O;8;6L)M>^S=T/C0868%,=Q(S$O+1PDHH8@@<E
M^(3-&!MDLJ;0^E2W_98][V&L<Q.">5@ 3OQ(/TZ'Z?;2NX^A=XC?[X 9_,)[
MCNY?E_UF_52GT+O$;_? #/YA/<=W+\O^LWZJ4^A=XC?[X 9_,)[CNY?E_P!9
MOU4I]"[Q&_WP S^83W'=R_+_ *S?JI3Z%WB-_O@!G\PGN.[E^7_6;]5*?0N\
M1O\ ? #/YA/<=W+\O^LWZJ4^A=XC?[X 9_,)[CNY?E_UF_52GT+O$;_? #/Y
MA/<=W+\O^LWZJ4^A=XC?[X 9_,)[CNY?E_UF_52GT+O$;_? #/YA/<=W+\O^
MLWZJ4^A=XC?[X 9_,)[CNY?E_P!9OU4I]"[Q&_WP S^83W'=R_+_ *S?JI3Z
M%WB-_O@!G\PGN.[E^7_6;]5*?0N\1O\ ? #/YA/<=W+\O^LWZJ4^A=XC?[X
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MTK*" 7Z?*#.85A>,;%<_\G8>&S\+K(L+JX'@R6ZZ[F-O CF(!UKH1*I]_P!
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M7D+<RAGO.&[]V)7*8T@/(L:RMWMQ!$&97+W$$<C275K>YWU@[?4WL(.=5)<
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M:7:D@?QFW5CH_P"C,:_6#[]FNP8SMYXVO'M<=Q!:\+\5V[NL7_.' 6URZJQ
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=2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g107876g33z96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g33z96.jpg
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M&"%669/4(G@C,38X=K6VUR1!46&!)C)Q)2<WD8*AM__$ !T! 0 " P$! 0$
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MF =#R'D&8-Q;/Q\R+W->7?7S3$4!50G-)%T&A/( S<OTKKO6Z(_7E\7!\<M
MT(9YS:QHNT5VQ6D3UD;I479VQ 60TP+>05HLHZ8@!(G=&6N>[;,'6_*+C(C^
M!"+Q$/+F_P *57MWVIB(VOFG NO0HG.C]C0_JE]FIGD.712S'SQ$;5K-UV7Q
M.9'>E:C"P5F49&2M  \@;[)UN\.=N=M06@GER[[+E133EURZYU;J1 1T8L#@
M5Z\^*-$Z17*_RRXW .V%EV^W'G$;68C$!ICZ:@16H0M%X"30K-EB,KVR$"-1
MG8SX@ 7&H=;.QT'V<QOXS=%'@/)?+T 7YW#B7.QR:K])^/ACH6S_ $R;8BD?
M]!W:K*ZL)&3C1(J5FQ>A%;3>IM@9^D$P%".?A:^(CI&F84),W:;WX.M86S-]
MWAIER<JK9V7DN;GDUZ=?(;ZK9#GFK)A$PB81,(F$3")A%K&]'1_MAYZ_YU>L
M_P#,GLR:C2G_ ,!GV+7< _.8U_WBL_;*V/69"W*Y8&VTJ6M80JA"$)VI:UJ@
M2$I2E*=;VI2M[UI*=:WO>]ZUK7KWF.-1XQ]J^_)^;?\ ]#OL*T)O4RY>Y)&U
M1%5LR;6D\I?Z.:!E=6!&OVF9L_3FQ&HOTDE.H6TSM+^;ZUJ)O4G6_8[TO,\$
M=NN-Q:VMQ;\V!KIKDM+,4ON0;%V.3LF_^;W';_\ S N]Y;>TSTTST60GEO1N
M8<6.^-7.:QQ#FU2Y@_/OY"9U(SQ2V]GK%$LKM:#"FVD\JITR&-L=TN[0X;$;
M,V^(94N1#9)QHSDP=,FQ_*)SWB1Q>XOLVS!(&%P!-^_=F&M!)L+7OFLW%(:>
MD?A]/'1T\=,73N=4NHY:R."3L;&C_A8G-;)--NM =*'FX#@"6N(PWH_+C9_@
M7CYSRRT6U2@K/I1F(5EJYJC$ZTJ'S\I&:9);+5-,5+5:KDR$0EMSHC:6PX]4
MJ8/2_P#Z%S/9SK2R.#A?M0D.#@Z[A;0\IRRXZV7RHJ=SZ"B@?!(6#:,-DB?"
MZ.T#A9V]%;\G&6N(<!WC;EM\BK\="XJ#&7OTGU#$\YZ-7>4V&B^-LX6%X/1A
MZY3L\<*'FRD^GU5Z;6*Z>8@F/G$VXAQA"/)E"'SK*?DRY.]Y1KR6TKBYI>'2
M7,CC;4@ FQ(RL&DBP-N"S)Z.-LVT4#:>HCIGPX>6,H86[UPQKW.ABWHXWAK[
MNF8UP):7V[XW4(X5,.-,^5@\37Z%T&E;\.NBMD/(*G\"L7CN0CEH84DD7SNS
M5B0)KE2)F5P]/$Y2@8:9+:1'8TH_(8A2(;*6V['FYI[*+1F02Y?"!N2!R $\
M<L[KRH2^V)-:R&>'VJG#JZ*ADH"'AC@VGDB+(XW/L"X[C20 ._(:0V#<1%T.
MX@/1V5SA/)+-7/(2G=+IUXZ[>6>=FP'_ .U;"9CUQ-6+H;PV,,M=<N YV&JN
MM)-%66AR'*PVV,?ELBY-W[S34&1X,;FN:QN]?O\ += ;<EI:=<@,[BX7C2-A
MECP*.BI9(ZZ*IBFJIQ3OC/:PWNS/DJ-P-DCF81V/OW=[^2&Z7 'IMM/KL'G'
MD[R+IW#KU;/.6]]RL)KF=RB\W/&#MCC$;$&DU"W4KI\<>Y! 5 7#8FOS8;1L
M9%;B>T8>BKUN0U! G>B>V1H@:P!S=X #([P<SE)/,3=1+%&*?$:6IHII<9FK
M)'T\HIWODD#I&&*2&IM9D+1O7&^UH%P6D7 K'E%32-0Z=?S5@?G%^K6'D_)H
M=KHW9O&J5UWG_=+56*' #R(W$.ITYL]9JD_)*0?FY:.IRC+U8YZYCY?<:$TL
M0B=O-;:P:'NW2R3<<P.=?OVNL'6!%K;UQE:YSMB43HJF=[RY]4^EIFR0UE Z
MJ@K98X6M(HJF+?DAN]O?C\A>5URZS1NW5\@R9*SW+D];Z)P>M<V,E?$ &P+.
MEN$WKR*-R;F20GYUPCFU<;(OU2H'A$M;J-6.RCB9\3\K2)I&-$F(5-I&+->6
M/+@)B;=D;&-T?^X\^^<#ED" =;+)KGODEIHYZ*.G>["V;KW44U>\RNM>BIX]
MXQ1/:;_E'M>]FCG $$V.U3VHWCWX06>UDKQSJT4_GW4ZXU8;_P"/">Z\1B:>
MOAY*ZA>*M*C&K/4+3.B18K8<M'I)!N:&5$3!EQTP''XOI<]DG#0U[2YA(;)N
M//>ZM((! Y1?7D*P^Q 46#R2&:"2*"IC$D]!VY1B\[[Q31D/DBD< T->(7;S
M+;I%B6U^U@^I'O&_PULMDY,'YGR3GW9NC/WD(.Y#=KY0$B)JHGZONM6'A<XO
M#MDFK39SEL?E#ILIAGVA1!%B!N,=@A)4 @2S /+GNC:&DO:UQ.KF"0#=!&5C
M;DURNKRLJ9*#"9)*5E/2P5=1V9C:2:>#==N]AJGT;G-E,3CV:X) NX. []K#
ML2]''5= J=V,Z&)V"51KKUHJ>JD&=QF1PVH-.ZAL13)GF5,(W>WEF*,>6W =
M'?/XM:W%?AR8;8EMQB0U&QJAUW,! WFL /?]D/$!SMUH+ARVOKJOO8!'N15;
MV.D,,M4Y\374AHX@; /?3PNFE<(9+-+=X1D$$;@((&QS,=??3")A$PB81,(F
M$3")A$PBUC>EY_W)KG_QCSW_ *EBYDTGY]OB=^R5KVU'_*)O\6#]X%'/0N?[
MAE%_XVZ5_P!53,VWV0?[S57^7H_W#5J7L0_W(HO\YB/_ )3UM<S25TY,(F$6
M*9GSI\-*Z8*5\[Y0<-$' A*<',"2/2*O%(#"HR2["(CYL5XBEZ/,@RV78TIA
MQ*7&7FUMK2E2=ZRXC>1<--CF%7>:.7T'J4XNODYX\<X$U,Y>NT\VJPN]AX]B
MIDDO;!$;=IKLJ(S.9L(*/N2J43 [AR(\IPS%9<&L,/LN/RFTNM[54-<= 3R:
M:'@>"DD#4\_/T:JVGDY;O$SH7!MU7NO9** X[W&%"8"69'0@0.!;XHN<,M$=
MRI6;YS(@$4)6/A2EO#URD+AJ5OUZ0Y\O6=AM;5896PUU(&BHIG.='V1F^P%\
M;XSO-)%^]>ZPN,\^1?,QG"J/',,JL*K^R&DK&L9,(G]CD+8Y8YF[KP';O?QM
MN;&XN.57>XUUOB?4*]N+Q3J-%Z6'IL86!GN4RW!;2\%TU#]B-CF]"9<AV!)E
M18BW&-3FHZI:6GG6$K0A>TXDKGOD?(\6=(]SW96%W.+C8<+G+5?0A8R**.*.
M^Y%&R-MS<[L;0UMSE<V N;"^JFT&]TLG<#O/A]KK\V\U<6)-V*H1BL)VQA0Y
M[<E(4H2#H>W.B#R:HDE,*6ZPEA]3*TH7M6M:W2QM>QMQY.E>B]E?M5:M:3"Z
MT=%'D5\^5JIQ0J:Q-T)LH-U+!D$0VPM>HI48\M#4Z$]\E^,XI*74)WO6LA%7
M\(F$3"*@3K56QE@ U,@=%0K-:8IN=6P,F:PR6.0ZV@>NP21<%:]2)K 9!88H
MDXPA:8B9\3;VT:?;^4L=;9#4\+Z)^/QTJOX1,(F$5!&6FMFB]E "#@LD;ILT
M>.M8F%-8D3Z[/+"(1\9#,16UJ=@2)X0C +1&I"6UOP)D:4WI33J%;6/#73G1
M1@WUSF%<B72>=OM6%0^<$A0>^R)AB&TW3RIP8(-!Q]BWMS_]*EDA%@"$X;,O
M32WX)6!*1K;,EI:I )M8'.]N>VO1902!?/351P'Y&\%LL4E- =?YX5B!J3/Z
M45D0[2)<:'<]%R9,,C=I:OG.M,5:%*ARF))Q?J',NL.H7(UM.\%K@;$$>1 0
M=/QKU%77#EQ=@$BSP,A$+!38Z$7#E1[[<J 3%DHS4T>0A26E*:D1)D1YF3&?
M:4IMYEQ#B%;2K6]QIJI51PB81,(M4/I-/]O_ $<W^>[CG_.H.;KLC_9-K/\
M35?^P5S'V1/[?L!_K3"OWK%M>S2ETY,(F$3")A%1CU= V@>@59 XTZ,;)@S2
M(!6&Q.B(+UDV.LM=)I8D(<;U."6$2+-"Y.D^UA$Q\.;'4A^.VM+\=.J*#]#X
MCQ_K3XV5T[F=(ODH/'EPALFTUP88DQ1Y!3*R0I$B9'=>4')KCQU$P[BUC"*H
M[&YL1_;+?R9!(T)'B-M-$5;DBN?T*-9;O(&UFJQ8M3'QK58_F4 6RS2Z'%-3
M!<4K,0TTA "JPRIY^!&=WJ&+8GD=QVVD2'M*C,\_645'K-;Y(0K(ZEU4%3W:
MKS<S7FAU2'#8#0ZAV  P%N=8A( :9;U5S &.2KY\4.<B09HAJ4,DLQXR51_5
M.>N=SR\;ZHORR\4Y#<9E@(VCFM*.$[6JJN6,I/KHQXH9?HRB2J9)GD_F^IS\
MNJ_3)9%?F*D?.A+1*<S"=9:DO(6N1;,Y:?QZ>5$#<3X_7!TH17^840&)F@[#
M6I0P35@XX>_7K;,00M -R%$B-1MBK#/;1-,P?9ZC$9:?G$IMUW>U[7/$HOS]
M2?(M7"+T%'-:2W>8+$9B#;$5L5H[$W"#JKT&2Q/^:^V1/@U]:P$(CI7S^*#6
ML,Q);&K7%4N;6N;<+Y="* \=\4^(\8YY5:!7Z%5)NJ]7N8!R5BF5D(T;M9'D
MKXHM4;*==C0VVW3,"VB6KQ&6REMF%;Y$L_$;:)27Y3@N))).M^/+J!S<GB12
M"-XT^/<1TN]'XIS!MP] /"#"MTL"O4\-:'M2;$$?0Y!6C80S*UN80#(2D9)F
MJ7,<B;E.+=4N>)Z2BKX#BG(JK%:AUWF]-#L,Q+/ 3J$ 'M.N1+JD*W;VI$CV
M&Y$K])FJY7V3BY+KSA-D&)9EK=:'1$-+GB>E%U5RH\>M$8#<ZW5Z>2;BPZV.
M!&HP.&B4.C<Y=M8NLBFMO16I@QZC2K3=1<(4^W&E5N8:L8]4:'*DD&=C?0D]
M/&V?EL,^7)%W47BW(^8D")7G7-:32"1:*U (SJO7!865+',2')<48X]!C,K^
MBX4AUUV ,3M," IUS4..QI:M;7)U)/E17.R$3")A$PB81,(F$3")A%K&]'1_
MMAYZ_P"=7K/_ #)[,FHTI_\  9]BUW /SF-?]XK/VRMG.8RV),(F$3"*,7.Z
MU'G58,76^64+3ZC7XZ)9RRV(C&%!1,9R0S%;?($9CC4:*TN3(882MUQ*=NNM
MHUOY2]:W(!)L!<GD"$VS*L2+\@/%?R0BV3CE/[ORV^$;K5+&$(5>G="KDZU3
M*^3$RAYR2*'19SQ%WYH/E/./2XL20B!KY+[_ ,E&M>NVZYA!+2+$',9:_CE7
ME(QD\4D3KEDK'QOL;'=>TM=8\AL38]2DW&"'$Z1P\3%YE>0)?D/*0I>NJM*;
M./-#@L&@*F1+&V=/1W-1695=7 FH-;D^P7"5&=W(0WI/KP\N<XN<.^<;G*VO
M **>".F@BIXK]CA8&,WCO'=;D+GE/.IU8.I\VJ@&L6BSWNIU^N70K7051.F#
MHX<*LAFW)TJKBPLZ5(:CD9Q]&_EBHT9QQV:WI3C"5H2I6JV)R )/"R]E/<A%
M1 %D VF')(5PM!-0(A<V!D31SZ9,5LS6RLL$?':D-^MI<H.;'SQ!%MM:_FI*
M%+A.[3(C/-H?CIT15O")A$PB\!4H.!C")HQ.BC! B!,*%"4YY$:$/'#X[DN=
M.F2'=I;8BQ(S+K\AYQ24---K6O>DIWO"+\$EAAX4,.!9\0J&,CX1823@/MR8
M)(81C-S($^%):4IJ1$F17FI$=]M2FW67$.(5M*M;VTU355#")A$PB81,(F$3
M")A%K&]+S_N37/\ XQY[_P!2Q<R:3\^WQ._9*U[:C_E$W^+!^\"CGH7/]PRB
M_P#&W2O^JIF;;[(/]YJK_+T?[AJU+V(?[D47^<Q'_P IZR:\FF/-!V^>.ZO%
MN;S:+06K\XKR';O#3"R4BD_.P&XZ NWV'G_FVAJ;2F9H&Y&L&RJZ_P#-7M0-
M$E(TMNY9V]>]N]MQX?9S:KIIOE;CGXEF%E5*8181]C0C]N/PG_P)_?SWR\WO
M_#K]^_HGBG[]_N_?_P#.6'O7?_7[5!U;X_X%1OAY2K@/+_S;9Z$1"C.GD3G*
MRU,?/RX<&?.\=HW)JQ&!_HHL@MIYVJ".DQ>FILB1F]P8EJ>ER2FD2)D5UZ3[
MUMM!>^OOK\O)I:R#4WYK::<G2;ZK&^Q$ZK8NF>%<OPIC4JMAE]U\RVZ\0N .
MSS^7F#2*/;5]#L-5@A+ ,D$*D</JL+];GU<G"K+LU:Y(V)]'I4PY< ALF_?2
M._$9Y WY=->15Y6V'*[ER\FM@KR>*RKD<\L_(H[Y D*F#\D:U1*)0$T3GU9G
MUVAF^(M'K)8Z;U@ :.V*P'^B+L!DF3 E"$U -5 )AY5.>#;4\P7+5=[QN[<M
MN3<ZAULQS<1QO>^JD:GD/VCD/XO;16FZ#SN\2/-#RC[]QB*\0[7P:H^-1,/5
MFI*HT?K?.#M:Z*KI?&2&][5'U(MT ,,*TTA)9=T&Z%7*M-VIJ"LE[601N-!T
M<7>0BUG>2YOQ!\26[XGE#1;RW\7!6OY%W5F_4-2.46'KB'?(KS=\F;+6*IS-
M-+H]XNE8#A-6DB*-7SI183!Y=!KZI@PI8M"62%X*2A^JV%C-QWC$IF=VQSMW
MK6YFY N=;#7RY9\ILIO>VN?DMR9\O1P5;XYU3MO7"W'N4$>W7P *D>4_E=RB
MR'JS::;9[L2HW,.;1[A7JK-Z/#JJ!)4H&-2%AY5Q&!6##HZ.\B*2T4]B>1#@
MT9@"^ZT\MKDYY:BX&G/J1K&=[$GEYLN]ZR/][6FU'Z/U:W7CFOCA;.X7L'45
M=P\SZ/,ZA$G5\-T^^QN$6*IL\KYK+N2 :(T8U- 6T\;,%0@T99K,/YPK2):$
MNV!R4L+%VZ+V:;9V&]>YM>_(+9D G32SEMF+<N5S:W'QYY*DU;JO2;[TGCO%
MS/D?;QE%=[YY<\FA]&!SZL%MW;ZKR>O44U31CEIC TC%V0";)V.HE;-4QXPD
M<33#>VEQC!"7,:G= :7;N8#'6.@)WKY<#:]CZ1JN21P[Z^?)E8BW1Q&?C43:
M[6<%WGGUYNW1")X'PD3Z4 !6.T/@QUH,6"@<HB<J6*N,L4&0%#7<Q651)];G
M.#DBXUM)5)]Z0['ED)DG2V1 &9,=QI8F^7-?7F!0:\N0</'8BQ\O'BOT5VCN
ME'O<8"YU6\4=GH/ACY =20<\C.@\LZ,V#M5-%T&90NU$Z?RT<>'<RK4:18#T
MLD"%'#M:,#8Y"/&K^W:LI^5%@1>PR>T  $7O>[;FUS:VHN.75-+B^=KW-LN<
M<W,3E;@O.:[;W'G?-NU5"?>NQTSKF^4\@Z%4)MFO7+.\TI<(KV>K44WTOG/2
M:X/&%TC[)JQL09%#O-. #G(4=!*JPDQ5ET-39I(( (N0<B#H38@W%\LB#XQE
MDOK<\E\K7L+Y@CCE_#E4]ZA"[+3B/G4##>4?>OH[QK\;J=Y <Y<FE:1+*N]$
ML54[04F-V8INC(=-TQN;Q\:ZS1OD1*XG5BL#>H>FM!D"8;8[G>C-VZ== 6YZ
MZ]]:_,A_2S.E]?'H=>3\ D+U'>X=3.]*LM(?Z*5Y_5.A^3_C/S>P74 @..(T
M2J7/PW&=5GA*T6(CYS0.=T/I8\73X1R<B9-'.6U<,-(BEY(=Z.L-T&PONN-C
MRD/L.%[ WY[:(3GK;O@/1?TG\6%E>7Q3JB';KZ0VE0^D$^C[D=FKU81=K#*&
M%C"'G/&/D@?0DW/"0QT0I/IRM)K4R4IA)64L*I1U^0>V2DNPXV$9M;(FW_V)
MZ#J.9!J[R7\>?XY/$O7:O!HO9"%%FM] '#OH#C' .%6U#824]NX<[YC,Z82Z
M14W_ )4YO4<'TZ;:*5MUM6G7H3%2D-N[?W.:4Q&_FXVU)(YB=#IR?Q3=S',
M.?*_1J/L6;'*::_SKEW-N?2IS).31*#3J;))1V5QV"#]8KHX(].88<6XXPS+
M<@J?;9<6M;:'$H4M2D[WNI-R3Q)/2;J0+ #@+*?9"E,(F$6J'TFG^W_HYO\
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MSJ]9_P"9/9DU&E/_ (#/L6NX!^<QK_O%9^V5D'YF,^8#_*Q*/"J70H74]7H
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M="0V^0?.#V>0VR=W[6$YB-M[+HF ^QALG@D;"^@9BU6T#?J\4:VH#G<ICI'
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M>8>+\RU&9AH^<NLFOR.F:F'V>8<LHB ("&-"0-W5NYVMX;:;"Y.#CH<)N0:
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MA_\ 1C0H;:"W5Y43E5QGE $<C(8?B\PZ$%L/3[# ^?H5!H1P./?ER=1OGKT
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M_10E;N(D3U $&&NO#XT'HT.TMK@R),.1[:-)D-.R'N&AY2= ;$ZVN,K\UE!
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M=VK4U8^,RU+?+U^ W('[?%FEKBY [ZPU!-^:P&=TWAR\"<M.3E.ISMU:*O\
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M>W^#^'1_0F]6GO+O!SZ_P'W;OOY4QVM/\6>EO6GM_@_AT?T)O5I[R[P<^O\
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MN!TZ>]OKS7Y=<L]47@;\R.MP*E^E(7I= Z8<, .Z2;=4H-9&JC< A\WZ0,J
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M?_U[/^/XWW<?0.I$]UAZ/K[+O/\ ^O9_Q_&^[CZ!U(GNL/1]?9=Y_P#U[/\
MC^-]W'T#J1/=8>CZ^R[S_P#KV?\ '\;[N/H'4B>ZP]'U]EWG_P#7L_X_C?=Q
M] ZD3W6'H^OLN\__ *]G_'\;[N/H'4B>ZP]'U]EWG_\ 7L_X_C?=Q] ZD3W6
M'H^OLN\__KV?\?QONX^@=2)[K#T?7V7>?_U[/^/XWW<?0.I$]UAZ/K[+O/\
M^O9_Q_&^[CZ!U(GNL/1]?9=Y_P#U[/\ C^-]W'T#J1/=8>CZ^R[S_P#KV?\
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M9+\P8WA\ >CJ1/=C=R_FA^;WW[)?F#&\/@#T=2)[L;N7\T/S>^_9+\P8WA\
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M _F&] ^ZUU_[TX[H.%_-2D\_3_TY.Y'CWS]K_JU;_6$]R_Y ?S#>@?=:Z_\
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MOQ+@C=7&TE39Z*\E;$]E=2$#*\MEUO;2Q<)B*M"D)WK<7.6>FG-XD4A#B1P
M2+!"(R80D*.A"1<-"W7$1!PZ,U#A1D./+=>6EB,RTTE;KCCBM(UM:U*WM6VJ
M*HX1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
33")A$PB81,(F$3")A$PB81?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g107876g46c77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g46c77.jpg
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M            "0H&!P@%! ,"_\0 4A    4$  $&!PL("0,"!P   P0%!@<
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M^[JF+(EN,7EDAIXJLMXM5^M5PW1TL'X925+)"J<NGIX7_P!TX;Z$L'_]0EJ
M^AGS#$<AW4[,"4XY?-T4M8XL69[W;+FNDE,N=;$TIV15,[<@6ROAGR#FNB"O
MS<N3+^K?D ]:\AL"S-]T6[Y9]H^ZE93\>KN9%\3?!MQNKV4/&?KO@3J5S'_0
ML;Z]T'3?]+I.?_5H#SWA+,5QX<;Z<_Y+C]C*#L,V)-4@\'DW&R<<IR^88=BC
M?*K2D2'63-\Q@<+ )V!D6^8H>-L.43&UP-@4 H!0"@% * 4 H!0'D++@06Z
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M?$JF)1/(T*%B94E$SEB7(D0;YFC8^6(1<(02]L;@>E0"@% * 4 H!0"@% *
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MIJ5/"4CFN:Y6N16N:JM<UR*CFN1:*BHNE%1="HNE%T*?I0@* 4 H!0"@% *
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MPK$A7?CR<"#:,W9M(D]$ZUC.=%E7(YR8$8J(]KD16JB(BN54[K=;IX@CT#0
MG!N\@FL&RZD%Z)%@M5XS*W 7VV:N<23(EP'!A<<( >]\A"HO. 'M_5%PRQ_-
M7,<2V+:BX,<_#7-Q&16__AP$H]BU:NC71=Y="[Z'44EDXR5V>LTZ5N;.,6<D
MIFSX^*]5K/Q2LVS-QV)B:N%SFZ$>VCFKI:J&&3UM;Q)X5AY_2H%N:V7&(R4/
M-8P1!-78N2L%*^)HL6ZODH8J"AD5M?K'/Z6Q(Q?^IS>C_K<MH1KPV]"A/B=?
MPW8&UIUE+I73JK1:>HGLK(UD@M*T)216Y\]!29BYO.I>JV(F#X+G5P59BU4I
MB;KUEHTD+F,3*#"7Y1!2P N=[6M:U\Q L,LK\EN2UN7*][\EK6M;^RU;232B
M>)#Y^O1&O>B:D<Y$\2*J(?3424@"XX'EAH?[>SQW4EZWMD7V)?C@-A]*.,>M
MK95D^=G.:N(G*VD>!I#9+S%R7[."_:BM7J[NW=F\(3D/*&TM@3/F_M-++TB\
M7'6)-"=C+8;\>R2_66Z55DJB\I:E3[,#*(+K.7!D)V)G4V288N*T(";3SQ N
M=3GJ 6+F+!G,@SX&/5AOGU.7HLQD28@PYIT./"CQ(3G/L^;F(;7PXBLB-PPE
M@XM**B*V*B(M%^$FA>K; R W\G(-F6I.V%+SEDVC9\M:$"#*WRNY8L]%EYZ5
M9,R45(T_"M-)=%9%AQ'PHMGN>YM8=83EQMYV:7%YQ'<CA#><JIA1K(SP2RB$
M(C\-?;X-5>[+NV&FK*ZJ$8%GE4!9ZI9RJ+N:),!12URP.#=)N40F<)JP*=:W
M0[U05B/SL[!2&V*U&8;%M%'186;AN<ZJSCDA.SCHL-$5KZ(Q'T5'83,I[J>;
M0;*2JV?=:TGSLQ(1HDRD?*G<I8-G6AUY/0($!S$NM =/P>M(4C/1'0HTMB6;
MB2B1(<2 Z*26ZU[[ZY[8O!TL*(%A[CNMFMM/=J\CO2,7['9D!OJJF,CD5$MB
M]4%%N>!'42Q@MC<ITO\ 7 &Y?@\^2_V?;5GVG$B0I2)$>^$Q(CT? C0:,<["
MBIG6,K545-%=2FFKYY++XW!DI*T+R24G+REH3463E8LI:MG6BCYB#"2-$AN2
M1F(ZPU;#<CJO1J+5$1:JAV;5U-=B@*1ZAYY]MNV9M+WQ.BNS(>TUU/0^['1,
ML8;+=M.\96ASJ(>A7F51HQ2\^B%[8Z7?B2<5:=ZH?<TN_P"G3.C$.A>I9W4[
M>_!I>3WD(F[KCD[+,%E'S9R)["N[[OJ%21.YQ/(=R5*N0V=)<+EO?,)B^'=Z
M VE?96@/NO;%;/L3::RN+Y3W$,X)RJ;IN4+TUO/TU.G8]70P(4 H!0"@% *
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M#6#&;17Q6/5S7IF\*(Y=L*/%+G;P^B62HXVY\6!,5G)QB'M.H=Q7"@E@B]T
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M6-Y"^U"_W6[X+*X2GNWEK]-_5Q#XD5^H#K=#=2>)/8?+N)W2)Y;N4I]M1)"
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M]CM-*TJ4;;(A-:UO7=<+42N:I6B4KW0^WW*.,/\ LFGG](J)_P#3J3]UI?Z
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M,R;$,X';*%@@L \B^>6548^YK6TPN1U:UT4IJ^-=9(U0D% * 4 H!0"@% *
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M0"@% * 4 H!0"@% * 4 H!0&*D&(R$I)R04QFM5.0\E_QKR12#>2":3DZ;.
M-V6<N2<7)AD[K]G4""YO#-P;J/C $&L]9\(X8F; 950"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
E"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g107876g57g04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g57g04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[16@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %82^50@X0DE-! 0      #T< 5H  QLE1QP"   "   < E  $G-B97)T
M:6YO0'1S8V%N+F-O;1P"!0 25%-C86X@5&AE<F%P975T:6-S #A"24T$)0
M    $,/H3^D,;:20K-%8WR6TV?(X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <35@
M0         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^
M-0 "  $X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              )9   &!P         !
M                  $             !@<   )9
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   )9     %)G:'1L;VYG   &
M!P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "60    !29VAT;&]N9P  !@<    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     8X0DE-! P     "R
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MV@ , P$  A$#$0 _ /4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT%'N34JQVZ)BR+VW<M-I=A;Q\L]AZI:C,63A[(M7D7,PD8J]30<PTNS,W5<
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M9?4G:?O PB=BYD^4G&7U)VG[P,(G8N9/E)QE]2=I^\#")V+F3Y2<9?4G:?O
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M9?4G:?O PB=BYD^4G&7U)VG[P,(G8N9/E)QE]2=I^\#")V+F3Y2<9?4G:?O
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MH\<7?S[3V='LE]+C?3NT7L,56%7\GQYK1^M KN<*_ RI]L[+_P#9EGRIP1^
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MV?QB4M]&KX$-A^D;NOVB1SYVX// U?V@QGW@+Z9^4;RTP#ZO=C?<)%L+SO%
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M\)8GV?Q7U(EL7SFEQ*^"4E(Z$CGDM+O6T;&1S=1V^?O%2(-6C9(O=*KN%E!
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MII%$"$ "E ,YZLC9#5U4,8(9%4SQL!))#&2N:T$G4D #4ZE=EB4,=-B-?3Q
MB*GK:J&,$EQ$<4\D; 7'4D-: 2=3O*D+,98281,(F$3")A%J9Z0WQH>C ]):
M4_RZ;DF["\G.$7L]%Z]2M)BG?F#^=G\8E+?1J^!#8?I&[K]HD<^=N#SP-7]H
M,9]X"^F?E&\M, ^KW8WW"1;"\[Q0"F$5+>>7@08^<:E?B7>=#LSX2=YI4^JU
M13PQ\D8O3F%>TE5TLYY2LJ;\^?%<V!_BJI[4Q&;_ &8\-4GBG]WE49\+W(3$
M_.L)^*4BI_T/?@;'S=ZC_+K%D=8Q_,5P^>=;"_EEJDRAY.X'Y.J]X<MQ&=,B
M81,(M+G![YPSF?\ 9*!]L'V0QP2;]INT>T7QNI6B=RSQ7T)@_LF+='DSK>IA
M$PB81,(F$3")A%XLK1XRO)/TIZA_J:4R4-E_I"9]4LOXU*M<)G*S .P&ROQ2
MO4I='[\Z-#^<_=OLML[/D6GY<;.>?8W\.J5TW )]'WRE_1FP7YX>O7WDU+GD
MPB81=3/_ +BFOJF1_!K810CQ(\5+C)Z/>E_Y;UK"*A_/#8%WE-OTW6FNMXPM
M7@"429=[5JT)OJL:?MC!E%6^H69X@22D7#5XVLUY@XDFOZJ[:2*+^LDM,M.N
MV!H1P[<YZ;;HN;]9L#SVY[>+[54>*_3SZ=._Q]%K[]UM@'&&8FK!QRT5.62V
MM+Y8);4M!?S=T8JKKM;1*N:S&JOIQ%PY;M'#D)%R91R9RNU;+.#J&64;HG4%
M(M#O/C*HITRB)A%67F1XM&U?JF(]IX/"*S6$3")A%6;F?XI7)#S,;"]FI#.=
MVNY+;0^A\0]VD4D<#WTJ\'G;# /B,"R;B_XM/'CS&:E]@:_F1LWR=P#T+A7N
M,"UW"9])'"#VWVK^/5ZG/-TN(7G'NWC(U/\ ]RD%[((YD<"?_/'S?&O^S4P<
M//@3Y/\ ]7>!^^X@O1QF.H?59K)XUFMO-=;/S V1+BOTS;*=C\:]Z*V,?@RH
M\YB]4*2=W>!S:GF]N'Y"_P ZOA Y"[9=F,<^&U*QZ/ONF\O%Z[5SZ:\#^J?-
MM1O9>+RYL'R'V,[*;._"*-4J^^ZKSB;VCE).=6L=,(F$3"+71TE_@DTQZ5NB
MOSB4SI=E^_:[T1B'LVKMMA/"6)]G\5]2);%\YI<2H@W_ .!3:'V,F_PA\X?A
M+Y ;7^@<0]BY95#WY3>6C]8+)-6^#+7/V$J/L_'YM]D>2FS'9[!?AM,K=1WQ
M/Y:7UW*I?2<^(7R8^P2/M'!9*O!WRVV=\^/L)EJ,6\&U?DO]35KNY_?-D\=?
M1_H7L+KG(^QW^8O@C^L7:SW2H5\<EL1]&T7K1J0.C/\ &UYB?8_37X>:R+."
M7O;'O3V/_F#%%JH^6.T'H[ ?<(UO R8%OTPB815EBO&XM7F1B/:M#(FHOIJQ
MKL!0?&&K8.\&1^>/]D%9K)96O6.7'_I&T_9R<_+'678/X\/E8_7:L'%/!N(^
M8U?N\BUIW7YJ"[^92W_GLGG6-Y9P^?P>RC6'\G_P1L#Y23WZL5\N/W@%TEYH
MM;>QL+G-8CX0KO/*KV[UUF,^&,5])5WO4JEW,-:U,(F$3")A$PBU,](;XT/1
M@>DM*?Y=-R3=A>3G"+V>B]>I6DQ3OS!_.S^,2EOHU? AL/TC=U^T2.?.W!YX
M&K^T&,^\!?3/RC>6F ?5[L;[A(MA>=XH!3"*EO/+P(,?.-2OQ+O.AV9\).\T
MJ?5:HIX8^2,7IS"O:2JZ6<\I65-^?/BN; _Q54]J8C-_LQX:I/%/[O*HSX7N
M0F)^=83\4I%3_H>_ V/F[U'^76+(ZQC^8KA\\ZV%_++5)E#R=P/R=5[PY;B,
MZ9$PB81:7.#WSAG,_P"R4#[8/LAC@DW[3=H]HOC=2M$[EGBOH3!_9,6Z/)G6
M]3")A$PB81,(F$3"+Q96CQE>2?I3U#_4TIDH;+_2$SZI9?QJ5:X3.5F =@-E
M?BE>I2Z/WYT:'\Y^[?9;9V?(M/RXV<\^QOX=4KIN 3Z/OE+^C-@OSP]>OO)J
M7/)A$PBZF?\ W%-?5,C^#6PBA'B1XJ7&3T>]+_RWK6$6OSGS3H0-\4*9"E0L
M0E8-<6%2R[-CN%*_+.>DIB+FZ\Q@JW.-"LUHR&;A$%<KQLHL1U,D3CSQQ5&L
M8JF1;TTV!^S_ #9>GK_7W*H\5_UT@@_KJ"V>:8'KU%K >U*O0_0&I=3M>C#K
M%9R 03$ 75UP8B9J&HJ'4<U0%,@UT1&)[DO9>H*'>?'TW_KS^-44EY1$PBK+
MS(\6C:OU3$>T\'A%9K")A$PBK-S/\4KDAYF-A>S4AG.[7<EMH?0^(>[2*2.!
M[Z5>#SMA@'Q&!9-Q?\6GCQYC-2^P-?S(V;Y.X!Z%PKW&!:[A,^DCA![;[5_'
MJ]3GFZ7$+SCW;QD:G_[E(+V01S(X$_\ GCYOC7_9J8.'GP)\G_ZN\#]]Q!>C
MC,=0^JS63QK-;>:ZV?F!LB7%?IFV4['XU[T5L8_!E1YS%ZH4D[N\#FU/-[</
MR%_G5\('(7;+LQCGPVI6/1]]TWEXO7:N?37@?U3YMJ-[+Q>7-@^0^QG939WX
M11JE7WW5><3>T<I)SJUCIA$PB81:Z.DO\$FF/2MT5^<2F=+LOW[7>B,0]FU=
MML)X2Q/L_BOJ1+8OG-+B5$&__ IM#[&3?X0^</PE\@-K_0.(>Q<LJA[\IO+1
M^L%DFK?!EKG["5'V?C\V^R/)39CL]@OPVF5NH[XG\M+Z[E4OI.?$+Y,?8)'V
MC@LE7@[Y;;.^?'V$RU&+>#:OR7^IJUW<_OFR>.OH_P!"]A=<Y'V._P Q?!']
M8NUGNE0KXY+8CZ-HO6C4@=&?XVO,3['Z:_#S619P2][8]Z>Q_P#,&*+51\L=
MH/1V ^X1K>!DP+?IA$PBK+%>-Q:O,C$>U:&1-1?35C78"@^,-6P=X,C\\?[(
M*S62RM>L<N/_ $C:?LY.?ECK+L'\>'RL?KM6#BG@W$?,:OW>1:T[K\U!=_,I
M;_SV3SK&\LX?/X/91K#^3_X(V!\I)[]6*^7'[P"Z2\T6MO8V%SFL1\(5WGE5
M[=ZZS&?#&*^DJ[WJ52[F&M:F$3")A$PB81:F>D-\:'HP/26E/\NFY)NPO)SA
M%[/1>O4K28IWY@_G9_&)2WT:O@0V'Z1NZ_:)'/G;@\\#5_:#&?> OIGY1O+3
M /J]V-]PD6PO.\4 IA%2WGEX$&/G&I7XEWG0[,^$G>:5/JM44\,?)&+TYA7M
M)5=+.>4K*F_/GQ7-@?XJJ>U,1F_V8\-4GBG]WE49\+W(3$_.L)^*4BI_T/?@
M;'S=ZC_+K%D=8Q_,5P^>=;"_EEJDRAY.X'Y.J]X<MQ&=,B81,(M+G![YPSF?
M]DH'VP?9#'!)OVF[1[1?&ZE:)W+/%?0F#^R8MT>3.MZF$3")A$PB81,(F$7B
MRM'C*\D_2GJ'^II3)0V7^D)GU2R_C4JUPF<K, [ ;*_%*]2ET?OSHT/YS]V^
MRVSL^1:?EQLYY]C?PZI73< GT??*7]&;!?GAZ]?>34N>3")A%U,_^XIKZID?
MP:V$4(\2/%2XR>CWI?\ EO6L(M9/2/;@@ V'KA:"VW4W+.BRLO7+'K:3W%==
M.GC[C$V&E3<W+KO*]"OF5A5/273RI'*\.=W5ALR,]7T7<@"H(^VCITN-YY^B
MP/7KS[ANYZ^/]?JX*VJ<=#R2N@=*JS%X;[,E5-64121V&U4=+-;L\/6HTSBT
M-UWZ+=\Y0FE!,_2<OD$7KE-<J[M)-PHH0/)WGQG]:*BF;*(H'WEM^>U:WJ+&
MGT5ML*WW*2L3>+@9"V%I,8G&U"FS]XL+YU/_ */V@Y'0QT",7"1Y(91.1GI6
M,0D)"$B/A&;CK4DS8N,<X$L@I9ZV8MU>*>G?!'(8F&PDE,E3"&1N?$UP+G&1
MN6QO11&4L:'!KI:B&DBN#E,\[97L#R+ED89!*Y[PUY&4!K'.< H"Y<;IJ#_B
MN221C[ZY0W+4*G.5)>$UCL:W1+)G,2U-DFIKI9Z?5IZJZ^2%O-,Q*]O,U7H]
MQWM\HU=KHQL@HVR9HS#-+"XAQBD?&2+V)8XM)%P#8D7%P#;>%C1O$L<<@! D
M8UX!W@/:' 'KL=5?7+:]IA%6_D5RFUCQ@85>2V6G95&]O>2;*)"MQ+>54!:)
M19KNQ=E<2,>").X?(=Z,4RHG-W8"4O<@(D6O/D3TE?'+:.A]OZXK*&PRV&\:
M[ME7A32=88-(\LG-0[MBS%ZY3GG*B#8%UB=^5(@L8A.LP)G$.H=1C]%-B6"8
MMA]/D$];A]52PF1Q;&))H7QLSN <6MS.&8AKB!N!W+L.#['*+9G;C9+:'$A,
M</P7:#"\3K!3QB6<TU'5Q3S"&-SXVODR,.1I>P.=8%PWKN=+=)UQKH.G-342
M=;['-.4K6=#J4R9C5F#AD:5KE6BH>1%FX/8$#KM1=LUA;K'11,JCW!S))B82
M!>P>EEH<(PNBGR\=1X=0TLV0ES.-IZ:*&3(X@%S<[#E) )%C8;EA[9XM2X]M
MAM7CE")118SM)CN+48G8(YA2XCBE564XFC:YX9*(9F<8P/>&ONT.<!<R9^MF
MXK?1MH^J$;_N7-BN;6H>R<B=?2NX(*\M23X0D=TA<9R>< K&HD>_V:M(!.-5
M330!\8AK(+D@]Q%"L5N*?489$!_9R[P</;LK_P#)?^*7/_%D.(LPKYK^VLZJ
M^;\5\ZS<5Q(_9.S%O&VTM>ZD#A0VEPW:_#>"JEPD5 EV-V2PW!,8^=Q-A::R
MDJ:J64TA;)+Q\)9,S(]PB<3F!8+"^WC];-Q6^C;1]4(W_<N6E'ZAJ8Z2OCD^
MWE3]AH-]B?H_!TF=K[TIZPP*_%_(NQ6;BBV"?$BB'<#_ ,105R&*;Y (;^_.
M#KMG,1J.$/ ]J(S3_P"&8=L_B.&5 =*X5/SFJG,D1CBXLM='E/=.,C2#IE*R
MV3L;12P&_&/F8]NG<Y6BQN;[^JRS#9/2C\9;7KV\5B+;[*"2L-3L$*P%U5(]
M%L#R3BW3-L*ZI;$H9-'ORQ.^'*F<2$ZS 0PAU#O=J\-J<9V8VAPBCXOYWB>"
MXG04W'.+(A/5T<T$1D>&N+(\\C<[@UQ#;D-)T5JG>V*HAD=?+'*Q[K"YLUP)
ML.<V&BY=>=*5QDK% HU:DV^RQDJ]3ZS!R MJI'*MQ>Q,*R8.Q;JFL29E$17;
MJ=Z4,F03D[DPD*(]R'K9?#JC"-FMG<)J^+-5A>!83AU28G%\7SBBH*>FFXMY
M:TOCXR)V1Q:TN;8EHO84G>V2>:1M\LDLCVWT.5SW.%QS&QU68?K9N*WT;:/J
MA&_[ES>JTGZV;BM]&VCZH1O^Y<(GZV;BM]&VCZH1O^Y<(GZV;BM]&VCZH1O^
MY<(JC\R.?6B=[4/7=;I"-X)(U?>>L=AR8S=>9L&XU^HR#US+%;*HS+PRK\4W
M"?96QDTR+&[H#+I=0".XP2O@P^HJ99P\MEH*NF;Q;0X\9,P-9<%S;-N.Z-R1
MT%=)LQBM+A%96SU?&Y)\*KJ./BF![N.J&L$>8%S;,NTYG7-N@JW'ZV;BM]&V
MCZH1O^Y<TZYM8!M3I0>-%RUQ=:K$-]DA*3]=DHM@+NJQZ#8'+I R:7?UB6%4
MR:?="'='!,X@'R]R.<UMEA-5CNRN/X-0F(5F)875T=,9WF.'CIHRQG&/#7EK
M+G5P:X@<Q5^FD;%40R/OE9(USK"YL"";#G*[BD]*AQAK],J,"_;[,%]"5B B
M'HH5..40%W&Q31FY%%0UB(*B7?D3][.)""8G482E$>H,_ :*;#<"P7#JC)\X
MH,)PZBGXMQ='QU+1PP2Y'$-+F9XW97%K26V) O9>)G!\LKV_NOD>X7T-G.)%
MQXBH(YG](3H+?7%W<FH*,C?"6V]U=.'@SSE<91\25V67C'PB]>(S;U5NEWEH
MKU'(U6'N^X+W/481#N-DL4I<$VCPG%:T2FEHJGC9A"P22Y.*D9W#"Y@<;N&A
M<-+K KX'U-'401Y0^1F5N8D-O<'4@$C=T%5*Y4<G]:;CX9:DT-4$[(6\TG55
M7ILRI+13=E!FEX>LU&)=BSD$I!TNNT%W"/>\KG9(G.D*)S)$%0Q2<IB<3ZOA
M<V"VVBM_@NS>UV.XWB(><M8:+$8)8Z<4\ NR68.>WC(W3,#1<A[MRN"-W^"5
M>'Z?.)Z.F@9K^SSQ%A?F=:X;H;'*;] 65<->7&J-$;XY ['O"5J/7MFU_7D9
M6RPD.VD) KFKI2))+X2;+2;--JF(NDNS'37<"J'==T5/J !XC839K$MG(<49
MB)IBZLQ3%*R'YO*Z4<368K6UD.?-''E?Q-1'G:+Y7YF@D"YPFT<S=H,5Q,EG
MS:MI,+@A <>-ST=*R&;.S+9K<[3D(<2X:D#<ME/ZV;BM]&VCZH1O^Y<D!;1/
MULW%;Z-M'U0C?]RX1/ULW%;Z-M'U0C?]RX10RQZ2OCFWWU-[(40V)^CLAK9A
M5&Y2UA@,@$HVG4Y%05&PSX$*U[.0>Y6!<QA4ZBBF ?M9PE-LYB$7"/B.U+C3
M_P"%U6RM+@T0$KC4_/(<0%4\NBXL-$/%#1XD)+M,@&JRS,PT3(->,;4.E.FF
M4LRC7IOS*9OULW%;Z-M'U0C?]RYW:Q%U%@Z5GB[)P,W&MF^S@<2$1),6XJ5*
M.(F"SMDN@EWPP6,PE)WQ0O=F IA O6(%'JZL]Q.#)(WF]FO8XVWV:X$VZ[!8
MU;"^HHZN".V>>FGA9F-FYY(GL;F-C87<+FQL.8JG%CYR:4E>"]DX[-4KF&P)
M;7$_56JBL"T) !*24F]>-A5D@ES+D;=Z73[XL#$QBG[HH)F .L=Z,3IAM%'B
MEI/FS:J*8C(.-R,8UILS-:]P;#-]JQ^"JEEV-H-EJ;%RPR8.]SJLTA,[2'5-
M1*.*+Q$7]Q*V]PW6XYKFT.JNE"XSTW5^MZA,-]DC+52@T^MR@M*K'KM!D8*O
M1T6]%JL>PI'6;BY:JB@J9),RB7<G,F01$H:>KE;/55,S+Y)JB:5F86=EDD<]
MMP";&Q%Q<V/.5O<1G958A75,6;BZBLJIX\PL[)-.^1F87-G97"XN;'2Y6>_K
M9N*WT;:/JA&_[ES'6&GZV;BM]&VCZH1O^Y<(GZV;BM]&VCZH1O\ N7")^MFX
MK?1MH^J$;_N7"*Y6@]_43D?2'%_UX2<3@6T^_K:A;!'HQC[X1CFD<]<"5N@]
M?D%OWF3;=[5%<#&."A13*! $Q%"V\^>VB^/5]<:XOR-X/86T7&RZAH&OLY&/
M[)*IG5:@5RO,L5!5 J9N^D[P $'J #&Z^O"+5CRRYMZ8W3NKA9?Z<E<206@]
MQO;W>BS$$T8OCP;@E>!,L&W2EG9)![UQCGNFZR[(@=:7_&'NQ[GL]F<>H<(P
MC:ZAJQ.9L;PEE%1<5&U[!,UTQ/'.+VF-EI&]T \[].G6UM)+45&'RQY,M-.9
M),Q(.4Y/W0 ;GN3H2.;59YPZY_:'T7K:V52[HWD\I-;=V/=V8PM>9/VH0MJE
MDWL6599::9F(]!$H@Z0*F<B1^HI5E0_:R)-D\'J\%P^JI:PQ&6;%<0K6<2\O
M;Q-5*'Q7)8PA]OWFV(!W$J9N%W;'"-M]H\*Q3!15BEH]D]GL%F%9"V"7YYAE
M*Z&I+&,EF#H2\CBWEP+QJ6-W*V/ZV;BM]&VCZH1O^Y<ZA16GZV;BM]&VCZH1
MO^Y<(JZ<H.D5X^[>UJVJE30OY91*W5R;.,K6V+-KV**6<*.@!9*<=&%82J%[
MTGWL ./7UG+U=>;;!JV&@K#/.'EA@FC[AH<[,\ -T);IIJ;Z="X;A!V=Q#:?
M 68;AIIQ4-Q.AJR:F1T4?%4[WND[IL<ASV<,HRV/.0MM.DMST_?NO8S9E$)+
MDK<L\E&34LXR2CY$%HA^M'.^^M47;U,A!<(*=Z,#@PG3[DP@41[D-2NY6O;I
M$>6.JX.JWWCH]3M [!.E3I$%$8ALI7P;KO8JPDZY(9(B_?/@\H@8H,1 %^I/
MNA#]O-K@M9#08C!53YS%&)<W%M#G=W$]@L"6@ZN%]1I=<;M]@-=M+LQ6X1AQ
M@%743T$D9J9'119::M@J),SVLD(/%QNR@,-W6!L#<51Z,/DYK75;*IZ;LZ=C
M-;[HUU3KR&/&1;=W$!/H*OX90SQZI(-E4&';)9J(.2M53BB"I^\ ) (;D<0H
M)ZGA<X4MMH\G^#;83[,R80'.(K W",&;05?SN  MA)G!,0;++GC[HY#W*[*F
M_8X1AE$\_MJ1D[9;7++R2E[<KB 7:'706/2MZVS=AU_4]"M&Q[45^:O5"+4E
MY8L6V(\D!:)J)I&!HV47;)K*]TJ7J(9=(!#K'N@ZNH=RBAKCGRXU3RA5MZ.L
MTK4F>DIP2DS^DL.VB@$MA-+EC^QBWDY'OX@,*][0!P1[V H]R)^^#W!%]'(S
ME?JWB\E45MF)VA0EU4G$H;]&XAM*B!J\6(._[8#B2CN\ (33/O D%;O@@MW7
M<=P'=D6G7A?R2UU%\YMNVMR2PC%\A%:E1:""48@=T2;D;@86YIY$7Y2QS+J?
M(=\<(*OCE_;ZD3=R'7'>P>R^)[.'&3B)IC\_Q?%ZZ#YO*Z7]A6XE-50Y\T<>
M5_%2-SM&8-=< D"ZUCJ.4[15N* L^;5&&X?21BYXWC:9C6R9F9;!MP<I#B3S
M@+>_M;9E;TYKVS;,MY9$U;J;-![*EB6J;V1%%P_:1R8-6JKAJFL?M#Q'NBF<
M) "?=F[H1*!1D1;-1SQWY.ZUY.0MBGM:IV--C6)1K$286.*;Q:XNWC07B(MD
MV\A(%52[R ]V<QTQ*?\ 9 HA\N$6&<A.:^FN,UIAJALA*XJ2T[ )V1B-<@VD
MHT".4D7\84%UG$M'F3<=IC7 BD"1R@F*9^^")A*4BEK1F\*5R$H3?8]!),DK
MSJ3DHE(L\P1CI#M<4J1)T)FR#M\F"0G.7O1P7$3AUB)2]75A%%MCYG:>JV_V
M7&V32MX[%?R]:A$%&T(U5KW;;5&1TM%B>3-*IKE1!K)M@=* P$45>^$*10"
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MN-]+=*H-;6UONMK?Q6WKG*RCCE*<C1D<AR@8ARH(&*8I@ 2F*8""!BF 0$!
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MRR,>[C&,J&OXP\8<R.9O^*253R6POQ"L>2+O>:6;$#.'->[--$98&L#XXW,
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MA%67F1XM&U?JF(]IX/"*S6$3")A%7?8G':%OU@MUN2MMEJUJL;727P7-0R$
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M+%*NEGF/^<U3Z6 ,HV-XN.2NCE>87TK\E-1[6MBE=F__ (ES)!8EE4^C9+!
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M(8PS4YC_ 'Q6\3D;-<TTD?:[Y5;IF-V:KU7<&*,.T5X_W*8M-K7UG>PUS?\
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M$\$S+@Y)89:A\<C;@'*]I%P#;19PHW0540650155:G.HV543(=1NHHD=!11
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MNHY<"W8,$6[5$5W*RSA84TBBJNJHJ?NE#F,/MC&1M#(V-8T7LUC0UHN;FP
M%R23IJ3=78XXX6".*-D4;;Y61L:Q@N239K0&BY))L-223J5]1(Z/3*S(FQ9D
M)''%2/(1LB4K!0R"S8RC,I2 #4YFSEPW$Z $,*"ZR0CWM4Y3>NCJ  Z@   .
MH   ;@ .A>^GK))ZR222>DDDDGI)7,9LW.L#@Z")G!45&Q5S)$,L5NL=,ZR
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MP5D%PB8P%Y8S<\JL#!J"LF=H0J;4\@IWKNWIFR92D;F<BJ*)"E*F)2@  W6
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g107876g62h01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g62h01.jpg
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M(9+)3@*Q8$=M8JBX17D6CE1DUV3)Y'JI_5P9RFY;=:'@%US>U['7(==LNI8
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M<2K>&R+X:ONJ5I0" Q>;PL)-&<@# %91Z\Z5,,<ZD@R*1R0M6;3#IE'GX>9
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MA&]'+"/IN7_M(@%/$#9!FFV?.$UB*Q1 =?$/4%1IXSZRLST'L_LQ/AUD)V]
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MZB&FA[5J6&6>1L48<Y@#07O+6W/ 7SX*.=>^U[8QC'_9U=I_P8QC_P"@%O\
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MXJ<$_O1A?YU3N'V.O?AB'Q-5_54]\?>;YK\+^TR-?>CCW:=GO\5."?WHPO\
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MGH%KW>[[=L=";G+2VG/KKH/&K@<P62<(G")PB<(G")PB<(N=G>/_ &ZZX_\
MB[8_5L!S\U]GK[O]C+^>VO\ _K,/7J78\^YFUG\W@G_>5"Z=\_4B\E3A$X1.
M$3A%CU1 I=3=9<8/654SZ6ZJK)LHIOM__%OONEG;;/\ _/.<YYQGT='(XODI
M:9[W&[GO@B<YQYRYS"2>DE?5L\S0&MFE:T9 -D> !S  V"CRQ9#':]% RKB+
M,2>AN;0F%:(HMV+?9NO-)(/CB#_?=1JKC=)@H0U=*H8QKNOHGLGHHGMMC;&N
M;28CANSE)054F$T]4*_'<"P-K&14\1CDQS$Z;#(ZAQ=$\.93NJ!*^, .D:TL
M#FDW':872U>*3U$#*R2(T^'XAB!<Y\C@YN'TDM6Z, /!#I&Q%C79AI()! LD
MLD,=BDHK:,K19B\5L>1EHZV=IMV*28M05%#DJW<KI;-=]G.BR011GJFGNEMH
MHXT5SMMKIMIM,8Q'#,(Q79C"GX33SOVFQ*LPV*9L5.QM(ZDPBOQ9TLC#$XRM
M>RA="&M+"'2!Y)#2TJ*EJJVCQ:K;621MPJE@JGL+Y'&9LU;3408TAX#"UU2)
M"2""&D6N05F&YJLG1]:*M2T$<RAOXGCQMN_CZQ]'P=<[J^,'35V(I^%IC.ZG
MIM]?0UQG;;S8QY^<V.NV5FQ%^$15FS\N+1[_ "F%QU&'/Q%G)@N?OT37FI;N
M-!+]Z(;H!)L N.Z#%V4PK'PXBVC=;=JW1U+:9V\;-M.6B(W.0L_,Y!&YNL79
M=  U+P-R><Z.E&P1N_CZQ=QHQ<.&KW= :FKL\5T9NFCMLZV31VPW<-7"*N=%
M$5-=4==LK+6,PZ*LV?EQ"42NCH8ZC#GUDC8))(IW,I6O,[Q#+#+%*6L(CDBD
M8_=<QP%=3XNR!U2^#$F4S"P/J'1U38&F1K7QATI:(VE['L>P%PWFO:YMPX$Z
MQ'9S BP65R TPC<0$Q.=RR#/"$@<!F3!1S%32P79_L^=IM&S9(@JCXB#=53*
MB>-L)Y44V_#GJL,Q[9ZMH<7Q&NI\,P:CP?:#&, FJ,1DH8*=TN$5TE":@SS-
MABB;4O9OQQO<7-N&ESCFN758?B4-11TU/+5ULU;AU%B$<5,V>20-K*=M0(Q&
MPO>\Q-=9S@+&U[ +/.B<:VVAJP,3%I )EQ=0>F7:$XVBU19ZABY34B,\3;;,
MDSNL,T:>SPNSAYJDX6);:^I#WF^G82U6%DX(^@H\)Q&DQFL=3-K(:K#&0LA%
M%658J:7>)[IETE*V'M:A,DP9(^I(Y"FF(XS(:NU>VHGK*::A@$I@DAJW/<\S
MP0F*7='_ (2S9B_E*@-C)8(K\I+&#K$EL6N 1Z+QIBE$Y";/SP=!2(L4^ K$
MHRY(ASY;1\9'(X<.VZ>F *C;U==)LINJXTSC?'A[:[=7B>TFS-!B&%873LPC
M$J[$,?IL J:2DGP]]5A<M318C6-GK:9@DFC:.Y[XN3D9$YSI 0[O2#RZ3"\5
MJ::LJY'5M+3TV&RXC%--'4MBK&13TT!C@E=NL<2:D/WVEX :01F"-V3)5TL?
M5BJ+^%*RA!+*ZT;3= MSZ*.-,*Y65#ZJ9(II83SA3*F[?&F-,XW\_HYQGG>-
MJ=FGX@_"&5&!/Q6-G*/PQLM [$&1AH>7OH@XU+6;A#MXQ!NZ0Z]C=< Q8HVF
M%:Z/$!1N=NMJRRI%,YQ-@T3D<D77RL'WOE:Z^&#E89+M0&#$#R=>JNT&03!"
M/9+NUA[EPR?HM1OC>N.%63QHZ:.TTD=]VSELX06QHJBIIKAV]LJ:R+#Q6;/G
M$)WS1P4/;&&]N3/II9(*AD5-O\M(^">&:&9K&$Q2Q21O#7QN R[7Q?D7U/(8
MEVO&&.DGY.JY&-LK&R1N?+N[C1)&]CV%S@'L>US;M<"="%V? )&_/C(N(CI=
M[%K*%UR<07*1,9NEL_;"G+@\/T6=*J$63?<FJP:,--$B98H+)L&+;=5O^'7J
M7:G9W$ZC$:7":/#*V?"=IZ39JOC?58/2N8:B*DEDQ"G;)*YU3!$ZJ?3PT[6M
MJJRJI*J"GC<^//L9L(Q.ECIIJR>J@CK,)FQ2G<V&ME!$;YF-II2UC1%(\1-E
M?*2Z&&&:&61X:]2)DG7.#^(IDA"L2G*7CXC678+!_*'A^-XV WB>T<I>#^R^
M)AMZ'A_LGG]'\/-D[9V:[H]Q^V,"[K%G*#"^5P_NB8]SE.4[2WNV=S<[_?Y+
M=W.^O;-=9R6*=K=N\GB':>]N]M[E1VMO7W=WE[<EO;W>VW[WRM=?% W63D^K
M%&Q>".)2AXGC1I!_'U3Z/@Z945\4.FKL13\)/&=U/3;8]#3&=MO-KCS\PCKM
ME9<1?A$59L_)BT>]OX7'48<_$6;@+G[]$UYJ6[C07.O$-T DV"KJ?%V4S:U\
M.(MHW6W:MT=2VF=O&S=V<M$1N<A9YN<AFOA5\M'3F):246&U!-EI!,@N6&N4
M-L^/$)B=AJ[O;=NB@GMA\J V>)ZY3]-%%=-#?=39+.^V&RN,4V/8.W$Z2B&'
MQ28CC5%VN#&>_P 'QFOP5\Q,;(VGMAV'&9HW;L8]L9<XLWCEB]%+A]::6:<U
M+Q2T%0)#O#O:ZAIJ]K+.<XCDQ4B,YV<YI<  ;*0N;&NL3A%1CRF?Y 7;/]#$
MK_F$^5NHZQZU':'J/J4-]RO3_P"R2G7AXURI\6:N_0QOG.-,[^H0ST<;YUQG
M;&OI>;TLXQG.,>?S8SG\'+]]_P WRJ?>_P#+\BD,U2G:N\; HXK?J_7:$P2C
M[7%W2V;U"1L67S:32B-@I ' @_;,SCD/&Q:-J*2%=W(U6C(R1,-&B8A++!NZ
M=+YEQGEPMGGX^'MY%;'*YT-\A\Y/MY51\5>EKJ27JW=D3FO8DQ"+P[5Q&!IV
M%9D\K6-U7;-?S^4R00H#@'6@&>E1B-B1@1OJM&3A=I%9HBV )R \LZ<D5D-[
M:U]---2/'UZVZK6TQOIF=;7R .O <_#Q$=.?H]:45$VAC6)3^PGB$Z\KYV'K
MB7,C4I7+X/18&U[2D=AKK#K377"\D+@ 1^2.<YUW,FQS$BOG3*>,9',YC[V_
M_P#7Y^;+)7AK]]S_ /JT\G/SK6Z$N?M9+@76?L.7)S@>\N6ZXJ"G6\YOBHFE
M'&HS,Y>2C\@JB#TRJ[0/QV9P@:DX0B" Q!.QG\IB+AM+')?0B5:8$ 7!(R',
M;DYVX=/DMKJE[V//;(G3GM;4]?HS"W2/22YV54P;LRZ[!V^4DRWE %J;S"7Q
MX=O6:M1E^[IN@7D+?Q+4/JB453B[A9\,E!!RXE =ZB-:#"K42+:#]'18:7Z;
M[M^'MX[E.FY^VM:^5MZW'Y/4IRZ@U8U\'MZGM;MLQ[&>^,NVR_0G3;"ZF\.)
M0\VB'],V+)-=$)YDCB/S9-%!,C(P.K >V=L5VS5UI#PZN;I/^M^?--;V-L^'
M4.>_DZ+*1O*+RV0[TV H.!@#\PG_ &DFC&HVL4B)&/BY2^K1-F[EEZOA#V4F
MXU'F:B-2@9.$1?&) (8-2\C#^,]3RKIKN'/I;._,>%_'UJG2PSOPZ./-ZQUJ
M$NLZ2REG=KNG-GT]*J.@]RAR-_TY Y61JV0$6<5G236&W<SC[B"2>R(,W2C]
MIZM9P%&N%UWP]S/MG;X-HS29K/*>!O<\3F>K4>CH4&5P1:^8%QXP+'QY#+-;
M$6Z_U;UGN_R?U=5X#3C=2H7!V-+#A[Y1)=BULV2TI+'</:;D5T4UWSYN&^'
MZ([&7) LV9HI"6+U1-HQ017)WKG@/6$M8CF)/B-LO+GZ.I:U'YC2]=3WN39M
M@@E95&(?WIC+JA8U'AZYZ1R/L<2ZPU9$92&K.-M'"")R=$Y&8EPU?"OF8BB.
MTG-%G@K428+,69M;^#GU G7R#T(",[_PK#KL!EZ?3?BK 4Y1TX<#[AMBX9:^
MIZS>Q%F5O/SL>JN4!TDZX 5RQC4?@E8NY6^%D1TJ-' H/05:9QHQ1;2%8\2
M1=5L-'!BJL)X#,"]K].I^;Y[JVN#?(GFUZK_ .OBT%1Y_L#2ZF^6,0ENS;X7
M[VM?>5DGF=?;>Q0A2M;Z=?,H:;_Z[MNNCF")0?*.,XW(:(IB,Y=Z;XQ>+>:P
M\GWU_'>_1T+$Z.N./S6/J4S=L:DC.9/TIN:3B'!&XD.RW6:$K'2I<N22C[!1
M<R^D+&-!'3]:/QQ<X73U6D1,(-9E)!AD.;EGSQH-'H-H-'=7RA9'5O7\A^;@
MLKW<:]M5IUU\VJIQ47P'T[(UDH$3+"K+<R=L9UBLTU>.9^O'"J A2OM7&7&'
M2;1NV=844$85<XWU4\0+9WYCU=?S#GMFAX=8]?M?HNN@$.=2A,  86(]B*EA
M*"O6#Z$.]HM@"[I%75-VY ,3CER;P*2V5;I^F]564354UU44QG?3&8JN?/:P
M;;!7O#TR:TS+8+"YE[F>WJGMFQ(.;L&/>R="/7/#YI\'P$XKY_Z\OOLVRV??
M"#P&VJ:VJC%SE73*60M8WYQ\JQ/VS?'ZE">]EV7UM[2]N;:[#RNO[$D4 Z%U
M))A6]9P&05T(+HIVW>C:(PO0">GUCD'<DD$OW]CMB"!QLW>*&Q3)(6W6:K.W
MC(@<,SKG_!ZE<Q?0Y96R^=1UUW3M?JM<75F16I1-CU>RNV/%NO\ V1L:82BF
M38&=]@K'E\DNNO)B@SK:SYI(T7+VU)):T,'/Y2''(H"+  B57*#MJR89ISOF
M#;,6!R&0YAPMY.DK$7!%P0+6)N#GK?HS)Z[A7^F-T!G\'DTM[<=;)?3E?U7)
M8--(D[FDIK.P%II8 F4)[P1G"HS44ZF)TG+DY0B#VC8(D.14+&2(QNS;.G*2
M^K?$#F(T/BRSO>PT61Z1D,Q;/.^7-F?]5@:N@?8<Z;O#M'J'@=;W/<L>J^%U
MO5,^W(&0L JRMS<B)C%+;=P=^W7+6?)4YQ+21%J#?NQL/V^#<71+%DAI=RYI
MMD.:]SK<]&>F0^907N3SVRZ!S]/^EUA?)]-NT3>.3?WP+5C\"MKK[2[H("1E
MAM)]F5*=C)RIERW7E!)P)S7*^F3"L01T:^T<1M6+^=TKC1THL=;+6]A?R*CC
MUFWE*Z/\Q53A$X10S>/8*H^MT4%3FZI>U@L.+RL1#$I(09D70MF<.HOUA>A1
M4:T>*#6"_LY=-8JZ23',=LZ*OW+5MXBZ= )TZU"0->I25&I/&YF"&2B'R )*
MHR::Z/0\ACA5B;!E6:GG\-V-*C5W+%ZVWSC.-5FRZJ><XSC&WGQGD55+_*,?
MDTE/^<(A_P!>KSP'_:5_\KZK^NL&_P ]Z]%[%O[[(?Z!B'^2KA:?N-?XNO\
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M;MO2J3PFK[@S4W7/I>_J"="EJ.[ 5[)9=;CY()K5)&IJ/M;>SXM(XU)$32Q
MP>L!B$B0)*+)AD3@(L5-J'FX\>'P]>?0N;O/DN.^:ZS<[[SV[I&EK-N3<FQ
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MC[YT7<%<[O':B0\2DQ7N0T@$<D2<A<D1DCOK7%B!:QR\9OD<@77-]X<3:V^
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M<T@AS7 D$$$$$@BRH):0YI(<""""000;@@C,$',$9@J.XS4%70PEJ8BL"BX
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M34@D5%1$UD\X<X2R/#G7Y$F-8M-1MP^7$:R2C:QD8IW3O,9CB(,43@3=T41
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M!R/?O$&^BV/]AQW-P[\ HO-8/HT[:J?PB?X:3\I/@Y'OWB#?1;'^PX[FX=^
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MB3L2Y:[N4Y1U*VEY.WVNYNMWK_;;QMHM)-U":3E<AE]<607KE],O4EI>,3
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M.$3A$X1.$3A$X1.$3A$X1.$3A$X15IO'_;FH/_,#^AQ'/+]O?N]L;_\ (O\
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M<%',Z*1$>R8/?7<NU$F)+U2[ES8.:; DGO@&@:DW:/%:_J3>RN6N&EAE<WX
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MG3_7Y%(/9:'SQI9_6[L# H.8LY2DCUD"9C 8R^CS"7%(+:\,U!$343^%9F/
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M.DXUCOST< T_/IW8D*G=0S/-0V;)1[2:U]8CE_6.VHI$J^CYI>+FPSVV:M*
M9"083B//4V",T?Z+QKVHT:N60Y&XMSC0^3AD<KCF09C,'FSN+_/EKTK9XW1D
M%E/;M]3-Q 0EMQFFND-1M8>-L,>ZEXA^;LNR+;$6U.V@Z=E9B^2-27$ BPMV
M0>FS!D>,3U%>VET'2^[F<+C*Y/R6TMSE!K8VR MS\0=;E0O46:%8]7.MER=B
M0A.\9C&X[:_7^@*@,#6-F/["W96K(X]%\06 G&;[!FP2T$@\8%OYT]<ILPL+
MT?OCY08$6*D=Z3F;:$BY^>W6;VR/!09!M];&UN(UTZ@-?'FKI=6*8NJF:.I6
M*%9%'8[\%%K6D<YJAB(VEC)H+G9B52>NZAA<V4,,=P :FMSP>--R" LXS.BX
M[J*&)"A6[)="$W)]>GCMT^)9 $ >K4]0.6G3=4$J^(Q6/=8O)L=B(^$#(7U8
M?8*CR<]LUH-:(SR<O^P9$ZSO(;+)&DEJ9D# @Q/G'#T46=.V@_,9#[H(-\1X
M?ZI2<W#AGEGPX]>6OE6(&32;WN-<CKF,^&N7$*U9&MEHCY2^F9F1GDXFI>PZ
M"[7+^J28FTS'(7'0<VZXYC<1@\;$L!HH,,&I&GVQ$JN@_D\G?+>NR,X1PU&-
MQT^]/6/_ /I7[[_E^4?-[9*W=9]@(;:THDT2CT:MX,1BFB^Y%[/Z5M.N(\]P
MW(Y&;XC\FG$3! I)MLOCQ4= ;]_LNQ\Q!+&[/.%N+=7E"H()('#753CR*IPB
M<(G")PBKAVJ_%(\_XZ#_ .HWYYIV6?WH3?T^A_QN6T;(?=EG]'J/\(6UXM"M
M_-C_ -_8A^UC_P#<(K^]<[H;5[, #_\ D&#Z#_\ 8TOTJX'<C%?!U;YM-^0O
M[[T:V^7L0^L(K^]<ONLV8]\&#_&-+]*G<C%?!U;YM-^0GO1K;Y>Q#ZPBO[UQ
M[K-F/?!@_P 8TOTJ=R,5\'5OFTWY">]&MOE[$/K"*_O7'NLV8]\&#_&-+]*G
M<C%?!U;YM-^0GO1K;Y>Q#ZPBO[UQ[K-F/?!@_P 8TOTJ=R,5\'5OFTWY">]&
MMOE[$/K"*_O7'NLV8]\&#_&-+]*G<C%?!U;YM-^0GO1K;Y>Q#ZPBO[UQ[K-F
M/?!@_P 8TOTJ=R,5\'5OFTWY">]&MOE[$/K"*_O7'NLV8]\&#_&-+]*G<C%?
M!U;YM-^0GO1K;Y>Q#ZPBO[UQ[K-F/?!@_P 8TOTJ=R,5\'5OFTWY">]&MOE[
M$/K"*_O7'NLV8]\&#_&-+]*G<C%?!U;YM-^0GO1K;Y>Q#ZPBO[UQ[K-F/?!@
M_P 8TOTJ=R,5\'5OFTWY">]&MOE[$/K"*_O7'NLV8]\&#_&-+]*G<C%?!U;Y
MM-^0GO1K;Y>Q#ZPBO[UQ[K-F/?!@_P 8TOTJ=R,5\'5OFTWY">]&MOE[$/K"
M*_O7'NLV8]\&#_&-+]*G<C%?!U;YM-^0GO1K;Y>Q#ZPBO[UQ[K-F/?!@_P 8
MTOTJ=R,5\'5OFTWY">]&MOE[$/K"*_O7'NLV8]\&#_&-+]*G<C%?!U;YM-^0
MGO1K;Y>Q#ZPBO[UQ[K-F/?!@_P 8TOTJ=R,5\'5OFTWY">]&MOE[$/K"*_O7
M'NLV8]\&#_&-+]*G<C%?!U;YM-^0GO1K;Y>Q#ZPBO[UQ[K-F/?!@_P 8TOTJ
M=R,5\'5OFTWY">]&MOE[$/K"*_O7'NLV8]\&#_&-+]*G<C%?!U;YM-^0GO1K
M;Y>Q#ZPBO[UQ[K-F/?!@_P 8TOTJ=R,5\'5OFTWY">]&MOE[$/K"*_O7'NLV
M8]\&#_&-+]*G<C%?!U;YM-^0GO1K;Y>Q#ZPBO[UQ[K-F/?!@_P 8TOTJ=R,5
M\'5OFTWY">]&MOE[$/K"*_O7'NLV8]\&#_&-+]*G<C%?!U;YM-^0H'M:41N2
MSFJ?@\>#G/4OAUZY[*(M7_JOK(<=ZOZQZJJKX7C> OX7I^CXG@J>CY_0V\WG
M^UV+89BF/;)=S<0HZ[D.[W+=J5$51R7*T=-R?*<DYVYO\G)N;UM[<=:^Z5LF
M"T=524&,=LTT]/RG<_<Y:)\>_N32[V[O@7W=YM[:;POJ%=OGN"T).$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%3[R@<1/3OI'VEBL78+E3Y
M.DYWL,%M4]UGA%P/"N"F6+)!/&RCA\[39*-V39/791PZ4103QG=37'*-1UA0
MY@VYEN?4&Q8C:W5^A)Q"##0T *U3!T='#1=-;+,D+CH\6;#/L)[;>K%@9=F]
M$E6>^<*M"#-PAOCSZ>?(ZF^6:"UA8WL+*QW(JG")PB<(G")PB<(J;RGH[4TH
MGM@V'K-.P<0*6H88GI^(K;L):];1:2DQ\;#Q))T^ 0F2A&GC*QX",&N%T?#<
MJH-\:Y7Q^#S6YZ/(#ZPI87OGGTD>HK;S746C7]?UI7(".DZY%4P\5)5(:K.1
MFX9+Z^(/&C]B8> Y0->>U7.\E9E2B,N1.K&&DOW(NW<F;E7RF'.JYSZ==/5H
ME@;=&F9OY=5_8QU(I>*,H2W'BY"\(0BXGM_)28[+#Q^62BW"4.D<#(3*;R(L
M]=DI0]<Q>3D!6C5^M[.8LVXAF,9LF(<<U;KD^2WB'!+ >6_C/%?:8]3Z8G2E
MENCH<WH6M&?0>TS$@#RD\!D<?L:MXE'H5"IE!CH=ZS)PXX" Q@6W1<!G*&CO
MSD$R"3MH5(M7,O\ -[>5+>N_HLL,)Z;4L.%%69!*9RPY(K)J^UY5.YG-S\EG
MLJE],R(5)JTV,R0@ZW7R!BC\,S2%Q4<B/CC9FH011&)J%22SJW]5OG2W6<[Y
MF_3Z%/>L*':SY6Q<%)/DLM#V\*V"[28QM#-1S<TY.:%$X=EU\'TY/NY=;M%Y
M-HRP86%)MQ:CK9D@DCK%5A0U30P%:4XN1FS>*SZP(W#8><*OB#EZDVC$$5/N
M@ 0&R7WV;!6&",G-E2*+'1+VH3>^MO<JJ(-_">WMY%+9WX_)[>VB^46J"$0R
MQ[0M2.LWK"5W'B&J3[."+I426?P0,M'0!=$0IOLS8%\ E$!1%^ST15*LQHI-
M]XV1S79-?3H5MKTK3;=ZV0"XSX67E2U@PJ:A !>'I3.K)[(J\DQ"%'W#5Z7A
MQDE'W3?)4 Y(,FI)JB[2W>A":6Q*/OA+UPZ77M_;V]CQNH1XNKV_2.!482SH
M;1,E+UB:$/+6K)U3E;:U-7&E06[/*T2C4'RX3<NQK7:,&&3I5P6V;#]#A)RY
M6?FTQ0O!1P[W9);X7/EYP#ZTL,NC3,J9HE1H&((UNFA-KA/[UB]ESX0[F5MS
MF6/9"I,F;UD^1GSHT7=*SMH)1?*;1=I)=GZ$9709N ^C55HAOHOU9] ]AXDM
MU^4^Q\=U'T1Z:TM"IT&FP=*;*M(E)Y--X#716>R8K5%<S.8Z%M)'*(/7SQ\H
M#!DWFL@D6&&FJ2XZ.?"$U\%F(3U]7SK^GV^3Q\;I;T:?+[::*:BM81$U9L,M
MU^T=*3:!12<0N./='SA)FW V&_AQ*3H.!^FV&SM=RZ@D=W;.5M-E6>K=QHAM
MKJZ6QM/;V\J6%[\;6\2D'A5.$3A$X1.$3A%ACL>"2<?L*D QH7';JI+[,WR6
M%D-E4<YV24SIG\&=D\YSG7/^[/X><*OPZAQ2G-)B-+#64SGM>89V!\9>PW8[
M=/%IT/!?>GJ:BDD$U-*^&4 M#XSNNW7:B_,>*TGW+51\@8U]')_U\Z/W$;)>
M]_#/-VKG]W<8\(U7PA3W+51\@8U]')_U\>XC9+WOX9YNU.[N,>$:KX0I[EJH
M^0,:^CD_Z^/<1LE[W\,\W:G=W&/"-5\(4]RU4?(&-?1R?]?'N(V2][^&>;M3
MN[C'A&J^$*>Y:J/D#&OHY/\ KX]Q&R7O?PSS=J=W<8\(U7PA3W+51\@8U]')
M_P!?'N(V2][^&>;M3N[C'A&J^$*>Y:J/D#&OHY/^OCW$;)>]_#/-VIW=QCPC
M5?"%/<M5'R!C7T<G_7Q[B-DO>_AGF[4[NXQX1JOA"GN6JCY QKZ.3_KX]Q&R
M7O?PSS=J=W<8\(U7PA3W+51\@8U]')_U\>XC9+WOX9YNU.[N,>$:KX0I[EJH
M^0,:^CD_Z^/<1LE[W\,\W:G=W&/"-5\(4]RU4?(&-?1R?]?'N(V2][^&>;M3
MN[C'A&J^$*>Y:J/D#&OHY/\ KX]Q&R7O?PSS=J=W<8\(U7PA3W+51\@8U]')
M_P!?'N(V2][^&>;M3N[C'A&J^$*>Y:J/D#&OHY/^OCW$;)>]_#/-VIW=QCPC
M5?"%/<M5'R!C7T<G_7Q[B-DO>_AGF[4[NXQX1JOA"GN6JCY QKZ.3_KX]Q&R
M7O?PSS=J=W<8\(U7PA3W+51\@8U]')_U\>XC9+WOX9YNU.[N,>$:KX0I[EJH
M^0,:^CD_Z^/<1LE[W\,\W:G=W&/"-5\(4]RU4?(&-?1R?]?'N(V2][^&>;M3
MN[C'A&J^$*>Y:J/D#&OHY/\ KX]Q&R7O?PSS=J=W<8\(U7PA3W+51\@8U]')
M_P!?'N(V2][^&>;M3N[C'A&J^$*>Y:J/D#&OHY/^OCW$;)>]_#/-VIW=QCPC
M5?"%/<M5'R!C7T<G_7Q[B-DO>_AGF[4[NXQX1JOA"O6QJ2LQKI)ZPA,?:.T?
M3\)PBQTT53\1/=)3T=L9\^/324WTV_\ OKMG'^_GU@V0V8II63T^!X=#,S>W
M)&0-#F[S2QUCPNUSFGH)6$F-8K*PLDKZE['6NUTA(-B"+CH(!ZPI$YLBZQ.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X15$J_I'1M)W3([
MLJ)"95T^F*)C>65O%YB694P?-&]VJCJ4N:S4V7!,9"CEKKADY#:BV;3"SG*;
M#TW"FV:22+'/IX^50  W&7J\GMZ[V[Y%4X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7G=.VC%#=R]<MV;9/S>(X=+)M
MT-/2VQKKZ:JNVB>OI;9QKCTML>?;.,8_#G'"A(:+D@#G) 'E*^VNVN^NN^FV
MN^F^N-M-]<XVUVUVQY]=M=L9SC;7;&<9QG&<XSC/GQGS<*ZZ+]<(G")PB_F<
MXQC.<YQC&,9SG.<^;&,8_#G.<Y_!C&,?MYX1-=M=M<;:YQMKMC&VNVN<9UVU
MSCSXSC./P9QG'X<9Q^#./PXX1?WA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X141:06(7SVJOX5<L=#S^/TL$J()6T%E[!N=AXQ"=1<G)Y)-=HJ3T<A")
M\T6QO'D3CU@X=L&,8V8L5D-=W.-_OO.CBC+"6EY>7.:2'=Z0 VXSL!F0,C<7
MOPZ4015V)5S:N-D[*1E*RGAE ?$T31.DDFY-P+'2/?>,/<"6MBLVUS<]4&=>
MW(2C.N4A"*2*V+K7!C8S+"&DIAG7EJO6Q*R9&V&Q$*^"'F MQ'XNY/Q. /I
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M(:XMT-];'IXY+K*C&(#3PBEJV&I?-1,(:RY+9*B%LPL]A8-Z-SP2 "+W:0X
MB>YWVE%0%Y)WA.J+=>UY!Y&PBTSM9F(B;2( R+YP+:*ND!9R9")](@8IT89H
M%C\8AI@4EOASZBY(X9N_!^;8BX"SV;Q%VL)-R,\KVW03;(%U^>RYLV)-@=(7
M4M4:>&1L4U4&1")CB6@D,?*V>1C2]H=)'"]@SW2[=*\4J[;1N,'K7%Z5?;L@
M"4829,[:FH$-%%HS$F#V*@IE@ZDF^F3"125@P!G=7AEG%@!D\(;#"#Q\'29K
M!5S!L)<&'?8#)]HTDW)N6V^UL,Q8$FQ)&>ML9<4CCDJ6BFJI&4;@*J9C(C'$
MTQLEWQO2MDD:UC[O;%&^1H:XN8&EA?KB799.*SWL*I*"1*51*.RBB8S4<7B8
M@4_/R U:4!&%6@"-92P-V-/9&9>;OT7!TOJP&LM7#I8B-#M%E$;R5Q&  '$/
M+R20 &N().M@ . N>8E8]T!%-6F1SI8F/HHZ6.)C7/D?4PAP9';=+S(X[UWO
MW6M!<7-8TD>R5=G!VT;E8\N*LZD[!ADKI!L=C)8#7DBE/L&TK3CT/ %0^[64
M26!'HC*7:A6,&S0J0.2\913-+H,VTC8"4'(19BQ:]K@^Q!<!=C"X@Y!P(R(%
MK$V!RNI+B+3'(US:FCJ(9:,21NC@DEY.IJ611N:1)) ^*4[\;WMD+XP'EH$C
M67TCL-VV+@H)9Z]41"Q=M8/- U=N;G: H80K\1-D9E'@TD [#S1UQ*'Z+'+Q
M[&",A0@CV-CY#OLQR72<-]W3?**$%S \M[YI=N7(=NV-C<"US]L!>Y&=L['Y
M5V*.9#4&EBG(AF93FK#(G0-F$T;)&;KWF5P;<QND$+HVR=[O@@D2[,>U,8B1
M6>Z(0&RY9#:D=IL;<LR+#(TZA]?.\"V1PF@^0)2H7+))O&09)B8EOP(C$F^#
MS!QC+W_6T7+1#!L1=N]\T.?]HTDW=J!G:S;D6&\1<Z+E38G'$^<""HEAI3NU
M53&V,PP'=:]P<'2-ED,;'-?+R,4FXTBYN"!BIKV]C$3-V:)%UE;$_8TV,!R*
MRI-"QL,7CD>BI^),IHRD35T=FX%Y(D-0;I=PL+CC H>3T&$'&1?J6PUT1-A)
M#;N8TO)#0XNN2';I!LTVSXFPX7UMC-BL<3ZAC:>JG%(UDE1)"V$QQQ/B$S7@
MOF89!N$DMC:YXW7$ML6%T63SM3)6<C[.C]!TRC=<5E0-=V9%K/B@.N#Y)AM*
MT)X_7D38)*9EYSF3S80/;Q,05CS5NW=1N09DZ0AL]".S.;8A:(Y%SY'-+"7"
M]MW*X;E:_?$'B+:&W&GQ*1K\1 $L=/34$%3'4Q,IY'-Y03.,@9+-W^^& 1,=
M& #&_E0T.87S?+NSH.,R*9!15;VI8 FL%!+>TYE!@L>) 8*[+C&)S1BX9$)0
M*E4J)# ),:>/C8#&Y4\#"WS;=RCZYOZEC 1$AIWF-+[[K7$@NL2+Z$ $BP+B
M 2N9+B+(Y)F-IZF=M,6BIEA8QS("]K7[I:Z1LLKFL>Q[VP1RN:QP)%^]7CG7
M:@1 EY.1?U3;A&N8.<'Q^9VNQ$1-K$ ;Q_N*34>-A9V8AI[) @E4RR3,'(M#
M3(Q#;#K#-P0V9.\(&Q%UAOL#G"[6$G>.NI +6G(V#B#T#)2?$V0&1SJ:J=3P
MO:R6J#8FQ,+MV[@V29D\C&;XWY(XGL&>Z7%I6RT_.)/*K([- #Q+#X37EM1Z
M,1!KADP:Y$@W]-5A+'3+*[-JW</\J'Y$8?8<DE7CO3#O#5-?5FW;-T8]H#(B
M!8N:XNUS(>YM\SED!IDOI232RU&(L>[>9!5,CB&ZT;C#24\A;=H!==[WNNXN
M.=@=T "P//FN<G"*C'E,_P @+MG^AB5_S"?*W4=8]:CM#U'U*R-$?B/IK]%-
M=_J@'X=J>L^M&Z#J'J4K<BJ<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(N7OE??R,S?Z0J__ *47YRJ/]V'_  N]2US:K[DO
M_GX/\174#3]QK_%U_DQSBK8U^N$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A%Q_P#*4?E ]&?_ %-?J3!.<RF_<Y__ &O\3EJNT/\
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MD&T(:IB_1]!'1?7#3&'*"\1(/>.)/&]W[V73;GMFN9VA(&XFUKHP*V%D<(S
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MK*$K"5@KR1R+J=7EE2"Q)4$1>R0LP Q..#2HP9%H.T%+GMF %$BY1+E#DHP
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MP)&NI&V0$@F8]\U+*O)84,&9N\$B6@3U5%+=\1]6;Z9?ZHX<ZKK(I+5KA?,
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M_I-_2K)<BJ<(G")PBX_^4H_*!Z,_^IK]28)SF4W[G/\ ^U_B<M5VA_WW!_\
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M$7FY58G%R48D;E@@#D[;+5LYP]1"OWRP);=% JBQ4>M=5_G*;B,[P(Y-HL'
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M6^[]\XV1;Z9SHBGG5/7.<:XYBLE3*']N+$+=N7 $LF#3ZL3.Q[(ZRU><T'>
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M;/FUQG/FUQG.?-YL8SG\'"A( ).@%SU!<?8[9\^Q(^L=H!))<B\<N:[Q,?\
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01.$3A$X1.$3A$X1.$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g107876g64j63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g64j63.jpg
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M:W _;75DV#2SJ"D:Q1Z"I1[&(\.HQ,4?X&!XF@)?^=VSV;.ZUOP'8>>U'/\
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MY(KJW;ZMQ:R+/%\>[QD\2/4.%(/8C=:R+V(3FSNXY["]'9K+(P/:7'?8[1S
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M@5U'2DZD2_+2JS.BM\-S4OF+I%-Q![(JLPS""D+LS@'00KVZ,859-N=C-L9
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M+PY$DXGBW!U;BWZK<2='Y'1H@_8NC"1J]:.3@'D)$'**Q@*'8!,)4SF$  1
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MO0&"Q3I=74;YK)+H^W90+,(V\S[+::]EM5#=TX1M*G\<VMU(B
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M@AW\ H9S%((#V,?NF$],'<D<II(8%]26Y$?;K2_Z]34PUP1N62*)?7;%B/P
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M<O#KY\9CX:Z^: ?'==8IQYX$3GS';P+"B?\ < NRZHT*41^P"6R0ZY^W\C'
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M_F9LY#% 2&?B3[% ,K+F8W$\LS;W(Y8 ^87R5>W;W5 'W57W$IGFEF/G(Y8
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M,F<2_P!WOHQX'Q]_S /\_C,J]=9U?,V;_P ZW(_V)$K _P!%O2S_ %5R$?\
M,O ?]Y#)7E7O3:TVKY"PN&RF8C]@7D*R]3*/\BEJ[100#^!E1'_SLDI](&6'
MU[7'O]D=PA]/_K+#X^GK4&3Z), VS%?Y>/Y-+9R*/L'L:-K[6/VUY1WTS:D?
MO[':EC;?V?=UZ,>]OX=_1?L/+_1X]_Y9)7Z0[H?7QMNW\V>1/[4>H4GT06)_
M@LU=I_SEK#)_LR15UI>F1$@/YMPR(E_@6DMBC_K&SF#_ +.9#](DOIBH_OO&
M/_[85B_X'[?USTW_ /;T_P#Y9KLV_3-J)1#W>T[(N'Z@WK\8U$?[A5?/.W^D
M!S&WTAW1^IC;=?YT\C?V(E94^B"Q'\)FKMOYEK"G^U))7IF739T^D(#(738[
ML0^1!J\K+$IOY""E:?& /X]C@/\  0R._P!(&5/\':8]/YR7#_V7"?V5,C^B
M3 KKQ<AEI/B$DLXP?QM)"/Q^^O9,.GSQY9^/N&URE>WW]_9Q3\O\[Z6QC?O_
M .;X_P NV1'ZYSK_ %6M(OYEL#_O'DJPB^B[I6/ZZ7\__.WA'^YCAKVK#A-Q
MFC_$2ZV([4+V_K']GN+OR[?VD5)_VWS^H @ #_#(<G6'4,F__.!0'T2VM%U]
MA$'+_6JPB^CSH^+RQ <_&6\OY-_<;KC^"BO9L>,''R/[ WU%25/'MV]]$)2?
MV_B,D9V)OY^7?O\ KD1^H\[)];*7@_F2F/S_ .;X?_#TJPCZ.Z6B^K@L<=?Q
MD"S?[[GO[Z]<STQIZ.[>PU3K=F)?L9M1ZRB;^\3IQA3"/\Q$1']1R*^6RLGU
M\GD']=->7!'X&353H^G\#$-187$QC^1CK-?[(17I$*A38T@G;5>LL$TBB<QT
M(2*:D3(0/(QA,FV3*0I  3"81 "@'<1  R.UU=O]:YN'[_I32-W^]CWJ8MC8
M1#:6=I& "=K;PH  .Y[(  !Y_*JD_++?1>3W(JW[(C%$QUO3SO-<:::($*FR
M/5H9\J2:N**1"D3%S>)U-S(HNA23=E@48B.7$Y&A!SM.'QQQ&*@LWW[7/QN\
M@Q.V\>108[<DDGC;1$*5WQ\4R, "37Y^R>27J'.7>70 6%OSQN&0 !/9(7(G
MO0  .5].&=7T&%NL<9) K)/ /C.GRCY!H+6:/![IK1JT1;KZDX2 \?;;FLH=
MS1J$J4Y12=LB+-5+-9FIBKMU8V/;Q3U-$99NH,3J3+?D;%GPFXW^1#P6I'9H
M+<=KFZ'?88@B&%AHAW9U)X'4SIO#?NESRPS('P^%:&\R((W'=WI)>RL&]'12
MIN;E#R4HB1N 76K6OV^V<9K] 4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2M%NH)Q5)RDT6_8UUNW3V]KE1S=M12IP3(J:PM&P_4:
MDX<&\1"'O$<D,(]1453:$D/HTJZ!0(E,@['TQFOR/D5:8DV%X!;7Z#9'A,WN
M3@?QELY\5#HGCXB#ZYK3^M>G6S^))M0JY?&LU[BI3H$SHOYRT9NWYF]C!@D4
MD)S,4C;$>JJH)"SM<"L@_9K()OD',?*QCM,R+V.>HG4:2$>Z25(55N^CGB2J
M)P.F15%=$#@4I@+G8R'MY@58<D*O&ZG:LI 9'4@D%74@^9!!T=]ZXC&T.3L3
MS0A+B-HYHG!#Q2#:2Q." 5DAD#+W (90PUVJS3TNN2SW>6A!HESDA?[5T,X8
M4.U.'"OF]L-8,T,IKZYK>1C*JGF8)JI%R#E911PZG8"6>N!*+M,!Y/UCB5QV
M3%U;IQLLFK74  '&*;EJZMQKR$<K<D   BD11OB:[#]'V<ER>(?'7LA?*8)T
ML;EV/OW%J5)Q][WV3X]NOANS$LT\$K-KD*DOS4:WVF*4Q2F*4Q2F*4Q2F*4Q
M2NEL=DKU/@I:T6V>AJQ68%BO)SEAL,FRAH2'CFI!4<OY25D5FS%@S;D 3K.7
M2Z2*90[G. 9]568A5!9B=!5!))/D !W)^0KZJLQ"J"S$Z"J"22?( #N3\A57
MBH[OUWSCZ_\ I/9NC)1]L+5FC=,V:O2=Q8PTJW@O<P=,V^F:2;+O6J"@09KC
ML6-CHV7<HM6DL^\31IW35PS<N=@:)[3"RQS 1R33*P0D<M%XNVMGWN,9)'F!
MYZ(-7K1/:XB6.4!))958*2.6BT?;L?/BA) V0/, @ZM0YKU4-,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4JL=HWOU%NMWL_>*P_6M$\#(E.GT-4?\)AW
MMSAWLS7ZXY1.7^H6-)7Q;8VQX630\3G9U2N)*&6132$;^7]XXF.+RFO3R<>1
M"$ L-'RTG!"/BS:J\E_>>+CB':6[/-_CQ(!8?$:3@A'?NS>6^UG'*"J.F*4Q
M2F*4Q2J^'+R_VNR[^N*$O*"NA1K \@ZJB1LU0+$QS%P19)),R*)%'!S.2F=*
MK.SN%#+J'[&*EXI%[GTM8VMO@[0Q1<6O8$FN268F61U().R0H"GB H4!0/7N
M?RWUWD[V[ZGOUGF++C;I[:R4(BB"*-PRJ.*@L2^W9G+$L3W"Z RW8.1FX;%Q
M%<OIBWJNY.=V]-ZYF)08Z*1>R%-<T%M*N894Z#)-(A%W4BX*J[022?BV!-L5
MT5$IBGK(,!BH.J%2*U"1PXN&_BC\20HEVM\T:S ,Y.U6-2$)*<MMQWW%[==6
M9Z[Z&>6XOFDFN<[/B9YO!@627'OC%G>W)2-5 9Y&!D55E*:3F!O?@>%FT+O5
MMPTRCPLR+6IW&QB2QPQF;!9&2,,4Z226.Y5;&?HJMO124;BW=HD(<@]R&(LN
M16;U=CK.YQ5W>30\KFT@W;RAW4Q[E0D!0W!@VR&Y*21Y$$ BL^CW,Y&RSV/Q
MMO<<+&_NR+NW,<3+,? =58NR&52G%2O!U ([@AF!GRSB5?IJF*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*5&YU2]]N],\8I:K5J0,RV#O61#4]5504\7D;%2[1=>^6-
M,I!!8B<14$I!HF\0,55C+S$.X(/D!0';.C<:M_ETGF7E:XU#?3 _5>2,@6L)
M)[;DG*,5/UHXY!6A_2'EY,=@6LK5^%_G)1BK9E/OQ13(S7UR .X$-HL@#J04
MEEB8'8%5BWBB-9@"IQS-1P+%LUCH>,;IF5</GJHI,8J.022 5%G#UXHW;D*F
M4RBBBHB!1,.=:4&>;WV YLSR.?)5[O(Y^ 50S'T %<=F>/&V),2%EMXDB@A4
M;:20\8H(@!W9I)"J]AR)).B:MN\'>.2/&#CI2M>O4T3WB324NNT9)/P,I)[%
MM":#R? ZZ8B1PWA"E:5B,6+X@K%0;)42 HHH)N*]194YC*W%TNQ;)JVLD]$M
M(=K%V(!!D]Z9P>X>1AY 5W?I#!?N?P=K9RZ:^FY7N3E[$RY"ZT\^V'9EA]VW
MC.AN*%#K9-;=91UL],4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE5<NI;H,FB>3ZMS@60--><D$9*X-$T4_!G$;6A@0"_1I +W*D
M%E:N(^XIF5,4SJ2>S:39($F1NW8.E,D<EAA!(V[K$%+=B?K26,F_97/Q,+![
M<Z\D$1)VU<&ZNQ0P?4KRQ+PQ_48EO(@!I(<M"%]OB'H/:HREV-]VE,P4:4UB
M3A?NXW'3E5K6[.W8M*1L%RAIW9H'4]-HE#6U\@2JV)V)A!% M7N!8MRZ?'*9
M9*&=RC9(Q".5!R=G,?\ E7"WEJJ\KBU4Y"S_ %O$@4F>)?4^-;^( H[&14)\
MJ@X;)'!=28S)EN-I>LN&RGHH@NY%]DN&]%]FO/#Y2$$B*21 0&-6Z,XC7Z'I
MBE,4IBE,4IBE,4IBE1<\Z^K/QDX0(O*I(29MM;V,F5.*TI07S9S,M7S@H"S"
M]3A$WK"C-%C*(&!N]0?VAR@X1=157DFQCK)V%GC;B[(8#PX?TIG&ET//@.Q<
M_9I1ZL*G6F/GNO> \.(><KCM_FCL7^T:4>K ]JBUKG#?J)=7"=BME<\KE-\8
MN+)7R$S4>.M2;K0EDFF!3^HR<'J\F+H\4],B8XENFTDYFRH**+#7J:P@Y! [
M>P:ZL<:ICLT%Q<=P\[:*@_)AYZ('NQZ4^K$BI[7-GC@4M%$]QK33,=J#Z]QY
MC^2FA\7)'>PIQVXP:(XHT)MKC0FN8&@5Q/T5)%2/1,XG;(_13%,)>UV-Z=Q-
MV25,4QBE>2[YT9LB8&C(K5DFBV3I9[B:X?G-(SMZ;\E'P51V4?( ;\SLU433
MS7#\YG+MZ;[!1\%4:"CY #9[G9[UGS,-8:8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*T,ZF'*$G$/A?N?;;%^5C=%H$U&UEV4 CE38EW!2#K[QF41*"RM;
M(L^N+A#R**D?7'H%'R  &986_M-W%$1M.7.3X>&G=@?YW9-_%A4NQ@]HN8HR
M-KRYR?#@G=@?YW9?M85KIT0^+Q^.'!:C34\P,UV%O]P;==O5<D$'Z4;9&C=*
M@12RJ@ X!-K2F\5+JLUP*=E-6"<()?4.H8^?+7'CWCA3[D/YI!Z;7ZYU\WV-
M^H4?*LV4G\>Z<#ZD(\)=>1*D\S\/K$CMYA14OV5E5U,4IBE,4IBE5ON3W_&#
MV]_Z[S'_ 'H9W[IS_P"@L5_T.+^ROR9UC_Z4YW_^HS_[0KOE?^)XR_\ :5E/
M_A=#YA'_ *5/_P#=^+_\QFJ2?_0-/_O=+_\ DT-<'B=_QC-3?^LY?_X]]GKJ
M?_Z R?\ T?\ _4CK'T1_Z68/_I@_W4E6,<X+7ZNIBE,4IBE,4IBE,4IBE,4I
MBE,4IBE5=>IYMD^U>84C4VCD7%7X\U-C2F*93^HU/?+D@TM%VD$!#X*X;1AZ
MQ6GA/NDXB'!![B(]NP=)67L6 CF9>,V5G>Y<GLWLMN3#;(?7BS^-,O?N&!K@
M_6%\<IU=/&&Y6W3]HEC$/-3?WJI=7LBGRY)#[-;./0H:\7T^]-DWCS"H+62:
M@[I^E&*NZ;210@&;.)N*=)Q>N(M0P@8GK_BER6Q>V5*8KEG77("4.Q3A(ZDO
MCCL#=.C<;C(,,=!KS$<B\[QQ\O '@\A]5I1]E1NG,>,SU7C;9UY6F(0YN\!&
MU::)_!QL1/ER]I8W!1A[R0$Z]:M?9Q>OT#3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*T)ZE.C%-Y<3K^A#LP<WG6!$MOT$Q
M">;D9VBHN7\C&MRE#S64L-54L$ DV P$6=R+4R@']$I1V7I+(C'9NV\1N-M>
M[L+KX".Y(1'/< >%.(I2Q\E1OC6E]?8ALKTW=M O*^Q97+V!UMO'L0TCQ@#N
MQN+8SP!-Z9I%WO556G23.X590B9O\$GHDJC=0?DR!G2!5FRWQ]EFJPIJA^I%
M4NW;N';.PJ7MIP2/>ADT1Z'B=,._HPV/F#7%9%BR>/90?S=Y; H3WX^(@9&/
M\J-BIUYAE^(JW)P6W<XY!<5M0[$E7(N+4->"J7H5#@9S^.*2Y6JUE<NR]Q%)
M66?Q9IU),1$?:2K8X")3E$>*]28X8O-7UJ@U!XOCVNOJ^S7($T(4CL0B.(R?
MUD(]*[OT;EVS73>+O9F)NA![)?;.V%[9,UK<E_@99(C,!^K(I]:VWRCK9Z8I
M3%*8I3%*POOCD1I7C)0G^S-Z[$KVNJ>Q\TR/IMT;WLL]*F94L37(5H1S-66:
M63(8Z,/!,)"143(HL#?T4E5"988);AQ'"C2,?11Y#XL?)1\R0*RQ0RSN$B1G
M8^@'D/B3Y*/F2!5>*X<]>??52LTSJ'IOT&>T-Q_0>J0EUY.W-0\!.*-#>)7
M-[,R(_0IJYT%2*)UK7_XGV29,S20/+P,>N^;(7:V=ECE$E\XFGUM+=/>7>^Q
M*G1;[7XQ^8TQ -7"VEI8 27KK--YI G<;]-J=<OM?BGF-,=5)#P5Z07&WAFJ
MSO\ ,(J;UY#J*&D9+<>P&*3E2)F7!A6>.:#6W*TBTJRBBYE%#3KEW,W%<ZSH
M%+(1FZ-'IP;S)SW>T'YF#R$2'S \N;:!;MVX]D[#W=C=0KK(SW.T!\*'R$2=
MMKZ!V&BWV=D\O=V-U+)E;5?3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I59;JE.W7.OJ0<1>F]7G*[JAT*2:[:W^5BJH5)L1]'&GY%I('(;LSD(;5+
M!=."=F%,HR6TFK3NHLHFGE_CQ['8W5^PT[CPH=CST0 1ZD-(1L?"/=7=@!:V
M5S>GL[@QP[^1T-?'<A&P/2,GT-686C1K'M&K!BV09LF3=%HS:-4B(-FK5LF5
M%NV;H)%*FB@@B0B22292D33*4A"@4 #* DDDD[)[DGS)^)JD)))).R>Y)\R?
MB:TSYS<[--<!M3M=G[:+,S#NP2XUVC4:KI-%K+<)XK4[QPBT%\Y:,8Z)BFA
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MSQ1,JAS@B5)+P2)O-CD\QC[2"SBEQ\D5NGAQM-:3F3@"2H8QWD:GB#Q!X Z
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M._3>*,6KMTW061:.C(Q;SIS+V,)N+BU/A!E5FCDBF*EB%7DL;LP#,0H/'6R
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MJ6=Q),OB1G3R N>2^3-MC]8GRW\36NSYG&P64JV]TC/%;.L"*K[+)$5B4;0
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MY%K-)#*#$$9WU& Z!Q[S+Y!NP)('?SUL>1-2+:62*4&((7?48YJ''O,/(,"
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M[URL2:TU 0%E=,TEY:%BI=PFDK*-(MV=1D20\"IO!0,X1[HJ)B->X0.PC)9
MQ",PT64'L2/0D=]57N$#L(R60,0C,-,5WV) \B1WU4'_ %^=\S\+H+6/$#6G
MKR&U>7^Q(6J(0D<H'U%W38*;A5%8]/TS JW6M5XDJ9 M04$B,E'!8V8BJFFY
M(%MAH5,TEU)VBM4+<CY<R#W^?%.3?(\35IB85::2Y?M';(6V?+D0VC\^*AF/
MP/$_"H4U?V<3GV510J5FXYJIE.<J:@["N"8J$ P@0XICK8PD$Y>QA()C"7OX
M]Q[=\MOR[9?JS_T%_P#$JT_+-I\)OZ"_]^OQ_P"#B\_O_P Q<<O^D6W_ /\
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M(#UK!^YB);G'1"X>4WF5QMB(VC50WM5W%$VR&/Z+-L:/;=7\@  #L =@#X
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MV5:+V.VMV_(ZVL[70NK96,<$4H'@"'Q6#E^7 Z(+*'+)J=IA.L<;T]E.BK;
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MBE,4IBE,4IBE,4IBE,4J$+K5UPHU;C%L#TP$T#M2TT4RW;]U/8-)=R7HB;]
M47H;=0 [_)D ^![#G0^@)=RYFUV?SEC!<@;_ ,DN54G7KI;EA\@3ZZKE/TGP
MA3TO?_Q.4NK GY9"QD?7V%K-3]H^VH>M16 U0Y <;+:"GI)P'(34ZKU4!\3%
MB96U,Z_,D\OT!2+EW1# /Y3=P P=OMN]W$)\;EX-;,N*OP@^,D<#31]O73Q
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MW'8*FE=E^!*]E!]53["S"L%UDY)1X5NOL\ &@J:#D? E=!5/ZJ:]068&IO0
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M?JE_"L'"P!X)N9)G6IYPT2,(&62BGIR (('[;%T^1SNEV.16(@;[D*9-D#U
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MQ?V:CD.(_FY%Z7 .WW+"W@P]_P"X8POQ]_GO_H_AZ_=W9>EC=?TXA_>:Q_\
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M5E'[F5DE&<5&(-V:!WTD\=/G1TTBF7=.%5E!,<YA'X\CRL7D=G<ZVSL68Z
MV223H  ?(5\=WD8O(S.YUMF)9CH:&R=GL  /E7N<\5YIBE8^VSK&H[JUE?M2
M7V/"4INQZG.4ZQL_R J>+GH]>/76:*G(H#:09@L#R->$**K)^@V=HB59 A@]
MQR-%(DJ'31LKJ?FIWW^1\B/4;!KW&[1.DB'3(P93\U.QOY>A'J.U5_\ HE;/
MMW'C;/);I9;ID!"VZ2M]ANFHW#KS;I3=4=/6QK.VA4G!P].+EF\G6]H5MBF"
MCMPPMUHD%P(DR4\+G*QK/'!D8A[LRJLH'Z+@=M_,:*,?BJ_&K?*(LT<%_%]6
M5520#OQ8#W=Z]1ID8GR*J/,U9!RCJEIBE5)/VG/54N$IQ:W<U:K+0)F%[U7.
M/2D'T(Z6(YC+;5VRJG;Q]689J6]5 O?OX0;@?M]MDZ?D&KB$D<MI(H]2.ZL?
MN]S\:V'!R#5Q$3WVD@'Q'=6/W'C^-50LV2K^F*4Q2F*4Q2MM> G_ !Z^%O\
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MXUT"OW2MN2O:_8'/UVQO(203'NA)Q9;1,S39C*-3?UC.4;()R#)4 5:N45
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MGG"S$^;2P2:'?RA/PKH/T97HBESV"=N\5RF8LU8]VML@HCN50>B07<))_E7
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MG)2K =_>-?#0G6NNFG+PVXZ]4_34_P >=HL_2:(;9C*\]-1K"D"GM4IJ;@6
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MAMH[JY\"*5C?2VT*2 F*-5VQ)0$ G7NJ">V@1VW6)DAMX[FX\&.5O;9+:))
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MXX\F-2;@=N1:54)4^NMFJ"82(!KV^+-HUU)/C (&,UJL^2$M7IAW\ABSAV,
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M[LT#^8XR)L D'BX5P"5%4O4.$MNH<3=8NY)3Q5#V]PHW):7<1YVUU%W!#12
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MMDH&-7.T=OUWTLI$7Z5DB,FK-DY76,SCG:P%)\)>/D8LF;"/#%)*UPA$:,Y
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MXKN\>ZN7E,-NUQRA5D.F\0K%)ZB!E=A7S?7$>W6ZX)5^<F-96]Y+1]?5I\W
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MR-U>S)86XQ]L1XC#=S*.S;8#:DCU<=O/W8]+Z[%O>31V, L;8^^PW<2#ZVV
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M[APNH1%!!%(HG56654,5-)),A3'44.8I"% 3&$  1SZ 6(502Q(  !)))T
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M\H"8/'N7\P!DFS?P[NW?T6:/?\TL W[":D6C^'=6[^@FCW]A8 _L)K1;H';
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MJQRQ+8\9G["96LZO35;S*RPD,19LO:W%<C'2!P40<+&+Z8Z_D>I<)B^2>/\
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M%1K[J\C%8[>S:QL?BY=R?M+LQ/WUZBK:DU71T_1IFM:%4TNW;PK=0@(4O;^
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MK(,IC'\LA9?8;F%3^#.#^ROJ-KJ:8=QLE>('\1F(TO\ U^X#/GL]P?*"8_\
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MR%ZFO+A=3K_9(*KWPN&EV9,3C)"?,O86K[^WE$=UU:7&KCFW."B&@=*(G#Y
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M  ,(RQ"'I&/4Q(\T/2-W?T*F3"Y<TFG$ *S_ $B@<8TSJ]R=)_I"^L_@4OO
M3^G?4_PG]*:B;UO9_B0OI^Z/[.!(O);3VK?A8HY/Q/ ^L!"LO@\?%[?6X^)R
M/EOAZ5B'58..M[_V _G\^,'X7M6^&[E[?VKG[..7U.?@\!Y\?%[<JUCKG4)G
M..;3F;,["D)':L_(=2^Y<=-&5>][+8TBG5>/=5FNRK1G,7^UED(;7&LJFS1E
M9*0>@P=-6*KE%)-D0KQ9VVGR85;XXM8%%NBX&*^NY(8#++(PDD4E88]-/<2D
MJJC8) \_= -3%U-)C%SLETS7DK=67&+QT-S=K;P1*88759+F8,EK:0J'=FX,
M%) X@,67WDIUD*U&:+E=B&U;6%[U6N145QRMS)ANJ+L&B:[)SM??6>%V6MOZ
MHTVQM'>M9>*8JIL7S>D_5OK:3J'=Q[4C0\B?"O3$C7BP>T2"&2Q:^C+6K)>.
MJ.(WM_8I98V$ZL>X,O'CI@QWQ$F3KF),<]U['$;B+*)BIE6_27'1/)$TT=VV
M2A@E!M'C4Z9;?GX@:,H./(R)<2>0<GR7U*79$K5*C5');//5PB= W%1]Y4J=
M;0IVQ6]EK5ZHZB)#1LJFY Q86T0=6M\0NBLA+U]LD9F[>TF2LEL+GP%DED'A
MI(3-:S6DJ%][CDAFW[RZ^O&\D3@@I(>X&S87)OEK+VIX8(3XTL0]FO;?(6\J
MQD 2PW%N1M'!^I+'#,A!#QCL6V=R!5O7R7;H.DCH.4$7""@=E$5TR+)*!W[]
MCIJ%,0P=P >Q@$.X9]5F4AE)4CR*D@C[".XKRRJX*NJLI\U8!@?M!!!K])II
MHID213(DDF4"D33(4B9"A]BD(4 *4H?H   !^@8)+$EB23W))))/Q)/<U] "
M@*H"J!H    ?  =@/LK]Y\K[3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*K:=
M<[_%5R7Z8')]#_!T-?[R5B[(]_<*:.B+GK*YQK-53X $%F#*Z$7(<P 9%90
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D%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g107876g64r13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g64r13.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "M EH# 1$
M A$! Q$!_\0 'P !  $#!0$!              <&" D! @,$!0L*_\0 71
M 00" @ "!00)#0T%!@<!!0(#! 8!!P ($1()$Q05(1DQ6)<6%SA!475WM=0:
M(C4W5V%Q>+2VT=;7(R0R55:!D966H;.WTQB8L=7P)C8Y0G;!"B<S-$-24_'_
MQ  = 0$  04! 0$              @$#! 4&" <)_\0 3A$  @(" 0(# P<'
M" @& 00# 0(#!  1!1(A!A,Q%$%1!R)A<8&AL14R,Y'!T? 7(T)55G*5LA88
M)%)SDY32"#34U>'B\35#8I(E1(+_V@ , P$  A$#$0 _ /W\<8QQC'&,<8QQ
MC'&,>./P\8QQC'&,<8S"YZ;>E5G96I.E6N;H-]\TV_\ I)>KM*MHC$V>.R5K
M-JA;'!'AN" J5!*0,SA4^5%Q,&S8<^+ZWU\.5'D(;>0QE5?(/>BJ^B\[]=_8
MC^UGC&/D'O15?1>=^N_L1_:SQC'R#WHJOHO._7?V(_M9XQCY![T57T7G?KO[
M$?VL\8Q\@]Z*KZ+SOUW]B/[6>,8^0>]%5]%YWZ[^Q']K/&,?(/>BJ^B\[]=_
M8C^UGC&6KT_I3UFZ6>E]Z?5[K5KA6N ]XZ\=BS5HB+N5]N'O,D*AQ(,"3B1?
M+19Y4+U$60ZUZD>]%8=\_G>:<<2E>&,_1#XX_#QC''V:_5^PG&/''X>,8\<?
MAXQFF<XQC.<_>^?_ -?Y_'^#C&0N5WS1@&X@FDK&DU7K5;:Z[8*,5,0&(M2O
M3L&1,:.UFK'\37&IEPKD6-&,%ZY+8@SU!"44H+22BQC"Q=]:\K0O.@#I&P61
M5.WC! (D=>VHSO0?9'4"O8E0=Y#X>Y&SP5KQ#56*U0X^S'6Y%:[M):XXSZ6M
M/<KA T52S(6ABM M")HVBE:-C&'EV<1@"Q\PL4FQ!@L="D$2)$A)9A01\"&P
MN3+FSIDA;<>)$B1VW'Y,E]Q#+#+:W75I0A2L6/7-'G5?/@HQ)L-)-"8Y=WV#
M+0I\E#:).8*8+Y&9;@N/)E+]XXKY[,#RM9]LP$+YC^LP-F>I8SG<*BV2<0*Z
M2@-&9\*<2@B7)D=!.8.%OP(Q,A$@*<Q*D0ATDJ+CSI3+2V(CY* U(<;<F1TN
M,9W^,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&1#MG?^D=$081'<NUZ%K2,3RXD4FX6
M86%F%E,Y3A_ @=*D((%<L>9.9'N^+)]0E6%/>1.?'F?1XKDN39TX^C:N&, R
M&O"\BQ@^GF.HZ$W_ $>MAU'L-G-1RWB#A.!C23F>6H<8LNQ$+EF*%YNG75Y,
M;L))>G8ZO+1ND';:&6_?*3]#OI3:D_V@S^C<VO\ H?XG_J6]_P L?]V<_P#R
MD^ _[5<1_P!3_P#7'RD_0[Z4VI/]H,_HW'^A_B?^I;W_ "Q_W8_E)\!_VJXC
M_J?_ *X^4GZ'?2FU)_M!G]&X_P!#_$_]2WO^6/\ NQ_*3X#_ +5<1_U/_P!<
M?*3]#OI3:D_V@S^C<?Z'^)_ZEO?\L?\ =C^4GP'_ &JXC_J?_KCY2?H=]*;4
MG^T&?T;C_0_Q/_4M[_EC_NQ_*3X#_M5Q'_4__7'RD_0[Z4VI/]H,_HW'^A_B
M?^I;W_+'_=C^4GP'_:KB/^I_^N/E)^AWTIM2?[09_1N/]#_$_P#4M[_EC_NQ
M_*3X#_M5Q'_4_P#UQ\I/T.^E-J3_ &@S^C<?Z'^)_P"I;W_+'_=C^4GP'_:K
MB/\ J?\ ZX^4GZ'?2FU)_M!G]&X_T/\ $_\ 4M[_ )8_[L?RD^ _[5<1_P!3
M_P#7'RD_0[Z4VI/]H,_HW'^A_B?^I;W_ "Q_W8_E)\!_VJXC_J?_ *X^4GZ'
M?2FU)_M!G]&X_P!#_$_]2WO^6/\ NQ_*3X#_ +5<1_U/_P!<?*3]#OI3:D_V
M@S^C<?Z'^)_ZEO?\L?\ =C^4GP'_ &JXC_J?_KDF:O[B]5]TGD575F_M672T
M/)6N-6A%M%YL$Y#2,N/+'!I3T<D20PWC+DA<"-)3'1CS/90GX\P[OA_F^.B,
M]WB[M>$?G3/ _E)LZ'7(H9$V>PZV7?NWFRXOQCX5YJP*G%<_Q5VT02M:&W%[
M1( "6,4+,LDH4#;&-6Z1W;6QER?-/G2XXQCC&.,8XQG&ZK*4Y\,XQG/CC'CX
M?@SG.?#/S^&,>.<?@\>/X^/O_CZLH?U;[#Z\@&J0K_=8!2P/;+.@$*N&Q!44
M2("5UV!#' ;ZV"#MM2+=K$0;=<;%U*>AU:X\V X]<SK@JP6X5 IEI1=;H4Z"
M^BH=]6][79/9B!W((^ &BH.P-K*]2L\,?L$<J^RUWD:2>8.TLL D+:BE**.J
M1?FCITJ %58N,JQJEW9$AIU>VK2\TF3&><BJ!:_PVZRR7/$G8BUM4YI]+<J
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MWHA(44L;2'FG8ZR-G)0GF5AH0,>-$KW(3M[NY^)]3U:[^GN]![SO'ME3J/\
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M/.3\[UW\V/N#O^@OOT/P[>FSZG/Y :LZZBP$%0 EE8Z%6$:VL4(TNND#HV
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MA5DUK9[;7$S<*CN9?&J*X(Q499<E166Y$=;N35M17(O-A6PJ=135FI:I2;4
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MY-70G^5N^_KEL_\ 3QUGX#[_ -^.@?$_=^['R:NA/\K=]_7+9_Z>.L_ ??\
MOQT#XG[OW8^35T)_E;OOZY;/_3QUGX#[_P!^.@?$_=^['R:NA/\ *W??URV?
M^GCK/P'W_OQT#XG[OW8^35T)_E;OOZY;/_3QUGX#[_WXZ!\3]W[L?)JZ$_RM
MWW]<MG_IXZS\!]_[\= ^)^[]V/DU="?Y6[[^N6S_ -/'6?@/O_?CH'Q/W?NQ
M\FKH3_*W??URV?\ IXZS\!]_[\= ^)^[]V0AV5Z(ZCU?H';^Q*K<-X-V2ET*
MQ6((Y/VY9IL-!(; =D1528BEH3(9PXG'G:RM.%I\<>./'E0Y) [=R/C^_*%
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MEA+(@P!N"))3LAAZ9F +C0QT5<C#*7'6H,2-%2XI?J6&D9PVF4RA)751H!M
M>NA]9[_KS%XBQ+:XRE8G;KFE@5I'Z57J;9!;I4!03K9"@#?H!D>^CWW)L'?/
M6"J;'V>89/7 E9MA#II1@6,#H?B!KL;&BVO8 \2"/;]C'1XT)*V8K;CS<=#L
MI;\I;\AV=A%CE94&E 7MLGU )[G9]<Q^ N6+W&0V;+AYGDG#,%5 0DSJHZ4
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M$X=,P2%AE9QCX8\TP^0)RU9\,Y^.7\Y\<YS\_+7G2$[ZM$]^P&OCV&OV9>'
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M&'?RI0\19BA)CGF7FNQQC/W;>DD["7>CT.C==]&O*;[']K[-G6&MI##ZDNU
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M5(.,Q8N'GUI2VA#$*"Q%'CX49AMJ+ &CHL4<.A,1X,"+&AQV6&\J""*M#'!
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M+Q2E/E5G&/'&<?'.,9SC/C^'/CX^'\.>=R!H:]WN^@>X9K?3U/V__C+3MSZ
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M;%M]^^N_;9WKX>@Q?$W*'F_$?/<P9#-^4^8Y*ZDK=0+Q3W)GA;3:908BG2I
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MVFFV4X0VG"$XQA.,8^\E./!./X,8^&,?-C[V,<YL]R3[R=GZ3GGWZ^Y^/O\
MOV?4D^OOSDXQCC&.,8XQCC&.,8XQCC&=>5#B3FDLS8L:8RB3#F(:E,-2&D2Q
M\MB? E);=2M"9,&?&C38;^,8=C2X[$EE2'FFUI8SL<8S'EW3_;KZ$_QCT_F5
M/)KZ/]7[#D&]4^O]HRI_24_<1;X_%-2_YB5#E$_.'V_@<J_YI^S\1EWM&_\
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M:\EXP*I4T+-/GBDI6,-QH$!O+KF&T_X3\M]6$QH,1K"I$V:\Q$C(<D/-H54
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M6_)S%0_F/AY3*7E-H<<7AK#;7D;1G^(*,'&<UR5"MU^15M/'%YC!G" !@&8
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MQX%"UZ0LMU*VBSTZNU\/60\4R1(0[[5MCW:K6N2W!*O,5^O3ZIJ/8IF4Q:)
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MN<']KI?\$3_W7'ZG, _2V+_4I"_M1X_E:D_J%/\ $F_]#C_5S@_M=+_@B?\
MNN/U.8!^EL7^I2%_:CQ_*U)_4*?XDW_H<?ZN<']KI?\ !$_]UQ^IS /TMB_U
M*0O[4>/Y6I/ZA3_$F_\ 0X_U<X/[72_X(G_NN/U.8!^EL7^I2%_:CQ_*U)_4
M*?XDW_H<?ZN<']KI?\$3_P!UR7--_P#X?G1%*MPVQ;9V_<-PAA4IF:BF1*U!
MU\$+N,+PM,2Q2HIZS&9HMSP_N\020!27O!*%3L,Y=9=P.0^5/D[,#PT:$''R
M2*5]H:9K<L8(UU0@Q01JX]S2)*H_W=Z(V_#?^'[@J-N.SRW,7.9AB=7%-*J<
M?!,5.^BPRV+4SQ'^DL4D#-Z%];!SZCAP\./@"1,&(,%"X<4<,&CXS,. /'P6
M$1H<&%$CH;CQ8D2,TW'C1F&T,L,MH::0E"4IQ\O=WD=Y)&9Y'9G=W)9W=B69
MF8DEF9B2Q))))).\^^QQQPQQPPQI%%$BQQ11JJ1QQHH5(T10%1$4!550%50
M  ,[G(Y/'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<
M8QQC'&,@$9UATN)<L*XM9GK^RBQTRTEFYMJM9%E177VY[1V"J"83,XU(;&C
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6C&.,8XQCC&.,8XQCC&.,8XQCC&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g107876g65v32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g65v32.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MT*"SRZ$Y.@!VTU(&F2#D9[8.NNV2Z-A^T$IXRGAK@*IL@E#*ZUT]:I:2=D9
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MMV_>P#3<RK4..S;3.R:^'FT_<XO8]OKA;7$8H2>A[0J]<J2:A3I)P2%(RX4
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MCU0!!XQ"*-G,38AV#\P<;8A+4:)0E(^+AX93EB+EZ(EA4ES#C\I",)PB<#!
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MDCWG'[@B@\/I=2H-U:MD?8>S&1L3>I+L5"IC&=<QPF-CF2A@N5<*G&M=IO\
M8P#TFPG&8(.P7(E'"PB"(8=R$T'KGPL\Q[#;ESKM\\?5Y[Y19C2G4JL:6?UO
MEK9&T=C0--:]?UEJ05L2;2I$2B5N?& PRSL)RH4>GRS)@C!K8@8@G99)A08-
M'=$UYH3#G$FY@N)SH!DY./CY^?[T6UW*43A$X14QO/L+IWK;35WS=%X&4JO*
MD>Q@*EHE32AHEEM3J1@$&,8F%S,[+:5.N,CX3^(L=*Y<Q<>(TZ^C+HZ&JKY?
M!I(72OQEV,!K&YQS/>XAK&YZN(R=!DZ+J.$N"^)N.;H+/PM::BZUH9XLPC,<
M5/2P<P:9ZRKG?%34L/,0T/FE9XCR(X@^1S6'SN7]MQT>2M:4S]J.)2I2<.(U
M\K"%XQG.,+1APPVYA*L?>G"T(7X9QYDISXXQO!PE=_T:8>1G_<PCZU[4/X*G
MI8(!,'#X) )!O+<C/0XIB,C8X)'8D:KY_INND']\VM_A_C^=\?BC=^U-_G_^
MQ3_.I^EC^P\/?ZY'_*I_3==(/[YM;_#_ !_.^/Q1N_:F_P __P!B?SJ?I8_L
M/#W^N1_RJ?TW72#^^;6_P_Q_.^/Q1N_:F_S_ /V)_.I^EC^P\/?ZY'_*I_3=
M=(/[YM;_  _Q_.^/Q1N_:F_S_P#V)_.I^EC^P\/?ZY'_ "J?TW72#^^;6_P_
MQ_.^/Q1N_:F_S_\ V)_.I^EC^P\/?ZY'_*I_3==(/[YM;_#_ !_.^/Q1N_:F
M_P __P!B?SJ?I8_L/#W^N1_RJ[4'[;+HU+EQXSYO9@QEYU+;D^=KR:Y$B(5G
MPR](0-GD)ZFD8^]6(L*2]G'_ $&5Y^[D.X2O !(93N(&0ULXR?(<S6MR?-P'
M<JW+_!6]+4<;WLI+%.YK26PQ7J%LDA&S6&>*&$..P,DL;>[@-5Z;ZWV70MOT
MT+L'6=K#W2F6!A4@2?"2?<1)&&UJ:?8=0M+<F%.AOH7&GC9S$8@/E-NQ9L6/
M(:<:3S\]/-2RO@J(WQ2L.',>,$=B.A:1JUS26N&""0<KP:^6*\<-7.JLU^MU
M3:[I1O#*BCJV<DC,@.8]I!<R6&1I#X9X7R0S1ELD4CV.#C.>65J4X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X18:P6.O5(/.
ML-J/!JR %LYD$CE@*0@P<?'3_P!)^<3(OQH41E/C][K[[:,?^*N5LC?*]L<;
M'R/<<-8QI>]Q[-:T$D^0"RJ.BK;C4PT5OI*JOK*AP9!24=/+55,[SLR&"!CY
M9''HUC''R6E<WO()O<N2"ZH:HOO:(RP^[#>M5;811]'BIC*\H?;+;GN+$0!,
MRSC'K89IL&W/R6TK;C(4_A+>=L+.^$!]RJ8;<P@$1R'QJQP.H+:2(EXS_P#*
MZ(#0G0Y7J,7HGJ;1&RK](G$5GX!I7-;(VW5SS=N+*B-P!::;A>V.EK(N;Z)=
M=)K8R,D%[@W)&GVTMG;7N-H?UQM'>MEN.Q'\9PKI]]GC!D,F!R,JRVAK</8F
MP*^5J(G'J(BV7,B7KIG$9QR7 A3F5-I1LZ>GIHHQ/3T<<4 __*7P@M=U/JM"
MSV)7=8])SD8+FG*]+X?L/#MLH&7NP<)4-LLC""WTE^FF9CJ:<@<Q=PUP51_T
M-<JC0R4(CBOCN=HCFEB=DJ14[IG.JM'M-RW*0J74O2HP(3L5RU-UX*3GK]8:
M^/CN$R#6]>TA1+FR;T^N.W)CE0=/DBAA-3F&XY28ZM.5V:F\1ES6P>)<:@$!
ME57-:((W; T=N;BGB .K'RA[F[<H&VAXJ],EJHB9[<^NXZN] USXN+..H(FV
M2UNB:<S<)^C^G(LEK:P-$E+47&.JJHR #2QG#1L=]GUI,7KG75GV;!I476:=
M\%QMM :T&M*B0J)K01">@:S#3X^7',S+A. 2G;)=+!,6LP8-'5MEG5R!^/#3
M5U5-52AT\KYGL!:9'G))S[7*-FL!^@QH#0-AJOGZKXBXDXLK*CB+BF[7&[7.
MXN#V&OJ))11T3<BEI:>$D04D;6$R&"FBAA8YY:V)O*M_N82L)PB<(G")PBI:
ME=CM [(.1*SK_<^LKK89[,F1!"U>Z #A*8Q"8<DRWHT,=.D//M1H[3C[SC:%
M);:0MQ6<)3G/)P>Q^2*Z>0B<(G"+%03H4G/-BAQ8=.)UN7%'V$?$F,2)@2=.
M&0S4*(5C-+4[!DRQ!& 3CLR4-N/09D:4VE3+S:U$0T="UL>HK8"PX(,3+&0%
M$"DQB##3.-$X881$S(DK;:Q))ER$$9!9\WJ2ITR-%92MYYM"B+*\(N-[U<LN
M^AE&'_2<]'+GCZ>'?+GT\N>&,Y\GG\OF\,9SY?'PQG/W<(HO1Z^Y6:P+%2LM
M+)):5*,2&UY=]V7FN*DD9*WUH0X^IR0XM*77$X5EI#:<8PA"4XDG)^SR"AHP
M-=]REXK[MFK!05%RV@DII,H/(<6IKVA>$XF2.DI?0A;C"FY+:,*=;3E6&UN)
MSC*5*3D#@_;YA'#((^7O4H9]7T6O7\F7_31ZV6_'T\N^7'J>3QPG/D\_CY?%
M.,^7P\<8S]W(4JHMJ;]U%I7XIK9%SA@R1[+N -?AP#%DM9S#'W/."*G6!QFR
M$(["O!#\N*+<B1UJ2E]]O*L8SE4U%55?.:>$O;'CG>7,CC9G8.ED<R-I/0%P
M)Z!=/P[P;Q+Q7ZRZQ6N6K@H^7URMEFI:&W4A=JUM3<KA/2T,#WC5D<E0V1X!
M+&.POYJO?^H=U*+1]<7.(:* ?3R=KLX>9K5L"H>SC#+Y6IVD<%LD&*\K.$,3
M9 M$-]?BAE]Q6,XXJ:*JI.4SQ%C7YY) YDD3\;ALL;GQN(Z@.R.H"<1<&\2\
M*BF??+7)24]9S"CKHIZ6OMU46ZN93W*W3U5#-(P:OB94&5@U>QJN+F*N84.J
M=>E!Y%H(DLQWB=@LA AF2RI3B_B6U)B@H;CBVVU)Q#'M(QAG'F;:<=>\JU>;
M.>23G&.@Q\>JI QS$]3]7124B/B%8$P9.92_#GQGHDEE>,92XR^VIMQ/WXSX
M9\JLY2K_ %I5C"L>&<8SR-E5NL/3QQ015P8LT\U()CA[$*2^RXMUMSVV,LLJ
MPZXAM;BO;H:PM:T84I>%9SXYSXYDX))'7NH&0 #T4DY"E8\M+F0!1.</%R3D
M^$/FRX(6'(@Q)9B9&C.O1A<644DPAD:20>0B(Q((S(D%EUY+DN2Q'2XZ@BU/
MZR[OVUM>Q[@%;!U'8J4+I^RK97PYTD=UK.AC6A,.H.0Z1,B5&VFRLXZT@R0*
M.G40G@+L5O$7Y=4S#,9=3@!C!SD ]?/R"+4XOMO96H=[]R]AV2XGR_7R5MJN
M:7-CYQ&4[!T)8IG5_1%CU]L8"MQU205-M5SO):J[$3'S'B"SA>E7!7M8D:V3
MEU8!#-@<%W]][1!'F0!IY9'9%V]$]C+=4ZOK R=90:K3.L.@0S;EQLMGN)<P
MP-WAK6S (]U2V6L4NNBYD#:$FDKMIA@/&<+5PM8#-GG2I0@?/@P6Y_\ M@8'
M0[>>F?J \RL^L=G-\;9=?9UP(U-5$Q]12>Q,"9L,9;24:TZMN>PME5[1X:*V
M)M%><KIBS4G7"KA>+C)4>@51VT AL.DET^M)4+0.YUQIC? )[]3@;9P443T;
MVCLEPVX*)PHDOZ4[&[@U%$A K,1(SI&O:U9?LZ6NQ+8ZNM)DL0(,Y=FK,=@J
MVB%B%+43.3O9H(R42FI<T!H[@..1UQ)RZ_ HN],[;;WLSQ6#KX1J,6^!KO=>
MY$"=L%V\Y#EBNK'8PAINM!( \+:P3R)]X#,Q)I@ZZ2=B R/NB$(*2C>W"*CE
M'F?H#3&[ADY]W_E%SY[>;>"0)J;BSI\64N&JM [6ULL>!VF<P"1NN[&*I,H,
M^KU?-GNFZ+E7X@ULA66*,(HCU\(J=$O":;#2X=CN4;:[N!VZ8UR<  DZYV\]
MD4"$;_[ ;?V'J:N@BE6J%UIW9+;NJ#10_1METRH6D# ZOA-J#3]AT:8N\*Z-
MD8C%YAL1*6;OK:XY06W9,&(C7A!:G #2==0"-L@\Q;C/;3?MT1>@'7S9IC;6
MLXUIL8P8)LHRX[/UW9F 3TJ17I5DU+LRW:N.EZX_-\9:J\=*4^49"MRG'Y<0
M?.8A2Y,F5&>?<H< #IM@$9WP0#]6<(KKY")PB_'_ /;A7FPV#N-'IQ">^NNZ
M_P!;52-71?J+]G$D61$@\;(H8\?33/)//PXLN3A/J/Q!(QE:LHB-83Z?PC"Q
MEJ,K0.>>HD,CNI$>&,;G]%H!('0N<>J_2O\ @GVFBHO1E)<X86"MO-]N+ZVH
MY1XLC*$QT=) 7[F&!K99(V9Y6R5,[P 9'$^-_.I7TZG")PB<(G")PB<(G"+]
M''V %YL*BO8C6ST]]^JM#:7=H(UUU:HXX\Y++ R<R&UG/D:=,0$"V2"\8\SR
M0H[&<X]'[^%XUACY*&H  EYI87. U<S#7M!/7D=S%O;G=W7Q!_#(M-$(.";X
MV%C+BZ:ZVJ:=K0'ST;8Z:KIXI7;N;33.J'0@_1-5/^EI^ECG KX63A$X1.$3
MA$X11RXR5PZC:9C9$T'7%KIN2@M6@>;-8A:V!LEU) !6TB3RK :A*3B2+")!
M&5%9S;$!(HCE_$1X-_W[?';[0BJ;2=QW/:H32MI4NDUQG G,Z&1%7%YRXE6I
M!!Q@"3L&L(HD\#HK!\5&E$O:0MQ7U<"4S\;EY]W,WXR3CH2?AI\^OR"*_.0B
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBUUW#VOT)HV8P#OE_'_6D_*&P^
MMJM&G779IR0\CS18XN@U6,6LSN9>?!#$J0/C#O'/F>FM-I6XG.I;;6U@+X8'
M>"/I5$A$5.P ZETTA;&,=0'%WD3@+M>&O1WQAQ9$^KM%FF_!<.357VX/AM5A
MI&-.)'U%XN+Z:@;X>[XV3OFP/9B<2 :2_*7W4WG^:U/J0'U?HTO[D;([%819
M=HR(3N/+[NOZ,JA+$,(185CSML["N,?"TYSZX;&<)2O,]7M-'@U-2^XS#>GH
M?R=.".CZR1N7M/>"(XZ./3JOP%Z+>$_:XBXCJ^/KM'O8^"LT-@9,T9\.LXMN
M,'BU<#MBZRVR37Z%5N1K)=*WUAJ%_C@]I&]L?:0=JH3F94'6#ZXE\%U,BK.&
MGI,C6@; C1FFJ^U(6RY+D75C)(?&<S+BKG)\R5["*2XR0%].REL-M=H:C!A=
M*WH!4/YZRKDP#@1'E<=#RZ8[RUUW'MRL[ZOA^EX=]!_H]E;X<M_8)+1/<80,
MM8R^U7K/%O%%8Y@>V-EJ?X$KV^%((="-B(6BNRV_8D9K?][C=?-2X8:8A]<.
MMYAR$:DB4H2AD-LC=T>-"(O,)C^H/(UW6(^N I<->&\&'_)A6< UE!1DFBA-
M;4YR:^O:"T.URZ"D)<W).'-DJ'2/!UY N+EXNX%X/D>[@ZT/XRXCYW/DXWXX
MIFRTL=23EU58^%'R30,<7XF@K;]-75<<@YC31DX6X6K=/:NTE6&*;J:BURA5
MMC*7%#Z\.:B*FR4I\F9Y>=GU")LHXG'@^5,2YQ*1_K?E.9^_FKJ*JHJY#+4S
M232'\Y[B<#LT?18WLUH#1T"\TX@XEO\ Q57ONG$5WKKQ7/!:)JV=T@B83D0T
MT6D%)3M/T*>FCB@9LR-H6K.]%9[&;NJW5@?G,G7%&2 VYV9?:SYXDX?'FXG:
MMT_,4GSHRY=34'%KL0]W#+N:F"CK9>\".6UH_P FPR_G.RR+R/Y[Q_>@X'3)
M[A<36DU]9';6ZT\(957$]'-!S34A/>9[?%D:<'PF#!]M;VI2E*<)3C"4IQA*
M4IQC"4IQCPQC&,?=C&,?=C&/NQC[L<L+=+^\(G"+B>2XMEY#+OH/+:<2T_Y$
MN^BXI&<(=])6<)<]-6<+\BLX2OP\N<XQG/)&,C(R,ZC;([9532T.:7-YVAP+
MF9+>9H();S#5O,,C(U&<A:ATW3/;,+:J^6MW=%-VK XI$EG:C_HY:WK?U$,9
M=PJ4)^?&%WB CWC>,M>_AM.2(_CYVT95CPYLY:NV/C>V*T^#(YI#)?7ZB3PW
M'9W(YH:['Z)."O2;GQ/Z.JJWUE-;?1<;57S4\D=)<OQVOE=ZE.YI$=1ZG/3,
MAJ?#/M>#*X,?C#CA;@\U:\T7E#UA8O-)T93=?7Z?W7DR@>B9=8,:SC:GJ]1!
M R@JD/)>#T'9=/UE4K[%/PG(3@FA&7=H.27S#XUZ47DRE-SD5G<_1WWSW/;/
MST10\4O=59<TQ5>T<WL89MY[95YSLA&JKM?7A-N!P])-3J$BH1M1RJH2< UM
M42# O@^IB1LN9MH=9KF2@+IYN/-<::XQC&F<=P#G/Q(ST^2+C-"^W2EZM;)#
MMTQKS4Q'6M_,N(6V58XUA%Q[]#G[/P<E4B]533 NQ!*:[*#;._*)"VB?V"_&
MDXJ@9X8\-E(G+=<8Q[6IQOC TP3OJ, 8^!P4R)ZW[,!ZW&.5,EO69<[=6^T4
M?83$[95O(NY',;KK$W6H^GB[+9G:M1+>O53=G%ZM+5N+6Y++DMIZ63PZIV:F
M!R]<;-QIUQKG&IUWRB@I*@;;C'KJ6UN/WY4-)V7>L(T;=MPS?ULV*9!P>NM,
MK=?(+%5[:E"[%S:3#V ,-#5P?JQ<X>6;!29U==H\%+@V<C !P78.Q&!KWQR[
M>_WY*+N'-?;X-5RLA=JP.Q-\NOK=2IVNIXIVPA:I$"U;9E9.[2QMRKUG8%JU
M\W=!4<=+*6V7?C%K)FX"*^[3C!*P"9J!337'*/I9VWQICR/3  1>QW+:*!6T
MR;06K]5KK\0>2/H)RWS$Z-[UH8-$HC9D+CP<NLHESGWIC#;"''/1;1AU;J<X
M\JDU #4GIC3OE4DG( ZYU[#[_?5<-=+6&%9YE.LDZ(:>2%;L(LW$A)&NOPO>
M_'RHI&"VZ\PU)8DJ:4P[&4EI]A2LJ2EQ"DX$#&1IK@C.?D@)S@G.F0=O+[_?
M%A\I52<(M*NK(T=8MB]I=G6%IF?LY&_KKK!V?-0EPE6]<45L3&H-9%8<QE8L
M*2#2&;:^B(EEHR1-+G2\RGF&5M;:Y.='!;:=AQ3^HPU :W1KYYB\S2._2>UX
M,0)SRM9AN XY]6](<\]#8_1[8*)SH; [@RU<0-AB);!77R[NJ7WFOJ"TXJ*J
M"JC=;6&4N=2PT@AC$;7N#G:L<-KUXZP;/ M,P-GM]@J!K2"0AI2T2L= OS\\
M??ZF2RWC"R02* 1,M2&I:7F@\\&V2BYC.*?4ZMKG/AN-.\DT_J4U0YIU:R:#
ME=!(W]%Y>1'D$<X?RG(QB/1U//6VGT@</UCG36!W!=ZOTL,I+H*&\V:.&>S7
M*#.D%7)6&*W.=&6.JH:LT\GB ,#=U>:E>5)PB<(G")PB<(OA#;;?GRVVAO+B
M\N.>1"4^HXK&,*<7Y<8\R\X2G&5J\59QC&,Y\,8X10*5JO7<Z!LL5/J :<,W
M')D2]H#YL=4N%=7Y5/!T"2LW%D+=9>2_3:V#K[C3:&FE01K'BCULN.KG)TUV
MV\M<_:<HHWCKYI?%2LM$SKP"NH7"A5K6%E N(ENP2]#IP:97JO7)&')2W4Q
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M37&PR/:T=3J>S1N3Y +%K:IE%32U#P7<@ CC;]*65Q#8HF#<N>\AN@. 2XZ
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MIM(+Y0NN=XO%7?*=DDL-5-6-H8+Y^'H*L6^MKIV,-1'Y0\Z-?1B_01_R?_\
M[5.Q'_Q_3O\ [&1YQ7&O]+4/^'E_V87QG_#(_J!P3_CBZ?[E3K]1'//%\!IP
MB<(G")PB<(HQ=EQVZ;;7);,F1%163RY+$.Q+J$MZ.D7*4\U%MC9$.Y6)+C6%
M(8L*"PM85W*222,)4;$EJ1N/?VS]77W(M'^LUZKEIVXZQ2BMC @D:ZL;Y:CW
M3?UQW(9M4UZQ4M58OE<$66RW&,%J0& U9A+UL#E( ZU3+:-AI28^(BO#Y(P-
M<;]!@==#H-?+IA%Z#\I1.$3A$X1.$3A$X1.$3A$X1:O[BT-L;<=K8;D=C=A:
MWT\@3$CS]=:D'BZ9;#YA#\I<Z68V\I92T1@TR,Y&AY!UB'7'<--R%.EGW'FU
ML;&EK8*2,D4$%15<Y(GJG.EB8S Y0RE'+&7@Y//(Z09Q[.%WW#/%]DX9MSW,
MX)LM\XE-3(^&]\235%TMU'2ED8BBIN&P*>WR54;VR2>MW"6N87.8&TS6L<'S
M#3W6S1FA(TAK5&MJ[59T_P ^2]D2P\6N9Y;B_4==L%U./$K6=<==RIY>2AB4
MG#JUJ0E'FSCEJJKZRM(]9J))&M^C'D,A9@8 CA8&Q,P-/98--UK.)N..+.,)
M&/XBOE;<(HL>K4)>VGM=&UHY6MHK52M@MU&UK?9'J]-&2T .)PH'MON'J?6-
MCSK@(FP[DW4\A7LM+Z=%_6EY;5CRI]>S8BO-A*(*94XT[-*7,L%:8AK5+9;E
M(;RC-ZEM5341^._DI:0?2JZIW@P^Z/(YYG$9Y6Q-?DZ9"V_#?HTXBO\ 0_AR
MJ-%PSPLPCQ>*>)JC\%VDC4\E!XC755WJ'!KFQ4]KIZISY0(W.C+@55?Y)^U_
M9#])WU?L];M7R_!7Y#="V#,S8IB$OP5['9.]TQV7(6',>I&(A=8#Q\*9"?4R
MNQN.(\^<CUFVT&E%#Z_4@C^C*QG+ PC\ZGH\Z]"U]22YI'\6 NA_&+T=\$>Q
MPA9_QXO\>GXV<840CLE-*-/&L?"!>]LN#B2"JO\ -42Q2L#VT3 >5;7ZFTIJ
MC1=:14M24.O44'YTO2F0T/"9Q:6G"L?('S,E4@S8BB\*5APH<GD"+F,^#DE6
M,8QC6U-74UDGBU,SYG[ O.C1^BQ@PR-NGT6-:WR7G?$7%/$/%M<;EQ'=ZV[5
M>"V-]5+F*GC./R-'2L#*6BIQ@<M/20PP-Q[,85H\QUH$X1.$6L.ZNV.LM.&H
M="CM'MH[I-,8=K>D-7#\6G8A-+B4Y:GE8+#B(-.KJ,.)?EV6W30XIF&E^2P[
M+4PIG.PI+;453#,2RGI&'$E74.\.!ODTGVI7Z:1Q![B< @9RN]X6]'=^XFI9
M;P]U'8.%Z5_+7<5W^8V^RTY!/-#3RO:9KG6GE+8Z"VQ5-2^4L8]L8>'CS_[2
M5WLQL^@P8V]++'IAC<9V'KG2?3[4-CEH'D['8$.>H9WYM8<B,:N@*CA<$+/;
M 53:!T)" \%J7-GXF^*]A%5T-"[%NB,TL8YI+E5QM+FX/\CI3S,A). U\OB2
MZG1N%N+GQWPGZ.J<4OHQMPOG%4SQ2T_'_$]!$^6"J<"#4\+\.3>/2VF*  SM
MN-T%9<0P.88Z;F:1Z=]?])U+KMI^C:>I<=ML-30S4-V8EAN.\:,OJ5+.V":V
MWG.,3#99^61>1YEHCX?1%8RF/'90G2SSRU,SYIGNDD>XDN>2YWD,G)P!H%YE
M55URN,\E;=[C6W>Y5!\2LN-QJ9JNLJYCJ^6:>=[Y'$G/*TNY8V<L<8:QK6BW
MI$AB*P]*E/-1HT9IR1(D2'$,L,,,H4X\\\\XI+;333:5+<<6I*$(2I2E83C.
M>65C$@ DD  9).@ &Y)Z +7;KYN>P[W^OKS# 01>ETV%H#I>P.8G-V+80X)[
MV%:[U*C/K]K%J94VAJ)1\-L,$)< ?/)$$X;G0&VKDC!'RMR2_&7CHTG!:WWX
M^EYG'=8%!6/KA/.(PVD\3DHY#GQ)VLYFRSD9P(GO&(= XM:7.T<W&QW+:V"<
M(OE:DH2I:U)0A"<J6M><)2E*<9RI2E9SC"4IQC.<YSG&,8QG.<^'";;K#1[+
M7);[<:)8 DJ2\K"&8\<K >?=7GQSA#;3;ZG%JSC&<X2E.<_=G[N3@]C\BJ!+
M&2 )&$G8![23[@"LWR%6M;JMV",W:V'056T-M<K6JWLD[K(SL?!C2T&JQ"=7
M-_!V$RD62VW#OL@(,D)>D+S&IKI:7&97D>*EOJ:8<DC&Y&HSU_<BD"^SO6UM
MZ1&<[!:31(B31HZ2PK:='P['GF%R&Q4)Y'SGF;E$7(DM$)A>,.2519.&DJS'
M>\C!['Y%%+96WM3P;06I,W9VOH=R BI1PY5)5RKL>QA@L$>V7FEBH5XB@D/'
M0A+S)67-EQF8\8:\S/?<;B.MO*8/8_)%&%=E.NJ(HB:O?6F40C[A9H',7L^E
M(B&7 ,]0HVD7)4;PS/R))H4.(^U6[B'.Q[21EM_.&\N5W8_(HCW8?38AIKZS
MV1KW7\R59[95AHRX;'UY"G%9=3NQRAR)$!,*U$([J9QH#*0V.7(;/")"E K2
M( 6J 7 #F#T!/P**4?E=U1F\_DQ_*;K[\I.7?0QK_P"LJ[BZJD?%+/9CIJV2
M/SBGT@VUFEL)@Y=0)3DDI&(7@]Q@XS@X[]$5A\A$X10"SF#SQ\34*U)A#)Q
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M;@O'D OI4KDLL*P44@6^53 P^H>P35@<]+PTU._15NXY(W&.X147JYXB9WO
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M53E[F,>V/G:537Y+>V?9#](WG>\]9=6R_P"M^1/1)])#:!F$O[_9;%WKB.A
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M7DA>X^$B283T@PWA.9\B6ZE]IAY>5+PYO:YL?G-./[W]Z+ V7H];C5HOWIV
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MYE?P3P)RG/ASR-/A<4\11/ =.R,_@:AJ@YG/5R4K?$]@]=ZWUYIFDBZ+KFL
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M5*&ULXU)N&S[&C_\.TSK@ BX[4MKJL*RWD;51V/5@#E8;=4X?L#X>OL)9?\
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MI/4SHB+)M6X(R/JW;Q&9*?E-S:M0*L0A-5BIN,PV&O<W0](.2&%$H[X01B7
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MPV.-HW<X@=!DD ]#PSPK?N+[FRTV"@DK:HL=-._+8:2AI8]9JVX5DI934-'
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M:AT:Y;$FORIFQ+QK^M0AT2LT0_(<>?/ID.2418L:*^[(QY9 SG4# SDY[@=
M3U18G7O8D!L)^,,:I5[J=GC[0*ZBN-0N*:0//Z_MPO6;FV4)/X&78P(/#2E/
M>!S!4S7):\K?Q9A<J0Q%%0K(1 B,=0=,@C.NN.VGQQM[LE9PW96N3+)V0'O]
M*+,5:<T,LSXVU IS-=)//YC,CSKD6>Z@1.=DXS':B$%1WW'\9:0WES^KP01N
M"/>BZJ=KZM759-Z1LJ@*I$*6N!,N2;C7556).;>1&<A2;#@CD0Q+;D.-L+C.
MS$/)><0TI&%J2G+!SC!SVQK\D6>BVZISHTF9"L]>F1(06#9)DJ*:&R(T2NDV
MIKXT_)?9DK:8"D&!I%Z"5=4B#+:'S7([[B(K^6XP>WE\>R+.,/LR669,9YJ1
M'D--OL/L.(=9?9=1AQIYEUO*D.-.(4E;;B%*0M"L*3G.,XSPBY>$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A%5.Z]M"='Z[([%,UZS6R-"/42L1*W3F
MP#ED-'=BWVLZYK, ;]4V"K5YK+UCM@K$J26L N'%@XDR5R,Y:2TY(&3C(&A.
M3G& "3L"=AV15W6^S8PP0M-;L.J]HZYOE0>U2^6H-Y<U:R:=K6XKQ+H%3N0L
M[6MGV:@% 39P38<$X42Y+M32:_.@P:V1.3J^),R6^8(UU&>@!.X!ZCICSQJB
MNQC8%#DG356C7:HR+-6H625BKK%D#.G0 Y*$+5/-"&YJB J%A#K:\RIT=AC"
M'$*RYX+3G,8/8HNL.V9K@Q#L1 3L"D%(%/PK-MG#K6!FPZOA+#DE6;%)C3W6
M0F$QFG9"LDUQ<88;<=S^;0I6&#V.NWFB[P"\TFULBY-7N-6LD<Y#(D0D@!81
M)ADP/#RHD(M.%NCI<ELA#%S2$"(1DQ%/,PI4V)'DK:=DLH7&#V19P>2'%X;)
M 5/A$X$CU/;SA\IB;#?])U;#OHR8SCK+OIO-N,N>1:O(ZVMM7@M"L8(N[PB<
M(G")PB<(G")PB<(L2>!"+.#,UJP0&"H*PBB ,T,E)4J,1$E8CT C!D)2I*LL
M2XC[S#N$J2K*'%>52<^&<-MD5.5*BT'7>R! YLKL"S7JP4:XR*^5O=UM5Z4%
MI-:/4!BR!A<NQEIR!>)Y>R4V1/?0RX9LV14)X\5(9 #<,3DD=-,;#&<Y[??Z
MT5\\A$X1.$3A$X1.$3A$X1.$3A%JQNC9'8INV,:OZ]Z:AE3$L1$*%=U[3*)"
MZ8IL>>_+8;88@!I$BYW^SQ_9../UL/$$18:9(Z1/.M,25)3L:2GH3&:BNJBU
M@<6MI*9O/5REH!SEX$4,9S@2/+B<.#6$A>@\+V/@IUN??^,^)Y*>FBJ9*>GX
M5X?@-5Q1='Q,C>Y[IJEC+79J!_BM:VNJI:F24LG9#2.>P$Q*B]+JRJS#MG]C
M+@:[/[>'.>Z%&]A0X<;7E'DJRE2D:RU%"RY3JFAM3;"VRDN.;LN9#")GSB'U
MKY=FNT@C=3T$3+?2NT<R DSS#;^B*H_E93J<M!9'@XY,+8W?THUXH)[!P3;:
M7@+AJ8>'44EEEDDO5VC QF_<22XN=Q+@7!U/&^EH QYB]4+6A;J8QC&/#&/#
M&/NQC'^K&/\ RYJ5Y:G"+SK[@?:(:^ZX34ZOH 6=O'LD:2F-7M14IF:9DBI<
MEOSQ9=T6#C$)H]O#:DRV:[ C2;.49RQEN&/'RTF6-Y:['/7M]8F>VDH&',E5
M*0T. W$0>6@GH7N(C:<ZN<.0^U^C7T*WGCB$W^\54/"? ]*2^MXENKHJ6.HC
MC=B2*UMJY((IW%P,3JV:2.@IW\P=+--&:5WEAM6Q]M]; A_:/=2*'K7;]R-C
MJ9KR^;\?'F[71_J1Y*Y4+2.DQCI:AZ.K%9#(ER[1;[P1N.PBB8;:ID-B?8L#
M>;OGMI_].H63UD0]I])0\T<4[F?GUM:6^-5$G'*V%L4#!H'8:'+TJ\W[@*B@
MA]'W %IOO'S:B>../@W@DU=NMM_JXW!KKCQSQH:4WJ^P0\WK+V6NBMM@M\>(
MF5 $4-2I]KW4E$JU8AWO6=1#5:JBO5F$^^_V@#KDQMXD6>63*G^O>@[9*&L9
MF%R3SYFOGCP^K8)/.J9E.V27C#SU+Y7@^K2O+GG1MEL0Y=M,5]9'SN( PV1K
M7S.!(.6:XOQ5$MMB9PK52,]8E)Y/0SZ#:?U2)TN2)&\:\7T(K*F5Q=EESB;6
MW>KR3-)-2\SB(#IWZP*;LN/:X#5#VT!E;BXKNKNUG=R],ZWTR.:7B3@OMR+$
MF1X4XC%(/.2A]"H>M:Z##5.N.)<GFWK*M<N+$['&-M%43,I(W')L]GC%15OQ
MCV)BPN:'8PY\E1+(7.U$8&BTM;;KW73?@#BV\P<&V)I++;Z$_1!2-OW$M>6@
M"2;B26WRSTCKC,PQGQN(KK<9&%IE_!D,Q(;W-B=AM?[CL+E&S<-K?:4[\(-3
M%U/4]!KA+6G3VJ&XB%2&9Y6I09PTC?Q=:=\)+IRSD;2)+0&5)F% J'\OMWXJ
M.>DC#PRCX>IMC4U,C*FZRM(U#7'2,N R8HO!>T[!V%V=-PK>>%J%L]*W@W^#
M]9ZB%[&<0<35U-Q)Z3;G$6$2NI3(]CJ5\C 7R6ZT_@>IA=[+><#F$*&Z([\:
MYKP[3\#85-T?M7>Y20;;U-HF",7M>QLI><9D6O:&P:\M@-J755$@/O#1#%&.
MMU^.TTL&"JCQ!\G/;Q'5MCA>Z6.GGNLK-ZFO<1 ''7V(G NF<XZD2Q\W7Q-5
MY)5\9^A'T?U,TEAX?OOIIXZN,KJB?B;C^KDAME35$X=726Z6.2:>B@P,17&A
M;*UH;'!6.>Y[E<&T*)T^^S8I@N,4J%;[.=W+$/P6>/;'P_;XXDS.PM_-P,AS
M$J8.KH>!(4M0%IN*Q<K)AE+TDO'C9DE!^%+>+G<"6B8TE(/9;#3#P6\HTY 6
M^VX'0$%Y8-@.AX3CW^$AZ1KI1BVRWR.T0.B#(K#PI";%;*:$Y C>ZGD=<9*0
M-PQE-55\S9 W1C&E[AHYJ/4VZ.V.WGSQE@CLG9MPQ'-D%EI4H4'%5^4E+4$Q
M;RXUME6OM8QX.$M#!H%N':[B)8C5K74$,%FIL;V(][(68'LM&F=R7;D#?F?G
M<G+6GVG9/LKYLIZ>MNU6^64R557.?$D=(]P :_425$@P88#D8#/RLS<1P!C'
M&0_HRZ8T#3&KXNQ:'K_8*-G[,K4NK"]U6>%%D1 <$S'A%4UZG5R# 832JX#J
MD;Y:'!I-6DRI-6;?PS8\HGS&5.ZV9SW<KG-Y6D'D&<DC.I)/M$G3+B!GIHN\
MM,%'3BHA@G%34QF)E9*T$,#VAXCA8UH\&-D0YPV&,ET0.)/:()W=Y96X3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A%I7W+U19MGIZ]S06NSFT1&N=V3KI<ZE6+]
M"UM8Y5>EZ3W!1HDD19Y=KI2X[T2TW*N/RXT.PQ)$H:F:TI$F-F1&=J:<$ZXT
MWQGJ#LBU:$=1MU2XC$*MU]W352([XVG>ZM62VQ&[_<-4#[UTIW'I:;=3ESR4
M+$3Q@[N&Y!S<<$-LUND5X8\V]$*LPFWAH6KF SUT [9PYIQCH, C;X(J]WSI
MR\Q].NV$EU]KFI0&KNMH31E@J2K%29@G<UA/;ET!-##X"J5*->76E58HMG9$
MF;O"!VQ2]C$,(IXYO)GW\M(SODEW-G731V=\:DD9P,:;[(KEN_7[9=V.W#:<
M72UOU^T1V%ITU5J!0KWI05M>J$M::ZVO32VWQ4$V];>OMD/V!C8@BC+IETL#
ML"9KVL,&Y4V!91H( S2" ,9!WSD'&"1IT(V)R!UQYHJVL6H[[&5UMTX3?H0+
M9.\ %YTGO_7M615P)+'5[&RSNW(MV+5:CI36QY6'2 USU39"E;:8HGY4-_'4
MUQV;&4,CNSEOM'7 P6YR?:Q@C.^,ZZZX VU1>SJ$(:0AMM"6VVTI0VVA.$(0
MA&,)0A"4XPE*4IQA*4IQC"<8QC&,8QRVB^N$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A%JSW/UK9]M]>[%2*A6Y%P-2;SI"PJK$*PQ*I/-A*+O36][M
M, =8YQ4''#DG:O6C'QTS)@:\W.Q'Q%F,2E,N8J:<'.VCAG?=I ^LHM-H?5W:
M<PI>R]+U,6U%4;/:>GI2?0[UM^)M"W6BP:7[1TK9-HO+EAEVFZ,5X16]8BBH
MX;7HUTD9L!!3JX]>'DD-OF:N8#KDX?J!C=I ]Y)W[=RBZ1;K_M %0:Q6">KQ
MM:DZ,-=DMDW+L$T>J$G&V ETU[NL6B"&ABR+VP9!_8!"_P!?/;%AW@*#!BIE
M:D?&D[5)B )B&1G0[\H QM@@^[3! QW]X18&I:!O&U]1ZW,P.OS5%KE=ZAT+
M7":L'V%1ZR6VT:D7W2.S0EEIIL#FQ#H$;6T#7=@-4-6UAP-9ZVWR8#M5?$5R
M;8B<L2 3J3EV<XVP"-<]\C.#L-]D7#>*ANG5>M0]IBR@54[#S>Q1$5UY%72/
MJ,%MK8E>W91JEINVN[1'Z-0C75GLU9L92-MDR1I4=QI%/U-32-KG07XQ9R,!
M!R,:<NN,X!!)&,G.,#&"=R<=$7K;KFB M7T"E:WK+:VJ_1*J!J0=+RL+D+'@
M!D89&?EN_P"M^;);C8D39*\Y<DRG7GW5*<<4K-LZDGNBF?")PB<(G")PB<(G
M")PBA^PIH0;0;N0LPL>;KD"HV298 Q9P6T*+A(P:8\5&$G3;C(5N!/@H?BS'
M"[S0Q$=UQ4]QN)AU6 W'W^Q%J9I<+5!N\!,BG:"U_I"'G6NW!!E8)O3;Y^RF
M EYT]#=@-3->22AF-!J,G!*+91\N;!@8+%@:9T.9/APECJCG&I)U'?L>X ]R
M+>/E**E-XTTG<P=68B5J'>1 2WX-6G7Y"7 AP[N%54K:#ABGU%U(#.X#VDW6
M[DALHXAE+M71(B9658'MKD>_'GVU'[,A%3$W4.T9A/3JBS4>PE:0#TZ!D7J6
M;CJE "M NE7LFT+9 ]QG)E>-RU6 1IDKV3>2DCVK ^Q,LU\Q.EQYR,'IJ=,;
MY&GR.N/EJBQ%BZT69RG"VP$HBNZU>Z]@I57<+W"<4&N57:]AMIK+=H,ELS;E
M,EFPC@RK^]#V,:8"RK"LK*E$HP-,3+FWSL0W. .F/A]6OQ1;:TOZQ<JH7-JC
M!Q!],=Y$X? @XQ%CLMRY"!:/;Q#9"'!EY$I@J)P()8R.A$E2XHXN2@LQYK])
M\OO]_A[@BD_ID?[U"_8'_P"9<(GID?[U"_8'_P"9<(GID?[U"_8'_P"9<(GI
MD?[U"_8'_P"9<(GID?[U"_8'_P"9<(GID?[U"_8'_P"9<(NO,D/#XLF=/*"H
M,*&P[)ES)D9<:+%C,(RX](DR'BB&6&&6TJ6ZZZM+;:$Y4M6$XSGD@%Q#6@N<
M2   223L !J2>@"KCCDFD9%#&^665[8XXHV.?)(]Y#6,8QH+GO<X@-:T$N)
M )*T3OOV@.N!^+$.TE (]CCM79DNV,EKZ-#%Z@IB8K>7G96P=]6<T.UA5QK3
M25KD28QDY,8PC.%COO\ 'FXALE2>1U8]E R0@1MG#G54N3@"&BC#JB1Q., L
M8#GZ2];M'H:XBF]2GXJJJ/@BDKW,;107ID\_$MS,AY6QV;@^@9/?Z^=Q($;)
M*6DB?G2<+0H=L'O!W3;+7.Y[GJ?3KI>%0X\?V70GYU5EW0<TXK$B/3K_ 'E
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M)0<@ND#Y#GGQJ&[8'-L3OD 8&PRMS:W,,)9!1.HZ-G**4O(;).T@\\KHL<[
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MI/D(K\1MYI4C<8[A%0>I->S=<;V #[)>+M>"]DU#M&[BW35CUD4#AS%JV)K
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M+*!L_<VRWTD[357&MBI:1CRTL#VNJ9W- );'$WF>UN",OY"=<-:<\P]=]'7
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M-0-'HF3'HTF7+3#CIDRI$)GV\-^2_AO#K[T1C\Q&==6I;#/YMI2$?U>$7 P
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ML.#"BMM1HD6.RA#3$=AIMIIM*4-H2G&,8P"23DDDG<G4GXKMFM:QH8QK6M:
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MS&'!48B//J;EONI7A?K8;:C(0MV4XRTA:\,9^U%RD+!4A5E 4\@97%LMH&V
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0(G")PB<(G")PB<(G"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g107876g66x50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g66x50.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X45>:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/G-T,38V/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!46#$T,"YA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!R<C$Y,C$P-"8C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,3DM36%R8V@M,C R,2 Q,3HU.3HS,R8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" Q.2U-87)C:"TR,#(Q(#$T.C4Y.C,S)B-X03M38W)I<'0@5F5R
M<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @
M(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X
M03LF(WA!.^* HB Q(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I;VX@
M8F5L;W<@,C8U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!!<FEA;"U"
M;VQD350F(WA!.R @(" @(" @("!!<FEA;$U4)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!
M.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C>$$[
M5&AE(&9O;&QO=VEN9R!I=&5M<R!H879E(&)E96X@9FQA9V=E9"!F;W(@0U,Z
M)B-X03LF(WA!.T5M8F5D9&5D(&EM86=E(&ES(&QO=R!R97,F(WA!.RTM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C
M>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @
M/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @
M(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P
M,C$M,#0M,C!4,#0Z,S K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @
M(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 T+3(P5# T.C,P*S U.C,P/"]X
M;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M
M,#0M,C!4,#0Z,S K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \
M>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W
M<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS
M/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @
M(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$S-CPO>&UP1TEM9SIH96EG:'0^
M"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'
M26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^
M+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)
M1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[05%"24%!04%!
M44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G
M:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!
M.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!
M64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%I045!
M07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!
M04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[
M05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"
M04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX
M0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H
M9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E7
M6C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ
M;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O
M4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX
M9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#
M0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[
M,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2
M,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I
M6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$
M.$$Y531Q:W0Q-7%S<F9Z3&)E6#)J8R8C>$$[,U9Z2#9I>4-N04%H>G9V+T%-
M5FY&5D-X<W)45712,6E6-VTU:U=+.$5+0T<X=5DT,#17<TA*1E-+4E5&2$Q6
M,C8Q<G9I;$AF-&0P+R8C>$$[+V9T-R]W0DHY-R\Q5WA1-R]$=6XO=T,O8C,O
M<%!V9BMQ,DMU+W=!3S9F.$$W.79F*VLK.2]W0W$R2W4O=S=P+RLO8C,O<%!V
M9BMQ,B8C>$$[2W4O=S=P+RLO8C,O04M4-S,O<71I<G8X3S9F+T%,.79F*VLK
M.2\V<EEQ<'HV3'!&=6=E935U-#%:9VEL=%%V0E9M,D-J.3EU5&I42R8C>$$[
M24HU25,T:#AT,C)Q,G5L5%AD.'0O97$W,C!0,7I50T=7345T.%EK2T-G2&,T
M85I$2$EX36AY0U O=T%/-F8X03<Y=F8K:RLY+W=#<28C>$$[,D)R9"]H,U0O
M=T1F=#<O,&XS=B]!1E=X5C,K2&10.$$Y*S-V+U-F92]W1%9B1EAF-&0P+R]F
M=#<O=T)*.3<O,5=X5C,K2&10+W="*R8C>$$[,W8X03!N,W8O5F)&6&8T9# O
M.$$S-V4O.4HY-R]W0E9S5F0O:#-4+T%09G0W+S!N,W8X03%7>%8S*TAD4"\S
M-V4O.$%39F4O.59S5B8C>$$[9"]H,U0O.$%F=#<O04Y*.3<O,5=X5C,K2&10
M+T%.*S-V+U-F92\X059B1EAF-&0P+W=$,S=E+SE*.3<O04Y6<U9D+V@S5"\Y
M*S-V+R8C>$$[045N,W8O5F)&6&8T9# O+T%(-V4O=T139F4O.59S5F0O:#-4
M+W=$9G0W+S!N,W8O0497>%8S*TAD4#A!.2LS=B]39F4O=T168D989B8C>$$[
M-&0P+R]F=#<O=T)*.3<O,5=X5C,K2&10+W="*S-V.$$P;C-V+U9B1EAF-&0P
M+SA!,S=E+SE*.3<O=T)6<U9D+V@S5"]!4&9T-R\P;B8C>$$[,W8X03%7>%8S
M*TAD4"\S-V4O.$%39F4O.59S5EA2-D)9>'EP27-T,E=J64]O83EU,U=O3F0Q
M855Q=SEI2UEQ;4]+<&).-60P;6)8228C>$$[9&-L:4QA:F)X*VI"3'E90E8K
M2W9W9V='=DTY8U9A,&XO92]7=BM9,5 K;T\S>%9-.%9D:7)S5F1I<G-69&EQ
M0G5&5G1:<W=W<45H=28C>$$[2D5"-T]':5%-4&9I-T0V8U!2=&EF469E4#!O
M-FTK0G%D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<R8C>$$[5F1I<G-69&ER<U99<G%&-S5G6'HO<#EN8G,U,&0W8WE89U=.
M:6ET4U1J>6-)5DA.;$9+=#(W9'EQ86%)6E1E-C):5D-..65!059I=R8C>$$[
M-&DP="M*<5%U-4A59'9F<F=63G-69&ER<U9D:7)S5F1I<41L+W=#3WIA+SAW
M,7@O>$]$1#!B0CE".30O4VI-1%<W1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%H<$Y4,"M/.5-X
M931J5SAK2$I)0W<U:V)N<"]S5#DR2R8C>$$[;UA34#DW.6$O=T-9,5 X07%$
M=#A65%!&6%EQ-T9867$W1EA9<6<U9BM/>F$O=T1-3F-F.%1G=SE'=V919F50
M,&]Z03%U>%8R2W5X5B8C>$$[,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A62F9,9FU#6%9V<F%45WAT6C=.>$9-:#4O8DYD
M=FI20B8C>$$[,$%/>%!81E9+.#AR1S8X,3)U=6U6149R1W%Q=D9Z2U-"24-O
M8FU%5E0V9THK16YB=&EQ2S!33EDW-U<Q57-18C1..%1->'$Q<&)S9"8C>$$[
M,DHR<61H,$A18EEQ;75+=7A6,DMU>%8R2W5X5D)Y+SAD;3$O-6AR:B]I8T=(
M;S)$-D0W>"ML1UE'=$IP=DYU:E$K64<P1U(U0G%+,B8C>$$[-75X1TEN64Y'
M2S$T8U%E8E58;W1F=GAP3DIP85AD=&57-EA&=$E*65AR>&1F145H9V9!<5%1
M461W9&II:%9X5C)+=7A6,DMU>%8R2R8C>$$[=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A69VXU871$*VMV355-8W-C:E<Y>$A$2C95355A;&<P
M<D9Y.$UK<7E-,TPT<28C>$$[,$E),T9C2E9/<C-Z5$IB*V(W4%%"8D)K=6\O
M54YX>6]2<S4K>E-V*S8O>#=91E-85E0U=&TQ2%9:4$QL945C,7=L>$A**S8U
M>2]6<B8C>$$[1DEU2F-60D@W>&Q90VA!+WEH:S1C4%9Z=$EC3DAX3SAF<'8Y
M1'!,,S@Q1&%Y4$AA46AG1EIE4WAI5#1A3$MN15--3C)K67AM=C)9.28C>$$[
M.3)Y5E)B>$136'I0-#5D4$QF>E!K<7I**UEJ-E!:=$5"1G%"=&(T,W-4;$0K
M*V%E33(V;WES44<Y4&YX8C1G0CE'4'!T:41P:$TS.28C>$$[4$9'=F12=C=A
M46-7<69M,S9T=4IT3VE%2DI&>39#37-Q8FPR54=89&QP4TUD1S<K3T=O3FAX
M84]J56IF5&XK<C5P<'!R9619.5<P2B8C>$$[8G5'4C=,.4A2<'%J8S1Q0S=+
M5FMD*S5+=6]&1C8Q<41S45EN:#-A36=W1T4K12MR:3E04&ML4U1F;3%A>5)"
M3&5/-E%P8F=T25DY>B8C>$$[5UIP031$3%%J:W%S=R]L56IC;DIE:'E#3DI)
M8S8U+V]R.4MD959P9D],-FY/9%IJ9&)&,$Q11C%I4FA);U%%37%34V-2,30P
M-C=K,"8C>$$[,D=1;%9B3TQQ4FA%4G=F5CAF4'E#8U)4:34Q=51G0T9S66UI
M:TQ!<5=E9&MB-%%10U9#>&9A-D=U>#)/4C9/3UDX35 V>"LW*S%-8R8C>$$[
M1%,V9W)81E5M,&4V4U!63E4P-&\O<4I/6GA+<6QO:7-Y2R]%=4%65C%R=7)%
M1VQ$,$]+<$)F9FU(9F%D9E@S,7940RML,C X='1&9"8C>$$[;W=4.35%;G%C
M5V%1:%-84E@T,"]A05AQ=W<P<55Y9FY32#%+4S)S.4MA5T]'4T]*=UI&.5)M
M9#5">%%!.%=,2VTQ1%%E*TY)5&%(."8C>$$[,4Q'-6QV;V)7=VY,,G1O8C)'
M4U=I4GE25E5O.60R5D=35D@U8V1H6'=X<$MY-"].0T-Y;&ET2EE99%%U-5A3
M2TM3=VY5=WE.2S=Q=B8C>$$[2#%+3E)21S-.:%5+84-T5',P<458.#,P87AU
M3'8Y1E!X4U)O-V-#5D]4-TUY1&EA9D=Y<CEG1W!*;TUA47HO5#=K,U9H8EA,
M2T9A928C>$$[2DI#;S9!=6]A;C0T17$K2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W-..&=&4'(R=&A&6E-:=UII,%5C44UV<5-Q+W!L128C>$$[
M:DQ29TM!0S(O3&QS34I6;$0V6'!R-F=U;W9B4G9F26=J:G57548Q56-T;%DO
M6BLR96U"54YP4"LY*W1F.'AQ9CE19'9I<5HT<3=&6"8C>$$[67%L9FU44T<Q
M6%10<7%516=L:&M2:7I)049K2%!D9#DT*U%Y55128CE0;#1*6#5(.&9.:$TK
M:F9M9%IA8F-/.3@Y,TU'5DQ70S%K028C>$$[8FE63E-3>4Q3:C!0>3(R2%-Y
M-&MU>D=B4WEK3G%(5R\W93509DQ':2MC8F)6,G9.8W9H9%%M3V1%:E=1,%5U
M.&)+94A&5B]:8G9T:R8C>$$[6D56<S1U<'I96E%R1TM/,S9745-+0G)D=7<R
M3#(P-&-J=45K:30Q+S%E8E4K6GE(4GA".4(Y-"]3:F-$56MP,%161#5Q6%="
M<3AW,"8C>$$[-%<U9T]J.%(V4F5T9E4U03EF;71F96TR2V]J47="*VM+1')E
M>3$O-%A&57AA3TYH4FQ"0DY30TYQ9S%R:7$P45%G,45A9SAU5F%$-R8C>$$[
M5RLO>C-X5F-%44YY0V=.44QY<'919$)I<3%9258T.%DQ2$555V=!;TLQ;U!P
M1TMU.4-#;%!45VQ1855(561$:7$X04%52%1&6%EQ-R8C>$$[1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867%W3#AS1W,O<G9M0F)A9C%6865+57AI6G!V
M5%9G.&%+,TI)*TQH67%%0W1"461Q:R8C>$$[;%4X=E4X,6YZ:%I.8F8X04M0
M0TPO4VIY:DAX,&8Y:R](,30Y=C0T1E)M:4-56#)T*W%Y<S,Q-$5&5DMJ:6)3
M,S1I:$QB:&%!;G8T1"8C>$$[<&EQ831Q-T9867$W1EA9<3=&54A,+W@R8E@O
M;4=U4"M*=UEE:EE0;U!V2#956F=A,UEQ;'5I9CAF+SA!>D=49G=X5DUS5F1I
M<G-69"8C>$$[:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-667 U36UJ8E9.86IJ,4(W.6ME23-,;4-A1E9U2WEO*SAS:VY**R8C>$$[
M0TEP0T)604,P1T974E-A;G X9#9L:3EX1W0U24]3449H>DDS4%0O66XW<T-O
M6%-0*T]H<F8O36%N+U5&8C1Q;65+=7A6,DMU>%8R2R8C>$$[=7A60GDO.$%(
M6G1F*UEA-"]W0TIW665J65!O4'9(-E5:9V$S67%L=6EF.$%(+SA!.'AK,SA-
M5E1,1EA9<30T<6LY<&-A>$996$TY-28C>$$[3&)817--<VIH64]16#!K+UER
M,F-54%=V:#<T4V=*>&=3-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867%K;FQN>3=0;R8C>$$[+W="83EE-U<X83191TYX1SA:4TY3>%=0-'!:
M5C1Q6$I!54M"53=9<75U9DMU;C-(;5<R.'=V2DU,>3%J.4M/24UV<$5F14MK
M1E,Q9B8C>$$[,V@V3FEQ<&]K5556.7)A>&]Q2V(T35%O04A*<E,S6FIT,TQ'
M<'A63F-69&ER<U9D:7)S5F1I<41L+S0W3G(O>D182"]!0D]$1#!B0B8C>$$[
M.4(Y-"]3:DU$5S=&570P5"]J+R]!3UEY8BM'2W!L:7)S5F1I<59N4V)$5&1)
M=F]R2TE1>'E*3$LV9VLQ6FMO5'54-%EB44%M;4),<R8C>$$[5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-662]E*UHU-V)Z9EDV04Q1=DAE
M>$Y+3&XT<41I2$QD<6)C0CDO,W%O<B8C>$$[4DI'93DQ<VQ':DEV9T%R8V%K
M0S!T=T<K17-+3C%(-#!/2W!T:7)S5F1I<G-69&ER<U915C9*63<V,74Q:F%3
M2D9K9VU60E9L5U5O=R8C>$$[96<S3D=J04E(:EAT:$1B0VI%:%%U+TU.<&$V
M-UDV33A->EA/;TI*2D9+:4%X2TEH5G5B5D90=7AP631I66U844DX6%9S8FLR
M;VQ1,R8C>$$[2W%*1V=$1&U%2F]'2SEA5C<T1W!"84HO>"\X02]-6DXO1$95
M>7A6,DMU>%92=E)%8D]C4VMR15DS.5%J<48T;710;WA64E$V:2MM=28C>$$[
M6E963'=X='=%6B]A<#A06%E(,G%2-S1Q:U903V1N0451:39:;RMF26A72W-6
M4$I3>DUP2D1"4W5X*S!F05E654Q)*V9F5SE35DMC:R8C>$$[:W)'-6I+2WIY
M0E5P4G8R465F>49/*TMO,DM4>E).66<S.%1X=4QH:$ML;U5757AC1'@T1FUP
M5#%0971-5E$P:S-N<#1P16II0T99>28C>$$[1DI%4EEY1U)5;T=$04=K5$8K
M6$5F14-+9$U65F]8.#1.3F%,2W8W:W1',7DQ23%O;G%F1TMH<3%P5&%N4W4O
M8D975%E&9&ER<U9D:28C>$$[<G-69&ER<U9D:7)S5F1I<G%#;TY.>#!/2W!:
M<% K.2MT9CA!36%N+T%&0C(K2W!N:7)S5F1I<G-69&ER<U9D:7)I065U2W!D
M+V@W4B8C>$$[9C T3F0K<4HK;&A&-D@Q<U9$96XT158T:SEQ,')48G!I<E=I
M9CAF+T%0>D=49G=X5DUS5F1I<G-643)P+W=$2$YU+RM-36XO04)%-"8C>$$[
M<6EC5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ45AU
M:#9V3C5P=$Y7:'9U1FI!<7!*6D5V4GA35&LR,C%F:28C>$$[5V<W.2MG<7%I
M=$52:W9T8D1/,&A..$1Y8FI50G)3,TE8-%%U>3E",SAC5E181EA9<3=&6%EQ
M-T9867$W1EA9<6QK=FUB46]T6&)2,R8C>$$[=D5'<'!#8FPW66-I=VE88VLP
M1DLP,S0Q<E1E;4MU,$1K.79C>FQ(4DQI-6QL:45I;$=+13!$1E=!659P559(
M5$95>GA6,DMU>%9+3"8C>$$[86)83#=4-VE+.7-5<S4S9#16+V5Q-FU)<G1*
M.$YF1VY(=E1T6$-19T9..$-867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T98628C>$$[<3=&6%EQ:'!.5# K3SE3>&4T:E<X:TA*24-W-6MB;G O<U0Y
M,DMO4%)*67!B-UA':61855AW46Q30T%Y5VQU<D1B=4-+2$973R]M3"8C>$$[
M*V-0:R]W06=3,FM'=&TT:W5B>%=K:'0W5TU33T55,#5.>6%.44-D:'9I<D-N
M+S5Y-"],2F$P<SE796YH0D)V.3@T>%944#A!>FPU*R8C>$$[5V\V861R0B\U
M-%=V+UI4:7)49C@U92]L>'1X,#-71'9V5T<R1D(T+S<P67$R9CA!;DQZ.'1E
M,FTV>B]Y271F*WEN1E=H+WIL-2M7+R8C>$$[144V8G)(3'5"1&)';C O5U)I
M<EHO=T-C=2]Y,7%+861R1D0Q4&]7,C,O5'AI<G8K:'90>3$O-G1U<R\X:4Q8
M+T%,2V-6470U+W=!-28C>$$[6F9L=5,Y>&%A6'%G=GEQ>')C4&(R=&5!8FQX
M3&973UA(<G0T-'%I5"]W035E+VQV>%!(5$Y92G!S1$1A:F8U+U=4:7)V*VAV
M9GDR<B8C>$$[+W=!8S-72V8X66)8+W-P>%9V.$$V1S@O3%=L9C!D<DAY.4,Q
M+W=#>6Y&6&8Y1&5F;'14+T%)-75S9CA!26DQ+S=+8U97="]Z;#<K6"8C>$$[
M3E8T-EIQ-4)0>#%I=&A194EP8T=U2W)V*VAV4'DQ<B]!36,W5U!N-D9R+S)5
M-'%T9B]N3#,X=6AY-&%:<35O1'AR1F)#<F1H+W919"8C>$$[=F9&5V]V.$%N
M3#,X=2]357IA6G$T;$DK3E5H=&U52#)*=49X5G-F.#5E+VQX53$P>E=!2R]$
M4T<Q3E(O,&MJ1E8T+S5Y-R],4VA0-B8C>$$[4#%G9C50;U<Q9CA!<4IX5G(O
M;V)Z.'1F*W)D<D@O26DR+S=+8U9D+S!.-2M7=CA!,6)T62]W0U)&<B\R531Q
M-R]O8GHX=&0O.7@R<R8C>$$[9CAI3%@O<W!X5G8O04M'-R],5VXO2% Q:C5E
M:&)F.$%:5&EQ1W5V*V-S9GEW=41%-S96<D1V031K:4)I=&QO=SAA6$IX5D5F
M.41E9B8C>$$[;'(O,6)D6B\U15=V+UI4:7%L8F8X-65F;#DV2R]7=$\Q6#%T
M*V9P=U<O2')T5&QC,399<7)F.$%1,V8U83!R*VHY62M8;U<Q978X028C>$$[
M>D59<7ER.'50>C X;BMF.5IU3DDP93)V<F4W=#=D<G1V<FMC4TM9,61)>GA-
M8W-U+TM6975+=E)C5F1I<6<K;C)$,VE8<C(P5%AK628C>$$[-'@S3$EP;%9D
M.6QC:FM"=64K2W!C<T=U,G0Y<45L<F)7<SA&,TUS>4Y,8U-23TM14E)%1E9G
M;$A72W8R<U91*V]71C=Q2FI8561$,"8C>$$[<3AA4&M94F-81%,X46%C=5!/
M,$Y+-U9P:7%%+W=T8B]!4%5Q848O=UDO-TES574O=W1B+T%057%A1B]W62\W
M27-69"]H83,O04]P528C>$$[,$PO9W@O,E)9<710;'$P53!B>71O25!G6%@R
M+S5C=F-9<35V3&1K0U(O:&919'5T6%5%57 O>34K-'A69"]H83,O-FQ4478K
M1$@O6B8C>$$[1FER=CA,5R\O57%A1B]W62]W0WE,1E=M.'-7<3 U959D0D93
M04MU0G5E9R\S:7A6;V57-TEI=BM&=$)+-V)H,5 R=6XO2&XS<FER;"8C>$$[
M.',R:FEQ*U9D0EEB2%IW974T+S0X<U989C17="]W1'%63D,O-$UF.6M72W4O
M=T%,5R\X03%+;6AF.$=0*WE,1E9V.$%H=7IR42M6="8C>$$[0C8P*S)V5V](
M+TQ(-&Y&6$AY,UIG:V8T5S!(8B],6'14+VQZ.7AI<3<O0S%V+S%+;6AF.$=0
M.$%S:7A6,RM&<F8O<59.0R\T368X028C>$$[6D9I<G8X3%<T+S9:5%%V*T1(
M+UI&:7$P95<W27)5958Y0DY304-(5VQ305(O=T%E9F5U2W58>7IA3TMR-58P
M1FAS9&Y"-C=J+VIY>"8C>$$[5F0O:&$S+S9L5%%V*T1(+T%'4EEQ-R]#,78X
M03E3<&]8+T)J+W-I>%994$QL:511958Y07%$>$DY4F5O2490.30O16I&5WHU
M8G-G828C>$$[9C18,$AB>&1193,O04,U*S1X5F0O:&$S+W=#<%4P3"]!24UF
M.6M72W4O=W1B+SA!57%A1B]W04=0*WE,1E=M.'-7<2]A.'$V0TLW0R8C>$$[
M<F=F.6E72V]J5#E-;'-*5%!984)O.7!+=SE.<&)E8WAS43%'-&QK=$9.1'-A
M66]41T,W,3DU134R9&U):58Y4C0W>5(R0VYQ47!T;"8C>$$[0DY.=TMI=4MP
M;FER<U9D:7%8,T=I5S K<S)U<7,W:64P4FM20E1I95%:9#EQ.4A09G<X3594
M1$9867$W1E=,870K6&5J-FQE,V0S2B8C>$$[3DY%.391,'E2.$])64MQ,5=Q
M;6QE2DHX5'8R1T<Q53=V.'5.3G9#>C-.,T\P<VMR5'E/9VI7<W)K33)X5G9H
M-58K16YP469S:D<Q6B8C>$$[6$=G:FI73F%K24%O2C-.04MB-$9867%L;FU,
M46)F6$Y0*V]816I2=VU26&-O<49I1G)S<&-.>$\O=T)O8C1Q:W-8-6,V9$5Z
M8V)U8B8C>$$[,#5(:6QK4VM9<3A)6E9);V]O2U-V=%1B86Q/27<R<4XX=657
M3DHX='9E1T,V6FYU*T1Z0UIK2$=J3V%Q1D,P0F%19V5'=TA407%E4"8C>$$[
M8S(V1VIY;W S,DQ!9EI&5#$X0FEQ-S%9=4AQ8S$T535C<6EN1VQA,3A+67%X
M0V(X=DY#=F)U-'5V<G-Z4&-Y=$Q+14U605I+;6DP5"8C>$$[8C174#1(<TU.
M<7 S;C5B84IE2SEX9#,X>&%35C=I5U9$16EM4U=P66EQ=%)F:F%G<C1F>6I'
M,5IL-CA&55@Q1G)*=D=/47$S>3AC0R8C>$$[<G5A9GI$-R]!0C99<6LS;5!2
M.4LQ=3-I=')Y.&5"25I/645-<6]3>%%R4G%G,2M&:BMV1E5Q:B]!0S4P<WA+
M:3-K>E<W>4I/=U529B8C>$$[17E"9W!"0S!!+V90,B]L+VQW,G%:*U=F2TYH
M-65A-V$Q;6QL83A+=$PV=D=G2VPR*T5+<3!&6D1T,D9!3FAG5E!-5F1I<D5B
M:CAS.28C>$$[1VUU6C5Z8UA#;31L95HQ0FIO1$EX3&-A<%5F8F)F>&\S541$
M87%D,RM71VQ8<E!*9%AL=S P<W(S17)O23%":VQR>6]/3$5,.&)51B8C>$$[
M9D0K55DR<DUS0W5X5DIV3DAL87<X>%=S3G1E4U-X<$)*-G%M26='=D5R*S!'
M2#=72W!03BM75VQ3,G)7:EAL=TQA47$P:7)W5FEY228C>$$[>4M1=UAB858K
M,SAV.&]W,G%C95AV2S%N;V-T,4IB>7E33F1I25-C=V=!.4E.5&E%5F%6-6Y!
M<6,T<3=&6%EQ-T9867$W1EA9<3=&6"8C>$$[67$W1EA9<3=&6%EQ>#=7+TEU
M:#9Z9'I89#4V=C%I6DEO*V-C:%AI<U1&:'A(5&,Y4U)H=%5*8V9L=F\P.%5I
M3DQ+2&)L=VM!449!,R8C>$$[2W1#1D)R5U$O1E=T2T-U=WAT5C0O3'92>4@U
M>C-$1U<S83%L06-"5U9L5F$P<'-2>$Y$5W4K3G%P>2]L;F]$>5--<S$Q1VMJ
M3$HV8R8C>$$[8W!50C0K45%H<6,Y;&-R5&QV,4\K*TYQ:#=J.'%T2&U!3%AT
M,D=$0C9",45F249I1'=#9T0W6C95,C)X=%5:<&XU9#9*<#@T;E-3828C>$$[
M5U5"-D=1;W=5>65Q5S1$:CA/.#=(8G8Y3TYQ:'HK5BMJ*VMK2UAL,FM58G=4
M4CA86&MS;'%734Q++T=O0V5O=W X=D1',5%H+TM$428C>$$[:7I5=DQR9SA8
M;T93-% W=F=%.$]V=CA!>'AT5UIA6'!S1VTR159L8FQJ1$1Y-$9Z5G9I671U
M92]807%+>%8R2W5X5C)+=7A6,DMU>"8C>$$[5C)+=7A6,DMV+R]:/"]X;7!'
M26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @
M(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HQ1#8S,S$X1#4T03%%0C$Q
M.$4P04)$-C@U-34U1CA$1CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @
M/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HQ1#8S,S$X1#4T03%%0C$Q.$4P
M04)$-C@U-34U1CA$1CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y
M,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I2
M96YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^=75I9#IF-&$R9C<X,RTV8S<Y+31A.#0M.#EE-2TT-&$Q-&0W
M,&0R960\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID
M;V-U;65N=$E$/GAM<"YD:60Z1$$W1D-$,C4U,4$Q14(Q,3A%,$%"1#8X-34U
M-48X1$8\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U
M.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N
M9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @
M(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#HX-$9"04$X-44S.#A%0C$Q.35%044U,C<R-30T1C="1#PO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C R,2TP,RTQ.50Q,3HU.3HQ-BTP-SHP,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL
M=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,40V
M,S,Q.$0U-$$Q14(Q,3A%,$%"1#8X-34U-48X1$8\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#0M,C!4
M,#0Z,S K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S
M=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R
M;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM
M96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM
M;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @
M(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y&86QS93PO>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54
M<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%10
M9SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXV,S N
M,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XX,3 N,# P
M,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\
M+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@
M(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4
M/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86UI;'D^07)I86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP
M93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN
M9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO
M<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9I;&5.86UE/F%R:6%L+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@
M(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T
M94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO
M=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z
M4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P
M3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM
M<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U
M<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R
M;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" $= B4# 1$  A$! Q$!_\0 '@ !  (!!0$!
M      <(!@$"! 4) PK_Q !0$   !@(! 0((#0$%! D"!P ! @,$!08 !P@1
M$B$)$Q06,5B6V H5%QDB-D%15WB8N-9Q(S(X8;=2@:&Q&!HD)C,W=I'!-$)B
M<H*&T?#Q_\0 &P$! 0$  P$!              $" P4'! ;_Q !!$0 " 0($
M P8"!@D$ @(#     0(#$00%(3$205$&$V%QD?"!H10B4K'!T0<R-3=R=7>T
MX16RMO$C0C-C4Z+"_]H # ,!  (1 Q$ /P#]_& , 8 P"OG(^WWZBT**D]9O
M:A&W&P;7TS0(^5O5:FKC7(MCLC:50HLP_=UJ NFOI.5<,HN??.8QNC;(E$DB
MDT6='713505&6GUNFT_)+7PY_+75G5>:O,;\=^,_Z3-I>^G@T:^:O,7\=^-'
MZ3=I>^E@#S5YB_COQH_2;M+WTL >:O,7\=^-'Z3=I>^E@#S5YB_COQH_2;M+
MWTL >:O,7\=^-'Z3=I>^E@#S5YB_COQH_2;M+WTL >:O,7\=^-'Z3=I>^E@#
MS5YB_COQH_2;M+WTL >:O,7\=^-'Z3=I>^E@#S5YB_COQH_2;M+WTL >:O,7
M\=^-'Z3=I>^E@#S5YB_COQH_2;M+WTL >:O,7\=^-'Z3=I>^E@#S5YB_COQH
M_2;M+WTL >:O,7\=^-'Z3=I>^E@#S5YB_COQH_2;M+WTL >:O,7\=^-'Z3=I
M>^E@#S5YB_COQH_2;M+WTL >:O,7\=^-'Z3=I>^E@#S5YB_COQH_2;M+WTL
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MN=W0[5]H\)E57(L'F&+IY36JU*M7"0K2C0E5JQA"K)TTK.4HP@I/=I+DB<R
M!2DZ"7T%((]>O< = * B'4?1]O>/IZYP?Y]_F=%K>\K<3>KM;77Y_!=#[8*,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , K3Q6^H5_\ S+<L?W);1P"RV , 8 P"M?*;ZCZ^_,IQ
M6_<1K; +*8 P!@# & , 8 P!@# & , 8 P!@%650#_IM,!Z=_P#T698.OV]!
MVU"]0_W] Z_T#.P7[*E_,(_VTST&/[JJW]0<-_QS%?FRTV=>>? 0 ?2 #_7
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MD!K8\6->@&E7E6,Z#EV()R)Y*Q5TC)H47K?RT!!(87GOOMM_WM\-]$7#P48
MP!@# & , 8 P!@# & , 8 P"K*O^-EC^5F5_U:AL[!?LJ7\PC_;3/08_NJK?
MU!P__',46FSKSSX8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# *T\5OJ%?_ ,RW+']R6T<
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M%,O9(7D1K8RJIC&5* $01$'!NH@(D[@ QQ[.9+S^7QW^/P\?A9W!1@# & ,
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M*O(KL6+QS7;!%FD6#&1!VT0-6>CNFKI_XUU6S\44F_(!@# & , 8 P!@# &
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M76:0A5KX/+<XP^.JU,77R]U:5''?2<%E%.4W4> Q&-C!2J6GTGMUKN^K/;]
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M90<7(R:Y>H=AHT64ZCV>@@9!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MKITX<$8SCM)./ZU]WJK-)KGROM_VER;M!DG:;+L52P^:9!EV RK!35",J%3
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ME.<XJUDZDW=WT]#Q<GCOT79-5K7E5R'MEF^686H]XX#.LJP&9?15_P#51Q^
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MO?-7\W#W]N7''-2VA_"_]\@6XS(& , 8 P!@# & , 8 P!@# & , 8 P!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M*_TS$3.82GY$:U(LE]-(_9(L@ (&$ $1)_L&#MC!:S\'J]?PU\.?DD6?P48
MP!@# & , 8 P!@# & , 8 P"K*O^-EC^5F5_U:AL[!?LJ7\PC_;3/08_NJK?
MU!P__',46FSKSSX8 P!@# *C\7_KWS5_-P]_;EQQS4MH?PO_ 'R!;C,@8 P!
M@# & , VF-V>GT3&Z_[(=>G]<J5^:^+M_@C:6]_/E^9KU[NO0?Z=._\ ]LRW
MP[];:!.^IKE*, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , K3Q6^H5_P#S+<L?W);1P"*MB;;FW,F&T(K5TQ\A^BMD7IWLB\1]
MLK<?+V^/HL!L#6VQ% U^LAX^QT6@6E_(V1\,I88NP2,[K,CZM56:%.!<R5ML
MNOXDOOT3]>O+S^*+UY"C & 5KY3?4?7WYE.*W[B-;8!93 & , 8 P!@# & ,
M 8 P!@# & , JRK_ (V6/Y697_5J&SL%^RI?S"/]M,]!C^ZJM_4'#_\ ',46
MFSKSSX8 P!@# *C\7_KWS5_-P]_;EQQS4MH?PO\ WR!;C,@8 P!@# & ;#G
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MKN2:-6B<JR1C9!9JB^7>=N22LI)6O>Z6R:M>VK>MT]>O0Y2:,R!@# & , 8
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MZ_\ TAIG_GLC#_4C_%+[H'*3?F0, 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & 5IXK?4*_\ YEN6/[DMHX!A33BY>H*_I7>I<@9F
M!;1\ENYU"5Y;7-+F&T9';_VE#[=OD6>0> 5Z_ ;3!1Y8EZX$'#"/*JV#QHJB
M<+?\/DK$M;Y_-W9<O(48!@U;UAK2F2TG/T_7E&JD[-@<LS-5NI0$%+2Y5%BN
M%"R<E%Q[5X_!1<I5S@Z65 RQ2J&ZG # !$G*;OH^OOS*<5O^'(G6PX!93 &
M, 8 P!@# & , 8 P!@# & , JRK_ (V6/Y697_5J&SL%^RI?S"/]M,]!C^ZJ
MM_4'#_\ ',46FSKSSX8 P!@# *C\7_KWS5_-P]_;EQQS4MH?PO\ WR!;C,@8
M P!@# & :"'4/_G[0_S#[A^X>_\ I@'&7;%5,4P@ B0# 40 0,4#!T'H8!Z@
M(AUZ"7LF >@@(9'.<=([-Z]/BK>7M&)0A)J4E=Q3L^G7HM;:OER/JFF!$@3
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MO;WZ[%M<%& , 8 P!@# & , 8 P!@# & , J+NN10U5OC2&\I=4K*B24/;]
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M_&]M-[[&$K7MU?KS\[[WY]2IO%_Z]\U?S</?VY<<<U+:'\+_ -\BEN,R!@#
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MI_J1_BE]T 3?F0, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & 5IXK?4*_P#YEN6/[DMHX!9; & 1_MD(4=5[+"R0\K8:Z.O[D$_
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MR:-&K!JW9,6S=FS:(IMVK1HBFW:MFZ) 310;MT2D2112(4I$TDR%(0@ 4I0
M #,'(<C & , 8 P!@# & , 8 P!@# & , 8 P!@# -ISE3(8YA*4I"B8QC"!
M2E*4.HB8P]P   (B(]P8!CL+;*_9#.RU^:BYGR!SY,]&-=I._)5AZ]E)R5$Y
MSHB;H(E.8OBS '<8.H"(GX_+P^.ONQDF"C & , 8 P!@# & , K3Q6^H5_\
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MP!VBC]O_ /1] _T'[!] _8. W;<T\83O^D'=Z0Z]X?[O3_3N[_LP!XPG<(F
M $0* CW (CUZ!U'IW]0$.G^T'9]/=@7-AE2 /4.G4![(B8!*(=1Z!T[79$0,
M/4 $.H&Z=W7 N:^.3*(%.H0AS"( 4Q@*8P@/0>R!A 3=.[KV>OI ?0(=1--O
M?OKY^)].T'W_ .7].OHZ_=U^P1[A[NGI#!1U#KTZA]G_ !'H'^_KW=/3Z/O#
M!+JU^0[10 1$0 "AU$1[@ /\Q'H =/M^[[<%O[>GWF@G( =H3  =!-U$0#N
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M]HQXZY;QC,C.RV:)UI;;%$/YN8.*DHZ21?QT0TB(=B>+9-ECR;Z2-,N7$/\
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M =HW0 [0]0!2E(4I"%*0A"@4A"@!2E*4.@%*4  "E        #N# -V , 8
MP!@&TQ"'+V3E*<HB B4Q0,41*(&*/00$.I3 !@'[! !#O , XDA&Q\LR?1TF
MR;/V$FQ<QL@T=(D60>Q[Q)1!TR<IG*)5FSA%55)5$X"0Y%#E,40,. <HJ:9!
M$2)D*(D(F(E(4HB1/M>+((@ ?0)VC=@OH+VC=D ZCU T!)("IE!-,"H]/$E
MA0*EV2"F'BP .A.A#&('9 .A#"4.X1# /I@# & , 8!M.0BA1*H0IRB(")3E
M Q1$H@8HB @(=2F # /3N$ $.\ P!V"=OM]DO;[/8[?9#M]CKU[/:Z=>SU[^
MSUZ=>_IUP#A'BXU1XRD%&+0[V.2>H,'1D$Q69)2(H"^(V.)>J(._)D <"GV1
M4*F!3")1, @<L$D@*F4$DP*B("B4"% J0@42 *8 '0@@0QB )0#H4PE#N$0P
M#<!"%$YBE*4R@@8Y@* "<P% @&.(!U,($*4H"/40*4"AW  8!NP!@# & , 8
M!\_$I 4I 23 A#^,(7L%[)3@83@<I>G0IP.(F[0  ]H1-UZCUP#B-(N-8F<F
M9L6K8[U^M*/#HH)D4=22Y")*OG!P+VUG1T4TV_CU#&4*W22;E,"*2:90.8*:
M8^,ZID'QH=%>I"CXP.SV.BG=],.Q]'H;K]'Z/H[L W             '0  .
MX   [@  ] 8!K@# & , 8!\P12 I2 DF!"G\84@$*!2G PG Y2].@' XB?M
M #VA$W7KWX!Q9"+CI9HZ82;%H_9/D@0?-':":[=XW*83>3NT5"F3<-S=3 =!
M8IT5"'.0Y#$.<I@.6*:8^,ZID'QH=%>I"CXP.SV>BG=],.S]'H;J'9[O1W8
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M$LS8O4&4F^;KR^EOB6VM_@9;@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
'& , 8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g107876g67a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g67a10.jpg
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M%R(Q05=S>).VU2-1=K@D,F&!)3=B<7<*-$)#4O_$ !T! 0$!  (# 0$
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M@/,!O'X(]Y?,#C1];<97?Y/V \P&\?@CWE\P.-'UMQE=_D_8#S ;Q^"/>7S
MXT?6W&5W^3]@/,!O'X(]Y?,#C1];<97?Y/V \P&\?@CWE\P.-'UMQE=_D_8#
MS ;Q^"/>7S XT?6W&5W^3]@/,!O'X(]Y?,#C1];<97?Y/V \P&\?@CWE\P.-
M'UMQE=_D_8#S ;Q^"/>7S XT?6W&5W^3]@/,!O'X(]Y?,#C1];<97?Y/V \P
M&\?@CWE\P.-'UMQE=_D_8#S ;Q^"/>7S XT?6W&5W^3]@/,!O'X(]Y?,#C1]
M;<97?Y/V \P&\?@CWE\P.-'UMQE=_D_8#S ;Q^"/>7S XT?6W&5W^3]@/,!O
M'X(]Y?,#C1];<97?Y/V \P&\?@CWE\P.-'UMQE=_D_8#S ;Q^"/>7S XT?6W
M&5W^3]@/,!O'X(]Y?,#C1];<97?Y/V \P&\?@CWE\P.-'UMQE=_D_8#S ;Q^
M"/>7S XT?6W&5W^3]@/,!O'X(]Y?,#C1];<97?Y/V \P&\?@CWE\P.-'UMQE
M=_D_8#S ;Q^"/>7S XT?6W&5W^3]@/,!O'X(]Y?,#C1];<97?Y/V \P&\?@C
MWE\P.-'UMQE=_D_8#S ;Q^"/>7S XT?6W&5W^3]@/,!O'X(]Y?,#C1];<97?
MY/V \P&\?@CWE\P.-'UMQE=_D_8#S ;Q^"/>7S XT?6W&5W^3]@/,!O'X(]Y
M?,#C1];<97?Y/V \P&\?@CWE\P.-'UMQE=_D_8#S ;Q^"/>7S XT?6W&5W^3
M]@/,!O'X(]Y?,#C1];<97?Y/V \P&\?@CWE\P.-'UMQE=_D_8#S ;Q^"/>7S
M XT?6W&5W^3]@/,!O'X(]Y?,#C1];<97?Y/V \P&\?@CWE\P.-'UMQE=_D_8
M#S ;Q^"/>7S XT?6W&5W^3]@/,!O'X(]Y?,#C1];<97?Y/V \P&\?@CWE\P.
M-'UMQE=_D_8&-VWEGL77\$O:[SP]WA7*G'OH5K,SRERX\R:40WFIN.@DGZS"
M(W(]E'3=LZDT%7"3!FZ=B@504&ZR@%3,RN_R:]<(J67CM+8RD& , 8 P"1J+
M[[O(W^'SBY_67)?!>I?5^D2N<$& , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , ]#ITV9-G#QZX0:,VB*KETZ=+)MVS9N@0RBR[A=4Q$D444R
MF4554.4B9"F,<P% 1RI-M))MMI))9;;X))+BVWP27,W3ISJU(4J4)U*M2<:=
M.G3BYU*DYM1A"$(IRE.4FHQC%-R;22;9KR@;FU)M9Y9&&L-F478CJGJQZ%H)
M2;1#6@D"O*^GA'(2:\*\>H-5G8Q<D5))14%!,Q<E$H&1. >>M:W-LJ<KBWK4
M%5WG3=:G.GOJ.[O.*FDVEO1RUVHYK6=E]H]G:5C6U_0M7T6GJ<:T]/>JZ?=:
M>[R%OT/3SMX75*E.I"G\10<I1BXXJP>6I(DGDMVDG'?BKMFK:?V6-O5GI]A&
M2\K)P$*W?PM/AY=ZLS8R4^JO(-'BJ1_1G+M5O",I9XBS0%4S<5%$$E>0L-#O
MM2MZMS;1I[E*3@E.;C*K.,5)PIK=:<DI1XR<8Y:6\?<["_@SMO\ B+HVJZ[L
MW;6-2RTJK4ML7=Y\-6O[VE0IW-2RL(=%4C.XA2K4)-W$[:AFM3BJV\Y*-^IJ
M$53(JD<ITU2%43.4>I3D.4#$.40]@E,40$!#](#USA^7,ZJ::;3333:::PTU
MP::?%-/@T^1YX(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MMS0JU+.ZG0A"E*O;RIS:ITI_\RC1G3K,I2E*!2@!2E "E*4  I2@'0   ]@
M >P #V 'L#...ON?,_< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@$H\W_=@V9^\HWWC5#(^7C'U1J'YEX^C*NRF1@# & , D:B^^[R-
M_A\XN?UER7P7J7U?I$KG!!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MQ:-3./%,V0%,,OM9IRB^^[R-_A\XN?UER7P.I?5^D2N<$& , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , CS1'O/<YO\ 7>C/]OU(SE+S^K]'
M_N;S_.UCLS:[^P/X3?X3M;_K+5"P\XLZS& , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# )1YO^[!LS]Y1OO&J&1\O&/JC4/S+Q]&5
M=E,C & , 8!(U%]]WD;_  ^<7/ZRY+X+U+ZOTB5S@@P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@$>:(]Y[G-_KO1G^WZD9REY_5^C_ -S>
M?YVL=F;7?V!_";_"=K?]9:H6'G%G68P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8!*/-_P!V#9G[RC?>-4,CY>,?5&H?F7CZ,J[*
M9& , 8 P"1J+[[O(W^'SBY_67)?!>I?5^D2N<$& , 8 P!@# & , 8 P!@#
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MPJ7.GNC>QA+$OA[FA-K%2+=F9Q1U@, 8 P!@# & , 8 P!@# & , 8 P!@#
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ML/.+.LQ@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M#8&2.JU4GE9N;%1RN#F8<)@BFE3+Y+ZO]N/C^Q<N"# & , 8 P!@# & , 8
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MN?UER7P7J7U?I$KG!!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M[C6=>U*R7JZ3+.O5*H0DE8[).2"@ILHJ&B&BKV0?.# !CBFW;(J'[B93JJ&
M$TB'4,4@@3_J/FEQKWI:HJEZNV.E99^=J#&[0B7V>M,4PEH5["PEC,WCIF9A
M8^(>6&,@;) 2\_5&[Y2RUZ/EV#J:BF*3A,PBM-<T<71??=Y&_P /G%S^LN2^
M!U+ZOTB5S@@P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MNL8[[^_O@3J3^J\L>Y=&"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MNGJ5*\N/B]6T^EK&I7EJZU.56WN:<ZD:56C'3YWE25W&CNJSHS6N=M:<LL-
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M+[[O(W^'SBY_67)?!>I?5^D2N<$& , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@&(V_7]#V"S;1U]I52N\>R<>ELV-NK
MD/9&C1T)>X+EJVF&;Q%NX$GY@K)$(H)/S1-W?9GH7^E:9JM.%+5-.L-2I4Y]
M)3IW]I;WE.G/EOPA<4ZD8RQPWHI/'#.#EM(U_7=GZU6XT'6M6T2XK4^AK5](
MU&\TVM5I9ST52K9UJ,ZE//'<E)QSQQDR1BQ91C)K'1K-K'Q[%NBT8L&+=%HR
M9M&Z94D&S5JW(F@W;H)%*FBBBF1--,I2$*4H  >Y3ITZ-.%*C3A2I4H1ITZ5
M.$84Z<()1A"$(I1A",4E&,4E%))))''5Z]>ZK5;FYK5;BXKU)UJ]>O4G5K5J
MM23G4JU:M1RG4J3DW*<YR<I2;<FVVSZLV>(8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P"4>;_ +L&S/WE&^\:H9'R\8^J-0_,O'T95V4R=9EWXZ<L@OD]
M(Z[<\=W5-4Y0LN2L >Z3^RF%F.]:T>.J!JS,-8.G244BU,9HL[*\9/7"W=,D
M02@/> +E<,KEW]6<]C[69Q)9QC#;?'/-_?WU7SKE39BM7;GVXSHC&Z"Z> [;
MZYD;!*U<K(%A]7F;O+-%0TL9T9OT%X15B1)-;J5!10G0V0JSUXSW&=8*, D:
MB^^[R-_A\XN?UER7P7J7U?I$KG!!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , E'F_[L&S/WE&^\:H9'R\8^J-0_,O'T95V4R, 8!KK:]NLU
M$H<]:ZC4&-XF89N1X6!E+A&4&*,Q25*>4D9.VS#-^PAF$3'%<R+EPLS<=4VP
MIE( G[Y (:XP=I#6^35UH]=C-0W"EUO8S.S,*E;YV;A'?IU^H5)IU_O52<0#
M(A7S6.BZ]=HMQ!VWTA5A9A1<BV9,TO 46B>?M?LS36,\<M=6'R[3:&I[=4[5
MSAY3I5>T5VR*UO2G&:NV)* FXR95@+ RM_))1Y!3:<<Z<GB9AHFX04<QC\K=
MZ@19(ZJ!2J$$U(^2^K?APXEM8(, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@$H\W_=@V9^\HWWC5#(^7C'U1J'YEX^C*NRF1@# -.;]T=3^1
MVJK/IR_/[9'T^WECT9T]*LK^IS;MG'R324&-&7CA](]5R*C,C.9CCE4:2T6J
MZC7R2S-TND<5/#SV&J-5<)M*:AV0VVK7!O,I;F<=(-69[3=)2;AF<O-PD!6[
M+<&< ?P(AI<;17JO7X6>FVS1(SR/BT$2(("=<ZK'WY>R*Y-^/=Y+P/BUS&1L
M;S>Y,&CHYBP,_P!#<87SXS)HW:F>O5KCR5*L\=B@FF+ETJ!" HX6$ZQP(4#'
M$"AT$ZE]7^WNRQ\$& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M1(F^>)(#XBC9L=50@=2B'?*8H ;:P#Q.<B93'.8I"$ 3&.<P%*4H!U$QC"(
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M8[@CAP0A5EB()K%3!4>@E*!N4IBF#J4P&#J(=2B AU >@AU#V=0$! ?\A]F
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M%.FH0X 8AR'*(E.0Q1 Q3%$0, @("(#@'QR,K%P[<7<M(L8QJ42E%S(.T&:
M&,8"E**KA1,G4QA  #O=1$0# /",F8B:356AY2.E44%1065CGK=ZFDN4 ,*2
MAVRBA2* 40$2&$#=! >G3 ->;DVK#Z>US9=A2I2.F==2:^.B50W=(L^>MV#<
M7(H$6631*NY3%02(G4$H"!"B80$ -3:GY=:RV/582==R2<0\EI5[#@V2;R3E
MJFNS6;M_2UEQ9E/'LEUG)$"'D"H]%R+D[YTT3*X)W?KU?3ZE,3+166AIB,8R
M!F#M['/6*+]N8#+1[ATU421=$ !Z@H@=0JQ 'H/4H"'^>"FC]#ZHL^L$[(-C
MFV3U.659BV91SAZNS3,S!QX\JL=\FD<CV0!4@."$*8 *@0RRZZGYX ;"A=K4
M*PV&3K$5/H.):)*Y.Z(9%P@T.5BH"3X6C]=)-D\!DJ8".1;KJ F/4WM(4Q@
MR!*Y5%P5,Z%HKRQ%GGJ](R,S'*%4?]>GH9!(X,!G77V> '57_P!. ? &QM?#
M9%*<%YJ(VU% SE6LA8X<9])N3_G74B >>GD2+_\ D<R %#]8X!F!5$S@)B*$
M.!?^82G*8 ]@#[1 1 /8(#[?U" _HP#R*8IP Q3 8H^T#%$! 0_S 0Z@/_;
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MEKA[S>Y+2%(EWBC^2KTEM>U23-VZ5.)SJ**/G[AT!1./>\(C@B)1Z"5,.@=
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M2A@87VW^G'AX'OH7:D]H[K!B>,H7-_DY6H\ZQG!V;+<%R50,N?N]]42/)1R
MJ'[H"<WZ3B'4W41$1#"[_-]W?W'.V[M;^TWOB[UQ;N=?)J</(QI(AZFZVK92
M-EXY/J)&XLV[Q%H02B(F!9- CCO_ )XJ]\ , 8^\M>GJ<-K#M3.T7TNK)KZM
MYG<@J6O-(D1EUXG84SXTF4@"4AWRKI9PHZ7 !_\ NEC'<B/0PJB8 $ Q]?-G
MJ)VI/:/I^F>'SDY1D]8.%';WN[HO0 X<+'\110X>N>@"8_M[I.Z0/T%* =0P
M,??WS_AGD<Q"]K/VF5>L!;5#\Y^3+2Q$:'8%EQVM9W+L&2B(MSM1.[>KE% 4
MC"7PQ*)0,/B  *?G8"6/3FS3S_G+S#DY)28?<E-QKRJH+=Z1->9LKTBCE?TE
MRX0<)NB*MG;I;\]R\;F2=..IB++'(8Q1!+';SSS[<^YR,-S]YNUY [:%Y7[]
MCVRIGBBK=#9]L\%99^D*#QPND>3.19TNB(HF=JE.Y!+_  RJE)^;@8^OF_?A
MX'R-N=_-5G-*61IRNY!M;$JW19J3[;;-U0FCLVY2D09#*I3)7WH:1"E*FT!<
M&Y"E  3  # PLY_=^G(VI*=J_P!IA,LD8Z2YV\IG#)#T#PD0W-=D.[ZL$!8B
M*C>615.* @'M.<PJ?_N\3 Q]?-^YEDSVRW:IV&(>P$WSXY-2<+(QB,,_C7>S
M9M1J\C$!*9)JX)XH"H0!*43',(JJ=!!10X"("#6?O[Y]?:8>V[5;M(&53^P\
M?S7Y&QM:];&G#,(W9]ECE%)0R9$CNE'[)ZA(*=\B20'2.Z%$XID,9,1* X"2
M65QX]_+Z/G^IZ9GM3^T=L3^N2D_S7Y'3;^HD$E;<RVS['('B2B)N\+8KMXJ3
MOF[Y@,HJ510Q1$IC"7H&!CZ^;ZO'^/694Q[8?M28U>NN(_GIR;9GJB2R%?(W
MVA/IMX]%<QC*) T*X]%<)B)Q I':+@J9>A4P(4H  8^OF_<P_9O:C]HKN27B
MIW9W,_D/;Y6#3*E$.Y+9,^F+ A!5$/1T63EJW*8WCJ@H<4A.J4XE4,<H  !C
M[R\>7(Q9SVB7.]P@@U)R^Y$QS9LQ0C4F\'MBY5] &38#E01.E!RT>FKX0*'
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MBHK.W"$1!LV,>DNZ6,*KA4C<JBZ@B=4QC"(X!EN 2CS> 1XP;,Z!U_Q*./\
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MI0-.A3OE06>JQU?C6\:V6=JE*0JCI9-N"JYBD(053G$A"EZ%"F7Q;?:9]@#
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MWD:_:1\@>)?N6;E!E*)MT'9XYTJB<C=\1JY S=R9JJ8BX-UP%%82>&H'<,.
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M@=<Z[IEB0G=@1<JR>23FU0,6G)O:A6)"76FJ+J]4 IE8>,(1)!JY;Q+<@O\
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M[L=OMBS89!ZG"0:*,3#LTF;"/9-F#(IDR$:BL8YE5E!RF6\^27DL&_<$& ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & : Y86.=I_%GDM;:O*
MO(*S5;0&Y+'79N.6,WD(>=A-=6.3B)5@N7\Y!Y'R#5N[:K%_.271(</:7*N:
M^J]2/D_HSK;DY_>4#2;7=]6/N7D#48+BYOZS;1G^1,TBYAT[*RU.XE-92>L?
MM!*25Q;7)E<T#297L$FUK25<1DRS)SR2D"F%?AG@UA+]>7DT^74N<2[WWY;Q
M_P#K^F'V/GGE^4#:^R(+8VI6U39<K8::B]0W+<FV*QR2V)5K+4-M:ZB=8S9$
M&VIXM.\WV?DKJCMAY07:KFJEADZE6GCA.Y)%)9*[&2)\>M<^&%C#[^"X8S]I
MD6<=;QQ>7E/AR7//''TX]N'L*56V50^)M+YHM]^;-MNU7-4U1MFR03NSD=Z:
MOC*_OJJYFM60.K@;C5Z_"2$=9'%:H$S74&=Z9RA:_)2EHL#SUDG*N&<-<LKA
MSSU/GSR7CC*;ZGQQRZURX</KR[6;'F-5R2W,Z%HA=W<BVU0G-'7S;;ROM-SV
MUO&IVN+VK0X9@BS03< #2 ;Q=BDV1()+HP! Z!/#Z()]&>#X+FEG"SQ3]N?,
M8XKB^M\^QKA].)J+C!);"V#*1=HM-<YSV14V^]OL5-A1NZ=<--!>J*=OV^P$
M(BYI+K>$==E*=!PD%'5V=ARZT4=/PCI!-I%R;-RBZ=G]5R7#''DNO'[A+KR^
M;X9X<VN1ACW</)]:<U!+:TM<Y;YJ Y!]I1)S^LWSDJZ.X->Z5Y!R-9A=5(K+
MF(1A,15$7=Q^KGIS TB;/'UUL_\ _!U9#(\9\%YX7'SY^/67CCQ?DFUCRY=_
M,L;C1O%/=DERYN58N+ZS4%I?J$KK ZRBQ"5Z F>*&BK@\B6K%<"+PKI"VS\^
M]FH=RFD]C;&ZEFS]!!\FX1(?5]/W83SGZ_LB+M&V79TAPU=[JEO.K$WM/A!8
MMGI[0V3N"GS>I;)>'NE?6A9^K5>#VS9[*T7>RL@K:Z<$W18$(ENQ34?%B)1!
MM&JV7!OESY8_V_<D5R?S<NWAQ7US]_0S71M]OCC>?'BJ0KGE+273RC2NR=SM
MN3VQJE8:'L+5I:'(QZKS6,>:^WB9?VV)VC*428=NZT:";U&JK.RW4J2-B@(V
M0/KXKARPNOR75G]NLB;X<^/%YX\,=7'.,\NM=??Q_'KFQ(S^X[78I.Z35WJ?
M(6G;8O&G=<KQDPQ:T-WH]],N:)5JZZ>Q#1FX>;XT<FUV6\;Q[J6(VGZI83D-
M_P 4!W1K@NKJX_JWW)\.2ZN9<\7UXX\/T\6L=?//+KYUM;).GZ5X^\F;UOOD
MFYNNSX;6NUK7:Z; S^Q./<3$6MU3Y>=UY-ZMAQ:T:J4>1B[4K3*E8SBQO;04
M4;2O:Y67BY$KYSRDEV=6>><YSS[<</T')9;[^[CCJX>"?'Q/CI?)3:VO;YS2
MC+)9I&Y*6"W;&'BU"V!QXS5CL&H[%AM,AJZ..)#"A!/K3L[0JT<S+XJB2]DM
M#DB!T4#8:SCDN"SPZL9R^I]??]0FUGF^+QV9RTDOT[OIUZJJ%VW1-1/#.F6"
MR<J-SNY'6'-=S=AT?L6IT785QG=5<A=546J7.V2MRV'K.&>Q<)"3,O& P0GW
M#U%Q/L_18IPU0=.F3M?!<5C*ZN/#DS*;>$V^3Y/KR^?E@W'?[QO_ %GL?C,Y
MUHUW?ZEJVEN3&W]L:"W!9(*_;0V35*EM'0M5DHE:9K=ON\(\O5<K5^G;OJM&
M(M<GZ<NSBZ0\4CPL,HU9.I\N:XI=S^GB:65CF^#Y\^#7VL]O-&*[$V),;:XL
M<Z.05"WMM!LEJ2P[?L^C;#KO8<U7H)2O!Q]U!>*NFZ8,#I(3$.RE'+J3CXZ2
M2Z,EIB92,DFH]<D N#2:7-+#7WVDERRF^W@^><?:P5AR8K]CTEPTW037NT]J
M(6GT%F]A=@VBZ2EPNM;?S4Y5X0RL1-3:BJZ#5FAXB[6.Z^BD<.7I^[_Q:O4N
M+6>O/=U=V#3X+@WS7'F^+[R5]C\G-P&*;7,[97U.WIJ/CWS09[@B:RJI&1E@
MMU*U93I[4FYJPR 3*?9FY,GBURI2H>(->EW5DJ"RRLS5I8J<X978W].&?J\>
M9&VEYY\FUU+TY\"G-M[%NL7!<$EX2U2S1QL.]N&MQ49/3%4M,2CPUY WDZ<H
M)!'TUHG:Z]7K$83=2%DHQ@Y$>\F3J7_=]/W0X_+^ODSKN'D[OY#LU9:I#L^S
MGY.,=<N+ZGM91X!K@&L5./8<P4;Z=T! ,9N$"KY?B394@4); 34-T<E%<=-?
M,N'#*]<?JT_ )Y6.O]>6<Y^C67V^!M?==XWD[V'R\<TIMRYL4GK*HZU>ZXF=
M/;&UU$ZOUY.2&BH&TJ/+O0[C>V4W:VI[&X4L<ZPKVL-AK2D69TQ:QK^263CC
M97%8REX<?/'JUW\ ^W#?#J?#RSZ+]3(4[]=]K[JVN\CFG,/<--:U#CW.5"3X
MN;5H>M*"S9WK4$-:GSXT#L3<^K)0JEH=O?7S+P8Z3\!FX*B\=(.BF0S6,8Y+
MGS67P;78R)9;XRZN7!<4CC=O[/E*9M+DXXN1.;TO0]0UG2I8N2TMLZ B(K73
M:6U=&/IF0OGKK94#'J2 RB@SMGMC^*L58CFJ4C-V&23B&[Q0'5'EEYYK.>/T
M?OV<1SD_S8X8QWKK[/3/,[2-!EV,72.I0V]-0]CVA^3NHFOT_ +,G,/,VDT&
MR-,23!U&(-HMXB\>"HN+R*:M8IVH<[F-:MV*K=$F7C+QRSP^AI9PL\^LVWD*
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# ,7O%,KNQJ7;]>W!@:4J5[J]@IEHC".WC \C7;1$NX2;8%
M?1SAI(,C/(Q\Z;E=L739XV%0%FKA%<A%"N0YGJL5&K-KHD[K6=CS/*;9*E)T
M:9BBO'S8[NLS$.O 2$>$@U<(R3<R\4Y6; \;.TGR0G\=%PFN4JH!R,=F]-Z[
ML+C5;Z3@E#2.E99&9UI*-):8CI2MN25YW5'+4LBP?MGDE#RU=?.(J>@I=9_#
M3K<4#2S%XNT9JH,_KP)A<.[EZ&K(CAQH2#G(B58UZT##5NRIW2KZV>;+V1(Z
M;JMN0D#RS.P5O3SZU.-;PSR+EE#2\"V95I*,K<P/KBO,(N5 '@7+^^?GS&/O
MJ\N1O!6@51;83+::D:8UXCJ;*4!I,>G/P(E5)F;B+%(QHQH.@BU#+R\%%N@?
M*,S/T@;BW1=)MUETE)]_?F7[^_(T77N'FHJE+DEJO-;VKJ*=ME;L2MPO)OD1
M&44L_/6=[<IPP4!GLY&E^JYBQR4C(RD#ZB]1OS/WB#J/5;.5D3W+[NSDO7&1
MC]_U-@UO0&J:E.P%D@*TJRF:Q8MQVJ%=FG)YT#2=W[:CW3:KPS=W)KMG!;)9
M%#/TFSE%9K"%'T2!1C60 WR??D/OS/LU]HW5FJUMGK:_J32L?ECN\ML?8B#!
MU(^B3MTG8J.AYJ<39KNU6T2O*M(IJJ^0ADF#1Q("ZDSH#(/7;E9G/AP(DEG'
M6\^)]3#3>O(S3+7C\S@E$M4,M9I:@;5H9:8453U\C5PIJ<&,XH_//G4+72@P
M]:GDS2XF#TLSX7G5QCF7D8[LGCEJ+;-;J-6NE=?.(^AMI%C4'L+9[35K% L)
MFG2FOYM@RM%9F(FQ%8S50F7\-+LU)-1M(IG;NG:2K]@P=-JFUR^^.?V)A8QU
M&2SFGM=6&(UQ!2-=3)%ZBLM4MNN&T<^DHC[*S=*8.8BO+1ZT8\:+&:-X5Z_@
MW<8Y47C96$?OHF4:/&#MP@I!CEW?0TT'";CV#U/I 7(*DC/EM*.I VQM0-'(
MSY)0)LCU+2P7$-:)LTY@/6R==+60JR4I_P")IP99#_BL9Q]_?F,+^'#T,X<<
M9=).YRNV-W2DG4S5-MV+>4"]<2\\J9CLRUM%VDY/>$:3%!PV=>,D]2@72:]?
M92T?$3#*,;R</&.FMR_TQX?:+CW\S%I?AUH^51HR;5GL2IKZX;;(8U*4UWNC
M<&MIQA'[<M<7>-@QKJ=H=XKTO+QM@M,)$RZD?+O7S-DO'M"1Z+5%$B8$\?P3
M]2))<NKAS9GE,T+KZC3M:M,<>[SEGJ-:N]/@;)?MG;&V5/MJWL2<I=CM<4O,
MWZT6.1D&[V6U]4W#,9!RY4ADHP[2'.P:/Y!!TS]_0O7GZ_KCV.!C.*VAH76F
MW]/PM";1&N-[3=[L6S:O&2T\R9S<MLI@WC;FNP5;RB;NM(RS1LDFFQK3B(8Q
MA@,I%-F1S&,++SGK)A8QCAV&TK_0*IL^GS-"NT::7JT^DU0E8TCY_'&<I,GS
M62;%![&.6;]#PWC)LJ)F[E(QP3%,XF3.<AB;3RB_?D8I8=#ZDM>T83<]@I,7
M)[)@*+9=9LK(N9UWW%#MRR#B<J\Q'D<%BIZ*771.HT0FF+\8PSZ5]6F:!+R0
M.F7^N?$F%G../VN/;XFOJ)P^T?KN9B)J$C;Q)GJT)+UNAQ5SVSM*_5S6L#/1
MPPTM&ZXKESM\Y"TLCJ$_\!(Z@V35^QKPFKT<[:0BBD>=GJ^^P8]N;9YJ<.^.
MJK!Q&GU\F*#KC:3B.NH%AM!7BF@"-%&):/Z<6:!V53T50R1K,58+88"IB:;$
M4DQ*R_USU<_OP&$N7T^^T^:X<.=(7FSVRUS26T6;R^LH6.O,34M];QH53N+"
M K[6JQK2S4^C[#KU9F42UUFWAWA'T6L$DQ*HWD?2DUURJ$\<O1/U*UG@)?AW
MI:2LDE:HL^V*#)2\55H21::EW[O#4-?<QE)@FU9JK8]8UGL&JUT A(%HVBV2
MA8PJJ;1$B8G, >UE]WBD_5=XQC[\/V-K573U I[BW.XR*>OGE]BJM#75Y9YZ
M>N+NTL:=5D:9"A/.;5)3"TFZ-7D"M)=\[.J]L"ZCB0G7$C(.7#I1E\%V<O$F
M%EOMY^!S&M]>574U&K.MZ,R>1E.IT8G"UJ+>S$Q/*Q,,V.H+&)0DYY])2BD?
M%H'*PBFKAZLE&QC=I&,P18LVR"4;SQ*9M@# & , 8 P!@# & , 8 P!@# &
', 8 P#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g107876g67b33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g67b33.jpg
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MG;8;7Z.?JFIR,!X$'N"U&L"@(.2XPF J"(P?@3G'-#N&O;/EP=8R\3*CQ7.
M=3W23.A#FWN&@M+B#O5#FO.R_!SG1\;Z4\%/$</K>B_27AO1O(F$<_59.1Q/
MC,O!H\B &WMABEB,SVR??#&0T6ZUX)/N;,%N $HM:9N-P<Z>(OV.I%4ZK](6
MMJT/\%Q5O"G+F:%CEI!RAK*010)3G[_+J2-2[-@43K[#>>%1 [\0ATMR?B<C
MA#.:R#\D,&D:XB XF7T:T_).IM]=_P &'#8B72].>%"&#I,_H=FR1\)XS(8N
MD!WACQF?%V_&^&O:S(=-Q$OQS#\7<(\;(,N/UWHW/<5(>VR.4P*J9E/X-7T
MAUD6;(D;I&V1;&F.9PU+8J-K8X^ZN %DNE33 ER&4O;.E4-R8I&XMR%L='5Y
M59;2M;>%D.9'-DQ0S332P8\9;(]LCXI3 7/D:*BC?,UT;'D.)+7%S6M <:6/
M\&<K9\'A_%^D/#.#<7XSQCB? ^ X4L&=E0YV7POB<G!))\O-QX3'PWA^3QB*
M7A^)DR1SO=+!/-D8^/BQ]>[H5<W^?:5G3N&12O7A1":^<&II>+6/?6(AB7.<
MAKN$V2PI&1A$?F1KO=,DV0X7'FHTJ=N'A*/!JKWIA:'1/A#'QX999V":=KW,
MQ@QY>UL>1-CO+WUU;:?"Z@"2=QM6_%XWT.9P#@/".*<1XSC,XKQJ#)R<;H\S
M$RWYD./A<;XMP+,DR\P,^(P]7E\)FZEC99'S#K!ICZIIED;RBO$IPB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*ORQ-J7"I=TGV
MLI.BMJ45P;J]74[9HQ5-&3^X53;-G6U[8C[V_.YM70:4R1H(<&&/,3>F+?%:
M=D-,;S!-J?"\2\PVZS'$F(V1O5MD^,R,+I)F1 L$4;@T=8]K20YQ.P+M]]J5
MQD DQ0]O5MD^,/8722LC!8(XR .L>UIISB=@3OOLN&5]V*EM$=?U$SRI?978
M.U.QL%I^/6BLC>N!49K*ISF)8<">K[';HJMB^(ND?F9GPW/#"[V YOD@;$:A
ML/) Y.+7M?@VYNBFM9CP/E<S5/JDDU#T!&7:M1!-M(8 TD'D#M=A:G#1LUD$
M#I"P.FU22 _)#"[4':7.MI# &DCL![5]8"P/M8PVRH%7I+NW/YUDM\G<9M;=
M6UK7\%D-4RGYF2>*+K2=GYRB<C?W5\*6*(/\TS'=CDT90*94>^,S.8C.5:OB
M9$CHWOHC1I#(Y)'O;(W4UPC#0X -K7JHM<=-$W6KXF6R.8]]$:"T-CD>]PD;
MJ:[JP YK0" _51:XZ:)M1KL[?FT'1CE%N42F.60U^T_U)N6$0R4IHLD4QI\N
MG8&R()*79R6A+7X<'4$>:V1AP@+>G..D+D)3NW$J"1K37#?%AQAS(IB-0R<F
M)[FEQ#A%#&]H%50U%QN@ZC6QY;F8D8<V.4^DW)R(G.;J](111N: -J%DNY T
M:/976(KN;:\/FNQ)EFU7)I%5D#VRKBGU$W;I!7Z9-5#?:E?ZYMC'&$#&GRWR
M*PDD;LFS%3I+GX985B1HE*4YC42,MN4,K'J=BQN9!HD:V1^-)+H(>3(8WSES
MB=VLU,C :WM+38;8<[6[&C<V'1(UKWX[Y=)#SK,;YB7$[AFID=-'*VFZ)LR1
M8=MXV_KH?&D\1?2I])]C;&US<(2-8WC<8PZU>@E<GDDU=50,Y(S$#:^CS1.&
MA4 (#UZ&=PIMR60YO11(=+L9S0YVH:&P,G#Z-.$FEK6 ?YVMQ8>XL<>06DX[
M@'NU L;"R8.HTX2%K6M _P [6XM/8"QYNA:Y/O6GN6(,\,L6L=F[?JT$ANO6
M>GEL*BT=H!XB);1;%Z0JM93(TQEA4C-Y<"4!8)<L/;3#)6:P)7-O;#S(^H3A
M7)%^W#ZIQ?')CQ2:8LB4/<9@ZXX7/:WT)6-TZFB_1U$$^D-JV8@B>7LD@CDT
MQ3R!SG3!UQQ.>UOH2L;IMN_HZB"?2Y5\68;(9U(?K8CUBV-;EXAK:J=;Y$:\
MV..BX>R@77W>ET5RTR&0RN&5]6##$&IH/CR%//9,_)01:/P>-,;FWMA\F,DB
MB1&P?&1&YC(H>LEG;4?7.-0PPR%K6ODD+B0XEC0=3GN<"0W3IEL/Q@1N8R.+
M7),VF=:XU%%$\@->^0N)#B6-'I.<X@G3I#?LR7?YNBL)K.0/5<M3,]6G/93!
M(RID%V5<T4XY#BS$5(L/K1>_Q)9$W5NEB-06@@K?AO2R.0/J5Y;#F5L R+U8
M#<(N?(T2$B-C7N BD,HU'3I,-!P+2/3-EK06G4=0"AN&7/D:'DB-@>ZHI#(-
M1TT8JU M/RS9#00;-KK#1MHUN!DU2.5<RZ,NL%U<AFS[VRO:V.F.!+3,'&V&
MP$,R:R.;PTFO3<?4KH,QU0.B]B7)W9M4(%AY/J#YJ..:80]K@_(=C@@.JVB,
MZ]P#1ZP;$ BC86LXY :0]K@Z=T (#J):(SJ]( T1(*! .QL!1\GG:%54)-<3
MLQHA:UPBL:[M2U?B=GUI$91'&BQH:DL)$P02$R=^;W^UY:QPI:CD3RU,)+<E
M/3N#6U1YR?9.N^ $;F</D>!;B"^1\<=1R/:XL<6%SWM!$;"\:076=B7 -&H[
MF8$C]K-N>^..HWN:XL>66][01&TN! +NXEP#19LO;G%$[MZ!V;5):QN<T25Q
M;U9.<Y)5(EI %*525G.,9R6>0:6:#.<8SD(L9SC&?LY1(()!%$$@@\P1L0?4
MJ1!!((H@D$'F"-B#ZE^SD*$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1<P65<V++E8[F,<EH79
MCJ^6U<2S8+(^&J&R72J%RI6Y&FY#[K"U*IA2-(06 >"!$+5(C Y,"5D-@9#A
MBOQ=(TOR(\@OLZ@Z..6,-KE1$I)/.P%WX^D$\71?+Z+B"(XV7Q_AW2!V5J?U
M[)^&\.XIPZ.!K0>KZJ2/BDLCW$:P^*,-(:7 QICNDY#,WPZ.N-R39_B%95[8
M=65G&U;)$4)<;AE@1?,2-+='%M:DR^3/C&TDMR5M=UQA!64S<6$YNRK6.2Y;
M?DXKK=+(W%B9+D3PY.1('RN,DL,AD]$.<1&Q[BXN: 3;OE4&M;[K-^%1^5/Q
M/.AZ,<*P^)<>XUP7I#QW.CR^)2NSN*<&XA]T@Z""?)DAP,3+R7SR3XT37N$D
MY+9^KB@ABZ\CUV84:YK7!D#N,;5KP9KL4 1"+ #6$TYN.S(#,X+\<.^,MI>,
M$!SA%X&#\2\YP'PJG->6N;H;3LT9O,[/ <-'YOI'?GLO-R=-LR2+(A.%C!N1
MTU'39Q#Y;;F-;,T80]*OBU3N.L_?; ]+FN8&Z:D(V!WB$2MZ:P^)3JMX165L
M-3<TQ9<JF;7"(0CK@E]9W9T;%2J%2A]A"!)&WQQ;@KTN4")N4M3>UO*(+J98
M^ZA+V2RXT4LD,\V1CN<Z0-B=-*Z<L<UK@)8V3.,C&N+39<'.<TZ1WF_"<^7,
MQN)\1Z-\*XGQ+A''.*\>Z.Y$^1Q"*/A>1Q7BLO''8F5CX^1''Q7A^)Q::3.Q
M()S#()99X\B>?%E..WOU8U$P54Y66MCRE2))8\Q99:8UG *"DC_P*L:^JY"S
MM8@8]8U"!HKQM6>=6,Q1[I8J!Y\E *QBGD9+\EN.'@7!$^+5N7/UY$^2Y[NS
M47SN&U"@.VUX[CW23,Z00<"BS6,ZS@?#,KAK<AI<9,WXYQ_C72";)R ?1;,<
MKC<\51AK.KBC.G47$]8Y67G4X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A%R!+3S2DOU^O\+NXC?'ZGXG3Q["(M-AI(:8E-)I-4
MKN4=@'O,N*M9-5B-06,S*8*9&F$6#!HC1"VF4]0(*&D2NEU;W;F-97=0#0>^
MRMO6GJ1#0TB5TM[W;F-97=5-OOLJ-KQHG'1NHIC%;#>(Y8R*Z+JN!AD[C%8G
M,6A(5?7P;Y_0%XB+^B,;GN*J3(Y''!"H*5-,B0N\?:%J=Y 06N1+]XRW5I<P
M.C,443FASFD]3>AX<W<.&IP/-I#B".1&X9;JTN8"PQQ1EH<YI/4@ACPX&PX:
MB"*(()VY$?-4:&D@?JWF+;=LN-G4)B,XASI+I=!ZRG*MP3V%-29Z]O\ #&=]
MC&8S5\G;7<H#7&5$993&!LBB-FCKA&WI*R(#"WQS:1IB:&/<QP8USV5H;H:U
MY#KD:19<"0YSR7!P)*?&]GM,3=#W,<&M<]@!8W0 XAUO:19<'&RXN<"TDKY*
M#KD@S96*^M$=FS@LDS72J=>&J0F(H^H=6MNIFS9?:4+EQI2A"8A<WOXY*2DK
MTC4IP-SFB:@8 4D-6'& R^/.ZP2=6S:>6<M!=1,T;(WMYV!3;!NP3X!2<QQD
M#]#?YZ28M!-$RL:Q[1O8%-V.Y!/;2ZHHT_9W2 6["GZ?2!T671>-8WW+)&6U
M,S>H+EU;%T5Y4C:VIRQ(4S4_JJ*:E*PG/J&(OG Z$(S EID7DU').N-S6 "*
M&2%K;)]&0S;D\[:)B!WZ03S*P^,$/C<U@ CBDA:VR?1DZW<GM+1*:[](OF5X
MZIJ(<UNZ]\[//L&D\ 91QILK2!LLG=HHO+F,KP-N:;0O5F:8J_2(ID;)O"ZX
MHV%QHV0*&N9J&>$.ICU'F IP C/SDF Q88 ]KSJ,CRT.!8W<QPES@TDL<^9S
M@ 66\:7.JUE)*/BT, >U[K+W%H<-#=S'"2YHLL<^5[M-LMXHNJU)6[J=:;OB
MT=BKR[N+*FCEJT]:R=4V%)C3U#G3EG1:SVEK."J ,L*!W<8JF;'$P&,*"D2H
M\Q,(!X2Q8T0RF%SG  ET<L=&]A+&Z,G;M =8\0M,4IB<YP )=')'O>PD8YA.
MW: ZQXKG=C:RXFL^L2S6"TIM74RG=>4O "G",DLJE*TIJ4G]FSYM$M:WA$N;
MY0QS VT'B-3B*OB<YK=XT3[5.- N/PX)\V3Z&,C,;'M8^5].O<RLC8:((+2S
MJFN8YI!#N=C99,GT,8QT;7M8^5].L$]:R-AH@@M+>K#F.&X=OOR7&F'0H$2B
M[^W1&X%S"_3:R9'9-A(B*OK@=*S17)H9$X,L87*@0M9$+(:4+;"(^]-BTA5\
MYL2[+Z_NK^[YDCPB4;3F:G NB#FL8V-GWR3K6!KG/!$UEY)+W @C3IH!K=(*
MVG+U.!=&"&L#&>F\2M#7.??77K))>X$?)TT T:01\A%UT,T4C3=$ZPO*PZ\:
M%]#':ZV+[&/5\ZJII ARNP)LG.9L+8V!MKQY;WRU)\F;!19L+9&F.O:9D:&1
MORQ,BY#)SBYQ=)$QY$PG99>-+],;-Z=Z8+8V7J-EP))()!DYA<XNDB8\B;KF
M N> U^EC3?I6\%L;+U&R022;(/W''09N3J%WS"N.75ZBF,!K2 6=\,B<!>WZ
M1%UA#V^OVB7PV3R%B7NE:3ESA;6W1UU>F?+BB+2M3.XL[0TR!N"\G0,P[:XF
MR%KY'QVYX:WK'%Y:YK2!(P/)< :-D@D@T(&636N-KRU\CV6YX:.L<7EKF@@/
M:'$D T=R"2#0G^F3E)$R=(1@02$I!2<D(S##1!*)+"67@1IHAFF"P .,9,,&
M,P>?$0Q"%G.<TB;)/?NJ9-DGOW7^W")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*E)PK7O &O6C;
MM@M=RF\2M2)"6:RQG)I:,1P\I@&9S2)F<F (R (\Y,'G(L9\1BS_  L^L;/T
M1TMU8>=JH:J>^M5;U_E7*^2_4\''?Y* AA$_0SILZ<11B9S<K.TNE# )"W_S
ML;Z)?9'HC:MAR7Y/HT[S/O"ZY_\ @D8_Y'<GK^B'Y%G_ *;_ /[M;?N]_)+_
M .A73C_O>=_^6I]&G>9]X77/_P $C'_([CK^B'Y%G_IO_P#NT^[W\DO_ *%=
M./\ O>=_^6I]&G>9]X77/_P2,?\ ([CK^B'Y%G_IO_\ NT^[W\DO_H5TX_[W
MG?\ Y:GT:=YGWA=<_P#P2,?\CN.OZ(?D6?\ IO\ _NT^[W\DO_H5TX_[WG?_
M ):GT:=YGWA=<_\ P2,?\CN.OZ(?D6?^F_\ ^[3[O?R2_P#H5TX_[WG?_EJD
M)K#"NT)DMIL7[2V[3LPJ$#2]ENC)#6QD2OISN:A&%C/)-0UA%E&"$Z[R&*<!
M=R@B*QG B3\?Q>:7$)>CS\9PX=C9<65J9I?*YQ9IOTP09Y!9;R]'GVA>+Z?<
M5^ '+Z.3P_!]T:Z3\,Z2G)Q'8^7Q2?*DQ&XS90<MCFR\?X@PO?%;6$XSB'<G
M,.ZLTYY]?!UGI5U'\HO$J4B2;0ZI@2B4'93 ''XCD8$^3!9)"/.==AYR()?E
MP+.1BSXXSXB%_+GM=;P/MQ\K](_;KK]9P?\ $9/L)KV7,OS_ $1?*-_O2:H_
ML]$/W=..MX'^3Y7Z1^W3K.#?B,GWG[9/HB^4;_>DU1_9Z(?NZ<=;P/\ )\K]
M(_;IUG!OQ&3[S]LGT1?*-_O2:H_L]$/W=..MX'^3Y7Z1^W3K.#?B,GWG[9/H
MB^4;_>DU1_9Z(?NZ<=;P/\GROTC]NG6<&_$9/O/VR?1%\HW^])JC^ST0_=TX
MZW@?Y/E?I'[=.LX-^(R?>?MD^B+Y1O\ >DU1_9Z(?NZ<=;P/\GROTC]NG6<&
M_$9/O/VR?1%\HW^])JC^ST0_=TXZW@?Y/E?I'[=.LX-^(R?>?MD^B+Y1O]Z3
M5']GHA^[IQUO _R?*_2/VZ=9P;\1D^\_;)]$7RC?[TFJ/[/1#]W3CK>!_D^5
M^D?MTZS@WXC)]Y^V3Z(OE&_WI-4?V>B'[NG'6\#_ "?*_2/VZ=9P;\1D^\_;
M)]$7RC?[TFJ/[/1#]W3CK>!_D^5^D?MTZS@WXC)]Y^V3Z(OE&_WI-4?V>B'[
MNG'6\#_)\K](_;IUG!OQ&3[S]LGT1?*-_O2:H_L]$/W=..MX'^3Y7Z1^W3K.
M#?B,GWG[9/HB^4;_ 'I-4?V>B'[NG'6\#_)\K](_;IUG!OQ&3[S]LGT1?*-_
MO2:H_L]$/W=..MX'^3Y7Z1^W3K.#?B,GWG[9/HB^4;_>DU1_9Z(?NZ<=;P/\
MGROTC]NG6<&_$9/O/VR?1%\HW^])JC^ST0_=TXZW@?Y/E?I'[=.LX-^(R?>?
MMD^B+Y1O]Z35']GHA^[IQUO _P GROTC]NG6<&_$9/O/VR?1%\HW^])JC^ST
M0_=TXZW@?Y/E?I'[=.LX-^(R?>?MD^B+Y1O]Z35']GHA^[IQUO _R?*_2/VZ
M=9P;\1D^\_;)]$7RC?[TFJ/[/1#]W3CK>!_D^5^D?MTZS@WXC)]Y^V3Z(OE&
M_P!Z35']GHA^[IQUO _R?*_2/VZ=9P;\1D^\_;)]$7RC?[TFJ/[/1#]W3CK>
M!_D^5^D?MTZS@WXC)]Y^V3Z(OE&_WI-4?V>B'[NG'6\#_)\K](_;IUG!OQ&3
M[S]LGT1?*-_O2:H_L]$/W=..MX'^3Y7Z1^W3K.#?B,GWG[9/HB^4;_>DU1_9
MZ(?NZ<=;P/\ )\K](_;IUG!OQ&3[S]LGT1?*-_O2:H_L]$/W=..MX'^3Y7Z1
M^W3K.#?B,GWG[9/HB^4;_>DU1_9Z(?NZ<=;P/\GROTC]NG6<&_$9/O/VR?1%
M\HW^])JC^ST0_=TXZW@?Y/E?I'[=.LX-^(R?>?MD^B+Y1O\ >DU1_9Z(?NZ<
M=;P/\GROTC]NG6<&_$9/O/VR?1%\HW^])JC^ST0_=TXZW@?Y/E?I'[=.LX-^
M(R?>?MD^B+Y1O]Z35']GHA^[IQUO _R?*_2/VZ=9P;\1D^\_;)]$7RC?[TFJ
M/[/1#]W3CK>!_D^5^D?MTZS@WXC)]Y^V3Z(OE&_WI-4?V>B'[NG'6\#_ "?*
M_2/VZ=9P;\1D^\_;)]$7RC?[TFJ/[/1#]W3CK>!_D^5^D?MTZS@WXC)]Y^V3
MZ(OE&_WI-4?V>B'[NG'6\#_)\K](_;IUG!OQ&3[S]LGT1?*-_O2:H_L]$/W=
M..MX'^3Y7Z1^W3K.#?B,GWG[9/HB^4;_ 'I-4?V>B'[NG'6\#_)\K](_;IUG
M!OQ&3[S]LGT1?*-_O2:H_L]$/W=..MX'^3Y7Z1^W3K.#?B,GWG[9/HB^4;_>
MDU1_9Z(?NZ<=;P/\GROTC]NG6<&_$9/O/VR?1%\HW^])JC^ST0_=TXZW@?Y/
ME?I'[=.LX-^(R?>?MD^B+Y1O]Z35']GHA^[IQUO _P GROTC]NG6<&_$9/O/
MVR?1%\HW^])JC^ST0_=TXZW@?Y/E?I'[=.LX-^(R?>?MD^B+Y1O]Z35']GHA
M^[IQUO _R?*_2/VZ=9P;\1D^\_;)]$7RC?[TFJ/[/1#]W3CK>!_D^5^D?MTZ
MS@WXC)]Y^V3Z(OE&_P!Z35']GHA^[IQUO _R?*_2/VZ=9P;\1D^\_;)]$7RC
M?[TFJ/[/1#]W3CK>!_D^5^D?MTZS@WXC)]Y^V3Z(OE&_WI-4?V>B'[NG'6\#
M_)\K](_;IUG!OQ&3[S]LGT1?*-_O2:H_L]$/W=..MX'^3Y7Z1^W3K.#?B,GW
MG[9/HB^4;_>DU1_9Z(?NZ<=;P/\ )\K](_;IUG!OQ&3[S]LGT1?*-_O2:H_L
M]$/W=..MX'^3Y7Z1^W3K.#?B,GWG[9/HB^4;_>DU1_9Z(?NZ<=;P/\GROTC]
MNG6<&_$9/O/VR?1%\HW^])JC^ST0_=TXZW@?Y/E?I'[=.LX-^(R?>?MD^B+Y
M1O\ >DU1_9Z(?NZ<=;P/\GROTC]NG6<&_$9/O/VR?1%\HW^])JC^ST0_=TXZ
MW@?Y/E?I'[=.LX-^(R?>?MD^B+Y1O]Z35']GHA^[IQUO _R?*_2/VZ=9P;\1
MD^\_;*VC2U@V_C=-F-V[DW@M@73F7OB@M^KQ(WHH_B'&IFL+$AR2VQ"$IO?I
MU1;J-2/X+DP0#B<"6'XP$)7.RG8SI;Q&/9%I'HR&W:K-GY3]JJM_8J&2<9TE
MXK7LBTC:0V[59L_*=M55OW[*6W*RKIPB<(JO>TZV7"IJZUY4NMX65KQ3<UV8
M8(-?UH4JV"<[?::]753;CZQ(H7@B(3IQ;4KG:<?KU+-7IAC:Y_:8.*0+40DZ
M0MQ4%%DT7>UFC0/*]N=>%UXTOBZ S?6246)-4E';T;6;4OR:%A4/$1OV23!Z
MCL<:/CC87B1LI$CJ6O4Q3UE:-,V9.(<5Q_L5JD'LL%B&>40@@;@#V_O*M<X6
M*I%[!>U*U-5]K]2M9:JURD<G8KBV-I.IK?O^?1]U1T_%VFWQ.@FV(5X\MSXU
M*)-;)[<UK7HPL1"Q@C3:@'\63+E2],024UR\?FWK?YU'[;KN:OJA[<W!ED#J
MFF7C3WKSMG7*G]G'.:.TQ0W3+GB]BF%8]/\ 4RAL5%PUH:ZV0RIE]XBE;4XF
MR,\"[*1>VDEA%@E?19]O+O[Q?NKM74K>W8V0B7;I6]+II^RH]2%$HJ2DW>OH
MLOIIYGCM;]J5A:%@H7:81YX;E-L,T+ F86?_ *5C;LVE)/AH%AJ1:VK'#(([
MN?GOV_8I ]$[;]AONN_F'+GV\N5NZ[9_6IL6K&URV&HUO<6]4H0KT"ZVH"D6
MH5J0T9"I&L2GR L],J3'EF$J$YQ8#230#+, $81!Q*Q77&)_8I2SM\AC#TTR
M-@=TP%C4^,3DC=V=S2&9S@M4WN;><H1+4P\XS@!Z8\TH6<9\HL^&>$7UN$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X15[=AUO3*L8C0D;CUSI=9(K=
MVPK)4=H[-*FR*.9E+PQ?7%FS%"K:#9Z@=H#'I)8\XAL0I^.2Z<-+K'(X[3].
MK^'+'T;$G,+)HY[70L#OW WK>M[V7*=1+%DD<VUG.M+#N4^[RU6CH1+;;I,)
MFHJ&3S^A9Y\_&Z+LD%DU@4A#X)%WANMU@<)%*(Q'Y+'@RUA+K1Z5E+U3&](P
MDD.XNM)NJ&P[>^]QR/L[5:_PL56?V1Z>VAMT9I$.LG2&-F-<MZ*6V5G6)BZ.
MS9E? J\02Q,^-\:^%,3Y[Z3GF/B/+<@</A3<> "C*AV2Y  )A2#1![C:K8W
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M?')N9V5K:5#V\.Z]:2D:6MK1(QKW!R6N*O*=.F;D*0HY4I6J<D$DIBAGG9*
M$60^5:USW-8QI<][@UK6@ESG.--:T#<DD@ #<DT%^5,?&R,O(@Q,2";)RLJ:
M+&QL:")\V1D9$\C8H8(88PZ26:61S8XXF-<][W-8T%Q 7AX+==.V@M7-M;6I
M7D_<6Q+A:XH(;,H_)5B%&(X*<*M6F9W!8<G2B/& D*@T "A&C" (\B%C&=TV
M)E8X#LC&G@:XTTRQ/C#B!= O:+-;T%U^+=%^DO 8HI^.='^-<'AGD,4,W%.%
MYN!'-*&EYCB?E01-D>& N+&DN#0216ZZ=RNN$G")PB<(N;PU"6EF%LJ@-2=
M-QEC$H-7$Q5,Q&O0B8!$D85JI\(<5ATS-3EIP-H'A8D:3FXA$5'2T9R9H(<%
MI.[SVE=(X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X15[;\(#E#AI\X0JQXG7>PK-M%E3K078
MT,EDUJ^?62X:^WRQR>NK#)AXB7>,LLBIMTLXULFZ98E4QB4MS J3A=/4-878
MI';?*M^_F.7MKOVOUKDW7GI-L70)E72+9V=TT^/M#ZM,FHU0Q>BVV8"8B8,2
M\Q*1R^<3N73HAJ>)+,98ZP*&D-S0V1F/QZ'-C0X 2">5LB7*R"DD&Z[3=GYO
M=9]:MBX6*I&[<=8)#9LPZ^YY3=+8E4UC_9-K!/;DF$1BJ$Z3(ZN@#//$AC_,
MWU,G+<SXO%,.28DK*Y4<E;?>!"047ZHO$I!HC<U8]7/N54V^FCFVLSF_:QJ7
M"M?+/F;3V>['Z@VU45_1,+"&JJ_B$"10ANMTVT)&J>2%4+>(2*%JU+0C/0'J
MY,6O0&-!)@_*6:4V.WM &W<"/J'?VCQ6A*;=86F4\VKKC=1UJ=(W;%5Q,S)^
M5.F%:<W'3&4 A:6!M*Z=)A!4 ?,1QC0-_P !"G$VB2*F](8>-406),,HO:MO
M76_C]/;:K1V^Z3HHIK+:&WL]DO;J0I402Z[(S7Z;=9055Q)YL?DTG^9Q$1Q7
M>0EP$LP7P4J.>_S@$=P%L]WG&/6X4*/5-27YH?)Q.O&1IUSRWO+1!*0<8VI9
MEY2 PJ0('-]7-QZO)J!>%2E2#3#683!PF&)4G3&X5 P5DLV_PR Y.9' -/WQ
MLC7%XMH;U;M9^4W<-L@WL=P+7T3X+.#2=(>F6#P>,8^G/Q.)03G*C?)$W&=@
MS?&'5'-CO:\1:]#VR@M=1 )V59->7&NS(GV/G9BK$VVA-6!5*GY7 V!W=6]+
ME[97-:4TFHH^8ZMS:-V;4CB<R,):,L_"4M, HSU#<&>TXGPB<86)*W7*,/"+
M-+)0UI ,IUNUOJFQNL.!)W(-BE^SOA ^#;B)Z,=',['.5Q$=$^B<N*S'Q.)B
M#'F,3L]PRY_C>8R(B+!R'AF29I9C;HB-V [S3VEHD$:.8GI @?F%\8S&EV:W
M1 2J:WEH<D&4:] XMBPH:=2@<41YJ=8@5$#).3G&)SRA $(&?GS7.8YKV.+7
ML<'-<TD.:YIMKFD;@@@$$;@BPOYZ8^1D8>3!EXD\V+EXD\61C9./*^'(QLB"
M1LL,\$T9;)%-#(QLD<L;FO8]K7M(< 56YUH5[ HTAVO>(["HHPNZ/<O82$)'
M1GC[4VN":&,;XQF,L3(6(TA*@J-M)@LC;60!@6Y"/.1)DQ6<YSSO<?FFD=PU
MLDTKVGA6!*6OD>X&5\3M<A#B09'_ -9_RG=I*^Y_#KQGB^?-\'F-F\4XCF8\
MGP8="^*2096;D3POXGEX64,KB+XI9',=G9( $^4YIGE  DD<%*G;/8!-KC24
MXL1&9&5\R9V0Q;#XE(78I!\YW,*Y"BPE)3 6)7)603E< Q6)NP8:G+R$8L>&
M<8SQ\6..7(BCF<]D+G@2/C:'/:TWNT$@$^L@>*^3]%.%8/&>/\,P.*S9F+PG
M(RXXN(YF#"V;(Q<=X>3)&V3[SK]'T1*6M.^^Q40NNGL"D^XA]DI+(9:Z@3M%
M5[ @CK%'G1WRXNXW #W[W/@]G&D.&0#:#1$%M:DU0 LH\P],$GTSA='C/#H.
M&S1102S3-?$V1SI6-91>&O:&Z2318]MZFM(=8%C=?0OAB^#G@OP><5X9@\!X
MCQ;BL&7P]F9DY'$L?$B$;IX\;(@;#\5=J ^+Y</6B>.-S93I:7-(*G]=]GCI
M>J9M:88=(IX5!V<;ZNC$4]AA\6-:4\GXLK2Y<U2-$$EF;1*GI>(Y0#(6]O5"
M*":=@LH?.Q,?XUD18_6QP&5V@22ZNK#B#I!T-<ZW.IC::?2<!MS7SOHKP$=)
M^D/"NC_W2P>$.XKDC$BS^(]<,.+(D8_XO'+\7BFEU9,XCQ8M,9N::,.IMD>,
MU@OQ7LG5;9:AM7S.JVY]&E41YMFAC2>ID4?7LK0\MLK95#0J4E*&!R Z#3(C
ME($:LPU"I$:C)!DO(MO$,+XAD.QCD0Y#V B1T&O3'(U[F.B=UC&'6TMLT"*<
M-UT^G?1 =!N/S='G<=X3Q[*Q&O9GR\(.48<#.ARLG%R.&Y(RX,>09>.['#Y0
MUKHPR:/2\G4!T.'H2DLMM52!I2(!N,J9%!JY/%4[$>]B*@<42!7+GPEQ6&S0
M]. C#86\JTC2<W)42>-@1GIF8AQ6TEXSN\]I71>$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M5;?9K':OL.KZ=I^=Z[NFTDQM.^65HI"HDEQ2NA&159\4KVR+$-F$UM.(NJ!R
MC,2@E?Q"<R52<%MEJH]X1,I3'$G21Y9ST)9-[=Z%;[ [6.0/;==WN7&M!8%'
M:)V!EM0SG5EQUPO:04ZKGL==HYN-=VW%2V55C)-(XPRSX(XW I87*'2V&RI\
MA)3TVKZ[;E"MNDC<I8I.[(Q/2% 1VX!NQRW !'K OGV;GEV*XGA8IPB<(G"*
M/NVG\U79G^S[<W^',DX19Y:(8GR0?)LM'$3*ZL3:633=2+GDB1R%KC;:\,Z-
MT=CE#3E6ZFI@*3SU&$IY"!$M1N*@Q/C*0X8R\D'7N'2"+,AD/6#2748A<C26
M. >P6 7-NZ-M->D"+7O_ (,<^#AG33A.;.WB%0_&>KEX5 [)S\:9^-*R'*QX
M6G3(_'>X2:9@_'(!$['1:@JH*63X)LN,A<&&-K41EAM@CVJ0RYPAK.;[$Y&?
ME,MD93PF6L:%"6K":B=AA.5><>0DFK1A.(S[3B\@=BX9ZV;0_ MQCB8YWI.D
M&IT8C#;>;;(T2-#+<:V!7[-^$W.CFZ.\#<WB7%F0S]"Y.LFP^'XV7,^/)GR(
MS+-@MPA!-/F&,PYL$>9CQ8[#)((@&,<=V\W=HZ"-IHH]3<J N=D)5<(BCLB?
M$:-^^<3RQKO;"B"UP ,*Z0H"2CW)J,RE49,4)"C3$YGFP4/Y\ >8%UN=B15@
M;UV60/;2_GW R0R&6/'.0W&TY$S#&Y\8B9(P$Y 9\F%SG-C>2YH],-U D*IC
MKR#%:*(V"EL[MJT'0M[W2L^@69KD G9[8WZ7GR=K URM>UM+*>85.9.>,1+\
M_*3$Z(!9> *0D>8K..]QRWOX<&M:*X-@O-;$ 1.) L_):!LT6>?,K[G\-+IN
M(97P?PX^%AQ]7\$G0[B;W0M;%)' WA^0Z2!CY9278T#6%T, +Y;+B"\\IX;*
MV)5%?R2OE$DJ1PMNX5+18"FGV1GB25[=C#&QC*4RM"D>7'TVYFPM:<AR<6<?
MDU800:6G(-.P !G$8US@ZGAK+8'DN(;N?1):++J.^P-<]N:^.<,QLS)ARVQY
MK,+ #\-O$))9WQP 2S%F.^6&/5),UDEGT8W]7\LT 2*P.MJ6TZJKZFT%E:_O
M*>;J=@+(2U-:OS31*6YQE*EXL*0*0X<6U8-Q1)X8WB6M)N'<"U"B7&X/1?Q:
M!0M2][I$'#B,A:\4<3#UM#B#IZB 400 ;.D@ DT-P*(7W#X>XLQO3CB<F)Q.
M(PGHIT5.?AMGDBD;CC@W!8FM='*QC)3D2F*4-A<YQ:VY #Z!N,V9_FW[ _[D
M;7_N&_<X^#^&X?\ >L?]<Q?(.@W_ !VZ'_Z4]'_];8B\/H[_ #-=6?\ <#5'
M]RF;F_B_]*\1_ON3^N>NQ\+/_I0^$+_3/I)_K;+77H8W>SE]LJ_@Z1ORZRQB
M59<"(LB8CWWT(#$T.%JY[3/+BIF9Z7"7X66].#>PG-Z5$1&R4"I*RDNJ[G+Y
M]W>>TKI'")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G"*MOM CU;NE(UW)K=9=FQUS6%X1BRI/8
MVIK^O8[2HA$PPV?HL74M#' '3US@D4,=@M\V2URB<Y6WLKZ=(#&MPC++(DIC
MSYI9-NZ! L5O5'EMN"/'>N7.Z4%=7*!UZVIOF47)K[L#V6V!!(_$F^+F[D.&
MTLM::NLIRC,M I!3%6_%T2&1V)#65Q,D;C-W^.-".LD\D2#:"G:0R%4O$T$-
M@4:';5 '<<SML>[M]7;H.X6*<(G")PBC[MI_-5V9_L^W-_AS).$6<FGR$RGY
M.!UY$*U34C3FP2D0&*'@N0&I2@"<7_ QX!'4ZE5G( 9$,W!X/3RD HPE\[IE
M 49;PB1D @.)T25IT7_-N_S_ $:[[[-E[?X/I7P])(Y(V9$CVX'$RUF*_&9*
M3\2EYNRP8.K WD#@26V -[%9-?-&9$_O#Z:ZJQOJ"2(U:E*-LDSD!&E.6Q\I
M/(0R!MP[#;PE+3L(3SG'(C,#/:B2/7&K,]EZWB3W,PN&-T7&<.M;71LU$.G+
MHWQD,+@!3@&A@:03J=L#^MNGV6_%Z*=!\=N*'\/GZ,1Q,GBR>'X9G>R7BXEP
M\C FCQGY4<<;8LB-F/'BQ0RMG<97 MBDVS70C?'%GK9KCM:%S:0.,A B9IXH
M21US+HMZ415Y*;;>$W27R'.0X^L&6#VC>)(O5A5#(PI <<2E5>*:1Z5N(%;@
M6-=$>A8! OG;A0KOI?B'!=&WXPZ7*,$8A:7XX=.P\18)X2_!ZR%KQ&9&@R!\
MPZIIC!/I:56EUWM%OPXG8"5IG"1W2Z+]U+"KB=Q@#S&HA"6G)<H;E4QO5"SK
M$RA1A[\3?.-A0+\94(0IDZ41F4@!%]SCA:Y_#A08!P? <"=3G'[T=,=C:NXT
M-R25]L^&J7"R,GX/X>KAP6,^"3H=F8\Q;/D9$@.!D?%N&OD#@WJ[;39W1C2]
MSG2'2:4D]Y(/*9;/:;55LC*%;+=$+Q2UX[AM2.P)P:'=VA9:(U0W,#JPO3I*
M5(4XQF%F-(T6&DTHH]4H(+,PI)XT3@UKPX^@3&7#076&NOGJ:![3Z5T-U\IX
M%D1PXV>S*>X</DGX6[.C;@RY8EAAR^MTND9/ V 6"*>ZY@2QA:X;U9=?,"S&
MFO6236MB13ING.T<X#33>RR=P0AK.914F7MDO>I2@<$N&]U:W]8VHE^6]E+;
M%1IR0Q<O6FY")E4^@Z0F\^8,#65@XG6[-I[#' ]H JPX'2/E$Z6T+"^\?#ME
MNEZ7\=AX=U.&8>A71=G%3)'&3Q'%EP^"38T>.:=)'+"YT8<Y\KSU40:S:ZT
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MWVC+]T7;;R;.L?AR[*>)5,U&R9I(<X%7T90N3FXL\?CBMNBB925]K(->>!:
M+[?IOZA2$WV]MU0 WYG;:]@K=.2L4X1.$3A%'W;3^:KLS_9]N;_#F2<(LY],
M&-0/DX_7,%["E UF1K7$"]P.R "MI0XF*LQ>X-:G"I.K2+@(0*4XE#<0O6!0
MJ%@,)BR!G+$O<Z/7]T=A9^*9VW.R,24@4>\@=A]7:OMG\G\O'PAL$8+G'HST
MP :!J#C_ ,'.(Z6N:00X%VFFD437:O!WHV:&#C-FN-4S6<22S2;'J$NN5$X7
M$NI#Y#!.U>)Y&XM!+2$ES?,HTX5:<TF8?#GO&<.*1&B,5('!21>X(S+&8PR1
MN$+<?.::8YK6R''R#1) :TGTC4=-+:U;TOI/P0P=,V=*,%_$\!V-P>/@?2^*
M<Q8LT6/B\0?P;C\T6/)UK1CP32#K'MCP?O$D(@?(7.T+2CL5'E)D6@]G$9BI
MS50;RJN1[;'^'M3RY/++$8<_GGMD/7OSHV)(1)5/G!AO?U2PLIK,P Y6<$E,
M8 [S##\IN]O 8*) LN:?2 !+AM\D=M$;A?EWAD@ZR?$^_P"OB,3,")T60^&-
MDDV3 6OR8XXY794(TFX +<[2X6YH"JHT 1/>ST=MG#?&4\7K\K=U_P!C6R82
M@<3L(]8L*E#8ZGUX",N"I2H9'H#.8F-Q8C>8K3&J#3B2/=Y"(8>[QRHI.'C4
M7.^XV%&0-3:^]$!Q-"P3_4('+>E]R^&@1\'SN@S79!GRC\$717A,N/$<K%TQ
MGA^3$,HREL9EB<\D'#F8UQ#:F8VQ7;^T!MNB5S&BJ]I;U%K_ #>*7FSG,+HQ
M(EL1>DAL-(PX)7%Z7&^@U/(FS*P#")22!"6XC3*%JY&0 1N.;AC''6/R+T,=
M";8\-E'WS<L:00\?Y_)S6[MWY?/.@QX##'Q3.Z0-D.)A9/!)A)AYS<;BD1'$
M++\3'>QPRHP&_P"5:7,EAB].)VLBZ;NN2(6 DMS7QP/4,::'AV;4MQC3EQ"%
MX6R9GBCT-R<2\M U"D;6V-Y1B1.6M\K2K6J?XHT\@U<(CT'2-\'QN<-ZPRNP
ML7<M;H#3U3@TV-1<00=;2*W!%;G] ?#[G<'/'./1Q?'7Y\O0OH^(W&&!V-!B
MO?PJ6*%YF D=-(RI9,O&<'M!ZA\.EKGNTB]A-7J+;U"NB-IEC*A,:HFXS81S
MVTJ'<@9,(2*),>G1@3.#>8A<U1+<-.A<A"5E)C#,X.1'E&CR7Y[AKS'GX;@7
M"LF$>B[2?2>&D71V-TX5NVQM=K\Z?!KFNP.GW1#(:9P3TAX5!>/-U$E969%C
M&Y-#R8R)2)8P!UL>J/4T.M?"ZWZR:Z]U(IQT;GZ6/1UD5Q6TZ<R)*]C=DC*O
M75[&4 FJ,IQ$DA:6(@E 3[9OQD\16<^3UQ%%DEE;>,&^*<0! &G,R1L +^_R
M&W5S.]6=R .Y=+X8,EV1\)W3IKHX8QC=+.D6.TPQ",R-;QK.D$DQ'\Y,3(0Z
M0[EK6@\K,J8<E,(EMK'#0EI2ULL9%!:D$5RPC<O) 8DE$I-?,OCGB:B*]N%$
M%ZPVQ[X<%-B-90*_@GQ1;S5\V\\^SU=G;ZUT7A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1>:F?^A\L_JT^_P#"U7,F
M?+;^<WZ0LF?+;^<WZ0J[^F[&,=9^J/AC&/&'2?.?#'AXY^DB:?;G_;G_ +>7
M.)?AV1^<W]6Q6^(_AL_K9^K8K->4523A$X1.$3A$X15O]FK'5\JJ:I8M.6O8
MZ3SQWOV+G:\P?4^=):TN^778S0JPGEO3QZ?.#Y%FJ&,L>@J&=S"7REYE<9:&
M6-Q]P4+7,_S%,SL4CGV<MR1= [<NWG7M]HX1UK3JNWZ8LIS9,-\U,AN+5>NM
MAH$R;87XYW97TEK*:"BZF1.5>J!/CLA13>K9:],T'GQ;B@8W).7(6=<S =X[
M(R5Y920:[#1K855>P;'>O5V4KE^%BOS*5B1'@G*M4F2X4'EI4^5)Y1&#U)OC
MZ2<G)H@^J>;X9],D'F,'X9\H<^&>$7_#%R(E40A-6)2EJH)@TR,Q02!4H 5C
M&31D)Q#P:<$O&<9,$6 6 8SCS9QX\(N;N=XTRRVBQ4B[VO737<DG:3WZ.56X
M3*/I+"?61,%2-0ZM$//< /S@WD@1JQC5)4!I(0)5(\C\A!N0DH\ZV[UX_;3^
M:KLS_9]N;_#F2<(L\E!M"9[^3E]=C<O& 3<JC.LR1Q0C4FI_BB%?88&]0A"$
MGP,/R(M7D_)8!EC+ 0)2 >#" X%W.CQ+>(Z@2",3.((YBL27?PKG=[<U]K^
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M\K$26(%-V<A$O4'' $0H)"(SE</CCD>\3ZNH;H=+HW=37[;%P&B[ZQQ!TMW
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M&?LSX9^WPS]F?#PSSGJ@JC>EH!I>IT]+/.]R<#:S9$!JC)82LGFAGAH3#LE
M_@%^J/ C/3!_ !YO('^"''.AQ+\(9_=X/\ 71XG^$M_L(O\ "K<^<]<Y.$3A
M$X15K=P?]&KME_4)H_OS%.7N&_AV/^<[]6]7.'_AD'YSO\#E8!!O]"8?_5:/
M_P#"4G*;_EN_.=])55_RW?G.^DKU/,5BG"*I_LH*+-N?J]":6 P.=\8=XA,
M$8<^$,E8L>.!8SC[!!"+'_\ ((<_RXQG%_"_F\[^Z/\ \;%>P_YO-_NK_P#$
M%;!R@J*<(G"*J9:0M-[N60Q*N"E3INL!R.<D^4H#\N:06T84Y:,)PQA$BR4X
M'HG#*DH)@QA0B1Y!@M4,P'0_YJ_^8?\ AE>_YM_Z]_\ 05K/.>J*<(G")PB<
M(G")G/AC.<_R8QXY_P!?\G_9C[<__3A%4]TT*B%&H4@+*$(0TFRVRA*@(BS2
M_(:9:KZK '&3  P/Q(4DCR(O(@AR+)8LX- 8 -_B7X0W^P@_5M5_B/\ /L_L
M(?\ #?UJV'E!4$X1<)VC4GH]:-A%*5&)P4$TG:0BD8%"9*)0+YD/F/3"H5F%
M)BL^&<Y\QQ@ _9X>/CG'-L'\]#_:Q_XPML&TT/\ :Q_XPOD:>JU"[4S614J1
M";SS:!J'U$8U*98(GTX"P%!\5",PU,9Z@ !-QZ9@O)@>"Q^!@1AQ.1^$3_VT
MO^-RG(%3SB[J:07_ /&[O55??._HJIT\F2^'LE=,4BV"D48K>S)(LA#JKFDP
MB\;3+Y.QM264QUOR2F5-#BU)S$ATS6X;2FX2U$V>54?Y<7>% ORXP=1$>IX
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M,Q"I08R:YRIT7)E(AD(6[ 37GSY_=( V\3N/;Y_=6\%M\M[]NH3.NT[;"#[
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M*U2M3/)!I2<E"4<G-4"+J\))$LHJ(L+&ZS-&V1HHG3S(<VSL[38+;U"@O/\
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MKA;&.+9_QWK!8LO/5&*VNTBP.TJ;\,1933"VE&6XM'\0EC$HPL!$A, W4)4
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M[-<-:V7!+AA$?LBLY.V3&#RI()<P2-G.R<WN24!YJ4PP@8@@'C)2D@Y.<68
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M+CR9$F2(FQ.I[1&9' '2&&FN!&ISM(]'L)NN5^##CE@?D29 B:QU.'5EY )
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M@=HNB2-@5_/3X/HIY^DW19D,^4^NF?1M[N'Q0SR0O;'G1R/S)'L/4M?CQL>
MU[=?5F1X<&,>OF:&6(^KM>=-HI&F^*S*,&T6F+G$N(G38!^@SBPH$;>TL(8B
M:EP[N.#%*=4S+3"<E)VTYK&6,XTH@DY9NXP*XIQ(D%I^/9&D$<P99#=WMM5#
M>[[*70^%K&:SX1_A%DF=+#..F7&C!"['<63QS<2RI'2]?J#6 ,,;V M<96R
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M'[8Y=6AH=AL]!VL]-0G=N2N/PMU1P=\P0ZMWN2S,HG5,2:H C7ILE*4XC19
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M](^X.L1F3N3<V2IY./7&+$B1E FZ_#X8F-,FB8/DPY"7/:'Q.&KTBW2X:B:
MZHTX@'E=KKX$,;&B41R!\F*^W.;UD;K/I; T=6WWLT2!MS-W6]1%R3.[1[*2
M6961)I.J:9%6$33P603M7:@(+F,0!*RJG-+9+6<97<H/GRE$.3N*F#E)RQ*C
MA*74@LY2GQSF9;!&8FA@ TN.O1U9DM[C9C=]\;I/H /LTW;9<W-C;&8FM8&^
MB]Q<&=67:GDT6'TVZ/D@/WH"B0LQ&X.^SE)M@T;I05.5U4%>4Y<<@D\5CS)
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M[Q7JX298E:7!T)>A <5"U*K -&BR4F"B7B2NJ+G\-QV9#Y&22%C &.<RZ;*
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MND:Z:5['MEB$36-U%Q)LDT"0T::)'+4#X'D8,<#GM?+*]CQ(P1,8+<XV'60
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MHU@CCS)4<=+8&UV<0G9(1K'<Q,H @)-%@:@1)F 8SY<\Z\6+DC"RF&"4/?)
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MB<T9.P*>Q.0M,AA<D[']CY0PR9K6%*V9WCKG'ZU<6]Z0K2Q9)/;EB$P"M.I
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MX5$YV356^.OBJP6E)(F=1*(3&X'.73,\&^A +*YL:8TN2A&_ -&%,D4IP&*
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M/27U@9%D6=6FSQSG.<^%H7=C'CG/C]F,67C&,?;]F,8QC'\F,>'+_P!U,_\
M*#V_\G%V_P#^M7ONGG577[;?\G#V<O\ D^?CS4PXMJ+KI"M>7/5.+UBV--!/
M+-)8^ZU^4[24XEP:Y>J6K9"6JD2MZ/EIJI>H<% @.0G[+DA!A,0WJTA"%$6G
MK.R)GS#(<\F8%K@^F[%@ ;L!IV &U4>T&RJSLB9\PG<\F4%K@ZFBBVJIH&D
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M<#4(@MYF  +3@ 64$@.#"" !"2E6Y$YIBRG$0E>=GQS+_*9_^U?^U9_'<O\
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MNZ+5%]K5 YT W,+)&D%?*'J3Y(2,T<6I7%D3$2$#V"6EG(%B),<4O"_8<!X
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M6DOM0KR$N^F=^V^NUAJ79^UZ)IBSIQ3,4M.K66U2$4J21TQ8(YKC[DW+URS
M?AR9Q7LS-DA<_E-1384/)QI.0D&^WFP#7[/:J%M"M@=/I;O[UZ0[25GTXV!<
MW/7F7(=O9#3.EK=2\]HVSHU7KDO4WQF<DP]IS!DTYD)PJO6U9A8 )&74P:4P
M>3<%9>?=Y^A".?@?X;=G(['?W*];N#NJ74!UW["6+"6BJ7AZPC@T+.Q>+2AD
M%3,S%95D1&O9-*YU''+Q121@B,?DSE)5D?/+4 =PM>$/ME/K>@8\^;0"S2JS
MZPM%H9#;D"BE6SG4_LS7ZYM36&.G=8-6:2@LT.L.(.K2\P*R\OT6D\@=5#?
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MGW[;#>P?O2M"51ZJM8Z.;;&UEIF#[1[#D579UP;5U[#[8K:"1YO@LIF+4:9
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ME&V!RHVUVA*\2)O0.3F[IF"9Q(29U*.>&N-+URM'XIR<DKWKSW?-V]VW>E;
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ME/['%E[04O:CW=?_ )^[96A-Y';[/._L3;ML[#P[*[CRY6M9>O<F0V)3M>W
M5'X6R/MQP6%V1*1016F>&)T?9%%&A2-2CE)+>VJ)<A(3>W;VB1+DI:A>SI4
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M848YOG5$;M2./CY<74(6RMEII4JP<?Z7+<;)><H8Y#E2[M$=E1; 8!-.$J9
MM]JN3X-4H7-/EPR3X)QXP4UO1[Z\\_K6WR37W2EX:43W8*O%B"\J-F%#V%,&
MW$:<7!$1/XLFBK[EU8$RY'A,\-"Y;[->PK @ E=V=Q"H(,*3KDH@ )6]';E\
M_:L&6B\+8XAMOIU*W/5;KVHIKDUP:;3.'-U=7AMC-;A(A.T4<<;%K>55[#Y9
M?:J+S-*Q.#(Y5]83H-D=T,5E2%U6J&=V:$0U)D?N]JFS5[5N.0'/;N_C1[EN
MG[*GV$1C0/;R0V37JBV(*ST-8*^35LFE#_"AS5M(9% AQXV719:W2.-HW WT
MBG!Y9ER9P0(,J5"<S P8QF5BL:/5Y326C>S35-GE6K6F-#O*&^9I4B$FI-M=
MZ[=M%G>,:I*KPCSDWUS;.P<BKY?74O@4L3(6F?*XG(6(MY0NK9A$U.)+<N#'
MU<_#;S\ZFJWY<Z!!]1'*MAS\UJ6[U8_!Y3UCWZPV!8X*K97%ZI8IOE:V)O,Y
MCHY8&[J\,AL=FL38 &.;S Y9* -4<FA1(# )HXYN"\TE06E$F.E!S\^SS]"X
M5HEI#N6GW/:]S=MZZTGUY%7NO#_K_"*WTH02,)%E)Y/)(](CYE9[V]LL?*$T
M,@6<\N&Q(E&M,:53B:K$M)R PM43]GFMA7=[]U)CN.O*QJ$TP=9' $D70H95
M9%=UW9EF3>I3+XA]'57+WK**87#(J> 0H*G[?%" )BO@J\H;6%0XD+G,!B)(
M<6-R4>?/[U69\GVV^DM].CC 8:HJ.>TVQ:VQ64618M0ZP0_7%D9-FB+8G45<
MXXKS7,8AT"DZN;UNBCL\$V,;)XP\/E0&*CAJSC#2DUV;\M^_OV\T/7:Z]VIK
M;)G=FME*S&:=1+RS2.S(M_DU5QNY')5,)*W@)JE\=+./DJ)&H-:H_(5SHF3+
M(D\'8:&P^)EK4)ZI4YJ4A0BG:N9\>1'AVWR^GW]#Z<(9FM;"VCK]WQU<(I@Q
MLM-N+ZR]<</=XRM0HGX5@',I]LK5PCVYW3K"T:L40+;%AYK:87(,. ",K4N#
M"@@=E^T5]9\CW<^[NY;L'KE=VBF[U(VAJ+7""@ ;!Q.7HMP[OD56P.<EV]'X
M4S(HZT1N.-RQQF3VF2,[N\I5R$W*V,J$"8\*!:D7J_1(!?;6XYFAV^!%]U_.
MK'NNV_\ 9O86NK&D&T#7JHTRV)V8XP=L1ZHVK(;5C2,ME:VT;TV39;)6QJ<8
M]-&YX5'E'L0TV,@:QMZW/V*PY$0BO=YY@*HCNWV"IF&[&1&J'O56I;BE$AUT
M:V2]I_;MU2.I$I&L5S;%0&N#8A!HO$G)L=K;G#/.DZ:>-BH:MO.J4IJ52=G=
MD!SLXY,>?/G9!X^[Z>8._F[J[#^E1QIC&E:B)4C3L?I*+55?=^U6_,<7M-WN
MZ.2J:0BPG-NDMDM=OR!2L>Y\GFYV27@]X=%JM0C5C4L>% B6DK 2'GY-JM?>
MO0N";3[M;-W-4MG:&6?>L8B&H$[B<"V3,+DQ4$F%3KI8VJ*PL- 4D>$OT$WM
M6,ED3DYGM.0O"&9LS>H.9UP0IG1JCO\ /GV=_?N9[!MON![;_@/:=ZH6_P#4
MO7*:I.OC7.NTMH5;;P(Q'Y(B.F%)+1.51DK39Q)ECA$:Z<3AF+%T2@*Y2HA+
M,J7B"M.1L)8CR4^?!.5*Q.W[UF:[/85K)6>^.R5S2K<][:4+%9S/)4=&Q+5!
M7=TFC>[=X:H+*DB#H-P ]$);'9JVIF#*;3,@9K>8FB1[QA0> L<E&<I+)I/S
M^OF#V>J^[Q-!:R="8;4U>:4ZJP>B)FHL:FHM0M8LU9SU7Y@JIC#D<4;2V21J
M2A9$),>[I/(M-1B%D2(PX23.<Y)SGA8GF?X_/VK*=N/>1=E;!;I;WH]4>I)W
MB779=TEJ>2PW:%K"1N/= Z>^##D$D0/1F0LC YR'"TTJGTS\P/Y[EE$VE9-.
MR<6 )37??AZN9[#Y-FASUTN\+J/;>@HTWV[5,<FE:V?$(7-EM9VE&FY]:T^7
M!N;)2SHI!'G5.<B$XL"LU-D91Q'BD7I,Y!@ R\9P4+%KLYK#C5)L)NAGO[HS
ML-DC-T5HU+*Q@NF%*BMHF,RFU8]%5.(B4AEK@N>YE%$#O\3P@*2H5"S+4K-+
M4HS2\>!96 >54>>]CNYFK\%L$W=V&L35[6B66]5=$.VR4S9"$")LJB.R)@B[
ML]?$BC2!+D(9&<E3/!+1G '!QC:)00\.#02O"V9&J( 486*RVZ-.R^87AKG<
ME4?)SHS26R,XF];/%Q; OSU%X_4M81I\<2QVO8D"JL^3KI-7<@;VE>\K88B5
ML25Y(<S\-CGD)ZTX6"GZO4/?W_2M(79QKU0>R>L%B5Y;0==FZQ76N[19]=)E
ML4AA2YB@=MR*%+VEDE#'B:!,)3K6YP,:E*Y6VIU2M*F(+4Y2JL$@3FE \^3:
MSCZ!ZS*7_;?KQ(9>O_1S2MRTW<GLRT;XK_9JE+:FVPYI=02" XCT'AL(\LCD
MATND:I/-3I/*CW!RBXDPEJ-9[[!GOHKEX>L]E>?V[K+ZP>X5?J]?<.[E8&D+
MM8KRKK0Z_-E(I<UJQ^D:Z+BT>EKU:$L90R6,15;7D\BE@QHU_C&5*0R3M#G*
M8PRLCA&4QX%LA2N1K,@P8M6D%CE0.?[:^O;;GNJ(.K BC[4[%HK<5<[6L&(&
M<1N7/Z,UUQK#):&L!XEMCRB'H-EXZZ2B2J,*GZLJ^FR N8U[7JPD#['$;^6M
M5-Z=*D"J&4FZ]5#E7>?;6U^.YY6K7^T&8;TLC1)FNL:"Z[K4TO-JU*NNI]WD
MMJ101F1/87YXP\-[XTXC;O#C(<C:T\37('5V5%J<OBI46 LLQ(B,&4 #M^O_
M '2HD=$<F5/SQ;(*TH/J3JVB0L.1ODCZYK97V#-5UI%O31\!8K';UL>:E*&.
M&1M3+'%O4N"H0@+TZ,#6F$F6JS@O/GSNI( Y?3?^R!W=JZGWXOCFGJ[3N#M3
MMJC%U-O[=L59YF^YM*16XJ/A)3G6-CO9[\\G3$PMHA+GDA@-;&1V#XK'MT<4
MD7+&D3.RMP1D';RY=N_CR\:Y_M52.DFY&PFG.][#J>S6CUKW-3DQV2UYI:>-
M6F- 12H!/QFQ4/LQPC\Z:9/7CJH;G*;U0JK=0*?P=[1/ $<->&]V1/A&#%)*
M,A%WR%6>1'J&YYGN'9WJUWN0@U'V7L?UW5G<\K:X*WW(9N)1PY/.&"+N=;)X
MU:.O#DR2!*H?)-(V ,2LOW0&1QK-U0@=#52UO=FHY%DE;DP!0-M^ZO;X>T7[
MN14B^IW4>=ZP,%_O5I;.U+LK8%O3B$N;NXT?$&*"0*/-->UXS5U&5"J.L;JZ
M%FSV6L[$2]SM^4B*,=W;R8)]5*C)'AY"'SY_?X=BK<[KMFHM$=Z=<M<KZ[-;
M Z\-;)+K7,+34N---;<9-I3;"*PS8ZSAF;VNB$N$UPU5'4JT$9*(;U)*I]99
M"6K D-$@4C@B^[VBQ[K"#ESW\]OOVV\3R"M;ZG953,EU6<':DM\;.[#(&CL^
M6(S+]MYQ(721J<D;'%3%M>$J"HK#B26.+I#$3HC)PTY"29(%F?=FAS@LD/X^
M;->2H54O:5(:#WNGR"G9WV7]4>ONH#K!6)Y(E4K,H2X-L98N.>7YMDPH"[VQ
M),0NLXT6M91,S--HPG<)(G=D3[@O)2A $&)4\N?:.[Z/9VT?5VJZOK:JC7"D
M-.ZGJ_4Z\%&Q5&Q-,\M\3MI39[/;PY(;\96F.X 3:/F&,BHAL=!J6Y.V-GII
M&4E.!L**+PF\O"A4D=FNB]IV'L+>MW1F,=);\W88TKXB3;<58X.EZ.(HY"T.
M!HYS+L2)(@+P<:@&0T+#4(24+,)!ZV!A)$+)/._N5SO5--$5C=<>G$\;H]7<
M122ZCHD_EQ6IHT;#ZXC@W(HY2H8XC&CE;AEI:6I0,U$606N6)S#B3E"14>E.
M)-$4GZAS]0\CP65G:'6NB+FVYW6K6M+1Z_4^W\@VHO0Q)%=[8I*X))YG6NQ=
M41NNYHW-CP^Q[ 9,ZT?+8FQS;6^4UQ('A.I*<G$DY-%SQ+<NT?M[=OXJ2.6V
MY ^CL[[[;'?SYK:I14#=:KI&H:R>Y0*<O5>5A!82ZS(:<"(4L<HM%VQD62+*
M4!AP4WQI0A,</2]8[)>%'E$<:+&3!2L5B8G78UV%D[AW57SC/-@3=B'.93MJ
MIC6%BTY;G^GX+-8-M= FFHVR/RD,</33>*6UK8VOSO/+X?)")9&RG=U+;"RC
MV)M*5%D*[0=SL:[.\7VGMWH<^Q;5[OLFJJNIZ5RR^Y]%:LK\<>5-,HE4KD39
M&6A )\;SD T9#L[*4J7XDJ,.,3-*8)N5*Q9DDA*4:<, !% N]NS?^/@L956T
MGIDU1S1N45+VJ:CIJV7S+5>#SZ,L%61T.Q]H9I?:)_F.K:Z'1=')5DWJRTWX
MF:((!=<F5L990VO"Z0&  U"/2"*=[L"QV6-C6U>/<.1/K6AWN:ONS:"UV@CA
M6-Z0*GW2S;69J8/C<QUW6[.N-SF60@7,J*MXO6"!V:3EIZS(E*Y\5J#3&XIA
M3K2EP?(< !A0*[?/SCZ5F"ZE:\:=,NU5\H^O=LZ/>Q6'?;O!Y@Z@T'>6FKWN
M;UTA7NMBZVZU[(R:2NZZOI"VHSSTRJ$-RH<?1JV\E*UI,FA* I*:V/GY^7=M
MOZANMCW9-<-G4!H=M1<=-1ULE-F0&H9(]15H>V0<E9?<Y"2B7.SQ'@@-P^-4
M=:5:^0N+4<6-*O1M9Z96'*4P['"QYK+7U76C>5<]HM3T5(KYUTDBVPI==JJS
M*VURT2HJ@7.:U$7KB5;]';$O=IP."DNCS2=BJY4C*:2$$B:5 ;":6A"<)^;E
M#ADN/9X#SZ_HM9&AM_'8U=$GN.XKF1V$*\+OLCT-!H@]66^5#5$]?H#95.)D
M=CV90[!L".@(9++9A+18]NLL(>&IS&YXB,<"-[7M6<89U_PU*<_IE;<@$5B5
M \^1^_U*L_HKMBX9QN38,C%5=3PRF]AJ5L:]&&%5YIW7&O@]>*Q2WB.&:TLI
MEFPN'1EZL+-T0ILDTH61R6K7M>WYCB5]3*QE'GG&NWS?GZ?9N/AR/U$_5X#G
MR5DO>W KQE.M=(36C*T@EMN-%[555=,[@MJ3R 5U5\CKB&II#F3,-@22Q3DS
M*FC4@ M3L:OTC_=!,<"C<IEJ8!Z8R"+YJ6V20#1(^L+TW55L585V'SY&Y=?F
MO>FT!(B\3E;;)M?M@**N)DGSI(/5,;R5K=3,=8L(4HV7(W9D?G?U2'5$8+"#
M&0X,%R4<*YFSW;_3[%<IPL4X1.$3A$X1.$3A$X1.$3A$X1<IO>%1JR*2MZOI
ME(#(E$9O6DXBDGE)2TIN,C;"_P :<FMV?@KU!I!"/+0A5'K_ '!YQ1)6$^1F
MF +P(6"<EC#T@M&G++V,Z]=1[ [-NO"R*OTFN&+'ZV,NN5/6/'-B+[GD'BT@
MKRLF&7R5S8 1*-H5*%Z4+IQF.OSD@F[HD(4+3U^#2G(AY\_1^WMGW]OT;>[?
MZJYJZCO?V*JK62HZSL>RNQ/9/1]20LEZ6)PK6!CA$DL#8-X&D9QA8PMDVCSP
MW)R(T,)&?C2QPC[(U?'1FO#F LPC&"CL)[!S53/2#96U-W[812T;L[C84]5F
M]JI*KK/0Q_V(UKN79"X4QL3>@IU]K(*? PH(NI9"!'38;"R)']]0#9\)7@"(
MA,K5F%/KW[M]OF\WS[CJ7W!CVFMP5D\Z[;F/M4J*YL,EF=72O['L5'!,R--&
M9&@?F=<0,N1QQ[,3-\C94*D)Z!6 D:E'[<\1A>3B102!S('K2B>0)]BJ&U6@
M?7EJ)VGU/K]H'2.N#>W7EJ==,[LFV*_FCS8T^9U%;36")&2&I'M;-I4C9&!Y
MP_&N3H@ 2F4KE"!$;Z@BB?+R;!Y&T((&^VYV]V_TU[?%3$[DDE/.6L\1:;0I
M[:6Z).[VY'VZBV#3^9/E>7*S7.>Q204:D39.6B41=)&$*-O+>"%3C(3'ABP8
MJ()4L3@>:F" @%WX WYV]?[>1Y/T[5EV[5^191O8E8K<[4TX(40->*PG,HA5
MG[)5^0!82+!=KVW74(AD9E(A,^!$&$'CD+N2XYP(YUP  RLD-6?W?5M[O>5>
M-PH6([L0HEYK?=#<S9 &@W:E+8#AHMER3V+2=A4VGJ*,2.S*LBU=W+L1438Z
MY739L>916,:)BSBF7I5:- 6G<W-*W &,.0%-GYOJ\>W:N_N6N#3HZ&*-3];C
MZYAR^O8 ?25:&PJ$.KPDD#G%HL9$6H;"RN+\@5+D3TM0MF4Q2IU2K%)*\[ U
M0#S,&^;)0L5EY]I^X:J\]BT=,):/@%ETO;UU69=\3*TQBDNELN-@5^QJA]-=
M5)3*'2-'OKO-;?RF/M=!::)<.11Y%+&@UN=4+<PJ$08]W=W^:-[?.%D!MV^-
M7VU0[K=] 'C>\UO-4NC B.<B3&Q6XM"8U>G+,R6<WJ5:( U1(#<_P@&)33#
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MA2SZ<CG,$:D8XU"D,78<@*2.IJLK+SW_ #\U) '?[1X_LKE?L5@W=%18-D:
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MGS]"FS57L+'._50OE[-MSW5K$=M5:H>MKHCN8M3OV;IA-+R"A6144\F%QP,
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MUKJV7Q&"3V8/=8/T=E$Z1NR^*MRVN[0B%A>5W1L91SFH(6%Q@:():8&,Y-4
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MM5ZW)6*<(G")PB<(N";5P:3V?J]LC6L(( JF=AT'<,&B*8U66WEJ)/+:\D3
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A(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g107876g67i40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g67i40.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4<?:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<V-VDT,#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S8W:30P+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R,CDS-S0Y)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" R,BU!<'(M,C R,2 Q,CHU,SHP,B8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" R,BU!<'(M,C R,2 P,SHR,SHP,B8C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86PM0F]L
M9$U4)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#35E+)B-X03L@(" @
M(" @(" @0FQA8VLF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,2TP-"TR,E0Q,SHQ,3HT,RLP
M-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$
M871E/C(P,C$M,#0M,C)4,3,Z,3$Z-#,K,#4Z,S \+WAM<#I-;V1I9GE$871E
M/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP-"TR,E0Q,SHQ,3HT
M,BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O
M<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R
M96%T;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @
M(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIH96EG:'0^,3,V/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @
M(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K
M6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML
M3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&
M:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='
M0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%4
M17AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(
M>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G06E!14%!=T52)B-X03M!
M04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%1
M04A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G
M8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%
M1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I2
M5&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P
M5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7
M-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E
M66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"
M455%0E%914-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO
M8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X
M9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-
M5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F
M2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K
M<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1E5K
M.#0R.$9X;WE16$5A)B-X03M445-8,FY,2D9);UI'53,X1E%Y;6])>%95+W=D
M-5(O-G-E;B]!4%-,1"]Z5&ER=CA(955F*W)(<"]W1#!I=R\X,#1Q-R]",VQ(
M+W%X)B-X03LV9CA!.4ES4"].3TMU+W=D-5(O-G-E;B]!4%-,1"]Z5&ER=CA(
M955F*W)(<"]W1#!I=R\X,#1Q-R]",VQ(+W%X-F8X03E)<U O3D]+)B-X03MU
M+W=D-5(O-G-E;B]!4%-,1"]Z5&ER=CA(955F*W)(<"]W1#!I=R\X,#1Q-R]"
M,VQ(+W%X-F8X03E)<U O3D]+=2]W9#52+S9S96XO)B-X03M!4%-,1"]Z5&ER
M=CA(955F*W)(<"]W1#!I=R\X,#1Q-R]",VQ(+W%X-F8X03E)<U O3D]+=2]W
M9#52+S9S96XO05!33$0O>E1I<6AE)B-X03LK5W9*3FYB4&,S1VDR0WA2,')3
M,&A*2DIO<7%!;%-72D%!2%4T9TTT4DUJ45%/;S9(;S!/:V988DQY8F%83C%Y
M02MO4U$R<U5N16UN)B-X03M,:VEZ3#<P>5%!=FTR-#AC5%!H;$MH,R]!27!.
M9CA(955F.$%Q>#9F+W="27-0.$%Z5&M82&0O9S=Y:B]!3E=05"\X07!&:"\U
M<'A6)B-X03LS*T1V2U X03%9.5 O=T-K5T@O;6Y&6&8T3SAO+W=$5FHP+R]!
M2U)99BMA8U9D+V<W>6HO04Y74%0O.$%P1F@O-7!X5C,K1'9+4#A!)B-X03LQ
M63E0+W=#:U=(+VUN1EAF-$\X;R]W1%9J,"\O04M2668K86-69"]G-WEJ+T%.
M5U!4+SA!<$9H+S5P>%8S*T1V2U X03%9.5 O=T-K)B-X03M72"]M;D989C1/
M.&\O=T16:C O+T%+4EEF*V%C5F0O9S=Y:B]!3E=05"\X07!&:"\U<'A6,RM$
M=DM0.$$Q63E0+W=#:U=(+VUN1EAF)B-X03LT3SAO+W=$5FHP+R]!2U)99BMA
M8U98=RM64$LX17E4439067A44DU(:6Q3,FA6;%I45E=69W11465H>%9.359D
M:7%596%F.$%J;5$O)B-X03LY=$149BMO*T1&53-X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5DLY9D%-3FM$=41E,C%2.'!14BM)=WAB.$A-+S%4
M.7EA)B-X03M91V@R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+<V0O35 O;$,Y5CDT9T%016PQ04%(-U)06E1S,U$Y8U9$179*)B-X03M)
M9&9Y.70Q-#!987I:0C%:4D5Y+S9D8DAE1F%R1V5N=VIT.%A5-&Q,,"]&1'-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<5=A)B-X03LO=T0S5FPO>D<R
M,R]!0V-'14XR1&UF-G!44$$P=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%9,+T%$0G!#-GAO)B-X03LQ,7!J4VU&3'!1:GE!8W9H-4%K
M57%V,F=+9%)I<5%(>35(-68X=4Q9>%1M94$V<G X:TE+2DAW43,Q<V]3:UE6
M5#EM<%E!5DIR:6QL)B-X03LK2TA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1E5S,2\K-G-V*UDR,B]W0U1G=VAU=V-Z+T%&4W%A,V,V=F(R1%,V5%IP
M9EAG)B-X03M:47-%:V=I0E5N8SAJ='0T5D=-839O=WAG6E9-.$DK85!W3E1S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F5B+VQN<51T)B-X03MR
M=6\V4UIB<5E746TK3U=C4&)S5%!5;4M%>'%Y,#5F835%655L;F5S-G1B-E)P
M9'AQ3GER=D)B3'ED67=#>$913G52560K<$E!-S1%)B-X03M*0DPU:G-V35!L
M<4153$Y*231F,&YP.&9'6&A7<3,Y=E=H:F%21T<O5E=0,S1P6EII:#)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A63$YF+T%,<7DO=T-9,C(O
M-4]$0T<W0GI0.55P;5-",7=.3'-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER>#<X)B-X03MP<GDU;#@Y-G9B4&-M84<Q:75F5%@Q0S8Q965&
M4U%#<2]W0RMX+VUC2U,Y2#@U,DYX9F578BLP=#!%:W-Q2T%J3TEG44A5<T]B
M5E5F)B-X03M#1#EO53AD<T-'3&%(;VPW<%AK;3%T3&MI3U).67-:1#92:4M3
M2S$Y04MC62M324LY:U!55C=K66Q,,%!&1'-69&ER<U9D:7)S5F1I)B-X03MR
M<U9D:7)S5F1I<G-69&EQ5V$O+T%(5FPO=T%X='0O>6-'14XR1&UF-G!69%DP
M5%,Y6G-J6F%L04QI,DQ"+U1,379X3#!.54MN.&-2)B-X03M):FMJ1FUL:FQX
M4DY&2%E'<#)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=DYV>3EH
M:&HX,S9P2D=X85-D3&@W:4@P=417)B-X03MZ3&-R1VM5;GA.>$UI2C9I<C,K
M3'=W<$PP3%5,0WHQ0WEM<W(R1EHW5S15<$Y%+U)L4#A!;G-2,'=)4UA73DPP
M,U1.0W0W6%0W5TLP)B-X03MT,3%$5%-);U561G(Y9F="2D-G5DIP=6-66D1I
M<G-69&ER<U9D:7)S5F1I<G-64TA6+TU6-W R<S(Y;3%P0SEN3D)09%!D=&-&
M2%-/)B-X03LQ-$=B.3)9:71F,V\T,6M!4&-J2FE.:3-,>&%E331'5FYI0D%Q
M=2LV-BM88VQL="MA1VHS141Z4C)&.7AI479-1U-&4V@Y6#!65G%Y)B-X03LO
M861Y04M61RLU1RM%-'DS4S=-;412;$@W938K-4-A:"MB96MX5W-V,5=X=3-V
M0D)C4U)P2D=N<$I*0C9O-%-U:G-"6#9U-V9$6#12)B-X03MK:&A,6FHW2FU3
M3$UE1W@Y=&-T=DU*>&0K8T]&,W Y=%HR>5AZ,TUG:'95:G5)=E9T,RM(;6AI
M5#%76FM6;61U:6=,.7%P1EE#1&IW)B-X03LP;&E2:V5'=5=X,RM/,W4O46=D
M2B]-3U1557181VQL175B<4,S6GA/<DMI6$U3>E)-9FA$1GER-V]"4550>&1+
M;5=/;3-.,F9W12MR)B-X03MK0V588V%0.78R2G9Q;#5(9&%Z6F%01T=%,&-I
M,VLW=7!24D9$=4]"86=K3$]60C16-#<Q<'1724<Q=4YJ:'=W37IY-690-VQV
M;E1Z)B-X03M"3F]/:%!F=T=!4VE215@V>C9N1#1J-%)";4IP.'--23)5-E1"
M-',K2&8T5BML4&-G-')S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER)B-X03MS
M5F1I<G-695<O;&YE86A.-3 Q<4LX;6-Y4G!-,V]'5V5244=M4VQ6;6ME;$YW
M=$(P-VY#:W,Y.#%A=&-A4C5F=F12=&Q2-3=D03!A)B-X03M306Q34W=7;$9+
M;&IV<W1253=61T)$1W1..'A8*W8X06LK1RMV;S!I=4)Q=&A%,&%),%)!5R]T
M>4]C8DY)56(T=6Y)-U509D9,3W-5)B-X03M/>%8R2W5X5C)+=7A6,DMU>%93
M;7,W4UHQ:VUG:FQK5DAJ5C-65TE34VY.45-/:F-2>4AE;4<R46U2<T-G2E!+
M=FQT-T=E>"]2='9()B-X03MA,TUF<%1X=WAR1'E3=&5.67=P1RLK>'<X4G4R
M,&%R2TI#6$5B2'@K.7%Y.'$K5S=+,FET-V9464)&1$4X169.0DDT:6Q*36E&
M-4]4)B-X03ML6$QN:T-D-C1M6DM:-G),26MM4C-.+T9%5&%(;W-Z,GIZ869B
M4W9::%):<SA-8D=%3%%Q27E2.$9+0VY(0GA&9TTX>&134'$U-S@O)B-X03ME
M=6@P:E-9145C1FQ"1D=*9G)!4DEK565T+W9Y9T@R+SAR<FI:4DQ,33AY959C
M*VYC:&1F4F8X06-D3%0Y-49E=T=.*S0U:WAT5#5O)B-X03LU1T5-.$(K;V8P
M4VUC<TU-,%IJ;5):23(K,&IG37!P=G5$:U=K16IK=7A1-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T98)B-X03MM6#5C-D90<'9N9EA69E5,83=:
M5653-5-">3=E<&-Y9V=-1#EL;R]18FU/,TU957-Z.#978W0U-58Q2S)I4U-6
M-4E30D9!<79)=T)")B-X03M+<6I.2'EQ0E-G64AW,W!G47AJ4DY";#!R>5!:
M,FPQ8E!$2DAQ,6A.1D9-<UE+8S<V04%Q16QU2V)%+V%F;'5E9S)X2UAO3TM(
M67$W)B-X03M&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E5S,2\X075R3"]!
M2FIB8B]K-$U)8G-(32\Q4VUE0G!D:7)S5F1I<G-69&ER<U9D:7)S)B-X03M6
M9&ER<U9D:7)S5F1I<G-6961E4U X4$HU>G4W6%-F<FMK;&QB,TUD,#$P-F-9
M6&4U:EEX<6=53CAB0FI6:G14<'9H4SE&=TE3:GI4)B-X03LO=T%C>4@O=&]A
M8B]!3E(X1TMP=FER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ5V$O
M+T%(5FPO=T%X='0O>6-'14XR1&UF)B-X03LV<%1003!U>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W-'.&@K6#ED<TY8=DHY5W-40VEI85!4
M<$5N4C19-%I:5FQE)B-X03M.14)A5#0U4&IQ-4Y+57A3>41Z;'%.-7 S;&I5
M3#)Z:SE+-F=J1%)38U$Q1'E!+V%"56)(-U1#9S9N65EO671O1W5A;')(:VDR
M=DY3)B-X03MM33EY,G(R35EC0D0X2S,Y=5%/8TMP1S,K<V]!-V12:55V47-5
M3WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<%IR+SDQ6F8X)B-X03MX
M='0O>6-'14XR1&UF-G!44$$P<%ID5W5V4')L;&-7,3E&1F\X4U-#*W-41E=3
M5GEP0TUS=&9H0VUH;T(R-S$R2U9(43<O54ID43%8)B-X03M4-S973V0W0U=-
M4E-X;UEI635O>$E!-CAN,U5K:6]P6'=X2VQB92MD4$Q6;'%B86)D6&YP6%-.
M2$A+5VIL.4=.-58U>'!*3T4Y1D=D)B-X03MD=W)/1%1(:$LX2E%7;69M8C5)
M,5-#.6XP+U5H8U(V9F)T95A:.4MA4&A#=%%35$EI0W4R=S8O4FA-4VMX2TUT
M4%!(;$<U<WAD:E8W)B-X03M/2E!1:75P:VQU259E1T]B:G=-;S4O0E5Y2W4O
M8V=93T5O-%-Q2'IN-5!#>7-D9# O:D)15$XY8F=O;DDP2$DX.7%N>'@T4W9#
M5EA2)B-X03MV365K87I,9G@V9D]*;3 R-$YR8VM&4T]94E=Q=$-F:"M,:EAX
M0GA)<%-+5%!!:#)+=7A6,DMU>%8R2W5X5C)+;U!6.4QG,514<')#)B-X03MD
M-4DT<'5.6&AB:$EP5F=Y;%<W149C5E-+-C!#>3!,>3=$63)43UE0,&YP.&=%
M:$)O5W8W96]52T951&%U=S8Q4&9&5U4T<3=&6%EQ)B-X03LW1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ;&UV+W=",5IF.$%-8F)F.&Y":$1D9S5N*W%5>G=.
M2U<S5W-Z=V$U6F%7=6Y853!.,FIU)B-X03LK<%)Q1&)1;$9*-'E.6&MP8FI1
M8F1X-S!.2G!,3D1S8F4V.'IA=G)C=&TT;')$8E=&,V-W=DA)26MI2'%,14I1
M<G%N<4TS44%.-S14)B-X03MY4V53*S@X:C9D9&$R,G%09#-3<DIC,CDY4%E+
M.&8Q85,U=$9665I70E%Y07%%6%I804Y"55DX4SA31# O=T1,1'DY6E=-,6Y(
M8UAZ)B-X03M25%<X3G-X1GDP4C17.&)X2GE%06E6-G))95-Y0FQ0.'5*:U8T
M>6=%+TIR>31,;S--="]Q1GA+,&-%2DUR=TXK-W1P24I%6&%%2&I7)B-X03LQ
M6#1E;$,Q04LT94UP-'EG1R])-U1B<31V4#!N<7,Q>EI33WIA9F)X>%)2=&)+
M.#!S-5%U-&U76#1R:#DR4W4O>6]F150T:DY03&YL)B-X03MF5"],-EAC5VYV
M3#E7=7!6;2MR>4974TYL:5-,.3)1;V5H5TYA.&U0=%1)13)W2G1/34-(67$W
M1EA9<31K045K,$$S2D]+=$I):VE")B-X03LT,D1O96I+86<O4TU68GA6,DMU
M>%9+4$Y0+TA-:"\W84=M+SE2.$=+<'9I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<5=E)B-X03M9=5,R361W1EHQ=&)I0V565D):=E13448R0493
M94LQ86<X34U7+U0O0496,V=H9F5E661%<SE.1W S1C=%=&=31E<T5G5A16Y9
M0F50)B-X03M+<"M726E385EX=U1L3&A!4$8S2FAG86Y9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9814%I:#-"-FI&5VM223!#26]20C!64E%$-D)I)B-X03MR
M94MU>%9"87I,<6M7;#-%;6Q1<&-A9W$Q=#1:1%)786]R5W)*,G)T>4AZ1TMS
M96YU9DUS+VQU,6LQ=3!I='(P-G!P-&5/3F=!26AF)B-X03M18U<T<3EW3UA,
M86YQ9$XV.7-5<W!U>F1,87I',%9(=6A'>'0P;%ER1UI+2&=(6E%X0VQU<$%/
M2TAJ+RM)=CA!;DMF+T%+;%A14#A!)B-X03MK93,O04=667$W+T58+T]5+W=$
M,4MU9V8X:C(O-TMS5F0O:4PO;DMF+W%69$$O-4AT+S)667$W+T%"1B]Z;% O
M04Y3<F](+TDY=CA!)B-X03MS<7A6,RM)=BMC<"\K<%8P1"]K93,O6E9I<G8X
M4F8X04]5+R]!1DMU9V8X04DY=BMY<D97=CA29C@U568Y4W)O2"]).78K>7)&
M5R\X)B-X03M29CA!3U4O+T%&2W5G9CA!23EV*WER1EAF-&DO-7EN+T%/<%8P
M1"]K93,O6E9I<G8X4F8X-50O.5-R;T@O23EV*WER1EAF-&DO=T-C)B-X03MP
M+SA!<59D02]W0U(W9CA!6E9I<G8X4F8X-50O05!5<39"+WE08B]S<7A6,RM)
M=BMC<"\K<%8P1"]K93,O6E9I<4=U=%(O-7E8=31$)B-X03MB,V9K=GDS8U<U
M8FU96EA$<'DV,31T8VM6>$))6GAY4VEB0DE+2B]X1B]Z;% O,4MU9V8X:C(O
M-TMS5T1V.%)F.#54+T%057$V0B]Y)B-X03M08B]S<7A6,RM)=BMC<"\K<%8P
M1"]K93,O6E9I<G8X0458+T]5+SA!,4MU9V8X:C(O=T-Y<D989C1I+S5Y;B\V
M;%A14"M2-V8Y;%=+)B-X03MU+WA&+W=!-50O.$%5<39"+W=!:C(O-TMS5F0O
M:4PO;DMF.$$V;%A14"M2-V8Y;%=+=2]X1B]Z;% O,4MU9V8X:C(O-TMS5F0O
M:4PO)B-X03M!2GEN+W=#<%8P1"]!2DAT+W=";%=+=2]X1B]Z;% X03E3<F](
M+TDY=BMY<D97=CA29CA!3U9(+T%&2S)G9CA!235V*WER1E<O=T1%)B-X03M8
M+T]5+W=$,4MU9V8X:C(O-TMS5E1J>6AR6"]/449Z-6ES-&9.4&PO4C=,45A,
M+UAB;3%L6G!K06I9<'=(<GDY6D])*WHY,UA&6'!U)B-X03M+=7A6,DMO92]S
M3%<O='9Q.3!P84QN2$I26&5-:#1:1FQJ64UH5FAX9$%E=4MQ4#9(=% Y*UA0
M+T%%;%A0+U941E5*<%9P;SDU6DI*)B-X03M:-FI0<45A9G4R=6MV6E@U=6=O
M>%EX3T4U2'%A041W1TMO=CE$,FXK+TQN+T%+4W)N+W%P:7)V,%!A9C<X=68K
M:W$U+S9Q67%H3'HO)B-X03M!03E9;'AE86<Y=3!C9G)33$QF5&]6:DQ"035"
M;"MY6%!%2'@R>%91*W5E52]1;75F,'50<3ES=VIU2E)Q379"2&(W25IV5F]#
M8U98)B-X03M2,UAL4U-D8F505G5C-WET06M3-FA-5TUQ535)04IA.&A55D=+
M<&@K:#=4+T%(-6,O=T135F,O.59-5E5B,C P:7AT6DQQ.'5P<F4R)B-X03MI
M1EI*<$QY-%96<6%#<$UN8VUM2V]!6'9L1V1H8E$V,E!8;%I9;W94,4=2;C5Y
M0W%C45I70DHO6C).8U984S,O04I1:6YE0UA70DA.)B-X03M(25EP23(Q0UI7
M5C%(27%16F1Q67%J8D]Z,&TY=&\W<3!U<')I,FQ&635O-WDT6E=(5%EI5'AX
M5E<O43EP+W9Y-2\V4W)N+W%P:7%8)B-X03MY,U!L5T<T83)L,5@P-VA*16AE
M1G11;41I4U%%;VA5>3$U3E1967%P>#-(;%9J2&-,<E)E0S995SEU4#!H2C9B
M4V]4>4--2DML:GE!)B-X03M)<64Q3W4V<7):5"M6-S9626),5D1C>7E)6EDT
M-'11;61M4E=+1F=&;$Y11T)&8U92+S9(=% X069L>B]!3DI6>B\Q57A64W5R
M2%-R)B-X03M317HS5GI.0D-P54Y,2F580TM#>D)6<51)0G5X07A60U=T,356
M=34T-V4Q,5@Q-353-&EI:C%#6FU9>"]B-'%*86UN6#5B-'%O;E9V)B-X03M*
M45AN*VTP-&Q78T5A:DM15E$P66EK=FII<6%285AP.'-34WA4,T5K56EH;S5&
M=3=H;%I71E%14DI19VI&5C,V2'10.2M84"]!16Q8)B-X03M0+U941E5S92]W
M1$M+3SAC;7(X2&IE5TXQ8E5*;$EA,T9::'9,+W5S9F$X3597=&,K5F)A:W,K
M='0V9#)V,6DR16UO4T)F4U9!1#96)B-X03M*1DQ,.$IA<'%A:S<P,D-Q2W-H
M-65V<%AI<W11835K:59(:U-'+VYK2W))3U--47-P,EEB9S1Q:2]W0D0R;BLO
M3&XO<$MU9BMQ;4MO)B-X03M3+UAY+W!X:48O<40R;G)K<D0V,3E02'E+:7!P
M>6Q(5$960S-U=DML,G-H='1836=H:49Z354Q0UDX25)U6&(Y-SA+-V)K.4U6
M5W@V)B-X03MX-4U2;&M85V]Y54UB1&QQ16I$-'HX2$I42U)V-$5F4$974EEQ
M-T9867%T:VI34TYO,T958T972&E#2TA&57$X<BM78DAY-7!P,"MZ)B-X03MK
M;&QI3&U4;DU63&9:5D%0:%92<W%!9$U65&9&6%EQ>#-Z0C5&,&97-VU7-FYE
M4T<T;&A317E1.$%F,U5Y5$DU<7)664=-1&9A;4MP)B-X03M/;C5385!&8517
M34XO9$I9>FYM.%(Y2FY$<3-+37$U5&)J>FQ&0T18;"]K:D1A8E).;BM6=6<R
M;7!186A&8UA2;'0W:')L15IO>7!Q)B-X03MY3TEZ.$9E2W1%<$<Y9D4T1G1M
M3TM%1G)E;69P5%-R;E0O<D5L<4QL4%1A94AJ-FEG;F9J>4)!<4YQ+V1V:7)%
M6"]+2%$O6"MT43-L)B-X03MZ1F-G;S!255$K;7!J8C%606I%64A(,69I<#1B
M0V=X=$YT6&XU3RM8-S8U;G5B>3=U-4IR<&UA-$MM3D%W:VM->F=!2G1763@O
M=T%/)B-X03MM1S!-<S!(4F].1S!Q2%1O2DAL:FE-:D=34VY*;FQK859Y94E!
M,V1Z,$="57=X5FEU<V9L,W!7<C9S*W S;#%C1UHS:%E);G!+;U-()B-X03ML
M4U!A4&M64$TQ2E!,=T]+,F=)=GEL,&1);TQ6-S8V:W-B6C%L:&=0<$)U44LX
M=51H2VM-25EH=%0W4"M58U4R:G9,+T%/6$]J84IQ)B-X03M.=F8R.7AC>E17
M.%1X2TI7:C1K=7I%=5%Q3'92=5!H-U9X4F)+.%93;GI,-5IS9DU.;$9:,VMK
M<V-C37E80TY#=U4X-#8P<E5-0TXO)B-X03M$1E=.,G8U4C906E-X6$9L9EA5
M5GA#,TI'9C S5V=4,%9"6&=V,EE35C8Y9#AB5&%J+WEP9GDT0DAX=DQW3D9W
M36)&;VE1.$Y20W@O)B-X03MD,"M!35)4=C-W,G1S-# R=V<P-U1R6%0W9FPV
M1FY$2$)&>4Y7-%)+15=P,C-O34-%4FER0UHO>6XP0V5E5V1R;316-5AN:UE2
M:4-.)B-X03MA>G%&*WES64AW57%012]A<FAT3G)*+WEN,&TT1G5S.2]D36QM
M;U-Y0RMK=D%+<#0X:G=032MP2DDO8C=62U5!=TQA8F574$EM:V58)B-X03M,
M=5<U<UI:,V%31T\S0WI-<D)5:D%',T96,V)I0V$O4E1&1$DX5EDY-7,X:S98
M-6Y.<CEF;&UI1G%*54AO37%L:VU#.#%*2W0S:EAP)B-X03LW:G9I<5119FQ,
M<$YS='ES1B]D2TPV3U-'*S5#2FI);'A1>CAF9TA!=3!A165&4&9$859.=GE:
M.'1S2#589#142654;FQ&.7 P.4]5)B-X03LW4B\W<U1B,C=9,G1S*W=)9&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<GIF6$Y0+TYT-6(K9E1B-'!&2F5Y
M0WIT4CE8-4,S4DI7)B-X03M2=51,4E%X0TQ1:VMK-S!W<%9:25!Z375)3E%6
M6G)Q1UE2<SA2+S!*5F%8,7@V2W=5-6M,.5AR-F]C+V(K>6%9<6QA4F9N2VLY
M,T9B)B-X03MZ6$0X6BM-33$P3% P>D=*=T998V%%,6IQ6&]"-UEQ;3@Q="MA
M33EN6GE#-&$R=4ED375N=6\Q*W)%>5AX1&E#4&]Y.3!.9&@W,7A6)B-X03M$
M5WDO;D)!26M.2GI"1&-X>7E3;3,O95131U57-V=#;DI9*T522E!%+T5F:$]+
M;TM&=GIN3W)18U5N1VMM84E..5EA>4TS;RMU4WAF)B-X03LP=V\U8T)1.&4R
M2W4P>&9Z:TM766QA8T5Z9C9E,#1S=U%N<5<Y9E,T.'4S<69A-U8W-'%M;6\R
M;C5M,C-L=49D375:<FY6,G5R=C%Z)B-X03MC1S)*5S-66E5G-#!65BM)2VI$
M+T%#>G918EEQ9W198C@T,F1X<'-5:2MM-W@X;4YN>&9N3F-&2D4K26YI<TUS
M4%=M-CE-5E%%;B]+)B-X03LV-EA!2G5Q1F\V<V=S-G%",FDS,W(K,3!P:7),
M=DI-6&YL3E0Q0G9-36MR,E5T5W-&:T5(=V=43W1'.4DQ1$=-2V%B:F9R6$%H
M;4=+)B-X03MU>%8R2W5X5C)+=7A6,DMU>%8R2W8O+UH\+WAM<$=);6<Z:6UA
M9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B
M"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP
M34TZ26YS=&%N8V5)1#YX;7 N:6ED.D4X13-#1$9",T1!,T5",3%",S<P.40U
M0SA!-$1#.#,Y/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ
M1&]C=6UE;G1)1#YX;7 N9&ED.D4X13-#1$9",T1!,T5",3%",S<P.40U0SA!
M-$1#.#,Y/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP
M1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO
M;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)
M1#YX;7 N:6ED.D4W13-#1$9",T1!,T5",3%",S<P.40U0SA!-$1#.#,Y/"]S
M=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)
M1#YX;7 N9&ED.D4W13-#1$9",T1!,T5",3%",S<P.40U0SA!-$1#.#,Y/"]S
M=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X
M0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L
M87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z0S,T-C$U1#$S,D$Q14(Q,4%$,D)"-SE!,C$X1C=!.$$\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,#0M,3E4,C,Z-3(Z,S$K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R
M($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D4X13-#1$9",T1!
M,T5",3%",S<P.40U0SA!-$1#.#,Y/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3(R5#$S.C$Q.C0S
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM
M<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O
M<B\Q+C O(CX*(" @(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE
M/E!R:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I
M;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO
M;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @
M(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^1F%L<V4\+WAM<%109SI(
M87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB
M;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P
M87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A
M9V5S/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C$R+C P,# P
M,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^-SDR+C P,# P,#PO
M<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I
M;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @
M(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86PM0F]L9$U4
M/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86UI;'D^07)I86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO
M<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S
M:6]N4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&
M;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I
M;&5.86UE/F%R:6%L8F0N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @
M(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E
M3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-
M86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0
M;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.
M86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP
M1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P
M<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O
M9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM
M<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB
M=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( 4 "6@,!$0 "$0$#$0'_Q  >  $!  (#  ,!
M    " 8)! 4' @,* ?_$ $$0   & @$ !@<&!0,$ @,!   " P0%!@$'" D1
M$A.7UA05%AI76'@8(3B8M]@*(C$YMA<C,B1!0E$E4B8S84/_Q  < 0$!  (#
M 0$              0(% P0'!@C_Q !!$0 " 0,"! 0$  T$ 00# 0   0(#
M!!$%(082,5$307&Q!R)AD10C,C4W=':!H;.TP? 50M'A4A8D0_$(%V-R_]H
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M^['V-^(?RK<;_ [6/E<!E]W]V/L;\0_E6XW^!VL?*X#+[O[L?8WXA_*MQO\
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MPD2E#57MQ^2N#1I9V6D&3K.63O)52*=CEO*%E048V]Y*[JJ355QH.E0BDO\
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MHT)5U5E;QEB2H.FFD]E[P.J?*@
M               $H<\_P-<SOI0Y%?I!<!)='Z/V+'JO5>Y5XI
M"9:O^,G>?TR\4_U3YE@7R7J_:)30$
M                     @"1CT=J=(LQ86$A7U<XQ\?(RY5&'<?SM4=H;DM4
M[".K;E#/6DNZB:743146HJ0ZD>YDWCMJ=%?)3#=1D[;0W*F^6IJ%[*C5DNKM
M[6G":IYZI2K5>:>&E)1BFFCV.A6EP]\$ZU:R;I7W'O&=QI>I7,-JDN'^%]/L
M[NGIJFOFA3N=5U-7%PHN*K0MZ5.I&4$T7^-*>.
M                                 $H<\_P-<SOI0Y%?I!<!)='Z/V+'
MJO5>Y5XI          "9:O\ C)WG],O%/]4^98%\EZOVB4T!
M                                        (0U[_<3Y)_3EQ\_R?:(W
M%?\ ,>G_ *]??R[4]=UK]"G O[;\:?T'#Q=XTYY$
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M]Q/DG].7'S_)]HC<5_S'I_Z]??R[4]=UK]"G O[;\:?T'#Q=XTYY$
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M %3YEC ODO5^T2F@(
M        !"&O?[B?)/Z<N/G^3[1&XK_F/3_UZ^_EVIZ[K7Z%.!?VWXT_H.'B
M[QISR(
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M[V=S%;NIR8RR11S(2KA!N@DL^<]XX4313*93."8QC ODO5_V++ @
M                                           $(:]_N)\D_IRX^?Y/
MM$;BO^8]/_7K[^7:GKNM?H4X%_;?C3^@X>+O&G/(@
M                                   "4.>?X&N9WTH<BOT@N DNC]'[
M%CU7JO<J\4@      &@[F=6H#D%RGV]#9X::%Y (\8*IKE_L2&DKY>:1RGVA
M5;57VEJ<RFHF]+?0T?8H&D,I=*)(QMJC_P!96)-> @W*3]^W8XY8Y45\S7-E
M+986[33;Z9QY;=VEE@K#HRMHZ2O4)OVK<;=>4B@:+UWLBL,J'BK0DY#3\_BR
MZVJ]AGWVQ36&3DI*0ND3.+O*P]7<&25:MH1M&&RX(R27/C)-8R\O?/3&W3&
M5/5_QD[S^F7BG^J?,L8%\EZOVB4T!
M                     (0U[_<3Y)_3EQ\_R?:(W%?\QZ?^O7W\NU/7=:_0
MIP+^V_&G]!P\7>-.>1
M             $H<\_P-<SOI0Y%?I!<!)='Z/V+'JO5>Y5XI       ,9Q2J
M<6X&V$6JUTM]/7CU(]U+"QQ;6I5CR"$L:MJV K?$JI!>M&K>1+%*.C,2/4BN
MB(%6ZSY X=8UW0Z3)VR9IU.K56E+Y,%L5T?5^&81"]IGRH8:YG)TS!!#$G,*
M(%*FO).L*/'!2ERNLIG&,X9?<'B]7_&3O/Z9>*?ZI\RP+Y+U?M$IH"
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MZ%6OZD].HJ#IPC2<8*<J=-[TZ52NJM2C3:7)2G".(XPJ%'4/E0
M                                       "4.>?X&N9WTH<BOT@N DN
MC]'[%CU7JO<J\4A(,7S9T63:^\M2W^]4+4\WI6TU>MF6V'L:GUH]R3LU&@;L
M68@H^:D8QV5@P).IQ+DV<."Y>-E#85+@Y4RY<KPFLO.?+L"B:/LG76SHYW,:
MVOU*V%$L'N8U]*4>U05LCF4B5!%T9@[?0+^0;-WI6SENXRU65(OA!=%;*?=J
MD,;'#758!FH      F6K_C)WG],O%/\ 5/F6!?)>K]HE- 0
M                                      "$->_W$^2?TY<?/\GVB-Q7
M_,>G_KU]_+M3UW6OT*<"_MOQI_0</%WC3GD0
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MQ/DG].7'S_)]HC<5_P QZ?\ KU]_+M3UW6OT*<"_MOQI_0</%WC3GD0
M                                                 !*'//\  US.
M^E#D5^D%P$ET?H_8L>J]5[E7BD-$?,O4>]>1>_K.BKR@XQ/-":TV#KJAL^->
MW%]G0M2SLNY0-=D:E"[0:T1U4E[_ &>Q34FC)U.#>VF5AE&KZ.CR0YE%Y%JY
MY(M)='EI[I9VZ/KE?P_L#9%Q!L.P'-8OU V5.\>Y&RZ>O"6O5*_QPJ%WI5*H
MS-M5*Y-,JJ]B+HY==4JW:S"3U,U>5]1I13V.;)%*[1=%Q@^OGOOOU?U!70@
M T(\]]52*?(NW7[?.BS<H]-6R'I373$(;FBQXV,M3+0<"E'W.'4I4Q;Z0WLK
M^S6;+BRYLL>]DLMVSMI'.BI&03*ERQ:Y5AX:Z_+S9SG#?5;=$"TNC;UOL6@Z
MXV$_LD.O0=9W2[M)W2.FW6[2\AUM7T]M6HJ*EVI-IHO)-E(-+-96<C/M8&-E
M9-E7\+J(^F*O73TV<)-/'=+#>,9>>WTZ?7 *"J_XR=Y_3+Q3_5/F6,2^2]7[
M1*: @                                                   $(:]
M_N)\D_IRX^?Y/M$;BO\ F/3_ ->OOY=J>NZU^A3@7]M^-/Z#AXN\:<\B)FY+
M<MM.<4(:MS&V9*81S;GSYC7XJOQ69>7D,Q:3564=D;G<,T",H[#Z/(Z65=$,
M51^U(FFIE0W9[MEI]S?RJ1MXQ?AJ+G*<N6*YFU%9PWF7++"QT3/M>"N .)./
M[RZL^';:E5E8T85[NXN:RM[6WC5E*-&%2KRS?BUY0J*E3C&4I*G4EM&$FO7M
M8[)J.WZ%6-E421S*U.W1I)2'>G14;+&2RHHW7;N6ZN.V@[9.T'#)VCG)L).6
MZI"G4*7!S=>O1J6]6I1JKEJ4Y<LDGE=,II]FFFO/#W2>Q\YK&D:AH&J7VC:K
M;RM=0TZO.VNJ$FFX5(X:<9+*G"<'&I3G%N,Z<XSB\21G8XC6@
M                                      $H<\_P-<SOI0Y%?I!<!)='
MZ/V+'JO5>Y5XI#\\?*6F[SAN1&]4J5;.'R-:M7)?C?R+:-]H\AH>D7IA,:.J
M6OO0:Y,5=8F58V/GGE>,=19?.7F8UTW>M/Y5DQRQQRKKT:V3\WZ V$='M%WU
M=IR4V1L>5TU(6/<.^CWI9GH_8S/9M2A$B:VH-9+&+SC0I3MY'KKYGAV+K'?E
M;NFZ_7W:R8PEU779);K'?N#8H,0 !H2YH:PC8+D+R&W_ "4)P:Y U>,K^H&-
MXKO*BVS<79N.><UG,;78&&:)LIZ 1@-DJ).;9%M",6-DE[!)R*;%J^3RBHKR
M1>8J.)+J\KS^O[L8;6VRR"J>BQI<)%:MVAL6K6K1CNK[<V42Q1>MN-DM8I73
M^IUH:JP4 ^@XSVJ*UFF%JG3M$;!;F*T7$M4W+MBI&,B1JC02?5+?9=7U?_*[
M?QWR#WO5;F_..9G)/%ZAJ?$)HZ!XMI50U3LLU8SR-:+L[F+EJ_L)9BIU8L+.
M*+Y<$<1,:>>8(I$143FG!U3I(X%\EZOVB62!
M                            (0U[_<3Y)_3EQ\_R?:(W%?\ ,>G_ *]?
M?R[4]=UK]"G O[;\:?T'#Q=XTYY$25RNX::IY@Q%2C-E/;5$.*2]E7D!,5&1
M8,9%NG.),$I9DJ65BYA@NU>YBXU0_;997349IY063P94JFPL-1KZ?*HZ*IR5
M514XU%)I\G-RM<LHM-<TO/S/O^ ?B1Q#\.;R^N]"5E5CJ5&E1O+34*-2M;5O
MP>525O5Q1K6]6-6@ZU7DE&JEBI.,E*+P>V:@U55-(ZUJ.JZ0D\2J],C/5D7Z
MP<>EOUBG<+O73MZXP1(JKIZ]=.7;@R:2*6%5C%1122P1,O5N*]2YK5*]5ISJ
M2YI86$MDDDNR227T1\OK^N:AQ+K.H:[JM2-74-3N)7-S.$>2',XQA&%.";Y*
M=.G"%.G'+Y80BLO&3TD<)J
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MTR\4_P!4^98Q+Y+U?M$IH"
M              0AKW^XGR3^G+CY_D^T1N*_YCT_]>OOY=J>NZU^A3@7]M^-
M/Z#AXN\:<\B
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MV<8P(VWU;?J#S:K_ (R=Y_3+Q3_5/F6(7R7J_:)30$
M                                  A#76<*=(CR8,3^<K?COQY07R7[
M\)+*V+:*Z:2F<?\ $YT?]PI<]6<D_FQCJ&XK_F/3_K?7[7U7);+W/7=;^7X*
M<!I[.?&O&TX)]91C9</0E)=TI?*WY/8N\:<\B
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MZX[1=L:V)!_+6>2UY ;(1E*\2,E&Z\"2&L.<-&2JTDYC)#$FC_U*9(X[4O\
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M6MC6ZG\'^'=(^*W$/"FL\5VN@\*Z%5TR^A<W\W4UG5+#5HVM>TTG2;:E2_\
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M?3?<%[#$     $RU?\9.\_IEXI_JGS+ ODO5^T2F@(
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MXIUKB*-I"PCJMY*XA:0:DJ,%3ITH*4DHJ56<::J5II)3K3G+S/;1U3Y@
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M2;W<*=2TX>JSA'M&53YVEA.6[W+P&G/(@
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M458/\-%ELLWJ9%$SJ-7'=KD(<AC)XP8N<X%\EZO^Q6 $
M                                    A#7O]Q/DG].7'S_)]HC<5_S'
MI_Z]??R[4]=UK]"G O[;\:?T'#Q=XTYY$
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MLD$,OGZJ::9%7CGO7"A$R%,IDI"XQB7R7J_:)68$
M                                A#7O]Q/DG].7'S_)]HC<5_S'I_Z]
M??R[4]=UK]"G O[;\:?T'#Q=XTYY$
M                        2ASS_ US.^E#D5^D%P$ET?H_8L>J]5[E7BD-
M57,CH\-%W>*W_P BV].VM==R.:O(;(C:34=D7Z)CKIL775'1:T-DPJU3=IK*
M3#A6N0L:P/$H&F,NSX4CSE>*$&<9-86W7J_J_5 IKA9QYI/'_3L=BJP-NK4W
MM1O6]G;%A[O9;'9Y^/ODS3:ZQF8UT]M:R\XW-$ECD(HS)^IERW.R,5QC"W>8
MQ)/+?3;;;U8*[&(  UN;VUWT@L]R8B6NG.3?^FO':[5E^X](9:+U'L)UJ>X5
MF)ADL0\_BW/8>PSL!L!4DO+14^P?R;J&GE%*\]A6D-ZOEAFG#&Z;>5MEK*WW
MZ/IMML"J=":_WCKZ$G6.\^0A>0LR_E47<)/%U-4M28@(PC0B*L1F+J4A(-97
MOG93O/3W:B;A/O/1RDRF7!ABVGT6/5Y_L@8_5_QD[S^F7BG^J?,L0ODO5^T2
MF@(                                                   !"&O?[
MB?)/Z<N/G^3[1&XK_F/3_P!>OOY=J>NZU^A3@7]M^-/Z#AXN\:<\B
M                                                )0YY_@:YG?2A
MR*_2"X"2Z/T?L6/5>J]RKQ2'Y\.0.S.*%\YC\G*=SBY-["U[7M3RFL:KI+5E
M:O&PZ95T(F5U?6[A:K@\0U_'JFE[%(6:P+MROY-V19JQ;(,<).6J+3#7D65%
M<J3;SEOU]5M]^@+8Z,#:$??J%OFM5+;%FW;JK5?(";INFMA7.3D9NT/=</*1
M1[1'0LI-R[1C+S!*[+SLU&1[Z4;$>8CTFS/J*T:-4R2:PULE\JSCO]W_  !L
MW&      )EJ_XR=Y_3+Q3_5/F6!?)>K]HE- 0
M                            "$->_P!Q/DG].7'S_)]HC<5_S'I_Z]??
MR[4]=UK]"G O[;\:?T'#Q=XTYY$
M                      2ASS_ US.^E#D5^D%P$ET?H_8L>J]5[E7BD(4W
M#SNX(:<V/9-;[CVQ1JULBMFBRV2$EZ=9I219&EH2-G(OTE]'U.2:+Y<0DG&N
MTLHO5^[17324RFJF=(F2BWNE_% QK@)OF)Y!2/+2UTVX-KGJV+Y%FA-5OV$9
MZIC6E13U7KA\HRCVBL9$OBM\3[V97R:1;9=9665ZCY0[G&$EC"^BSZ[@V(#$
M     $RU?\9.\_IEXI_JGS+ ODO5^T2F@(
M                         !"&O?[B?)/Z<N/G^3[1&XK_ )CT_P#7K[^7
M:GKNM?H4X%_;?C3^@X>+O&G/(@
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M>_W$^2?TY<?/\GVB-Q7_ #'I_P"O7W\NU/7=:_0IP+^V_&G]!P\7>-.>1
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MRY*0B:#5KC))-8QTR\/*W[?WV6.@/;ZO^,G>?TR\4_U3YEC$ODO5^T2F@(
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M:JTJ$Z#N*'B04:D:<Z=1QGASC*47"<4FU\K34EG?9[;['1T3I@
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M,ZJN!?)>K]HED@0
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MP/3:O^,G>?TR\4_U3YEC$ODO5^T2F@(
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MD<[9^KPPV5IKE5T-%:J=7L-VU]Q<U9NFG[3V9$13D]8AIZ7UAB/Q)RC@V/\
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MZ/T?L6/5>J]RKQ2          $RU?\9.\_IEXI_JGS+ ODO5^T2F@(
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M8]5ZKW*O%(          3+5_QD[S^F7BG^J?,L"^2]7[1*: @
M                                        $(:]_N)\D_IRX^?Y/M$;
MBO\ F/3_ ->OOY=J>NZU^A3@7]M^-/Z#AXN\:<\B
M                            "9)#0+Y[M4MZ+8T"1)K"TLRK<S=8TR1V
MT,DH6.1<8-Z/EB<Z6$L+&,51)B<S+#=3'4L *;    !*'//\#7,[Z4.17Z07
M 271^C]BQZKU7N5>*0          F6K_ (R=Y_3+Q3_5/F6!?)>K]HE- 0
M                                                 "!6[Q*@])%+
MH3ABM&/(3C'7D*/(.,]VC*6[2]RL;FTU5D;/5A>20JMQC[+E(O6;T!!VIGLX
M1Q@^Y:\?0H<BS*QU"HZR6[C2NZ5-4ZC751=2DZ>>G,UWV]AG2EK'P.MIVB\2
MKP9Q[>SU:C#YIT--XITNQAI^H55_MH3U#2Z]CS/_ .:=);\VU]#3'CP
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ME)4'3362A1U#Y4
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M?QENMO7$9ZJX/7C,!_-ZYS(;=@<3&,]6>QZL*VJ>66?OZNUZ48O5CKSCK_H
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M==7W?=FJ>C]YU_U^_L]7_P#0!W7OENB?D@VUXMT[RJ 'OENB?D@VUXMT[RJ
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M]_5U=?W@#B//XRW3?:;^K^#^S,E[W'I7IFVZM@W<?^7H_<53..]_]=Y_)_[
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M-4LOY1R[?KX,X<JG,!XW[K_T.OP$OOCUN'S< 'NO_0Z_ 2^^/6X?-P >Z_\
M0Z_ 2^^/6X?-P >Z_P#0Z_ 2^^/6X?-P >Z_]#K\!+[X];A\W ![K_T.OP$O
MOCUN'S< 'NO_ $.OP$OOCUN'S< 'NO\ T.OP$OOCUN'S< 'NO_0Z_ 2^^/6X
M?-P >Z_]#K\!+[X];A\W ![K_P!#K\!+[X];A\W ![K_ -#K\!+[X];A\W !
M[K_T.OP$OOCUN'S< 'NO_0Z_ 2^^/6X?-P >Z_\ 0Z_ 2^^/6X?-P >Z_P#0
MZ_ 2^^/6X?-P >Z_]#K\!+[X];A\W ![K_T.OP$OOCUN'S< 'NO_ $.OP$OO
MCUN'S< 'NO\ T.OP$OOCUN'S< 'NO_0Z_ 2^^/6X?-P >Z_]#K\!+[X];A\W
M ![K_P!#K\!+[X];A\W ![K_ -#K\!+[X];A\W ![K_T.OP$OOCUN'S< 'NO
M_0Z_ 2^^/6X?-P >Z_\ 0Z_ 2^^/6X?-P >Z_P#0Z_ 2^^/6X?-P >Z_]#K\
M!+[X];A\W ![K_T.OP$OOCUN'S< 'NO_ $.OP$OOCUN'S< 'NO\ T.OP$OOC
MUN'S< 'NO_0Z_ 2^^/6X?-P >Z_]#K\!+[X];A\W ![K_P!#K\!+[X];A\W
M![K_ -#K\!+[X];A\W ![K_T.OP$OOCUN'S< 'NO_0Z_ 2^^/6X?-P >Z_\
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MP?O! #V8YV?&_B9^5K<'[P0 ]F.=GQOXF?E:W!^\$ /9CG9\;^)GY6MP?O!
M&#Z\/T@5R@'\O-;'XLU!XTN^S:LC$O\ C!N-==U%479-LI,#9R'4Y;,C%97:
M#KT=<XU'")R-XZ?:H)NWZ:17S@'_ ,>W]C./9CG9\;^)GY6MP?O! 'G6X-&\
MT]SZEVCIZQ;]XOQE?VOKJ[:UG9&%XN[63F(^&O5:DZO)O8E1]RW>LDY)JRE%
MUV)WC)VU*Z32,X;+I8.D<]TUW"V:?8OH                =#.VJL5?U=FR
MV.!KN)=\E%Q.9V8CXGUI)K?_ *8Z.]8.&_IKY7__ ":-N]<*?^">0!WP
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MU<E-,W(Z+;3S\46L&:J+8;$<XGC.\166YW&<($6P[[LRV<)8-D^<%##Z8W[
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MEJSBG\S-QD8RDW;TF5&36/=/72"#UR[3QD[5!LHHJX)C)DBGQ]X8?;IU!D0
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M6'&J'=%/*^LDL?\ XRHU*4[O':3:Y*WY<;\KIO*?Y/-G.WEGH^^?7 /TVCA
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M6T#[I(0T,?-;3B'<PUUY[9Y3/AN:2,@22SWV>P,DWA-YY^6>&\N6S36/3?\
M=GZ ^Z.;4,][@ZC((4TW"''2[;$CFD4\+#FTGUI:=1?0T @V6ZZAFA8NJLJ>
M/B"$S4\R67A$&_\ *J7##Z[\W)GZ^;R_/.?-[].Z!M?Z*-54_$I-%DH=:BLM
MT;Z8:G4*H99CG6+3:EE2K9(=8QCX5A4%<2+>+RD<[<C5)-)MG"":9<83_*^N
M-_7_ # -DPP    ,YZL9S]_W8Z_NQG.?N_\ 6,=><Y__ )C&<Y_[ #\ONM&S
M/4%[BYW4]NXZ<F-D\E:SSPLC&_ZWUE)0/(#4-\B*I?[<TFW=KDIMQ:W4;)S;
MP](<QMBJ=/.S,JR0@\R^3>E2'-L^JDN5Q\UAIM9VZ;?1OZ_0>+,#0D!I]RMQ
M?-#MI"9Z&568Y#'UXHU[QQ=\["KJ-BF+T:%-UYV&BR=WYNN\E\^TB,'A^GD^
M(U F"'EM<V_SX6>O3;^/EWSG=[C9AP@LVB]5\CN3,IK:RZTHG&F+X[\.W]FF
MXV<KM>UA%[.GH:4B(YP\E?2FE;86FQL7;%M,**KHRLU-NF6)3+F7<I=O&2;4
M4T^;,ML9>%U\O+"^BWP"3=H8@C<@MS6%]B$^UHPZ63CI!ZU<K&:8V<EJ%2 K
M*%>BXCM9Q.XUU(U%28-+M&^/9Q\W(56435R@V.2K.,)_+R-[],]&_/H]OX+?
M8'U:HS#EWUI.P1&(+/+J1Z4WD[#;+72.T_U*7U:C7[2E88JPX)GU]G7L;64H
M4\4T=8S7H] YU8HB)UW)CUYQT?+R+RPM^C?EGZ^>%UV!R>C^Q74MO=&G+U+U
M/_K?;*_S^4YD.XTS3V^D_1[&[=5\^Y/1\^N#N&]Y)&DKF;,7!L8*@6.SE B&
M<)])IO9<G(M\=,/E\MOOMOOD'Z:1P@     T.=)9&O++S#U%7KA*:-C=;-N)
MN];#6"\E*^\L^K7M_CI1JI:6<5%(VRFI$OCNIMX)@RG4Y=23JL,^D)^&9+S3
M.,P.2"V;6>JSCKC;'D_KY;] 0SMVS:UV+2]D7#:=0@*"JWZ*C14[Q7I]JE'<
MB[IDRI:GJ93ZFE+:\=V)Q,%M+:'9QTRT>N+6ZKIV+1\\<,UG!5,DFMEE_.^;
M^Z>,>23QW0,CY&**.IWFC8-DXC,\OZ[*=&$7C>M.9;$V-&RKUK0G5D1U5AUU
M3*1'UA=7-6Y)5K_;/*>D^N"=\DVP4LXCC:+Y\XV79<W9=%OA8Z VB](Q;==7
M1/BG7Y6S4FT:EB>>VJJ5R%C%9N$F*O#N6D!9Y-A3ML-<.7,=&1WK1>&>3$#;
M4T&G:6AE)-MA)=KD^$,K+7_B\??&5]<^:W!K7U:A0).T<2ZKL].GN^$A.=G2
M0M:JQNAXM72ZM5AZB^4T@CURYLU=2$;61U?/9'"AS,O3\.BLL]K!RYS\I/+Y
M^6/3KEMYW7T2_P P#RS6Y:I8=5<;8_DWF&?:ICNCPYP/=+XV>=MF,+;HW<=C
MCZF\KGK\W<^U\;J9K5,U%9AU3+.+1A',0=-<K105YYGCSG'FQG&&DWG&^&\Y
MQL]\; W8\697DVXXQ\<EU4'#I5?0^H5E',NFV4EG"BFOJ\<Z\FH]ZWJDBJ8V
M5'IW><NCN3*F<9RKDXX9=7ZOW!LK$              8+=M7ZSV7B&+L;7=%
MOY:X_P#6M>Q=JE 6K$#*?[?_ ,E#8G8]_B+?_P"RE_UC'N''^TG_ +G\A>JI
MM=&UGKAXR#.OZ?T$          !T<Y6*U9RQ1++7H.PD@IR-LT&6<B6$L6&L
MD,H=6(L$45^W<8CIR*54.K&RS3"+]BH<YVKA(QLYR!T,IJ_6<W<H;8TSKNBR
M^PJXW,SKU[E*E /[E M#96R9K#6AW'JS<6W-EPXR9!B^02SE=;K+GO3]JY>,
M9>.V=@,:OUGB]YVCC7=%QLTS#U4;8N*C 8O>8SN,-?5N;=B/]H,L/1L8;^AY
MD/1^XQA'N^[_ )0R\8R\=L[?8&"Q/&S2C&A.M:36O*E>J<_NEFV&_A+]5JQ:
M(MY<;98I2SRLV:$>PN(!JY)(S#LD<6/B6:4<S[ILU33*4QCN9YSEYQC.7TQC
MV!F5KU)JF^1D!"WG66O;G#U1=LYJT3:Z76[%&5IRS13;LW$ PF(UXUAUVK=%
M)!LK')-E$$4DTDC$(0I<,M=&UGKN#D6C5VL[O*UJ>NFNJ);YRF.L/J?,VBHU
M^?E:H]P=)7#RM2,M'NWD$ZPH@@IAQ%K-5NVBD?M]I,F<,M9PVL]?KZ@SH0
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M>K0*#ET;!W3A&(@F;"/27<GQ@[A4C<JBQL8,H8V<=8-M]6WZ[@RP0     &
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M#48"'M%H-E4J^36*?CX]O+3><KE*MG,F[=9[TI5/^>,&#+QC+QVSL#.A
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M%(0N,%*4I<8P4I2XQC!2EQC&,8QC&,8QC&,=0@/D
M
M
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M #JMDG654T%#_P QTBD,;[\Y'$#L
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M%LXZ,+(R2B1GK[$='L&.'2ROHC)JW[M!/$';
,            #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g107876g69c93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g69c93.jpg
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M9BP)7?5&W_=TLRUD:?PD<3W*C?&5IV.O0_7Y73,X;MTZCZ_.RM3-:W.ZX/\
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MVGQ:EEPR<Z!TMWTTGBR8"P%]R06-V,I*Z35MG6W->%;4]@#;55D-";76=:7
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MS%\$D4@:\<TG:7V3_3#.$&WUIJ?9ST8<6/7B[B>);+L?K\'/,P<"#1I']/\
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M!:X$7!!!U5(=%;_6&]Q7/4_S*T=S]=I(T_ED@8:R1!#3?'^C)WLG'D8OS_\
M5PTOPWZ6N\LW1I=SV'U];+"[5P;RW/Z?757LB(B?")\(G\(B?Z(G_P /**Z>
M$3PB>$3PBKD<0*WZ!?MNH83)Z6LI'9T,V-DL(X!\9+K"T#'E1T;B2+")X!!C
M&++#$) /]<;)7-DMLT6YWO\ R!]W)5W<;\K6_F?CS7Z@$#J>A#BTD4(L5MG+
M.PT8 C&PBMG$/JX*6TD'C1L41I23V@BRHU)#81U^XK_PF*R.6O(Z>5C<>0T\
MK^*6L[3F-1TML?Y*Q/(5D\(GA$\(OXYK7M<Q[6O8YJM<UR(YKFN3X<US5^45
MJHJHJ*BHJ+\+_'A%1?+_ *LIK=QS>1SD#"*;I<XURJOQ4V*Q)/ Q7?ZL%=,%
M&OT_PXA2WJB*JJMW:AKO<?KXJC='.;[Q]>5O@5=I90P(I)ID\0H88\Q19,[V
MQPCC#QNFGGFD<J-CBAB8^21[E1K6-5RJB(OE +FPW.@5B0T%SB &@DD[  7)
M/@!JN6WZ=M<3V/9>Q/N[I!Y76':-W8XKF2F,5)JGD>'(@  @$5?XC98$@UU;
M9,:UJ26&/4GZ6/)E^K<J2&-BIP?[-H<__P QVIOY _/S7-8 UU7-7XS)<NK)
MW0TU_N4D)RMRWU&8@-<-+NB)L"2NJ/FFNF3PB>$3PB@O4;+34O,NBW&*%4[9
M5.$UUED@FP(2XS3 Y^P*H16CJUR$*1:Q"0I K7)*K_M_2OU?"V8 7M#O9+@#
MY$B_R6"I=(RGJ'PB\K8)71"U[R-C<6"W.[@!;FM?^*<4]?-%Z^9-$R6,Z!G>
M@XRKTNMUNEJZR_N=]<7]9$??ZK6:"PBGLCM ;8SEDEEDEM*IBF_AA_MT=>..
M-DDDD$CN\YI:ZS6BX#0#W6M:-  -AS\;K1HZ.@?01#LH9XYX6R2RR-:]\[Y&
MATDLKW N,CG$DDF[#H,N4 9[T^N+*ZX+G)S+>PT557Z3I.>P^FM293;/3\SS
M/2-7G^:7YQLZNGL);/#UM%/':3OEFN!UAMY)IGG+*^)A:0Z6)#2X"U@\M!<
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M+<71MW"S:6&VG0[&_37GIMJBN(GC@4^DP]FNCTDE)B.=](PXH1U_I+/4E'=
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M=++(]?\ 9K(V.<Y?]D1?) )( %R2 !U)T 5XV/E>R.-I?)(]K&-&I<]Y#6M
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MZS&3MZ N_EKJC]LFT6=NZ@NSN;.GKH"06S1E3A'U91TY'7MIN0;&]K;WM]?
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M64#7]1@8%#1XCC+Q8PQ&DH[_ 'JF:P);S.2\8-ON.DVRDCZ5]"L3>">$^/\
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MCFN15145%1?A?"+#:33YS'4Y.AUE]49FA"E!@,NKZQ$J:L6:S/%JJZ(@\Z6
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M6-WTRP3,D@GCCGBDC;I$%I+7 @@V(.X*ZJ*6.>-DT+VR12-#F/8;M<T[$$?
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M ',TCO/318CZ#.&\1[W#?IL]'.(L=JQF+UO[!JK';/2.GQ"=IV!NS0_!?O\
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M5SBC SR1X:Z@F)>^5)Y\_6UA9<<BQV!1R_+U\ZOQNOQ =G+((J<:-IJ<=E"
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MTAUKANVIZG^7U[RJ6<[?0=!S^?YJW<WC<QDH$@S].& JL1DA+8_NG$(GQ_\
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M<URO0:RJI73K$-(_X18XVE5T+?ER4TSOCSYZQ[^CQ18=6R\2>B+B#$?1KQ,
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M)-Q=B^$57#HIN&:3#J2HPSB3UZ*0XC72B'UBD-"/M81$9*AF9WL^IYW%S:R
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MD2N>0::5),:>7+,8:1.5-+,_3<YSW%SB7.)N2=UU,,$5/$R&"-L448RL8P6
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MS/&_,@,SU.0Y]9K"G1[=.UL;'5,@!#26Q-/WI+;Z\F];'6^EVKF<9FEK:F'
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M?D"I#,'86YA)=C:G94FQM3"[,DPF7P<0:P31O:&M=-3PS2,8T,8V21MRYC
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M$<5+45]];P _<R,$#7YFR$EO>8'M+6YAJ,SAF) .OL@'0&P)6I5/Q>>F$,U
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MJZ X W&MFY=1SZ[HL#TST$]G]M5<GGL\WS>[+I/4VR]1M;C,MN,U@<A6I6[
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MS,QO-AE]Y<4PCLST.@YK$\G6EXN"GMK?3S30A126=%7:#.9ZRV55'):8T2_
MBE)97*=N=P"-;@G9%YKKVQMA=GQ/'B<,ZU3'],[!!SG0A[:DH*8NAHK'D?2>
ME5.HJC@]>?G;K[SL)*ZRK0;DVVH*>JU,%]4UFGCSE%>LNCC<:"^G^(#^?Y<K
MHHYF?>G".Q^;N+JDWNI^SR_DW3NC;C'<^93XC'9CK+[$3/ZBVK+G;VUU75LQ
ME-:S&4%*=N-#25PDQI33 !Y[!&7Q&Y %]21];Z(K3%]K,&;NZ+&"YCH\U7J>
MGZ?C69Z2S-A.YS>=)Q(>J)V&;#M6W2W</]/$8G55!%O8YT*AL;JCLZVAM+:<
M(K[,938G30 VOK8VL?GY\T7\ZW[6X/CFFU.:O\OT>\7 \WH>O]"O,EF@[7/X
M7F=]<;6D36WYQ=U6SO&JR,#HB[.II1+?1NJQG657368H=M)6R&DVVU) \2+:
M?,(O/8^W?,:_:6&0;5[0\2OVI',%VE=4U,^1,ZF. XQO.P'R7T.D)NR2VIG1
MK=,TW%OU\C,G)JH[]5KVQ8VOX7MK>U[7VM\]D6-%]V>$V#WQ5EI>V<[^6\GZ
MU70!4RR/NZ+M-]4YK"TM.LA441>M+MM)D(#Z-TD+JYNRR\DQ*I9I]J<I\M2-
M>1&]_#?X%%[.R^RU-Q3N''L+M+"JI<%T7FW;=-8W,U-HK>[BU'.]#Q*NS==7
M?L2&L'K3JWH6I(MOS*<ETI%?4?C6%>D9$%D#;@D;@@>XAWZ!%3D7M]L=GRK<
M7_*Q<1=[V^]G#O7?U_AN*K3!YNZ^G]HLWZ/95LMK77Y$.6QD.WV^CCKIZ&0N
MJRLHX8X,LGWGSEL=;VM<VM<<M]M]!YHMMN+]6J^O<KY_T>&)E,1L:(8FQSY4
M\:&Y_4B2/JM;DB4<_P"7V>4U0=KF[%D:O1MA6SL:YR?2JU(L2.B*O>3=CW^T
MZ_WG"[O$U//J/FH?-#\=#)>"W.DM*G:/WD,]SK#*TLG.5LI\F4%(J*&H(L7U
ME>0Q]K<$V1LU72B!8$&][WTM8Z:>.^Z+9>.2.5C9(GLDC>B.9)&YKV/:O^CF
MN:JM<B_[*BJGD(OWX1/")X1/")X1/"*JMAC^0T6%>5K,1C%PW,LW:6@@!F8I
MRJG+YZEKOS;%M16RAN% &AKZQGU#B10QOB&CB5JL:B)()OH3<^.Z**7G9>6Y
M'0YNSL:>P$UO2\IS_P"@P?.C_O[Z.YZ5EL!@,]I2VRL*A^QMNU$25=9/.0'5
MQS;NTC>.D!SBUC[A?\B3;W#\D6;U_2N8\DU6-RUD.VNTG;=A*.&/1TK));&V
M0:EHB-7JYQ6Q(/7,*(Q>-DOCW32.M;W(TC?K:3!]A8D$]$4*[DOK?R+FSKOJ
M'/\ (SXP47'8\2C$PU1<S2U&*CO++,U-72QAI\TG.*,G9:J* =(PL?EQM?=0
M,$"CLG/"Y.AM[SS_ %T]]D5&ZRD]6ZKV&M3KH'07N^YK38L.BYJ)S+++E6S[
MS(G\BRV+QMXW 5EM<QRY?16,,N'L>B$<YH1M7:ZDRJKXZ2YL\O89K:;'<Z\M
M;G];7TLBEM19>IR/RM=6\*J ZC26 ],7<?X1T8N>S>KWA5OQE<EJ[!P[?R=)
M>GY<_G-^)3QZ,8(8*J@U)@&>L<\<=%G:Z_/>VMQ\;CWVU!13>WV/K9=WUICB
M,IE=33]-O,E:[/8 YC/7'/;G:&XX/2\]EUNIC5PUMJ"L1DZ.WS=NUEI^S4XN
M+F*M:=MUC4LXU'46TZ$:Z^6I^)/BBEF(EX-WCG3*S,Y/+ZGE>4T1F5H:XW&B
MBY&,[%_-1)/D*FPKAQFU%7+(;2UEK6A#@E0P&I4RDTY$));4'>Q/CK[_ ,T5
MP469S>7A)&S5!2YX<V4*<L>DJPJJ F:MI*G,UTDT(,$$<CP,Y04="$YS546G
MIZNM@^@, 6&*$6<\(N7_ +&?^ _4I] [,A?I%-S?>:F%SE^&_EKA+F)&I\_Q
M]3I+41GPB_*J]B?'\I\[D6M)4@?BB)\LP^>BYK$=.(L"<=C'6M'GV+Q__D.?
M^O4#S372IX1/")X1/")X1/")X1/")X1/")X1/"+BCQC$]I_4,_Q#[KI/9[L7
M&^<0]%TF+Y7SGC-_/E!1,YG7#-BM[XX6=L5S8FM,;%/.2).4XR$Z:$P:NE"J
M@]][HZ7+&(8Y'9&N>^09M7:V Y 6_(KCJ."LQ[MZZ7$JNDIQ420TU/1R&)HC
MCL,[R#WG.OJ2";YB"&D,;B_9#UCR'K#S@_H?1O?+W-5GU.!S69"ZK-)H-EH'
MQN>)14(;_A99Y%1'F&/1 ZP3ZS#)&1M:V28IWRO#6TU/XDQZ-'4ZJ,1PV'#J
M=U148WC%O9CC%5>2:2W=9&TC4GF=FB[G&RGOZ6OIMT?B06E[CU&\U=%H.JUZ
M(%RPZTFF<'3$&_N@>AZ,U\4*6.ZF^Y(H4+QQB:$0^S_<6MM+@NLIJUD[),L;
M TAGWP-";6LS^Y^=A;;7-PUA%11B6MJ7RLDJFZ4SG$D,+LPDJ+@9IS?06!8'
M.S=YY:SL+YHKK$\(O&77A'HQI@L)*1_5]"2L1WTH_P"/K;_/_I=]+%<U?EKG
M,8Y45S&JEFO>R^5Q;>U[&U[;>\<CN+GJ5!:#N+_ZKRBT@(TC9WL<84QS5C,-
M2*8J-D<3(8HF2I$SZ8XHV(C/A/J5[I9I'/GFED?=TSW#*#E:=V,N&DDW)(N=
M2=^5K  -  @,:"#N1L3J1I8#W ?SW)*RWF)63PB_$D<<J(V6-DC4<UZ-D8UZ
M(]J_+7(CD5$<U?Y:[_5%_E%1?)!(V)'+0VT.X]Z6!W%U^_(1/")X1/"*D>Y_
MWT^,';_YD_0\\V-/]_G\>S;\I_O_  Y[4_C_ .;R[-SY'^2H_8#F3]?FJ_\
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M:L(2O0&PJ=*-C&Y3FA21P->S&\TLN7<GN<G'$J%)8\]J9RWR2DF22"XF^@U
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M5<]=P'^*W,MQS22V_9 ]YG;#)V]@@'[DYM!>Q?M^B#C$_, ^9;.BGL:R*?\
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M#06O *J"Q@H[MO$:CU_,$@ N\F+6]!@[:7UR"M=KBW4=OHP*^:7!"Q89=M+
MWMS\R>M]+>019OVJT F2]BNF7[^N[CE.G@]/<I-RX?(1B_.^Z=5]![.7F<W
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MM\UO,MSG1LH)[#:@1AC4NFV>>B*,UCLR,0&7.772',K[%!64[W'+KI<$ZZ=
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MJVBHZD68ZUN+@X:LJZT(=JOG+/L#9811!H6(KI9R)8XF-3Y<Y$\D D@ $DZ
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MDNF1JQAG;S/4EHJ.^/CYJ+PZMM&+_*(J/#:K7?VN1'?QY@=!,WVHGC_I)'Q
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M@%&^%D_W5^?O21/@EG^I?RE):GVUL'$:'4=#]?JJ%@.HT/U\/<H\W6]5Q?\
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MG^BL<U4_V5/)N1L2/>HL#N ?<H9/QOF9+E=)DPFJO\_$!-B*W_[#13(6I_\
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M*F_ [^+-_F)_@USS_E%E_P!6:_\ []X[1W4?NM_1/4J;\#OXLW^8G^#7//\
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KA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g107876g69n61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g69n61.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ [@)= P$1  (1 0,1 ?_$ !X
M 0 !!0$! 0$            (! 4&!PD# @H!_\0 7!    8" 0$% @D&" <,
M"04  0(#! 4&  <($0D2$Q0A%3$6&1HB,D%8EM475).5TM<*(R0S45=AUA@T
M0E)QD90E-C<X0UEW>(&UM]@F1%-68I*AHK(G-7)SH__$ !P! 0 " P$! 0
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M"W7N%VGO^.Q4](6=A+)&M9FNS$5/P[TGB,Y6%D&DK&NT_P#VC5\Q67:N"?\
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M<$A>RV6:2@@JJEMNE55MGJ!XGM=3J;E>9J^),>KK^M8O7R--[QMJ9(HC??\
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M23(4"D33*4A"%#T I"% "E* >@    ?4&>H8QD;6L8UK&-%FM8T-:T#8-:
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M<I:+LEG) /2.,DXV:CV<M#OV4K%R+=)VPDHYTB]8O6JQ0.BY:.VQU$'""I!
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M%< C!1E4EU6[-4Z;]ZYF5G!$JVUFEDW*2 Z?SJ+=1_/3?1,[?'G<6-QEW)Z
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MM[K9).Z2#D<]V<B][7U_81GFEYU?EBLBWQEG:\W-W._[M\:>S[ZUJ#A5?Y3
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MI=&[>$>E" F086-5M$K1EZ$$6N2-0!XZ?]=QIJI,H %VN!)L&D ..ER1<@6
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M'+7G3H1WHNO\B47UI'6]FVRAI:+<&K:Y9@UW<[.=:C217BA<>(C&C<&:R)I
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M*=1$!'H JID.=,![Y"F,  /ZV>"6/  )+7  O=&"2" "]H<Y@)TSM!<W< D
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M221DQRU-;7@=^-]O=\>SPX#@.#<&4TC7U#0W$<6>PZ&1Q>Z-CCN1).^21K7
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M4LI&O6;*.._.J0HE\0E@VX<;@6M:Y %R>9.FP/,:V'-8WORN8VUP[,38%Q
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M4G$Q S\Z[CI)\X\NKX,90?9-^]:]Q:Q%P2;#:QUYB]@I$CA;.T"\6>PO?-F
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MQ8F5YC($<,;(PV4!C72 A\N7-(),V=KP&-:TM(+6W;SNAIP[VGN+KLU(;:S
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MJ=<9U*<U/;&T84MQE"JS+J'4L!D"#(.\$\4,+2&E[WNDE#"7 !L;'-:TN:6
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M1?BBF1!E'0,WM>'CT"D\.,1*)R%Z;:C"ZS]8'4<QW.@C)_: R6ZEPC/C?5=
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M_95G%$U&]L&.89444AT[:-CC$^V[FL?8E@^U%+/?DI=@T<[3)AU7%4,WR.<
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M <P'Y6M(=_;>\]"-U57;L%^4>P0CK/O?EA)<BIAH0KA6HJ62R0C".<]![\?
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M9+0LJ9<-^3&S.ZKNO?Y:]%K]#+UBAI+KE50-])F[*S3J\,10H")0640L! Z
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MK^$ <-TNI6FNN2#\_J!03IVN$2F'ZO5;;!3@'](^&(A_FCD_1%1S?"/[S_\
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M3(>5J+"VW/QQF_QM\%<>BWB'ZU7A#!S+JFK/X4)'FODG.&LO?2%U;LN4,;Z
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M@3C@,;KU$"J3[^XF]!].^) $?>!2#Z!LQ_T:8L0<'<6>D3BK'S>[PPMI[\R
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M02+ =,I2&\0IN\0I2CU*  #LI/L^;?FB^_C0>S]#W<C*8'04S!_Z/W3T,B
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MAH9[(+$80\7&1+$C:.CV;5%V4A^KYM^:+*0[3?L\P;@S#D'10:%7!R5J%:N
M-RN0<>;!P"'P3\(%P=_RH%0+X@./X[O>)\['92?9\V_-%[+]J!V?;H$RN>1=
M+<%263<)%7K]T6!-=$W>273!2JF BR1OG)J%Z'(;U*8!QV4GV?-OS1?!.TZ[
M/9);S"?(:CIK@1%,%R5RY$6!-N19)NGXA:F!^X@DX731+WNZD1=8A *50X&=
ME)]GS;\T5CKO:+]F_4QE3P&_J:Q6G)N<L4JY-$[ >/'LO8I)65EG"KQ]77+H
M$5WJHF08IK$8,&Z;=E'MFK)JV;I.RD/U?#=OS1>"O:'=FLM8X>UJ;VHQIROP
M4Y6X5P$)?"MHZ'LDS6K#-MF\86MEBRJOYJGUJ04>BS%\FO$-A1<I%%4JCLI/
ML^;?GXHLC-VG?9[F,X,;D/2#&=E.1T8U<N0F<D52205(X$:H(K%41;H(G*H)
M@.DBDF8!(F0"NRD^SYM^:+^?&==GL -@#D-1P!DJ99F'P;N/1HL8JA#*M@^"
M?1!4Q%52&42[AA*HH41$#F 792?9\V_-%Z*=I_V?:RJ:RO(NEJK(E,5)52O7
M0ZJ13*(K&*FH:J"8A3*MVZI@*( *B")Q 3)$$KLI/L^;?FB^2]I[V?)%DW!.
M1%)(NBW%HBN6NW,JR303$.+5-0*H!R-Q.FF842F!/O$(;N]2E$'92?9\V_-%
M_6W:?=GTS3%)IR*I35(RBJQDVU>N:"9EECBHLJ)$JH4HJ*J&,HJH(=Y0YA,<
M1,(CCLI/L^;?FBJ/C2> GVDZE^I+O_=;'92?9\V_-$^-)X"?:3J7ZDN_]UL=
ME)]GS;\T3XTG@)]I.I?J2[_W6QV4GV?-OS1/C2> GVDZE^I+O_=;'92?9\V_
M-$^-)X"?:3J7ZDN_]UL=E)]GS;\T3XTG@)]I.I?J2[_W6QV4GV?-OS1/C2>
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MKVXJ^YBZ_>.05]FM@[WEK%2[S2YVI76YUC6%/TFSV';H2,6?.)RF0$.FXJ-
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M- >ZNM$5:!9RMDDVS<XE3<NV,4NU;**))N%DC*$ TAI.P^.P^\Z(M;Z*Y_\
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M0LO%_9MA1M4O'V"SI3FF]$RR5DGHE@$7%S<\F_V8X+,2\;& $<PDI '#QFP
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M E,4#%, @)3  @(#[P$!Z@(#]8#A%_<(OX4I2% I"E*4 Z 4H 4H!_0 !T
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M:QZBC@L>9DHLBW<+ I9I .HOIYHN:_\ @:]K]_S@]3_V&3_=]ELS/L^01/\
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M4AQW6ME;0KU\JFC:1?*[?]9R"S5HK41:-9ZR0%EC6DRW^#,\O D;N!\,P&&
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M^7YHGRA'4_V<]A_?*M_A^.S\?+\T3Y0CJ?[.>P_OE6_P_'9^/E^:)\H1U/\
M9SV']\JW^'X[/Q\OS1/E".I_LY[#^^5;_#\=GX^7YHGRA'4_V<]A_?*M_A^.
MS\?+\T3Y0CJ?[.>P_OE6_P /QV?CY?FB?*$=3_9SV']\JW^'X[/Q\OS1/E".
MI_LY[#^^5;_#\=GX^7YHGRA'4_V<]A_?*M_A^.S\?+\T3Y0CJ?[.>P_OE6_P
M_'9^/E^:)\H1U/\ 9SV']\JW^'X[/Q\OS1/E".I_LY[#^^5;_#\=GX^7YHGR
MA'4_V<]A_?*M_A^.S\?+\T3Y0CJ?[.>P_OE6_P /QV?CY?FB?*$=3_9SV']\
MJW^'X[/Q\OS1/E".I_LY[#^^5;_#\=GX^7YHGRA'4_V<]A_?*M_A^.S\?+\T
M3Y0CJ?[.>P_OE6_P_'9^/E^:)\H1U/\ 9SV']\JW^'X[/Q\OS1/E".I_LY[#
M^^5;_#\=GX^7YHGRA'4_V<]A_?*M_A^.S\?+\T3Y0CJ?[.>P_OE6_P /QV?C
MY?FB?*$=3_9SV']\JW^'X[/Q\OS1/E".I_LY[#^^5;_#\=GX^7YHGRA'4_V<
M]A_?*M_A^.S\?+\T3Y0CJ?[.>P_OE6_P_'9^/E^:)\H1U/\ 9SV']\JW^'X[
M/Q\OS1/E".I_LY[#^^5;_#\=GX^7YHI9Z;WIR'[2BKODM4O:SQ9THJ=.-O-R
M8S\K>>0<C%O2G\Q%T-$]4KU(H3J3:%<L5+4XDK3*P9E$Y*':"\3("8M#-^\=
M;"UA<=;&YY>_6Z+K9JG5E%TGKNIZKUK!-ZW2:7%)1,'%-S'5,1(IU'#EX]=+
M&.XD)64?+N9.7DW:BKR3E';M^\55<N%5#4))))W)NBV%D(F$3")A$PB81,(F
($3")A$PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g107876g70r02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g70r02.jpg
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M;$AUMG,3TBTIS&5W(ZBXT.HY]G6BUPCV?ZXB*O*NQ/>VI8-0AV6?37[+)O\
M66PN;:+;8>)5M@BHEZM+-P&)+#\L;%<>EQV'4O.M):\5X97'@?8BEFM6>MW,
M"+M-0/A;363D5$X-8:Z3A&0I6&YE242AQ0<](A3(ZE(6C#L=YQ'GH6C.?.2K
M&(((T(L>119SA$X1.$3A%XK_ &BO_A5_],\(HIZ+_O'J_ID?_NXKEW[QV?B5
M1FX]OX!7(Y1759.XGZN]]_Z6I_[YU_EF?6'K]Q57_5/J]X7LI/\ Q,J/]& '
M_=43D.WGM/O5EL_(1.$6*/2BL$&9F@Q:3AN&*(R@X5<UD:@N5CPWG1XM9&1C
M,> DA+0S$5-?QEF+A[+[N,H;5PBY,AN]7=8_NRX=?!/2FB2]FT.IB;I:A:>Q
MX=(T4%.+@)%>E-KJ.!:Y\QLE%D-#FI"Y?JREOY;PVVO.,F5MKW-CNZ]_5U(N
M@H'LAI0E;AVJY^W=31]SN-,0R^L1VPZV2L<"RMQ$O%J]&'IFM$)D\<^F2C,3
MU)HBJ.QF2Y!91YV$URFU[&W.W#GV=>Y%G)>^]'P;0U2)6W]:,W-^TQ:.W4LW
M>N*LV;C-91(BUA0)!%11!U]AQIY QR*F7Z)UE>6L)=;RJ,IM>QMOO;3U<T6#
MC=H^M<N6;@1M_P"FGIE;+0 )Z.C95/\ 2"C126H>.%3<9,8]#/FD4K'1HV<^
ME>(MN0$)S+;6RF<KAK8\>'+7U::]FJ++V;L#HJEW89K:W;BUE6=@&7(;0REG
M;O7!=FENDLH2,:;"S"+,]+A-3B$#&W&$+(N+2W"P^M6$YBQ(O8VUUMRW^SBB
MC _W'TR$[-T_JDBP#)VR[()GERV4'@$<955,Q''Q%9)9>(^O2;Y8UJAR!5.C
M0L$L@9/QAD*:AJ@MD)RG*7<!U&Y'/LZT6/[A=IW>L-8UZH%2VM@;"V]L@'JS
M7E;(62%3:^NPG<.901LMK(1Y44.'@X2TEQ665.R9$F.UZ2)&];GPS6YKZV %
M]!<GL^/:BT[5_;'9 XQM&M]N=+)Z]>S&HPKXYM&)8WK+I"QUV9,BCW(D._2Q
M0@6-M<:?/A16:M)FRBQ/*Y#D=AGU;#3TEH-LIO<VMQOW>[3375%MFIN\W7G9
M^CH/8$C?ZCK2A$K18*K'5L"Y5003@DPY*5'A"ST=!9Z.)LQD*U"M4:K8ERRK
M%>,"Y[R<M2/.3!:0;#70&]K#VGV7Y@HMEV]V3 U?0DC=.H2NK=JH)SP8FB_"
M.X:11*+;BI6P11$H<SL<X0S7(\^'$P6?9'(=D$)I(8H.U&3+<7Z$&W=8WXWL
M+G=[NOEJBVFR]E] T%10?L;=VGZ78:T\"'6\&8V/5H,ZMF[ .R3&#",*:1C$
M8CI&$W(GC$3(<9Z:+8=(H:Q%;=<0RNWAIMO!L=W:BQ=YW=/#[2T%KZCPM?6^
M'N'-C+%B4W:U3KYP52P@:(8C6:DTZ1(?/[.CDF792UKJT:1"%Q(GP@2FQX;[
M;N5M"3?33=QZ^7K]6ZR+)0NTG6HF8K%?&=@-,DSETF.#JD*&[+IY"=8Y[<YT
M7F&'CPS#SDZ4LJP\+988PMQ\FTZ/82Y,0IG$97<C[#Q19NQ;^T;4+CC7EKW#
MK*M7KX-?,JJ!V\5L58FQ<:$X3>GO"9Q%B:Q&2-8?(X<>91A<"/(FH\Z-'>=0
M#7$7 -N=M/CGR12#6[+7;B"%VBI'@UHK1R(W/"V"O$X1D(6@N^/HI@TH.>D0
M9T5SS<^CD1GW6E^&?-7GPY!!&A%CR*+-\(G"*#NR7[R=Z_ZL'_WC#\LSZP]?
MN*J_ZI]7O"M%J?\ >MUK_0"F_P"[HWD.WGM/O4MW#L'N6_\ (4JDG:W]\CK%
M_3TE_?Z=R[=S^S\"J.WL[?Q"FOE%=.$6-,R",,05EB!V"Y:*-G2!8E4MF DH
M18BNNPARITC]@AXFR4M1LRW_ -ACX=],Y^@A7"+DL+[U=U36[[-UX&]*:)*V
MA3Z6/OUC%(['A\#1E>*2A\0>MXXJHX%9(2EDX;S0Q$E4U45:Y/H?0M.*3DRL
MM>YM_7U=2*2;1W<W9:=G6/2'6#KC!W'L'58@&YO4^8V,,J.MJ!<"D'#\BA"3
MTV'A=J,QIK<X<M]I8W+,D?-QZ@^S"(O0(R@"[G6!W:;QZKV/41VD(L=:_*+'
M*SU23O2=H&R -KHW&,T,_I*WE9(13^Q94]*)+(6UJ J2<!K%(E3AIB&&Q'E3
M(LH8K*%0Y$G$Y/.L3I:]^J]M1K;O[T7WC.[._P"C;NTGJ/LSU:$ZJ'[\/%*K
M2+;4=T -C9:L(R/$=S') ( .%*1!6^2&1Y$]4R,F(B9B0VW-]"^RW&5I!()T
MYC0^O3W'U(K'=PNS@_J=IY6RY%7>N9@K:J[1*A64F(E<A%;79W9.![9BQSF9
M$0 'CQH,Z9.)OQGVVTQD,92WZ?T[4-;F-OC?;3VHM&T=V&[$'=M.Z?[#=:I.
MMI9"FKNU5V9K^Q3-C:J)L-2\QI%:-V2.#APZS94(0]*A19\]>2;+*\M1XZ'Q
M;I,0VUP>-B#OU^/#BBL#3>P.BMB6LK1*%N+65TN81N0Z5J]7N]<.G8341U+$
MUUT:-(R966X+ZT1Y[B&UH@R%H8EY9=6E&8+2!<@@;M>O4>T(L84[-]<@=BLE
M1-[YT^'L]-BO3;8"*[&J0XG6XT9QIJ4Z;BS"S+@SU-Q]A$Q$O#3D3+['K*&L
M/->?.5UKV-CNTWHMU8VEK.29)5R/L.D/V -5F+R8!LVH&X7%4J4VV[&MQ(<B
M=F9!K,AIUIUD[)9:&.MN-K1*4E:<YBQY'?;=QY=J+7#78+15=H8K:)S<FL1>
MMSSBF %[F7FMM50\^AZ0PJ.#.Y)?!QF0EZ)+;5'&R)3V%Q9.,H_8'?,6-[6-
M^.F[MY(LF[NG3S%.K^PY&U-=1Z#;)\$55[K(NE=8JMA*$G9# \8%/ND4"R9&
M:_$EL1H,.4]*>?BR64-9=8=2A8W(L;C4BQN!ON?4B]=#W=IS:6;+C6NU-?7W
MXG/)CVO-0MX&PIKSCF)"FLEU"YTI,%E[$.9Z&0_E$=[,.8EIU:HLC#8@BUP=
M=WQSZMZ+X:#V T9M4L; ZSW#K._FJXTY)."J?=J[8IXR(T\F.[-E111"4ZB
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M-->&ZU^>_BBK<$':RV-8O)1]=:EU^NFN;;4K<-M&T#MYUC,H4\V2UD'"VO:
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M:4U^2*W6)K'-CKE< 3J\/F"7RXUE LL5)2"(^/';DXJHR7E]7J4+T$;G-;N
M:;ZZ7M;4ZZ7%]=!?AO12X_2;YK3?-V-CZC;R WI%Y,P+J?6LN#7S4R/9=P$J
MPP]#S5Y;4-ULV1?B270Y! A<IV,ZVREY+:F7&U1H1SSO)/9<WTTY#VVXBQ1R
M$ZGIK.F_)7::%:HDQ+3=-T5CL%NZWQZ=(2?#QZN)S<2@:[61 _UL"YD?:F*S
M"@%9<3.'JVS#CL+DCW$XG,;O-SH+;^)UZ[^<-_?JB@#<!T?K3KGWVJNX]!;
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M=&_SHZIK**"2HCW]-24%55PUL\3AYS"8HW/'U6;KW:TYN;7>^:/!V%K,[@V
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M'S?_ .=P_P#6?^1/\K 0_FS?*L_[)"_SQQ\W-^T,/_GS_03YO_\ .X?^L_\
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M@<#J"&DY#5N A)0[>>/L'NT]?'>J:]G?^5M\F!_5YW/_ ,,!G-E3_P"+:_\
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M%Q8VOKKKRMZKW12%4>S6B[C28>Q(6S:8)J!.WVNCB#5DM%=!1#!ZH6,G6IS
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MR6X$0O,JFOP=9)E00B6MUH<0LQ2WGZM5Q/K_ *"1D<.D'%'9D=EV7%%NP?\
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M;VVQ9-I;&.UENT./%I12<)&:["UAJ>>(FY!$9*&3B3\=J.2(BX'=S!UT'F@
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MNGCF#L9VRK(*N9OGMIYW$8/AN;ZM/0T3B8Y9 "&=/*R:JG< 0;FQ]<G?6@4
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MCG;S_P!QC_A6KJ_SCUZ&J)] ZU8XU WGM*X@#=8LW8/MUV2VN\&LHJ<%/L5
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M4L=4J=MS9&R+;O/8E.<UF*3K@CK37%0E3L3S4<:=)Q#%C.V*:TQ'AY)FYP@
MVV-'XD0PT,*RELB1D3I3K<.<'6 O;?<BVO5KN[;'J'$&AHWW)W\NH \?CU5=
M$F]]=9VY.FS.A;3LT/7B!.)KFW4PJ&BXFUZ5/D31 >TPS;L),%\&Q)0+29$O
M%\DH$:-)?$QIJ9&)%@\6%]-PXF_"_'M*@QYC=IWVO>VE_CEKW";O9QL:L]%N
M_FQ-JP(82Z;CTCO*V3JT-?=E#ZR-%Z))U2N@(TQ]F,^05 ! H*YY-V)"43+R
M24]N# C2(X^) =F>RVX.;O[=]M;<O4K6   X>\[_ ([[6M?SJ?\ JL]:OZ@-
M-_X=5SE7_7=_G.]Y13_RJ)PB<(G")PB<(G")PB<(G")PB<(G")PBYH=N(V=:
M]G>O&[YN,M5"]UFU=9[<4<\<1 9XZ7&7O5<B4O'CAIDT<#V2M)D.X0PQ.*CF
MEK\Z8CS>SV>>*K"<5PYNL\$L.+0,_C21QL?3U@;Q)CC?#+87):QQMYJ\VVPB
M-#CV!8RX6I:J"IP"JE/U89II8ZS#7//!LLT=1 '&S6R21@DEXM'XS8S74?L#
M=]H7**05U]W^-I[-_MX^#+*(U'L^D#UUL)9;-"'LORXU$N-66.#E#S4:2T#.
M QSA/,2#.]/G[*BB=CN&4U+3N;\Z88Z?Y- YS6?+:.H>)7Q0N<0TU,$V9[(R
M09(Y'!MW- 6MHL3;LOC5975C7_,>-LI1653&/D&&8C2,,$4]0Q@<\4=73ED4
MLP:X0S0QE^6-Y<N@,[LQUU&U55XF[VU"S4$Q<S$V+&Q:DZ*>8PCTF/593)9Q
M$MYS'@EF-%]-)?=4EEEEQY:49Y%N$8J^84S<-KS.79>B^23YP>MI9YH&\N-F
M@:D@:KT-^T. QTQK7XSA8I0W/\H^7TIB+;7&5PE(<3N:UMW.)#6@D@+GZ$N$
MWLYV <[&QA!8-IRA44KK70^;"/E""]Y5:BXPQ?ML8#SVHY$. ,( U^OT]HBP
MU,*AX4LU(BPDS8S">O;2C!\,^:W/9)7U53'5XB(G"1E.(8WLIJ/I&DMDE9TL
MLLY82UCW-C#G925YT^O=M'CGSY'')%A-!1RT&#F=CXI:PU$L<M;B0B>&OB@E
M$,,%,)&M?)&QTKFLSM:)2Z*Q57K8'9[L7&QERIWNVU/4^N)^<94R;JVCH!H8
M<LHM_'[%)#&=@6>V0X$IE2D26P6'$^*/,<<UVU#Q!3X/A1_OU+!/6U;>,<^(
MNC?'"\;P^.FAA<YI MTMM>&YV%C-75;0X\!_<U=54V&T#SNFIL'9-'+41G<8
MI:VHJ6-<#9W0WM8 GH]SD%Z(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(M
M6N]:B7&I6"L3VFGXAH5,@/-/)PMEQ+[*T>:XA6,X4C.<X\Y.<9QG'SXSCQQP
MFY<@>LTZ?7J[8=#V93C=PZ^F<T-QF3E6)!"@?LS^KK"WA?BMV+)JK35=D2E*
M5E^P54_C/F^CPGF<&X!]O;Q[-=PX"RQ2-(=>VAU'QIV[AV:*R_)5$X1.$7SR
MY<6!$DSITEB'"A1WI<R9*>;CQ8L6,VIZ1)DONJ0TPPPRA;KSSBDMMMI4M:L)
M3G."+@S5O+2,#-CW07?-;?&#5WQO.MTBS4M[$"W1:@V4DH"+,@C<I(HY.>&X
MCO..1RE;RQG.6G&ICOG/9G3X^/'\%D+--#KQY?'QHNJ&C.W^DNQ,=IW69&X$
M7U9\V5&G:YO4-D:OQ\,H('D@)%4:RE7Z*G&[ \RE?@A3N%9QC,*I:1OM[1_6
MK/<*J^,B1@"!\\L4F1QXP7"E$2,^8ZAB)!@0F'),R9*?<REMF/&CM.//NK5A
M#;2%+5G"<9SPF]:]TWTA3MO5&[[QW)K2J6YS=-P7;:H%V%40MB^ J$/'0:]K
M^.@=88$U N<_5!(XP6BMLLKCGC!E#F5N*<<<O%65=*]QI:JHIG$!KG4\TD)<
M ;V<8G-+K&]KWZECJ\.H*]C(J^AHZUD9+FLJZ:&I:QYM<M;,QX:2 -0 5<'Y
M*?5WZMN@_P"Q[7GY=Y]'SUC/VMB?Z_5?FKX/HSLY^C^"?=5!^SI\E/J[]6W0
M?]CVO/R[Q\]8S]K8G^OU7YJ?1G9S]'\$^ZJ#]G3Y*?5WZMN@_P"Q[7GY=X^>
ML9^UL3_7ZK\U/HSLY^C^"?=5!^SI\E/J[]6W0?\ 8]KS\N\?/6,_:V)_K]5^
M:GT9V<_1_!/NJ@_9T^2GU=^K;H/^Q[7GY=X^>L9^UL3_ %^J_-3Z,[.?H_@G
MW50?LZ?)3ZN_5MT'_8]KS\N\?/6,_:V)_K]5^:GT9V<_1_!/NJ@_9U*U3I5-
MH0E("BU*LTL$AYR0@+4P(JN"4/NX3AU](X/$APTO.80C#CF&<+7A"<*5G"<>
M'Q3U%14OZ6IGFJ)+ =)/*^5]AN&>1SG6' 7L%LZ6CI**(045+3TD )<(:6"*
MGB#C:[A'$UC 387-KFPNMFYA7T)PB<(G")PB^ JX^R,(/1O_ $EJ')<8]WC^
MS(:6IOQQCY\>=C'CC^'A%^)/8QJ,ELV3W$S;MLVN)M^\:XE)O-U(65#9@5<[
M4+@9E.W^SK "1^88]I*?091%8S,0VTQA#SN4_D;:Z;RJ[4>5_:#8'9W;J79[
M#J;#:7&: 9S0-&'R4>&F>&"?":(UT\[:JLFR_*9F$LA?FG!9$UWM>"Q[(85L
M5AVT6);/LQ*HDJIJ*H=;IRZH;-4]&^1E7/T$;'0PQ^;$QPS/: SSGD?IQ\EN
M#N=9Z7ZRKMV$,@Y8HA=L@AT<A")M1JB5NATY5XZ98Y3D!>88@I&A9Q$>?9QF
M-G*'?!7HT?JW#H*JFP_#Z:NJ!65M/0T<%95@/ JJJ&GCCJ*D"0EX$\S7RV>2
M[S]=5XY5OAEJZF2GCZ*"2HFD@B%CT4+Y'.CC\T >8PM;H -- -RZ%<^Q?.J,
M^4B($!O3+>$@?(=C+^*SGK+C#CC+N83<F._+;PXTI*TI<8:6VYC"L84VI:,^
M*59QSX,4Z7YKQ+H'OBG^;ZWH9(W%LD<QII>BDC<TAS7L?E<QS2"UP!!!"^JB
M##64G2-:Z/Y3!TC7@.:Y@D:7-<#H6N;<.!T()7YDO9W(N5O>I>L=*IM%TBP@
M1=JSCQ%9:8KDLP0*, YTDG+?0986U, 2WUO0XSBFDM86VM3F<XQ^,_(OA'E3
MVVJ,*VSF\HF)S8#A&T\5-B.$8CM!M!/+71T(H*VLA^2#I*!\<]-6,C8V>6SR
M"U[ P GW7;FKV1P&&NP./9NDCQ"LPMTM+64V'4#&P/J.G@AD;,0)V/BDA+W%
M@!#;%A+C9?M!#K?<$C5RL*Q)7!BJ?PO'@K#N649<\[&??YWG>/C_ ,_/VVO
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MO8>I\G$L_E7DQPUU)Y06RT\<<% :R.40.D;,*V0-H1+1?-[Z=]$YSFU?2-G
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M;B5JWR,(PVLJ*?0RZY5K@F.VU'8L4"++9FL-1X=@%&8T0;D;=OE=\FHT.VN
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M3C&$I2E.,)2E.,8QA.,8QC&,8QCPYZ@&,: UK6M:T -:&@  "P  %@ - !H
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M8V_N:X@8NQK8(!TO6M!K&NZH7J6;(4# Q8\].CR%15&3LPU)4B-?,W_^@=W
M;KWN38VO?ASNBSW:O.NND.XNNRJ>)TM,B:EZA[3J]7UCL[-@HH2?83:@ 16P
MZ<6'Z]M%;V1LJPHK"JS:-?QI\?8UA'&(DK.%#RCQ>";=X-R1=PU&O,V.H(MJ
M02+;]R+2:)Y/#L*$U5U?-TT2_.<7TT*ZEM5$?O\ 7]8SZ!==MWH[M.X$[%BV
M:MV8T0KY9BZ*JUV%5L>)N;2JO$A1)DB"ZN.S.<$NOZ5[VO<   #46W7%^KDB
MN/KOHML.M[BV2+<.6"@ZXD]7^M>E-1;VUC? ;6X:0SI1$5-FK;35DI)3/K%U
MF/RVYEF]10QBJCL"T1FIAA"0E"X6YG,20=QO>QW\+\]_>6@;SZ6=F3.V01+5
MTAPK,A5O5&O9.^M@;;$V6+L37-8L"C]M%]G=%6?6I2O[%-1IDX\]3Y5$S7F?
M3SALJ;)'9AYAQY:YH&O,D@"Q!W7:[AIO!Z[;]"@BL:+W=VZC=QDUS7NN8VL.
MU?:] Z1OTS9<Q;K2-2]<KT,J<.&#I.:T_(-3)HVA)10Y(^PPX$ B8+N%%CT0
MX<M^;AN4@F[1]6W$@7U]_9N1331/)_[P@;S)*MY"9(HL7M+L'M&-VA"VB 0S
M,/EU%I= >;UNG5*[J[<A/PK'KEI;+[-9J+M>'R4B'9&'X<!F,PRCGERD6X<=
M;[N(TWF_!%CJ3T_[6@NKUCT.YI#K4&M-$T-MK6>O=MYLKUGV==]F;DG2PEQV
M&"M4BOB'-:@#M/*E)=F:+-EK69+I'P$NL#FEX1)<TF^9VI!(W 6&FFM];VMH
M$6T7_H3N!T!VR&T,=2DD+7U<ZX]1>O4^858AN1->U<"H#N(H<<Q!6\'<DQ#)
M2,,CMJ?DE((QJ*M3+4UMMF YMVDWO=SG'KX6XCVGF46WUSJ'M^B;SVH#@Z<Z
M^[2TCN"\Z0)3MC;?GNV,A3M/:@I==KT#5\'5OP*VY.LU?*UU).AETV+%5AR9
M;)8O#5,;7$8%V@\YP(OH-!<\;\CQ'LZRZX\QHG")PB<(G")PB<(G"*O=%_6,
M[!?T1T5_=]D\\YP#_K*\HO\ H?8'_=;3+I\2_P"BVS'_ *W:+_;PI6$YZ,N8
M7#S;-JO59F>4KWO""[#!N[ WYUFZ<U"Z@#-@UW.I>HM?4RC-6?;DR\!Z%L.Q
MU7759V9O?=[1&WU&HD"L%B'*(!SE/EK3=JV5@+V (W$^OERW '7GZE!&@X>_
M=MVM.EX>Q>PE.TU:>^+D1XQ7=B]HXQ5OK]IOI@(OM]74-K;PL,_=XNA;IWI?
M:'6!9-%G$0B,"-8;GK; 681AD,%)L. O;=H=<QWV &@YZ]HT6%@V.[_'_K[K
M$??NX WN&1[L;3 6#79?97909JL;UDZLN[=V-J[6!>=;C3FK;;4MH:RT]I?$
MW9&"-@V?NHA?K2<MMR,!++?0N2;[G2U@= +W-@=!;B38;ART4-5F\=J3O7?<
M&PYE\W';=D0^A^_;'V/'B#_<5A:-\WNGC8])H1.JVU5:I6A=CZUV6^0F#JGU
MV!PR=0UI7+9#/OH"$J\1L;X^/W*;"X!U\X>C>VM]V^XW7M?0B]U^D[K=K>C:
M?T#IO6.LII4CKVDZWJ(&ESC)JRV"?*K<0-$^"7LD;<0)GT0U0UM?!@N7*PP!
M&8A@AD0<*'0A\4J$W))WG537PH5?]]_N^CO^T!0O^[[+SSORA?7V#_\ D39[
M_A\372;.?5V@_P#;>(_[VD5@.>B+FU"N_=[4SKQKHA?[?Z\1?5(8!TZF 8ZR
M-PV/>"F'&ZW0J2%82[,,V6PS48CQ(T9EQ$5A,HG.5'&0)LIF0+FW>=PZR> 1
M52Z7]5[?5[AL'MYV49'$>UN^LLOE!T5:9PC2&ODM1D5_4-4EJ4ZEUT6.B#8]
MJ,1UY01FCX\1EZ8B)+,G;.=_%;]4=^_4^WXW NB_*(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(JS]A.HVCNS*04[9-;G1[G4
M5*<I.SZ4<)TG9]*>4I;GG5RZ@'XA1B/AUQQ[X+FJGAU2%JE+'+DX2ZFP<6W
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M.C@DJ:FH>(X88FESWN.M@!N  +G.)#6M!<XAH)%=M?2-7[[V7#WI6;I*M;-
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0(G")PB<(G")PB<(G"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g107876g71o53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g71o53.jpg
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M)6&4TM@G.4)28G&!DR:QLS4Z<W6'D:&XP?_$ !P! 0 !!0$!
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ML;[C8(V.FP?A7#XJE.*4XI7;P-@G:K+L+!69J5KT[%.$W<9,PD@ZBY2/=)&
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M%UF<[NT1,2DX[4?J14/%E8M6+*-,O-2C=1XV;C=>1@>C11KRA@TAZL3OH%#
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MC]?_ +-+G_P7CS(_WQ/Y2_VT]AO?X'=?S>7]2GT>]\_B/U_^S2Y_\%X\R/\
M?$_E+_;3V&]_@=U_-Y?U*?1[WS^(_7_[-+G_ ,%X\R/]\3^4O]M/8;W^!W7\
MWE_4I]'O?/XC]?\ [-+G_P %X\R/]\3^4O\ ;3V&]_@=U_-Y?U*?1[WS^(_7
M_P"S2Y_\%X\R/]\3^4O]M/8;W^!W7\WE_4I]'O?/XC]?_LTN?_!>/,C_ 'Q/
MY2_VT]AO?X'=?S>7]2OJ? NP:B:2*F*[(=%#U>RD?.+L9-'UCYG]I,T,)4_6
M/UF] !ZA^L?,>/,C_?$_E+_;3V*^T![)=Z'8>SS:&^^O<]:^7T>]\_B/U_\
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M7Y]_'F]LWO[:U?;>AW3^Z(JHRV 9^Q!4! 5*G&K458@B'U'35I;F .0Q1^L
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M;1[=:2>MF**[]ZJ"+-DBHZ42(J[=K""39L0QEEU1!-(AS" < $]@3]76C,J
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M]S__ -G]=02_^EC_ /<1_04_IJP+MV8Q.J79<Q#&(8N!Z\)3%$2F ?F!8/K
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MR3:]1'$ ?I ,.P/KZUO!Q7['="5/%'B++RDKYL=CC4CDT=<Z+)BA(J-\I5D
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MY5Q</>WEEC;:-;/#SV[VD<,%F;^2\O;MTO+@W22FT,,<,TQ,T@
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MJMC_ &M> G^D?B?_ &:N?^'U^/W6?$U^REC0?_U6C/\ _EJX]FX>_P I7?\
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M0OOSJIVZ1!6MJ(MJV7=H,UC.(XULN)52VO@HCM,]"BQL&[(E\BA4:/9ZMH1
M$G4!W,>67?#&<X)FERW!#RWV*+F;(<)74LDL;)WDDQ4C<\B3!>JI[]P2H'->
M*$M1.;KEV4S3L[0T[MGK]5-PR5)'VRHRH$;6BESOI,*L1/1X&,*8F,FL9A((
MBHPDD4E#M5A50=(-M8S&&O<+=&VNT!##GM[B/WH+F+TDB?L>XYE/O(2 PT5)
MWOAOB;&<46 OL=(P9&$=W9S:6ZLI]>]#<1@DCJ#R2#<<H!*':LJR Y%5L-.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI45>Y^$K]A.O\ ;Z7#>:5WB!:W;.'J:GL.
M6=YJWNO(@C5UZB?"*R[<[ZO"\]1?A$IA1T40,B40DL3>"QO8IGZPMN&<=P89
M-!R1Z\AY9->I0#UKHGA9Q>G!7&>,RMT V)N1)B<Y$R\Z2XC(\L5R9(]'S%MG
M$-[Y6CYK6RQGHQKD]/M^;]C,-J]U="#:ZQ135'3(8Z?PSN&OL FDVFTW#(0*
M=DG*>:$ZQ;' 3-V,F@U5'XENX(2F5LC87DD0ZPM^-MWWL/"Y)33>O+U0GU*D
M]B";?B;P8_ _%V0Q,>Y,5<$9+ W0821W>&O2TEHR2@D2M;Z>TED! >:W>11R
M.A,H>1U<_K!4LNS-"/9Q*&=41&+CKD;18^-2J-?3CV&@GE7$Z>],V9(\K9K<
MCSCMU,FLZ"9)LTJY<2(OA=K*+&4K0VWU?JOC,9;>P>@=>*]99E\^8IVRR9WU
MD>[1K5B=3,>[HZ;I[#YI0+?I%E2+7YZ3@9-_\ _1CZM)2S:26;P:[XIE5&SH
M _5LZ'Q[D@#M]]0K9]_?#"U?(8BZ,\PL>A4'4D*=B>=U13HAM4]-;Q P47:[
MQ6:/DV>/<35E]=H% B:S:K,N2IQ,W1L^(W5=/G$*\DV1'JO7*P.N@(ZGWEZ=
MAU.] GI])K;>8X9X>W;-'#NV5 J6?77,H;)[U@F54.8SVNP>31,7)ZO6[%9H
ME;%[G2HQU5]*J&D922)18.(V%E*X^:V!FK#"]6!RBKSLC8^)!/T]_O!W]M39
MD,QQ.4T>+T>5SS+)'7:A#"VA+Y(5.I.]'J]>5*X1%O%VAS'J6>$AE".'20I-
M'S9B<J[@@E$%5 ,JFSVWT^%?DV1XA-0]9KALQRJ6@,YMK>YTZ!-2ZB_AZ)>V
M[MS.M+768L8U5E6+:B_F'<RWG8M!C,)NY1S(INBK/55E5-GX_1]GPKN)[*LO
MM-E1N=GS>@V.X-ZO+TA"USU/KTO94*7/^Y\O5!&=D(YQ*)U>;]Y7Y7@".BQ4
ME[JGQC1;UF\U*^^?YKG.3UQ&GY90*3FE2;NG3UO5L_JL%3:X@]>G!1Z[1A*X
MPC8Q)T[.4IW3@C4JK@Y0,J<X@ \4K-N*57GXA.GSK:AUOK9FB@.=@[.2Y,_A
MFB)S>Y$4MRHFE=;%(>T!SM8PT:J>(7<*D*4D>\F9%(XA"N?1.8.W0S27]P-6
MN/0SN3V>8#<,:_%N;WP!^Z"*1[XWVOP5X?LY,Q?\=Y]>3AC@"U.:NY'4%;K*
MQJS8FQ@#:$MP+A1=)&I),T5K P'M4>YEY1G$%D.;4C,:T00A:16XROLU3$*F
MJ],Q;E([DW12")?C95Z+F3?&*/D=X[7.'U&Y%7-P]U<37$GRYI&<CT79Z*/H
M5=*OT 5R[B/.7G$V=RV?OSN[RU]<7LJ@EEB$SDQV\9.CY5M%R6\(/411H/2M
M@\L5"TXI3BE5;:XX#J5W9J.\*#\#C':%E'Y;K+O_ "496])BTB$IMJ?F^\;M
MDGS-N@BHNH($09I724<G,JHF!MBMA^$\1+9=[O'%KFU'=I(&.Y8@.I)4DD =
MSY*CH#7T)PU'_A)\*,EP>OX[BKP^FGXAX;B^5<7^!N6)RF.A'5Y&BED9U1=E
MI6Q5O& H;5I/-=KY[K5=FPO$;JQ>Q=RQS*[;&25I/>9&.LV>U*>8O[JHS;1Z
MEP>M)6(=MW5I48,VC$]@734EC,VK9L9V**"1"J;/QKN'N5YA)VZO:!(YQ0I"
M^5)@:*JEV>T^O.[=68LY%DSQM>LB\<I,PK Z;A<AF<:];-S$76**8@H<#*5C
MLMU]P2>)%)SN(Y#-)P2=F1A"2V:TR1)#I71V[?W%***\A5@CT[8^?OGEF(T!
M$L\[>.W$H#I9PL<ZE?6<P3"[,2W)V3%\FL)- =0+Z^$G,YI\L2[/:J@JVJ[R
MW%?PS@+(ZK;9=9O N)D'JL.@LJE'G;IJ'**J[/Q/3M]%;#- 01X(U6/"Q)ZR
M>)& /731K,T$:",S&.-"FB!1&/-$FCQ%B,:+<68LQ%J*/L?><52OVTA(6/A6
MM<81$6QKS*+0A&4"T8-&T*TA6S0K!M$-8M%(C%O%MV)",T&"2!&B30A6Z:14
M2@0%*U@7KOU_+1ELO+AF.ES1Q+C8%\[+F5*"C+SXF*<9Q:I!"?("LN)R$.,D
M>/,]$Q"F]_S* @JNSWV=_'=90?+\S4>)R"F=T52016J#E)\>HP!GB3C/CNE*
M$X3<FCQ6(M2%'SX]05*<%*T=XZ-#&9&<+"=5*^=1RC+<_E[-/T/-:!29VZ/
MD;C-U&G5VMR]LD 577!]9I*&CF3R>> LY<K YE%G2X*N%U /ZU5!,I6>'.1,
MICG,4A"%,<YSF I2$* B8QC"( 4I0 1,81   !$1\N*J 20 "22  !LDGH
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M]@A+7!Q-FK4JQG*_/1[65AIB,<)NV$E'/D2.&CQHX2$Q%45T3E.0Q1_$/D8
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MRN.L<SDYL]PSE[E+"SRMZH_"6*R$N_9X+Z<?\Z@N""/:)#S#3N3"D/ES6?\
M-*KJ-.*4XI3BE0I\03'5=BZP7Q*'*JG=\Y13U>@/VGJ+(L;+12+2JA(Y1/R6
M*]E(,LQ$- 3.7R>/FJ_UG0)Y;)PGD1CLW:F31MKPFPNT;7(T%T1'M]].5)/+
MD8G]RK#L36D>(6&.9X6R"P@B^QJC+8^1.DD=U8!I3Y9[AY8/.A31'OR*?05N
M+K+KJ.[X'E>L$,D+NWU)@YFR( 4J+>T1XJ0]K:HE+Y 5%I9(Z5;HAY%'VDR"
M)"^?I"/S6/.+RM]8$'EM[AUB).R8'U) Q/Q:%XV/TDU,\+YA<_P_B<N.7GO+
M.-IPOR5NH]PW:+_JI<QRJO;W0.@K>G(NIZG%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4KXN&Z#M!=JZ01<M7**C=RV<)D60<(+$,FL@NBH4R:J*J9C)J)J%,10AC%
M,42B(<J"0002""""#H@CJ"".H(/8UZ1WC=)(W:.2-E>.1&*.CH0RNC*0RLK
M%6!!! (((JMZ\]%['G=LDM8Z2:(.&7.04^*G\TD2*/\ &;J8ACJ"V=07LO25
MXZ@J*D1,VCY%C'@H!()I73F.\">AS$<\:VV7@]LB7HEPNENXOI#['F>F]LI;
MNYD[5W3$>+MCF\;!PYXL83]MV+@7R[+/P%8>*<2" .>.\YHC>A=(6$DT$LQ7
MFNY+T:BKK&'?VY8^X;UWNE@-UR%Z54C3]TZE1[BZY-+JB;T_%HO&"SUW&E5
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M+;Q&- P_JMDE-FL7S[2J\VGW&#Y;4;+'VFK1K69A;;4Y:N1[E^Q0,J"#R*>
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MEHS>SCYQ/3\76XULP;R#^+8B922EVGO*.I!JB@V!983G,F5)2U8V4N0NHK2
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MY<AO\X">)&'7+YAY@(IK$-Y"/D8.4/$F2 U&;>'IK\7;H-?8W,/O!'T5Y?\
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M3?$OB'QEQA966.XES<N5M,?,]Q:)-;6,4D<TD?E,[W%M:PW$YY-J//EE V2
M"=U#;?H6P=GNY\7U5F;U;Z5C=*Q$VNVV)I$J:$E;Y,N[.SK[:-DY,B:W_530
MLI%K)-5VSE-/X:4.D5-Z]9O8^5LF3'8ELDD,4UU->>RQ-,O.L""-G+*OSCRL
M"01O:@[ (;J'!EW9>'_A;<>(EKB,9EN*<MQ:.&<;<Y:V%W;8:UBQ\E[)<6]N
M67=S*8+A6D5XV/F6X8M%#+%/LVK^&+TRK3@KU?+G5J?D.!_BK?<+;,%.?S 3
M&7CB3#.'<^L0\S?$QJP#]8   (@.-)Q#EI!H7(B7MJ**)/N;D+C[&%0&0\?O
M%*_C,*<0QXZ$C7EXS&8VU*C6@$G-K)=1Z].2=2/L&ID4G-\]S:.&)SVC5*CQ
MI@*"C*J5Z)@&ZPD\_([@D6T; Y5$1$QEE_<5.<QCG.8QA$8N:XGN&YIYI9FZ
MZ,LC.1OOKF)T/H&A7+\KG<UG9_:<UE\EEIP3J7)7US>NN^X1KB20HO8!4Y5
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M>).X<Q[UNW^<4)^'7:KI(_\ 64[+R$?^$43*3_#F "]9_??X2T_PA'UH_?\
M-KS#*<#@0&4GDDZ @GW556Z;W[K=#\#T/6OJ+Q<N()/!'P-2.:*1Q8WH*)(C
M,/)M;6&;:J2?Q4P,4G3W)/<;3=*D%XN[5T[\/W<R-6Z[DZ*^9.E2H)'6,FV;
M:Q1UG+@Y4RF$J#=$AU5U3 !$DB&44,4A1$,+A@@9NSV0/^<#J==3:S #ZR>@
M'J:T_P#8WR1Q>,G"1D=(PRYV-2[!0TDG#N62- 6(!=W(5%'5F( !)J5/4]JY
M9=6>M3-XW7:/&F 8VU=M7*2B#ELY;YU7$EV[A!4I%45T52'3524*51-0IB'*
M!@$ CLF0V1R!!!!O;H@@[!!GD(((Z$$=01WKGOB'(DO'_',L3I)%)QAQ-)')
M&P=)$?-7K(Z.I*LC*0RLI(8$$$@U6VSC)+[M_*O?D][\']&-)Y\7\*O\-\(,
M='QH.O?]OVOAQD2F8 MZO;%Z46OJ]\!)R?++^U%1S#?X0UK8WOF+:UWWR^]K
MOKKVKN$D\'_T5((O.B\W]OS1^7YB>9YGF33<G)OFY_)(EY=;\LA]<IW5BG<5
MJY>]2.T+-FW7=NW77K94&S5LDHNX<+JYW8B)(H(I%,HJJH<0(FFF4QSG$"E*
M)A .06*(&3QQ)  OK4DDZ  G39)/0"N+>&DB1>(W 4DKI'''QGPP[R2,$1$7
M-619G9B%55 )9B0 !LG51Q\))JY9^'QU]2=MUVJITM-=$3<)*(J';/=DT)XS
M<%(H4IC(.VBZ#ILJ "FNW6262,=-0AASN)B#F[X@@C=N-@[ZBT@!'3U!!!'H
M00>HK=OV1DD<OC-QFT;I(H? QED8,!)#PQA8I4)4D!XY4>.1>Z2(R, RD#1O
MB??O^>''_/ZO^FF+\UR7Y<7\;^M:XE5Q_+U*\=7BF?EX[O\ R\T_N?S[F'+^
M4;[/Z(I5\/A*![_4-C,J>0NK)IFC3CX__M*.UYA)F<Z@_P )Q38I!Y_^Z!0_
M@YT#CWIQ \?[F&RLXE^A1%S:'T;8GZS7,/"/W^#TG/R[G*9*>0^I=I@I)^)T
M@ZU9IS2ZZ?3BE.*4XI5<W:3L=1[RK;NI^<8\^[7Z+.1ZD7=J/#/$XJCT9$ZI
M/9>7W0%/)C6I.-?IH.F*;-RA(1TLS2(M*P$J1D*FWX/#W-J+?/7F07!6<3B2
MVNI%+W-T0#M;2T'O3HZ$JQ8%'1NB2H6US?BKB2QOFO.$L;AGXMR4\9BO;"&0
M16-@I8<KY#('\7;2Q2!70(RR12H TMO+R$Z-PSK9XG>9TIO6&/8S*J_7VC<4
M:W4K2Q>Z<_J3$/,K.(3L;^HH.01C4 2:-FB<I,1#5!%,C%!-+S2"4RF9X*O;
MDSMA[^65F!FN('2R6X;H6D,*3L-N=EB4C<DDD[ZU!8'AGQ0QEDMJG$F)M[=5
MY;:TNDDRLEG'KW(1<R6BOJ)=(J"6:%0H$8"]*P2!H':OJ_L\IV7[-YJKW 50
MC3QK73<TLYY*?Q^NJ$<?*B]5R>1@:VT22<-EW7RA\A1S)I&M%)!0)ADB_DS2
M.3+=X'-8Y,+A;P</!G#M9WL 2+(3 J(Q/D$EF8D$+R>:S%VY1R,50+@6^.XL
MX6S4O$W%&-/&+",Q)E,9=&6XPUL0WG-:XF2WM44,A;S/9XXTB0R:F19)?,MX
MR+8\WW6DQV@Y;9V-IK,B)D?B&ON(O(U^D1,[F(FHUP5)]$2S0%4Q<1[Y!%<J
M:J+A,JC5PW75T#(8^\Q=R]I?0-!,FCRMHJZ$D+)&XVLD;:/*ZDC8(.F! [!A
M\SC<]8Q9'%727=K+TYUVKQR  M#-$X62&9-CFCD56 (8 JRL=G<PJE*<4IQ2
MG%*K'Z>>4?W3\1R%1\P:GNF.SA2A]1".Y6"N3I\?T_B]:ZKD@F-^,PI^8_\
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M+$XF,'J%N\90*4LT#S$!1DP4^HZIPYM/&TZ/FO8X3N'%V=KCH^O3\3'SOT[
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M.!DK)1;*D*:S608.45&[A:/6<-VHRL6#E CPB"#ANNRE649),<7'Y";'S%T
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M?2U:E  445U"^OI\A.9IS_JQQK\B)/1$'P^)[L>I^CY)XWXWS7'F:ES.9E
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M=#LD$$'?4: ^CZ]_?<G\HQ_QXQ7QS/Y4!F$@,;\2C\># 5A; ^%GZ_B 9BX
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M*2"-@D'1'<$@^A-?/%_87>*O;O'9"!K:^L;B6UNK=RC-%/!(T<J%D+QN%=2
MR.R./>1F4@F7N>YY2\IIL%G^>5YA5JA6VIVL3#QX+'(F*[A9Z^?/';I5Q(2T
MS+R3EW+ST[+.WTU/S3Y_-33]_*OGCQ;Q6$3OJ:S/BE.*5$RW]D)2R6:;ROK#
M6&&PZ1 OUH2ZW"0D'$7A&,2B7D5VTT>^,$':E@NL:4WNCCF=(SM\!P>-0NZF
M95V;:W1NJNO7^Y^S^OM]O2N_S'KA%U>U(ZSJ-HD-OWH6;QFGIEJCV\=&4F/D
MR%+)UG%: V</8#(ZDZ(4C1X2'6D[S:V#6-)IE_T"1C6DFFIOT'0?I^OX_H^
M%24XJE4Z>%Q^_!XA']($?THU3EB'O)]8_2U*FSWM_(Z[&_S5V;_90Y<D^0WU
M4K%?#A_(DZ^_ZJROZ76+E(OR:_;_ $C2H2^(VX73[\>%P1-=9,G[JTE]Z10Y
M2_X1=LP07^]*8 _#("**WU?A$A%,_J)][SHW"@!X:XQ) )]B7J0/2VO"/N/4
M? ]1UKD7'C,.-?#H D#\)2=B1\J\QRM_*'1OB.AZ5=MSGM==JD+P17#A?/\
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MNRJ_:XN\1'[K#BA%SQ147EH&O?)!5$Q^.+#_ #=\PF!:(IQHK_%BS^#+Z@8
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M!SY,9+!8YY)B!'C8%6TQ)5)=)-=!1-9%9,BJ*R1RJ)*I*% Z:B:A!$BB:A!
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M85LGOVOLMY27PMFLY,ZD6!."CR"7O^(R,N&;B^3AN*^!CES0N1"DEPD*5T<
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M_2_S[_S$XYYOF#[C^M2GTH/%4^P_2_S[_P Q..>;Y@^X_K4I]*#Q5/L/TO\
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M_P"EWPO_ -H;?]>OW]T(M?V&NY/]E4E^JY3\!Q_Y8Q7\Y6J?X%,=_I<\+O\
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M+&W4UE?V4R7%I=6[F.:":,[5T8?<RG:NI9'5E8@UA4:,U7H+JL!F*3"U:IU
MU6UMX:AOV;9Y/VK#;98GP$;P<BF@15PYJCQXN)SG])45DQ6E68(SJ4K'V'8I
MFMLU;/<%HK;*6T9:96(2.\BC7JZ[Z"0*/K!TC>X49._9>XX=\9.';W/M-CN'
M?$WAW'/=9B&62*RQW%^-LH=O>0,Y6./)11( %V64\MO)S6C6\UC:WS6J^=:<
M4JO;Q1:X><Z::+(MT04D*;,46VQRI2 +AFLTN$/%NWK13R$[=9O%2\@8ZR8D
M.#?WR>KT',4TYP[)R96!2?=E2:)AO0(,3L%/Q!=%Z?'1[@5VK]CY?"T\4L'
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MGH=#7;TWZZU\1HU(3K_X6F;81H&*ZDTO/RK<\@T7;])4&L9%C>15BTRNUY3
M8^XCG=9RVH5MNW852L5QDO#OI!U/65V_</4I"?5A2Q</%*H6WL:[@#N3V._7
MZSVU^G<M^Q?6FN]CG_75_8+'-5Y3KGV3HG9:OIPR+%8EAL5#K=XK3&N3 O4E
M11A7S>\O7+M9D*3XBS)J5%4J9E0,J@.M_2-'[P?ZJQ/M-U//V(G,0T2HZW;<
M*VGKK;+;:,KTZJ0-0N 1R>@T:8SF]P$[3;W$S-:GXBP5>95*F*J#61B9=A%2
MD>_3!NY:/5 =;&M@Z!'U$'^JH>K^#QE+SL%3>PDWK=SO=H8%Z_2.GO-9SS#]
M7N&KW#KA'H1].N"F@W7.9.>SV4LZ,?"C?@H"<,+]2"BWM27I4NW^4S*KS'1'
MUZZD:V>O8]1WZ'XUT[#P8\HBZ.XI3/7[BX;J]?9_K[Z[+0,DOD*]@9WM?.]M
M%G]BI>@4^TT^QHGM4XK47L0_ARD5JZ)7D6_A;01G/,E.8[WKKO?0D>FO0[]!
MKK]>QTJ;G2+J#6.D6(AB=2N-CN42>ZV^\@O-(,8J&K[BWOR/5:IGU2BP^2J+
MGT&1%)&OU&.5=-V"BCYX=TNZD'"@JH22=GOT_-\?B?B:CSFRX=J>]UMUU$?C
MLAZF1;_,,^=AY*QL]JTX19*XSC(P^M!R6*:*O&1ED3'3.BWITLV.45@-S8K@
M?@W#16I]VZR;K<3C]TELFC$AZ CF(4Z/8F53VKZ SJ?X//"#&\,N/)XF\2+B
M'B#-1]5GL^'+-E;%6DP]UT-S*L<P1@"K/D[:0>[UM#YKM?/U.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI48^V'4W+>XV;PV;ZDK88UO5- J>J4FT5-: )8Z;H-+5>?(=CBVMNKUO
MILL)64G+P\C"W"HV:MRT/+R+&2AG1%B&354'7W$?8>E1U8^%EUQ9U.>J2L_K
M<BC:.G^S=*K%,2%JKZDW+9AO%O6O&@6-99O3VT>UT!:><*FA'\=&LJE QPHQ
M$=34HUHR;-E5#$=M=PWVKO7Z3]?K4*['X36R'[<TVWT:YTNH=6:UVBZW]I7T
M UUG42SD]<>O]$K-54?SV$GSUW0)71KN%/@828T9CL==K*< S3F/W(%KBFE+
M$5Z#@#MUT5[#L?IWOIUT.OU^E2OC?"%ZKQ68W#)FTSKYJQ=^J$ITXF%E;;7C
M2R>3R^L:!LCIZQ=EIA&Z%R"VZ38$49A5FO&DADHUF:$.Y;+O73M7GF.P>FP=
MC\WYN@K[*>$/U*<Z7K5^?_NBOZ_MA-;<7_(5IZM-\VE+!NM$7SS4[1\7'4UC
MJ*DC9H-]*/4H9]I;ZEUZS2\C::M582=6(^24YCT[;&@#ZC1V/H^W6]5S<K\*
M/KSE4=0F32Z;/;76;[GDN]5F6M,[0&SM&P8C3+;1,\J[J/I.:TVN+5*/AKO8
M7,PL2"1NUKG'?RY:;G,27NKJJH3O?0=1KU^.]]^^_L^C5<-'PB.I9;SMUJ>!
MHLE5]Z:;RG<,B<3U;9YU'R?9=DZ8[%/P3N%IT5I@R%@))S;B%8V+1K%6Z(]G
MYEW08&LK//415>8]/B- 'UT.P^'37PW6[.KW1B@]6;Q?M*AM3W37+YI&>Y+E
M]CL^VV^MVA^%/Q(;DGGS"-2K-*IC%@I',+M)1[]=-H8TP5JTEI,KFR.YZ;FE
M4)V -  $GI\3K?Z!6W\ZZZT+,-I[$[Q7'-C5NO9R2R^5T5O*2+-S M7.24!K
MF]7"L,4(QH[C$EJ^S25ER/I"5,[DA.Y;G9HF!J539Z#X=OMJ.$MX;.(S&J:=
MH"M\WQA1]IM-LOVL]<8+4%J_U^T+0;UEI\<M]RM-;A8=C=9-U8J2*2,O65;_
M /N?OYIHQL3FGJS3-N]357F.@-#IZZZ]]^O3OV.M^F]5KK+/"*ZUY5#4Z$C[
MEM=E0S_7NOVOTYQ9;#0D5X-]UF<23G+ZDFA4LUJD8_K*:DJZ&V2DM'R&C74Y
M&KFRWV1>,VSE)3F]=#>B-_6-'U^'V=>U8M8_!:ZIVFF9!FTS<MU?9QCR148J
MCR%HH,W#38DUR;V<KY5W8,QEY_/; K:IYU'2-OPR:R6XSM4;1U=L$_*LV*(@
MIS'9/39W^<:U](UZ'?Z:MVXKS3BE.*4XI7X43(J0Z2I"*)*$,FHFH4#D4(<!
M*<AR& 2F(8HB4Q3 (& 1 0$!X[=JJK,K!E)5E(964D,K [!!'4$'J".H/454
MO1I$_A]=C'^46-0[/JCV'L+B>RFQ.#&"'RK1G@IDDJ5).3C[<;"O_P#!T&RS
M@WPZ3(D+)"L'PUO>-]FF7\.6 N8QS9*Q0)<H-<US;C9690.K.O4D#J3SJ!UB
M!^D<O /&G@>'B.Q42^(W!%DEGQ'8Q@>U<18*(,8,M!&HYI[N#WVD2,<[2M=0
M<OXS&1/;7^/\7-9KYMJG#Q%]DV3'.X?AO.:5K2E0H%JL'99A8,N6;%0B-RT"
M"QT\KFN4NI->P13%W9](DUG5)S>,=,95S'W*69V&%BIJ88-(X5>U (;IVUU^
M )UO[-@_IK7?AC=_]T[2;! TJ[:7C^YP%NZCPW8345,CSB7H;CIQO,E=X*O.
M.INAN'ETM_RA8 C9:R'9,+82 T5JOF5@EY*+5@YR/,Q490!V(ZZ&SO8Z[(.A
MZZ'3I]?6J[Y;1^XQ86_.&]FHH=?$/^D4MZ*I/*7[4B[P@T'O76H<*.RC"1PT
MDN8BR42B30IK$FE\BJNF81(I"5 ZO6EV.G7R]CH-;Y"=GZ?7?QU6Z8?Q6^WL
MG.6L(>Y=>YG0)*H]_'M\ZPRN8WEE9.@2_61I;OW#+EV!LE8LMAN$Y5=+?05:
MC;*I,4>J(61[>(^5SAPA Q$CZU4Y1\&UM>O3KO6P-]-CTZ_76)TOQ>M^G\UR
MDMF[!8WFCJ>[L1_7W4^PEPSK)[MC%&SZQ]6KIL"4G7-.QKL3;<8T9S"66"CU
MW=M&:SQ//F\BPA-7I"1HV7>2:G*!OIO2[T-@D\P'8@$=#U'7Z#Z"/>U]ZNUN
MMX?H6MM;NSR72$O#E2NZNR9Y&Z#6DK=2:MXE<UC*&H5"K.M 3B:16-4R2'8Z
M8G8$6+B?80DX[)&VE6GN&!$*'IL]^E5Y0&Z=1S: .CW7>OI(/3^K=29U'Q4=
M=E.R<A@],W7-=0R>R):QB5A7C:%1\^FEG,;T6LFX5W8\X?0^]7?39*&N5SC6
M\A5K[*4&J959X&9^;V;K69_!KW!:O]S5 HT"1VT?C^["Z(UH=^VR>GP-7A>'
M#*RD[X>G1&;G))_,S4QTXZRRLO+RKQQ(RDK)R&+4IV_D9*0=J+.WS]\Z65<O
M'CI95PY<*J++*'4.8PJ\O\IOXQ_2:E'>[S5<TI]AOEWF6L!5:M&.)::E7A_2
MDW:H   1,A?-1R[=+&2:,&3<BCM^^7;LFB2SE=)(]V&&2XECAA0O)(P5%'<D
M_F  V23H  DD $U(8C$9'/9.RP^)M9+S(Y&X2VM+:(;:21]DDGY*1QH&EFE<
MK'#"CRR,L:,PKMZDU6T]CM@G^]6J1#J(BGC%U3^LU*E"A[U8SXIW+=U<ED?,
MQ4Y2R)KO4V[HAQ!R$G/NF_NPSFO*ISF3DCL+6/#VS!F5A+D)5[23]"L0/?EC
MT"1Z<J ^^)!7;O$G(8[@;AFS\(>';J*ZN(IH\IQ]E;<^[D,V0CQXI7Z$V]@4
MB9XR-QF"SCDY;J.^5K/N:]7S_3BE.*4XI45.X/70O8[)7$%#/0@M,ITBWN^3
M6M-8[-S WB%\UV!!?H^2[5C+@7Y/>+)B8&:IV<P1%9U$M"A)8N^]@N0[#GMY
M5,-S%W#POT;IV+)\I>V^J; <UT3PRXX/ W$B7EU%[9@<G ^)XDQS*)8[S$7?
MN3'R6]R2:VWY\2G7FJLML76.YD-=/TX[,#OU&?0ET:#6=UR]U\TMBI+Q(C)^
MPL$>=1B:?;,/,!)$SBS5=4")E%*.DDWT6!U46S5V\]97'^Q3!XCYEE<#S;29
M3S*T9T>0M\Y 0.OREY6[DA<KQ0X"'!F7ANL5+^$.$.((OPEPQEHF,L,UE.!*
M+.2;J#<V:R(I+'FG@:&X(5I)(XIA\BZYC3BE.*4XI3BE.*4XI3BE.*5 ?NKV
M LM9:P'7'#1^5NQVY >#KC9FL(*4.JO 60G+_+KH@<\6FS8I/_DEVJ!/AC-9
M"=**J4"HV<S6)LHY"]_>>Y86>GD+#\M(-<D* ZYB6US ;WM4[OL=C\*N#+"_
MDO>.>+A[-P-PCJ\OWE78S&1B*/:86U1BHN&FE:'VF-2><20VAY6O%DCD5UUP
MVL]=,AJ.4UCR<)03,5IJ8,D"3FQV9^(.)Z?=E]1SE/(/C'^%0456%A&I,8U-
M4Z#)(>8%]>27UU+<R="YTB;V(XUZ(@^A5[D ;8LVMDUI'&_%U_QQQ-D^(\A[
MC7DO+:VH;FCL<?#^+L[*,Z (AA"^8ZJHFG::X90\K5N[F)6ITXI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6K-GQRB;U
MG<_F6B102==GD  %$A(E)0\F@!C1T[".S)J"QEXM<WO-' $424**K1XBZ8.G
M;1?)M+J:RG2X@;ED0]CU5U/RD<?ND8=".A'0J0P!&P\+<49C@[.66?P=P;>^
MLGWRMMH+J!]">SNX@R^=:W">[(A(8'EEB:.:.*1*]<GWF_\ 3.UQ'6WMW(K2
M&>.5?DS#NR:R:WR#*0R/DG'U>^.CF7&(?QC?VFQG;U=16&(5,LDN[KHM+*$W
M<V<.6B;(8Q0MP/>O; $<ZN>K2PCIS*QV=*-/UY=2!HZ[7Q'P?AO%+'7/'?AI
M D.;1?:.+N!%9/;+:Z?9FR&&C"I[3!<2!Y!'$BK=$L8$BO?-L*M33,RD$&CM
M(S5\V.5%\Q=)BDY0.55(3(/&BQ?6F8JB*HF1<(F$#I*")#B0_P!>N$$$@@@@
MD$$:((Z$$'J"#W%?.KH\;O'(C1R1LR21NI1T="59'5@&5E8$,I ((((!%?9-
M%%$512222%905EA33*05EA*4@JJB4 %102$(43G\S"4A2B/D4 "E>:^G%*^9
M442*JK$22(LL"8+*E3*554$@,"0*J  '4!,#&!,#B($ Q@+Y (^:E:ION&99
MID_DEFNE51E9C#+V^TK+UT9&8BF];NDE3K707TNI'0\@PCILCFJ7>SQBD;8&
MDI%">3&0!D$DU9.VZJ[(W](T?JV#^D"MK&12.D9N=),R!DQ1,B8A3)&2,7T"
MD9,0$@IB01()!*)1*/I$/+ZN*I7\3002.<Z2*29U"ID.=-,A#G(B E1(<Q2@
M)BI%,8J91$0(!A H  CQ2L.T31Z-DU1EKUHMEC*G585$57TM*+>VGZQ PHM&
MB!"J.I"2=F**3&,8(.7[Y<2H-&RRI@(-Z"":YE6&"-I)'.E51U^DD]E4=RQ(
M '4D5+83!9?B3)6V'P=A<9+(W;\L-M;IS-K8YI)')6."",'FFN)GC@A3;RR(
MH)JL*%@=!\2*Z0UUOD--9]TKILN25I=&DA486+=IABJ8K:>L*2"GJ0K!/OP
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6Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g107876g78x09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g78x09.jpg
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M @,  P$!           ("@ )!@<+ 0,$!0+_Q !&$  !! (! P,!! ,*# <
M   $ @,%!@$'"  1$@D3%"$*%18B%SEW&3$R.$%7876QMA@:(S0W<925LK?5
MUB0E,T)#6);_Q  = 0 !! ,! 0              !08'" $#! ()_\0 5Q$
M @$# P(# P4'#0T&!P   0(#! 41  82(3$'$T$4(E$R87&!D0@5(T)2H;$6
M,S4V4U9R=(*2LK/!%Q@D-#=C<W64M=+3U25#5':3U"958F2#PM'_V@ , P$
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M2H"U(PI0,A(US5L[7?G-JSEM7W;,2<>I>.Z)!3>?/#)E\:]IQS-&E+>YXU)
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M,(L?-(T#'S&,I5..IG6;BJ X4D\B,9)QV&<X^G!)]!CK:I]E]T1;:CIOD;R
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M]S9_^SWK_K6I^XP\=_YRMT?[SH__ &/T?JIK?W"E_FR_\W1_?@[_ /WN;/\
M]GO7_6M$=QE]//2W%V\'[#J<O<[79B(5^"CRKH5 EM0(QKK:Y$B):AX"']D\
MYEE 3I;RGG&P5E"L>VT:5AWAK[U57"$02+%'&'#L(@X+D A0Q9VRH)SC'5@"
M>JC4>>)/C[O'Q,LL%@NE):+7;8JQ*V>*SQUT35TL*LM/'5-5UU7R@@9VF2)
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M/I)UYYMC(,XG[V%=RM+;]$/;7EO.,+PE1(G?*<J2I.,_ZTYQ_1T6DXN5&?\
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M*<)QE6<8^N<)QCO^]C'[W6^Y=;A6G_[F;^L;3A\4Y&E\2=]RL &DW7?'8+D
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JFW6-L5EIDG-9=9*"H2OIY+955=1;6N!I9:J2"0R\2GL*U06H%$'48__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g107876g79n61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g79n61.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( .H"6 ,!$0 "$0$#$0'_Q  >  $
M P # 0$! 0          !P@)!08*! ,! O_$ $80  $$ P$  0$$!08-! (!
M!04" P0&  $'" D3$1(4%1876)C6&!DA=WFX(B,Q-#@Y5UF6E[74U0HD)4$R
M,U$V0F%Q@?_$ !P! 0 !!0$!               " 0,%!@<$"/_$ $01  ("
M @$# @,%!0@ !0,#!0$"  ,$$04&$B$3,11!42)A<8&1!Q4RL=$C0E)RDJ&R
M\!8D,\'A)6+Q-'-T=8*SML7_V@ , P$  A$#$0 _ /?QB(Q$8B,1&(C$1B(Q
M$8B,1*!?))UWJW%_.PVS<9NJN?74WV'DU%:M**[6;2X/%7.U1PA538:W"C(6
M0O<>1]Y&WH?U4J1K3+["E;7J: $^1OQ[>?N^A!B5[+]E]5>8^XDN$=8[F/[^
M*ZAYH[5U/E?0Y/+*5SJX4*_\C!3"\D62#U&/^BE@KTH?IN<Q(("]R5D=1X:V
MDQ(\K1*NE;R!V^0-;)\$CZ^?^G\D@?POZGZYV\QP*3>_='8#UJN?Y>3M/(5^
M(:V$H1-YF-+(DZSKM8KEHH5#%OQ(;J6K*..1=+<VAJ)(W(<;0JK!0#JO7C^+
MO/\ (_RB:(> ^T='[CSCL%@Z:>;L):J>GNX\X!26Q 8-J%3Z;88T"NBE,!!X
MZ/)7 BN+;5/EM/D9>]_?F2Y#FM*U!@!K7C:@_G$^;W-W'J7-V.!<EXB7#U+J
M/IGLPKE0CH1X)'LL#G0!(^48M-OB5R:M T^>@0F([(4.5_\ C);TE[<K_P#4
MWK90#LGR -Z^I^GR\1.$$G^_^-:[V_IOJ_T $[OYSI-&'VRNVU=&#T_MHRT(
MFZ@$*<[7*>'$T<Z&.2)4!BN%))B(50:G11LMJ*+2Z0:>&T --\_H?O\ )W^7
M\XD =G^1\N9\S^I)U K=MX%Z'Y!RBI=2KHNW+YC>MO4^XV4<($VP6^!+7NH3
M'&%JDBK#7CT=LG7B4J/$EP52DN*C5"Z(WHCY^_N =CY'W!]OI$^M[WR?XQU'
MVR7[*4+6[F'%JGXF_5]40@FD!9<*U]YIY+](%2+//368408:LZAY F7NUET$
MK,",_L<J&TI,"54KOM  !)8;\^='Q]?;[AN)?CS;Z WZ&J1BS+YW8^>K"G%!
M-ME3]%NE>L"-PHL]DU2KYS:S6RH6P*IN4F,_*'E$O0R+$F')C(^XTZ]%EU\]
M[^X@_F"/TB6)R,1B(Q$8B,1&(C$1B(Q$8B9L?)>>]'\HX/>O0G"O11'E#/*:
M@U-GT)CEW,;M NA*;9A8YJ=,/W@$;)A-Q8A+;28XQE49[Z"5N-?46I>IIV[T
M5WOV.R-?D#Y_VB0)V#O?H/R .\:&NL^F;'U>N=>[9]7IY5KA="A&$\XD\WC%
M$4D76>;TT@6G?@SS;I1!>O08]HD?BUQ5O[@1T,IEI3W:76AH>2?/GSY/S\>#
ML1(KZ-\BW3+7OY%K5POHIN!2.)<%XW:^.(L?*8=:*U:XGBJQUO)O!>BT:!8R
MK4]Q"DL,6N&4$);TE\1':;5IS= HVH(]^[?D^?I['^43FO)/L7M%W]-<QYO5
MO44;W#0;?QVY7#KC<+BU3YG(X99PH-DC5HBK=40@ *25:[)O5/;C%?K(B+=_
M%NH;4_$=15@-$A>WSH'NWOV^1_7_ /!B6O\ %G=_3/4/2OM/GWHL?6Z?OE<;
MSB0I?*ZM,$6(?S>%TVHW>R3Q<R\P@XV?<;!,A0J^Y9)[\B6#C&XTYFJ-Q ZT
M_B(L%"J5.]EMG6MZU\M_>8CN_3.^=4]B!/&_#.KL\!%U[@KW?>F]2ATFMWNW
ME6B%S_0BN4:K"[>U+ "V=/Z_.C)IV!*E.,+1#B/0W&'$3@"A2Q&SO0&]?F?G
M\OY>/,3DYWH3K_CWDM9$>K2@3T#V.[]@(\SXJYR:*#I1KJ860RX0KYF_1+2N
MF\^YV9@CHI"3<94$L[4@\78E#,^;+>DO.4T&/CP -G?R^NO<G[M^3$C2Q>[R
MW3"'CTGQZ8:H$:Y^RR_G3OM$L@NFF30XA5:J;(6*ERBT7=I$_2U)2$-#;-23
MB-D14V"\P1:1(E0FZ]NM[ .T[@?/Y'Y?AY$2.N3_ "6F*5QOG<GL4,CUCK/7
M.V^E:?26T&>.\? (K/'+P\.1$+6VZ&>=4.#.B"2 ,6#@J?D6"SSEJ;_]S-W]
M1^O9MCKP!KY$_+[MGY$__'LFM7*K^GJ7.JAT)-6M-)3; [!;55NL*(/LX7ZJ
MW&]Q"L:!.)0?O[VWMZ-(A3Y<2;"=C38SRV9"-Y C1U](D@92(Q$8B,1&(C$1
MB(Q$8B,1&(C$3&GH_NOJ?$ODBL?,K[-1,\B( <<IYHCL. C-\CZ)UX>3?IEO
M+'XP]@^Y6SQVO3ZZ;>.$WP(1)2).2Y!=9CQ2%P*"GC^+R??W ^6OTUKS^OA*
MQV;W/Z3UY\\>6TMZ%.<VG=<]$>D*%TSH]8XE1>E'FZ?0;7:!U2CC.>1:"8:G
M2!D8:/@*V ",E)C6W)I)^8XA][=>U>YP%V!K0V?I]0?GK\(EF?(?NPL@-[,L
MG<.Y([#R+SH]SV;3NBG>8AN,=@L*[37)<LS6R7&!\8$3CIDV506L<[GSZR$?
MN)N=,B0'IZD+8$T9?X=+HMOQOQX.O<_J?/CQ$G'X[N]>A.Y3/4G\HF/% V*C
M]KA!:[SV)#$-)YC6C='K]J@T:63'#8$PZ6"-F&XIPH7>GR733<],:0B F,PW
M1P!K7Z_7V\_@?<>WB)T*5<O6/K'T%ZBI'#_1$3S10?,)NO<Z H'\OIO0S/1^
MD$:Y^?ES%SDW2-._*:H'FJ;$PA=>:9=*PG539#R)+&FW*_94*2.XGR?)&A]/
M'UWY^GWQ)+NWM"W>=!7(.3]AH;?8O4Q_F9;H/0:[P\U7 =-'UBHR_P L,W2*
M:ZR6H+7V&I2=- ZO%8=*$CC9(0.8TVT-<(4[0=D'0WH;]]_3QO\ G\Q[^2$@
MF^^YKE<>ARK!PR]2(G(+)\7G;/4%.'3JO5G2$#J-6L3HX ;)N$A)0@@E6MLR
M!!.M.$YM6>GQ)&I, EI*)+CMUK8\]X!]_;7M[_/]?PB<G4?DW8K-*\XTVST.
MX=C[/</+7$.W]'E #W':'-*.=#K4%R6[1ZK<;?17^@VB:49)D9%2YP%>8',/
M1HS&F%*W#BU-?EM> &('@GYD#>@=#[S_ +Q-<X,O4^##G:CRHFID6/+U%G,+
MBSHVI#*'M1YD5?\ AQI3.E_3D,+_ ,-EY*VU?TIWEN)]6(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(E6?8/FE?JWD+?+F+[)YK.A
MW>EWL9;8E<AVMV"4I)A!H>C86>1%Q)2'933?W_KR5-)TC['&'T*4WN2GM.];
M^Z)#%6\+6.9<[EU7OGHNT=\ZN9X[;N(TFQS^?TSGU:YK4KM'D-GI@.D4_34*
M=89SS^M2C,TDF3('_4&*VAE;3D=W>P T =GR3O\ [_2)QOGSQQZ<\_C.6487
M[FGGN/\ ,E@A[?-I'F_E\!1JH"9B'I57=N7YI/LT#\RB?7A;-HDR2<3Z_P")
M:6MUI&LJ6!V>WR1]3[ZT#$X;E_AKT1Q,O;&>4^WR%5Y]<.O6_KA6@N^=>:V#
M2IUVL&C1T2BTGC$\XAE^.AH:B6RMGZ"4?BXT1AU2D8+ ZVOL->YB6>]1^9@G
MIFH586Y;3_-[[S:\A.G<GZ?568,L[0[Y7M/H@%$C2:%CCHF3'E2(AFO$?NPB
ML9:-+<9?CQI#-%;MWXV"-$'Y_P!/Q]_I$K6KX[R/0ZOW^%Z=]'WWO%R[WST+
MS&59(=:"\QK-%J]9+HL]<53^;@IQ>O-&8-K8B'I94B]-<G/1UQDLQ&2)C9&O
M=HC0  )^\^?O(^GW?R&DZH/^,A3_ ![O',;7V"HRRO:*)6^=Q;/S[S5RWD<*
MI@J^5'F)$YX)49.B]I/6*<-B2#LDC<(8=V0RR]!!0-LMI2[_ "- ^-^"2=[&
MHDG6+P:^3.^F+*![23K!?T56_/=?<^WGM4M BO-<#KLVO-13E?MCQ<->J[>&
M)JU'P$V&%4PPG\-%**7O4E-.[VV-ZV?<_,[_ "_[\XG;?&GBX3Y(=Z\68M8>
MPG>RV*NG3@VD<[%\AYA7&ZL'D!QD.D\R#FK'!KSDQ$V7+/S4&9"C$K<5>V(J
M8B$K,W=KQH#ZG9\^^SH;_.)=[(Q&(C$1B(Q$8B,1&(C$1B) /J3A$;TWP'I?
M")EE?I\;HX6*'>LL86V:?$IBF1A?3[8MV<,;F*6H;IC;:IT?2=/;<^_O:-(5
M4'1!^D3J'4O+<+IMC\J6%ZYR@Z_+UXBW2%%:"-34W)R-55U?0^4\LG&V$0M"
M_P 9N2TV34E6OH?1WK?U=5#?Q>/XO]O?^L2'^T> A?8K)ZYL4CI\\"OU=ROF
MO,)T5FJ1R*:2SSE_ZS1F*\L]#V==+?\ XN0GFQ2(?^5,J1_DP&UKQ[;^?U_*
M)>BG5J+3JK7:O$4VZU7P0@+^*;BMP]S=BA\>!^,<CM*6EMR1J/IU:/J._<VO
M:?J+^S[VZ$[)/U.XD+<V\\Q.=^A_2W?VK3(*RO1L;BT>76'!#<./4]<<J!>I
MQUQBJ2$APQL^@LJ<]IV ._+UL)81N9IS;J1.P!]-_P"^OZ1(X] ^2#W2^L5'
MT+Q;MAKSQWNK4PCS.3=H%,K_ $>OV[FQ(K^?*J=MI%DDCX1)L:=^^6"SV"<-
MZ!,>===;F.,CECZAM @C8)!UO7D??_W^>T@NQ_&,%LO(JG4S?:[+<.P5?MYO
MT&]V#I].KW2 MBOUJCJ@VL2;Y :E,U/7.C$#Z#;=*%$!C8R9%9(PBB9#DS4N
MO?Y]AK6M#8\#V\^^QOW._OB=QJWQ]P0(CS]'F],@2C?%?0Y/T27(5KD-$YT"
MN1TD#G5_5;'U&D;$#JH$'C7X48?+ER+::;CCVHD@A)BIB,P:=WDG7N"/?>A^
M/S_VW$Z3.^-:8WR"M<G"=K!2AH+I/6^@$Q73>!4?K/.;7OJIV<<U%-4.QFHT
M^*:IKTYQ%9L]?N@:0A;DAZ:/D_4CM1*AP&)U[_1B#^H\:/S!!B7'\I^> WE7
M@]&X6"LA>VP*8V:<4?,LL0WYTZPV K926X8J*MV(%$,D"\E@.&C.OMCAS4:.
MY*FR$OS)$6.R3K6_D/\ YB6'RD1B(Q$8B,1&(C$1B(Q$8B,1&(E*[AXDH'1N
MA^H;;T L]9:OZBY9S[EUCI*Q+$75<C<_CFD#[ ).JFREO&=3BT<P+>4+BJ"%
M14&8P[)<0G:)!B.W7NN_SW_[?(_6)64+\7ANE\;\P<VYUZ8+U&W^7.@]*Z'5
M.F/<JK]EDEB?1IA21(9F50Y97P[6AK!:3&2[)?*(F;^R0J/&<^[I%>_RQ(WW
M:^?_ ,1)%K/QLTFR'>KW'UGT,UZNN76X-##&2!D! Y&$%@N<2G2%9A"*_P O
M("=L2V2+C<N40646J1N)&3IAM:Y[TX7]@!V@?G_/_NS^&DD7RCX*Y#Y%O?:+
MOSG4C;G5SD:0,'/O'W$4FIQH8Y*:>Q*+V<ZH^WLO">,?GQ%A@QI4O<#;JH;+
M:-T9BP&_E_OKP/\ :)U3J'A^^S^L=0ZSYP]0VOS01[N,"P>V QW/:MT8-:B%
M?%N AMLJ^K!.%RZ!<DA7G84DZ(D2]27_ *9-4-!%&Y*ZAAH!EWKV.]$?<??8
M^X_AO42/NB?%W4S<+B<CG?2T ;9QKDI/BGZ1=DYA4_2$.X4TH3=L"B)>NWJ6
M,AP+F,LTLD; V$7)9BB=$9 9L,Z!TV,0#^^Q[G?@D?\ 1_TG?F)WN1\>H!1&
M+-A]*EQ&X_BGH7CM;#-$JXQN2CHI9TV6Z7N#5EUFOPIZ",B5(W5Q0 ? D./K
M<43:=4M;E.[[O[W=[_[1(JZS\73_ $[G/,N6.]P!.U*A<$I'"GH]\\]T+HQ"
M BF@HU?7?^4V"::"V?E%Q-1&%/2G&3EK&L2E-/M0UN1T*5(/Y)(]R3X)'DG?
MD>01]Q'R_'::?4&GP.>T6ET 5,)D1E'J=<IXT@;E_CS,Z!60\,+#F%YVT-[F
MDY4>$V_/E_3;_$2ENO?<3]_[NK9\DGZQ.V8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B)5?VY5%6_R;Z#@:+VD7^7\=Z>=2Q4R\L)--R!% LLJ #(3!R4E
M'@LLBF&^1%CY<+9I$5 DB[+"32@HA5?##\1_.)5[T.6X.=[72.=D35(J_9EC
M>-GBO5^@V0<-(<EJ5?M;AT, XJR7EM$4]0Z/+9)"YL:H)A#XH68P>Z+.(,,T
MZGVRH!UO6P=^//D^/)^[Z?>/'S(2 +:S,W7[2GF[<S^4I^6^V_Y2ZZDW*UU!
MRCKL5GW6TV58M.K$MQU&Z7OS[J0K<I5:3'_5?_\ #(EZU+Q\_P"'[.@?P^6_
M&OK$NWP 76"\WTZ)\V'J_3>1%XE/&\QM/.10$G0JST^;SZ5%N-CHX9IO=0**
M"K=HD\Z/BMJ#3;=#,PS25&U6%.1;>AO>_.][WK?C>_SB9A>HZ;\F/BL7P;K!
MCY6[WW"N6/USY=X]:^;&O)7EZC0+!4^M=@K5.LC#EEKU4F&ARE!Y\MI#HS4:
M:G;WWXLZ&^AM]$9<!4['8!]ECON;P0I(^?W3T58EN,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$3+;VU$K47J&KJ5G\JM5UHW&8A#D'"NM\A7===9N4BY&Y<FL
M\LL4X_ BHO=IDA:S6)<:KA3EGIRI58M!5E5=(;@D9K]/(&_+ ZT/O^X>3$@_
MH31M4*^:Y4U(1[)W=OD"WTE5;0K]:OZI':3Z*_4(DV[%3^:JK.R"_+VN0?CU
M[&[D-"=5S[TIDUI,AKQO^ ]GS^SW?9[O?_\ NWK\_$2U7&*_5;00]05OR=;Q
M7->667C?, //N@<U"@S5;HG?2H7KP^W7," GL.U4U<ZM7I/$3%I$E6'FYYT=
M''V]I9)95O<&WH=V]^??Z>-??]=?=[>('O[;^[Z_=,\N]4KY#O%W0?$EOL?R
MA]/] 4WL'O/S9YXO?-+-YS\YT@68I7339A=BTJPU2I*/1'78(!0Y/Y<_!E);
M(.OL3HS[#2MQEP=K=P[ -*Q![F]P-_,ST.8EN,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$2H?LNW\9IO/:K/[,"#W*')OL"%2J%:C(X+0[=>)("QQAC/1I1_:
MJFW1P,&02M!.9;(A,<)(!A)4,&-W>'4A$Z2[WX.C]1[@?=\_T_")GJ;!5(%3
MC8F5<ZET:\Q_.7,=>++4 D)(BE]JD=<[=,L03SG)=D3I[+M/M,GE55GQ0LMT
MO Y< I<.R+V$@D=-R\D_3R=_AH>_XC?O\]Q/MZ&R95"OJ>4HD:]C_IG\@>^E
MN5I"T]5WR5RF^AOU#Z-.QDZ+;K:IZ_,.N.?F"OR_;C8G5<^V2R:TFH^7=_!]
MC7^$G8[OS_BWK^6HD[U7E%.[7"])\U\N=<M? N+V:G><?T9ZIYDF5T+/J_60
MI^\'>H_H=-* K#5V+&:H8WD5;Z1]<-+(+:)3HQ?\-9]RI#$&V-!M]WGW]]>-
M??\ 77^WB5!T=Z!^X^TIQ(Y+Z"\;?(U\:=#=]^>P/17//2-H]5@^BT/O-LHI
MBLR(W,?-%LNM8=BQ*C0ZD]M^/8W8A)>YDB4WJ0,@K90UM#FW(R>PRL>U00 0
M1L>Y ^9/RGH)Q+<8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1((O'I+E%".RJM,GVZVVL?]+\VJ_*.8],[-8 'UV428^K.+Y14
M;C)JRI,5UN7%19$BE2XSC3T5+R'6MKJ%)^GYD#^9$3M'..R\XZP@BFDV!R43
M#:CJ/5<Z$L%+O%=3+V[J&NR4*Z"J_=*\W-VP_J$Z9!06YNX\C45;WT'?N""/
M?^H_(CP?RB2?E(C$1B(Q$R/^97_1\\Y_VB'@K^\73\22^Y_RO_P::X8D8Q$8
MB,1&(C$1B(Q$8B,1&(D(=/\ 1O&^/M;W>+J.A3?N(6V'@:=+FGDN.RF$;;&C
M42)&D?7A2&%N.I;:8<;W]=QI/^%D@I;V'CVV? _4^/R]XE02_P E%2FO?@^:
M<AZ)>9CBTLQ4R410[4F0[]!+++2!;=IFK6MUQUG:/PB7/J-M?20[I_\ Q<O3
M/N3H?76_YZB3]P?NW5.K$UM77AYOE8M32WX4DTS;WG)[*HNY++S$N72Q81IO
M:MH:4F84B275+^V+&>WK:-1*@?W@?PU_7_V_&):_(Q&(C$1B(Q$R/^6S_-_C
M5_M</$__ %*]8DT]V_R/_(S7#$A&(C$1B(Q$8B,1&(C$1B(Q$8B-[UK6][WK
M6M:^W>]_T:UK7^7>]_\ UK6(G5@=YI5GE.PJU<*M89K#"I3T0'8!):4S%2XV
MRJ2['@2Y#K;"77F6E/+1IO3CK:-J^\M.MUT1[@C\HG:<I$8B,1&(C$1B)D'[
M=_UH/PJ?UA>[O[GUCQ)K_!9^"_\ (37S$A&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2DW>^YV;GHF]5(.%:H=B1,#&@U^ $Z
MB?"IJDVSAG+>8L&S M^)RZYO5=5AV%L77*EOC+5I<!:-7\BS)F0V9 #P=[^[
MV\_^X]MZ\^?;<2;.!_IT0YV#.=-E,&;1*6:6'/27J21L<JD$"JYE9_2,OSF#
M H,LW+$MCI!9=&C,5>0ZW%<AI><;7(<H=;.O_?\ /W\^_P!8DVY2)P9.S5L*
M0#"3-A!B2MBD.Q*^,)EH$ @=ELI2MZ*&ARI#4DG(:0M"G683;[C:5I4I.M*U
MO:)_8UFK<TR4KL.P!)=@!L1I)H%&+0'S(B-,1IR'(*#&I"YH]B4WO3D9V6PR
MV^C>E-*4G?VXB?T#9*[:AZ2U7/!;(*4^_&23 E()@>J3%<VU)CIFCWY$;;\9
MW6VGVM.[<9<UM#B4JUO6(F5/S*_Z/GG/^T0\%?WBZ?B27W/^5_\ @TUPQ(QB
M(Q$8B,1&(C$1B(Q$CGH?6*%RT8^3N=AAB],QMRTP4_6FEGHWVNIU*:$#VI91
MR$EQEQ#TYN&N+'VA>WG4:0K[*A2?;]?8?K$S<L/HSN7J@C,I7G6$NHU_\2Q!
MGV[95B)/CPY>AK,N418U"G6*..9E..:CF1(T5N&V\MF2M^1IM2+H55&VT3]_
MD?D#K9]_!\;$21>6?';51\EVP=SLTKJY\@E+\T?MPN/&1Y3[#RIC:C"2NCQ=
M2)[ZI+,_[X;Z_P!-.Y [_&.(W0V?X1K7L3Y.AX'W :^7G\8E]*OSV@TCZNZ9
M2*C4MR&],R%5JN!P:WVM+^KII]8R'%4\W]37U/N.;4GZG^']GWOZ<MDD^Y)_
M$DQ.X92(Q$8B,1&(C$3(_P"6S_-_C5_M</$__4KUB33W;_(_\C-<,2$8B,1&
M(C$1B(Q$8B,1&(C$3ASI\16ALHL:F)APHC#\A>TM2)<I_49AR0XS 'PFI! G
M-4TTO<<>.BRI\I>M,Q8SSRD(54 DZ'_?Z?C$RH]%>Y8)B7+H7,E:<TF>L:1F
M'!=G#PVG(D]YIR9)G1"57MP25!6PVXZ+;$S%KTEQB0OZNUQM75J/N??Y#[)'
MW;WL'8]OO_.)93Q%7;[6J"5;NPB<X^?-N675G--E!QI]V37:>.T&>%'A<,I(
MAQ/RU_4,VU*F#9\>.PIEQ3RW4LQLUL:T-#6AY&@3YWLC\OEO7WE+MY;B,1&(
MC$1B(Q$R#]N_ZT'X5/ZPO=W]SZQXDU_@L_!?^0FOF)",1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B86]UZ?\F5,]S<7\O5#TKYXA5WTJ.[[>J.6*>:R
MA*7SJJ\K;C&Q-9/:3U.*NW%90DI#&/G(RP32I<-Z?L=M,A,9KKW#\?T#E=(\
MKU!E<#S;W\"_#8>977SM=:YV3R):FW(I_P#I[#&K6VMK%J86GM8)W[7N.+ML
MSERZZ%NH"WBYT)H8E%KT0K?VH[B00.X:\C>O,[L2[G[S](>D._><_+W3^&\@
M'>-JSR8%U#J/0.5E[Y*[1W#H-+5;9(6O5MFTCHE!YV.:C.1"L[>SEB@37DK&
M[,Q7$MQ/&G$='\%P7#<[U#Q_+\D_5&1R5W'<=A<C5AKQ7$864,=;;[VQ[&S,
MVPL&J4>C0Z#5GI."6D;<JZZZFBRFL8RUK8[ULYMM=.XA5#*$0>Q/VCL^-R'O
M7'N;V7PDE\>7/.J='\R^,;WZ$JWHE[T3>;N&7U/DU,L?(Q-.(5-RO3'K=67(
ML"YN%U1&A\@]-=&%+)!%*)F=B/QA/*=-=(]+<PG6^;QV!S_5.'PF1P8X/$Q+
M?W?R671R=N57DBY!C7AGQ15W%Q2@LKQWL].KU.RNWD9632<)+'Q\9[EO]9W'
MJ5HU00KVGO7PV]:+$@L!LZ\VE^,3UYV;U$]Z9 ],/\RZ[4>*=$JU5YAZ<XQ4
M[%3>:=P'GJT\9L<<.)/%SS+I;GQ)J,*.3@I1X2^LO":C)?1'25*:]U_TSQ73
MXX&[ IY#C<GEL'(R>0X#E<FC*S^(>G(%5#6V4U4D59M9:RE+JQ:!4Y8@L:JK
M^#D6W^N+"EBU.JUWU*5KM#+W'M!+>4.@VB1Y&B?<_/UWV9Z.J_R0^3?, WCZ
M:/YXZK9^Q5HWU&WR0Q WU\O1.$S>F;3S@(.)/$:M4ZD6?"P"-D/L-RK65<)C
M!4")""29I&7&=+<'D="]2=06<G\7S?'4<7?5Q^,MJ5<95F<PO'_^?M>L5Y&3
MDUBUZZ*&*XU:UV6.[7*B+,F\9N/0*^RBQK5-C$%K"E)L^P 2553H%CY8[  T
M2:N3/DJ]-M=M)].:9Y1KR$%^3>/\9TWG#E5.;ZH[+_#QQ!#O+?1-6;\LTW&N
M4IO<>H?HGIA^N)<B+<030DN[L"=!\ >)KP">2_\ $UO0#=?)G#(I_=P7N:VO
MAS@_#^IML53W9)R=KD:8;K/I#SG-O]5K/[/X9<WX+L[2;"? -O?W:_C]E"GQ
ML$[&Y:0'[+]''?D\KOEH_P ?3RCS_/Y3VZP5HM:I(4I?.NE>86T%6D]%&,!R
M4S5-Y[/?FR$5 852FP6,;O\ 20DP.C3AP^/KUO2W!T] 7]0T\H>1YFOD>)IO
MJQEMKP^-KY#&MO.#8UM:_%9J!5.394?0HL_L$:QDL=KXR;CG"AJO3I-=K*6(
M+V&MU7O&C]E#O[(/E@=G7@27*Q\C_&K#WJF\#(<W]%46?TRX7^A<KZ3T;D!*
MF\LZ;;.:12$VT"JB:*$4V->D1A<]P80-5,*,+?0^[!FO*=8T[C<CH7E*.'RN
M93/X/,3 Q<+-Y' P>3KRN1X_&SV1,>S)JK3T!MK$%B4Y-ME>_MH "1=7,K-J
MU%+D+LZ5N]95+&KV6"DGN^1T2H!UL>)Q9ZN\[Y'Z%)=7O-8]"Q--6PY<*Y+J
M'$H?8*89.V2G2:61).6WBG++EW.#"2#(S(K=.Z:;&UT>7TQL%&)"0U4_+=-&
MR->/D/)U\_O('X_/YGYF>N6CXO9P)R,2C4+C=MYC0$ORR\,E:*.WRIJQ'3$U
M4HH\*YN6;%WH8M]Y;Y$T3MM1JBIT^4AZ$V9?DD9,.A^\[/X[_P!_;]-Q)TRD
M3*[TE5KRGT!T&PH'&C[YBE>>(G&:FWQYKH%2Z&5K/1;>1M%,M%T>K!U_G<:O
ME9@FVO%@UAYS/#))0+O/.6$755C0\QKM ^]M^=:V!Y ^ON/8Q(HOW.KO8:98
M:)2J!<4]L!S/?1+IQ>/3CP9VV4[ILGIKU4##[_*&P0MF=ZE(.\P(4D6,L,U^
M,P 8:6R+<I4Z.)J#[$G8^SKS\QK\=:&]Q+H<?$O6>S>F3W'V2O**;=:OSFO<
M^/S^9D*Q''=,#4JQC#EY'<ZN(BMJ+MU^"1YP$E)G#8XPK.I;]9?D;_)9;<:)
M]AOW\[^?N?'G_?\ .)BO\@_FWWUS.E^9;5Z"^2EWTWS>/[[\11)W*5^/.)<9
MT0)S?0-/:$E_TYHQ>98(GY+)_P#=_@&6-QR/_P"B2I+?].1EQ2NSI='M?SL^
M/LF>H#$MQB(Q$8B,1&(C$3ASUB 58:\9LIL57Q,=3:'B9DA%&06W'5:0RVJ5
M,=99TZ\YO3;+7W_J/.;TVVE2]Z3M$STZ=[TADI3]3\[5FR=#L#JV(*3T:KE-
MBHLJ>IB.QN/&EQ?S5,N)+<=96T0KCL22ZVE+"G&EZ=W=%?S8ZW[:U_N?8#Z^
MY'S$3@*?Y)ZUV8G%N_H_IAM8YV:\:A4*)'(3X+#L^/.4EV,-OOXT?6EQI,EM
M3@*;1G(D2,J0.'11S>V76*EU4=JJ"=#9\>X_R^_C7GN]_.M[B:/56H5RE"8X
M.L"XXD9&UO3,:/I6TI^W2=*^S:U*VE._N)^QI'W&6]:TEIM"-:3JT23Y,3LF
M4B,1&(C$1B(Q$8B,1,C_ );/\W^-7^UP\3_]2O6)-/=O\C_R,UPQ(1B(Q$8B
M,1&(C$1B(Q$^:;-ACH<L@0EQH$"!&?FSITU]J+#A0XK2WY,N7)?6VS'C1V4+
M>??>6AIEI"W'%I0G>]/?VB4AZW[MYG2)^ZI28Y/HERFK2P'U6XXTS6WYGXQE
MA,5XA&L$.2]^,0IU,-X6S.1]1.EN:VG6T+N+63HGP/SV=?3QKQ]Y$2I\+F/K
M?U*=2OJL*TTB@.M[U*8F'Y-;9E)0U"CIU"K:F)@J0IR+.?DHEQZL-;*-,2HL
M@U];_&*GW(G@:)^[3'S[_:&O!^FR1K\XE_N'^4N8<)3J76T&"!]S3.Y9H@6(
MH2^MC4]MM213$M(Y"/H$'6UM.M24;6A#Z--NZ^]EMG+>/ 'T_P!_?W]XEF<A
M$8B,1&(C$1B(Q$R#]N_ZT'X5/ZPO=W]SZQXDU_@L_!?^0FOF)",1&(C$1B(Q
M$8B,1&(C$1B(Q$^2>IM$&8IV2[#:U%D;<EL?=^O&1IE>U2&?O-O)V\RG6W&]
M*9>U]].OM:<U]J-R4]K*Q56"L"5;?:VCOM;1![3['1!T?!!\RC#:D E201W+
MKN78UL;!&Q[C8(W[@CQ,MN0=8YT?]/%0#_<.RWM3!2Q0QXV5;.CHJ*#4(YSH
M=2$_DU1C JHIE[3EOC'XY4:JMN*TU^=1T/O?>?ZGU!CWX/2/'Y/[DX+CAG+Q
MRI95QO'V<@]>9B\M?E&R[+&5GT!O3Q'Q+C97>H#>A;VKI>>\-=5F=2YU Y7E
M\XX9SF=+,_+KPE?%OXVJ@)5C''P[BI?)7(J%=E3;7U:]MMM5,Y5.AQB(Q$8B
M,1*7=1\K%^@^U_+/JZ-;QPT1YXHO<J@2ISXJ3()69[K@44*AS8)5N6W%'M!5
MCE/269$20N6EU*&EL[3O>]JX_J*O"Z4ZBZ<;%>RWF\OB,FO*%BJF..-NLL='
MK*EG-H<!2K*%()(,\UF.7RJ,CN %*6J5UY;U  "#OQK7T.Y7OJWB/TQ5?1G:
M?1OB#T10..%_3@"F"NZ4WK/+I?1Z[NT4 )(K%5ZGSY\780;X6UP*])7%E!"L
M4C734_2R9A,Q3C,:'FN-ZLX#(X/BN#ZMX3-Y2K@+LJSA\KC>07!O^'S;5R,G
MCLU;*;1;C/>H9;JV2^I-5U=H!9K-F->MUMV+<E1O""U;*S8O<@[5L33+INW0
M((*DC9V3/\"_C:+M]!^/.U7[MI;O$/QG3?2-=Z,2[= G7BV]R*^@*? !+)2I
MITJ8CBA5;)QWEC 15P_J#6V1 )B>^X.W/D5LZ[J^"ZWQL/B:N';JK)X&[!KX
METQ,;AZ^%RGN%:I354;;+ZR!9=6*._(-MY119V ,(]^&SVFT8JWAS:.YK3<H
M&R23H*1L ]VAH ^-R8O%OCVT>,SG<:-6.D1[#Y;M]V5?>#<FGCR6CO GSVG)
M5UHH8[((RXA#GDHN[^/JP=F(/<K^FW]O;)3RQ0@]B^JNI\?JFGB,O(P6IZAQ
M<087,<DCU^ES*T:7$S+:EK5TSEJ 3(M9W%W@#TTJK1;N-CMC&U5?NH9R]59!
MW46\L@.R"F_*C0[?OV9W#NOE\KU_U#XH]!0K:/"#O*-A[D:+UJ4+DRYMQ;ZY
MRU?/8; T@U*98%+"R5?F<E<J/+3,8U^':TRY_C,\W$=05\9T]U7PCXSVOU'3
MQ%560MBJF*>,Y$9K&RLJ38+E_LU[67L;[1V/$E;0;+\:X, ,=K25ULMZE1K&
MCOQHG?SW[2C4KXJ;X]WN5(;[?5D^127N^/\ (V1Y6Y0B2^JN=[9@H6_36KU^
MDNJYKE4ZSLLV1^-NL:--LHT$95K7U"KVW+^T7#'#*#Q.3_XEKZ/;H:OD1F5_
MNX<,7/;E'$^']?\ >24,U 89'I$_VIWXK'D. _K$^JOPYRQFFLIM_5T/L]Q.
MO3+ -[;^7WF\UN\OE;-[CX[ZX:MH^(&Y?PGIG()=+<&2729:;?;"!-QS<<LF
M4B+%BCFPZX[T-R&Z[(6^E:'FTHVE6HXW4%>/TCRG31QG:WD.8P.37*%BBNI,
M.BZIJFJ[2S-8; 0P8!0""#N>IJ"V57D=P KILK[=>2793O?L .WVUYW,U>-?
M$/U_G_H/A/;[QVOD70C7#.Z=$Z3+Z1.YG<G_ $)VZL="BVZ*@;U3IQ[H)R)%
ME4J-88H^J5NJU^!54QHBY4[;TY##F;WRG[2^,S>%YCB<3B>3PJN7XC"P5P$S
M\5>#XC(PFQF-G&\?3A4NRY3T-9DWY-[Y!9@J (6$\5?'6+=3:]M;FFUW[_3?
MUK5?N\66-8VBO=I54=NO?R)N 1Z%01$U\:6O%0%D8JM(E0"-E"PIL9:D)<2A
M^+)FM/LJ4VM"])<;3O:%)5K7W5:WOCNC]#^DRTB7RUVHAZ Y&UTDD/$#'G^@
M]BJ,=@'(?E#7QG..M77GH@DS(D.OK=<+"ZS$)RE(=5'W*EO?A=)C_23H1H_D
M/]Q$L3E(C$1B(Q$R/^97_1\\Y_VB'@K^\73\22^Y_P K_P#!IKAB1C$1B(Q$
MXDT>!UN ^5L1D4!%Q6W'9)(R1B"X$=II"G'7'I<UYB.TAMM*EK6MQ*4(3M2M
MZUK>\J 3[ G\/,2K5C]J<@A&M5FB,VOLME6XXRV*Y6#79$+?:4_]5MLEMZ+
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M1K[P=Z_+^7U_.)PU]]7>6^5V692^G^D^!<XN(]F'(GU.^]CYW3[+!CD(S<V
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MN5Q:4<5TV'*RZL;'S:;[K*5M])* EG(T6$VUTI79ZAYES[6\[U%B\%8R4X.
MR9N5D+QN1:X+VI\/C6778MM526&HVM;W5X%U8['M>RL(,/?EK[*W))=:K5#<
MI_1^'^>[=P_E9VHKF/QK+T'J 'AG2ZR*O+9L6B0J/4>>V$]'JDP&W)^I<+L?
MABEI)17F'AG5?V>X#\;Q7&YV37F87-\WA<QGT9-G=?1@\5D\WQMKX+IEV^K=
MF\C50,A<JSUK,;#I>]M6*_JSS5KSN0;!6VJS"PK<.AE0"JR[)Q\*Y?67X>L5
M548W<X--8I1[6[%[5[>W8OX2O W<?)7-K9TKT/+@@NM]I*6HW?>:_H1SR,2
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M#;V=C1^8_+^?S/WQ+5Y2(Q$8B,1,C_F5_P!'SSG_ &B'@K^\73\22^Y_RO\
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M2Q)IN9-4Y*B?@'+@90!Y(.NW6O;9)+;_ $\#\(F@7A;DEUXCYHI=!OX4;4K
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MO-J2XTZVI2'$*2M"MIWK>^0LK(S(ZE64E65@5964Z*L#H@@@@@@$$:,VD$$
M@@@@$$'8(/D$$>""/8S]LI*QB(Q$8B,1&(C$1B(Q$8B,1&(F1_RV?YO\:O\
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M113DG*IM>S(2VB_)QFJJOIR /B;-GX'$9J!;;8]YO>W,MO9:T+7Y)%GFLH'
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M%Q<4<4,BV=IT7!*Z_O Z!(\;T='SKQJ6#\-?&[SWQU/L?3+'>+5Z#]/7QB1
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M(K2'9,A]]>E.NN+5\G9&1D9=SY&5?=DY%I!LOR+7NNL( 4%[;&9W(4!068D
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M!?95"NI/DKUZ_P HBC6Z@.Y^6H=G>'S1'1;?S6XUN[W<0J)18;];"$8VX)!
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MXLA;32E[VI3:-I0I6]JWK>]_;GIHS,O&#+C963CJQ#,*+[:@S :!85LH) \
MGSJ6WIJL(-E5=A T"Z*Q ^@+ Z$CSF7G+@'%9\PIQ_BG+.7$2$-T=/G<_H=9
MJ,J9 ??B2GH<I\$-@N/QG9(^"^XRXI2%NPXSBD[4PWM/OY+J'GN91*N7YKE.
M3KK<65IR&?E9BHZJZJZ+D6V!6"V.H(T0'8>S'=C'P,+$8MBX>-C,P*LU%%51
M8$@D$UJI()53H_,#Z"3/F'GKC$1B(Q$8B,1,@_;O^M!^%3^L+W=_<^L>)-?X
M+/P7_D)KYB0C$1B(Q$8B15V/L5,XA225YNTY<05 5'9VF,VU*FK?F+4Q$TU!
M7*B.R4K?U]S:&7/JKW]J&M*7O6LS/!<'G]0<A3QW'UA[[>XCO8UUA:QW/NP(
MX0A=G;#0'EO F+Y?E\/A<*S-S'*U5]HTH5G+.>U=(70L.[QH'9]AYGBF]Y>[
M;YZH[V'XESHO7)?3.IVZH<VA5TG&-1>?52+<X<.G0+$9BN3[1##:WHD-('78
MI0U*C.R'(D5F8IQ26_KSI[@N(Z&Z?NO=+;/@L>_,>Y71\VUJ7;,:I;4HPVNH
M7L(H!KI6\!2X5-L.08V-RG67*IR?( X_'EU%*)I*6:GMI[EHLOR37<^B+"2X
MKVY6PD*&]57QS?'KRWX\N)ZY]4GF;=TNW/1CG:.P2QJ8![I5HC[FJA;<95(F
M+%U>LL$98RI5QF4N(,B/3)R].F#!B=-^6>L^L>1ZSY9\_,+U8U9=<#!]3U*\
M2I^SU"&"H'NO-:O=:5!8JE:ZJJK5>SX.%3@T)12JJ$4+M1KPI/:!LDZ79]SL
MDEC]IC-!,U">R,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B>?'TOSOB
MURZKZ O%"X)Z"Z-<JKZ=XSSC1"N^F[1QVC6OT;TL$)K)R56XP5@YJH3.=54Y
M21AZZS0L2/*BV&?!V0@BQJY1"ZOL-Z'V2?X=GM'Y@'?GP#\O/F)IO\>3]$>\
MH4!KG]/LO/1T [TT98J+<;=*OMFJG0X'3[?&Z2)+7*:S&E61U%Y;/28QAZ/'
M7.@R8KZH\=2]L-P;^(^0?O'L1\C^D2Z^1B,1&(C$3(_YE?\ 1\\Y_P!HAX*_
MO%T_$DON?\K_ /!IKAB1C$1B(Q$8B,1&(D8]CY37>V\YL_,+;)/L5JVCI HX
MQ7;&7J\HH,ELN1YP:<2"OQIK@4O&==@&1WU%1R0]]^));<:<4C?MX_.NXW+I
MS<<5&ZAP]1NIKO5'4@K8J6!E%E; -6^MHX#*01N1=0ZE6WHC1 )&P?!!UK8(
M\$>QGC>ZI#F?&)WP#Y>['VFJW7AE[CKD<\K@3K/<>SV;AH:39>?E9'F-KCIS
MOE)JW/JU:(*0EKI'2;U4OH34NMM$S99@?+)A_I7I_DCU)@7<[QO&VXW)4,JY
ME]V!QG'X_(6KCYM2\Z<^KALW)R\C&+WX]^)AW>HFV%=2"TU7:9U!PU>?4,>Z
MQF"*Q5*WL9V0O38V+VG+QJEKL:JIW%Q*.5K9B'KK=+_<@[&GGL@+9(MF-W"C
MA'*X0C#:CZ!%"[/3:W;H77%J!6FI\XMW06U$=/PFBIV=M$DG5AU<A19,5,:P
M0I+GJS\'%ZDQ[ZL>O#QL_(7(KN;+Z=;)Q\K+Q'X3MOHS.2Q..-:]KM3C4EDI
MS;<JVQ'+8MBCFJ_O#I?*J&<,Y\2EZGH%','&>O%N'*AZS1B7Y0N'<$LON56L
MQJZ*D9 N0A.\/'/3/.>J18<%)T&&M;S,)W=;42-OKTT21!4*8;+6.KU)HD6G
M-D(B]#H$>4\O3[;T9R9'=3(W\^\[TERO#.]GP^3?A!K%^+]''4=U1L%S-1BY
MF::J:S4X]6QT4=K*X1U*CKO$=2<?RBJGKT4Y1"$XQLN) L"&I1;D8V(++7%B
MGTZU<G892ZD-+(9JLV*?/*B19T=V)-C1YD5]/W'XTIEN1'>1]NM_<=9=2MMQ
M/VZUO[JT[U]NM;^S[=:R2LR,'1F1E.U9258'Z@@@@_@90@$$$ @^X(V#^(,X
MN!5ZT*D:EBZZ"&RDI4G4F )@0Y&DKU]U:=/1X[;FDK3_ $*UI7V*U_1O6]9=
MLR<FU>RW(OL7Q]FRVQU\>WAF(\?+QXD5KK4[5$4_554']0)SF6).,1&(C$1B
M)D?\MG^;_&K_ &N'B?\ ZE>L2:>[?Y'_ )&:X8D(Q$8B,1&(F??OSP)R;VUR
M^R K35*K(O#M>D"@]P*TR/<K0*A11UC_  ,:CMDKM115>MS1$](?K]FFFX\0
M?)??CDTO"ILS2-JZ6ZIS^F\VFVB^\8PN6RS'KR#C4V,7I[CDLF-E66XY2H+;
M2M3,Z@%-.J[L7T+<IV!WZ(5BO<1X/L.Y1OSX/</O\3S*^7O7'8/C.]12O,7J
M.?(F!H))?Z*1[/V#FM%I]1K7YD%D0KQ=:IPNX74)$Z>^$<=)W&AG"MGDV&.^
MR2&+GOS&99'Z'Y+B.-_:!T]7F\6::,EJ1WY-7&+DWY12JY'P*<SF,/#R/0%H
M"XV:EF.*F4JXKT57G651D<!GV<ACU7WXOK;NPQD<H!3?=94PRTQL.^^BR@+L
M65+BN #VGN"^/8CQ?LU/[=1*Y>:B3CDAEA#BRD*?%CDHPHS'(#(A%)6L/&(8
MZ8:KDA$K2AQA$-MJ4SK[5H:=2XTCYGYOA<OA,Z_#R5 -5EB^+*+GK"V.BIDG
M&MNJJR-*"]0M;6P59E*L=ZXSDJ>2QDNK[E<J Z/5?3]L*IL]),FNFYJU8E0[
M5J=@JP5PRB7<PTR48B,1&(C$1B(Q$8B,1&(C$1B)D'[=_P!:#\*G]87N[^Y]
M8\2:_P %GX+_ ,A-?,2$8B,1&(D2]K[/2^#T UT&ZSF6H0N.IR&)1/&Q"]AF
M)VC210%@E+AMSR2TJV[J.V[]Y++;CR]I;0I>LSP/!YW47*8W%X"$W9#::TI:
M]./6/XK\@U)8U=*^ SE=!F5?<@'&<QRV+PN!?R&6VJZ5^S6'K6V^P_PTTBQT
M#VMY(4'>@Q]@9XM?6'NCO7R2^I@_F+R&\&M71;00O(V@SB<FLUT?50E._3BX
M%ZF:DF@#8$H1C5 &06T>;,3V93O^(@2I;RFY$GZMXGB>%_9ITY9F9I:HTKB-
MRU]0R;Q9F6'%PVLJHL9W6M\AD^PJ( -NR(H[!S*GB\[K#DAR/,HZ8"FS]VX%
MBU56MB6!\C%L>_%L1@U8<ADL#,".TL=LT]07QI?'1S_X\^/DJB+GPKWTV[&Y
M-FZ#UDE5 H:[G')[$%UFJ$3$"01ED:_69S4U0:.LCN$AR;*E-Q&Y,A]Y_P":
M^M>L<[K'D_C,CU*,:E!7C88R++:$*L_=D*CA%6ZY2OJ-V=VE5>[M55'5</#J
MPJ5IJ5%50  JA0J@ ! !O[*Z\#?N2?<DS2+--GKC$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$3!KT%U+GO*O3O;8O,?8/;?(XFSG8KWH&TJ\^UOJ7
MG-[L0[ED"Q*"UN\VJ,[NF]HL',0PR3($ XQ15DG0A\>,Q)L28H[=T E02H;0
M.OM:8#>O8?($[V? &OE[II?X9'T@;Y?YLSSJO=0K]2?W;"(YWM$!8WJ%N?*7
M2PD2?2+=$=^QY,SIA23,OD);K<?;@BP#EMPX+.VH4>#?Q'>OR]OP\^?'M_6)
M;;(Q&(C$1B)D?\RO^CYYS_M$/!7]XNGXDE]S_E?_ (--<,2,8B,1&(C$1B(Q
M$8B5"]J>0JS[1XI9^,6BU%ZN*L4!YE]$2(@E72TUJ1 GAEW,%&F@#9\6%*C(
M1*- !W*GD=OM;^D<C?>TI.?Z<Y^[ISDJ>1HHKOLJ8$=S%+JU(9+1C6E;:ZK+
M*W9"]N/D)H^:F]C:NJ%R%"2 ?S&_!&QX)T1OP0?OGD1NMZN7Q1=EE^8>ADK-
MZ)X56ZB0URJXWWS2;Y#S?FP\H:ZH$OE<L2[7Q7IG;ND5$6=FLE>97[F';SE.
M1':&JU+M0(D8!"?HKB;DZMP4YK"+<1G795=G(8/'=05Y69GVU5\?=AWUFC.Q
M^+Q+WKK]/-Q,[BJ\DGO\8UM==UFI\MQ-&4&JLJP[+A4U5&5F<?ZZTUOZJV(J
MEZK23WMZ;I?V+O?;8"5&C=7LP,2Q3^C\DZ(%F#SD9DW!IL9SJ/'1Z'")[E_V
M*JAAZRQ28IFYP&6Y\TV4L&ZP,B#)LQ: $]5;8B^BK(3FJLS!Y'C\A;*>ZFS,
MM'#\UD^G7C<M]O-Q!BLERX5EGI4U58:Y=[W5U@Y%8RB_,.0XK+Z<R,>ZG*K*
MN2Z4U'D^+Q?5?(XX-7B9@R%-;Y*5]][/E-CXZTV,?0?X8)K-YO\ ?O.KDQ I
MUVV[4CD6.B)&1+(3#2&&X,"0_MJ:;L5J-7&VS7VHOW]&(H\E];[_ .((R](7
MN6KDW5?[->4P&LSN/ S<=V+N:ZJ\<L;+%7NKQ\7#Q\'"K5GUZ#V5=NNVI/'8
M-ZZ>Z\X_+5,3-WBW*H5>ZQ[E541FT]^1E79F6[!=^LM=F]]UCZ/>=)FGF7VT
MNL.MO-J__%QI:7$;^S_+]BD[WK?V?Y-Z^W^C?]&\Y05920P*D>X(((_$'S.B
MA@P!4@@^Q!V)^F4E8Q$8B,1&(C$3(_Y;/\W^-7^UP\3_ /4KUB33W;_(_P#(
MS7#$A&(C$1B(Q$8B48]X^"^5>\N4+Y[?EN"3@AU\G1;/N9>G!-7LTA\7M-H)
M5&D]"YJFX%!<0<MFO[-'M-A9$N2ZQIV',*C2>S]+=4Y_2V>,O$T]5G:N50%Q
MELOJ46:J3(R,7+..K-9W6&JO=@4 _:5&3SY&-7DIVN!L A6(WH,5[@5V RL%
M 8'Y>VCHSRGQ+[[@^%/LSPCNE7Z#TCSP3,)9$]XU7"6Y5A?,_F(^OC[%U)\Y
MTBH<\F;B"YA%VB5P@0+$PX_4PL*CS)CTECZ.KRNFOVG\2M29.+1R:H2<&RZR
MY\7TS4UM@P#9@OET@NJ)E/0%JM<BMRH ?GV3P61P^4V=Q%?H,!NRBI<7%HO&
MK#VT6)A7WB]SLNC7JKIVK]K6D]3?C[Y%?/GL(-"70+<+EV-]M3C@N#(CO_6T
MLJ1'LJCCD39%B@,MZA(0],L(@-!DR'?M%22$7:']\&ZJZ YCIEGN=!?@ ^,@
M%@4 K1CZK-6E!+,7]-*+;K.Q-V)6WB;)Q/4=.>ZXF71=@\A[&BU $<DD@5,K
MV,>Q#7ZK.J(KN%5F]Y?S-#FRQB(Q$8B,1&(C$1B(Q$8B,1,@_;O^M!^%3^L+
MW=_<^L>)-?X+/P7_ )":^8D(Q$Z-?NF<]Y:&=L/1;G7*8&:;<=W.L)6*.0XV
MT[&8=W&;?<2_+VT[,BH=3%:>4UN0SMS2=+3O?KPL#-Y&],7 Q;\S(L.DIQZG
MM=CVLVNU ?[JL?.O"GZ3SY.7C8=3795]6/4HV7M=44#8'NQ&_+*/&_)'UF%/
MJ3_U!OFCG$DY1_.<>1WSIC$&9H5%KL T<A/%8;I5B5$8&@(3[DQ<+\M_$RTS
MC()4:&[N8\VIM#+,WK_3_P"QW.N"9G4^97Q&#JMCCU65G,<.%(2RVT>AB';!
M/M"^SU R&M/#'5\OJ/.R"M/!\7=:7<HW(<BIQ<*I1Y]6JEF7+S5*_;0U+74Z
MD%;FTZK3WG_Q??(U\A/4BG8/D"Z&[YRXU:3M;L)3A("4!LO3+4&"S*Y#,4(T
M>IB:G'HX"V5B 01#+Q#IPF">?BQB%,4Y"2A.=S_VA])=(X#<7T/Q]63D&IJS
MR"JU5*6FJSTLJRZ^NS)Y"ZBXH6JN6NMU#"N\(=2.)TT;[ZL[FK7Y'/I:S5^1
MWBH=UG=K%P?6LQ<-16!6K5)WGM[R2[,Q]&/E[QCYE\85HS4O-'*A/, UD>%2
MK*F 4L1LA8IP6/)BCB!LO9S!LH1G,,3)2-RI$M3B]/K^_M6M(TGB?-]1<UU'
M?7D<SG69UM0L%1=*:UJ6U@SK6E-=:(K%5.@NO'CYS;:J:J5[:D"+H#0V? \#
MW)/@>TM!F$EV,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(F#GM#
MAP[E%ONG1;[\@''N%T&T>A0/JFO\PO/ Q'2+*GI-6I(2C#IHP=^L-FSW>%&@
MU]A_0T94UPVIFD/KCZ>:^LJXI\>$W_=WL@:)/CZ#?SW\OI$U.\AW2Y]#\_4>
MX7ZP66V60R]:'';-;>0N<),GAD>VG(@$KOE[Q@Z_7ALT&P/>"/R"*GSP94&P
MO1H*RBH3$6\$^ /N!V/;ZGS^/T/B)97(Q&(C$1B)D?\ ,K_H^><_[1#P5_>+
MI^))?<_Y7_X--<,2,8B,1&(C$1B(Q$8B,1(P['R*H]UYW8^7WMZV-52U09 T
MTBFWFY<]+2X,N,_$DP7CM'.5\P^,F1Y#K!(-(FO!R\9:HA:!-B*6PKV\?GY'
M&9=.;BB@WT.'K.1BXV76KJ0RL*LJJZL.K %+ HLK8!JW5@#(N@=2K;T?!TS*
M=?3:D'7U&]'V((GE?ZW\4WKCXT"\SIOQUGK7VSBD5[5AN/"^JW&.4!&DB6*O
M*F/7L)5#G$2=@&3R$.6S"I@*/T@=:8XZ-'N0R+"VVP]W#C>N^#ZN"8O52T\5
MRFO2Q>6XZFRF^DV-<J##NMKY):;$5@6R;6PVH9V..[-LC%7X1565:QD4.-64
MW!;$=?&Q96>U74^W9I@P'VA\I'?-?DB^-OOT"=5N_P!>(^0_0D9V:#+S#8'L
MEIY_NT#&B:; X_2*^:>G\WFOV!.QX&J1S%TB T:CP)\5]4=Z-FUC$_:!P5E=
MF!DCJ7@_L6I72_#XN><=C4*1\;=B,,Y10.^^]ZL:V\EG6Y"P>:7R71W <@EC
MTT# S&#:L=LV[&#L7)*XR9=?HGO8! I-52@#T&4=LT;IW0?5?F&E.W#F-DYE
MW+BZ),K\'?*3;2O6><3&H,@9LU%836#\0/65P"4S8XG-E!*X9?DMD&T$)C3&
MG4XZ_$Z%ZYRTQ\VOD>&YEU4-A9.-C<5R*NRW+2QLR*+;<SOJK]2NI,G+H135
MW55LQ4ZN#UIT70[(N-FX"'N%ZV96;B% U1?^R2VE,4=[]C6/1CVN?4"6V  S
M4'R#ZVE>EP+SA"E."305$*)8B8%YV15HQ18[4EY#J#&X14<N:^V^H>/A_I.P
MPQMMN4=<=2IQ?)^N.B4Z2R56OD!=1D&Q\6G)4)F/2+>Q2IH]2FT5J1ZMMGP;
M,VRF. 0!T'I/JI^HZ&-F'Z5U(1<BVABV,MIK[B"+BEM9<AC76GQ*JN@]Y/DW
M7S0)N48B,1&(C$3(_P"6S_-_C5_M</$__4KUB33W;_(_\C-<,2$8B,1&(C$1
MB(Q$Z5T'G-%ZM5B=*Z-50UPJY>+,BS1)J(B2UI,Z!,%OR83^ON2Q9),&?,8B
MEQ<B&5@?B''(,R.]O3FO3B9F5@7UY.'?9CWULK)94Q4[1U<!A_"Z=Z*61PR-
MH!E(\2+*KJ5=0RD$$$;!!!!_V)$\U'J?_P!.&%9L9GKWQW]R+>>+ZK:)0[DU
MP=G$.62)RI@F*VV,NHU@A<J?!'"/SP@]LV ZI.,EG(41F37XRY$O7:.G?VS9
M5"58?5& O)8Z^&S\1:TS0 EK!K,2PKBY3M8:D!2W!%5?>VK6"K,+G\%BYM;H
MR*X;>TM+:"L5[E2Q/[1%T">W[0+!0=#R(5IGR!?+9\9K;%)]J>0KKV#E5=CM
MKD]7H<VSW:O00D<8VAN6N\IU<@K"1%=K!4R^%T=JD49&WJ05 BY3\M]_.9O3
M_P"SSKPG+X3E\3B^3O) QNS'P[&L+DE7X_6,]CW9&0H?**Y-MI(2JUT1%7&8
M^+RO##T\:ZW)Q$&_A\Y[+R"?<U9G<YJKKJ1*Z<54JIK[2[?:9R=:?-OSO?'#
MZ,98B_KIB\;M+JF&U5?M,95*<V])?+I::B6%]3]6F_<BB4S9;C1E+4-LD-CO
M+U+D?03S[F/V3]7\66>C$KY?'79]7C; ]NM5^^+;Z>2Q+.5"TUW'^S=F"KHG
M*5\[C@JN91E83,=!WJ:_')&]ELG%%M="@=OVLOX969NVHV%6UK/6+I3[L/8+
M4VU5RUBY+3;\<A7#0TU#>9=98D-N(D#I,EK:5,28SNM_>_\ UOLKW_0XC>^>
MY6#FX+FO-Q,G$L!T4R:+:6]V'M8JD^58 CP>UM>QF4HRL;)!;&R*,@ D$TVU
MV@$:V#V,VB.Y=@Z(V-^XG9L\LOQB(Q$8B,1&(C$1B)A5\J/;^<>;_='Q!]LZ
MV7G@N>4>_>T5'R0NO6"V$TOV?S+(I==@CJY51AFP%IQFU60&%B1QPV3M$@BT
M_*W'A-293&6X;@^3Y_+;"XK'&1>E+Y-H:^C'2K'K9$LNLMR;:JUK1K$#'N[O
MM#2D^)1[:Z:W:QNT$JH\$DL3L*  ?) /W>/>2/)^4'O75=JB>/?C)]<=80^]
M^$@WONT$#Y3YC)V\XEI@P.-=!?)G#01I"MR9*F@(Z5M+>XND-/*VMK;!T5Q6
M#]KJ#K3@<$@%FQN+:[G<U=#?I/7BK7758Q\#=CJ-AO(.IXSE6ML4XMK>WVK=
M5*=^Y!/=L#\1\_;7GA)G'_FY]!C(2KUZH\M^'!!6.A^;7?/G)C'<>A"XTF"Y
M]X,:M'4"\, T:COO);ED:02:BQI,=,@45FQT[1*N+R'[-^*<_"\'S?4ME9(%
MO+9]?&8EK!QJRNG!K:XU=HVJ9"]S E;:P2"M#7FV ]UR4 _W:T[B!X]RWGN]
MP2K@ 'QOWG1X_P !7 ^@EFK/Z^]+^O?8=C^N\Y)8Z7UR6!IRF79D>0N-! UB
M,Q8!;4MB)'C$4Q+IIJ1MO\3$:'OI94SZ1^U/E<&I\?I[AN Z=I<+W-@X"OD.
MRJ0K6VW,:KBA9F0VX[,NR"S D&V.+QVL%MQ>^U?X7M/<RC>]*S=UBCR1I7 T
M= #0UJ/YW\9^6_)X&)7O/?#N?\SCQ8T*,Z4" X[UI**@#MBF9IZX$?QMIL!1
MR IQB85,EYI&=]:0Y,DON/O+7I/+=0\WSMK6\MR>7FEF9A7;:PHK[W[RM6.G
M;14@;15*ZU1=*% "@#W)576-(BK\M@>3KZL?)_,F6:S#2Y&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$Q7[1X#Y?ZIOWJ^]^>NPF>;=?.E
MBO#>[)N//*ST2G$3"J!6"$L57W;.'8NE+5*K%GKVWK)S^WQX:'5?3V)F+A/Q
M%W Q4 $>/<:.CY.]_?\ /P?J?;WB:I\39ZS&YE6(7<(E"B=,',S1I_7,99V9
M2)3(XE,A!"01=F98.,))@6!L^;!()<='D9$N$B1*98;D.P.M^-Z^6_?_ &B2
MKE(C$3K]MM5?HM6LEUMA)D-5Z@!+6:QEY"7G&!@,% ?)E9[K<=MZ0ZB)!C/O
MJ:CLO/NZ1]-EIQU2$*>\3I7/^PU7H4>T*CQ;%4R=)>AHMM>OP5^IG@$4F):/
M"2LZ)/7MG0<F(=W+C$F)3T5IZ*3%SEQ#(8P.@5(U_P"Q'L8F4GS!]9Y6:X%Y
MZCA^F<_+2(WR">%2,A@9<ZY/>8'P/0M1DSYSS44DZMJ'"CH6_+E+2EB,RA3K
MRT(3M6J2:@[/@_PO\C_A,U?_ %X<5_VO\N_Y@5/_ ,MB1T?H?T,?KPXK_M?Y
M=_S J?\ Y;$:/T/Z&/UX<5_VO\N_Y@5/_P MB-'Z']#'Z\.*_P"U_EW_ # J
M?_EL1H_0_H8_7AQ7_:_R[_F!4_\ RV(T?H?T,?KPXK_M?Y=_S J?_EL1H_0_
MH8_7AQ7_ &O\N_Y@5/\ \MB-'Z']#'Z\.*_[7^7?\P*G_P"6Q&C]#^AC]>'%
M?]K_ "[_ )@5/_RV(T?H?T,?KPXK_M?Y=_S J?\ Y;$:/T/Z&/UX<5_VO\N_
MY@5/_P MB-'Z']#*E^A^"?&UZMTE_OH#S-T0TP,_*!UJ+G:,BWAX*7R$ME@5
M9HQ)DO$88GE9Y!,/\4N [,D./2HDC[RD[SO$]3<]P?CBN5S,2LOZCT5W/\/8
M^D4FRDDUL2M:(6[>\* %82U9CUV^7J!.M=W;]H#W\'6_<[_&9Z4/XK_*'G8B
M]8?&/R,=B\P6.6,6)(_EG9N-=)J!:%^-1/89)TN[UZ3 =:CR4K<0Q%EPXVU*
M2K;/WT?>5MF5^TG+Y=!3U%P/!<W2K]Z&RC)P\BMNTH2F1C9*L-J=;*LWW^VK
M P0A)JLNK)&M>&7WWY4KY_,^_P#O:3R?3^@\4N;A+MOLOPMW0-]>PN;NH3@O
M.^.]Z(_FC&OP'X^[4/J<*C(;U*4ZX=;US65-,I6XI1:.M[6F,7U!U)QO+8BX
M^#C=08 "T 861U)D<GQ%8J.CV8F9COD;"A12?BU2K0 K('FQB\3C8UYR$P\!
M;R7)R*L"BC)8V;[R;JU4_;V>_P!RWG9.YK-&DQYD=B7$?9E1)3+4F-)C.H?C
MR8[Z$NLOL/-*4V\R\VI+C3K:E(<0I*T*VG>M[TJ9*?MB(Q$X6RV,)3ZZ?MMF
M)1PU;JP4K8[ 7F;4F(*"!(+Y,L2E*0E:TQX,"+(E/[2A2M--*VE*M_9K;WB1
M75_0?-SX"^6,S-(\T'\P!LVSH'ZV8&^>*J-)EA9MCAWH\_8'HX\93WP@LQ/>
M.S)K,45L&>@G-BR8(O"A5(U_W]?^_IXB8G?)_P"\_#E^8^/K5%]E>5KINF?*
M'Y"O]PU5/0?)K#NJT2M$+FNQW2R:$6V9^1U, B5&6:L1/\*(%ID,*FS&-/-[
M527$!^UX/\#?(_,34+^<R^.']O[Q5^]+P_\ CG$AH_0_H8_G,OCA_;^\5?O2
M\/\ XYQ&C]#^AC^<R^.']O[Q5^]+P_\ CG$:/T/Z&/YS+XX?V_O%7[TO#_XY
MQ&C]#^AC^<R^.']O[Q5^]+P_^.<1H_0_H8_G,OCA_;^\5?O2\/\ XYQ&C]#^
MAC^<R^.']O[Q5^]+P_\ CG$:/T/Z&/YS+XX?V_O%7[TO#_XYQ&C]#^AC^<R^
M.']O[Q5^]+P_^.<1H_0_H9_ESY+OC>=0MIWWWXG<;<0IMQMSU'PU:'$+UM*T
M+0J\;2I"D[VE25:WI6M[UO6];P"0=@Z(\@CW!^L:/T/Z&4D[Q-_]/IZ9F/E.
MU]=^-6WFY2G')5CB^B^*U"TRG79<>:\_*M-(Z)6[#(DOOQ6=2)+Q-;\B/IR&
M\XN&^^PYLG%]8=3\,JU\;S6=CU+X6EK!D4* I4!:,E;J0 &.@$ !TP 8 BR^
M-59LO4"3[D J?U71_P!_N]IGDOQ%\'U-D.%/.'S 1?+YW2EN,2^4_(OQAJ!I
MW[C#C:)D(K8)1";#7/@BYTV+^=,*E*&164/QT-MJ1N*?M=ZAM04\KQ_!<SC[
MVU6=Q^P=@J2 EJU!_39T5C4V@[;#;G@?A,)[/6% 6[M[1<$7U0H/< +.T6 !
MOM !QIOM#3:([ FSVGF4V/+XA_ZH#S%9AT5>U)K'H^Y^8NE(F)VY)0VW/M<C
MI\\PI,>-+<=VN/ 87,F,1$N;8CL,H8LGK#HO-5DY/]GV#4S#1NX?/MP2IT#M
M*:ZJD!+*/>PA5+>_<VYC R*SNK,R01[>H]MH_,7/:I&M^Z'7N/(!%X_)WR M
MU^U$HOK_ .5?XC^ITUZN/1:XGB_7:13[VJZ.E J8,@M(,=0?KLD%L2V<:=@C
M@D8BX5ECG&I&HK+L=6K\[D=)7TUGI_C^9P<GU@;1GYF/DXQQ^RSN%:I7ZXN-
MAJTS6LG8KCM[B#/537E*=7.M@UX*H0_=L>^@JD:W[*#LS<3-8E^,1&(C$3A+
M+8P=.KA^W6<E'#5NK!"MCL)B9M28@H&$@ODRQ*4I"5KU'@P(LB4]M"%JTVTK
M:4JW]FMO>)#@GTQR.17;?:+A8-\?%T']&7KB[VQ,;EJ:^-NRFVZ4:)R[5+@C
M(HFV27-C0LEV>E;AV/.K<MF)8A\\5&J1KZ?D=_\ ?>)D![)]9^5COR1_#Y:
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MZC_6/YE_XJOV$O/?_!R?^ZQ'>_\ B;_4?ZQ_,O\ Q5?L)>>_^#D_]UB.]_\
M$W^H_P!8_F7_ (JOV$O/?_!R?^ZQ'>_^)O\ 4?ZQ_,O_ !5?L)>>_P#@Y/\
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M'I/2B'0>5VDM>C1@9V+M7J;EQKG$J'76ZS30/(3O5XU+( $P@D:PPS0-CE<
M#9Y1$Z0C&R]Q+2)D5I3%=C"!U[:UX4_>=@;_ )['T_6)H%D8C$1B(Q$X\MHJ
MH432"<'LFU#YN@SI9F3(%-%=QG=#W"<>&_%EOCT2_HJFLQ9,>2[&TZAA]EU2
M7$OQB9V4*[=CNP/C/.+5U@W#-VWO'L^KW;I5,"5RM&3 SA?5^MUNHUNO02P^
MU#:S"?BB@TQ#"4EB_P"24]P9),S]2BTZ9,@ D@>P0@$[]P"?O/O^'F)&-3]
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M$1B(Q$8B,1&(C$1B)_-)3K>U:UK6U?9][>M:UO?V?Y/MW_EW]G_U]O\ D_\
MK$3^XB,1&(G\TE.MJWK6M;5O[RMZUK6U*^[I/VJWK_+O[J4I^W?]/W4ZU_DU
MK$3^XB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
5&(C$1B(Q$8B,1&(C$1B(Q$8B?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g107876g80d83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g80d83.jpg
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M 0$! 0$!_\  $0@!,0)> P$1  (1 0,1 ?_$ !\  0 " P # 0$!
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MK>Y$"NQ+ RY*P0X,)1@N9XZW\3>QT=;[;WW\AOR]/TZ1;FN]NU6T5[6$^O\
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M)[ -DO!<>P.P-[(!/?\ LT-^FRBTZ;W941\]IL)M1;BZIVKM@/=-Y7.,"BR
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M95;?Q'4>JQ4;!2$R:+I-]V==D ]V8XDMGUF4T_\ BOM>$'V4O"'[/\R+YO>
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M;/S/WE$_)_T/^A/4?[MZ;_1N-GYG[RB?D_Z'_0GJ/]V]-_HW&S\S]Y1/R?\
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M,+?YUV2227;U>02Y&6]#7-**6C:DQ\$T8<V)TDMAS8>#6A;*A)MH0V_C[#Z
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MOVT+]7'*X,$ES2-I6A&H5:S*MOU*BO*@&A EE'3L^AA\7BNL]NHQ5:]LK:7
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M\&G^=*]L_P#K;7'[K0OZ[Q^,+EOZL8?_ &O(_P!\GXI'LR_I?4GZP@_X-/\
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M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%3OX@O\ N4>F/^$]E_\ TX<Q;_\
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MZ6$GW/%G+W&/].74WT0?_4[^CF\IYFC"[H@R/D P60?8R&HW'A$<TRZ#'_\
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M4'83+8>8>MJDZNTO8_ET6@ 3UP5LR-IUI67578G[=#5 BH'3K!RD'.JCR:I
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MA9SC]+__ &(I_P#RT#_H[[GH/L#_ /;#)?\ AJY_^TPRZCJC_1\/_P Y'_\
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MLRQ>$V)L(N9 00@&66(34S9C#9XY)-/6]J1?A,M9MXVS4R==_7U?#V)J%B/
M96[T?9SSHJ,%DV'3R678S#FY:Y"O!8=!D6T9RZK+%#'[+SO<H@FS5?.FRBA
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M][3-\3^J-PSV*'O86M"_9,-,>8I4>,:G#4EGV,LH7UU72[[H89)@Z^JCD[9
ME_>>0V4C7HW.>?N37RXRDSJ'#4!$?=;;< ;$9DDV\WH:C[.G\^;/$=*\C@YO
M#>F<0!K;19O)/Z0ZFRIL#W['2=6MIS"&'40Q=K(14=Q>'X4AA9!$#XC'>)QW
M+S+G;AAON?U91,W^MTNTQ-Q7>^^1U.[: \M2#4-";:\OK+8%+H4"THN(6F:]
M9(6\=V(:5\>U!8'&-*H2J'F:9F_9.]A'C\)9\*W)2=0KULZ_'68X);]F.W59
M5L6G.#2;%IDL9KM9*8'<6LG:\AG'DM1-E^IJ)GQ\.29EKEWI:+,49K4&*I2T
M+TE^G2$;WM;4HR0RBXZ2!ME@>^6LZ)KI2_@KH^1MA6B_Z[L\%\?6A]?Z!LZX
MZXO.5L3T-0P5V*N=KII50F>MHH:FW51 ,UY@+<**,@C [,<^.$P2:&/GLY5A
MK6X36BABJVJ=>W6\"2R]CXI>8#W"V3.QY<QS7QN) +=M):X%=?TO>LWJ%EMV
M:S->HY&WC[GO45*)\<]?PW&-AQX%66(1R1O9*P!QYEL@#V$"TW-,ND3A$X15
MZ]9Z\>;8\R;ZUS5X.BK1;M4W556 \L\(L#[)FC,F0+I)<^^L(8F#>$,*6;+O
MZ(8Y\Y>_I^I]'=$D3;$4U=[_  V689JSY-$^&VQ$^%S]#N>#7EVO76EU'1.7
M@P'6'3&:L_\ \7&9W&7+)'<MK0VXG6'@>KF0\W-'J0!ZKXW1I\2H(Y\<)HOK
M]=]9P$PRC%#2X9=X3"F"SXX3B&"S8YCEB$81D"DQRCSQX2QYX=?G/DL=<Q&0
MN8O(0NKW:%F6K9A>.[)H7EC@#Y.82.4<C=LD86O82UP)_:&K:@NUH+=65D]:
MS#'/!-&YKXY8I6A['L<TEKFN:0002%Y^82OIPBD(#;.S5==#J:V^6E?7ETXY
M"]8$Y-%A!R$;X6$6(.2"7 @80:P11OX 8)L HGL>#C"#%EAB3UM(LYF(:D=&
M')W8JD3V/B@CL2L;&8YQ:8(RUP<QC+36VFQ-(C;: L!@F >N>GZ2Z8M9&;+6
M<#BK&1LQR1V+4]*&5\XFJ.Q\KIFO8Z.263'N=0DG>QTSZ+G4W2&L3$?><;KV
MR_Z[P<;!M!T7RGT.(\K.;$6**TIRZ_9L8!(NXQH/Q"F/- =]PQ1Y-82R.SNY
MY)<\^[ECJ'.6NUC*796AMIH8Z=PC:+M>2K<#8VD,;[W7EDBLEK09VO=XI<22
ML>GT3TECSRI]/8N!_.@\R,K,,KGXJY#D,8Y\KN4DGX.N5X+%'FYPJ/BC\ 1M
M:&CT ]L;*7U22C WBR"U&8(Y9)7X6A."[-4SGD*8*>X>L_I^Z"S9I3YU7672
M_-C+(P[&^VYY3]VX\WEXJ3L;%DKC*#HY8756SO$)AF>9)8"W?^8DE<Z5\&_"
M,SG3%GB.+CD3=)=,V,LW.SX/&RY=D\%IN0?5C-D6ZK&Q5[8?K7OD,+&5X[>O
M>&UV-K^)X $8]V#=.V1AWXH^P[;%#:#&+![C@Y+Q[//<!XKG!N4G4GS!RW"[
M"-<W)%S@F:+X\ 3\R!,,8>KC.H<XQMIK,M?:VZ^66R!9DW++8C$5B0GEMLEB
M$"&P]A:Z>$"*4OC :+#^BNDI),?*_IW$N?BX:]>@74X2*]>G,;%. -X\9(:=
MESK-2.42,JV'.G@;'*2\_E7N7:B7M9]UWVRB8IT.%671X,9<X8*Y$;BQ&290
M2_,A(6!L(XC0 R<)H5Y4 \X6,$H\&4<09_-5_"\')W&""J*431,XM;4$GC,K
M%CB6NACE EBC>'-BD:Q\8:YC"VJUT9TK=]Z]ZP&,F-R^[*67&LQKY,B^ UI+
MP>SB^.S-7<^"Q-$YC[$4DD<YD;+('8_+:6Q\R1S9+O9YBQ2;6;$3.X-GGR,O
M0^0=T+GDFESS*)M8>7V.PSE=S2MP^L!3LYQ\,(\;1S.6+VR.R-UTC'W90]]B
M5[C)DF&/(R.+G$O?>C/AVWOY.L1Z9*7L  OCI7IML4D+<'BV0RQ8J%T<=.&-
M@AP4@FPL,;6,:(HL5,/&Q\<08RI,72P!DCG./OK=R[649-LUFP;6#F\C!C:9
MCN"X\R>U:K%$N(ZSZD^L.:"EQ^Z!3QNX38%N6849&(TDD>5V'/YN#QS#E;T9
MLB(3EEB0%YA@]VA?OEMLD5?\A'*SC(R$F)KPQQ:;%GHSI.X*@M=/8F<4'3FJ
MV2G$YL0M6S?LQZ+=20SW3[W+!*'P/LAL[HS(UKAX5^S+-WC*ILKBPV*G-.Z8
M-9ZM]_3KX7RFA!0JJJO^UY#GX@R(4\&"I*9@$1FM"ZZ'BBD'^M#G3%E[FC!;
ML6[5";\'LN4O>GQMLP8N-L%*+F6RB,U:[1!6D$;S#'\+6ENVFNQTQC 66\93
MQ^.S-49F3%Y7W!EA]"WGIGVLK8,(DKFPV_<>;5V%TS&V9ORCGMD >/2V5?G.
MT+U9;X_^C%E8V'VK(?"<DF( (>"$%2J'(,EG,G%4*A0E@LQ<\Y4@XD69,TLV
M6<F5O+Y.QF<E<R=KM-;EYEH<]XBC8UL4$#7R%TCF5X(XH(W2.=(61M+W.=LF
M]TST_2Z6P6-P&/V:V.K^$)',BB?8GDD?/;MR1PLCA9+;MRSVI60L9$V25S8V
M-8&M&C\URWJ<(MGIGD?8GM1T9JK6F$.#2KJ\-@N61N>(ZI>!"7U7%X)ILG_@
M#,'A#DTA,++EA*Q&KS^87&3!49W%]$?X/.'EDS>;SEALL6+KXMV)\=K-^+?M
MVZ5QL,1<.+_!KTGOL<23#X]7F&B>/EXO[:?:+B.@,-BI<@X26,AD_#@JLV^8
MPPU;+II_#;M_A1O=#&Y^N(?*QI.W!=&/8I^J2O5%ZH='M_P\[%LYG;)&E\EW
M_P":M2U*M:Q!+EBZ*CV-OJ\[3':; NT,>6/?::CZ_LKZ:7K/%X)7\(<I>?4K
M=<>X=Y=B'$[/IIH'8?:1V7Y+KZ+-:BB@ZZH(01]8:!ATJJBB,Z2(*OIC$4=$
M!".?40 2"P@:P9%A@0A$#+*%&52"0CD3188296SYG[46Z\A%7'TEN%YJ%+0,
MZ]&NQ/O5_P#P?*R-J%QV20B @I%UN$S5=K#79 U]OQ,I54"13+:Q+A*B#=DW
M)ME]P5IKCG(&]_0;\P/4#S/EYHH*I_K>^W!15M@Q5FDK:(.Z\M4:_HHF!U@L
MF=U]-0ZYCP)J5K6L8:[C7Z QVY1XR8BTC4FTC1V7*$^O3K0HF57'S'?>G'_[
M=^8_0?\ JBD?79?VGV]ZFA^S%P?8- ^/A/FDP=Q0F?7MGK4[[2!)WEW]I$Q^
MV_8\Y^NL>L3A#1OJ]]C]Y94(K><(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(N47Q"]Q[!TEN3S!L"LVJX+Z/K]-M/96UZ17'#$59?:.
MAN^@*I88'24<B)<]GK=7OEEL"7%I#-B$:)G*-E!)+EGWTF$JP6ZF1ADCB=-.
M^M7K32,:703/BNR,+'D<F"22&-CRTC8/<$!?0_L7Z8PW573'7V&OX_&39;,V
M^G<%T[E;U:"2?#Y:YBNLLC2=4M/8Z:HV]D,/0I6C ]AEBD#7AX: J@TK=GH*
M3S>\U(]V'N]UO7=/JG!:2ZHQ%EM^U=8ZR%TWI'<FUH-<BQ&Y,%P%0GLWX-5@
M@S"+U>5LR*BPA[RD[RV<M2C[^RRR"HRG4QO)K9A'%6L6#:MUJWCDCBYTHC\5
MY=MSA%KY!>D9/I;HT=<U>HZF%Z4J](]+>SXSQU<M'1QO3V?STG4W5?3/3SLW
M(8O GFR;*'X4L33-EFL#'"-SG:;J6\/2;_;%>\VKMTWVZZ=KPVKMVH=J0*]D
M&:":7#UQID^L5J+5=RV;T<@.H/WVLZL=Y4IRGJ2)I(>)TR^\8U>0D>,<>RL^
M^ZI!#:>;-1];E7%YD6,M-DD]YBKEKQ,&NX0N?P>6\3QXEW(\Y_(>GT[=ZXGZ
M6Q&+ZENOS_2ESIY]C!P]8U\;[..J(;]YW4.,P/@W(<S[I8-#$V;,=2T:XAD\
M 0.L"5T*X[[L][9>>PX=N6];3?\ )5OP:4O;_MQOY]$MK>C;M059-8"=S:IK
MQ*G9C 51.>LJ^>:B>2RUK$FQ&/C3E\Q##+]RC@9=<:L3IO>:9 JXAMTQLFJ/
MD>P5+,C75VEX#I '@1R:C# UP#>I_DAC\1!UI*_IS&3Y,=0]'2-CZ:]E5;K.
M3&ULOTK>R%JDSICJ*['9P,,EED,]]HLL%"\8Z,5.*&9K(>ANZ_4#_5N@'*6D
M4/93FU$ZHH58TSM0%VKV?1-D[/V.#5ZM3E=&OV%C*O\ L^R!GV.2RS.VE.6Y
MVH&JOVV1N1) V)FCJ8YEBZQ\TU=L0LSR6ZQ:ZO-!7KF269TT'AB&O&6Q^&&-
ME=X3I&-XZ!UXOTMT#3S_ %C5M9;,8*MCF=0Y?(=4=/S5;& R^#P.$ER&1REC
M+8<T8\-@*,L%$465:V3G&/FR-.L(1&QYBK?1-N,FGG>YZ1VYO#:^L]IZAVN7
M7JE:MNWJS:"N.TZ];:[;KIIK';NR(TMALU07- 8'8Q9RPM:4\8ZV$7=-"Q&9
M:IAGS5FMO16ZM2M8K6JP?+%6ACNQ5I(WQ16_=:Y>R.5S26$-<'!C9R[B"T.;
MW&7Z;@@ZTQ?5?3G2G3N=Z?ZDZ=BNY+']-XFAUCC.G[N.NXW%]3_R<P;K5*AD
MIJ\SZKXH9XYXZD&=DF,$<M>.Q!TH\F7)ML+S)H>YOF;UV]L.K*:<Z>65<.J=
MO6WW*+"Q>&A"3DC8=.#(9F0T\!$T1H90YN$F6)'7?-#DXFP9"Y$QK&,99E#&
M1N+F,;S):P.(!^ $-((&B"/1>&^T7&5L-UYU=C*=>G4J4^H,I%5J4)WV:E2M
M[U(Z"I%-(UCW>ZQ.9!(U[&NBEC?$0"Q6%Y@KC$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$6M*:=5T3ZUVA.B7+K#>2E)MO<"CXQ'6(M"H&0)R&DW7
M^DF5<E#%6BY9?Z8A((XNO]&/7+S[$TL4$,DCWQ5FO;!&X[;$V61TL@8/0/D<
MY[OFXDK'BJ5H9[-F*&..>ZZ)]J5K=/G?#$V")TA_G&.%C8V[\FM 7'WT1Z(^
M%IY>WJ]H%_U*&PV78!WN.T7%+U]"^!K@VV$IV%FPO),C=>47/:ZS9S2W*VMK
M+&UD5._KD QRG01R=7CX^L<K1,U&2]8I4G0AFIF-#7TS'+"VNQ[FOE? 8XG,
M;$'.:0T:V0#YWF;GLXP&6-7)UJ$&2R+;!L%M623X,DV6*R^V^,%D3+3)IFR%
M^N39'D]MD=$M>>=/*F.NF8NN-2:JDUON*N)#VV2:MJB%-]K!0D32MSF&9PR3
M-%<8Y4+-%\R?*("6;$Y?T.3E\WFBFS.7FG@GFR%M\]5[G0/=,_E"]W9[F $!
MKG@<7D#;V_"[;>RZZKTYT[!4L5JF(QS*F0C8+3&5XRRU$!RB$KB"Z1C-\H@7
M$1N/-G%QVICH6O:1J^MBU#7M73U&M"$&F0J$HF HV1S(F0UB>1WU]:8Q@P,F
ME*./+EG,,GSRE(GDS[^MS#LVK%R4SVII)YG!K3)(XN=Q8 UC1Z-8QH#6M: U
MH&@ %LZ5"GC:[:M"M#5KM<]XBA8&-+Y'%\DCM=WR2.)<^1Y<][B2YQ*W+F.L
MM.$3A$X1<S_27PO-)[XMC;8U8?6#3=^L!4K"S%58-6VIUK;3]_6(>6"F,XXN
MHWI67UICVE7=U>=T7),PL'WPPD^U8\?U/T%TMU>YDV:Q[C=C8V)F3HSFGD?!
M8 &122\)8++&- ;%[Y6L/A8!' ^*/;#[M[._\(3KOV>T8\/ ^IG,)#VK8_+"
M5[Z;/2*G;B>V6*$>D,@FC8--B;&T *J7^95/_6@@_<AW_P"[W.+_ ,1'0?\
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MZ3]CN;=O[4[8LQGL1-H76>W=/J_56O*?J*P3=O;C9*OL.U_5\]%W:J6C6M5
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M#-Q:&)=)-(KD?XH-<0!+\HL0(191QY8K+K,[PX.D)#V"-S=-#>#7!X:&@ -
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MM.?6;%!X(\)@>ZPZ8/C9#)]%G.&7Q.G")PB<(G"+YVHOBY[TSVU&^[IVO_\
M(C+<HT_5 Z1/O\H^-,E?8J<67XM_$O8>6Q,1<NFF2'\*=)<CNNZ7U'B5_P";
M^=:>G8OP?X_CO]X\'QOYOA?F\N!&M@:[<M[![ZUV73G Q"EXHF?X_@^+O;3$
M?@Y\=:WK7;ERWOOY=E]$O.27,)PB<(G")PB<(G")PB<(G")PBC>X:;U#L-Z@
MM%_U5K>\V6J9X25>Q7"C5BS/:WG&1T7'F@;.E9K!/G@5UT3ADN(&[Q(ZZFQ[
MZDZ^MRMLLC YK)'L:[LYK7N:'#RTX @'MV[[5;9)&!S62/8UW9S6O<T.'R<
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MF85*U,FL2"1:D3NPAB"AB79:_J.$>>0GJ#&&3O&L4[+MZB<=.<PC;=\V=G-
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M![WXI/TQM.QZDNE?-3Z5U>70(]JKVKQM6%T&HNXTR7=\++75@(K)THFQ *\
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M=F#6'+T%>!4!HFJBOYLSL&ILMNL4D*\1;$*:WV>?R-2[X#:QYF,N+I>!;V<
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M+:O@&DKTM(LXETJ"D?.>+/ZJZN6T *QJ \NLH G(@Q\,>)$,>>,B:5H+6R/
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MIJH^D-D;8U%K_1.P:?L;46DJ1+#L??&P-2V1)8-66G>C=EG&KK/FS="MJF:
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MOXT-P?V$\(GXQ]S_ *NGD[^-#<']A/")^,?<_P"KIY._C0W!_83PB?C'W/\
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MX1.$3A$X1.$3A$X1.$3A$X1>.6*.>*2";#&2*:/.*6/+KZ<<XY,>\,\,NO\
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M(G")PB_F6/66.6/?>7766/>/?>.66&777?7T=]XY8]]98Y?Z?]&6/?66/?\
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MJXW(0MX$=E8-QD#N4&:-2Q,RZZZ[:(&_3[1_O19FU>M?/U*=;NKEEV! M?\
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K<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g107876g94z42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g94z42.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!1P)= P$1  (1 0,1 ?_$ !X
M 0 " @,! 0$            '" 4& P0)"@(!_\0 6A   0,$ 0 $" @)"04%
M!0D !0,$!@ ! @<("1$2$Q05%A<8(5>6&3$X=YC4UM@B05156).7M]<C-UEA
M>)FHMM4D)C)1LPHI4G:X)2<T1H$H,T))<72ALL'_Q  = 0$  04! 0$
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M1E=C,BZ!K(S:K@-DU$;'=!/!OAS]Z1]-^=>Z>?G&%=I/XYLC1;G6$_W4$UC
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MCRHF&!R4,,4,F.NR0[SH9VM$;9(G1!H:YQ+V/)TU"G[@+REVQOHIR(UIN=M
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M3B>;+W9R"V#K;"$ZBFL^BN^0&[';HI&4U)U'09.&1X@*9OV\3FC.=FH\G'F
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MZ3;(E\%>AV6QE*_+:?;:)C V+HX"XM!Z0OWI'!I:7ANZUH&I:"[RAJ6KWO\
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M>]AEO.&._M/V">_;@/-.8]5+[TGP^_&_V-;N_5P/[7T][#+><,=_:?L$]^W
M>:<QZJ7WI/A]^-_L:W=^K@?VOI[V&6\X8[^T_8)[]N \TYCU4OO2?#[\;_8U
MN[]7 _M?3WL,MYPQW]I^P3W[<!YIS'JI?>D^'WXW^QK=WZN!_:^GO89;SACO
M[3]@GOVX#S3F/52^])\/OQO]C6[OU<#^U]/>PRWG#'?VG[!/?MP'FG,>JE]Z
M3X??C?[&MW?JX']KZ>]AEO.&._M/V">_;@/-.8]5+[TKO\0NDCX[<R"Q")01
M:2Q#8(UBL5R@T]8CAY4J*;988NR4>>B2I@2809752R>-<'K<NW2RR=*#+,DE
M'6/.9[9+*X!C)[(AGJO<&>$U7/?&QY_:LE;(R-\9=H=UQ:8W'1H?O$-78[+;
M?X':R62K2-BK>C89/ [K(XY98FD!TD#XI9HI6LU&^W?;*T'>,>X"Y7_KEUVZ
M41*(E$4!2/Y4>G/F$Y)?O"XJ413[1$HB41*(J$LM7[) #]3;>+00M*MD(<@I
MWNC;4/#%8BM*+,9CK/:FKH>*!OC$C$Q0DMJR*2:!Q%NUM)FJ*T9#'"+!<@;6
MNU*W:CB->&@ .G80>KCQX^M%$$1X^[HC &\%>P%Z[6V26XPRQ64L3T/5!:A3
MU?N-78TJAIK)>1-S;A:%!TD\84M#@TB$&9"0NW1="F*+DHG4N!Y:#]MU<]1I
MKR_2BNA>&" ?)&*2)D\EBY _J?=&3]N8GDXD()"]IIH17_V)%CTB)1B-6OEZ
MKXQL0)PNG_(WQ[FUL*L5=?B]05A:*B41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1%5PI\M6#_ -ES:G[V-.5(-_<J;^<*O^&MKOZ__9;E
M?Z?[/_\ Z[M,IWFD"@^R 2\7V'#8K.XTY52<.(_,8^)DP19PWOE=!PH+,M'K
M+-="^>5T%LD+JHWRRNGEC>][UIQ330/Z2"62&0 @/BD=&\ \QO,(=H>L:Z'K
M7(XO+Y;!W&9#"Y/(8B_&US&7<9=LT+;&/TWV-L59(I0Q^@WVA^Z[0;P*R<>C
MD>B(4=&XH!#1B.B&]F@D#'AC(,%&-<<LL\6P\6.0;,62%LL\LK(MD$T[9999
M=GKRO>]'R/E>Z21[Y'N.KGO<7O<>USG$DGTDE8+MV[DK4][(V[5^[9>9+-R[
M8EM6K$A !DGL3ODFE>0 "^1[G: #7@LS5BU4HB41*(E$2B)1$HB41*(OFU_[
M0@1?88\4A.+I;$:XRW0179XYWLW6?-+:N;-72J=K]G-9L@]>)(9Y6O=+!VXQ
MPO:RRG:]<]RQC?\ ^;DT&^/%[ [K#7>&.< >H.+6D]I:.Q> >[G(\#9F(.(C
M<<O(YFODE[/%K6N(ZRUKWAI/(.=IS.OS8UZXOGY*(E$6VP6!339TJ%0?7L8-
M3*8'+O;!XW'F*Q(P2N.'.RS^S-DWQS67\$&,'KY?L8W[MJU65RZL$\KVP6;5
M>E!)9MS1UZ\6[TDTK@R-F^]K&[SCP&\]S6CM<X#F5M4J5O(V8J=&O-;M3;_1
M5X&&263HXW2OW&-U)W8V/>[3DUI)X!33?AKRKM*$X3Z/VU/*Y:/N)6E'+1$I
M<NI&VA)J'<F\65D;K7&H%'S,>HZMCW6+MRBC?+MJ8VO'?E#A.A-GQI2Z 2B
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MU;(.$6:EML+)\/%FO!78U];I;-@.92FF=.X,#GNEF\'X..H;N^B,SNS#);L
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M:<@T>\=CW#VE2,1UBC/;&P^MH7>44P2PS54RM@FGADIGGEZL<<,+7RRRO?\
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M,6ME6C;/%''&V&-T$^S:UL;6J(QVS^%Q$AEQ>,IT9'1= 75H6Q'H06N$7D\
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M2RE2*YM3A(IG66L&"VC>#5N6Z4F\+^S( ,U*>O*YFCB3&YYC)#7%I<UI$O\
MH\Z__/>Z_I+<COXK5H>-+/YK'?4^)^Y*4\0T?SV7_K#G_P 33T>=?_GO=?TE
MN1W\5J>-+/YK'?4^)^Y)XAH_GLO_ %AS_P")IZ/.O_SWNOZ2W([^*U/&EG\U
MCOJ?$_<D\0T?SV7_ *PY_P#$T]'G7_Y[W7]);D=_%:GC2S^:QWU/B?N2>(:/
MY[+_ -8<_P#B:>CSK_\ />Z_I+<COXK4\:6?S6.^I\3]R3Q#1_/9?^L.?_$T
M]'G7_P">]U_26Y'?Q6IXTL_FL=]3XG[DGB&C^>R_]8<_^)IZ/.O_ ,][K^DM
MR._BM3QI9_-8[ZGQ/W)/$-'\]E_ZPY_\33T>=?\ Y[W7]);D=_%:GC2S^:QW
MU/B?N2>(:/Y[+_UAS_XFGH\Z_P#SWNOZ2W([^*U/&EG\UCOJ?$_<D\0T?SV7
M_K#G_P 33T>=?_GO=?TEN1W\5J>-+/YK'?4^)^Y)XAH_GLO_ %AS_P")IZ/.
MO_SWNOZ2W([^*U/&EG\UCOJ?$_<D\0T?SV7_ *PY_P#$T]'G7_Y[W7]);D=_
M%:GC2S^:QWU/B?N2>(:/Y[+_ -8<_P#B:U6=<?8$G")BHF9W-DHG%9#GABOR
M0Y$.4,L\!#S+'%9NXVDJW72OE:UE$5TE$5<+WP53SPRRQOFK92R;$ ,>/ Z:
M+4C$8II WV\06T@X'L(((/$$%:UW!4A3MD2Y;45I]-[/YYPUZ)^FK79(M<->
M8<"".!!"QVK=!0-YK+7+Q4UN:RCN"1!RI9OR.Y#LT+9KQ\>KG9!HTVB@U:HV
MRSO9-NV11;H8=E)%)-/''"U]S)V6W+;1%C]!9G UQ&*<=!*\#5SJ1)/:223S
M))6/&X.B_'4'F7+:OI57'=S^=8W5T$9.ZQN2:UHX\&M :T<  !HM[]'G7_Y[
MW7]);D=_%:M;QI9_-8[ZGQ/W);OB&C^>R_\ 6'/_ (FGH\Z__/>Z_I+<COXK
M4\:6?S6.^I\3]R3Q#1_/9?\ K#G_ ,33T>=?_GO=?TEN1W\5J>-+/YK'?4^)
M^Y)XAH_GLO\ UAS_ .)IZ/.O_P ][K^DMR._BM3QI9_-8[ZGQ/W)/$-'\]E_
MZPY_\33T>=?_ )[W7]);D=_%:GC2S^:QWU/B?N2>(:/Y[+_UAS_XFGH\Z_\
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M7RQM<-2-6N>T$:@@C4$\00>PJC&ALI_NO541)D=Z\FHM)I# X/*3$@M =.
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M#KJ=>?9O?Z<O6BC+1/+/<YO6/&>([/DJ=MT2J5\:968DJ ,&P:;>T/O:.NY
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MLCAI[<_<POV3HL,_'5[4EO&Q31840GHLI.[*2.EPY8(Y8FRO!EAOL9!'6 ;
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MXF/=873<LWK5;'-)PV73O?!5)3'+#/&][96O:H==,L-.=?0C9@.T:V!%@LO
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M-02W0_'KJ?D[!U<D6\N.(2F&TS<L$.(8(A!KD)K#<*\08ALF2/B.!:(+:R?
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M>?L-_>WX2GCZ_P#Q3VB^?L_^/)Z1<[_0[Y1_X<?O%T\55O/V&_O;\)3Q]?\
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M"/*Y-7\7%-W958HW0(,P=FQFX@#M(W0?CU.GR>U%IT;Y:;3E JTS1&00;'(
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M?J]4;-C\'!B:\EB.K#8L8(7(I1=MF_)D7OF;"UM/>?6-60QM:]Y8S= D(<"
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M52L5GW\L^C9JRM=X/CYI#6A?8IM=$R5[B6;LI+-+C\4-AF-DZ<8E9.<D9Z9
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M5D<0;$1N;]Y9%XVS=HJ)-7[9HVU<]BX\5=$,,CGQ2Q-FCWR#(P%SV%KBT .
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M]6@(/-%9S4<YFAN0;0@&Q%(N_E>LS<;;YR"&!RT=CY\)+HF,D@QS@ -R&6$
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ML.NU/$#)V2[ VH;U=+<X :3-#V8$-"[B,).&N< 2AU-$WMX^ME$U6GCMU4M
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MOH\WHPEJ'-^&CY^,KQ-[()L74W!!I"RSFF"4M!QAF$S;1UD4;&<;$,!RM'-
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M^'E7FPMQ0F&M![Z*HRDSDR1;AY3F.4>XR+*^3E/$KV6__P +C:T!SM--!H>
M/8TGG\8151 =(K/]BRI>\08AX^(:;UX)ZDDD/D ;-64P(YNN:SV%[]@LC5NZ
M;Y8R.,'(GXH$/,VJ&#>Z&)-!!XS)-KWKN#KX^2\^@Z#5I^(C0HL;R;YZ;^U"
M=VAG$6L2)!-9<P@VNG[)U'EW;QUI2.\5$^0^R6R:Z+_#/*3V3%G[CRN"?^RH
M=PVR:*7P[VYK0= >9!]>N@[O].TH]=](MR&D[?>IJ%NXPC%$.3/'[7&C"0+7
M+F>GGFIMJ;*V_KQQ)$HPC(!2LXD$B0UTQDL0'-GXKPY FS9I+8^'8+)5W "
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(2B)1$HB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g107876g97c73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g97c73.jpg
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M09'L' 4&P:IV1-E5 XW,.B$GVI"T51N<KTM)5.,G&X,<R/+EIW(>"\%X/)X
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MI:GLAWSZK MQSR-H,2C,I&BRHSL-7K1*-MC&(]8RT8H6&7@$]*?'!467ZF2
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MG\&1?*&/_6=/C!.J_P#'Z2_,JY?N/C]T5V3?&&S\AYO]0T]C'>?P9%\H8_\
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MW/#7,^U0\X2AX$?^*IZQQ_\ VEO7Y*>=0UP?3C33C33C33C33C33C37Z5O\
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MZ%M< *2)'C(C;I7)&JSS2@Q4,+<?AY1MLMEAY2<N#.J3Y'VLX<1G*<\^^U'
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M%((CE&X"*=$>?$62P[D4A]C+;R_GW<-R#(9O)7*S%Z\]IVB<@KUH.$5^E@&
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MZ,XSG&?PXSG'+W(]\?SC5K@^\?YCK^?<!W9\UEX_-Z0_]GCD>^/YQIP?>/\
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M!8XHB68,R!MCVMB3E<O6$R#S;2D6[EIY ?)X,?6/?6.^?U+WL<;0QKSU.[@
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M1^0(=<<=?)<<6M2IZKN?.4X(ZT-XM!$.F*.Q7JVQ$ON+&;<$S(@XX"*P4#P
M UJE[8^U\C;EO6,6$M3GJGFIV[V/,[GQ,DRT+59)9">2TCJSL22S$DG4+^+&
MZ8_-Q<OKY[ _VH\R?3'<'V56^2\5^I:Q/8[VG]@7/ES._M+3XL;IC\W%R^OG
ML#_:CQZ8[@^RJWR7BOU+3V.]I_8%SY<SO[2T^+&Z8_-Q<OKY[ _VH\>F.X/L
MJM\EXK]2T]CO:?V!<^7,[^TM/BQNF/S<7+Z^>P/]J/'ICN#[*K?)>*_4M/8[
MVG]@7/ES._M+3XL;IC\W%R^OGL#_ &H\>F.X/LJM\EXK]2T]CO:?V!<^7,[^
MTM/BQNF/S<7+Z^>P/]J/'ICN#[*K?)>*_4M/8[VG]@7/ES._M+3XL;IC\W%R
M^OGL#_:CQZ8[@^RJWR7BOU+3V.]I_8%SY<SO[2T^+&Z8_-Q<OKY[ _VH\>F.
MX/LJM\EXK]2T]CO:?V!<^7,[^TM/BQNF/S<7+Z^>P/\ :CQZ8[@^RJWR7BOU
M+3V.]I_8%SY<SO[2T^+&Z8_-Q<OKY[ _VH\>F.X/LJM\EXK]2T]CO:?V!<^7
M,[^TM/BQNF/S<7+Z^>P/]J/'ICN#[*K?)>*_4M/8[VG]@7/ES._M+3XL;IC\
MW-SQ_P#OC?/8'QQ_^^/_ )H?AX],<_\ 95;Y+Q7ZEI['>T_L&Y\N9W]I:JGN
M,KL7TENM0T3H*V6&_4+M:6UK[29FU9LR[2G6K:"9B$8FCVIN:]LE;)K]%(DY
M6QPM>FGY)R-F:ZM:E/@)D!IF:H+BMQ5K&2R<$56UA%-O(+2C6NF7I]W)W:&.
M/I2&SY2D<4LL:H'CF]QBACUC+/GMG7*F%PEJQ>I;G<4,.^3F>Y+M[)=["LSB
M:;KEL412DEL0P3-)W<U<D\Q]XLUGX[T9_6XP-@K9Q&WMQ7E]M#EBV'==Y[A%
MG;#(JQA1);H-7O$#!QPRGLK]CC@(YMH$;U8V''_5>M7#MN_+*Q6FM"A6'A%5
MKXW'M'$@]2AIJTLCMQ]4[.2S<G@<\#9(^SW ,@;(OELK<8 V+UO-999IY#]4
MY2M=@AC4GGHC2,*B\*">.3W?BQNF/S<7+Z^>P/\ :CSSZ8[@^RJWR7BOU+7O
MV.]I_8%SY<SO[2T^+&Z8_-Q<OKY[ _VH\>F.X/LJM\EXK]2T]CO:?V!<^7,[
M^TM/BQNF/S<7+Z^>P/\ :CQZ8[@^RJWR7BOU+3V.]I_8%SY<SO[2T^+&Z8_-
MQ<OKY[ _VH\>F.X/LJM\EXK]2T]CO:?V!<^7,[^TM9PTIU,Z\]>#Y:9U)K2-
MK=AG6$B2UI/E+#;K<:"E3:\1SELN<Q8;$W&96RPXN,8DV@''!QW%C*<894B-
MR.<RF56..];:6*(EHX$2*O K'D%Q!7CBB+\$CK*%P"0" 2-2^(VO@<#)+-B\
M='7L3KTRVI)9[=MTY![LVKDL]@1\A28Q($)525Y4<6*Y%:G].--.--.--.--
M.--.--.--.--.--.--.--.--4=@K55WO2 WB/9LD"Z>[UMIL"V"W,1[ACD[&
M[$NLC(PJ!DD9>7+ 1^<'&QR49,%#S@E]EMC[_G-JUZDW:GD(EN56E;9]"J(Q
M8B,AM0Y?(32U@@?J,\47TV2$#O$C]NRA?'7<;^*R:?0_82P^-OK73M)S-]IV
MIV%A6C9V[A:]>ZTIC""I/8^D0V"PAEF^E([/[75XN=)UP[3C33C36$K[USTQ
MLN;]\MNI(Y5CRP@9Z>B9:?J\N8PVE*&VI$^KRL,3)H:;0VVS[H.$Y9:;;;:R
MA"$IQHNX>S39&Z+WG3,X**7)&-8GR%.YD,3<GC4 (EFQB;=*6T$555/*6E*(
MJHA554#8,;NG/8FOY)1R#I5ZBZUIX:UR"-B26:**Y#.D)8DENZ"=3$LW)).H
M3\#/KS_%*P_6=M+[9\@O82[-_@;(_E3NS]MZD/3S<_V;5^1\-^S]/@9]>?XI
M6'ZSMI?;/CV$NS?X&R/Y4[L_;>GIYN?[-J_(^&_9^GP,^O/\4K#]9VTOMGQ[
M"79O\#9'\J=V?MO3T\W/]FU?D?#?L_3X&?7G^*5A^L[:7VSX]A+LW^!LC^5.
M[/VWIZ>;G^S:OR/AOV?I\#/KS_%*P_6=M+[9\>PEV;_ V1_*G=G[;T]/-S_9
MM7Y'PW[/T^!GUY_BE8?K.VE]L^/82[-_@;(_E3NS]MZ>GFY_LVK\CX;]GZ?
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MWH<*P##@@'6;^;WK7M.--.--.--.--.--.--.--.--.--5+ANGFL(7MW:>X
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M))8;0LDVI2+KLU&C_>K)++'DAHZU<Q:+7-_'S^6400)"5Z+%5FXX6S%[@)/
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MRL5%Y$+0XE*T*2M"TI6A:%84E:%8QE*DJQG.%)5C.,I5C.<9QG&<9\.=*!!
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MLJS3B1>]/3""R=UP02ZC5;]3^D!LMHTK9.S&X>NDII7KS$Z\)O4#L7&UJ9L
MRWEIG@J_&52,IL6%"V".EYT\IT6+?FVH\)9[0X9#@Z36B$R][:\,.1AP]#*I
MD<J]H5I:GD-BJL"]TTKSO8=I(GCC0!G$99@I+ 'I(UK^+WS8LX>QN+*X"7#X
M&*@UV#(><Z=Y[;=\D$=:.I&L,\<LSL5C:81H7"HQ7K5M=BC]XMSG6K5#>U^E
M.S=6ZOW=-1T%0-C 7."V/(!&SHRC:^[L6AUJ'8FM?A2 6/;#"I0LC$..DEPQ
MM38![@U+.W,>L-XTMPT[MS'1M+:J-7EJ*RQD+**EF9S':9&/2JHJF0\!>"Z
MUI[RR[VL6,GM#(XW&YF6.&CD$MP9"1'F7K@.0I5XA+11T]N[R.W<J&+CA'*Q
MQ/?G>EEMN^XC4W2B;VC5.OFR[KK6VV\#?% K3Y)U*?(R68%5;'"AS!#A4:TW
M(,@1RI3/F?2"T604G*<W3MC&PP8R2]N&.G/E*=>Y! ^,M3 +8 Z5:>&1HP%<
ME2S]'JZBH!U8]-\U8MYN'%[/GR5;!9&WC[5N/-4:Y9ZA)9EK6(DF)>,!PD?>
M>)Z [,-76ZX;WJO9G2E#WA2PY.-K]ZCSB6(R90RB3BSX>9DJ[-QI61W'6'E
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MG#PB%>L]D8P04G+>>59#?VY\?FJ6"?8,KW<J]_S2HW-BE%^''HTT\P80M%5
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M6]YB25/EJ6V)[0XXX. V,/E:LMJ6O,V'L^GLG;M3$0'O[SCRS-Y)R7L9;,V
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MH9G D>DY]C)A.<,#X<<SA/.;[@H7I^T7L^O0T[4M*E!N<7+D5>62K4-C%/'
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M65 R6F>LC*M*M=,;&S=-1^K&["I](2GMH4YO@N51MC&MU:$Q<K![N9+?D/\
MY0*T\K7GN W6687.9/,IAM-?1A*@<KV&V:HKWN3BO1;S&!C%C\A\K\YFO%W?
M2%_N\7_*^\,QD'1T$F7UOK4* O\ EF+ 7/>G0W2_GMI!E/-_F/RR<S]9D_\
M"3B30[@5A$>][WCN/6O/Z*><JUWK3C36N O\;C$?[/"4_P"HT/FW+_ 23\*D
M_LHZY^_UTH?P#E_M]-3^W_C!=._DY['_ *V1?.$Y#ZZ>W_P3R_Y[#KZPP_\
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ML/2GKX>6[F:UCR)Z$$$]VK/#%7FLSLTZS3R>4RR%Y%;69NY/^%/3;\KG7?\
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ML<6S:RU][O%#_=IRSV4W=/N2/*%X<CB2G<2U#- L7 57=9Y3;AV\:#FTVRP
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M+B $/8-&:=V?'SYO'8E[D->I)BFM"1&O04+"BXACB[ZK#9)L-(A,:,\,;(O
M+\=)(TC+U-L9C/QXZQ;OQ9Y:#0R)B[65J.V.E$L_D]ZQ2Z:B12@2O'%:E223
MJ(CZNM0;H4:D576M.K- H\,/7ZA3H6/KU<A15ONLQT3%CH%#&P^4Z^62XEIO
M"GRS""#"WU.$EOOD.NNKU^S9GN6)K5F0RSV)'EED;@%W<EF/  4#D^"J JCA
M5   UMU*G6Q]2M1IPK!4J0QP5X5+%8XHU"HO+%F8@#Q9V9V/+,Q8DF5<L:R=
M.--.--.--:X"_P ;C$?[/"4_ZC0^;<O\!)/PJ3^RCKG[_72A_ .7^WTU/[?^
M,%T[^3GL?^MD7SA.0^NGM_\ !/+_ )[#KZPP_P#Y?=X_RC;<_LFUJ\'.D:X?
MIQIJ(6F^U&E&5,"T3+,27>K,+3JHRZ.:^J8LAHI9HT6TH08A [CHH);N'S%#
M"IPSE*WTK4A*H^]E*&.DH17;"P29.XF/HJ4E?RBY(DDB0@QHX0LD3L&D*1^U
MX+@D S&+P.7S4.6L8ND]N'!8R7,99UD@C%/&PRPP2VG$TL;2*DL\2=W"))27
M!6,@,0I5]J.Q8HN<I<RU.10,W,UPHMD<T9+,U7SG8V8!RV>,*\I81S+HZW4-
MJ8<4C*F'76\X7EC<I0R\#V<=86S!'9L5'D5)4"V*DK0V(N)4C8F.12I8 HW'
M*,R\'5,W@<OMVW%1S5-Z-J>E2R,4+R02EZ60@2S3G#02RH%G@=9%4L)%!XD1
M6Y E_)#41IQIK&&T]0T[<$3$Q=M3.C.UZ:&L==G*M9)JIV2 FQ6GF&9"*G($
MP$X=W#+[J%M*<<&7G+;JV<OCCNLPN;P&/S\$$-\64:I92W4LTKEFC<JV45E$
ML%FK)'(C=+,I!+(>0W3UHC+L^UMWYG9]NW:Q)HR)D*4F.R-'*8VEEL;D*,KH
M[U[='(0SP2+UQHP8*LBCJ0.$DD5XK1H33O7XZLZD@SS(ZS;;G+K:XQN?DK%9
M[-?[)$1H$I=;!,V63S(NE2;$7B.=)?E3Q</,MLLA(<6VIO&#C*VW]JR4\#6E
MDBN9VSDK\(M36[MS*7((8ILE;L7)N^+SK#W)=IY4ZE55C!*D"5SEW>/:!!D]
MVWJ\-C&;2HX7$V6H5L=B\9M_&W+-BKA<?2QE;R98JKVC96*.I7EZ'9WG958,
M<N%6>N@S\552YN,'LLZ)(2$/ NF,)EY$")PSF3/% \_M+H0&2!T%%X;]G9=(
M'96YAU]I"YY[M2.U!1DLPI<LQRRUZID46)HH.GOI4BYZVBB+H'DXZ%9T4GJ9
M0=1BQF1GH6\K#2LR8VC+7KW+ZPN:E>Q;+^302V..Z6><1R-%"6[QTCD=5*([
M#W>96L'3C34/G+]4*W:*52YN:9 L^Q'YX:F1*QC779Q^LQ69N=;9?'&=$&S'
MQ>,EN9/(%2ZC'JQ\O/?P?(^SE*%.[CL=9L+%=RS6DQT!21FLM2@\IM!61&C3
MNH/;DRO&&^I0LQ"ZF*. R^2Q>:S5*D\^+VZE"3-6UD@5:*9.V*-%GCDE2:7R
MBT1"H@CE*'VT@1/;:^Y&]56)M]<H4A+('MMMCYN4KT1D0]Q<B!74"KF2$ELB
MN1X^ D&#94V86.Z]ZW&!D/92O":S9.C!D*>+EG"7[\5F>I7[N4F:*H$-AQ(J
M&).[$B>$DB,W/M W!X\U\%E;>(R.>KU#)B<38I5<A<[V!5K6,B95IQF)Y5L2
M&8PR@-#%(J=/TQD!7F6\S]1.G&FHE(7JJ15PKE"D)9 ]MML?-2M>A\BG.+D0
M*ZD9<R0DMH5P ? 23!LJ;++'=>];CV=M[*5^7 ER=&#(5,7+.$OWH;,]2OW<
MI,L50(;#B14,2=V)$\))$9NKV@;@\2U?!96UA\CGJ]0R8G$V*53(7!+ HK6,
MB913C,+RK8D[\PR@-%%(B=/TQDY7F6\S]1.J/=R?\*>FWY7.N_\ DUGYS7M"
M_P -[/OP\Q'_ ,5K7<>QK]Z^V7^2+<?YYC-2;MU_>_6[\K/3'_$L'(;MC_O?
M9E_*_LC_ )\CK1=D?5[K_ K/_P#+6U;OG8]:1IQIJMLGV\ZZP\L;!R6QV!9:
M.+,"+!56KDXZT2 ^L4M"<LUUQ#R6'VUMJ=86XRK./,AQ2<X5GF-KME[-J5R>
MA:W*D5RM--!- <7FW99:\C13*"F-97$<BE2\;,AXY5B""=KAV1NBQ!'9AQ3/
M!*D<B2"U1"E)5#QD]5H%2RD$*P#>X0#R-6-'?:*89)87YV"&6WV5^52?.T\A
M+C:_*O"5I\R%8SY5I2K'CX*QC.,XYTN.1)8XY8SU1RHLB-P1U(ZAE/# ,.5(
M/! (]1 .M6961F1APR,58>!X9201X<CP((\#QKEY[UYU&)FYUFOSM5K4Q*M!
M3EW*DPJM'K8+=<ERH>/7*R333K [H[&18]"R5*,>'0M./(TI;F<(S%7<WB\=
M?Q&+NVT@OYV:U!B:[1S,UR6E6-NTB/'&\<9BKJ9"9GC5@.E"SD+K+@H6[->Y
M;@A:2OCTBDN2AD @2>40Q,P9@S=<I" (K$$\D >.E-N=9V#6XZW4Z5;FZY*J
M.3'R;+!8S9*HV1+B3<)9.'%*1ZB0!+&5ZUA&%J9RMOSM*0M3"9O%[CQE;,X6
MVM[&W#.*UI(YHEE-:S-4GX2>.*5>[L031'KC7DH67E2K%?H6\9:EI7H37M0]
MV98BR.4[V))H_;1LZ'JBD1QTL> W!X(('KRTJ!!14G-RI&!(N'CS962*RVZ[
M@8"/&<+,(RTPVZ^YAD=EQS+;+3CJ\)\K;:UYPG.;<MUZ%2U>MR"&K2KSV[,Q
M5W$5>M$TTTA6-7=@D:,Q5%9SQPJDD V889+$T5>%>N:>6.&) 0"\DKA(UY8A
M1U,P'+$ <\D@>.N*"FXNS0D/8X,O!\+/Q8$S$'):?829&28K1H)2626F26L$
M"OM.X;(9:>1A?E=;0O"DX\8^_4RE&EDZ$PL4<A4KWJ<X22,35;423UY0DJ)*
M@DBD1^B1$D7GI=58$"MFO-4L3U;"=W/6FD@GC)5BDL+F.1"R%D;I=2O*LRGC
MD$C@Z]7F7JSJ/VJTP%(KLM;+3(MQ->@A%'2TDZR20V&(A24*>6R&R02XE*EI
MQE++#B_E\?+X8SG$=E\MCL%C;F8RUE:>-H0F>Y:=)9%AA!"ERD*22L.6 X2-
MF\? :R:=.SD+4%*G$9[5F0101*54R.>>%#.RH">#XLP'W==.%O-5L,[,UJ&E
MD&S=>CX&5F 4BG,J# LXKQL$1E\@5D5[!XP[SJ4#/O.L81E)2&%Y2G-BCGL3
MDK][%TKBSWL=6Q]N[ (IT,-?*Q//0D,DD212"Q%&[A8I'>,+Q*L;$ W)\?<K
M5X+<\)CKVI;,,$A>-N\DJ.J6%"J[.O=NR@EE56YY0L.3KLVVVUZBUV4MEKD4
MQ->A66R).16.66D5ETAD5M>1P!RBW<*??:;\&1W%8\_F5C"$J5B]F,QCL!C;
M>8R]D4\=119+5EHYIA$C2)$K&.O'+,_,DB+Q'&Q]MR1P"1XI4K.1M0TJ<1FL
MV&*PQ!D0NP5G(ZI&1!PJL?;,!X<>O@:D+:TNH0XC/F0XA*T*\,X\R5XPI.?#
M.,9QXXSC/AG&,_Z<<D58,JLIY5@&!\1R".0>#P1R#[OCK&(()!\""01]T>O7
MURNJ:C%8N=9N7OA][4JW*^]6SRU,L'JV"V/<ZS0?L_NK%.>UCC^N<#]J8\[X
MWKQ'/68]20YY5>6*Q>;Q>:\X^:[:V_-.5N83(],<T?DV4H=WY74;OHX^MH>]
MCYDBZX6ZO:2-P>,RW0MT/)?*X3#Y;3AOUN61N]J6.KN9AT,W2).AN%?I<<>V
M4<CF3\E=8>M='I./\0M2_I=@?ZFW[GS9]%)];_#_ (8X_P#L3<.NH]DG\([O
M^A+/Y_C=<7HDOQ>O7G^;[-_7+L3GUAN7]^[WWZ_YK!J=^B.^O/O7_.8+_IC"
MZV.<@M<1U^>/?NPM\M]MMQ1+NTY'7FRHG;6IX_K9!R5ZWN''25 *Q!O.-U;3
M&M]<6^D;6K]P\TR%L:6GC'#H0WUC9" FHML8O>*4%/S95<5EGKM6LMD'6&FS
M+,.O@R6YYXIJSQ<*8%0=+@>'46Y7[0V?AMH-V<[8LKMZ#-X*QMS<4V^;<.(V
MA)/!F(S<4-?W3G,WC<MMZ[C0*LN$KTHUAM1A60S-8=XYI9MB6(/O>^"UL[?6
M.DZ.P5=B[E.CV"<Q38CM JJ2RVM:BVE,OFQ":2<E\Q3EM@6U(HP-H7[D$!!P
M*1C%68X(SA@?)Z1R_D4C1(40S/C^]7FP8^GNS;"=7=.?IQC'6&+]2ZBZ&%I2
M]D2RM@=H'M4.S;L^+IO3J'*6=@+D:P;.R8_R;R*7=8K>4C'6VYR\N/!M)+)<
MZX]845M>?)LNSW*INO?<GVTA?2)76G:8UFFX;%D*1*ZF8VH,+/0>:IE1%&D:
M,#!NV%-B+D,+?KC47$QZW(J&2"R5EBL@BKB2I27&O@HI;5CNH%F6T:Q*/WGA
M,LQ<1]V%X#EV;VS\\;5Z/4HZ.!7([6V?7[.;78IB\GN?.G&82'*U]QOMV22G
M;&0X3+U\O+<6D:44!5;S6+$X6Q:,SIEVU ;W>U/Z23>M$V%O23VIKGLGMK6&
MLJ^#>KB3 5+5ZY_6Q=QE:G3FWR _=2+J,W8R(:4$#(=KC,2.97613@4*7BQM
M2%G TYX*:UK%"M8LR-#$'DL=%A8EDE\#TM*D8=20).HB0E6.M:Q\VT5W%V';
M1R^%VE!M_-[%VYG\]<FQ&,2YDL]Y'GHL77R.398Y16L9*I12U7DE1;QLO%=9
MXICTQ&MV^_R&@.V"Z#V2. U8#G22J_8J]:>U&[(VDV!Z5:(O,>O;,UKRH[!C
MJG=8E(S6Q\4J2//UN4\4^Z-!L2C@Y%YXH1>QO?T UEO*R\;QXZHTL84]T?)D
MGE@:6%N3!WRJLXX'+E>1)7L;AHMX]G8S.QH9MP3#=0NTKM#L^VK-E::UV3$S
MC;E7,Y+"SY'%6"[83SI!#!G8UB17MO761/'BMHW:?ZL[2AXK8UBU]#4SL;JT
M=>RF=N=A=M]=[["3=?.(GJ)!;BC !MYZRU:@YB,7>9E^S2K4)-$AQV)P'-D(
M83Z:M"F1KLT$<SRT+)%<U:-:] Z2 ),]1F-.Q8X+=RHC4N@+=)$:G639P&*I
M]H.W[-G"4LS9RFR-P.N"?;>RMM[UP]JK=BCIY>WMBQ+)M+/;@[IYQB:J4*YM
MU(Y9_))?(4<Y(UOM[8<YI?K$B$-V;"A!^D[UOK\N?9VY==E56^Z_+B[ =* T
MN]6 "%MMETS@QS$:-%6]^RL8>CEM%3\JMKV>.QYZL*6\AUK78G;UB<)Y+%7E
MAG#(JM- C/%';X]L6B[L\-X1IZV@L[MO#5-T[\:U%@;4LW8-G,S'3;;>*P.0
MP^9CL48J\N5Q%*>WCJ&Z#$IL26,:E!NB<-'3KAB\\-AME;(>O$ ^G:.]W>_;
MW<%VOV?1[TQ>U:Y&T9BZ%BF KH;H^->C:@'UTD6<%NC*$EID7%2HTTMU"2FK
MSP5Q#(/)Z8PHQ8>*X$A$YN=T"#WP/?FT9^5,)Y'2 I3@\&5M8/!KBKJ' [13
ML>3LU6[0W6E;$>?)-V^:HY(I5RX<YJ3<DF<,E23%,>[,"^3M55"4;VIE>SQH
MG:N\V=J;R]^M']*M,ZPI\5C8]XS3(_4Q>SX0 ^K^\;,EFN2->/"F"6'<FQQ+
M3,6(#%@K$BV7Q2/*"N6JTS6I]S-MM+$K=Q#WK617=A+WW3UK(K)R.&!+%G;E
MB",6H,!)/MW:;[>VGYJR_P!#S5SV3LG"8GSI/N*+;]N:'(>=NX\M@NPRUD=>
MYFC9K$DMB826'61-@/I$K+:ZW1M.919+W2-,RV[ZK%]C;OK5^; M5<U4\#+.
M/N.S-::>L%>K!\TU&!66<B$M&CB.,AH(2V>X.3"8*.*2:U]+AFMK3D:A#8"-
M%)9#+QPLA"/*J=1C1CP3RW!*@CCG8K1QU[+;F#4<1E=T5]J9"QLC%9U*DV/O
M;A2:LJ*M6\RTKM^&HUB6A3L]44DBM*4)A#IJ\V+%R>T]*W<>%NNY;WUPK'=S
M04-UMNMBM]^S.S57LAD*#LID*?DR!;%::G4K"XMB@6:66<Y#$I**AY3!8CCC
M.PP,M>W"7AJPWY,1=?(1)%#T))&',!**#'%+(@YGC7@." Z\$<]]PEBOM_=.
M)DM8K;&(WO?[*=XVM\XNEC,.*E3(48K<V">2G DE''9'(TE5LQ1K"%;49CCM
M5S'(%;:9WU-O&NNMU+CZ%8-BP-, V9J.J[IO%..G9;9U8Z_-G>P7ZTQL^-B1
MM"YQ@0>,Q*V)CVN7R*5)'$.+RLE[&NX80SWY6F2!Y37M2U(90BUY+W'5!&R$
MK'T$ENE#PG(4 >K7S_V018G-[XR<V8IX6YE)L#N3(;6Q.3BJ5L#?WD83-AL?
M/3D[G'BH\KS^3T7[JMWD=>%%'$::UP678]XC=,=Q9GK[LO=MRZNT"^]89O5F
MQY&R;"G)P%2;=!D;[B:9<YA>+M8*'$ H858&GB3(R/;?.0RMX N1??G8Z\+V
M\6EVO4AR,\.02S76.!$([MQ2>6)/I*3,W/0>%9B%Y 95 [=0PF(GW/V9U=Y8
M+:N+W_F,/O\ J;AP<%#"U*DH.-MIL^SE,75'FJEF+,O6*16.*Q,RPEU6:.!$
M]/L-V"N-\B_23W32NT-BJJ4?5.CKNHK'792YQ$8"]+;"CXNXS&O&W<@>H$EU
MH+ GI&#8;$GFQR6BWCA,Y4OS2HQ0M@(K=:#O&ERXM(ZQ,S!86:))R.KDJ"&1
M7/*<@@ ZL;,V;C,//V&XS=. PGG*;(]K"[DHW:^+LV)4K8:6QC:N:9>^+R5@
M8IJD%MVDJ&2-HUBDXXWD:JUG%:CI@-)AY^ZV<0(J1.<G-@VZ9NUH/,E37CS'
M3IV<((+<1DA]>!Q6LLB"M>#8[",>;*M0LV&LRF5DAC)"J$@B6&-0H"@!$ 'J
M'B3R2?6=?)^X<[8W'E)LK9IXJA)+'!$M3#8VKBL?#%7B6&)8JE1$C!Z$'7(W
M5+(W+.['CC(+_P#<'O\ 5.?[BN65]8^^/Z]0R?5K_P"I?ZQK7;Z)C\7UU[_F
MVROUQ["Y.;E_?N]]^O\ FL&NU?1%_7EWI_G,'_TSA==?I[_E:^DD_I?U%^JQ
MKDAG_P!X]H_^PO?GIU\I[3_A1V@_Z6Q?]F+K8_S4M= TXTUK*])M:MC5FE:1
M37IJ0K&K9C<<?&[OL85MNFOP ZLJ&DG82/MM^UW#3UTIE(F)Y#(M@G82.PM#
MB8X DP-@]2U;AL^&I-8R/>QI-=CH,^-A:"O:9I^\02/!5M215[%F.+EHHI'X
M(+LJL5''.^T2SD*U3#"":2MC)<M''F;"6KE!$J]S(8DM7J$,]NG3FF 2>>&/
MP/=QLZ+(3JG%&.VU?8+I?3I?=>Q9:@7SM)ORO 677]ZW-$R4SI$*BFGP%6E=
MBVVNZ_NUTCH^29F8:&O;@2G"8C$<;!S0<T&E<;/6%HU9-P6$QU1+5;#8R5H;
M5;'ND>1:TJRSI4@FM5ZSLA222J&X5^M98VC8A]2IOE+L6T*DN8R$M"[N7.0)
M8I7<O')+ATI/)!5ER%J"C<N1QN)H8;Q3EHNAX)DF0&.$6BQ;(B-&3M3D=Z6B
M JVJN_W8C5T1G;EPWO$U2X:TJ(B$4RH;(WQJ\Q%_J@(!!KY55-EIIJ&FYA(S
M!KR@(=#+63!%4DR,<R8V"6:[MC$W9/(:^-DFKVYV!L3U,9<4U9G8*%G6.,O&
MG+* TA)P[,^0BPLU63,V:]?&;XS^-B.5MYN*M;QU5.*E7(9O&N+U6-"[/6>6
M40S2]*NQ2,+K)E![&6&N5WT=FTKU-;:U_IZ,VCV.H^QK#=K];;[ 6<,BFR\9
MK65F+8Y"PDA<J9*V/*LZ[+MT,28$W'^#1IN(Y$J]AVL3%-+NNG6CHVK[4\39
MJ15ZT%:6%A8C>W''!WDB5["0_P"%K7D"L6\54N4$C1ST\$&P<E=ERE'%19+<
M%+(3W+UJ]!95J<T>.EEM&&&2Y4EG'./>U"SH$ #OW8E:%TJ<V9NXKKS5)79^
M]X*K[+[R=Q(*QD1MSOM/LQ&M8ZO%2]?JI[SY(TQ#1 XS7N;'Q13(JZ_[20W&
M-1L@TEQG(L1T\<,M.E/&23T]N8"6$/7JV(1<>58YID #1R2%O;.ZEN]Z07+K
MX'#J39',M@:LN1S4%;([SW9#8:.W=JV6QT<$DL%9V9EEBB51W<<;!3 6(C$;
M@$>+<[7O.![2WBF*VU8:9LNH[YUE4- P5JV5V"D")_28(\ -&-!:CINO;C2M
MH5R\PS,IG8M[LDOF7 L2B)&9?C7 E.2=RO#C9<-7L"C%8J3XNY8R<D%3%H(L
MBS2LY:_8M5[%*:M)W?DM6&/NWBZ4C#AAT6[=K,P[EN5#E+%/(5,YCJN#ALY#
M.R-/AHUKJ@3%U*%NGDH+L0D\OO693+'.6DF*%.9-BWI,)&P1NI=>O0^S\:S
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M_P!-[IVSBHJ>,KY;!807,/VN;'H06(=I[:VU4GV]>MM6LKCJ.-N9*]<VI=9
M(+.?MV9+K ]?#PND>9*9C:]*DM"RU)N>T+3<MO=*KY;YV.M]NL=MBY39\70J
M_.TU\>&GBS(N(.%FY!N-%:"'%RZ(A31"7GRY-\W8L?Y\QTNV+&-R&:NY'/\
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MO-_G2C/2\ZXNIFL=WX \KQ5_O/([T7#-S!8[J3NR>">@\J-2CF;J+TXTT_\
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MY(MQ_GF,U)NW7][];ORL],?\2P<ANV/^]]F7\K^R/^?(ZT79'U>Z_P "L_\
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M6G9I1%""\BJU[=&(\[6-[>14DNY.OF,"\1BC22U%2DQJK,R/]6M<NJ-*_(C
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M<;&+;Q0K!9B?J%[/XZG7Q_G*MB:6*3'9##2I3R&&K12.LDB PTLS2M/5SD#
MF6TLXM,859S)$Z\:['6NQY!CNDL'6KK-2 4O*[Y%O$*J>),# F8K76) 2MO
M^9+8(D5A<?-AQ+B%($+DW9!K&%FY5F[V8Y(P5NPNCC,Y>LP7+?:!#GJ+9"6>
M"O=I[:\IBQ<E?D+!#3YK7X*;*1#-::RG#3]6J;LJ"6;M"L6\?7BD@AVY)CK
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M8#'98??=SA3KSS3;:6W77%)PIQQ:5+7G&,J5G.,<J68D$L20  222 /4 ?<
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MQ&<YRE6/'GI69"2C,I(*DJ2I*GUJ>".0?=!\#[NO#QI( )$1P&# .H8!AZF
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M5:Q:J3&!8+T+5V=N"C1=22?2I).E2Q7CJY ,FQO?0@TZ13,[,UX%/#S)403
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MZ%+$JO/KZ03PO/N\<<ZZ)CT%7P"Y60=B86, 03('R)BPXX$-"D^8LXLM[++
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M)- T:UXXPHC"F%I(BP5L*KN>G!-3=RJ-;C*V;L.P;SWRU3*NZ&U)6T^9DB!
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MQM]\IE86Z,8<1!8J14I^@"G)<LR/)6D/1Y4$1+$<BL6D90QO!IG_ "ENWO\
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MO!!9"0K;7A9E< E^5;5@=2'W.O=AV*-*["N%U@[3UMA-I2+%L.%/2%<7+D/
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M<2\\28-EG+)+[SR$.NO/(6XXXA+BU94G&<4[R3J5^\?J0!5;K;J50. %//(
M!( !  \-5[F'H>/NHNB1BSIW:]#LQ!+.O'#,2 22"20"?'7]=A89_P!T?71,
M8][KH9;EO6@"N>ZB!F_4CHD?.UGVU [7\$RDGUN&F_O&\)3\G DD'1P[CNR2
MG#,.@D\DIP?:DGQ/'')\3JIBB;O.J*,]Z )>44]X%'"B3D>W '@ W/ \!X:I
M_NWI+5=XV:S34ON3?E3KUYKH-4N^N*A=(1% GH((1D!\,&'LM4LA=-]VX\=B
M/LJZ/(UWW=%:\34J+=?+=G<=N*;&PPQQX_&3RUI6GK6[%>0VHI68L&9X9X5G
M[MR7A\H27NS]3[4 #5,QL^MF;%F:7+9NK!=@2K=Q]2W"*,\"((V1(K%:P]3O
MXU6.P:4E?OE!+@N2QM]&QT16(./B8]H>*@J]$BQP+&7,H%C8B)#;&&:R\^O.
M4#AACH1EQYS.4MM^9Q>?#*N03O)-(SN2\LKL['CEGD=B6/ 'B68D\ >L^ UM
M4<<5:&.*,+'#!$L:#GA8XHD"J.6/@J(H')/J').M;_3@W/8+LIV=[E")6[KN
M33!=<]#RBDK2W8:-K8P@Z[VN/<7C&"H"R7MW!$*2VE'A[(>*^GV@5SPVW/KY
MKQ&'P#$>5IWN6R2<^,5FXJK6@8?XLL-8<2@\_5*1X'QY_M-_/NX=Q[M4<T).
MYP&$EX/%BECG9[EJ,GZJ"Q=;F%AP/:.I!92=9K[FTZT.56C;OU['.2VP>N-Q
M:V/'0X^%^U62G+&S'[%JH^6TJ<PJ7KN<DJ2RAPA]$7D09MP@EI&>&]H>/NFC
MC-R8F$SY7:.0&7B@7GKMX\H8LM23CD\SU>'(4%V$)C16=U&OJKL9S.+7*YS9
M&X;"U-O]H^'?;=F[)QW6-S D%C;N5DZB%*U,B!&"Y6-#:[Z5UCC=A9/6^Q*G
MMBCUO8=(DVI>LVF-9DHXIO*?6-X7C*" 36DJ5D62CBD/ 203F?6AG#OCNXPM
MO/-PQ&6HYS&T\KC9EGIW85FA<<=0Y\'BD4$]W-"X:*:,^VCE1D/B-<UW)MW+
M;4SF2V]FZKU,GB[+UK,3 ]+%?&.>%R ):UF(I/6F4=$T$D<BGI8:F_)+4)IQ
MIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIK^9SC&,YSG&,8QG.<YSX
M8QC'RYSG.?DQC&/ESG/X.- "3P!R3X #UD^]J@&N9%'9;MA)[DB\^V:>ZX0\
M_K;6TRGQ6!;=H6A#3&PK+"/X\6BHJ&A$LUM)3>%C&K<$D "7FENH;Y7B)AO'
M?,VX8#WF VC7M8C#V!XQ7\U=4+E;E9_J7@@K!:G6O*2]4,T3LI8#O^XJY[-.
MR>MLZT.YWAVD7,?N3<E,^UGQ.U\6SOM[&7HSP\5JY=9\D8GXD@598)XT8*6R
M]W KLQ+::*LE<%4=8=5VBK;9B D85E1+E'DTGR"$^3"E^9N$=E'T);2IQQ;*
M6D)RI>.>.V;&W;FR9<GC(C/D=I9;$[OIP*#U2M@K0L6 ..6Y6B]J0!0S,4"*
M"6&N8;&M009Y*EIQ'6S-.YA)Y#QP@R,)BB)Y\.#8$*DG@ $DG@:S[3;;"7RJ
M5^Y5LM!T'98H.7C2$*3G.1S&4N>J>2G*O5%#+RL8P=6?6#%,O#NX2XVM..AX
M7,4-P8C'9O&3">AE*D-VK(".3',@?H< GHEB8F*:,^VBF1XW 92!K5^E8QMV
MU0MH8[%2>2"9"#X/&Q7E20.I' #HP\'1E9200=>JS$Q0QI$F/&1X\B8G""Y!
MD(9HTI&,XSA)!:&TOOIQE*<X2ZXK&,IQG&/DQS+2G4BGEM15:T=F8 36$@B2
M>4#C@2S*HDD X' =B/ >]JRTTSQI$TLK11GE(FD9HT)]91"2JD\GQ &OAN%A
MV2\GM1,8T<IQQU1C8 J"\NNY5EUS)"6L/9<<RI67%Y7YEY4K*LY\<^-%I4DE
M-A*E5)RS.9EKQ+*7?DNQD"!RS$GJ;JY;D\D\G0SSLG=M-*8P !&9'* +QTCI
M)Z>!P.!QP.!QKD+BXP]X0DZ. -(CW?7@/EACDO!/?)_#".O-K6,[]ZG^$94A
M?WN/E^3'/4U2K8>&6Q6KSRUV+UY)H8Y7@<\<O"[JS1,>!RR%3X#Q\!JB331J
MZ1RR1I*.F14=E61?'VKJI <>)\&!'B==_F1JWK@(%&*2A)0[!*6G6WVDD,MO
M);?:SXM/(PXE6$.MYSG+;B<86C/RI5C/+<D44P42QQRA'611(BN%D3Q5U# A
M74^*L.&7W"->E=T)*,R$J5)5BI*GUJ>".5/N@^!]W7/RYKSKSPHF+C?:<QT;
M'@9->409D(,87VM]7CYGR?4-M^O>5YL^9QWSKSXY\59\<\QX*=2KWODU6O7[
M]S)/W$$47?2'GF27NU7O'/)Y9^6/)Y.KDDTTO1WLLDG=J%C[R1GZ%'J5.HGI
M4<#@#@?<UQ,04(*&_'BPT4, 2ZIXD%B.$9#(>4I*E.OC-LI9==4I"%*<<0I6
M5(3G.<Y3C./$>/H0PR5H:52*O*YDE@CK0I#(Y()>2)4".Y*J2S*22H)/@->F
MLV'D65YYGE4=*R-*[2*H! 57+%@."1P"!P3[^N\V*,R\^0T.PT05ZK)+[;3:
M'B<LH]6SE]U*<+>]4W]XUZQ2O5H^]1X)^3E]8HD>21(XTDEZ.]D5%5Y.[7I3
MO& #/T+[5.HGI7P' \-6R[E54LQ5.>A2Q*KU'END$\+U'Q/ ')\3XZX\@ Y]
ML\0A,^Z"?*?XC,Y]N3ZO+/E,\4?]Y3ZG.6O![SX]7G*/#RY\.>37@/?<P0GR
M@<6.8T^GCIZ.)O:_31T$IP_4.D]/J\-5[R3VGMW^EGF/VS?2SSU<IX^U/5[;
MVO'CX^O75;@H1D?(C,/%-"J';$R,W'B('R*RO+K0V64LX;R.TXI3C;.4^K0O
M.5I3A6<YY:2A02/N4I5$B,:PF)*T*QF)&+I%T! O=JQ+*G'2K$D 'QU[-BPS
M=;3S,_47ZS*Y;K8<,_46YZB/ MSR1X$\:[V!1</J*P,/@I;*1UDX9;P^H=*L
MK2PI["?6*92O.5):RK*,*SE6$XSG.>7Q%$)#,(XQ*4$9E"+WAC!+",OQU% 2
M2%)Z022!SJWUOTA.IN@,6"]1Z0Q'!8+SQU$  GCG@<<ZZ0\'""!DQXD/%"@&
MY=48"/'B,AEJ?3Y7U$C-LI9?R\G[UW+J%Y<3\B_''R<L1T*,,,M:&E4BKSES
M-7CK0I#,9!TR&6)4$<AD7P<NIZAX-R-7&L6'D25YYGEC"A)&E=I$"GE0CEBR
MA3XKP1P?5QKF%C(T'"<!1X(>$CM")P*(P/A(K'CAD9.&6T> [.,YPTSCP;;\
M<^1./'/+D56M  (*\$($:0@10QQ@1)ST1#H5>(TY/0@]JO)X YUY>663GO)9
M'Y8N>MV;EV^J<]1/+-[K>L^Z=<0T)"AB/@"1$6*"4XXZ2$, (P(0Z[X>M<?&
M::2R\XYY4^L6XA2E^&/-G/ACGB*C1@ADKPTZL->5F>6"*O#'#([\=321(@1V
M;@=3,I+<#DGC7IK$[NLCSS/(@"I(TCLZ*OJ56+%E Y/ ! '/AKMI$$0^DI H
MZ24CX$20EEM+Z1$K]9@5+V$X<P/AS&%X9PK#>%X\V$^;Y>7A#")!*(HQ*(Q"
M) BB00ANH1!P.H1AO;! >D-X\<ZMEW*]!=BA8N5+$KUD<%^GGCJ(\"W'/'AS
MQJCO9.($WKM[5?7D5S! <*/8MI[%(:QZU$  S R%<IR",)\4>UR4K,O^ KBD
M/MBN#%I0IA]*N<'[3J<._MY;2[.(7ZX*,62W;N61/;C'UTQ]G&842<'COK-N
M](.Z8K(L+QS!620'70]J3R;=P>9W.PZ)+#5<-BE;VILRM:AMWRG/![N&"NO+
MCE2_4A(92->SV;ZJ2NT[)5-X:3NZ=/\ 9S6X3\?4K]D3)U>ME;?=627KG9T.
MVA>9VFR#ZW5LN^I*,@2B'9 $8M?B*Y])8_)+6CEIVX?*L?8(:2'GAXI!X">N
MQ("2@>OQ < !B/7K,V'VA5]OT<CM3=.)])MAYV5)LEA^]$-W'7D4)%F\!:)'
MDF4@0 ,O5'#<C589GC'$BXE"[G]C]9M)A.QO1;>ATZ'CU#EOZO1D=NZC6'+>
M/#,P%',S$;8*P$5G[]J+F73Y(5O./:EX7YD-Y)Q-"Q[>AF*:H?$19%C4F3_)
M9NADD(_C(%4^YZM;'+V7[(SS&WLGM;VE#4E/4N-W_//M/+4@WCY-+.]:>E?E
MC]36*JPP2M_>QZN>]\8]&?0J](;^B^?]JN4\PM\+8/Y0'S6K7L(3_;3[%OR_
MA_9^GQCT9]"KTAOZ+Y_VJX\PM\+8/Y0'S6GL(3_;3[%OR_A_9^GQCT9]"KTA
MOZ+Y_P!JN/,+?"V#^4!\UI["$_VT^Q;\OX?V?I\8]&?0J](;^B^?]JN/,+?"
MV#^4!\UI["$_VT^Q;\OX?V?I\8]&?0J](;^B^?\ :KCS"WPM@_E ?-:>PA/]
MM/L6_+^']GZ?&/1GT*O2&_HOG_:KCS"WPM@_E ?-:>PA/]M/L6_+^']GZ?&/
M1GT*O2&_HOG_ &JX\PM\+8/Y0'S6GL(3_;3[%OR_A_9^GQCT9]"KTAOZ+Y_V
MJX\PM\+8/Y0'S6GL(3_;3[%OR_A_9^GQCT9]"KTAOZ+Y_P!JN/,+?"V#^4!\
MUI["$_VT^Q;\OX?V?I\8]&?0J](;^B^?]JN/,+?"V#^4!\UI["$_VT^Q;\OX
M?V?I\8]&?0J](;^B^?\ :KCS"WPM@_E ?-:>PA/]M/L6_+^']GZ?&/1GT*O2
M&_HOG_:KCS"WPM@_E ?-:>PA/]M/L6_+^']GZ?&/1GT*O2&_HOG_ &JX\PM\
M+8/Y0'S6GL(3_;3[%OR_A_9^GQCT9]"KTAOZ+Y_VJX\PM\+8/Y0'S6GL(3_;
M3[%OR_A_9^N)[T@-UL",QVL.A'=FPV9[&4!#[#UA':@J67U8SAI$E=;#/20<
M8WE7AZQY4>^AIO/G5X_(G+S)%&>JQFL0D8^J,%AK4O'^3"B*S?>ZAS[^JKV-
MXND>^SW;!V54J*>,LF&S\^Y<CT?XS08JC3AEG8?XJ"9"Q\![^N36W6?=6YMI
MU;L-W9D:SF2H)>9;2_6^CE.R>N]63"\8]5;K9,/Y4B];&$2E&!3V_7PL,6WD
MZ((6E80D4L9"I4KRT<0LG3..FW?F'3/87W8HE''<P'QY4\.X/2P]9:F<WWM;
M;&WLALKLK@O]QF(_)MT[XRT:U\WN"L#RV-QU5.#B,'(2>\A/3:M1D165'$LE
MC8]R!UQ#6&=^Z'U]V1UC.ZJV3'OE0<OZ@P"2CGDAS]6L,?E3L+:JS)>K<5&3
MT,2K+P9.&W&7FED 'CEQIIH9$AB\G:Q%R*[48+)'RK(XZHIHG\)()D\ \4B^
M##P(/#*5=581&<PE#<&-GQF0C+03<,DD9Z)ZTZ>,-FM)P3'/"WBC<$$%HW5X
MW=&HU!;M[:=/F&Z5V4U==>S6JX9. ZQV6T;#>^2[YA&/X,/&W]7Y*1+L2H0W
MJ\RULBRB 7VT)6X]/RJS3G-BDQV#SI-C$7:^'NR>VFP^2D[FL)#]5Y!=Z>[*
M,W/=P2*K#G_^) JC3(,QNC:@%/<.-N;BQD/M:^XL-%Y1<[A?!?.N-ZA*)47@
MRV8F9& Y)FD+N9<WZ6GH.A/JY;=AU<D4?>E0U@U5N$"4"<_SLDL)H3[.'$_@
M5E@A]OQ\<8<SG&>6?0?<Y)[O'+,GN217:#1L/?4^4@\?? /W-90[4-D#PES#
MUY!]5#/C,M'*A]YE\A(!^\Q'W=??QM?H]OI$!_5ON'^SWCT&W3\%-^-T/UK5
M?91V)\/I\GY7]0T^-K]'M](@/ZM]P_V>\>@VZ?@IOQNA^M:>RCL3X?3Y/ROZ
MAI\;7Z/;Z1 ?U;[A_L]X]!MT_!3?C=#]:T]E'8GP^GR?E?U#3XVOT>WTB _J
MWW#_ &>\>@VZ?@IOQNA^M:>RCL3X?3Y/ROZAI\;7Z/;Z1 ?U;[A_L]X]!MT_
M!3?C=#]:T]E'8GP^GR?E?U#3XVOT>WTB _JWW#_9[QZ#;I^"F_&Z'ZUI[*.Q
M/A]/D_*_J&GQM?H]OI$!_5ON'^SWCT&W3\%-^-T/UK3V4=B?#Z?)^5_4-/C:
M_1[?2(#^K?</]GO'H-NGX*;\;H?K6GLH[$^'T^3\K^H:?&U^CV^D0']6^X?[
M/>/0;=/P4WXW0_6M/91V)\/I\GY7]0T^-K]'M](@/ZM]P_V>\>@VZ?@IOQNA
M^M:>RCL3X?3Y/ROZAI\;7Z/;Z1 ?U;[A_L]X]!MT_!3?C=#]:T]E'8GP^GR?
ME?U#3XVOT>WTB _JWW#_ &>\>@VZ?@IOQNA^M:>RCL3X?3Y/ROZAI\;7Z/;Z
M1 ?U;[A_L]X]!MT_!3?C=#]:T]E'8GP^GR?E?U#7$[Z6+I 7CV:F['MFRYU>
M/ 2K4#4.V):?/<S\B&1&3Z;$@>M=7X(;21(CX4I6/'.$^*L5&R-QKXV*D%./
M_&FM7J4<2CW22MAV\!XGA3X#5#VG[-?VM3(6LC,?J:U'%926=S[RAZD:<GU#
MJD74#L _:SOTWFH2-)MO3WJ7)JPW<G[:Z,%V.W' J5A1%6$K@RR6M6UV68\P
M<ZN5=*DB1EX0PN8BRI")SDQ'";8/?I8@SV<3_!Q &;$X^4>J=I6"F[,A\8@@
M5 ?$A'5'UA3KN?>X-22G:VGM>7@6VM,J;@RT!^JK+74NN-@E'*3F4M(R^ [V
M-Y(SLRI%)JNMZC7*'1X,&MU&I1 <'7H..;RV)'1@#261V&_.I;KSF<8RX040
MX\482MTHM]XEYUU>GV+$]N>6S9D::>>1I)9'/+.['DD^X![@  50 J@  #HE
M.G6Q]6O2IPI7JU8D@@AC'"1QQCI51SR2>/%F8EG8EF)8DF4\LZR=4+L.B-M:
M$MT]LKJ5F%EZS:9!R;V!UMLY^(>KR\L]X>V3^LYM7@+2[":G&$O@%8:@7_!*
MG/6#!1D0QS"WMC.[7OVLQL3R:>E=E:SE=GW)/)Z=BPW'7:P]D^TQUJ0#AHG"
MU6\.>I(H*Z=YQ^^]I;]Q%#;7:UY;4R>*KK2V_P!I.,K^692G43^\X_<U$?3<
MUCX3R8YXBU^/DA>F2:S;D[;'?S5E=3@3=]*V]H*<9_@S0[YKBSR$0I]/R+7$
M6&J1TV-+QV5?(Q(X&#0^GP<PRA&?'GM>U+"4P$W)CL]M>ROA)'D\1<E@+#UF
MO:I165L1<^"2B./K'B% U:?L"W3D29MD9K:&_J+^V@FP6X\97N!"?:K<QV6L
MT9:=GC^^5C),4/M>MCX:[7QC_2WYZQOS&V;]B^7/9=[//C$OR7FOV=JU^YP[
M:?B3+\N;9_;6GQC_ $M^>L;\QMF_8OCV7>SSXQ+\EYK]G:?N<.VGXDR_+FV?
MVUI\8_TM^>L;\QMF_8OCV7>SSXQ+\EYK]G:?N<.VGXDR_+FV?VUI\8_TM^>L
M;\QMF_8OCV7>SSXQ+\EYK]G:?N<.VGXDR_+FV?VUI\8_TM^>L;\QMF_8OCV7
M>SSXQ+\EYK]G:?N<.VGXDR_+FV?VUI\8_P!+?GK&_,;9OV+X]EWL\^,2_)>:
M_9VG[G#MI^),ORYMG]M:?&/]+?GK&_,;9OV+X]EWL\^,2_)>:_9VG[G#MI^)
M,ORYMG]M:?&/]+?GK&_,;9OV+X]EWL\^,2_)>:_9VG[G#MI^),ORYMG]M:?&
M/]+?GK&_,;9OV+X]EWL\^,2_)>:_9VG[G#MI^),ORYMG]M:?&/\ 2WYZQOS&
MV;]B^/9=[//C$OR7FOV=I^YP[:?B3+\N;9_;6GQC_2WYZQOS&V;]B^/9=[//
MC$OR7FOV=I^YP[:?B3+\N;9_;6GQC_2WYZQOS&V;]B^/9=[//C$OR7FOV=I^
MYP[:?B3+\N;9_;6GQC_2WYZQOS&V;]B^/9=[//C$OR7FOV=I^YP[:?B3+\N;
M9_;6N)STBG5PW'J*79;ELR85\C%>H.K]@RDP4YGPPAD=$E7H<'+KF<^5"7#F
M_E\/-E.,XSGR>UG94GM,=<R&8L?XM3&87*S6)"?4J">I7B+-Z@#*/'U\:]+]
M#MVHP?3,UC<-MFF/[YD<_NC;U6G$HY)>1J^1MSA5 Y)6!O#Q .HO+C=FNV[:
MJ_(5V:ZL]?Y''JK$J6*&<WOL.&<_N\*Q&C>M$UU%R#65B2J3UORWJ\^5/NI&
ME%QZ\*=-Y;[!JRU+.R=K2^%LSNAW/E:Y^JK+"A:/$PRCF.<2EIN/#Z?"\D1E
M*DG9EV2L,C7R-+M3[0*_ML<M2*5=A[=N+QW=Y[,H27<=JNW$M0UPE3J')\FL
MQ0V%O#1J/5=;5*"HU(A1*_5JV W'1$4$E6&AV$94M:W''%+>*+*?6Z6<<2X\
M6<:^^86\\2^ZZOI.,QM'#T*N,QM>.K2IQ"*"",>U50226))9Y)'+22RN6DED
M9Y)&9V9CQ#.9S*[ER]_.YN[-D,KDIVLW+<Y!>21@%5550$BAB14B@@B5(8(4
MCAA1(D51*5I2M*D+2E:%IRE:%XPI*DJQG"DJ3G&<*2K&<XSC.,XSC.<9QX<S
M2 P*L 5((((!!!'!!!\""/ @^!&HH$@@@D$'D$>!!'J(/N$:I*Y1MJ=9IN7E
M],5U>S=*3LB3-2^GV#&PK30Y$US+TB?K=XG.1Y&'*=4LARJJQZ]#^4,Q[>%/
M$'(X6V W;V77[ES9.-;=.QK]B6[<V9',L&6V_9F8O8L;9>7F*S2D8F1L2?I@
MDX2NH+R6!T!<AAMVUX(,]:&(W!6B2O!G6C:2GDHHQTQ1954'7#.B\(+HY4KR
MTIX54/O-]Y.OH>,,7*7M^MYA./ BO7G7MSCI@5S'R+:?1&PTN%ZQM7WJ\-FN
M8\?E3G./'.)!.WGLZA'=YJYF=LW0/IF.SVW,W6N0L/JDD%6E<@ZE/@0L[>/J
MY'CK&/9YN:0]5""CEH#ST6L=E,?- X]PJ9;$,G!]?C&/N\'PUR_#NZH_.PQ^
M9^P/LGSW[/W9'\;X_D;<7[(U3V.-Z? C_CN-_7-/AW=4?G88_,_8'V3X]G[L
MC^-\?R-N+]D:>QQO3X$?\=QOZYI\.[JC\[#'YG[ ^R?'L_=D?QOC^1MQ?LC3
MV.-Z? C_ ([C?US3X=W5'YV&/S/V!]D^/9^[(_C?'\C;B_9&GL<;T^!'_'<;
M^N:?#NZH_.PQ^9^P/LGQ[/W9'\;X_D;<7[(T]CC>GP(_X[C?US3X=W5'YV&/
MS/V!]D^/9^[(_C?'\C;B_9&GL<;T^!'_ !W&_KFGP[NJ/SL,?F?L#[)\>S]V
M1_&^/Y&W%^R-/8XWI\"/^.XW]<T^'=U1^=AC\S]@?9/CV?NR/XWQ_(VXOV1I
M['&]/@1_QW&_KFGP[NJ/SL,?F?L#[)\>S]V1_&^/Y&W%^R-/8XWI\"/^.XW]
M<T^'=U1^=AC\S]@?9/CV?NR/XWQ_(VXOV1I['&]/@1_QW&_KFGP[NJ/SL,?F
M?L#[)\>S]V1_&^/Y&W%^R-/8XWI\"/\ CN-_7-/AW=4?G88_,_8'V3X]G[LC
M^-\?R-N+]D:>QQO3X$?\=QOZYI\.[JC\[#'YG[ ^R?'L_=D?QOC^1MQ?LC3V
M.-Z? C_CN-_7-,][NJ6,?)M=I6?\R4TW82E*S_FPE*:GG*E9_!C&,9SG/R8X
M]G[LC]S=R$^\N%W&2?N #$$D_<&GL<;S]W"L![I-[& #[I)N\ ?=UY9W9NV;
M*;5"=:]6VJUR!N,LM['O<*?3-80*7/O<R+I4JV/+3[PN/X54.$&,4ZG*%M9)
MSA0R\2?M2S&YU-'LPVGELO8G'0-R[@I6,'M;'JWAY2TMM8[F1>+Q<TH(8I6'
M#)WIYB:]'M&EB2+&[,Q2I11^V.*QUB+(9>R1X]TJ0%X*RO\ 4]_+(R*>>0O@
MPRWI#2[&IXV;DIF;(NFR[R>B;V)?#VDM%SLHE"D#A!,8\<1]?AVUK&AXQO*6
MAVE+6E#27$#L;AL39$>T*MZS=ORYS=&>L+>W)N"PH6;(6PI6."",>%;'4D8Q
M4JJ\)&A8A4#+''";AS[9J6O%7KK0Q..B-?%XV-BR5H2>6DD;_P#EM3L \\Q\
(6;@<GCJ;_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g107876g97z41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g97z41.jpg
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MB>2G%QD<1&&2(1;[06,G0Y;ZFQL[<<XSCCQ]GP/YJCZQZI.N^P&]?3[3UG[
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MTO6=) =E^H/M/5.=F[/B?;E<LY :K0NN]3 YM;8H<^MJA [Z5V:7AD@YC,&
M!=D32'Y,JQMPH *GDDA<\?G/G/\ !BN[>IWUS[-4SNATO]43JGJ.3V/L76,%
M?]5;EZ^AS4$'=+CJ78 NP#T'=?O$L?+$3M:7;[1)=#LXD%)D]=:7#'3AS!O#
M"JH1M9"<;L$'X CGGX\^*[!H/=/J5]Z-Z;7<M_7JW=%.C#G7NT:Z$5_>80+^
M^$N^[+1$+#HMX QA<R(;IP:M12[+TA$U4P/)37AZ1,B:4L11RJJH0H ]6YL\
MX\ 8^9'G/Q\?,52JCKOWTG^EC"]#1STY-CP-P)V>T*?[8O/U!74Z-2VNPF=S
MN;J1LIH@LD[8UAO=6'*XT*7970+CKK3>3+J=?I?I^GZ??63<N_N;N#SMYW>,
M8^6./GC'XU9SKSI[O2H>HWZGUY):YN%@H-]].O46D-6[7)"D*A[2N%<TQ4*O
M80XB8M]YR27GF@2<E865Y2N<PG#CCN64+XJS(VH,CZS$C\X^'X\5#:I=&.T@
MGTU_0<U9CKW>X6R.N_J.ZWVQO6I)!M-G=9T2+O';EG/W*VLI=QF$*;&&0Q:;
M*^(ZI3$R&XI*LX3A(?;]O\?'\%7;AOD.>"C 'YYQ@5T'66\-O:E[?_N@BJ:U
MZ0;<[<-;OVNQK*,0TX.JYURK74Q2=EAJV!VR&+%8)V-JZP1K$4G2[4%''HH!
MT.1A%!BE'H#[*A (C]0&!GG///PP#_#C^/'=AG6[U&^FG7_TJNN12E]IR^BJ
M+JO<CW9@OT!$:LM/:6I;?V1=KO>ZKKN-?;BB6]3*)7H5R#U$W9:2=!AY[$2V
M>^RR&X=7?2_3Y4RK%SP"2,;N!CX\#R>/CGX8YJ-PKT\^Y4OTP-V: L?5O=J-
MB6/UJAF^ET2Y2XFQ+67T85J=2$3[H7N\8D2&[ 9CO""L2TV^.1FH-SO>66IY
MLFTZZIN7<"".(L?+) (QC'!_'BK[O4#T'N'9'J7>C)M77VN;'9]:Z'O?;$AM
MZWAH*7@6NQ]QUYK(74Y%BD86CY%@W.$$88[*6UX<=A/(QA.$8\JL4@(XSR=N
M!\\'FJ&+AU=[YZDVS=(O0OK;ZC?4'L*:[+2;(/U0,V10]^^E,>"$[:Q.E[1E
M7NWQ:@R"Q-'.SBN0IVB'R8EG$$-$0'D9?'"J?']/T_-S5X92!NVL,><8<8'
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MM5NX9&02,$><GD$9^7'W<XYJ1VTNC=<71]U7+JU6M =7N[^[*:6KQWMU3]'
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M?'V55ELOOCV1Z@6CL/0=]3M)=DK!K7I\UV;JY32U MVDFZ_?3.SA6H:/I;9
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MC4T:.G-.P55W#(/) ^& !@YSCD_/^>LS%M<=_+WLJW]LY.H]&:XWMJOJ-?\
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MT/!3MC<VW*;:[.O391N'(-$'Z_J*X5FO,&H[[*T27)LQ@>OXSLIKY=KRI5,
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MI%9H(CKQIRBSP*H^YNP^M[B(<AWBJVMW,%VNHBN8>Q-8?=1*PK-:KG*J-X7
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M-F-(PW,3$E+CN2ASY$0X1@%(,,G*?&S$LZ$]O-;L%E7;G.UO*N%."5/R^."
M<$$@9%:,]O+;L%E7;G.T@@JP4X)!_AP0&P02!D5)3F"L%<48\)3CQ[?"4X\8
MQC&,>,8^GA.58QX_#QA6<8_#&<X^O%*Y<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2HZ]DZ#9K?2$3=;ZOT7LC9PTL C@V=\!\3JQ"KLNPC/RPRB;&$%"D63D"B8]
M$:B8:;<F-,/.(EK8:A2<\#A'P\DT<9!W&$X8D [>,@'!^?PS6:!U5\2/*D9!
MW=DX;.T[>"0#ZL9S\,^/-5I]=*3.NVSNS:=9]?.IAFLB.^C >Y3+1K Z";BZ
M3SI?7:"$ZA3B%(:$GK*^]$&%QRQ;S]=FS2TX^F.Y7;4$-R=Z9]B0;YKE2;0E
M=L@),W=D(#@/D 9(.?4  OUE(&].P6.#N37 8VF4Q(K?2]U^' ?*J!Z2#ZA@
M+G<A%75CQ\ 3 A"Q<*(-&#8D8>.'#XS,. /@0V41H<*%#C(;CQ8D6.VVQ&C,
M-MLL,MH::0A"4IQ%DDDDDDDY)/))/DD_$FHPDDDDDDG))Y))\DGXDU[?*52G
M%*I0]6FWZ4NE)IZZYW0ZN]>>R_2#M!I#==03V&M0U&M1^UC.OMD$J!K;<PIB
M7]O A^S]:R+S8Z[.%Q%V9$6M/&Z\G#<.5)95>F<D88A@0=H).,CD?<0,_#X?
M&L4^EI:3'93M]NSM[O+MWT0W=V+?Z]T_1('3W0RVF+31M<:5![!)7679KB3M
MLR1;C%BL%W+L,17Y>'QP6+AZ'$(/()-#A2CC  "L!R<L,$DX\#[ !X\_'P*L
M'[U:RVM>ZJZ=;[RV#I'UIU_3K+;-Z6K6%6JT3;9<:):41E38&Z+FLZ.U56:\
M%A29DF17:-/LY*:[E.#46$Q]GS547&?J[CG@$\?@,$_CC[#5)/5P+U,W-;*2
MUTW]:CU3ZYM_8=XVG2]58[#[%,;+I>T+?IFBZQV;=U3M1;UU*-!6.*W1]N4V
MSBX9-VHD;,'?-N@6I#((FJ$J\[@.43  )Q@$ G .5/S'V_;YK9^UN.OHB@U
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M]+G0CCC,2,J4"=*S8+BI<(>5#DA+K@XLCMX '@BX9F$41W$/$&8("O. 1]N
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M):+A;KQK&MUBB ZUI_7JCF:8"*9"%K+B;[Y:FWH$)*LC@A?J;1C:26#8!;/
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M==CLNY7VLR[T)*-M)&Y20"5;&5) )!&0/%='&_<CCD*/&717,<@"R1[E#;)
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M.Q1HM/8E"UYLX\[*KXXG2ZM;CNQR"5HVAMU =Y">XR ]W82,KZ"68,"7Y].
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MV!(OEM>SWH!Z<=MOJ@@YW<@DC!' P 20=Q(7(SSFN9[L .,=ML8!SRW.21C
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M-$949A^6VI+[C+:UY1CT&U&+:W')^AB\C:?J#RH) /S _&NZM_V"'G/T4?.
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M'EO0^U=RX.!G%=UY@K9IQ2L-[UH6Q]D49JN:LW"6T=:46JH&E7<-6@=KEK"
MK!!)G:ZH4?0J$IBP#8[X]Q_"DY0I:&Y;<T8Z0&S<D3HC[I(Q*NUAL+%1D@@'
M(YX//\QP1EB=$?=)$)5VL-A9E&2, Y7G@_\ =@X(J'NL2D/[DUECKA5.R@!*
M_5)+I[$N&D1Q8BP73\R-O59#P2+N!HI)*TTA6DE'8L:D-P?F:\NP-H@,3R.J
M7,2*;^W)WV@/ZP4PXY(7O)M#=O #!L?6SAMI/B2I%=XBD$SP']8 PX)8JIE7
M 8Q$!6!QG=D;MIS@25G_ -/W3A^EZ^TJ]H.W[*USUMK5C[%IV/ISL)IT/7]O
MWJT';S/;KI?!> @.FO"0$R,^^+>AP752AK6!LY$G,KY6M8KR4,\O>6-YF6'9
M)#*6C10@R,'.XL.#D^>1C&6PW<@9Y>\J/,RPE)(9"8T4)R,<Y)!P0<8/(P!Z
MK7>1]1]>,_AGS^'C/[/V?X?I_E^G[?IQ2B?'M3X_#VX\?A^'C_F_=_\ R_3]
MGTXI7GBE1;[/; OE>&TZ@:TEFJC<=HEB8X7M=%1&7&GZXCU06Y;C4VWCR!6!
MEM@J!%$X4-UJ-.RPVF?.0UF1!89>WK&*)VDEG"R1P*I:#N-%+-W&[2B)@K<J
M[*3DCX<\G'>="Z1I-Y/J6KZW':ZCIN@V\$UQT^=1GTW4M:?49QIMK'ILT-O,
M&>VO+B"656>+<3%$6"2LR4R&[KI6XWSL#=-<2C-KBC]L">Y;%TDCJ*W3K0C2
M>G=6$C%":'7K#%FJ4X_;]D6*$\1^S2GR3"P0N)"L67"ST'IA%<QPV,4P2-FM
MFTPQ;IN['[U=7(68F+,<BI% C;=R[CN8L@"Y^F[?2^J-.TCHO2];CM=/DFZ<
MN/9DVF)-JQU*P/5/5'44-MJ[S:3OL-0BM-.T2SE2'O0&5A=SRR68%NLNP+K"
MZHV1KBA[!;A-C$7:H5VU)',D8Q=J!]O"HI/,)LI#PF*03%S)RQB6RAM#_L^)
MAIK*LMIY">(PS2PD[C%(\>2I7.QBN=IY7.,X/CYFOCW7=,.B:UJVCM*TS:7J
M5[IYF:&2V:4VEQ)!W3;RYDA,G;W]MB2F<;FQD]ZYBJ*JO7U+NQ],Z\=;R_Y9
M:ZA;28VC(EZ]'50WA6:L],EB)Y3YZT?+2(Y7 R!@>F0UD.Y&(?:"8>(Q0,_\
M$E'ZCI+2;C5=506]TUF;-1=/-&?I@JNJ;8<@H7;?@[P5V;LI(,H>+Z\UVTT/
M0I6O+%=02_+626THS;L[122;KG!#B)1'GZ/#;]@#Q$B1:0MI^H1IRQZ^-BZ5
MU+UWI_:-A_>_35DBU3KNP@%HJ6O7<D(D+(N:"'M#H X9 KXVN?&BR9$P-,D0
M9;\5,"'/8]"L^E[^*ZB:XUNZO[.+\IJ%CGEM9()KGT,V]9&+L[M(\V"%#J&7
M=N93Y-J/6^ES6<T=ITW9:7J4XT5P\]K#>PW5I9,)%41M%&(TBC2&.W+J28W*
MDKVPZ_)UGW1T)7]A6*P;;U7L$#',]V7>P0(O0#042*K N2!(CEHMT:MQ4OV^
M37UD,39-:;2T[.B$[''BFX;LHO LU]YT_J4MK%%8WUK*8^GAIDJ7,<CR3.)5
M<& S,1 )=FT39(#1Q$QL%1H<&G=7:-;WMS/JFG7MNLW5SZU!-9R1)' C6[1G
MWI;= ;EH0^YX ,NLLX$BLTJW'=>JW>C78';G5X?*E6 !5Z?9-_Q+TBM5!^HU
MTDO<-HCHUW+;HVO3KPD_EMV0.9G9EU]4H<XS%'0X1B.$!3N:^L].74ECJ[ 1
MRS3PZ8UMWK@3RH+"!S=J;BZC$D7ARH27:REF9D:21:W^GNL;%-3Z?0M+!;6T
M^MK=^[V[6MO(=3NE&GL+.RE,<W+(&WP[D;"JLJQ125M4?]_V?_'GC5?0M:SG
M[I3A1R.JNK$1>1\%]6Q-EO(/D69LEH=%AT>',F0L1QP0G+6HK\O'PVM,F.RR
M_#8<E1'XV'2@*<T,XDN#@D;$]((&26.#DD#CGC'.3@YX,YHG[)<9Y&R,;>.<
MN0#R0./QYXYX.K,/TYM?9<@S'H-BB;4!#C=OAAI&;:+'&+*W7XS%@(E05!MQ
MT=>7%%Q;K)2)&: 9(%G4S84)$\H.)1HT^98H\;U,9*J3P2%W9 #.J%!@@@G=
M@<$X!&9TR1QXWCML0I/I)"D^G!=5*#!^)/Q!. 17X6OK_M;6#&#EL^Q:]6SB
MS8@181EFJM@BVEN#*$B"D(&Q3#YI$YUR+88,A6$.-P9,!Z1(21=C)=>S5)HI
M#A0Q8 $@AEV[@2"=R+QZ3\#SCC.*JLJ2$A<EEVY4JPVY.03E1CZO\61G%=XZ
MIQB W=NG#L<QKEY0?<6EQ3]/N@BNOS"L(MM&OJ=()#GY@<8:A0":FV"CR+2/
ML* ;B69C@JHX+RQED^TQ2KMD&8IB&5C@%8VX) )&0./25SR,MC-DX!BD!W F
M.7U*6X(1AR0I()YQZ2IQP"P45_3+YPU<17#/CXB?V^Q7C^!^'N1Y_'^J?CX_
M#[G]]][V<4KGQ2JT^Y^Q>P>HK)?=EZ[>N#5)IG5NZ'![I =19^IH>T&+2+9&
M3"#)"7$L\JTL WY3P^(E3J'7FH"!\,J,<M(R1-Z9!9W*0P3]ONRZA$C!6E%P
M;<HQ8+@&()OQN)P0,DD,$(]P]F.B='=1V>CZ'K2Z<=4U/K[2[2803ZM#U#)H
M#Z?.T\<+0QRZ>E@]TL:S2D*RJ9C-+!,+"=*G]JL6FY0.S]ZF#JT-(7RB>GS=
MSC%:UD.<&N6F\F*P9/3FL00EO4[@A8)925*D?$<=-R'HXPA.,.1VX!/H+4QQ
MM80J9&6&76X4+SD'MQ(Z(.6BQM55 'A<%E"Y++]"=//I^F3]!:5#-?W$.CZM
M[9=*M7OM=F6<6&DVM_;643=VZTT+V;..!(XP MJBO/##;*YE@S>!JMOV3NBU
MR-=:MTWLV%0_48&P[K- Z@IHDI3-5L5A$4BX8)6*L"4RH"%0Y#TJ?#S*7FT!
M7R^<^XU7WY>L[Q06L7?N+NW,VB,T(>YD=)KGNDC8J.VW(( !P C;<^EP.5O+
M_3=#Z8T]-;U[J;09M7]BD\NEQW?4FIW-OJO4+ZB7@%M!97UQVI2LB+'#+L L
M;E+8\6UXD=EOISHJ".NCZ*3(-2PJ=M;@QB0>KM$K$]R5^79;XF,#=>O2 F8[
M37P&6'G'U.X0W\L-:AUJ,!@QH+6>Y[Z.Z%#FVM3A'FD7'83'JG ?/S&,9Y)+
MER?#O;0=2/6BG58[6*Z_4[TWZ+.]U:^A$?Y(MMI[^LJEUO8[F=0@&6WSM+?/
M=S23PY%5Y-6G1N.I5>S=DMI)@V>!;#]G[,;QI .C5K9!@9>XQ$E)#RY5[LMJ
M<I<>M5W65,=C.%H:9<=SW$AQ9EY$X&++$(GNUA//#I-GO@:"*+2-.N)+F:T1
M[=E02 6T,(G,LUY<!NVQ!'H=&&)'13\R:G;6ESKVHA+A;F>?J#5[2&TM]0FC
MNUED,+O=W5R;7L6VG6?;,J!D.9$E4[X8Y9%P#;+I1JX$$RY>C+U5MH"RM0$[
M%L,?96:>-?L&J;C$E79@;7*Y619*M'['/(5UTKDJ0FRJR8BC2H1IJ4U&<S*0
M6]Q+(ZIJ5O-9.EP]I$;0W#B.^@*V^Z6:5TFBA5)=FQ5$T;.DAVDBH.\N[.""
M*271[RWU".:RAU"=-0%I&\^FWL;7BI!;PQR6]Q.\D)D+N[6TBQRQ;7537=S!
MDEK\1'50;#N*B74OKI[9T%%+WM8<5\90[05=*4 .;@%J^S8CA'7%!M)4@7B5
M[&/G*V7<M#*PJ(MF?)ZL<:7,A%S%I]Q;QW0LV]XTV+O/<P)LN9(V23M1)=W4
M*)&TI.V:,0D2%H@F]+(]C"AL9]7M+R6P;44]TUJ<V\5E=2-)913I+")YI+"R
MN&DE2#&Z"4W*F,"X=[IO2/9O8B]]J*I>;D4N<JMB^N,:,2<M]DLX&0E_6TQ2
M)H7\IVVY[:90]H<A64M1FH4>/%#LQ&((^ C' =;&UDMM&GMH(X%F?569!!##
M*"+P>F7LDJ2K;\9+%B6?<2S5ZG[-Q>Q7G4=M>W<MVUNNA*DAN;BX@8'3B>Y#
M[P ZB1=A. H4!8PH5%%7<<\^KU:OY;/9A;DKLAO^0N' &_,;NVJZJ$+:@MBX
M&7;X>6J+ :$3RXY$"+YRS%0.)E(28[;:8<^:Q\.0[Z!;D""$ DGLQ^2?A&OQ
M('Y\@'Y@8P.[AXAB\GZ*/SY/H'S .3]H'V@5A+X65?1&,Y\>?/GZ>/Y?/CQ]
M<XQ]?'USC'Z^90_[KCY$>/MYR?X/XZRUR5&=0E*U(SA*DJS^*<JQ[590K"DI
M5E2,^[&?"5X2KQX5C&4Y3G-=X^!R<_:/QS5,CQ^A^[Y_FK<8_<R#"&],=HG$
ME(,E3NRJ%EP4S DM3QV4U<M[9,TD\TVQ+9G^<M0X493OV>X/F/NN>22$)YC7
MCF6WX(^C?G((/K'@>>/B3C.1QQ7.:X?I8."/0_.1@^H>!YX^9QG(^1K9YY 5
M!UQ1X]B/'X>U/C^#^'C'C^!]S\/[S[O][]/'%*Y<4KU)Y" *@RR92;$&C8$=
MV7.(3Y+,.#"B,(RX_)ERY"VV(T=EM*G'7GG$-MH3E2U)3C.>5 +$*H)).  "
M22?  '))^0K)##+<2QP0123S3.L<4,*-)++(Y"HD<:!G=V) 55!9B0 ":@+3
MNR&O*GV5[<C]@V.F4D'7K!U^K$ ^1NP:0HN;L]2DQA\!T0SA,T2[\RM27525
M.LQF8\R5/=AQ8,IYJ7ELYI+#33#'+*SI>R%5B881) S,&/# #GCSP!DD9]>U
M/HK6-0Z&]G$^CV6IZK=7MGUE?36D&E72"VM=/U)'FE6Y;,5PNP9 0*SL\4<2
MRR2QJU@O(>O':<4KXUBL(*I 3%HLY<> KM?&S#!PV6E-0AHH6/87)FSYTM]2
M&8\:,PVMUUUQ6$I2G/Z_&.9(HI)Y8X88WEEE=8XXT4L[NY"JJJ,DLQ(  ^-8
MIIH;:&6XN)$A@AC>6:61@D<<:*6=W9B JJH)))P *JFV\2ZF7K9>_+OMJTZ,
MDZ;M77+34L[<*3=K>[N<B$G7EJ97)!$9677HR*O-))K:4OBX2R3S*:HV9<>&
MOMQX?9V*:W;VFF6UE#J(OX-5OQ%!<6\ L$D6WVRJC2@$S*O=)#L$![W;&X;C
MY]J;].7E[K%WJ5QI#:7<:'IC37-K=W)U-X'O"\+.EN2HMGD[&UHE,C_0+(60
MA5AAM$6._.]N94LI+: K]1;J"_77L9%U)B3";U\E^(_^4%SKE>19U)#R8+R9
M,8T??RVAJUD7) PU^5EGGK1W]QT_8B]S]2FN"49><JQNB#]%!+*8<R!Q@I$,
MDPKM>,PQ<I?I'^5-7,DC"']772[0'Z*V4@6$;+]+=00"X;M%2666=N%N'S'(
M;B:172K<=DU*9$ZO%:_5:Q&^.[':02>M(QD\Q'H<>K1H1"'F4W"U978+SLSY
M=UUI,I46-&$P)#F6*[":EC:O%=06$5ZCWCW/8?3>G]&DCA<Q$W)G+(=I:]E8
M!<@' 9FD8#,K%6FG>EM2GTV6/3X[(W$6L]6=1QRW,8E5;-;<"1=X6P@4ERA"
M@[5$:$A8$#16]V_//Z]4J$W?34G67<.EXM?[-[*K>F1,6TPYVL]L&[^%UL2H
M^U&11>17BU4L)\J)'RK!&A1BL] )U][[0@CYLA+#:X")\+:M))XY2;>-I25(
MDC5#('C)&X,H!.TG SC@D#D$@[5G)<1REK=&E;:1)&J&0/&2-P90"=N<<XX)
M SS@ZH]PH?4J 2H5&@;+%:V;O59W1JR&2SVFI6W9^HZQIER;;0MT!%-;0IE4
M'R>U-B;>C':_9+$ >E3"M@'UB6.J5B@2V9]6NB'?M%]ABD(]V>+N-+A2I#^H
M^[@\%01Z5+992*Z!7N/6[1LX4Q/CL/#O:3"E</ZB(!C!4'@*6#,IKIVHMG K
M-0[5<+,<T(]LX'=[=VM/W3MG8*WL*CV4K*T]7*F:TQ6-23[69V9,-V8N=<=D
M$$@[&Z=(4NIO-,!TT1+D;)+&RNJJLVQD6W5+=61E^E9EE:4*$"J!XRNW<?(?
MFLL95@BK-VV1(%6 -&ZCNLZS-(%6,*N !ZEV[F\[^9Z=:^I74&W7ZO([*]KN
MK)&J4NK42+0SFD>S.NM6_GL:.V!N_0]:7S5P]\-9X K5-N1 AUN61>!WHK(0
M+^T'9:X @=2].>XN51NQ;7 9F?>)H)).UM79O20[E)D3Z^,J.<>27U9[BY5"
M8;>X!9G+B6!Y!%@;-Z2'<I,J9+#U(.0..6VS4IPE*4X\^$XPG'N4I2O&,>,>
M5*SE2L^,?52LY5G/USG.<^><]7/5YXI5.GK73K7%ZXZ;A0.L-S[C:Q.]H];"
M.PW7O7NBB&\[E<](_DW?2EFDUY@5&D$M<F01,6#) MB0'PDR!8FPP!FS!/RA
M6X^J]/)]6TX."3@ Y'GYY^5=5]) KU" $-G:WZJ>E[W*Z!1G@PJW6ZU]H.NA
MK5L/8CD0@H6,KH[8EIV'L"RVPF#R4G$(-;E3VQXF#*+3X+3#DJ7A]1]V1E@W
MRPV<>/P_EQ66NZ7=/;6G^WG5SK?K.-J\'1[%0-N=G^TNQ=H_:SJPO6S0SH!=
MUKNM80YQ$21?3T4F17B89;?'BH4-E]Q$=E^42'JH%!4GXY  !'DY\Y^''P_B
MJG/TY^S/9BM;TZ8=D[=IKICK3KSZKVQ-XT2HZHTMH6IZQWAJH12H=LLFO+2>
MV!6@HLKLT?9?R28E69^RD"\5L<6'&XT<7.(Q8 ]5[A1D L2@')/!Y ( ^')^
M>./SUMS\5BIQ2JO#'I3:1L/6SLUUI,7C9"P?9+M-L+M^J[#I8(9=]6[?NFP0
MFS1!"@S6@[@]N)2[17QZA39B 1>(#%SAI9Z2U,<7A5V\Y!XX 7[" ,<_>//\
M&*SKTSZ9@NH8;;,R1LR\[PVYO[9T[;N[=S[%BU899+Q;Y @97AS,<#2@E>J]
M:K8 $(AP0=?#C418*G9[K;GPY3<>,HS9QQ@ 8 'P^/Q^9J9W%6U3;"_M@JQ?
MXG6I_P"VE;>*O_K9_NQ_FM5R7%6507N[L>%3UZ[B]=0H&Y,;#K4[M-LO%L%"
MF9X[-:/][-BU\L'C.0%S#,?XC.8SY5UR#''?9[,V1.E0X@WYU?7VMBYO=+O&
M:(PR?D^W[;OM/<3289%8AMJGX[0"26P #G%?7G2_1%TW6GLTZSNKO2WT6^B]
MG^A?D^YN6@F%]:>R31+RWN7$PBMGPV];=1*\QF:-(HY)9Q&/F'KQN:HW'<=G
M%Z>* '"78CI3 CW43H:3,N=R%%*W&F6=\T_;Q4I*R$6? #*>DPQPXC&MYIIG
MWQGS6&TT6"TDBM4>Y5]MEJC&)[L"*)D=A$L8B/A@6(7)!C7)SMS66STGIG4=
M-Z9L;CJ:"[$'1?M1FETNXZNCCTO3+FWO9(M/CM4TV>,B&6*6Y"QR330R:?:E
MB'2U).5*7O;5!79%":N%8N^V;7#[P]A:K0[ELR;3Z1&U$>#UQHE*=@HK&5MV
M"L+:ECU(D%(CJHCD>;,'Q_FQ(8-.UY;.X2"8QO#;1G2K.::* 2RFY1WPH;N?
M4D!SD*>> <AV<<_J?274-MHFKMIU_I73VGR^RKHW4=6TW0H]2U5^H[.YOC!&
MLWOV&L[]6CFW1P2*) \44TG;N;JZBDGT*V:_M\[MF^R8&OA;Q:HZ?CJ':OGR
MI].B8%EMPC$-CLS!XV1%>4B(EV;#6PK#,IQU2'G$.)]NGJT MX[:(&9@LER=
MTX E.Y;9LMAF!'/!!Y&/!KB_:WH:=.673FD)-K,ZV^I=2N)M>ACAU.0SV_34
MY,PBFG2109"L4JN-T:J"BE3FR#D+7B5>B0*#1,=R85(01L1EF5)>E3Y;$..U
M'A17ILQ]QZ0XVVAF)"CR)<EQ2L(8C,//NY2TVM:;E1W(5$9V) "JI8DLP50
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MI2AC3/Q&TE67.?L9QG'G&?.,_7&<?AG'[>1M2].*5\*T6(;4*U8;89Q/R(K
M0K8"F!8PB;)9'!H+Y&;@>&$1II4K-^6C._*CAL.5/FO^R-$CO/N-MJJH+,%&
M,L0!D@#).!DG  ^9)P/)JJJ695&,L0HR0!DG R20 /F20!Y)Q5<6^-TA-GTO
MH%V3IVSX>JM-%-^A-BV IL^H-!%/4IS2>XB,G!N39R@9NI,9#0S8S)="ID&1
M@U L8<C.&PX.3.[#$4:\@:,R2B$HHC;=Z^]$!C;G=R0<>>"I ).-Z&)D:\@:
M,R2B%D41MN]7=B' 4'=DD''!X((!)Q,_7^^Z1LO96UM75J%</MK4*:8Y8#92
MHF1=,.,7H(H\%E4NV26$B;1&Q"1_7+T%["<Y4W(A?.P'&YJM9XF2..1BN)-V
M &!8;&VD,OE3GQG\^#Q6J\+I''(VW$N[: P+#8VT[E\KS\_SXK-?,58J\9^F
M,_R9_9_V_3_+]/V\4HGZI3G_  8_9^S_ )OW?_R_3]GTXI7GBE5P]Q6Y&V2A
MBFZ2JMKF]L^O8ZI;)UK9LB%A (F%?#L0)86PUIL\?\AC<U^MPIZGQY#XN,/Q
MG/L*0Z:!&XXR:T[%NJ2W4D8T^\,L$\8?<[&%"Z[XXSW4 <KAAC@C=Z'7=[5[
M-C'T]#:ZGU3?V$7L\ZQFU'1-<L1<BZN[F72+22[LS<V%A)^5;2)+Z6$)-"5]
M,B^]HMK=VKSQ+IX;=@[L=V*ME/TV,NYZ-VQU9J@Z1L&O0Y1=8T5:]5UJ-?HH
M.4\,UK#P*0 '4=E66)1D>R#FL358AC3LRTW20E>V-C8QR7+0I^3KBX14E<"2
M[CN9>R6 ,YW;VF/(0E@1G**D7HFJ7/2TW1'0^GZEU+/I=H_LZZAZAM(++5[F
M 7_5NG]1Z@^CO=QI/KD@N#=3ZJP#QVLSW43Q#N3VD5AI=F_5/:=KVU0;4;ML
M6NPY-=VSLJB"(U9KMPK,%FN4ZQR X5I^!<QPV:Y.;ALI1(D08Z8*<);B/M0C
M,4L-A05_!'!,BQEV#V\$S&1XW8O+&';F(L,9/ )S\<E2K'PKK_0-/Z>U?3[7
M3I+R6.\Z>T/5KB2^O=-OI6O=2L4N;IDETR:>)8C(Q*),YFR6D5I;:2WFEDWS
M2KAJI9]<B;9&NKU+&!;%%$C"VT(J;&)E3ZV/P?'C:R?*L--N&2$,G)=@RXB'
MF1X-B4N;(=89D^Q[,!F5W_L[6$ZS.TD)D=+-NTX69^TSRQ(21&K(H96(+R$!
M0"5_;$>4^UYKG]3EO'!<+#')J""XC:2WC$\2032!09G1V964,L<(+2-M4\E0
MVI;!>E.R,+CS&([T5+DIB9+?PS[<PTJD);:4O*D9>=RVA#,9*5J==REI"<^_
M.,^W.%"\J2&P"JC.=QV\@#P"22>..3XKYEC>1FRLBJR@NLDCA<&/U *3D G
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M=M+T5G&$YKC'(^ ( /@>/)YX!7G'WGQFJX.,CR 1S]H4G.>/(P?E\N.=O?\
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MD_+/P\#5G"EA)'"\43@; Q+!BH <AB.?4"3YP<^/ DMS!6"O&?IC/\F?V?\
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M4/3&FK'I^BW%O:=0ZSU9U!::=VI#I$2V\JMI%]*KM(TT=MLE[,DJ:A=7$_\
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M, %7<8PY'VJV.DBGI#+#1B8N)EJIW7J[6!C<^\*%6=-/TT6+RN(XGNA8VA9
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M<+3G&''''%KQCW+6M6<JS\].07<CP68CX<$DC@ #\ /N%?6Z A$!\A5!YSR
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M(SC'N1YQC&,>,>U*LX3FF<#.T\\^!GGYX/GY_P H&:JT98[6F5L':IW'! X
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M(\T G#<HTL69+4?MXQO3*C)^)$U_>"2Y60E/MLY$(W!K,QIH&0EOMVQ]EWV
M'6XT/'PS$E^-.7$#+1]I9CL.I^ ]F/)6G*UW;)M[EQ NZ)I@W<15[((^E!)Y
MC 9 T@RA8@Y (%8$T^^DWM!:7<BQSI;.HA=V%V5_86"H,2LRN5A([FT8VMM8
MUD36]'N1JY4>Q?DAFLTR5LVN0EV8J.N$.ABI,BS1(V!I"Q1\S2C0\:\E;$KY
M<A).QTMO*2^LICXF=2\N;:.WN83<":X%G,W91X&N7 A8[UB(5"SCE<H(SD87
M9Q4EIEE?37EE<+9FVLSJ5LK7$D=VEG$3=(O:><"20+&V5;#M*"#ZC*,G^@:C
M^"GZXS]U/UQG.<9^F/KC.<YSG&?QQG.<YSC\<Y_'GS&?)_3^:OM0>!]P\>/S
M56'WXWO(T5O3H:4BOU22L_L_;8N35S+A1=IN$)6IB,3-<UX.&,NIGW,\1)#*
MQ562+D<7+NMAJ(6?(C133LJ/OVD7>BNU]0Q'$=P VK]*#N<GPJ@%FQR$5B =
MN#(6D(FBNP0W"1'<N-J?2?6?/.U0"S8Y"JQ XK6IV)NNE[:1N. 1-5'0.J]Y
MS>MW:?76J]T2KM#US4&*ELX[J_:&J*_5J(-F1C8>S$W)=Y+E:N%A9EU^JK7,
M""R\>6Y5)M(FB[1P\TD0GMWDB"F1MR"2.0L[#:54! K$X9N&(.&FDB>/MD;Y
MI(N];N\6TNV^-9(Y"TA!4J/0 Q.&<X)& W6='AZQ'VMC;/7W4(*^#=*;Q[G[
M0(S:7,N$P)-TK3-=L2](TFX"#$*YGH^J;F4^V:T(>2Q'D6J&1-U@K,<,QHY@
M7=*SF/MS2%#+%:Q^K;D2NY$K*04!D0;2>2%P&'&0;Y2QC[<TK*98K:/#;0>Z
M[XD=""@,BC:Q SM(#  $BI"538HI%<TD!(Z.U'JO=&C=I=*:T^O7Q/=$ 5*J
MW93<]?WD1 $]2-P9[X;8%=?JU:&V(U=WC+,UMPQ!"?:QO\VK47"T9W3'O221
M317;#>(B=\$+1!A+D90AF("8QP2 N\UA:,YE(FDDBECN6PW;.&@C,2E9<C*'
M<2JK@>"<#>*W-N<S7,UQ\_?QCSCQ[59]OG'G/C*?K[?;YSC'GQG.%8QCSC&4
MYSG&4J5RXI6M/L&U2Y^_=OA@FI#6R[ )]0F#;*6UK<FQ#S(V#3->/N5ZO73.
MT'; W@78WQA!TQ+JT(1 %I V26^])!QZ$*']O%&HL[9GNDMT;1#'+[PI/T,U
MQZG@]W53N3<NT2%RVY!@.96/W!I&G11=']-7-UU':Z%9S^QF;3]5.NP/,%T?
M5-;5;R\TG\@+:-W[)9H1;)J,MQ+.;NRC5$NY-7N)H:;BLNQ8=3U&*W/2%U"]
M!=L;WL]3"W.QXMV#8?95F!')Q X*/V6>69J'Y3PB V 49&E!6S&5&B$194LB
M<^>D[6. RW+VDW=@:ULTE>)#'M:WC= J%8U4RB,JS*2IA] .U2 GIW3%AHKZ
MCU'<=+ZL-3TBZZ<Z2L=1N]+LFTWW6YT+3[RTA@M)[.RAMWU+\GRPSRP/-;SZ
M&WNL+BWMS%':=@%[$(U@54LF8]=KM.M'2<SJ<'LG5A"D5R;%!"72=JV.T\BR
M 1)0ALN-;U-TPU3([X@I98!6?)&6"7#L4&R2\;0B5Y-A>25-72Y:VN5F<%WV
MQ0<H[ 0=K=*LN&5"H!12AC&E/HL.H7.H"UDO;_4[#VIVO4=UH/4$&JWT4MW<
MK!I^B$-87=Q;Q:&^G!M3MM39;B"QFMXDFLHY;.6Q2W_TZR$VW;XWILJ3L2#8
MLW;2'5D@]52!"*=O@I2-=LQ8QBXGPX0?62) JF'))NN@ITA2E&FTF1H,HP\)
MA<YK($=I:0=@QF*[U%>X 5A8=[.R)7<R!4R%PZC&WAG!#'YO]L\,.G=)=)Z%
M'HDMB=)ZJ]H$(U"&&2TTBX#:T7>UTRSNKN>^@AMBZ6ZK=Q)@6Q-M-=6[)<RW
M"<YROFZOY_7<B.[%[:=EV'U*4ZC>NT\JRMF:PKPNZ&5HQEH@E,U/A"DIQ\QC
M#BL8PK/TSC//IK02&T32".!^3;+XJ?%O&/*>G\.*^(>KE*]4]0AO/Y9U(\AA
MYNY2.']7V<_'[*C9R6KG:<4K9>_<^C+_ -D=H9'LD?+J(ZI:^+F6G,13Z8U\
M7\/$',?"TR4-J]RY>)2DN-+0SEA.6\.+\E]IY&_1QD9"7QQM]6";49W9Y&1]
M7'!&<G.!]#>PX'L=1-ZCF731G=E<A+SC:1D,/B=QR"!C@$['7/*:]ZK^9#N^
MTQ '8[LL+/4>GFE3=N[9'2GK)^63,X9.A[0L!1^:)F1R(PI"/266Y%::^VAK
M@W$68F2:!MF(K16!W4*9@@*NPQ%"<#:<@Q*!D$$;<D'TD<@ $@D-V\:DPP%7
M8#MQXQLY^C  /P"_MO2P.>%;#$'H8;<009.)YBZ'U!.@%G@_R@B9G9BW0N!E
MDDF\X#6&/LB):&'B\"6JJ%W)!N2F4!:AK::CG(S)G%_:)P#-(" <D!.25"\J
M8RO!]0X\CY$BLAC) ^ED& ?[&!RH'*F,KP1N QPV<Y!(KD[N*GO6\;99G7W5
M#T ;7%@WZ2T_L<=62!--7="L6<H[#O[=GE&FSJT7%]&+"P-E%TK&O0,U]2!+
M00L%*B>3E@0^$+8W?5'HV ;1M^KGP<_&@C;:5[TG)SNPA8>HG RA4 #T\@L!
MSD$ UM,?N9%J"K5':Z>UGVD9.Q]=1Y3*)K;C+4&+63[H_P"$.RS\U%\OS"25
M3'IC[,Y+;<=AF.X.DNRH'7LB2V!^$<GP_P#3&>?!\?#^45 ZX3W+<'P$D(..
M<EESR.#P!QCCX^>-H#D!4%7%&?*4YSG"LY2G/NQG"L9\XQ]<9QA.,XS^.,X2
MG&?QQC&/IQ2N7%*Z%M'9-9T_KZU[,N2B:*Q313I@RH,)G'"6(C2VVL_+#1S+
MTE[/Q'6\..JPW$ALY<F3Y,2#'DRF<T$$ES-'!%M[DK!5W,$7)^;,0!X^\G@
MD@&7T'1+[J/6-/T/3! ;_4[A;:U%S<16L!D8,PWSS,J+PIVKDR2-MBA225TC
M:&=8[#U6A;J[*6W9A.MU'79,OUI"TXTH@;EV,@2OU-=P!AV&H+KD8K6)$G#^
M9#[1)+2QK#$G,Q&6HS\EN3DM))K2PC@5Y)E6_>1-J!%6*7UE9.X5<#'D<$XP
M22!7IM_T;?ZMTMT-I^AP7VHZU!;=<W6I6O9M8[*&#1]4!NY;/4A>O;WR)LV(
MT!83.R=LAI$C-A/(:O&Z<4JN/U+%:]CZVT42V94+Y>*P)[0ZO(/U[7 LJ4M!
M"4@;;&!T*"R-D0TY62)OP1B6'YT-Z<N9B"*>P7D0L<ZOI+WHW>I)9SVUO-)H
M]XHENW1(47="79F=6QM0,V0K!=NYQVPQKA.OO<EL-'EO[6]O((>HM-D,%A')
M+<NX2Y$:HL;)R\A2, NI8L$0]QE!HZ&]GK^0M%3N!^A[0L56$=D.PNQA<L-5
MZRT=0U:]>SHQ:CV:JT0Z+@0#U<E2CQ25*O#;C!2M2"[[;2*W$L-?)^AOH]JD
M,\$=U8PS2:1IEI(LD\QA+0W2%+F*>YB=GBE58T46^&28(,]UHY5\IBZBOGNK
M6XGL-6N8(]>UR^B:*TM>\JW%BZ26<]O9W"I'/;N\SLUV,/ 9"/H%F@?&%"[4
MUT#1*YI**YM$U7 76?L[K*SE0%'ISYF.4V-:K+9A)MM$.=*-/5J*/@UU=B>Q
ML =$83A:<LN"!IF-<-RYT262ZEU%O<HI9-7T>[@22XN!&R6L,44D9R@3O,[2
M]H>[.S?,.\;0QECU/;PV4.BJNJ30PZ!U!I]Q+%96C3)+?W$]Q#. LC2BW2)(
M>]F\1,>1VXY%N>!#:@$^%W>,NFH=IR*W/Z:]>Z?'L08M5LE UAI4/7D>B7"R
MOLO//RJI9K9]DCYPE)\F;8%MLQI@QJ8/BQ*02RDBETY[>_L1*NOZI.T,B3=M
MXKEKHW,$0QQ/# '97[:1ER2K[6)N+9M32>VUF*[TC5#;2=)Z):K<1O;]R*>T
M%F+*ZN"K'-M=71B22,323"-0KQ@H%M-Q\'B&D*'2.;=:'I%C\0&GG<R'FX>(
MC.(K;KZGI*GG4,>Q+CN9#^7%XRO+SN5>]7A$F[N2;\%][;B!@%MQW8&!@9SQ
M@8^0KZCBVB.,("$V)M!.2%VC:"<MDXQDY.3SD^:CEO\ _LK](/YT-L_V+>WO
M,L/['=_O=?\ 2[6MJ']CNO\ U"_Z3;U^;[-INEUWIH6T:A$:]TN9HBH=$VH+
ML--FS]C&]F#;'G::85!DB):1Y$#)FKFDI!Z 4B&IDAPB5BD8I3+20VHL,RR%
MY0^7C(<!!&5[>7!&0PP!M(*XP""*KZ52&99"\H?+QD,!&(RHB]>>01P-I&T8
M48(K7@UU#J/7&VU70VZM1T>^,N;5C=%Z86V47O57B[)Z2VF;(V*7W''H]0C'
MZ@8C,W>5&.0]I('0A\21,C-.F"AL>7N%>F)"TZF6*1D';-VX0*VR[0;!%O;#
M*=HP8\DG!.,%5:8D+3JTL<C(>W[TX0(QCN5 01%VVLOH!4QDG(!S@85I]4\U
MKC;/07LCV!KNI-%:[N=AGE=0E2>DDSY TK1M'[(C4K7,"9,+URM3V,#JU$@M
M0XK4!J+.#-@RV(XE$F-6*YJ.'CO((3)*Z+MD EP"'E3<Y #,.3YYR#D<XW-J
M.'CO((6DF=5Q(!-C(>5-SD ,P.6R<YR#D9.-S7E<BJBJ<4JI7UC-%[7WOUVU
M<,H&HSG9&AT/L9KW9'8CK!6;TK79[L'I"O!K?%,T8:=Q/&-$WA5K*5"\9I\F
M?$9M.*K\FRZX1:@1)2KT(!/.#@@'Y'X'P?NSCC.:@EZ&77;M%0+W.V5M'KCL
M7J?K<#T]T_UP-4[9=N5*,;OW!K:WG)PW; _7:)\M-$"TC7,MB@05RHPY9[[2
M=)QL3I3QI<559"#CD,<DY'P\#'@9R03^&/-7)>H1MS;&A>D':;<VC _VWMK6
MVE;O;*-%R,2:Q","Q+SV; H,MMYHNFJP_FK.H6^R]'()$9B267F'G&U*L4 L
M ?!(!^[-4 ].>P3U&[C=&ZUUV]6?9_J5Y[7YNS?:335],AKJ)UO6QFJ#-W_.
MY7(0N$W.ZZ?DO<1PT-G7MA=;GEH990++:WHGEI60CTME-F/!P>>0,<GD_;S^
M:ML/BL54L>L]V/[M=<=-5JX=8VJ-1-=0K]I2+M?=)DM%+; ;3=MY4C7\;6NM
MM>SJZ6#_ #!J,>^T+5=[+*3$@5GYX17X/Y1RXQ0<J] I.#G//'PX!/)_FJ*/
MJ1=U.YU7W_W>B]<]ZQ]+TKTXNI6G.Q$VCKUO1+J.[!7K8EJ)%2]?OY>VB9QX
M12&-?!WZ_!AT4C7##)^<LTHTMYB''BJJB@A<C)9BO.<  #D8QS]^0?'SJWJX
MWS>>ZM>UX;K.KV;6%*W!UZ%[#7V2J=OH4RWZOLQ\8DZFDU_6MMKYJ06/S0GP
M80ZYNC9XL).--3_LB5,$98<59Q]_GY_]W'\/'PJ-&JNZPCJ)Z>GI_P!J[2 .
MRMQV!L'K5I.!;':UJ/:.YMDIO\#4%.(W&9LY@6-+6@6=E%9<G)0A:O80G&OG
MVY;CDY$CPJX@%F *@9.,D 8SQCX?=]E1(ZE=J]==OO7*O6R=95[:U; @_2E!
M4F7!V_JZWZELCQ8=VYGG7Y4&N70>-*30BX=C@LQS3#"H$B>P1@M.JD#Y*$*J
M1B,\@^L>"#^U/RK8IXK'5!%C3KVB;+U_M#>^R85"TM4>V?;"XA!E!IA61:G]
MI8[([R#+L>V[")B$'8E1E@JP$K@"?%94<GJ&X#"($:,"+6&%UR]Z:&:VM(&F
MNI=-T^)S+*G;%M[E:.([:-BN91(S.X^J Q9CZ@A^O;0ZSJ^BZQH'26ARZQU1
MJ7LZ]G>EW4^KZE;I8)H'ZA^D[H673MG<R0B34H[R^NKV[AD86D2SFYN99'N[
M>SEA@6NVAH%A@.:F[,M:_IM5"7:E:[$672MIMUFK6N]G3)DG9P:X&RHHFZ[L
M6VR#9XAJ^*&7* 21^""2)>A$#4[YR2$-XZL+BP:>21HI;AX[J..-YK=<6[Q*
MC =B)507!8!PV,"7:,>F0:5U?/9S+U#T*^L:GJ%UI>J:S<V74]CIUC?:SH,<
M<>@W.F6MO<0*-$TZ.UM(=>DN1'=QS&(PVVK0VL1C^$;V %C5J;B%+K^P&=A5
M6KZ%B;Q,B94MJ/KR@28E@KFN(77V0V0^9W, 6(JD2UEF8"@@2.Z(DCW5RK(G
M8EHN6*0L P>$P2/>FU5@"9IP8WG:]&T"U?,G;4L79@P8 ((DV[;2+N2]C[L5
M[H[:-J&H=82=*6UQ%&SZSK*26=]KDO62&'M],7@N+^33[=YQ=73K<),HCLSH
MMA>3T=CE9=]WA;;70J%0;U<J=H8S;1^O)$:8$F3FXVRQ<0CE^-$BMQIDX8.@
MR"(EOXB1A%<J,^OYY,M*>7U0J(+2..:::**6\6,S A@-T#$8)/ 8D!OBN".,
M5\J^U1[>/1ND].T_5M7U?2=,U/J^VTZ;64>*ZCB:30KB2'8\DC/'%//,D-PV
MTSPB.11VC&38UR%KQ6OYZ.Z81D]O'<LA"6B$N3LW9Y*3+C8'PXDKY:T'9Y&3
M&3&(SAV&\H0\^TQ )D6LHREF%+G(RTZ[]0Z>R1:;IX.446=D@4[F()AC1%.5
M5B<D#+(I^+*O('PWJ\-Q<:SJY11(QU'4I&=>VBL$NIWD( D:/YL%1WR/2C.,
M$XZ8 %&6U3I>$CH4:7#@R9LCV._+.E(3\V$YF"UEV:_'EPFEOL2X\5YE3>$.
MMN>5M95MF5"0J^MBK,JK\1&P5O4<("K$ J6!SQCS6B+:=07?Z)(W2-Y&P=K2
MHSH>V,NZN@RKJK @ @^H$^@D?,=;DNM(0\S#CJEN/)3AE.8:9;0],IO#R65O
M(7)=0UA"$*?QG#JW$(2V\I-VX @$X).T#.<-M+[3@D X!/.!X )R*QB.0AB
MK!%+E@-HV;A&'&0I8;B  !GSG&&K:)] B.Y&U#V"9?PVU(1LRM?$CJ8AM36L
M9JON0Y(RE_)3+#N%9^61,B,04+1)6.?DR'2C<3QWVEL&OM,(R1[G*0P+%3]/
M@@#&P$8]15BQR X4!"WT9[%$9-)UL, &_*4&00H;^I5()]1?!!R-RA/)0L2^
MV_GGF=>U5T?9I"X"-;W\KKP8V:OPRE6DA2 [T5F:T5ML,).D5P:[#D&:ZQ*;
MG&&X<9<=X^$:>2[EM96 E6935R!2Z!SA"RAR#@A<C<<X;&!GG:?N/BKXPI=
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MBR^$^?&"8Y*8,[Q\U$2EAUO&/0K?!@@/D]J/G!!X1?@?4/N//P-=W#^PQ?\
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MC%:2Z)(Q(TAZ-/BL(<9S$?DJ1*Z-) E_$L]E!?"8&"&*YN&MH%GEPL4LTBD
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MI\_^:R\4RHJ#ZK@W^_[$D&-O#;T4D1R3]4MTA6P*G+&-,-P@#E:<(%B12+7
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M&;CH;E9AQ\#G%9AR)<:3(Q6<$"+VC,626>>$S&1PDEP&$@.$![3,Q+H<Y))
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M&+,6 \ EF)\[CYK]^*LJ$W;<%509;7.\+QLC-%J]$B7+7KT9G4P+94XB7W7
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M2'4_-8F,L:RZAK('IZ==0<O@]48SN"N3C/)._P"[.?@5)W'TCIQF(DZOA9@
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M$)['W8C\CV_+JV8WF._?:[/2S#%QO#./"^1C=\_'SQ6PG=.=]L4&TD8N-^6
MX4_5QG) ;D ^1@YK)+M'Z</Y7\7U 7LI6PW%<^'T*E(2N/&<85'\H3:&L9<_
MK9"EN9QAW*<90MUWYA].<8DN?[2'Q/\ 59\\_'&?CQ]_@59NN?[3_/[V/.2?
MBH^/(^_X5M*>A#!U6/T/N9G5N\I&[XCNUX<DT0<T)'T=' 3E5(5&C0V$-HE2
M;.N9#BMNO./FY+8?$=IN.)%Y(/33D!JQD,T?<A$)[9  F[NX;CD^<+@\<#GY
MG  @M6,AFC[D/:^C( [O=W#<>?@%QGY<_$G&%O0Y%5%5Q1]4ISYQG[J?KA65
MXS],?7"\XQE6/V*SC&5?CX^O%*PIV'V]3M(:HLEXO%J+4D/[8U>CVL)6)EO(
MU\S97<" Y=D%$'%$S?LV=):G9:F1'(;^8^(BT/O2&(K^U9VTMW<)#%&LKG+F
M-I%B#J@W,N]F7&5!'!R,Y&,9'4]&].:GU5U!9:5I.GV^J7.7O'T^ZOHM.AN[
M6Q7WFYMVNY9H#%WHD:+=%(LJ;S("BHTB4QE^X6@KB%!,6#NY>RMBK>J!(*MG
MB_5IPE+J^XDDIZ%;N$9?JTF2.-,@5RZ\]&@3,$L0"&2$"QO&&E.1>E&EWL;L
M4TJ%4DN&=T74 HDM\#]:,.Z R;\."P(R-K)M(S]-6WLTZPTVZNGL_99I-O97
MW4-Q=WUI;=?K!'?]-&&%OU*W.W4$CFM6NUCO%DFB['=A$,MD+9@KXL#=A.GJ
M;_M6=7=XR:;&)3]/NU(W!ZH@9SC5?36WYN\J^V*ATAM V'M&5%=C61C$:%!F
M/$%-XB':NX7QS9DL=3,%J)+02%1==Q&U# W]P"U<L9?4UN&RAR2 OE9-N>@N
M^B_:4VB].Q7O2B:F\$/4HU&UE]H-U$&NS>I%TI=M<2:L3-)H$<BO9/W)98UA
M!,EI?K;$R'J?>7KQ4958A ^X&QA]'J^U2=O@T49ULE"@2=4/4UQ('2D?Y*J-
M8@B:](;PS'-1TM_$4^J6F Q\K#LL#1DTF]D#L^G0F5[=8VE:^0O[P)!ONCF4
MY9_BA)\8SDF,\5J/LIZSU"._EN_9OHTVJW_3]OITNK3];Q7%V>H1J0-WU2_=
MU%N[<WJ,6>U<L%V=ONOW);&6\D=/BE1\$I!<6[")0XL^&ZXP_&<<BS&$2([B
MXTIIF5'6MEQ"E,266GVE9RV\TVXE2,<L05)4^5)!Y!Y!P>1D'[P2#\*^59H9
M+>:6"4!98))(9%#(X62-BC@/&S(X#*0&1F1ARK$$&O<Y2L=5>W_<H_8MPM\2
M@]MK_0XVSRY'K]0ZQ$T7)/#Z-M34<M^R;',)F$:^F00CG*Y_X)2I]QO"OMAR
M3B7*CA(\4%U]M8-;6\!N=$MKDV<:ZG<SG41$US97P6*TC*I+A#'+Z\#GT;=J
MER9>#O-32]N;E+/J.\LQ?ROHMG NDM,EGJ6FLT]]*&DAS()H/HP6.WUE@["(
M+##?3-_Z]YV7M^TZNW21ULV%MP3;58G@.MP.)/1HK6^J=83MO4B'F'1H3U>B
MV\CF'%E1H_AJ8NHL$G1Y!ZQR)!F>U"VU3W.PAO+!;KN6\ME,LNJR,AU*[O;U
M;&Y;=<,)6@4,5)^J)R@91$!'RNDWNB'4=7N-/U1K!8KN'4[=X="B1QH]AI>F
M/JEHF+1&@2Y?8KJH!?W=9-CM,S2VC=8-L K 3M.O']TVK<]NE08>\AA.Q:ZE
MTAH%JS:TM\E1*[%?0(@0)RQ,#X>'?CN-3,*F+BQ(42,+DC1''ZQ921)#=#3X
M=/@#-ISI%="X,EY9*$N96!=F7>WC *^G<S,7#OZ%H6HPS23V1U2XU2Y9%U:.
M2:R-J(=.U%VDLX 1$B,8TX.XB3G 1%0I',3D%72573ZGVEH>WNLI(F6W"SI,
M!IXNYMRP6][3E>W;G[)K=>/0Y,6+4S3"Y3$W*2N'6"8:0Q*80AYN0ER(ZXMG
M=L)>U. (NZ9!VPO=,7)8$'<#CX>&X^/D5NV$ICG $9D:0=M0)3%@L0<[AQCC
M!# CG/FJ S/4S6M8BVR9+]1.,W!HU:Z^V6P9C^G+7Y346K[L;IX_7J\14BL9
MF/%8H"ENRAGP<RGFAD#!MB04A2X;$L+AV*@69.YIE7]?-C=%NW\DX&"S<_:<
M<'-2PN9&VXLSEVF53[Z<;HB^_G/&TL^"2,;N."">KT7H]7X%YV[5)_>6%6"T
MON$4ZV-J1T8!V%%OV1:M5CU#YCV'X*8M6CR4V.\U-R/"5]C"V$RK&-?@LVAZ
M4]>]T2D1%J6 MA<?U81MC$IR!CECE4?G+$\$':,7/=,4C86I91;B8_KK&(Q)
MZA\23PC<Y)X!SMK,VGNFE.NFQ=,P*EW]AG)^SK[;8%.%.>GI30L2PRNN]AKY
M'8T$A-)BL"Q334^G@9L!\PQ\@:>%CWC#+Q&,N!C%+<LJ2EK,CMJI<^^.=O>4
MA#@')X9@<> Q X.3CDNG5)6:T8"-%+'WUR5$ZL(S@'<>&8>GE03@X.ZMM/&,
MXQC&<Y5G&,8RK/CRK.,?CGVX2GSG\<^U.,>?PQC'TYSU<]7GBE:_M\OG<KLY
MW6]7K1VI-[E->-]8>EH;3O6G1];GPJ:2MF[.SNAG=A5SL.0O?S0\R ,4B]0Q
MM0J=CA3'85>8?>D,OUR?@LY8*9Y/V?I^/_=\ZR * A(SELD_8#C'WGS\_'SK
MKWI:-=G^N'>K<G2'>O:#;_:N,YTEZ[]FK9/W-L:7M2Q:$WF>/$:=?M20+5(E
M2OAA3JG56H)!RI"9%9AUTDTF1(D$2Q:M'PRA@ /45X& 0 "#CY\UL1\5CIQ2
MG%*I@]97M#W8ZQZ?K-MZOA*74*(Q?-,1=J[YL1<$;M(F/=MW4K7C.M-<:M+U
MP^/)&;(Q8<3+%=;1A@,!J>"D2OLNW"6,(!U7H%)P<YPV /F!G)/X\?/SQ45_
M4<[S=TZ5O[NF/ZT[CKVHZ)Z<O4_4'8FT4@OJRFWYCL5;]BVDB3)5*W6"S1G3
M]1I4+7P9X9!5KV97K'BQ3'B#YUUE,6)$550I"C!)9MN?D!CD8\GD'GC \?&I
M^=P^SY<?UA>V 7UGV2 Z+M^BJ'M<QN+K+?:H+W"/LE@- R@30U,KS>)6RXYS
M8F'15/,[#K @3'JE:MQ<Y%NE'(@W;4 5:!DC&/..<_CX\#\?LK&>CN]6O.I/
M1;K9=>U&R-N[0+[)([-B#[+5]:;]WC8!RXM^M!>!K^PFY%#SLBPXU36R ?6+
M>S+\%&D=DNU%=M6]+>+J>6H1EB!CC'DA1X'S('/G%1MZE]L]0]Q_7*O6S-+Y
MO:JN"]*4%1I^=A:TO.K#/V\-[<SSTK$6O[ !U\Q,&?9]D&?!,1H;HU^5\Y"9
MDKE0)C3*KB"(^<<N/!!^!^1(K8IXK'5*U'[E[/U;(VC20'1#?NVAH;L=V>D1
M-@5$/\V!-O3^P^SS:VX<N)7RT=R0!E%YP"6J.1F-M$!LU##V?<ZVSU$VEV]P
M+>9]7L;9FL; &"5F#IBS@3+ D$!PJN,@>EAQXS]1:M[,=!Z@30-5O/:YT;TY
M/==$=!))HVIW1BO+1(NBM M098I+JW=4O$MHKR,/#&6AGB+KPK-WA?J#;F;:
M3E/IC=G<H^%&^[BO/>,9^&]$;:2E%.6K*68V/@(\H2IMEQQE3;36$?&PC1K4
MG_;_ $[//[=O'#9SN^><@9Y&1GG$0OL;Z79B#[>.@ =TG/OHY&Y)&;)U #+N
M=YY]3J&!9L[?&?4(V^II.<>F/V@4O#+V$MYK#V$)1AEF&AKW9J'N2EV&K$=2
M,->?@H1';0\U[OA5_(MMSG7M-'(_KC><DY^M\\D<^<DX/FX>QKIH,<^WCV?@
M;UR1?@DMO:5FQ[^ 2LH,@.[E\N2C8)S%TPV]9=T;:[(VVT:0ONAY_P!C:/@)
MJ&P(K4(LXS$A[&0T11'5''3,,2D*QEM;HQIC*4>UF5(4AQ+6MJELEK;6,4=W
M!=KONSW("2N2T.1GD9!^W/Q(%<U[3^F['I?IOH?3K#JK1^KH?>NK)3J6BR-+
M;*TDNB%H2^Z6/?&1Z@LQ?+9:- 06L0Y"UXO7P)%4JTM]Z5*K0"3*D.9>?DR
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M2>"BHK8O%I-YC%YBE$!HQEK#"OB$9:R$H2EQ:?F+ \!AKP2SA:QA 8_E"U.
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M_P"-E_ZBM#_8D>U#^WND/^-=2_[%I^G3Z:_\FM\_YDU#^D3C]26I_P!DL_\
M&R_]13_8D>U#^WND/^-=2_[%J0'2#LYK[MGLWLAM;60RY#ZMF!I>LHS<03(B
M4Z3"#[Z[/0RX/(F13V&FR4-:F6BBYK*'F7942.S)BN/Z>K6$^G6]C;W#1&3-
MU)]$Y8!7:(#(95;RI&=NTD$ D@XXSVK]!:U[.="Z(Z=UZ?3)M0[O5%^1IEVU
MS&MO=SZ0L)<306MPFYH)0&:W$3E&6.1V20)8WR#KQ&JB[YZU'4/7MUM=$, =
MY2"U/L):M$WXE $1(KA -->@3%,1C]P"&V6OF&',(;)B!TW"<8^-$97Y1CN+
M;H#7+JW@N8Y-."3Q1S(&NG9@DBAUR8H)(R<$<I(Z_)B.:\OO?:WTM87ES930
MZP9;6>2WE*V,:J7B<H^%GNH9@-P.!)$C_-16 -J>M)U(N:==X$5_=C>:KM2F
MW0E\[3JLS[Q !V:N:W$^%?'_ (LU:9#?R[+GP6G,^[WR&L8QG,G9= :W;^]]
MR73SW[*>W3;/,<22;-I;-L,+Z3DC)'R-0FI>UOI>Z]P[4.KCW;4;6[DWVEN/
MHH2Y<+B\.7.X;0< \Y85E/\ 3L=,?^3>^O\ ,BH_TB<TO];C7_[+IO\ E$__
M ,+4C_KS=)?V#6A]]G;?R7QJ?G5+MYJGN-2CEZU/$ND(37; JM$V+I7/L.5@
MAB%&GI5$D0YQ<*0:5'DMJ<1!+R)D+.4?:,2&F5"5*YK6M#O=!N([:]:W9Y8N
M\AMY>X-FXKZ@RI(AR" 60*V#L9MK8[?IKJC3>J[.6^TQ;M8H)S;R+=P=EQ($
M5_25>6)QM8$[)69<C>J;EW2DY#5T=87WWON@];Z!^<K9*;2JL_E-5:IG\CZ?
M8KN623N!R(!%+R&K(\B1^43+F(R^]AC*G58:'#FIYN>*%$,L,+SOL3;NVLWJ
M94&%4L>6(&<#^4X4$C+%$\S[$V[MK-ZF5!A1D\L0,_9^<X )%=6VO4(ZZ7B\
M=?60C6[_ '4#M^[7#_S?6CL$POYT;HS:\62F!&3K9V9-F8E6D4UBM-QDW-$?
M,HL_6F0D5PGC<CLYD2;)A]=L&7]<0>#-&1GZ3@$*<,?0>!NR0*W8K29$FSVO
M7;9&)X2.98_)[F /2?5]7P-V>*DUJ#U#.NN\+OK[7U$1MW\H=EXV7FM*LVC=
MK5 )G&JB"X%ES,L=DJHT"TE2FG%L*CD)28#V&@]DR L<N"%DX9;*>)'=^WM3
M9G;-&Q^D&5PJL3X^P9Y*[@"1KR6<T2N[F/;'LW;98V/T@R, ,2<>#P,^5W $
MB<?-2M6O&?PS_)G]O_9YS_D^O[.*43_!Q_)C\<YSG\/UY5C"L_RYQC/[<>>*
M5!7OMN6J]?J3IC;]V@V2?5:1V JQ0VW5Q&2Y-N(_2=AB6W$H>D0!T=*II*(T
METF3'QW'741V7G);T>.]+Z/:R7LMU;1%!)-92*G<;:I(F@?&0&8\*?JJ3\3@
M D>M^Q_I?4>L]5ZHZ9TF6QBU'5NC=0M[1M0N?=H#(FK:)<L"RI-,Y$4$C%8(
M)G"J795C5W6)_P"G3Z:_\FM\_P"9-0_I$Y(?J2U3]W:?XV3_ *FO1O\ 8D>U
M#^WND/\ C74O^Q:?IT^FO_)K?/\ F34/Z1./U):I^[M/\;)_U-/]B1[4/[>Z
M0_XUU+_L6L;[A]9'JEMK5M]UA5JYNY%DO]7+5$$J?2:]\E@J>C+'0?FL#+L3
M(Y9^8D-X6F .G3%8^[&B2'LH:5GMNF-1M[B&>1[79#(LKXE?.U#N.,Q*N<#C
M<P'S(&34WTW_ *F+VB=.:_I&OZA>]*&QT:_M]2NQ#JMYW?=[-Q--V^_I5O &
MV(<&:>&,>7D106%\#:TNMH<3A>$N(2M.'&UM+PE:<*QA;3J4.-KQC/WFW$)6
MC/E*TI5C.,<C^GS_ (J^1""I*G&02#@AAD''#*2K#Y%201R"17/BJ5@/;?9/
M6.D[-3ZG>ORW^U;P/LA,'BJ:UOU\CYBU6(U,*_-KI==.N,/)9=2I$=++KR&\
M9DRT18?MDJD['2;S489YK;W;9;O"DG?N[6V.9F*IM%Q+$",CEL@? $MQ4+J>
MO:?I$]M;WGOG<NXYY(O=M.OKU=MNH:3<;.WGVL P(7!(&68*OJJ$>I>_.AZX
MG=ED-#MS01UI-$M^ %*T5M1[[1U[+IU# L$&Y,>KO#F4J+AB4+)25.8J^%QL
MNYL/RZVWE]#?=-:E*=/BC?3V:&)--E/Y2L@$NEGN92I!G#GZ-U;8%,O..UNR
M*Y+3.L]&@_*T\R:LD=Q/)J\).B:J>Y9/:V<*R!EM"@!DBD3N,X@RN>]@@FT&
MOG(%F A+(*^<^R[ (&FQOVB-(AI_R!6&S/A_/""\6$5%3/EY#?S(XG"B$(+W
MOC38K$EIQI''RQM#+)"^W?%(\;['21=R,5;;(A9'7(.UT9D889200:]"@F2X
MAAN(]_;GBCFC[D<D3[)4#IOBE5)8WVL-T<B+(ARKJK @?7YCK+4.^Y?>32/1
M6EU6];O:O3P>Y65RK!6J/4I%FDY),C9!5Y4Z0N4-$#6D18ZLLM32K,^?GXJA
MD*:S!)O0=FUM);MV2+8"J[CO<*,9QQY)/W @?$CC.S;6LMV[)%LRJ[CO;:,9
MQQP2?S# ^)&1FNC_ /:(_3_SG&/L[L%X]RT^?S8BO&,(]WWL_P#CIY]JO;YQ
MC&,KQC./>A&<*]N]^1;SYP?XW_\ C6Y^1KOXF$9^<A_#ZE8'T)Z\'2#7 O9\
M6Q#=Z*>MV]-O['$I'ZZ%RL8KUWM,P\$3+4NX,)9(9A/(3+CIRZU'?]R<2'&L
M?&YEFTB[<Q[3#Z8HT.9,>I5P?VOC-99M*NG*;3#Z(HT.7/UE&#^U\9^>"?E4
MK]:>O+T:VKL.EZSK4#?*+#>[.$J8-<S5?QXGVJ?G,#H.9#(2Q&2^8^),EK#V
M80J;(2C*EMQW<)SS7DTB[C1Y&,)5%+'$G. ,G&0!X^9%8)-)NHT9V,.%4L?I
M""0HR<;E S]Y ^VKI.1=1E<?[O'TS_!5]?*O'XI^GCQ[,YS^K.<X5CQG"<9Q
ME6<*5RXI5*+OJC==.K&S.P&I=EU_;S]H@[YV":==K].$NC%PC#P]V$XRX>M-
M>(.)=;:R\U(P.Q#F1G&)H^5,A26)+G4_D"^U"WLKF!K<1M9PJ-\K!LKNSG;&
MXXS@C=D$%6 8$#ZH3_4_];^T'0>CNI-!O.FDT^;I#1K55O=4N%G$MLLRRAUL
M]/O85*LVQD,_=BD5XIHXI4=%^G^G3Z:_\FM\_P"9-0_I$Y;^I+5/W=I_C9/^
MIK!_L2/:A_;W2'_&NI?]BT_3I]-?^36^?\R:A_2)Q^I+5/W=I_C9/^II_L2/
M:A_;W2'_ !KJ7_8M9TZ8]N]7]P=Z[YOFK!EY'!!6I= 5%[\LJZP*==*@+AV(
M,D?@R1),\)2VB)=0?P&))..1E*5-<8@.1H3\A.KJFFW&FV=G#<-$7:YO91VG
MW85XK%%R&5&\Q/DA2HXR<D"N1]J'LVZ@]F?272&C]0SZ3-=W'476.I)^2[UK
MA5M[S3>B[6#?'<06=SDRZ7=[W2W>",")7F$DJ(;)^05>&54_M;UDNI>H-D73
M5]D"[JFV"B'Y]:-21-$%-#5E!CGP)R(6+!;0!9QAF2EQA$B0)BM2L-_,PLR(
M+T:4_P!K9=!ZW?6EO>12:>L5S$LL8>Y<N$<97=VH94!(P2H<E<[6VL&4>9ZG
M[5^F-*U"[TVXBU=Y[*=[>9HK*,1F2,X?9W[F&4J&R S1*&QN3<A5FC5N3UI.
MI%^J(@$$KV[&ID#:NBKJ\HA3JJPQD1K;=^O-BV!MM;-]DK5.> U8DT,94VEJ
M227$COR(C#KDIF6L.@-;MIY)))=/*M9:E;C;/,3W+O3KJTB)!MAZ1+,A<YR$
MW$!B #S^J^UOI>]M8H88=7#IJ6C79+VENJ]K3]8L;^< B]8[S#;2",8PTA56
M902PRK^G9Z8_\FM]?YD5#^D7FE_K<:__ &73?\HG_P#A:DO]>?I+^P:U_D=K
M_P#'5.7J5W6T]W/"6\[J2#>X$>DE!XHVS=JR@(K+Q2*[+A.0)P\D;"3L+;CO
MI?B,E<DX7L:>G0(T6:.D3.=UOI^_T"2".^:V8W".\9MYC)PC!6#*R1R+R1AB
MFQLD*Q97"]ETQU=I75L%U/I:7J+:2I%,+RW[)W2*74HZ230N" =RK+W$P"Z*
MKQL\N^0==15(VS?7YZ-:JV)=M:6$'V#DGJ%:#51-/P=8C(D-PJ!GR!L_,6/9
M+E7SK3"949Q+>"@4;+4GVK7$;QGZ2L>CW<B)(K0 .H8 R'(!&1G"D?@34HFD
MW4B*ZF':ZAA](2<$9&=JD9^>"1]M13WOZ^/2'9,#5T6O@=^-.4[>FIMCEE$J
M%5XR%5^DV5DP8;AY9V!*4\17%0I$*,M+++[_ -QR2PC/Q.;,.CW4?<W-!ZX9
M(QB0_68<9] X^?D_96>+2;I#)N,7JBD08=OK,N!GT>/G6<\?NCCH%GQ_XN=C
ML>58QGSKFH_=QG/C*L^-E9^[C'WLX3Y5X_!.5?=YA_(EY^[M_P#&-_0K%^1K
MSYP_X;?T*LDZ5][=(]\J7;+UI&'L"$)I=C9K!MF_5%=<?^T)(]HDPL=-ASS0
M HVJ,Y_7$>":?)C<_ 66'P&"(EZ?HW5I+9NJ2F,EEW#MON&,XYX!'YQ@_ G!
MQI7-I+:,J2E"67<-C;N,XY& 1^<8/P)(($SN:M:U<4?P4_3./NI^F<JSG'TQ
M],Y7C"\Y_;E6,*S_ '6,9\XXI4*N^VT*[IC2==V?;(IR97:3O#1UE,,UX4X5
M)9' MC@S$[+3>7(T&.K,2 ^AA\J0&P'9JXL#,U$N;$9>EM'@>ZNI+>,H'EL[
MR--[!5W/ Z+\R>6&0H8@9;& 2/5/8_H%[U3U5>Z!ITEI'?:KTIU78VK7MPMM
M!W[O1;JVBW-M>5P))5+I;PSS+$))NT8XI&6'?Z=/IK_R:WS_ )DU#^D3DC^I
M+5/W=I_C9/\ J:]-_P!B1[4/[>Z0_P"-=2_[%I^G3Z:_\FM\_P"9-0_I$X_4
MEJG[NT_QLG_4T_V)'M0_M[I#_C74O^Q:QWM[UI.I6P-3[0H0&M[P2<N^N[K4
M0RIM-JK4-)6R5HF&'9EN1[[*?;C8F36<OK8C2'D->]3;#R\);5GMNEM2AN;>
M5WM=D4\4C8E<G:DBLV!VADX!QR.:FNF_]2U[2-&ZBT#6+R]Z4-II.M:5J5T(
MM4U!I3;V-]!=3B-7TB-&D[43; \B*6P&=1EA=O1W</TJGO);D-8>JU?=PU+B
MR8,MK#@F(O#<J%-:CS(<A&,^UZ++89DQW,*:?:;=0M">5E&)9!P<2.,@@CAC
MX()!'R()!\@XKY4U92FJZFA*,5U"\4M')'+&Q6YD&8Y8F>*5#C*R1NT;KAD9
ME()[1S'4?40Y7=_14&6*ARD[2^,8V1?M6Q$PM+;4,N9L^MH.9]ESF*#J9.:[
M 2SEC$%R+%D3)*G7UJA,QQ!]\3.+T]J3AV7W/$=K;7C;M0LHP(;MML7JEG10
MV<[@2%& -Q:2(/S4G5FD1-&K_E',M]>:>@CTG4YS[Q8KOG],%K*VS:5*$*6?
M+$+B*<Q1=U-WPT8,O6_[@1&;GA@-E%V]KTZ:K1&V)"2U0UYIO4=&L<M'R54E
M)1B/9@Q@=F:M6 L-8YQ9<L,1+&9GS-[TWJ+VVF6Z/I[2VD9L[A/RG8@QS75_
M>W$0.Z<>8I(VV_LC;P$1R'V\WIG6.CQWNN74D>K)#?S+J5JYT356[MK9:3I=
MG.XV6C8"W$,L98_1*8R9)$#1EYT:Q[%ZXVY9I-3J";A@K%U[2=FN*/T6U5F#
MFLWYJ0\!]LTZ+@L?:?PX^521RU(=QE3S<3,QP8:0,YR\TJ[L8A-/V-C75Q:
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M^EON7\4IZN?^C;K/^GCBFT?NU_!_Z-/TM]R_BE/5S_T;=9_T\<4VC]VOX/\
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MMU[K@4ZD=8ZG'I>A]D5:.ANNE$E+58;_ '6HW&*\*)V9G8(PC"2+ :X#UAN
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*4IQ2G%*<4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g107876g99g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107876g99g01.jpg
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M 0$! 0$!_\  $0@ [ '^ P$1  (1 0,1 ?_$ !\  0 " @,! 0$!
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M5Q<\3OOY>/C2PX#=;R++ZKIG5](O-UV54J:+ 7?8L8#%NYX?F6T]8VZP.8$
MED(N9*A^9, 9%BP4S68C4Q^-&CMRGWTL->9"E8%"ZC]9QVW7=\P=)T&+MQXG
M,.*NK(5M$]-A(Q\Q"-F9AX7[)CVDA'4MJ=9F![9Z9AQW,DBZIYW*YN=U_?[>
MK@HL. WW\ON%QAO3OJ^'L5YM@O2%"@V#9 >V@+B0C"LMY)A[\A:+S"BQ</>I
M T7+TBUVEP!&%O'WE9?*NRGO!S"YTUW;O)N[/?>EAKIOO?R[UWYKK)H"R#C
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M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%
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M\%7SXR_;?_NX-P?W@NI?_P!8N+#B/3[%%W?J_P#O!/C+]M_^[@W!_>"ZE_\
MUBXL.(]/L2[OU?\ W@M8^.]?;G9<OO%HRW==SERU<%UAOEHEL@4:U.J5U]DO
MTBVK=US?+5KNZV755_D5)6&A&1P0R'VK$8C27#M8.DV'\\SL. ^,,/-__3:7
M3C^G9XCVCRKL?@Z+NZ#L,"/_ -9;,](T_P"-4/M]FY>9WGM*_9E.$3A%RH+2
M'YL-ES'G-O2H[3F,9SC.4./(0K'CC.,X\4YSCQQG&<?GQGQY#B0UQ&\-)'C
M5J=[F03/:;.9%(]IM>SFL<0;'?J-RV&;0ZLZ]I5@[TN#;10SH[3T2RN:QI]<
MN)TK;Z<['[2ZJUR.S9(4F#&Q-P*I=E-UPFD@1*>::(1).<2)C3$UG1T^(SRQ
MX/FCF8ZJ,?.)9(F-BE!PZIG=R;@XVS2QLD;E:WO&D: D'Q7 /A#QK%:+X(VS
MX?C-'/M-+0-Q_%*_"Z.FPS%&O^#_ &AQN<4,T<TG)<YQ2AI:Z P04]Z6&5@,
M<3G1.^>_NF9FBT#7CE0US>6+T#LU=U7L[UZ&7>CW.^W>FBKB'(5)B4WAA48-
M9T;#U9.0*PF M5,K!5SQ(VIS"U%BS)IZCE:B$PNC?4T^5S+Q0Q2NA>V0C6[F
M<A4-S7=^FD:.]C"JV-^%&EQ?&<;;B>.82_"*N@KMH< Y&6F:_"\'PK%*C#*F
M'$GQN+Q)58>[!-H(C4$S 8GB%.+0X>,L*T_4M3@T/LT/V2 O S=6K]?";0!"
M3FXX4!5V7=IZ<J\F:61B4X8-'2@R^D8T02_"'!Q$%"2BY!N>0B- ,N6JE=-A
M[J=\+J.HG=&]XNZ20\WJI UNF1C&NA:2X$O<;MLQK27]3BFTF)2XOL%/@-;A
M,^RNT&-SX?65<+GU59B#A@&TU>R&F)C;34M'3SX/#))4LEGJJF8FG#*2&"1U
M9#5L%47 @"2HA0S-5&#"V;FS8XPT6^S:"$@LO+0&,P4FR"0QJ'!1ZQ)0TE$5
M68ZG587,]"SEQ/FSO;,U@N]QA,9<X&-H;J\Y0&N)=H#8FQMN!/48;4XQSFLI
M\8IZ6+E*JH?A;Z%\]0QV'P,IAFK)'4\3()W2S'DV.<72 /#1:+,^[UQZJZXK
M]Y[$IBVBA3@5%U#:[;4Z(.N9Z7>01R " 38$DK">A->L('R9TIV;&E%I<?S'
MFTJ;>2E"4ZB+$:B2&@O',U\U5'%+,Z)@AD87R!P:038N#18AK3<&Q"\GPSX1
M,<K<(V(,F'XQ#68OM-AN&XEC$^%4<>$5E)-6UD,T=/,V5V0S1Q1MBDCIHGYF
MN(<TDDP/L+13)+MT5Z^ZPA*@L%MFBZ+6(\J3+GH&M%7X$;UR?,ENNR5P1J)+
MY A+D/YQ'A1WWG74--*4G,@K"W"V5U2[,6T[II" &YB 3E:  +N(#6@#4D#>
M5V&";7O@^#2GVTV@E$SZ; *C%Z]\<<<)G=3MF?R4,4;6QB6<QLAAC8P9Y7L8
MUI<X R/V,ZI&X-^J#VC-2[)@U/9->L9&MT@X-,2[>(DZ]L+]2L:22"32)[KI
M0>FJ;#=SYOJL&+L. .C89:B)C,8]!B3#!+SRI@=)!)&U\S',$3A/&)69<G>@
M-=RL Z7& N))-UH]A_A&I)L&Q-NUVT>!RXC@=;0P5V+4D]+'AM2S&J)N)4)@
M=3N,+6T\WQC@K=<\LF"RS/+W2&1_9#.H\F5U3(WB11;BC9_P?L^[H-HQ'+8J
M\?5U,M$2B$:'+9PC(J/:),>->=KO2I6434U*IBL1,HCF$XGP[$Q\9-A$T1I\
M\=(Z.[.4-1+&Z9LP/SS&"8:8 =[RDCKW+=+$_P )3(_A%@PAF+X8=G^>8?LI
M+09Z;XP?C^*8?)B\&,1NN*E^'QR283LZV.,&(XCB-3R@,E*3#BHP'UF)UJS7
MVDTFXG_P1Z.KUBN-4V#:)2 5HV?9=F4&B9\Y^G)K-A;J8"'<"TU3XDX"DG"$
M"O1O4PD?!-PQ6Z3$6R1P32Q,YU6/9%+"P9XZ>.GFF-A+RC#(\Q- #V/#&ND-
MWG+DV$]7M]!74&#XKBN%T7RDVMK:+"\1P7#XW5>'X!08!C&+BS,3Y]1.Q&LE
MPRFB#*FDJV4D$U:_E*I_-Q32&,U!I&#L6Q5@GKHF_KUD93MF;%V98;@<@P]'
M:EV7J:BW^N":E(%S1D$_L^";M1VNB(%S'6;%ZG#*X"$5MHA*.$VK+JJL=!'(
MVH:)RZ6GIX(XF%U74T]3-#(Z4.#BRG+(V/<Z$Q<B'2/<_*&-6DJ-IMK)L#HL
M0I\<@9C3ZC$\!P/ :+#*.67:W:/ MI,7P:OJ,2CJ8JB:BP"6DP^DK:F;"YZ
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MRYLMQ#*$)7)F2WGI4I]6,NR)#KCSRUN+4K.;AO\ UC0?^VTO_P >-=C\'?\
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M:&>%OSVO_6D8-6D"[AI:]RMTG-6M:G")PB<(G")PBHCW\_Z%];O_ #W=*_\
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MY?J'M57E]7L6*:?Z\(HLC7$DU.E*E:*C;HH.M?9TN,H26UCLZT5>P O;L5Z
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MQ7:.+'V^JZT WN]MNDY@@,J73QF)Q9EC*WH\V%AP!-[_ /=Z!Y!I?BHZ3?I
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M6SI=@DNR8NX;>6$5FPV%S+N&;K7Z:TW8V9,D;,?FK=6I)Z/%Y-_0-W8H%KD
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M2G&HT.'$C-./R9,AUMEAEM;KJTH2I6*F,?*]D<;'222.:QC&-+GO>XAK6M:
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MV7&(QWE.]!LN0=H<&:-#S^#733O[D"]]^X]6ZQM;D]N!;9':-QL?^$U6AO\
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MD#X9'B!KX3EE=)GSX=5U%%#2F2A@--S">F%/32MACJ\/JVU,;>2,^E&Z.&&
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M")PB<(G")PB<(G")PB<(G"*G^X(^6+S/<SCPQ+ACI"?]N$Q&XGC_ %HJL?\
MIRZS=XC_ #^U67_.\8_E]BU::<5\%.__ '%K$K/HU;-UYU^VR#9S^3Y\&M S
M&MSLEI/_ %T+*1H*'5X]R7DYQG\I7*U2MD--G)'6NOS'%>:VT5AI=5G\R67G
M4L.JSX_R);<5G/\ LQGE+OFGWW:J1H1TZJ]7+*OK6=Y0/5&SK_=NJUJH%4VK
M8Q6M[7M6=<IFFAFA3U["0[/KIZO!7AH#L;(3K4FQ.*O(AD,D(DV7"'*ES!J6
M"34)Y,CIW;NF_$<-520;@B^E]UNFW%0=-T?V*)[=HE_JM#V>'">R_)]A#TZ\
M/Z;JUW=$ZD[1[?M&Y&[:#U*<108SD:C6 98BH^FQTAB8XVS#$PWB29PJ)-Q_
MXMU^D:>_:A!_\/H.N[_94QHMU[(;I)WW5=)OVV-A[5;ZZ;HE[)89[ UZ[T4Y
MN$7VNTT/#V*D5B!L$K$T^/CT./9P]:JUG"ZS(11\6R#1U01,B60J9J%@ 2!:
MXZ.+3O-M==>KQ64&Y) X'I%C9W"_DUW\%81W0?<4/8.Q O7M/W;6F[M;O*1V
M<E+F[5K;FH+U4MM"MD2>NL2ATAN_RV:WLN;LXO6K%BP2JG63< ,DNFQV58N6
M+%0HNW2_[/0;Z6O<^+AV=*=]KITNWVMTVT/$GW&[LIW5?M&7)7,?FJVJ *OF
MP]H$;%*'W4.'=+"CGDR*YINOSITZ!8X\W#;^]!GP<3GS\/L$8OM>0VV$RDFJ
M+C2_#_[K^+=QT4D'HXZ?Y;:G?O\ *OMU_8W@&WYUPZPB;ML@)4X6G]*;NWE2
MK)M&18+_ *7(Z/JM@I)O5A5D=:K.D)1]Z6\SIJSC*\HTS ,54!=$(#NPB,]B
M'&EKVUOZ]W98CR[]$%P0.KR7&_R:]0%@!P6]3D*I>;[_ "@:]Q<0>MVLF'DK
MFN2[]>RD?"L>?'BLL@*^!>4G\^4S'7[&A"O=C&8+F,>.<Y\WUKX+J9V?%ZPC
MO0VEIF'BYQEEE'_=#8B?\07@/PXUK<FS^'M(+R^NK9&]+6M$$$)\3RZH _P'
MR>:CGKR^?4X1?H5:,CBJ!I#4M(*E1D"?K_26N(QN)+GQ(L@2,"5" *<*$6'7
M4+@C4NAYZ,SI*6HN%0I2?2^,=W"/EC$B^IQ&NJ&,>YM3B-68W-:YP>^2=SPQ
MA LY]GM.47=WS=-0ONC!FQ4.#871R21L?0X/A[9FO>UKHHX:5D1DD:2"R,&)
MXSN ;=CA?O3:6O;@7UH7!]L"_73<:1,"P_:$3UHO$B-,O2I0N/Z;TI"-&9DQ
MW9#\1#S3+3[+CBDH=1E6#R<F5[N3?EC(;([*[+&YQ(:UYM9I)! #B"2"!N*V
MG+0YHV<K'GF:YT3,[<TK6@%SHVWN]K007%H( ()-B%_!FP :Y&9F6$V(!1)$
MMB!'E&24,7&?G2<JQ&A,OSGF&G9<C*588CH4IYW*58;0KPSX3'%+*2V*.25P
M:7%L;'/(:W>XAH)#1<7)T%]2HEGAIVA\\T4+'.:QKI9&1M+W7RL#GEH+G6.5
MH-S8V"[1+K:U.(0XA:V580\A*TJ4TM2$.I0XG&<Y0I3;B',)5C&<H6A>,>:K
M&<T$$6)! .H)&\7M<<=01XQ97 020""0;$ Z@V!L>!L0=>@@]*_OD*4X1.$5
M(/*,5B^7#J-?0>LJB2O=Y7=M E -5%1B$J25<KW8C5-AG>EP+'E9T4;"&"YI
M$R39'3$AP\2<5?87'A.XY4TV(.[?ZBJ7;CT[MWC"X'X4/*(_1'ZZ_P![JR?X
M;^1IQ/8/:IUX#M/L3\*'E$?HC]=?[W5D_P -_&G$]@]J:\!VGV+2;V'WQY1&
MW:F\HE2K1K$19>L\"@[8CVNXV6X$)<?4]L;60]OTC4^PY>I-6S=JAJ\72\*B
MUW%'LL,,RS$'.;5AQV4NR,V@ %92V^=RT>FX'7>=]M/]K+)H"[GM/8 _IFWN
M3IY;#0"QW&_03K;R#\[I=PG"+L!18H")03(0D0#&!DEF:-*BIDD<2'S(Z\.,
M2X,Z(XS*B26',86R_'=;=;7C"D+2K&,\@@.!#@"#H00"".!!T*@@$$$ @BQ!
M%P1P(.A"VT'#1'?F]^L]'O=[5L6GPNHNO[D0IUUN5JLH,UL&K:&LQ1J+$K R
MZ5F1:MG2S*$Q@U2Q:JJ0N)^0U52EA'0C,YQ6L:!##4/C9D>:I[ YC&M<&.F:
M+YBQP;&!J797!H[X-) 6O $,4[V,R.YP]H<QK6N#'2MWN+798[;W97!H[X D
M!9'N3775/6U=-V)5 H;LRYPNI-?)N$%EQA+5V-E([5 MV7"O:XJ&ZMAC@5X
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MK3!L4"]-$W"STZ1;99""<V+:R92'[/LT>G:W9G!A4M86''LO>]C<FUAXA]J
MWO:WK(ZB-+=/2MA6G3=UM5,:N5WB+#2KD2GV6NU20/P/(T^CD%-IIH$ZVK&)
M.;2L"Q#.6YB6IQ8FTF3 "*ZZ,$0%JA3[^_O[5*?")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(L7/4RM63&5%1;#LC./#
M$UK&8TU/ACP3XR6,H<<PGP_);>RXUC_L9QG.,R"1N*@@'>/+TJ)R>B8RU*6&
M.O,X]^4L$8R)'Y_S8]9C*CY3C'YO?%7GP\/'/CC.<U<H>D#U>U4<F.@GU^Q:
M(O*R^2F[;]PK[J WIF5JZ;5M>:\* YT6R7$D +.6DW;S!0B_#B.5N3!6.4"9
MK#29*R+4A<QJ8PJ+AF.Q(D;K#,1IJ2.5LHDSO>' M:'#*&@ 7S WS%QW6L0;
MWT&\PNMIZ.*1DN?.^3-=K<PR@ "YN#>Y/1N6IH9_D[GE#I[Z6I3.CPK><YQF
M43V;)=81CQQCQ4D/5BTG.,X]^/-CJSX8SXXQGPQG9G'*(;N6/BC'VO"V9QFC
M&[E3XF#[7!6KUA_DR&XB$B,YN;LUK6IQ$J;7*B:SJEGO\IYO'O<CLS[0K6[,
M5Q6/R$RECYR&LY])F(_A/HU8\F/Q#_E4\CCQD<UEO(WE+^*X\:QY,<C'_*@>
M[KD<UGH;G]:W#=;O(5=!^O\ (@'#M',;]M\++;R#&ZY\4^!9DISA2\Q: +@A
MZ4_%RM*<LLV,19)+&,>"9JE94M6KGQ>MF!:'B%IZ(AE=;_&27C_NEJUTV*U<
MP(#Q"T]$0L;?XR2[_*6K<*/'#Q$"&+%088P8.C,PAXX?&8A0(,.,VEF/$APX
MR&H\6-':0EIEAAM#33:4H;0E*<8QK"222223J23<D\23O6N)))))).I)-R3Q
M).]<SD*$X1.$3A$X1.$3A$X1.$3A%#/8/2H3L/J"WZ@L!HW6Q]J2"D-6&N9'
M^V@9BK68-<*Z6@-E81$9(<'V$ +EN0Y\*3#FL-.Q)#>6GE9Q(-C=01?11 YU
MUW\NDQ*RCO/NQJQ1[21.OW].N.NN3LT+,$BQ\2GO#%ZE56FQ N=!FFHT^.':
M.O3"\N/,)R![$&+&7' >GVI8\3Z/8LI3I+<B=@P+;GMOM5=6BAAPZ3K-5&TC
MBN$2$.F,5R6=D%TZXQ;6IQ2P-.7N3&BG6!K)R0X-AQ(];0T(0OU#T^U #TF_
MD'#MZ]ZU\]5N@_:36G;'96^K5V'L=.UV7MY)R=0 L/63I+L&J)+DLYO^S@-&
MH-0U34WK7CS"N9(JK'-K*9FRD$;T#*+=<S)<" +:CIX>+4GTJ ""3?3_ '\0
M&NN[[;[HN4JI.$3A%"NX]X5O2SVN$6(>;(L["N9*J)^#P6P68H'B!]>WC8).
MP?!NJ!+#9#$&'%I?LV0T+%NJC2#,.9,>C0&)+Z) O[V]:@D#?[]/V+DC=^ZC
M,V</40]P:+%#_LIL5,&![#/JTB><J?P\"A'+Q$$O4J'92])4S;1E7FV"-8IU
M<EP#$86[ (07Y$6W]6_U)<::[]WEW+E$=WZO%7C\'<^S9CV9)"('DX]AV-VN
MC3T\ [:A]:-75D0Y2P=I(5II)Z!5S%@@V":)E#I\4:[&*#7)2W3]H]6]+@>_
MKX>58:&[7:(L(9LX&N!0A'EMT]\..9H&Q\6>T0]@#39FEDJ73G*DBVW@191%
M8M),48J 0V+D0*I:Y>)>&*R=6/FQ]?#HZ]WN.(2XT/&UO+N7.9[.Z.DE:\&B
M7?UZ;9HM#F#W(%:M\\;"9V@3G ]?8LQJ& ?#TR1;3@V:"#P[A/!2Y!QG ?+"
M"3K,5R+)<7M[]N[WZU\XO:'1TT=,*0[A,EQH_P '%#VXU+OCY"W1KA-)#ZH1
MUP(;K"BNT1%DDAROL,UKB%:1)../F38<UZ$PY(2MT^_1[0EQQ]]>W<5_M1[%
MT2R:J=W+.R0"TA^]62D5^0D6=.&+*\)V>2U2 E":R("OV67+NEB'M+KX&$'F
M%G8Y*!A32G''$MS;6W\O7[W2XM?H\1]6]<Z#V/TT2) !4*W/ORK$D!B,Y\%K
MBV.$3+5,DC:R&N1AVOMB=?V.P%(<@0'K%ZG5RPD3"4"8HQTB\S%<A+CWW=NY
M<.O]G]&VF:T."7?,F7*=J*1J'ZQ<1K1R'?SSM:HQVN22=?AQK+5+>8C3F*W<
M0#Q&JF8XHR2@&'Q@4K,AS8^OT;TN/5Z= N9CL?IA9J& 9N7K1"6>56'%PJ[:
MYPL0<5L$WJD?"LYZ&"?!5'X0;&KARGU*5:"(>'<C0Y^-5)!G'HUKA2L"L?<S
M2 <-+*!B5HN<AHM60PT=6=?W^;FQ2[1LD;J:*]6"&:ND;:!XN\E(P0_,K,HU
M[)GKCC7FE%R(@<0FWB'E'IX>51FTN+GR'4:;NU?0UN#0VR6!M,V!F.6A%;TR
M,'PV@E[/TI\C"V:;U]1<7&SP:O$J -RYV^NO# 5;N1)D79BJV1(A=G8D0I$V
M/%[_ .R7]=N/3;WZUQM9=NZ#L D1BDF6Z6-9I\>["3ADHET:7#.+N9N6\N4F
M!'@BTCM:!:=LB6N;.QC(>^1V&$O)!39TF;>7Q>_'3A?<2F8>]^OR#34:[E:
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M'K8&F:+INC&[1/DAZI&$LDY]GKU5M\/8CL2'-:,.;&JY@2H"=:L98C)MLYJ
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M^]+>+2UK@:?[^A<"?TG%-S-7T(.N3G55;OM<V+=B<\S&;+'0]!T&$Z^5O2C
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C1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
